PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ERICSON, J; THOR, S; EDLUND, T; JESSELL, TM; YAMADA, T				ERICSON, J; THOR, S; EDLUND, T; JESSELL, TM; YAMADA, T			EARLY STAGES OF MOTOR-NEURON DIFFERENTIATION REVEALED BY EXPRESSION OF HOMEOBOX GENE ISLET-1	SCIENCE			English	Article							CHICK-EMBRYO; SPINAL-CORD; NEUROBLASTS; HOMEODOMAIN; ORGANIZATION; MOTONEURONS; INDUCTION; MIGRATION; LINEAGE; ELEGANS	Motor neurons in the embryonic chick spinal cord express a homeobox gene, islet-1, soon after their final mitotic division and before the appearance of other differentiated motor neuron properties. The expression of islet-1 by neural cells is regulated by inductive signals from the floor plate and notochord. These results establish islet-1 as the earliest marker of developing motor neurons. The molecular nature of the Islet-1 protein suggests that it may be involved in the establishment of motor neuron fate.	COLUMBIA UNIV, HAMMER HLTH SCI CTR, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Columbia University; Howard Hughes Medical Institute; Umea University			Thor, Stefan/Y-5804-2019	Thor, Stefan/0000-0001-5095-541X; Ericson, Johan/0000-0002-8019-7127				BLOCHGALLEGO E, 1991, DEVELOPMENT, V111, P221; CARPENTER EM, 1992, DEV BIOL, V150, P144, DOI 10.1016/0012-1606(92)90014-8; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P1, DOI 10.1098/rspb.1981.0079; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; OPPENHEIM R, 1950, J COMP NEUROL, V210, P174; OPPENHEIM RW, 1988, J COMP NEUROL, V275, P159, DOI 10.1002/cne.902750202; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1991, DEVELOPMENT, P105; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH JL, 1988, CELL TISSUE RES, V252, P491, DOI 10.1007/BF00216636; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	39	573	592	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1992	256	5063					1555	1560		10.1126/science.1350865	http://dx.doi.org/10.1126/science.1350865			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1350865				2022-12-28	WOS:A1992HY07500029
J	HILLS, BA; MASTERS, IB; ODUFFY, JF				HILLS, BA; MASTERS, IB; ODUFFY, JF			ABNORMALITIES OF SURFACTANT IN CHILDREN WITH RECURRENT CYANOTIC EPISODES	LANCET			English	Note							PROLONGED EXPIRATORY APNEA; SEVERE ARTERIAL HYPOXEMIA	The mechanism of recurrent cyanotic episodes in infants and children is not known, but a deficiency of surfactant is a possible cause. We have measured the amount of surfactant collected by bronchoalveolar lavage from two children with recurrent cyanotic episodes and from two controls with anatomical airway obstructions. We also assessed the physical properties of the surfactant by changing the surface area (A) of a monolayer and measuring its surface tension (gamma). The cases had lower amounts of surfactant extracted, which could explain some of the abnormalities of the gamma/A loops. However, the finding that the cases had reversed loops (ie, the surface tension is higher during monolayer compression than during expansion) shows that there is also a qualitative abnormality. These features suggest a possible diagnostic test if not a mechanism for this disorder.	MATER HOSP,ANNERLEY RD,BRISBANE,QLD 4101,AUSTRALIA; UNIV NEW ENGLAND,DEPT PHYSIOL,ARMIDALE,NSW 2351,AUSTRALIA	University of New England			Masters, Ian Brent/F-3733-2011; masters, ian/E-6071-2013					AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; CLEMENTS JOHN A., 1965, HANDBOOK PHYSIOL, V2, P1565; GOERKE J, 1981, J APPL PHYSIOL, V51, P1108, DOI 10.1152/jappl.1981.51.5.1108; HILLS BA, 1988, J PHYSIOL-LONDON, V402, P463, DOI 10.1113/jphysiol.1988.sp017215; HILLS BA, IN PRESS J APPL PHYS; ROUSER G, 1968, BIOLOGICAL MEMBRANES, P5; SKIPSKI VP, 1963, J LIPID RES, V4, P227; SOUTHALL DP, 1985, LANCET, V2, P1125; SOUTHALL DP, 1990, ARCH DIS CHILD, V65, P953, DOI 10.1136/adc.65.9.953; SOUTHALL DP, 1985, LANCET, V2, P571	10	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1323	1324		10.1016/0140-6736(92)91962-8	http://dx.doi.org/10.1016/0140-6736(92)91962-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349993				2022-12-28	WOS:A1992HW83700005
J	IRO, H; SCHNEIDER, HT; FODRA, C; WAITZ, G; NITSCHE, N; HEINRITZ, HH; BENNINGER, J; ELL, C				IRO, H; SCHNEIDER, HT; FODRA, C; WAITZ, G; NITSCHE, N; HEINRITZ, HH; BENNINGER, J; ELL, C			SHOCKWAVE LITHOTRIPSY OF SALIVARY DUCT STONES	LANCET			English	Article								Surgical extirpation of the affected gland has been necessary for cases of sialolithiasis in which the stone cannot be removed by dilatation or dissection of the salivary duct. The ability of the piezoelectric lithotripter to deliver shockwaves to a small focus makes extracorporeal shockwave lithotripsy of salivary gland stones potentially safe. Its safety and efficacy have been assessed in 51 patients with symptomatic solitary salivary stones that could not be removed by conservative measures. The stones had a median diameter of 8 (range 4-18) mm and were located in the submandibular gland in 69% of patients and in the parotid gland in 31%. A total of 72 shockwave treatment sessions (maximum 3 per patient) were given under continuous sonographic monitoring. In 45 patients (88%) complete fragmentation (fragments less-than-or-equal-to 3 mm) of the concrements was achieved. No patient needed anaesthesia, sedatives, or analgesics. The only untoward effects were localised petechial haemorrhages after 10 (13%) out of 72 treatments and transient swelling of the gland immediately after delivery of shockwave in 2/72 (3%) sessions. 20 weeks after the first session 90% (46/51) of patients were free of discomfort, and 53% (27/51) were stone free. Stone-clearance rate was higher among patients with stones in the parotid gland (81%) than among those with stones of the submandibular gland (40%). Auxiliary measures such as dilatation or dissection of the salivary duct were required only in patients with stones in the submandibular gland (20%). No long-term damage to the treated salivary gland or to adjacent tissue structures was noted during the median follow-up of 9 (1-24) months. Extracorporeal piezoelectric shockwave therapy seems likely to be a safe, comfortable, and effective minimally-invasive, non-surgical treatment for salivary stones.	UNIV ERLANGEN NURNBERG, DEPT MED, W-8520 ERLANGEN, GERMANY	University of Erlangen Nuremberg	IRO, H (corresponding author), UNIV ERLANGEN NURNBERG, DEPT OTORHINOLARYNGOL HEAD & NECK SURG, W-8520 ERLANGEN, GERMANY.							COLEMAN AJ, 1989, ULTRASOUND MED BIOL, V15, P213, DOI 10.1016/0301-5629(89)90066-5; EPKER BN, 1972, ORAL SURG ORAL MED O, V33, P2, DOI 10.1016/0030-4220(72)90203-4; IRO H, 1989, LANCET, V2, P114; IRO H, 1991, J LITHOTR STONE DIS, V3, P211; IRO H, 1990, LARYNGO RHINO OTOL, V69, P102, DOI 10.1055/s-2007-998153; KENEFICK JS, 1961, BRIT J SURG, V48, P435; PATEY DAVID H., 1961, BRIT JOUR SURG, V48, P435, DOI 10.1002/bjs.18004821015; PATEY DH, 1981, OPERATIVE SURGERY HE, P835; Rauch S, 1970, THOMAS ORAL PATHOLOG, P962; SEIFERT G, 1986, DIS SALIVARY GLANDS, P91; SELDIN HM, 1953, ORAL SURG ORAL MED O, V6, P579, DOI 10.1016/0030-4220(53)90160-1; SEWARD GR, 1968, ORAL SURG ORAL MED O, V26, P137, DOI 10.1016/0030-4220(68)90242-9	12	101	103	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1992	339	8805					1333	1336		10.1016/0140-6736(92)91968-E	http://dx.doi.org/10.1016/0140-6736(92)91968-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349999				2022-12-28	WOS:A1992HW83700011
J	JEANRENAUD, X; GOY, JJ; KAPPENBERGER, L				JEANRENAUD, X; GOY, JJ; KAPPENBERGER, L			EFFECTS OF DUAL-CHAMBER PACING IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY	LANCET			English	Article							ECHOCARDIOGRAPHY; VERAPAMIL; MOTION	Although attempts have been made to treat hypertrophic obstructive cardiomyopathy with right ventricular pacing, the usual treatment for those refractory to medical therapy is open heart surgery. To assess in detail the value of non-surgical therapy the effects of acute and long-term dual-chamber pacing were investigated in 13 patients with hypertrophic obstructive cardiomyopathy refractory to medical treatment. In the first part of the study, atrioventricular (AV) sequential pacing was found to reduce peak subaortic pressure gradient in 12 of the 13 patients, from 82 (SD 42) to 47 (34) mm Hg (p < 0.002), without concomitantly reducing aortic blood pressure or cardiac output. This effect was related to AV interval. In the second part of the study, a dual-chamber pacemaker was implanted in 8 patients and programmed to the optimum AV interval for the individual (50-90 ms). Patients were followed up for up to 62 months. Pacing resulted in a significant and long-lasting reduction in severity of angina pectoris (from NYHA class 3 to 1) and dyspnoea (from NYHA class 3 to 2). Echocardiography showed no significant change in septal thickness or left ventricular contractility but there was a trend to a spontaneous decrease in obstruction. In patients with hypertrophic obstructive cardiomyopathy, synchronised and ventricular pacing at optimum AV interval for the individual reduces the intraventricular pressure gradient and improves functional tolerance. Since the effect is longlasting, such pacing should be deemed an alternative therapy to surgery in selected cases.			JEANRENAUD, X (corresponding author), CHU VAUDOIS,DEPT INTERNAL MED,DIV CARDIOL,CH-1011 LAUSANNE,SWITZERLAND.							ASKENAZI J, 1984, AM J CARDIOL, V53, P99, DOI 10.1016/0002-9149(84)90691-X; BONOW RO, 1983, AM J CARDIOL, V51, P1386, DOI 10.1016/0002-9149(83)90317-X; CANNON RO, 1987, J AM COLL CARDIOL, V10, P53, DOI 10.1016/S0735-1097(87)80159-6; COHEN LS, 1967, CIRCULATION, V35, P847, DOI 10.1161/01.CIR.35.5.847; Duck H J, 1984, Z Gesamte Inn Med, V39, P437; GOMES JAC, 1977, AM J CARDIOL, V39, P641, DOI 10.1016/S0002-9149(77)80123-9; Hassenstein P, 1967, Verh Dtsch Ges Kreislaufforsch, V33, P242; Hassenstein P, 1975, Thoraxchir Vask Chir, V23, P496; IWASE M, 1986, AM J CARDIOL, V58, P104, DOI 10.1016/0002-9149(86)90251-1; JANOSIK DL, 1989, J AM COLL CARDIOL, V14, P499, DOI 10.1016/0735-1097(89)90208-8; KALTENBACH M, 1979, BRIT HEART J, V42, P35; KRACJER Z, 1988, CIRCULATION S1, V78, P35; LEVINE RA, 1989, CIRCULATION S2, V80, P662; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MCDONALD K, 1988, EUR HEART J, V9, P893, DOI 10.1093/oxfordjournals.eurheartj.a062584; MCINTOSH CL, 1988, CIRCULATION, V78, P487, DOI 10.1161/01.CIR.78.3.487; POLLICK C, 1988, AM J CARDIOL, V62, P1252, DOI 10.1016/0002-9149(88)90269-X; POLLICK C, 1984, CIRCULATION, V69, P43, DOI 10.1161/01.CIR.69.1.43; Rothlin M, 1971, Verh Dtsch Ges Kreislaufforsch, V37, P411; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SPIRITO P, 1987, AM J CARDIOL, V60, P123, DOI 10.1016/0002-9149(87)90998-2; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; ZILE MR, 1987, J AM COLL CARDIOL, V10, P702, DOI 10.1016/S0735-1097(87)80215-2; 1989, J AM SOC ECHO, V2, P358	24	238	251	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1318	1323		10.1016/0140-6736(92)91961-7	http://dx.doi.org/10.1016/0140-6736(92)91961-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349992				2022-12-28	WOS:A1992HW83700004
J	BROOK, CGD				BROOK, CGD			DIABETES - WHAT SORT OF PREVENTION	LANCET			English	Editorial Material											BROOK, CGD (corresponding author), UCL, DEPT PAEDIAT ENDOCRINOL, LONDON WC1, ENGLAND.								0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1156	1157		10.1016/0140-6736(92)90745-O	http://dx.doi.org/10.1016/0140-6736(92)90745-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349378				2022-12-28	WOS:A1992HT23600015
J	DRUSANO, GL; YUEN, GJ; LAMBERT, JS; SEIDLIN, M; DOLIN, R; VALENTINE, FT				DRUSANO, GL; YUEN, GJ; LAMBERT, JS; SEIDLIN, M; DOLIN, R; VALENTINE, FT			RELATIONSHIP BETWEEN DIDEOXYINOSINE EXPOSURE, CD4 COUNTS, AND P24 ANTIGEN LEVELS IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A PHASE-I TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						ANTIGENS, CD4; LYMPHOCYTES-T; DIDEOXYINOSINE; HUMAN IMMUNODEFICIENCY VIRUS; ANTIGENS, P24	AIDS-RELATED COMPLEX; ZIDOVUDINE; AZT	Objective: To determine the relation between exposure to dideoxyinosine (ddI) and increased CD4 cell counts and suppression of serum p24 antigen in patients infected with the human immunodeficiency virus (HIV). Design: Open-label, phase I study. Setting: Two university hospital. Patients were studied in both inpatient and outpatient settings. Patients: Of 36 HIV-infected patients enrolled, 18 had adequate pharmacokinetic information for analysis. Intervention: Dideoxyinosine was administered intravenously every 12 hours for 2 weeks. Patients were switched or oral administration at twice the intravenous dose. Pharmacokinetic profiles were obtained twice during each period. A 40-fold range of dose was examined. Measurements: CD4-positive T-lymphocyte counts and serum p24 antigen levels were determined. Plasma area under the ddl concentration-time curve was determined for a single dose and at steady state. Results: Increases in CD4-positive T-lymphocyte counts were independent of ddI exposure and were proportional to the starting CD4 count. Suppression of circulating p24 antigen was influenced by cumulative exposure to ddI and was statistically significant. Conclusions: The CD4-positive T-lymphocyte count increased at low ddl concentrations or exposures; the extent of this increase was directly proportional to the patient's CD4 count at the start of therapy. Suppression of p24 antigen was related to cumulative exposure to ddI. Therapeutic responses can probably be obtained with ddI, while minimizing long-term toxicity, using daily doses of 10 mg/kg body weight, or less.	UNIV MARYLAND, SCH PHARM, BALTIMORE, MD 21201 USA; UNIV ROCHESTER, MED CTR, SCH MED & DENT, ROCHESTER, NY 14642 USA; NYU MED CTR, SCH MED, DEPT MED, NEW YORK, NY 10016 USA	University System of Maryland; University of Maryland Baltimore; University of Rochester; New York University	DRUSANO, GL (corresponding author), UNIV MARYLAND, SCH MED, DIV INFECT DIS, PROGRAM CLIN PHARMACOL, 10 S PINE ST, BALTIMORE, MD 21201 USA.			lambert, john/0000-0001-5404-2415; Valentine, Fred/0000-0002-6046-5913				AHLUWALJA G, 1988, P AM ASSOC CANC RES, V29, P349; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; DARGENIO DZ, 1989, ADAPT 2 USERS MANUAL; DRUSANO GL, 1990, 30TH INT C ANT AG CH; EGORIN MJ, 1985, CANCER RES, V45, P6502; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; GILTINAN DM, 1989, J PHARMACOKINET BIOP, V17, P601, DOI 10.1007/BF01071352; KNUPP CA, 1991, CLIN PHARMACOL THER, V49, P523, DOI 10.1038/clpt.1991.63; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MERIGAN TC, 1990, AM J MED, V88, pS11, DOI 10.1016/0002-9343(90)90415-A; RICHMAN DD, 1987, NEW ENGL J MED, V23, P317; ROCCI ML, 1983, COMPUT PROG BIOMED, V16, P203, DOI 10.1016/0010-468X(83)90082-X; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450; YARCHOAN R, 1990, LANCET, V336, P526, DOI 10.1016/0140-6736(90)92085-V	17	51	51	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					562	566		10.7326/0003-4819-116-7-562	http://dx.doi.org/10.7326/0003-4819-116-7-562			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1347442				2022-12-28	WOS:A1992HL25800007
J	COLOMBO, MI; MAYORGA, LS; CASEY, PJ; STAHL, PD				COLOMBO, MI; MAYORGA, LS; CASEY, PJ; STAHL, PD			EVIDENCE OF A ROLE FOR HETEROTRIMERIC GTP-BINDING PROTEINS IN ENDOSOME FUSION	SCIENCE			English	Article							ENDOCYTIC PATHWAYS; PERTUSSIS TOXIN; INVITRO; TRANSPORT; LOCALIZATION; STIMULATION; TRANSDUCERS; MASTOPARAN; MECHANISM; SYSTEMS	Guanosine triphosphate (GTP)-binding proteins are required for intracellular vesicular transport. Mastoparan is a peptide component of wasp venom that increases nucleotide exchange in some classes of G-alpha-subunits of regulatory heterotrimeric GTP-binding proteins (G proteins). Mastoparan and other compounds that increase nucleotide exchange by G proteins inhibited endosome fusion in vitro and reversed the effects of guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S), a nonhydrolyzable GTP analog. Addition of beta-gamma-subunits of G proteins to the fusion assay antagonized the stimulatory effect of GTP-gamma-S, confirming the participation of G proteins. These results indicate that GTP-binding proteins are required for endosome fusion and in particular that a G protein is involved. Given the function of G proteins in signal transduction, these findings may provide insight into the mechanism by which endosomal vesicles become competent for fusion after their formation at the cell surface.	NATL UNIV CUYO,CONSEJO NACL CIENT & TECN,FAC CIENCIAS MED,INST HISTOL & EMBRIOL,RA-5500 MENDOZA,ARGENTINA; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; Duke University; Duke University	COLOMBO, MI (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110, USA.		Stahl, Philip/D-6315-2012	Mayorga, Luis S/0000-0002-5995-0671; Casey, Patrick/0000-0002-7366-9309	NIAID NIH HHS [AI 20015] Funding Source: Medline; NIGMS NIH HHS [GM 42259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI N, 1989, BIOCHEM J, V261, P905, DOI 10.1042/bj2610905; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1987, NATURE, V328, P112, DOI 10.1038/328112a0; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; COLOMBO MG, UNPUB; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, J BIOL CHEM, V264, P13171; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KOCH G, 1991, FEBS LETT, V291, P336, DOI 10.1016/0014-5793(91)81315-Y; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TUICHIBAEV M U, 1988, Biokhimiya, V53, P219; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751	31	140	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1695	1697		10.1126/science.1348148	http://dx.doi.org/10.1126/science.1348148			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1348148				2022-12-28	WOS:A1992HK81200034
J	WARLOW, C				WARLOW, C			SECONDARY PREVENTION OF STROKE	LANCET			English	Article							TRANSIENT ISCHEMIC ATTACKS; OXFORDSHIRE; PROGNOSIS; PROJECT				WARLOW, C (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; DUNBABIN DW, 1990, STROKE, V21, P36; DUTCH TIA, 1991, NEW ENGL J MED, V325, P1261; HANKEY GJ, 1991, J NEUROL NEUROSUR PS, V54, P793, DOI 10.1136/jnnp.54.9.793; HANKEY GJ, IN PRESS J NEUROL NE; HUNTER GC, 1987, ARCH SURG-CHICAGO, V122, P311; KRUL JMJ, 1989, STROKE, V20, P324, DOI 10.1161/01.STR.20.3.324; LOFTUS CM, 1987, NEUROSURGERY, V20, P490, DOI 10.1227/00006123-198703000-00026; PATRONO C, 1989, TRENDS PHARMACOL SCI, V10, P453, DOI 10.1016/S0165-6147(89)80010-0; WARLOW C, 1982, RECENT ADV CLIN NEUR, V3, P191; WARLOW CP, TICLOPIDINE NEW ANTI, P185; 1991, LANCET, V337, P1235; 1991, J NEUROL NEUROSUR PS, V54, P1044; 1988, BRIT MED J, V296, P320; 1985, NEW ENGL J MED, V313, P1191; 1991, LANCET, V338, P1345; 1991, NEW ENGL J MED, V325, P445	20	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					724	727		10.1016/0140-6736(92)90608-6	http://dx.doi.org/10.1016/0140-6736(92)90608-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347592				2022-12-28	WOS:A1992HK32000013
J	WALSH, KP; SREERAM, N; FRANKS, R; ARNOLD, R				WALSH, KP; SREERAM, N; FRANKS, R; ARNOLD, R			BALLOON DILATATION OF THE ARTERIAL DUCT IN CONGENITAL HEART-DISEASE	LANCET			English	Note							INTERRUPTED AORTIC-ARCH; PROSTAGLANDIN-E1	The systemic circulation of newborn infants with congenital left-heart obstruction is supplied from the right ventricle via a patent arterial duct between the pulmonary artery and descending aorta. The duct closes during the first few days of life, but infusion of prostaglandin E2 can prevent closure in some cases. We report four newborn infants (aged 3-8 days) with intractable heart failure due to severe obstruction of the left heart in the presence of a closing arterial duct. Infusion of prostaglandin E2 did not improve their clinical condition. Cardiac catheterisation and balloon dilatation of their arterial ducts resulted in a dramatic improvement in the babies' clinical condition; during subsequent surgical repair of the infants' hearts, the arterial ducts were found to be widely patent. Balloon dilatation gives immediate and sustained wide patency of the arterial duct in infants who do not respond adequately to prostaglandin E2.			WALSH, KP (corresponding author), ROYAL LIVERPOOL CHILDRENS HOSP,HEART CLIN,LIVERPOOL L12 2AP,ENGLAND.							COLLINSNAKAI RL, 1976, J PEDIATR-US, V88, P959, DOI 10.1016/S0022-3476(76)81049-9; FREED MD, 1981, CIRCULATION, V64, P899, DOI 10.1161/01.CIR.64.5.899; LANG P, 1977, J PEDIATR-US, V91, P805, DOI 10.1016/S0022-3476(77)81047-0; RADFORD DJ, 1976, LANCET, V2, P95	4	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					331	332		10.1016/0140-6736(92)91648-R	http://dx.doi.org/10.1016/0140-6736(92)91648-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346412				2022-12-28	WOS:A1992HC77100005
J	TAMKUN, JW; DEURING, R; SCOTT, MP; KISSINGER, M; PATTATUCCI, AM; KAUFMAN, TC; KENNISON, JA				TAMKUN, JW; DEURING, R; SCOTT, MP; KISSINGER, M; PATTATUCCI, AM; KAUFMAN, TC; KENNISON, JA			BRAHMA - A REGULATOR OF DROSOPHILA HOMEOTIC GENES STRUCTURALLY RELATED TO THE YEAST TRANSCRIPTIONAL ACTIVATOR SNF2 SW12	CELL			English	Article							DOSAGE-DEPENDENT MODIFIERS; BITHORAX COMPLEX GENES; ANTENNAPEDIA GENE; SACCHAROMYCES-CEREVISIAE; MOLECULAR ANALYSIS; SPATIAL REGULATION; TRITHORAX GENES; SELECTOR GENE; FUSHI-TARAZU; 2 PROMOTERS	The brahma (brm) gene is required for the activation of multiple homeotic genes in Drosophila. Loss-of-function brm mutations suppress mutations in Polycomb, a repressor of homeotic genes, and cause developmental defects similar to those arising from insufficient expression of the homeotic genes of the Antennapedia and Bithorax complexes. The brm gene encodes a 1638 residue protein that is similar to SNF2/SWI2, a protein involved in transcriptional activation in yeast, suggesting possible models for the role of brm in the transcriptional activation of homeotic genes. In addition, both brm and SNF2 contain a 77 amino acid motif that is found in other Drosophila, yeast, and human regulatory proteins and may be characteristic of a new family of regulatory proteins.	UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA; INDIANA UNIV, HOWARD HUGHES MED INST, BLOOMINGTON, IN 47405 USA; INDIANA UNIV, GENET PROGRAM, BLOOMINGTON, IN 47405 USA; UNIV ALBERTA, DEPT GENET, EDMONTON T6G 2E9, ALBERTA, CANADA; NICHHD, MOLEC GENET LAB, BETHESDA, MD 20892 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Alberta; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	TAMKUN, JW (corresponding author), UNIV CALIF SANTA CRUZ, DEPT BIOL, SANTA CRUZ, CA 95064 USA.							ABBOTT MK, 1986, GENETICS, V114, P919; ABRAMS E, 1986, MOL CELL BIOL, V6, P3643, DOI 10.1128/MCB.6.11.3643; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BUSTURIA A, 1988, DEVELOPMENT, V104, P713; CABRERA CV, 1985, NATURE, V318, P569, DOI 10.1038/318569a0; CAPDEVILA MP, 1981, ROUX ARCH DEV BIOL, V190, P339, DOI 10.1007/BF00863271; CASTELLIGAIR JE, 1990, EMBO J, V9, P4267, DOI 10.1002/j.1460-2075.1990.tb07875.x; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; DUNCAN I, 1986, CELL, V47, P297, DOI 10.1016/0092-8674(86)90452-6; Duncan I., 1982, DEV ORDER ITS ORIGIN, P533; ENGELS WR, 1986, FOCUS, V8, P6; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORQUIGNON F, 1981, ROUX ARCH DEV BIOL, V190, P132, DOI 10.1007/BF00867798; FRISCHER LE, 1986, CELL, V47, P1017, DOI 10.1016/0092-8674(86)90816-0; HAPPEL AM, 1991, GENETICS, V128, P69; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HAYNES SR, 1989, DEV BIOL, V134, P246, DOI 10.1016/0012-1606(89)90094-8; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HUANG D, 1990, New Biologist, V2, P163; INGHAM PW, 1985, COLD SPRING HARB SYM, V50, P201, DOI 10.1101/SQB.1985.050.01.026; INGHAM PW, 1986, NATURE, V324, P592, DOI 10.1038/324592a0; INGHAM PW, 1983, NATURE, V306, P591, DOI 10.1038/306591a0; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; JACK T, 1988, GENE DEV, V2, P635, DOI 10.1101/gad.2.6.635; JORGENSEN EM, 1987, GENE DEV, V1, P544, DOI 10.1101/gad.1.6.544; Kaufman T C, 1990, Adv Genet, V27, P309; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KENNISON JA, 1987, GENETICS, V116, P75; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LEWIS RA, 1980, GENETICS, V95, P383; LINDSLEY D, 1987, DROS INF SERV, V65; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MCKEON J, 1991, ROUX ARCH DEV BIOL, V199, P387, DOI 10.1007/BF01705848; MCKEOWN M, 1987, CELL, V48, P489, DOI 10.1016/0092-8674(87)90199-1; NEIGEBORN L, 1984, GENETICS, V108, P845; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PATTATUCCI AM, 1991, IN PRESS GENETICS; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PUSTELL J, 1982, NUCLEIC ACIDS RES, V10, P4765, DOI 10.1093/nar/10.15.4765; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1987, GENETICS, V116, P389; SCHNEUWLY S, 1987, EMBO J, V6, P201, DOI 10.1002/j.1460-2075.1987.tb04739.x; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHEARN A, 1989, GENETICS, V121, P517; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; STRUHL G, 1981, NATURE, V292, P635, DOI 10.1038/292635a0; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TAMKUN JW, 1984, P NATL ACAD SCI-BIOL, V81, P5140, DOI 10.1073/pnas.81.16.5140; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WINSTON F, 1987, GENETICS, V115, P649; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0	67	809	835	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					561	572		10.1016/0092-8674(92)90191-E	http://dx.doi.org/10.1016/0092-8674(92)90191-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1346755				2022-12-28	WOS:A1992HD39800015
J	GROSS, E; GOLDBERG, D; LEVITZKI, A				GROSS, E; GOLDBERG, D; LEVITZKI, A			PHOSPHORYLATION OF THE SACCHAROMYCES-CEREVISIAE CDC25 IN RESPONSE TO GLUCOSE RESULTS IN ITS DISSOCIATION FROM RAS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; YEAST; EXCHANGE; KINASE	IN the yeast Sacchromyces cerevisiae, addition of glucose to starved cells triggers a transient rise in the intracellular level of cyclic AMP that induces a protein phosphorylation cascade1. The glucose signal is processed by the Cdc25/Ras/adenylyl cyclase pathway2, where the role of Cdc25 is to catalyse the GDP-GTP exchange on Ras3. The molecular mechanisms involved in the regulation of the activity of Cdc25 are unknown. We report here the use of highly selective anti-Cdc25 antibodies4 to demonstrate that Cdc25 is a phospho protein and that in response to glucose it is hyperphosphorylated, within seconds, by the cyclic AMP-dependent protein kinase. It is also demonstrated that, concomitantly with hyperphosphorylation, Cdc25 partially relocalizes to the cytoplasm, reducing its accessibility to membrane-bound Ras. These results are of general significance because of the highly conserved sequence of Ras-guanyl nucleotide exchange factors from yeasts to mammals.	HEBREW UNIV JERUSALEM, ALEXANDER SILBERMAN INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem	LEVITZKI, A (corresponding author), HEBREW UNIV JERUSALEM, ALEXANDER SILBERMAN INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL.							CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; DUFAU ML, 1977, P NATL ACAD SCI USA, V74, P3419, DOI 10.1073/pnas.74.8.3419; ENGELBERG D, 1989, CELL SIGNAL, V1, P1, DOI 10.1016/0898-6568(89)90015-6; ERASO P, 1985, FEBS LETT, V191, P51, DOI 10.1016/0014-5793(85)80991-1; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GROSS E, 1992, MOL CELL BIOL, V12, P2653, DOI 10.1128/MCB.12.6.2653; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MBONYI K, 1990, MOL CELL BIOL, V10, P4518, DOI 10.1128/MCB.10.9.4518; MUNDER T, 1989, FEBS LETT, V242, P341, DOI 10.1016/0014-5793(89)80498-3; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931; RUBIN GM, 1973, J BIOL CHEM, V248, P3860; SCHOMERUS C, 1990, MOL GEN GENET, V223, P426, DOI 10.1007/BF00264449; SEGAL M, IN PRESS J BIOL CHEM; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7	18	79	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 24	1992	360	6406					762	765		10.1038/360762a0	http://dx.doi.org/10.1038/360762a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1334534				2022-12-28	WOS:A1992KE47200041
J	BRAHAMS, D				BRAHAMS, D			LIFE-SUSTAINING TREATMENT FOR BRAIN-DAMAGED CHILD	LANCET			English	Editorial Material																			0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1472	1473		10.1016/0140-6736(92)92052-H	http://dx.doi.org/10.1016/0140-6736(92)92052-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351139				2022-12-28	WOS:A1992HY31700017
J	JONES, MH; JENKINS, D; CUZICK, J; WOLFENDALE, MR; JONES, JJ; BALOGUNLYNCH, C; USHERWOOD, MM; SINGER, A				JONES, MH; JENKINS, D; CUZICK, J; WOLFENDALE, MR; JONES, JJ; BALOGUNLYNCH, C; USHERWOOD, MM; SINGER, A			MILD CERVICAL DYSKARYOSIS - SAFETY OF CYTOLOGICAL SURVEILLANCE	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; ATYPIA; COLPOSCOPY; EXPERIENCE; DIAGNOSIS; SMEARS	How best to manage women who are found on cervical screening to have mild dyskaryosis remains controversial. Cytological surveillance misses some lesions picked up by colposcopy, but colposcopy is emotionally traumatic for women, the majority of whom will have a normal result. To determine what proportion of lesions are missed by cytological surveillance, and whether any abnormalities persist after colposcopy, we studied, by means of colposcopy and biopsy, the prevalence of cervical intraepithelial neoplasia (CIN) and subclinical human papillomavirus infection (HPVI) in two groups of patients who had had a first smear showing mild dyskaryosis at least 24 months earlier. One group was recruited from a centre practising cytological surveillance, with colposcopy for patients showing persistent or progressive cytological abnormality. The other group all had early colposcopy and treatment. Of 214 patients recruited into the cytological surveillance group, 70 (33%) had been referred for colposcopy within 24 months. Colposcopy of the remaining 144 (after a mean interval of 27 months from presentation) revealed that 54 (38%) were disease free, 64 (44%) had HPVI/CIN1, 8 (6%) had CIN2, and 18 (12%) had CIN3. A smear at that time identified 12 of the 18 (67%) with CIN3 as needing close cytological follow-up (1 patient) or prompt referral for colposcopy (11 patients). 137 women in the early colposcopy group attended for the study colposcopy (after a mean interval of 32 months from presentation). 37% were found to have some abnormality persisting after an earlier colposcopy, but none had CIN3. Cytological surveillance of mild dyskaryosis resulted in a 12% risk of patients having a small CIN3 lesion after 2 years, but this risk was reduced to 4% by the addition of a third repeat smear 12 months after the second. With such a policy only about a third of women would require colposcopy, and the risk of missing serious underlying precancerous changes would be low.	LEICESTER DIST HLTH AUTHOR,20-28 PRINCESS RD W,LEICESTER LE1 6TY,ENGLAND; ROYAL NO HOSP,DEPT COLPOSCOPY,LONDON N7 6LD,ENGLAND; ROYAL NO HOSP,DEPT OBSTET & GYNAECOL,LONDON N7 6LD,ENGLAND; WHITTINGTON HOSP,DEPT HISTOPATHOL,LONDON N19 5NF,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; STOKE MANDEVILLE HOSP,DEPT CYTOL,AYLESBURY,BUCKS,ENGLAND; STOKE MANDEVILLE HOSP,DEPT OBSTET & GYNAECOL,AYLESBURY,BUCKS,ENGLAND; MILTON KEYNES DIST GEN HOSP,DEPT OBSTET & GYNAECOL,MILTON KEYNES,BUCKS,ENGLAND	University of London; University College London; Cancer Research UK								BIGRIGG MA, 1990, LANCET, V336, P229, DOI 10.1016/0140-6736(90)91746-W; BUCKLEY CH, 1982, J CLIN PATHOL, V35, P1, DOI 10.1136/jcp.35.1.1; CAMPION MJ, 1986, LANCET, V2, P237; CAMPION MJ, 1988, BRIT J OBSTET GYNAEC, V95, P175, DOI 10.1111/j.1471-0528.1988.tb06848.x; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; JARMULOWICZ MR, 1989, BRIT J OBSTET GYNAEC, V96, P1061, DOI 10.1111/j.1471-0528.1989.tb03381.x; JENKINS D, 1988, BRIT MED J, V297, P918, DOI 10.1136/bmj.297.6653.918-a; Jenkinson E J, 1990, Semin Immunol, V2, P51; JORDAN JA, 1988, BRIT MED J, V297, P6, DOI 10.1136/bmj.297.6640.6; MCCORMICK JS, 1989, LANCET, V2, P207; MCDONALD TW, 1989, GYNECOL ONCOL, V34, P345, DOI 10.1016/0090-8258(89)90170-4; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; Posner T, 1988, PREVENTION CERVICAL; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SANDMIRE HF, 1976, OBSTET GYNECOL, V48, P56; SMITH A, 1988, BRIT MED J, V296, P1670, DOI 10.1136/bmj.296.6637.1670; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; TAY SK, 1987, AUST NZ J OBSTET GYN, V27, P140; 1987, REPORT INTERCOLLEGIA	20	57	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1440	1443		10.1016/0140-6736(92)92031-A	http://dx.doi.org/10.1016/0140-6736(92)92031-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351129				2022-12-28	WOS:A1992HY31700004
J	BLAU, JN				BLAU, JN			MIGRAINE - THEORIES OF PATHOGENESIS	LANCET			English	Article							CEREBRAL BLOOD-FLOW; XE-133 INHALATION; DOUBLE-BLIND; DURA MATER; HEADACHES; ATTACKS; EXTRAVASATION; PAIN				BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND.							ANTHONY M, 1969, RESEARCH CLINICAL ST, V2, P29; BICKERSTAFF ER, 1975, NEUROLOGICAL COMPLIC, P81; BILLE B, 1962, ACTA PAEDIATR S S136, V51, P3; BLAU JN, 1981, CEPHALALGIA, V1, P143, DOI 10.1046/j.1468-2982.1981.0103143.x; BLAU JN, 1991, CEPHALALGIA, V11, P229; BLAU JN, 1970, LANCET, V2, P241; BLAU JN, 1985, J ROY COLL PHYS LOND, V19, P166; Blau JN, 1987, MIGRAINE CLIN THERAP, P3; BLAU JN, IN PRESS PATHOL BIOL; Blau Joseph N., 1987, MIGRAINE CLIN RES AS, P241; BRUYN GW, 1984, PHARM BASIS MIGRAINE, P267; BUZZI MG, 1990, BRIT J PHARMACOL, V99, P202, DOI 10.1111/j.1476-5381.1990.tb14679.x; COUCH JR, 1983, HEADACHE, V23, P94; DALESSIO DJ, 1982, CEREBRAL HYPOXIA PAT, P28; EADIE MJ, 1985, BIOCH MIGRAINE, P1; EKBOM K, 1991, NEW ENGL J MED, V325, P322, DOI 10.1056/nejm199108013250505; FEATHERSTONE HJ, 1986, HEADACHE, V26, P39, DOI 10.1111/j.1526-4610.1986.hed2601039.x; FERRARI MD, 1991, NEW ENGL J MED, V325, P316; Fisher C M, 1971, Clin Neurosurg, V18, P267; GLOOR P, 1986, TRENDS NEUROSCI, V9, P21, DOI 10.1016/0166-2236(86)90008-1; GOWERS WR, 1988, MANUAL DISEASES NERV, P776; HANINGTON E, 1967, BMJ-BRIT MED J, V2, P550; HAWKING SW, 1988, BRIEF HIST TIME, P9; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; Leao AAP, 1944, J NEUROPHYSIOL, V7, P391, DOI 10.1152/jn.1944.7.6.391; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LIVEING E, 1873, MEGRIM SICK HEADACHE, P26; MACGREGOR EA, 1990, CEPHALALGIA, V10, P305, DOI 10.1046/j.1468-2982.1990.1006305.x; MARTINS I, 1989, HEADACHE, V29, P660, DOI 10.1111/j.1526-4610.1989.hed2910660.x; MOFFETT A, 1972, J NEUROL NEUROSUR PS, V35, P496, DOI 10.1136/jnnp.35.4.496; MOFFETT AM, 1974, J NEUROL NEUROSUR PS, V37, P445, DOI 10.1136/jnnp.37.4.445; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; MRSULJA BB, 1973, SLEEP PHYSL BIOCH PS, P271; OLESEN J, 1990, ANN NEUROL, V28, P791, DOI 10.1002/ana.410280610; OSTFELD AM, 1960, JAMA-J AM MED ASSOC, V174, P1188, DOI 10.1001/jama.1960.63030090011010; POINCARE H, 1952, SCI HYPOTHESIS, P142; SAITO K, 1988, ANN NEUROL, V24, P732, DOI 10.1002/ana.410240607; SAKAI F, 1978, HEADACHE, V18, P122, DOI 10.1111/j.1526-4610.1978.hed1803122.x; SOKOLOFF L, 1983, HDB NEUROCHEMISTRY, V3, P225; SOMERVILLE BW, 1972, NEUROLOGY, V22, P824, DOI 10.1212/WNL.22.8.824; WAELKENS J, 1982, BRIT MED J, V284, P944, DOI 10.1136/bmj.284.6320.944; WATERS WE, 1983, BRIT MED J, V287, P1442, DOI 10.1136/bmj.287.6403.1442; WOLFF HG, 1963, HEADACHE OTHER HEAD, P269	43	127	129	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1202	1207		10.1016/0140-6736(92)91140-4	http://dx.doi.org/10.1016/0140-6736(92)91140-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349944				2022-12-28	WOS:A1992HU68400010
J	RAMSAY, LE; YEO, WW; JACKSON, PR				RAMSAY, LE; YEO, WW; JACKSON, PR			CORONARY ATHEROMA REGRESSION TRIALS	LANCET			English	Letter											RAMSAY, LE (corresponding author), UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; TYROLER HA, 1989, AM J MED, V87, pS14, DOI 10.1016/S0002-9343(89)80594-7	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1241	1242						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349984				2022-12-28	WOS:A1992HU68400058
J	MALAFOSSE, A; LEHESJOKI, AE; GENTON, P; LABAUGE, P; DURAND, G; TASSINARI, CA; DRAVET, C; MICHELUCCI, R; DELACHAPELLE, A				MALAFOSSE, A; LEHESJOKI, AE; GENTON, P; LABAUGE, P; DURAND, G; TASSINARI, CA; DRAVET, C; MICHELUCCI, R; DELACHAPELLE, A			IDENTICAL GENETIC-LOCUS FOR BALTIC AND MEDITERRANEAN MYOCLONUS	LANCET			English	Note								Genetic linkage analysis shows that Baltic and Mediterranean myoclonus, two forms of progressive myoclonus epilepsy, are closely linked to marker D21S113 on the long arm of chromosome 21. Baltic and Mediterranean myoclonus are most probably due to mutations of the same gene.	CNRS, UPR 8402, INSERM, U249, F-34060 MONTPELLIER, FRANCE; UNIV HELSINKI, DEPT MED GENET, SF-00290 HELSINKI 29, FINLAND; CTR ST PAUL, F-13009 MARSEILLE, FRANCE; HOP INSTRUCT ARMEES VAL DE GRACE, SERV NEUROPHYSIOL, F-75005 PARIS, FRANCE; UNIV BOLOGNA, BELLARIA HOSP, DEPT NEUROL, I-40126 BOLOGNA, ITALY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Helsinki; Val-de-Grace Hospital; AUSL di Bologna; University of Bologna			Michelucci, Roberto/AAB-9074-2020	Tassinari, Carlo Alberto/0000-0002-4183-5165; Michelucci, Roberto/0000-0002-9655-7940				BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506; ELRIDGE R, 1983, LANCET, V2, P838; GENTON P, 1990, ACTA NEUROL SCAND, V81, P8; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LEHESJOKI AE, 1992, NEUROLOGY, V42, P1545, DOI 10.1212/WNL.42.8.1545; LEHESJOKI AE, 1991, P NATL ACAD SCI USA, V88, P3696, DOI 10.1073/pnas.88.9.3696; PATTERSON D, 1991, CYTOGENET CELL GENET, V58, P168; TASSINARI C A, 1991, Neurology, V41, P281; 1990, ANN NEUROL, V28, P113	9	55	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1080	1081		10.1016/0140-6736(92)90667-R	http://dx.doi.org/10.1016/0140-6736(92)90667-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349105				2022-12-28	WOS:A1992HR44600006
J	OPPENHEIMER, S; HACHINSKI, V				OPPENHEIMER, S; HACHINSKI, V			COMPLICATIONS OF ACUTE STROKE	LANCET			English	Article							INFARCTION		JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON N6A 3K7,ONTARIO,CANADA	Johns Hopkins University; Western University (University of Western Ontario)	OPPENHEIMER, S (corresponding author), JOHNS HOPKINS UNIV HOSP,CEREBROVASC PROGRAM,MEYER 5-181,600 N WOLFE ST,BALTIMORE,MD 21205, USA.							BARER DH, 1989, J NEUROL NEUROSUR PS, V52, P236, DOI 10.1136/jnnp.52.2.236; BLACK SE, 1982, CAN J NEUROL SCI, V9, P291; BRUCE DA, 1979, CEREBROVASC DIS, P191; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; DUTHA AJ, 1987, STROKE, V18, P386; GHANDHAVADI B, 1988, ARCH PHYS MED REHAB, V69, P130; GUPTA SR, 1988, STROKE, V19, P1477, DOI 10.1161/01.STR.19.12.1477; Hachinski V, 1985, ACUTE STROKE; HART RG, 1986, STROKE, V17, P586, DOI 10.1161/01.STR.17.4.586; HELGASON CM, 1988, STROKE, V19, P1049, DOI 10.1161/01.STR.19.8.1049; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; HORNER J, 1988, NEUROLOGY, V38, P1359; HOUSE A, 1990, BRAIN, V113, P1113, DOI 10.1093/brain/113.4.1113; LODDER J, 1988, STROKE, V19, P1482, DOI 10.1161/01.STR.19.12.1482; MELAMED E, 1976, J NEUROL SCI, V29, P267, DOI 10.1016/0022-510X(76)90176-3; MYERS MG, 1981, STROKE, V12, P200, DOI 10.1161/01.STR.12.2.200; NORRIS JW, 1986, BMJ-BRIT MED J, V292, P21, DOI 10.1136/bmj.292.6512.21; OPPENHEIMER SM, 1991, BRAIN RES, V550, P115, DOI 10.1016/0006-8993(91)90412-O; OPPENHEIMER SM, 1990, ARCH NEUROL-CHICAGO, V47, P513, DOI 10.1001/archneur.1990.00530050029008; OPPENHEIMER SM, 1985, BRIT MED J, V291, P1015; POUNGVARIN N, 1987, NEW ENGL J MED, V316, P1229, DOI 10.1056/NEJM198705143162001; REDING MJ, 1986, ARCH NEUROL-CHICAGO, V43, P763, DOI 10.1001/archneur.1986.00520080011011; STARKSTEIN SE, 1988, STROKE, V19, P1491, DOI 10.1161/01.STR.19.12.1491; WARLOW C, 1976, BRIT MED J, V1, P1178, DOI 10.1136/bmj.1.6019.1178; 1984, STROKE, V5, P779	25	96	100	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					721	724		10.1016/0140-6736(92)90607-5	http://dx.doi.org/10.1016/0140-6736(92)90607-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347591	hybrid			2022-12-28	WOS:A1992HK32000012
J	COX, PSV				COX, PSV			PREVENTION VS CURE IN DEVELOPING-COUNTRIES - THE PENDULUM SYNDROME	LANCET			English	Editorial Material											COX, PSV (corresponding author), UNIV LEEDS,DEPT PUBL HLTH MED,TROP HLTH UNIT,20 HYDE TERR,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.								0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					664	665						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH743	1347349				2022-12-28	WOS:A1992HH74300015
J	HAGIWARA, A; TAKAHASHI, T; KOJIMA, O; SAWAI, K; YAMAGUCHI, T; YAMANE, T; TANIGUCHI, H; KITAMURA, K; NOGUCHI, A; SEIKI, K; SAKAKURA, C				HAGIWARA, A; TAKAHASHI, T; KOJIMA, O; SAWAI, K; YAMAGUCHI, T; YAMANE, T; TANIGUCHI, H; KITAMURA, K; NOGUCHI, A; SEIKI, K; SAKAKURA, C			PROPHYLAXIS WITH CARBON-ADSORBED MITOMYCIN AGAINST PERITONEAL RECURRENCE OF GASTRIC-CANCER	LANCET			English	Article							CARCINOMATOUS PERITONITIS; CLINICAL-TRIALS; DOSAGE FORM; STOMACH	Attempts to prevent peritoneal carcinomatosis after surgery for gastric cancer by intraperitoneal administration of anticancer drugs have not been successful, largely because the drugs are not retained in the peritoneal cavity. We have assessed the prophylactic efficacy of a delayed-release preparation mitomycin adsorbed onto activated charcoal (M-CH). 50 patients with gastric cancer and serosal infiltration were randomly assigned intraperitoneal treatment with M-CH (50 mg mitomycin intraoperatively) or no anticancer prophylaxis (control). Survival rates for the 3 years of follow-up were significantly higher among the 24 M-CH recipients (1 was lost to follow-up) than among the 25 controls (p < 0.01). There were significant differences in survival between the groups at 1.5 years after randomisation (difference 34.6% [95% confidence interval 8.5-60.8%]; p < 0.01) and at 2.0, 2.5, and 3.0 years (41.7% [14.2-69.1%]; p < 0.005). The concentration of mitomycin was significantly higher in peritoneal exudate than in plasma for 24 h after drug administration. Side-effects were slight and well tolerated. Thus, peroperative intraperitoneal treatment with M-CH seems to improve survival after gastrectomy for gastric cancer, presumably by a prophylactic effect on peritoneal recurrence.			HAGIWARA, A (corresponding author), KYOTO PREFECTURAL UNIV MED, DEPT SURG 1, KAWARAMACHI HIROKOJI, KAMIGYO KU, KYOTO 602, JAPAN.							DUPONT JB, 1978, CANCER-AM CANCER SOC, V41, P941, DOI 10.1002/1097-0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M; HAGIWARA A, 1987, ANTICANCER RES, V7, P167; HAGIWARA A, 1988, SURGERY, V104, P874; HAGIWARA A, 1987, CANCER, V59, P245, DOI 10.1002/1097-0142(19870115)59:2<245::AID-CNCR2820590212>3.0.CO;2-K; HAGIWARA A, 1987, ANTICANCER RES, V7, P105; HAGIWARA A, 1986, ANTICANCER RES, V6, P1161; HAGIWARA A, 1983, AKITA J MED, V10, P187; IITSUKA Y, 1979, J JPN SURG SOC, V80, P442; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MIYAMURA S, 1961, J ANTIBIOT B, V14, P251; MOORE GE, 1961, SURG GYNECOL OBSTET, V112, P469; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RUSZNYAK I, 1967, LYMPHATICS LYMPH CIR, P495; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; Suzuki H, 1983, Int Adv Surg Oncol, V6, P271; YAMADA E, 1980, INT SURG, V65, P387	16	164	167	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 14	1992	339	8794					629	631		10.1016/0140-6736(92)90792-2	http://dx.doi.org/10.1016/0140-6736(92)90792-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347336				2022-12-28	WOS:A1992HH74300001
J	HJELLE, B; APPENZELLER, O; MILLS, R; ALEXANDER, S; TORREZMARTINEZ, N; JAHNKE, R; ROSS, G				HJELLE, B; APPENZELLER, O; MILLS, R; ALEXANDER, S; TORREZMARTINEZ, N; JAHNKE, R; ROSS, G			CHRONIC NEURODEGENERATIVE DISEASE ASSOCIATED WITH HTLV-II INFECTION	LANCET			English	Note								Although human T-cell leukaemia virus (HTLV) type I is known to cause a number of diseases, there has been no convincing evidence of pathological changes after infection with the related virus, HTLV-II. We have found an endemic focus of HTLV-II infection among members of an American Indian population in New Mexico, USA. We set out to determine the pathological consequences of HTLV-II infection in this population and identified two sisters (aged 59 and 46 years) with a disease superficially resembling the myeloneuropathy induced by HTLV-I. These women had a syndrome similar to the olivopontocerebellar atrophy variant of multiple system atrophy, and HTLV-II infection was confirmed by western blot and the polymerase chain reaction. Thus, HTLV-II may, like HTLV-I, cause a progressive neurodegenerative disease.	UNIV NEW MEXICO, SCH MED, DEPT MICROBIOL, ALBUQUERQUE, NM 87131 USA; LOVELACE BIOMED RES FDN, ALBUQUERQUE, NM USA; CAMBRIDGE SCI, ROCKVILLE, MD USA; PUBL HLTH SERV CLIN, JEMEZ, NM USA; UNITED BLOOD SERV, ALBUQUERQUE, NM USA	University of New Mexico; Lovelace Respiratory Research Institute	HJELLE, B (corresponding author), UNIV NEW MEXICO, SCH MED, DEPT PATHOL, ALBUQUERQUE, NM 87131 USA.				NCI NIH HHS [CA55480] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGER JR, 1991, NEUROLOGY, V41, P85, DOI 10.1212/WNL.41.1.85; HENEINE W, 1991, NEW ENGL J MED, V324, P565, DOI 10.1056/NEJM199102213240815; HENEINE W, 1991, LANCET, V338, P944, DOI 10.1016/0140-6736(91)91808-8; HJELLE B, 1991, J INFECT DIS, V163, P435, DOI 10.1093/infdis/163.3.435; HJELLE B, 1991, ARCH PATHOL LAB MED, V115, P440; KIRA JI, 1991, LANCET, V338, P64, DOI 10.1016/0140-6736(91)90065-W; LILLEHOJ EP, 1990, J CLIN MICROBIOL, V28, P2653, DOI 10.1128/JCM.28.12.2653-2658.1990; LIPKA JJ, 1992, J INFECT DIS, V165, P268, DOI 10.1093/infdis/165.2.268	8	246	249	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 14	1992	339	8794					645	646		10.1016/0140-6736(92)90797-7	http://dx.doi.org/10.1016/0140-6736(92)90797-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347339				2022-12-28	WOS:A1992HH74300005
J	HUANG, YQ; LI, JJ; RUSH, MG; POIESZ, BJ; NICOLAIDES, A; JACOBSON, M; ZHANG, WG; COUTAVAS, E; ABBOTT, MA; FRIEDMANKIEN, AE				HUANG, YQ; LI, JJ; RUSH, MG; POIESZ, BJ; NICOLAIDES, A; JACOBSON, M; ZHANG, WG; COUTAVAS, E; ABBOTT, MA; FRIEDMANKIEN, AE			HPV-16-RELATED DNA-SEQUENCES IN KAPOSIS-SARCOMA	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; ENDEMIC AFRICAN; HOMOSEXUAL MEN; CELLS; ASSOCIATION; CANCER; GROWTH; AMPLIFICATION; VIRUS; RISK	In the USA, Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS-KS) is ten times more common in homosexual or bisexual men than in heterosexual men with AIDS. One explanation for this finding is that AIDS-KS may be caused by an infectious agent. Because there is a high incidence of human papillomavirus (HPV) infection, especially HPV-16, in homosexual men, we have sought HPV DNA sequences in Kaposi's sarcoma. We used the polymerase chain reaction with a primer pair specific for the highly conserved E6 region of HPV-16 to detect HPV-16 homologous DNA fragments in tumour tissues from 97 patients with KS and in KS-derived cell cultures. HPV DNA sequences were found in 11 of 69 KS skin tumours from homosexual men with AIDS-KS, in 3 of 11 KS biopsy specimens from homosexual men who had no clinical or laboratory evidence of HIV-infection, and in 5 of 17 KS skin lesions from HIV-1-negative elderly men and women with classic KS. The same primer pair amplified HPV-16 homologous fragments from two different continuous cell cultures derived from pleural effusion fluid of patients with pulmonary AIDS-KS and two continuous cell cultures derived from KS skin lesions. The findings suggest that HPV-16-related DNA sequences are associated with different forms of KS and may have a role in the pathogenesis of this neoplasm.	NYU MED CTR, DEPT MICROBIOL, 550 1ST AVE, NEW YORK, NY 10016 USA; NYU MED CTR, DEPT DERMATOL, NEW YORK, NY 10016 USA; NYU, SCH MED, NEW YORK, NY 10003 USA; SUNY HLTH SCI CTR, DEPT MED, DIV ONCOL, SYRACUSE, NY USA	New York University; New York University; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center				Coutavas, Elias/0000-0003-4904-0081; Friedman Kien, Alvin/0000-0002-5854-2852				ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; AMBINDER RF, 1987, J INFECT DIS, V156, P193, DOI 10.1093/infdis/156.1.193; ASHINOFF R, 1991, ARCH DERMATOL, V127, P1813, DOI 10.1001/archderm.127.12.1813; BARBOSA MS, 1991, J VIROL, V65, P292, DOI 10.1128/JVI.65.1.292-298.1991; BAYLEY AC, 1985, LANCET, V1, P359; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BIGGAR RJ, 1985, J NATL CANCER I, V74, P793; BOOTH M, 1989, LANCET, V1, P616; BOSCH FX, 1990, J VIROL, V64, P4743, DOI 10.1128/JVI.64.10.4743-4754.1990; BOVI PD, 1986, CANCER RES, V46, P6333; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FOLKMAN J, 1990, AIDS RES HUM RETROV, V6, P107; FRAZER IH, 1986, LANCET, V2, P657; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; FRIEDMANKIEN AE, 1990, J AM ACAD DERMATOL, V22, P1237, DOI 10.1016/0190-9622(90)70169-I; LEY C, 1991, JNCI-J NATL CANCER I, V83, P997, DOI 10.1093/jnci/83.14.997; LI JJ, 1990, LANCET, V335, P1590; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; NICKOLOFF BJ, 1992, LANCET, V339, P548, DOI 10.1016/0140-6736(92)90364-9; NICKOLOFF BJ, 1989, SCIENCE, V243, P1736, DOI 10.1126/science.2564703; SAFAI B, 1981, CANCER, V31, P3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCINICARIELLO F, 1991, LANCET, V337, P501, DOI 10.1016/0140-6736(91)93446-G; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; VILLA LL, 1991, VIROLOGY, V181, P374; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990	34	113	115	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 29	1992	339	8792					515	518		10.1016/0140-6736(92)90338-4	http://dx.doi.org/10.1016/0140-6736(92)90338-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346878	hybrid			2022-12-28	WOS:A1992HF63100003
J	WONG, YH; CONKLIN, BR; BOURNE, HR				WONG, YH; CONKLIN, BR; BOURNE, HR			GZ-MEDIATED HORMONAL INHIBITION OF CYCLIC-AMP ACCUMULATION	SCIENCE			English	Article							NUCLEOTIDE-BINDING PROTEINS; PERTUSSIS TOXIN; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; MOLECULAR-CLONING; ADP-RIBOSYLATION; PHOSPHOLIPASE-C; GS-ALPHA; RECEPTOR; SITE	Hormones inhibit synthesis of adenosine 3',5' monophosphate (cAMP) in most cells via receptors coupled to pertussis toxin (PTX)-sensitive guanine nucleotide-binding (G) proteins. Mutationally activated alpha-subunits of G(i2) (alpha(i2)) constitutively inhibit cAMP accumulation when transfected into cells. Cells have now been transfected with mutant alpha-subunits of four other G proteins-G(z), a PTX-insensitive G protein of unknown function, and G(i1), G(i3), and G(o), which are PTX-sensitive. Mutant alpha(z), alpha(i1), and alpha(i3) inhibited cAMP accumulation but alpha(o) did not. Moreover, expression of wild-type alpha(z) produced cells in which PTX did not block hormonal inhibition of cAMP accumulation. Thus, G(z) can trigger an effector pathway in response to hormone receptors that ordinarily interact with PTX-sensitive G(i) proteins.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061				BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DIAZLAVIADA I, 1991, J BIOL CHEM, V266, P1170; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HINTON DR, 1990, J NEUROSCI, V10, P2763; HSU WH, 1990, J BIOL CHEM, V265, P11220; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES SB, 1991, MOL PHARMACOL, V39, P239; KATADA T, 1986, J BIOL CHEM, V261, P5215; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAHAN LC, 1991, MOL PHARMACOL, V440, P1; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NAMBI P, 1988, BIOCHEM J, V254, P449, DOI 10.1042/bj2540449; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PARKER EM, 1991, J BIOL CHEM, V266, P519; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; WONG Y, UNPUB; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	36	250	254	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1992	255	5042					339	342		10.1126/science.1347957	http://dx.doi.org/10.1126/science.1347957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ695	1347957				2022-12-28	WOS:A1992GZ69500045
J	SPEISER, DE; STUBI, U; ZINKERNAGEL, RM				SPEISER, DE; STUBI, U; ZINKERNAGEL, RM			EXTRATHYMIC POSITIVE SELECTION OF ALPHA-BETA-T-CELL PRECURSORS IN NUDE-MICE	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; BONE-MARROW TRANSPLANTATION; CYTOLYTIC LYMPHOCYTE-T; ANTIGEN RECEPTOR; NEGATIVE SELECTION; SELF-RECOGNITION; IMMUNE-RESPONSE; THYMUS GRAFTS; VIRUS; SPECIFICITY	T LYMPHOCYTES expressing alpha-beta-T-cell receptors with sufficient affinity to major histocompatibility complex (MHC) molecules expressed on thymus epithelial cells are positively selected and mature to functional T cells 1-6. But several studies have demonstrated that athymic nude mice 7-9 grafted with MHC-incompatible thymuses developed T cells specific for nude host rather than thymic MHC 10-14. We examined this paradox by analysing the specificity of T lymphocytes derived from nude mice. We report here that nude T lymphocyte precursors transferred to allogeneic SCID (severe combined immunodeficiency) mice with a functioning thymus (but lacking T or B cells 15-17) generated host MHC-restricted effector T cells but also contained T cells restricted to donor MHC. If nude T cells were depleted from nude lymphohaemopoietic donor cells before or after transfer, only host MHC-specific T cells matured. The results may explain the unusual MHC specificities of nude T lymphocytes described in earlier studies 10-14 and demonstrate two separate differentiation steps: in nude mice, T cells may be positively. selected for self-MHC restriction specificity extrathymically; then a functional thymus is required for efficient T cell maturation.			SPEISER, DE (corresponding author), UNIV HOSP ZURICH,INST PATHOL,EXPTL PATHOL LAB,CH-8091 ZURICH,SWITZERLAND.		Speiser, Daniel E./F-2173-2013					ANDO I, 1981, NATURE, V289, P494, DOI 10.1038/289494a0; BEVAN MJ, 1978, IMMUNOL REV, V42, P4; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; CHARAN S, 1986, J IMMUNOL, V136, P3057; FRY AM, 1989, SCIENCE, V246, P1044, DOI 10.1126/science.2511630; GILLIS S, 1979, J EXP MED, V149, P1460, DOI 10.1084/jem.149.6.1460; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; HAMAOKA T, 1973, J EXP MED, V137, P1393, DOI 10.1084/jem.137.6.1393; HEDRICK SM, 1979, J EXP MED, V150, P646, DOI 10.1084/jem.150.3.646; HODES RJ, 1989, SCIENCE, V246, P1041, DOI 10.1126/science.2587987; HUNIG T, 1980, J EXP MED, V152, P688, DOI 10.1084/jem.152.3.688; ISHIKAWA H, 1980, J EXP MED, V151, P965, DOI 10.1084/jem.151.4.965; KAST WM, 1984, J EXP MED, V160, P1752, DOI 10.1084/jem.160.6.1752; KEEVER CA, 1989, BLOOD, V73, P1340; Kindred B, 1979, Prog Allergy, V26, P137, DOI 10.1159/000314466; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KLEIN JR, 1986, J EXP MED, V164, P309, DOI 10.1084/jem.164.1.309; KRUISBEEK AM, 1981, J IMMUNOL, V127, P2168; LAKE JP, 1980, J EXP MED, V152, P1805, DOI 10.1084/jem.152.6.1805; LAKE JP, 1991, CELL IMMUNOL, V135, P259, DOI 10.1016/0008-8749(91)90270-L; LONGO DL, 1985, P NATL ACAD SCI USA, V82, P5900, DOI 10.1073/pnas.82.17.5900; LOOR F, 1976, EUR J IMMUNOL, V6, P663, DOI 10.1002/eji.1830060914; MACDONALD HR, 1987, J EXP MED, V166, P195, DOI 10.1084/jem.166.1.195; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MARYANSKI JL, 1981, J IMMUNOL, V126, P871; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PANTELOURIS EM, 1971, IMMUNOLOGY, V20, P247; RAFF MC, 1973, NATURE, V246, P350, DOI 10.1038/246350a0; ROCHA B, 1990, EUR J IMMUNOL, V20, P919, DOI 10.1002/eji.1830200430; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SOIFFER RJ, 1990, BLOOD, V75, P2076; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; STUTMAN O, 1978, IMMUNOL REV, V42, P138, DOI 10.1111/j.1600-065X.1978.tb00261.x; Wortis H H, 1974, Contemp Top Immunobiol, V3, P243; ZINKERNAGEL RM, 1988, J EXP MED, V168, P1187, DOI 10.1084/jem.168.3.1187; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZINKERNAGEL RM, 1979, J EXP MED, V150, P693, DOI 10.1084/jem.150.3.693; ZINKERNAGEL RM, 1980, J EXP MED, V151, P376, DOI 10.1084/jem.151.2.376	46	40	40	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1992	355	6356					170	172		10.1038/355170a0	http://dx.doi.org/10.1038/355170a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY629	1346064				2022-12-28	WOS:A1992GY62900061
J	SIEGFRIED, E; CHOU, TB; PERRIMON, N				SIEGFRIED, E; CHOU, TB; PERRIMON, N			WINGLESS SIGNALING ACTS THROUGH ZESTE-WHITE 3, THE DROSOPHILA HOMOLOG OF GLYCOGEN-SYNTHASE KINASE-3, TO REGULATE ENGRAILED AND ESTABLISH CELL FATE	CELL			English	Article							SEGMENT-POLARITY GENE; SITE-SPECIFIC RECOMBINATION; PROTEIN-KINASE; SPATIAL-DISTRIBUTION; MULTIPLE FUNCTIONS; MOLECULAR-CLONING; LETHAL MUTATIONS; NERVOUS-SYSTEM; PATCHED GENE; EXPRESSION	Intrasegmental patterning in the Drosophila embryo is regulated by cell-cell communication. One of the signaling pathways that operates to specify positional information throughout the segment is mediated by the wingless (wg) protein, which is the homolog of the proto-oncogene Wnt-1. The early role of wg is to stabilize engrailed (en) expression by initiating a phase of en autoregulation in the adjacent more posterior cells. Here, we report that the segment polarity gene zeste-white 3 (zw3; also known as shaggy) acts as a repressor of en autoregulation. Genetic epistasis experiments indicate that wg signaling operates by inactivating the zw3 repression of en autoactivation. In addition, we demonstrate that zw3 encodes the Drosophila homolog of mammalian glycogen synthase kinase-3.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	SIEGFRIED, E (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.		Chou, Tze-Bin/S-1188-2017	Chou, Tze-Bin/0000-0003-2453-0164; Perrimon, Norbert/0000-0001-7542-472X				AKAM M, 1987, DEVELOPMENT, V101, P1; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHOU TB, 1992, GENETICS, V131, P643; DEGROOT RP, 1992, IN PRESS ONCOGENE; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, IN PRESS NATURE; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FRASCH M, 1988, GENE DEV, V2, P1824, DOI 10.1101/gad.2.12b.1824; GAY NJ, 1988, NUCLEIC ACIDS RES, V16, P6637, DOI 10.1093/nar/16.14.6637; GERGEN J P, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P49; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KORNBERG T, 1981, DEV BIOL, V86, P363, DOI 10.1016/0012-1606(81)90194-9; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOORDERMEER J, 1992, IN PRESS DEVELOPMENT; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; PERRIMON N, 1989, GENETICS, V121, P333; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROBERTSON HM, 1988, GENETICS, V118, P461; SAKSELA K, 1992, ONCOGENE, V7, P347; Sambrook J, 1989, MOL CLONING LABORATO; SHANNON MP, 1972, GENETICS, V72, P615; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1988, DEVELOPMENT, V103, P391; SIMPSON P, 1989, DEVELOPMENT, V106, P57; Spradling AC, 1986, P ELEMENT MEDIATED T, P175; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	74	368	375	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1167	1179		10.1016/S0092-8674(05)80065-0	http://dx.doi.org/10.1016/S0092-8674(05)80065-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335365				2022-12-28	WOS:A1992KE60400011
J	BERATAN, DN; ONUCHIC, JN; WINKLER, JR; GRAY, HB				BERATAN, DN; ONUCHIC, JN; WINKLER, JR; GRAY, HB			ELECTRON-TUNNELING PATHWAYS IN PROTEINS	SCIENCE			English	Article							CYTOCHROME-C PEROXIDASE; TEMPERATURE; COMPLEXES		UNIV CALIF SAN DIEGO, DEPT PHYS, LA JOLLA, CA 92093 USA; CALTECH, BECKMAN INST, PASADENA, CA 91125 USA	University of California System; University of California San Diego; California Institute of Technology	BERATAN, DN (corresponding author), UNIV PITTSBURGH, DEPT CHEM, PITTSBURGH, PA 15260 USA.		Beratan, David N/C-5098-2011; Winkler, Jay R/B-7372-2009	Beratan, David N/0000-0003-4758-8676; 				BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; EVEREST AM, 1991, J AM CHEM SOC, V113, P4337, DOI 10.1021/ja00011a050; HAHM S, 1992, BIOCHEMISTRY-US, V31, P3472, DOI 10.1021/bi00128a022; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCLENDON G, 1992, CHEM REV, V92, P481, DOI 10.1021/cr00011a007; MCLENDON G, 1991, STRUCT BOND, V75, P159; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NOCEK JM, 1991, J AM CHEM SOC, V113, P6822, DOI 10.1021/ja00018a017; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; POULOS TL, 1987, J BIOL CHEM, V262, P13881; TURRO C, 1992, J AM CHEM SOC, V114, P4013, DOI 10.1021/ja00036a081; WALLIN SA, 1991, J AM CHEM SOC, V113, P1842, DOI 10.1021/ja00005a065; WUTTKE DS, 1992, BIOCHIM BIOPHYS ACTA, V1101, P168; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007	18	494	494	2	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1992	258	5089					1740	1741		10.1126/science.1334572	http://dx.doi.org/10.1126/science.1334572			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1334572				2022-12-28	WOS:A1992KB96400024
J	NOEL, GL; HERBERS, JE; CAPLOW, MP; COOPER, GS; PANGARO, LN; HARVEY, J				NOEL, GL; HERBERS, JE; CAPLOW, MP; COOPER, GS; PANGARO, LN; HARVEY, J			HOW WELL DO INTERNAL-MEDICINE FACULTY MEMBERS EVALUATE THE CLINICAL SKILLS OF RESIDENTS	ANNALS OF INTERNAL MEDICINE			English	Article						INTERNSHIP AND RESIDENCY; FACULTY, MEDICAL; CLINICAL COMPETENCE; VIDEOTAPE RECORDING; PHYSICAL EXAMINATION	STANDARDIZED PATIENTS; SURGICAL RESIDENTS; SIMULATED PATIENTS; 4TH-YEAR STUDENTS; AMERICAN-BOARD; PERFORMANCE; COMPETENCE; CERTIFICATION; RELIABILITY; PROGRAM	Objective: To determine the accuracy of faculty evaluations of residents' clinical skills and whether a structured form and instructional videotape improve accuracy. Design: Randomized, controlled trial. Setting. Twelve university and community teaching hospitals. Participants: A total of 203 faculty internists. Interventions: Participants watched a videotape of one of two residents performing new patient workups. Participants were assigned to one of three groups: They used either an open-ended evaluation form or a structured form that prompted detailed observations; some participants used the structured form after seeing a videotape showing good evaluation techniques. Main Outcome Measures: Faculty observations of strengths and weaknesses in the residents' performance were scored. An accuracy score consisting of clinical skills of critical importance for a competent history and physical examination was calculated for each participant by raters blinded to the participants' hospital, training, subspecialty, and experience as observers. Results: When observations were not prompted, participants recorded only 30% of the residents' strengths and weaknesses; accuracy among participants using structured forms increased to 60% or greater. Faculty in university hospitals were more accurate than those in community hospitals, and general internists were more accurate than subspecialists; the structured form improved performance in all groups. However, participants disagreed markedly about the residents' overall clinical competence: Thirty-one percent assessed one resident's clinical skills as unsatisfactory or marginal, whereas 69% assessed them as satisfactory or superior; 48% assessed the other resident's clinical skills as unsatisfactory or marginal, whereas 52% assessed them as satisfactory or superior. Participants also disagreed about the residents' humanistic qualities. The instructional videotape did not improve accuracy. Conclusions: A structured form improved the accuracy of observations of clinical skills, but faculty still disagreed in their assessments of clinical competence. If program directors are to certify residents' clinical competence, better and more standardized evaluation is needed.	WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA; UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of North Carolina; University of North Carolina Chapel Hill; Dartmouth College; Uniformed Services University of the Health Sciences - USA								BARROWS HS, 1987, J MED EDUC, V62, P805; BLANK LL, 1984, J MED EDUC, V59, P401; CALHOUN JG, 1987, J MED EDUC, V62, P754; COHEN R, 1990, AM J SURG, V160, P302, DOI 10.1016/S0002-9610(06)80029-2; DAY SC, 1990, J GEN INTERN MED, V5, P421, DOI 10.1007/BF02599432; DUNNINGTON G, 1990, AM J SURG, V159, P423, DOI 10.1016/S0002-9610(05)81289-9; ELLIOT DL, 1987, JAMA-J AM MED ASSOC, V258, P3405, DOI 10.1001/jama.258.23.3405; FEINSTEIN A, 1985, CLIN EPIDEMIOLOGY AR, V184, P638; HARDEN RM, 1979, MED EDUC, V13, P41; HARDEN RM, 1975, BRIT MED J, V1, P447, DOI 10.1136/bmj.1.5955.447; HARPER AC, 1983, MED EDUC, V17, P24, DOI 10.1111/j.1365-2923.1983.tb01088.x; HERBERS JE, 1989, J GEN INTERN MED, V4, P202, DOI 10.1007/BF02599524; HOPPE RB, 1990, J GEN INTERN MED, V5, P415, DOI 10.1007/BF02599430; JARSKI RW, 1985, J MED EDUC, V60, P545; KROBOTH FJ, 1985, ARCH INTERN MED, V145, P1121, DOI 10.1001/archinte.145.6.1121; KROBOTH FJ, 1992, IN PRESS J GEN INTER; LINKS PS, 1984, MED EDUC, V18, P46, DOI 10.1111/j.1365-2923.1984.tb01476.x; MILLER GE, 1990, ACAD MED, V65, pS63, DOI 10.1097/00001888-199009000-00045; NORCINI JJ, 1986, J GEN INTERN MED, V1, P166, DOI 10.1007/BF02602331; NORCINI JJ, 1987, J MED EDUC, V62, P457; NORMAN GR, 1982, J MED EDUC, V57, P708; NORMAN GR, 1985, J MED EDUC, V60, P925; NORMAN GR, 1985, MED EDUC, V19, P43, DOI 10.1111/j.1365-2923.1985.tb01137.x; PETRUSA ER, 1990, ARCH INTERN MED, V150, P573, DOI 10.1001/archinte.150.3.573; RISUCCI DA, 1989, SURG GYNECOL OBSTET, V169, P519; ROTER DL, 1990, J GEN INTERN MED, V5, P347, DOI 10.1007/BF02600404; ROTHMAN AI, 1990, ACAD MED, V65, P391, DOI 10.1097/00001888-199006000-00008; RUTALA PJ, 1990, ACAD MED, V65, pS53, DOI 10.1097/00001888-199009000-00041; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; STILLMAN PL, 1990, ACAD MED, V65, P320, DOI 10.1097/00001888-199005000-00013; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; STILLMAN PL, 1989, ACAD MED, V64, P454, DOI 10.1097/00001888-198908000-00008; THOMPSON WG, 1990, J GEN INTERN MED, V5, P214, DOI 10.1007/BF02600537; WEBSTER G, 1985, RESIDENCY DIRECTORS, P123; WOOLLISCROFT JO, 1984, J MED EDUC, V59, P799; 1988, GUIDE EVALUATION RES	36	158	163	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1992	117	9					757	765		10.7326/0003-4819-117-9-757	http://dx.doi.org/10.7326/0003-4819-117-9-757			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV424	1343207				2022-12-28	WOS:A1992JV42400009
J	PAGLIARO, L; DAMICO, G; SORENSEN, TIA; LEBREC, D; BURROUGHS, AK; MORABITO, A; TINE, F; POLITI, F; TRAINA, M				PAGLIARO, L; DAMICO, G; SORENSEN, TIA; LEBREC, D; BURROUGHS, AK; MORABITO, A; TINE, F; POLITI, F; TRAINA, M			PREVENTION OF 1ST BLEEDING IN CIRRHOSIS - A METAANALYSIS OF RANDOMIZED TRIALS OF NONSURGICAL TREATMENT	ANNALS OF INTERNAL MEDICINE			English	Review							PROPHYLACTIC SCLEROTHERAPY; ESOPHAGEAL-VARICES; HEMORRHAGE; PROPRANOLOL; NADOLOL; LIVER	Objective: To assess the effectiveness of beta-blockers and endoscopic sclerotherapy in the prevention of first bleeding and reduction of mortality in patients with cirrhosis and esophagogastric varices. Data Sources: Pertinent studies were selected using MEDLINE (1980 to 1990), reference lists from published articles or reviews, and congress abstract lists. Study Selection: Randomized trials comparing beta-blockers or sclerotherapy with a nonactive treatment. Nine randomized clinical trials of beta-blockers and 19 trials of sclerotherapy were reviewed. Seven trials of beta-blockers and 15 of sclerotherapy were published as full papers. Data Extraction: Crude rates of bleeding and death in treated and control groups were extracted from each trial by three independent observers according to the intention-to-treat principle. The quality of published papers was systematically assessed and scored. Data Synthesis: The Mantel-Haenszel-Peto method was used for statistical evaluation of heterogeneity and for pooling of the results. No substantial heterogeneity was found, and the incidence of bleeding in trials of beta-blockers was significantly reduced (pooled odds ratio, 0.54; 95% Cl, 0.39 to 0.74), particularly in patients with large or medium-sized varices or in those with varices and a hepatic vein pressure gradient above 12 mm Hg; however, only a trend toward reduced mortality was obtained. Solerotherapy trials were highly heterogeneous in the direction of the treatment effects on both bleeding (pooled odds ratio, 0.6; Cl, 0.49 to 0.74) and mortality (pooled odds ratio, 0.76; Cl, 0.61 to 0.94). The quality of the trials and the rate of bleeding in the untreated groups were the major sources of heterogeneity. The favorable results of sclerotherapy were obtained in trials with high bleeding rates among controls; several of these trials had a low quality score. Conclusions: Beta-blockers may be recommended for prevention of first bleeding in cirrhotic patients with varices who have a high risk for bleeding. The effectiveness of sclerotherapy remains undetermined. Further trials in high-risk patients may prove useful if improved criteria to predict bleeding risk become available.	OSPED V CERVELLO, DIV MED GEN, MED CLIN R, VIA TRABUCCO 180, I-90146 PALERMO, ITALY; INST BIOMETRIA, MILAN, ITALY; UNIV COPENHAGEN, HVIDOVRE HOSP, DK-2650 HVIDOVRE, DENMARK; HOP BEAUJON, INSERM, U24, F-92118 CLICHY, FRANCE; ROYAL FREE HOSP, SCH MED, LONDON, ENGLAND	University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			traina, mario/A-1309-2012; Burroughs, Andrew K/C-5645-2009	Burroughs, Andrew K/0000-0001-6527-457X; politi, flavia/0000-0002-6162-8972; Traina, Mario/0000-0001-5041-0858				ANDREANI T, 1990, HEPATOLOGY, V12, P1413, DOI 10.1002/hep.1840120624; BENDSTEN F, 1991, HEPATOLOGY, V14, P1016; BOSCH J, 1984, HEPATOLOGY, V4, P1200, DOI 10.1002/hep.1840040617; BURROUGHS AK, 1992, THERAPY IN LIVER DISEASES, P114; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; COLLINS R, 1985, BMJ-BRIT MED J, V290, P17, DOI 10.1136/bmj.290.6461.17; COLMAN J, 1990, HEPATOLOGY, V12, P851; CONN HO, 1991, HEPATOLOGY, V13, P902, DOI 10.1002/hep.1840130517; DAMICO G, 1990, GASTROENTEROLOGY, V99, P1558, DOI 10.1016/0016-5085(90)90458-D; DEFRANCHIS R, 1991, GASTROENTEROLOGY, V101, P1087; FLEIG WE, 1987, METHODOLOGY REV CLIN, P291; FLEIG WE, 1988, HEPATOLOGY S, V7, pS128; GREGORY PB, 1991, NEW ENGL J MED, V324, P1779; HAYES PC, 1985, GUT, V26, P1103; IDEO G, 1988, HEPATOLOGY, V8, P6, DOI 10.1002/hep.1840080103; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; Kobe E, 1987, Dtsch Z Verdau Stoffwechselkr, V47, P151; KOCH H, 1986, ENDOSCOPY, V18, P40, DOI 10.1055/s-2007-1018322; KORULA J, 1991, GASTROENTEROLOGY, V101, P800, DOI 10.1016/0016-5085(91)90542-S; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEBREC D, 1982, HEPATOLOGY, V2, P523; LEBREC D, 1988, J HEPATOL, V7, P118, DOI 10.1016/S0168-8278(88)80515-4; NICOLUCCI A, 1989, JAMA-J AM MED ASSOC, V262, P2101, DOI 10.1001/jama.262.15.2101; PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71; PAQUET KJ, 1982, ENDOSCOPY, V14, P4, DOI 10.1055/s-2007-1021560; PASCAL JP, 1987, NEW ENGL J MED, V317, P856, DOI 10.1056/NEJM198710013171403; PASTA L, 1989, J HEPATOL, V9, P75; PIAI G, 1988, HEPATOLOGY, V8, P1495, DOI 10.1002/hep.1840080605; PIAI G, 1991, Gastroenterology, V100, pA784; PLANAS R, 1989, Journal of Hepatology, V9, pS73, DOI 10.1016/0168-8278(89)90322-X; POTZI R, 1989, GUT, V30, P873, DOI 10.1136/gut.30.6.873; POYNARD T, 1991, NEW ENGL J MED, V324, P1532, DOI 10.1056/NEJM199105303242202; RUSSO A, 1989, WORLD J SURG, V13, P149, DOI 10.1007/BF01658391; SAGGIORO A, 1986, DIGEST DIS SCI, V31, pS504; SANTANGELO WC, 1988, NEW ENGL J MED, V318, P814, DOI 10.1056/NEJM198803313181304; SAUERBRUCH T, 1988, NEW ENGL J MED, V319, P8, DOI 10.1056/NEJM198807073190102; STRAUSS E, 1988, HEPATOLOGY, V8, P1395; TERBLANCHE J, 1986, LANCET, V1, P961; TRIGER DR, 1991, HEPATOLOGY, V13, P117, DOI 10.1002/hep.1840130117; VOROBIOFF J, 1987, HEPATOLOGY, V7, P648, DOI 10.1002/hep.1840070406; WITZEL L, 1985, LANCET, V1, P773; 1990, NEW ENGL J MED, V322, P863	43	285	292	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					59	70		10.7326/0003-4819-117-1-59	http://dx.doi.org/10.7326/0003-4819-117-1-59			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1350716				2022-12-28	WOS:A1992JA43500011
J	ROTHSTEIN, JD; MARTIN, LJ; KUNCL, RW				ROTHSTEIN, JD; MARTIN, LJ; KUNCL, RW			DECREASED GLUTAMATE TRANSPORT BY THE BRAIN AND SPINAL-CORD IN AMYOTROPHIC-LATERAL-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXCITATORY AMINO-ACIDS; HUNTINGTONS-DISEASE; RAT STRIATUM; D-ASPARTATE; NEUROTOXICITY; INHIBITION; RECEPTORS; DEHYDROGENASE; SYNAPTOSOMES; QUISQUALATE	Background. Amyotrophic lateral sclerosis (ALS) is a chronic degenerative neurologic disorder characterized by the death of motor neurons in the cerebral cortex and spinal cord. Recent studies have suggested that the metabolism of glutamate, a potentially neurotoxic amino acid, is abnormal in patients with ALS. We hypothesized that the high-affinity glutamate transporter is the site of the defect. Methods. We measured high-affinity, sodium-dependent glutamate transport in synaptosomes from neural tissue obtained from 13 patients with ALS, 17 patients with no neurologic disease, and 27 patients with other neurodegenerative diseases (Alzheimer's disease in 15 patients and Huntington's disease in 12 patients). The groups were comparable with respect to age and the interval between death and autopsy. Synaptosomes were prepared from spinal cord, motor cortex, sensory cortex, visual cortex, striatum, and hippocampus. We also measured sodium-dependent transport of gamma-aminobutyric acid and phenylalanine in the synaptosomal preparations. Results. In patients with ALS, there was a marked decrease in the maximal velocity of transport for high-affinity glutamate uptake in synaptosomes from spinal cord (-59 percent, P < 0.001), motor cortex (-70 percent, P < 0.001), and somatosensory cortex (-39 percent, P < 0.05), but not in those from visual cortex, striatum, or hippocampus. The affinity of the transporter for glutamate was not altered. No abnormalities in glutamate transport were found in synaptosomes from patients with other chronic neurodegenerative disorders. The transport of gamma-aminobutyric acid and phenylalanine was normal in patients with ALS. Conclusions. ALS is associated with a defect in high-affinity glutamate transport that has disease, region, and chemical specificity. Defects in the clearance of extracellular glutamate because of a faulty transporter could lead to neurotoxic levels of extracellular glutamate and thus be pathogenic in ALS.	JOHNS HOPKINS UNIV,DEPT NEUROPATHOL,BALTIMORE,MD 21205	Johns Hopkins University	ROTHSTEIN, JD (corresponding author), JOHNS HOPKINS UNIV,DEPT NEUROL,MEYER 5-119,600 N WOLFE ST,BALTIMORE,MD 21205, USA.		rothstein, jeffrey d/C-9470-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001355, R01NS030086] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01355, NS30086] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALCAR VJ, 1977, J NEUROCHEM, V28, P1145, DOI 10.1111/j.1471-4159.1977.tb10682.x; BEBIN EM, 1990, ARCH NEUROL-CHICAGO, V47, P188, DOI 10.1001/archneur.1990.00530020094021; BENJAMIN AM, 1980, J NEUROCHEM, V35, P67, DOI 10.1111/j.1471-4159.1980.tb12490.x; CHASE RA, 1985, NEUROSCI LETT, V55, P89, DOI 10.1016/0304-3940(85)90317-9; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DEBELLEROCHE J, 1984, NEUROCHEM PATHOL, V2, P1; ERECINSKA M, 1990, J NEUROCHEM, V54, P1335, DOI 10.1111/j.1471-4159.1990.tb01967.x; FLETCHER EJ, 1988, BRIT J PHARMACOL, V95, P585, DOI 10.1111/j.1476-5381.1988.tb11680.x; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; HARDY JA, 1986, J NEUROCHEM, V47, P460; Hughes J T, 1982, Adv Neurol, V36, P61; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; MCBEAN GJ, 1985, J NEUROCHEM, V44, P247, DOI 10.1111/j.1471-4159.1985.tb07137.x; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PERRY TL, 1990, NEUROLOGY, V40, P20, DOI 10.1212/WNL.40.1.20; PERRY TL, 1987, NEUROLOGY, V37, P1845, DOI 10.1212/WNL.37.12.1845; PLAITAKIS A, 1980, ANN NEUROL, V7, P297, DOI 10.1002/ana.410070403; PLAITAKIS A, 1988, LANCET, V1, P1015; PLAITAKIS A, 1988, ANN NEUROL, V24, P446, DOI 10.1002/ana.410240314; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; ROTHSTEIN JD, 1985, BIOCHEM PHARMACOL, V34, P73, DOI 10.1016/0006-2952(85)90102-9; ROTHSTEIN JD, 1991, ANN NEUROL, V30, P224, DOI 10.1002/ana.410300223; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; SCHWARCZ R, 1982, NEUROSCIENCE, V7, P1771, DOI 10.1016/0306-4522(82)90034-3; SHAW PJ, 1991, BRAIN RES, V539, P164, DOI 10.1016/0006-8993(91)90701-V; SIMPSON MDC, 1988, BRAIN RES, V462, P76, DOI 10.1016/0006-8993(88)90587-2; SPINK DC, 1986, ANAL BIOCHEM, V158, P79, DOI 10.1016/0003-2697(86)90592-0; STEVENS TJ, 1983, IBRO HDB SERIES METH, V2, P171; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; TESTA D, 1989, J NEUROL, V236, P445, DOI 10.1007/BF00328503; TSAI GC, 1991, BRAIN RES, V556, P151, DOI 10.1016/0006-8993(91)90560-I; URCA G, 1990, BRAIN RES, V529, P7, DOI 10.1016/0006-8993(90)90805-L; VINCENT SR, 1980, BRAIN RES, V184, P99, DOI 10.1016/0006-8993(80)90589-2; WEISS JH, 1989, BRAIN RES, V497, P64, DOI 10.1016/0006-8993(89)90970-0; YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762; ZISKINDCONHAIM L, 1990, J NEUROSCI, V10, P125	38	1023	1042	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1992	326	22					1464	1468		10.1056/NEJM199205283262204	http://dx.doi.org/10.1056/NEJM199205283262204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV469	1349424	Bronze			2022-12-28	WOS:A1992HV46900004
J	KAKOURIS, H; EDDIE, LW; SUMMERS, RJ				KAKOURIS, H; EDDIE, LW; SUMMERS, RJ			CARDIAC EFFECTS OF RELAXIN IN RATS	LANCET			English	Article							CULTURE; UTERUS	Relaxin is usually considered to be a hormone of pregnancy, but porcine relaxin has been shown to increase heart rate in rats. We investigated the cardiac effects of synthetic human gene-2 relaxin (hRlx-2) in vitro in isolated rat atria. Synthetic hRlx-2 produced concentration-dependent positive chronotropic effects in spontaneously beating right atria (EC50 [concentration required to produce 50% of the maximal response] = 0.09 [SE 0.03] nmol/l) and concentration-dependent positive inotropic effects in electrically driven left atria (EC50 = 0.31 [0.02] nmol/l). The potency of hRlx-2 is greater than that of endothelin, angiotensin II, and (-)-isoprenaline in isolated rat atria. Relaxin has powerful chronotropic and inotropic effects on the heart that are probably mediated through a direct action on relaxin receptors.	UNIV MELBOURNE,DEPT PHARMACOL,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,HOWARD FLOREY INST EXPTL PHYSIOL & MED,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne			Summers, Roger J/F-6351-2011	Summers, Roger J/0000-0002-8367-4056				BELL RJ, 1987, OBSTET GYNECOL, V69, P585; HSU CJ, 1985, ENDOCRINOLOGY, V116, P2029, DOI 10.1210/endo-116-5-2029; KRAMER SM, 1990, IN VITRO CELL DEV B, V26, P647; LANGMAN J, 1981, MED EMBRYOLOGY, P74; OSHEROFF PL, IN PRESS P NATL ACAD; PARRY LJ, 1990, J NEUROENDOCRINOL, V2, P53, DOI 10.1111/j.1365-2826.1990.tb00392.x; SANBORN BM, 1980, ENDOCRINOLOGY, V106, P1210, DOI 10.1210/endo-106-4-1210; Sherwood O.D., 1988, P585; STLOUIS J, 1983, BIOL RELAXIN ITS ROL, P128; WEISS G, 1989, BIOL REPROD, V40, P197, DOI 10.1095/biolreprod40.2.197	10	104	106	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1076	1078		10.1016/0140-6736(92)90665-P	http://dx.doi.org/10.1016/0140-6736(92)90665-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349104				2022-12-28	WOS:A1992HR44600004
J	KONG, XP; ONRUST, R; ODONNELL, M; KURIYAN, J				KONG, XP; ONRUST, R; ODONNELL, M; KURIYAN, J			3-DIMENSIONAL STRUCTURE OF THE BETA-SUBUNIT OF ESCHERICHIA-COLI DNA POLYMERASE-III HOLOENZYME - A SLIDING DNA CLAMP	CELL			English	Article							CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; ACCESSORY PROTEINS; PRIMED TEMPLATE; REPLICATION; REFINEMENT; CRYSTALLOGRAPHY; CLONING; BINDING; COMPLEX	The crystal structure of the beta-subunit (processivity factor) of DNA polymerase III holoenzyme has been determined at 2.5 angstrom resolution. A dimer of the beta-subunit (M(r) = 2 x 40.6 kd, 2 x 366 amino acid residues) forms a ring-shaped structure lined by 12-alpha-helices that can encircle duplex DNA. The structure is highly symmetrical, with each monomer containing three domains of identical topology. The charge distribution and orientation of the helices indicate that the molecule functions by forming a tight clamp that can slide on DNA, as shown biochemically. A potential structural relationship is suggested between the beta-subunit and proliferating cell nuclear antigen (PCNA, the eukaryotic polymerase-delta [and epsilon] processivity factor), and the gene 45 protein of the bacteriophage T4 DNA polymerase.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, HEARST RES CTR, DEPT MICROBIOL, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University; Cornell University; Howard Hughes Medical Institute	KONG, XP (corresponding author), ROCKEFELLER UNIV, MOLEC BIOPHYS LAB, NEW YORK, NY 10021 USA.			O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38839, GM 43094] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; Arndt U. W., 1977, ROTATION METHOD CRYS; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1988, XPLOR VERSION 22 MAN; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; FAY PJ, 1981, J BIOL CHEM, V256, P976; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kornberg A., 1991, DNA REPLICATION; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; MAKI S, 1988, J BIOL CHEM, V263, P6561; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; NOSSAL NG, 1984, BACTERIOPHAGE T4; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ODONNELL ME, 1985, J BIOL CHEM, V260, P2884; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511	44	661	675	2	35	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					425	437		10.1016/0092-8674(92)90445-I	http://dx.doi.org/10.1016/0092-8674(92)90445-I			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1349852				2022-12-28	WOS:A1992HT07800006
J	KELLY, RW; LEASK, R; CALDER, AA				KELLY, RW; LEASK, R; CALDER, AA			CHORIODECIDUAL PRODUCTION OF INTERLEUKIN-8 AND MECHANISM OF PARTURITION	LANCET			English	Note							HUMAN-FETAL MEMBRANES; PROGESTERONE; LEUKOCYTES; PREGNANCY	Both prostaglandins and antiprogestagens can induce labour and ripen the cervix, but the mechanisms are unclear. The collagenases that bring about cervical ripening are neutrophil derived. We examined the potential of uterine tissues to control neutrophil attraction by measuring interleukin-8 production. Choriodecidual cells in culture produced substantial amounts of interleukin-8; release was inhibited by progesterone and stimulated by the antiprogestagen mifepristone. Interleukin-8 production was similar in cells from spontaneously delivered placentas and from those obtained at caesarean section. Since prostaglandin E and interleukin-8 have synergistic effects, we suggest that interleukin-8 activity is the final common step of prostaglandin and antiprogestagen action in parturition.	UNIV EDINBURGH,CTR REPROD BIOL,DEPT OBSTET & GYNAECOL,EDINBURGH EH3 9EW,SCOTLAND	University of Edinburgh	KELLY, RW (corresponding author), UNIV EDINBURGH,CTR REPROD BIOL,MRC,REPROD BIOL UNIT,37 CHALMERS ST,EDINBURGH EH3 9EW,SCOTLAND.							CHEUNG PYC, 1990, AM J OBSTET GYNECOL, V163, P1445, DOI 10.1016/0002-9378(90)90603-5; COLDITZ IG, 1990, IMMUNOL CELL BIOL, V68, P397, DOI 10.1038/icb.1990.53; HEGELEHARTUNG C, 1989, HUM REPROD, V4, P369, DOI 10.1093/oxfordjournals.humrep.a136909; JUNQUEIRA LCU, 1980, AM J OBSTET GYNECOL, V138, P273, DOI 10.1016/0002-9378(80)90248-3; KALEY G, 1971, ANN NY ACAD SCI, V180, P338, DOI 10.1111/j.1749-6632.1971.tb53203.x; NAKLA S, 1986, AM J OBSTET GYNECOL, V155, P1337, DOI 10.1016/0002-9378(86)90170-5; ROMERO R, 1990, UTERINE CONTRACTILIT, P353; Roseblade CK, 1990, ACTA OBSTET GYN SCAN, V69, P399, DOI 10.3109/00016349009013301; STAPLES LD, 1983, PLACENTA, V4, P339, DOI 10.1016/S0143-4004(83)80037-X; STITES DP, 1983, IMMUNOL REV, V75, P117, DOI 10.1111/j.1600-065X.1983.tb01093.x	10	139	141	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					776	777		10.1016/0140-6736(92)91896-G	http://dx.doi.org/10.1016/0140-6736(92)91896-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347804				2022-12-28	WOS:A1992HL50100004
J	QUATRARO, A; MINEI, A; DEROSA, N; GIUGLIANO, D				QUATRARO, A; MINEI, A; DEROSA, N; GIUGLIANO, D			CALCITONIN IN PAINFUL DIABETIC NEUROPATHY	LANCET			English	Letter									NAPLES UNIV,FAC MED 1,DEPT GERIATR & METAB DIS,I-80138 NAPLES,ITALY	University of Naples Federico II	QUATRARO, A (corresponding author), DIABET CLIN,TARANTO,ITALY.			Giugliano, Dario/0000-0002-9377-873X				GIUGLIANO D, 1980, LANCET, V1, P653; PIRART J, 1977, DIABETES METAB, V3, P97; ZIELENIEWSKI W, 1990, LANCET, V336, P449, DOI 10.1016/0140-6736(90)92005-3	3	24	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					746	747		10.1016/0140-6736(92)90647-L	http://dx.doi.org/10.1016/0140-6736(92)90647-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347615				2022-12-28	WOS:A1992HK32000044
J	REINHART, WH; BERCHTOLD, PE				REINHART, WH; BERCHTOLD, PE			EFFECT OF HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN THERAPY ON BLOOD RHEOLOGY	LANCET			English	Article							GEOMETRY; ROLES	Stroke has been reported after high-dose intravenous immunoglobulin (IVIG) therapy, so a study was conducted to find out what effect IVIG has on factors influencing blood flow. The influence of IVIG on plasma viscosity, blood viscosity, and erythrocyte aggregation was examined in vitro and in vivo. For the in-vitro experiments different amounts of IVIG were added to whole blood or plasma from healthy subjects. The in-vivo effects were assessed during five courses of treatment with IVIG (24-54 g/day) in 4 patients with chronic immune thrombocytopenia (ITP). Concentration of IgG infused correlated strongly with viscosity of plasma and whole blood, both in vitro and in vivo, and plasma viscosity increased to beyond the normal range after IVIG treatment. The changes in viscosity that occur after IVIG therapy can impair blood flow, and in patients at risk of cardiovascular and thromboembolic events they might be sufficient to produce myocardial infarction or stroke.	UNIV BERN,INSELSPITAL,DEPT INTERNAL MED,CH-3010 BERN,SWITZERLAND	University of Bern; University Hospital of Bern								CHIEN S, 1975, RED BLOOD CELL, P1031; CRAWFORD J, 1985, AM J MED, V79, P13, DOI 10.1016/0002-9343(85)90540-6; REINHART WH, 1990, EUR J CLIN INVEST, V20, P458, DOI 10.1111/j.1365-2362.1990.tb01884.x; REINHART WH, 1985, AM J PHYSIOL, V248, pC473, DOI 10.1152/ajpcell.1985.248.5.C473; REINHART WH, IN PRESS EUR J CLIN; RIENHART WH, IN PRESS J LAB CLIN; Somer T, 1987, Baillieres Clin Haematol, V1, P695, DOI 10.1016/S0950-3536(87)80021-5; WOODRUFF RK, 1986, LANCET, V2, P217	8	171	177	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					662	664		10.1016/0140-6736(92)90806-E	http://dx.doi.org/10.1016/0140-6736(92)90806-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347348				2022-12-28	WOS:A1992HH74300014
J	MURCH, SH; BRAEGGER, CP; SESSA, WC; MACDONALD, TT				MURCH, SH; BRAEGGER, CP; SESSA, WC; MACDONALD, TT			HIGH ENDOTHELIN-1 IMMUNOREACTIVITY IN CROHNS-DISEASE AND ULCERATIVE-COLITIS	LANCET			English	Article							CELLS; REJECTION	Both immunological hypersensitivity and vascular abnormalities have been implicated in the pathogenesis of inflammatory bowel disease. In an attempt to link the two hypotheses, we sought evidence of local production of endothelin-1, a potent vasoconstrictor, in patients with Crohn's disease and ulcerative colitis. An immunohistochemical method was used to detect endothelin-1 in tissue samples from sixteen Crohn's disease patients, nine ulcerative colitis patients, and thirteen controls. In the controls, positively staining cells were infrequent in both lamina propria (mean 0.9% of total cells, 95% confidence interval 0.1-1.7%) and submucosa (2.3%, 0.4-4.1%). The percentage of endothelin-immunoreactive cells was significantly higher in the two disease groups than in the controls. Among the Crohn's disease patients, there were more immunoreactive cells in the submucosa than in the lamina propria (19.1%, 15.2-22.1% vs 12.3%, 8.1-16.5%, p < 0.001), whereas the converse was true for the ulcerative colitis group (8.6%, 1.1-16.1% vs 24.4%, 14.1-34.6%, p < 0.001). Immunoreactive macrophage aggregates around submucosal blood vessels were common in samples from Crohn's disease patients. Endothelin concentrations, measured by radioimmunoassay, in supernatants of homogenised tissue samples were significantly higher in Crohn's disease and ulcerative colitis than in controls. We suggest that local endothelin production by inflammatory cells may contribute to vasculitis in chronic inflammatory bowel disease by inducing intestinal ischaemia through vasoconstriction.	ST BARTHOLOMEWS HOSP, WILLIAM HARVEY RES INST, LONDON EC1A 7BE, ENGLAND	University of London; Queen Mary University London	MURCH, SH (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, DEPT PAEDIAT GASTROENTEROL, LONDON EC1A 7BE, ENGLAND.		Sessa, William C/B-6844-2011; Braegger, Christian Peter/ABC-9884-2021	Sessa, William C/0000-0001-5759-1938; Braegger, Christian/0000-0001-8069-9875	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMBROSIO G, 1991, J CLIN INVEST, V87, P2056, DOI 10.1172/JCI115236; BANERJEE AK, 1990, GASTROENTEROLOGY, V99, P1190, DOI 10.1016/0016-5085(90)90654-J; BUNCHMAN TE, 1991, J CLIN INVEST, V88, P310, DOI 10.1172/JCI115293; CHOY MY, 1990, GUT, V31, P1365, DOI 10.1136/gut.31.12.1365; EBINA T, 1990, JPN J CANCER RES, V81, P1307, DOI 10.1111/j.1349-7006.1990.tb02695.x; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; GASSEL AM, 1990, AM J CLIN PATHOL, V94, P274, DOI 10.1093/ajcp/94.3.274; HALSTENSEN TS, 1990, GASTROENTEROLOGY, V98, P1264, DOI 10.1016/0016-5085(90)90343-Y; HIOKI Y, 1991, BIOCHEM BIOPH RES CO, V174, P446, DOI 10.1016/0006-291X(91)91436-G; INAGAKI H, 1991, GASTROENTEROLOGY, V101, P47, DOI 10.1016/0016-5085(91)90458-W; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISAACSON PG, 1983, PRACTICAL APPLICATIO, P249; KAUFMAN DB, 1990, J EXP MED, V172, P291, DOI 10.1084/jem.172.1.291; KEICHO N, 1991, CELL IMMUNOL, V132, P285, DOI 10.1016/0008-8749(91)90028-A; LEHR HA, 1991, J CLIN INVEST, V87, P2036, DOI 10.1172/JCI115233; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; SANDERSON IR, 1987, ARCH DIS CHILD, V62, P123, DOI 10.1136/adc.62.2.123; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V168, P1230, DOI 10.1016/0006-291X(90)91160-T; SESSA WC, 1991, BIOCHEM BIOPH RES CO, V174, P613, DOI 10.1016/0006-291X(91)91461-K; SESSA WC, IN PRESS J CARDIOVAS; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; VANE JR, 1990, NEW ENGL J MED, V323, P27; VICAUT E, 1991, J CLIN INVEST, V87, P1537, DOI 10.1172/JCI115165; WAKEFIELD AJ, 1989, LANCET, V2, P1057; WAKEFIELD AJ, 1991, GASTROENTEROLOGY, V100, P1279; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZAWA T, 1989, NEUROSCI LETT, V102, P179, DOI 10.1016/0304-3940(89)90075-X; YOSHIZUMI M, 1990, BIOCHEM BIOPH RES CO, V166, P324, DOI 10.1016/0006-291X(90)91948-R	30	132	139	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					381	385		10.1016/0140-6736(92)90077-G	http://dx.doi.org/10.1016/0140-6736(92)90077-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346658				2022-12-28	WOS:A1992HD65900002
J	MEDORI, R; TRITSCHLER, HJ; LEBLANC, A; VILLARE, F; MANETTO, V; CHEN, HY; XUE, R; LEAL, S; MONTAGNA, P; CORTELLI, P; TINUPER, P; AVONI, P; MOCHI, M; BARUZZI, A; HAUW, JJ; OTT, J; LUGARESI, E; AUTILIOGAMBETTI, L; GAMBETTI, P				MEDORI, R; TRITSCHLER, HJ; LEBLANC, A; VILLARE, F; MANETTO, V; CHEN, HY; XUE, R; LEAL, S; MONTAGNA, P; CORTELLI, P; TINUPER, P; AVONI, P; MOCHI, M; BARUZZI, A; HAUW, JJ; OTT, J; LUGARESI, E; AUTILIOGAMBETTI, L; GAMBETTI, P			FATAL FAMILIAL INSOMNIA, A PRION DISEASE WITH A MUTATION AT CODON-178 OF THE PRION PROTEIN GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CREUTZFELDT-JAKOB DISEASE; SCRAPIE PRION	Background. We previously described two members of a family affected by an apparently genetically determined fatal disease characterized clinically by progressive insomnia, dysautonomia, and motor signs and characterized pathologically by severe atrophy of the anterior ventral and mediodorsal thalamic nuclei. Five other family members who died of this disease, which we termed "fatal familial insomnia," had broader neuropathologic changes suggesting that fatal familial insomnia could be a prion disease. Methods. We used antibodies to prion protein (PrP) to perform dot and Western blot analyses, with and without proteinase K, on brain tissue obtained at autopsy from two patients with fatal familial insomnia, three patients with sporadic Creutzfeldt-Jakob disease, and six control subjects. The coding region of the PrP gene was amplified and sequenced in the samples from the two patients with fatal familial insomnia. Restriction-enzyme analysis was carried out with amplified PrP DNA from 33 members of the kindred. Results. Protease-resistant PrP was found in both patients with fatal familial insomnia, but the size and number of protease-resistant fragments differed from those in Creutzfeldt-Jakob disease. In the family with fatal familial insomnia, all 4 affected members and 11 of the 29 unaffected members had a point mutation in PrP codon 178 that results in the substitution of asparagine for aspartic acid and elimination of the Tth111 I restriction site. Linkage analysis showed a close relation between the point mutation and the disease (maximal lod score, 3.4 when theta was zero). Conclusions. Fatal familial insomnia is a prion disease with a mutation in codon 178 of the PrP gene, but the disease phenotype seems to differ from that of previously described kindreds with the same point mutation.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106; COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10027; NEUROL INST,BOLOGNA,ITALY; HOP LA PITIE SALPETRIERE,NEUROL CLIN,F-75651 PARIS 13,FRANCE; HOP LA PITIE SALPETRIERE,LAB NEUROPATHOL R ESCOUROLLE,F-75651 PARIS 13,FRANCE	Case Western Reserve University; Columbia University; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite			Tinuper, Paolo/AAB-7760-2020; Avoni, Patrizia/AAC-1879-2020; Cortelli, Pietro/K-6063-2016	AVONI, PATRIZIA/0000-0003-0719-6803; tinuper, paolo/0000-0002-0588-3063; Cortelli, Pietro/0000-0002-3633-8818	NHGRI NIH HHS [R01 HG000008, UM1 HG006493] Funding Source: Medline; NIA NIH HHS [AG-08012, AG-08992] Funding Source: Medline; NINDS NIH HHS [NS-14509] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000008, UM1HG006493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008992, P50AG008012] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; FRIEDE RL, 1964, ARCH NEUROL-CHICAGO, V10, P181, DOI 10.1001/archneur.1964.00460140067009; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1992, ANN NEUROL, V31, P274, DOI 10.1002/ana.410310308; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; GUIDON G, 1978, THESIS U RENNES RENN; HALTIA M, 1979, Journal of the Neurological Sciences, V42, P381, DOI 10.1016/0022-510X(79)90171-0; HIRAI T, 1989, BRAIN RES REV, V14, P1, DOI 10.1016/0165-0173(89)90007-6; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; KITAMOTO T, 1988, AM J PATHOL, V131, P435; KITAMOTO T, 1991, BRAIN RES, V545, P319, DOI 10.1016/0006-8993(91)91306-L; KOVANEN J, 1988, ACTA NEUROL SCAND, V77, P474, DOI 10.1111/j.1600-0404.1988.tb05943.x; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; MANETTO V, IN PRESS NEUROLOGY; Maniatis T., 1982, MOL CLONING; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MAY WW, 1968, ARCH NEUROL-CHICAGO, V19, P137, DOI 10.1001/archneur.1968.00480020023002; NIETO A, 1991, LANCET, V337, P622, DOI 10.1016/0140-6736(91)91696-R; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; OWEN F, 1991, EXP NEUROL, V112, P240, DOI 10.1016/0014-4886(91)90075-N; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; WEXLER NS, 1991, ANNU REV NEUROSCI, V14, P503, DOI 10.1146/annurev.neuro.14.1.503	27	497	544	1	48	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					444	449		10.1056/NEJM199202133260704	http://dx.doi.org/10.1056/NEJM199202133260704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1346338	Green Accepted			2022-12-28	WOS:A1992HD16400004
J	HUANG, YY; COLINO, A; SELIG, DK; MALENKA, RC				HUANG, YY; COLINO, A; SELIG, DK; MALENKA, RC			THE INFLUENCE OF PRIOR SYNAPTIC ACTIVITY ON THE INDUCTION OF LONG-TERM POTENTIATION	SCIENCE			English	Article							TRANSMISSION; HIPPOCAMPUS; STIMULATION; AFFERENTS; VOLLEYS	Long-term potentiation (LTP) is an extensively studied model of synaptic plasticity, in part because it is a plausible biological correlate for the Hebbian synaptic modification that forms the basis for theoretical models of neural development, learning, and memory. Although these models must incorporate algorithms that constrain synaptic weight changes, physiological evidence for such mechanisms is limited. Examination of LTP in area CA1 of the hippocampus revealed that the threshold for LTP induction was not fixed but could be strongly influenced by the recent history of synaptic activity. This effect was transient, synapse-specific, and dependent on postsynaptic N-methyl-D-aspartate (NMDA) receptor activation. These results suggest that the threshold for LTP induction may be continually adjusted according to the recent history of NMDA receptor activation and provide a physiological mechanism by which LTP can be transiently inhibited.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Colino, Asuncion/H-6970-2017	Colino, Asuncion/0000-0002-7061-9197	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH045334] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45334, MH00942] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAHAM WC, 1986, NEUROSCI LETT, V70, P217, DOI 10.1016/0304-3940(86)90466-0; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLINO A, 1992, J NEUROSCI, V12, P180; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; Gluck M. A., 1990, NEUROSCIENCE CONNECT; HEBB DO, 1949, ORG BEHAVIOR; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; WINSON J, 1986, SCIENCE, V234, P985, DOI 10.1126/science.3775372; YANG XD, 1991, P NATL ACAD SCI USA, V88, P4299, DOI 10.1073/pnas.88.10.4299	18	332	334	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1992	255	5045					730	733		10.1126/science.1346729	http://dx.doi.org/10.1126/science.1346729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC506	1346729				2022-12-28	WOS:A1992HC50600043
J	BLISS, MR				BLISS, MR			ACUTE PRESSURE AREA CARE - PAGET,JAMES LEGACY	LANCET			English	Article							ELDERLY PATIENTS; SORES				BLISS, MR (corresponding author), HACKNEY HOSP,DEPT MED ELDERLY,LONDON E9 6BE,ENGLAND.							BADER DL, 1988, CLIN PHYS PHYSIOL M, V9, P33, DOI 10.1088/0143-0815/9/1/002; BADER DL, 1990, PRESSURE SORES CLIN, P191; BROWNSEQUARD E, 1953, EXPT RES APPLIED PHY, P12; CHARCOT JM, 1877, LECTURES DISEASES NE; GUTTMANN L, 1955, Br J Plast Surg, V8, P196, DOI 10.1016/S0007-1226(55)80037-9; HELLIWELL TR, 1989, BR J HOSP MED, V42, P140; HUNTER J, 1853, WORKS J HUNTER, V1, P247; HUSAIN T, 1953, J PATHOL BACTERIOL, V66, P347, DOI 10.1002/path.1700660203; KOSIAK M, 1961, Arch Phys Med Rehabil, V42, P19; LE KM, 1984, PLAST RECONSTR SURG, V74, P745, DOI 10.1097/00006534-198412000-00001; Munro D, 1940, NEW ENGL J MED, V223, P391, DOI 10.1056/NEJM194009122231101; Paget J., 1873, STUDENTS J HOSP GAZE, V1, P144; PAGET J, 1863, LECTURES SURGICAL PA, P17; Paget James, 1862, BRIT MED J, V2, P155; RICHARDSON RR, 1981, PARAPLEGIA, V19, P235, DOI 10.1038/sc.1981.47; SILVER JR, 1990, PRESSURE SORES SPINA, P97; SINCLAIR AJ, 1990, BRIT J HOSP MED, V43, P334; VERSLUYSEN M, 1986, BRIT MED J, V292, P1311, DOI 10.1136/bmj.292.6531.1311; VERSLUYSEN M, 1985, J BONE JOINT SURG BR, V67, P10, DOI 10.1302/0301-620X.67B1.3968129; 1990, LANCET, V335, P1311	20	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					221	223		10.1016/0140-6736(92)90016-V	http://dx.doi.org/10.1016/0140-6736(92)90016-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346181				2022-12-28	WOS:A1992HA58900013
J	JABS, DA				JABS, DA			MORTALITY IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME TREATED WITH EITHER FOSCARNET OR GANCICLOVIR FOR CYTOMEGALOVIRUS RETINITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY-SYNDROME; VIRUS RETINITIS; OCULAR MANIFESTATIONS; RETINOPATHY; DISEASE; ZIDOVUDINE; THERAPY; AIDS	Background and Methods. We performed a multicenter, randomized, unblinded clinical trial (the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial) designed to compare ganciclovir with foscarnet in the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS). Of 234 patients, 127 were randomly assigned to ganciclovir and 107 to foscarnet; the study drugs were administered according to a common protocol at the 11 participating clinical centers. Antiretroviral therapy (with zidovudine, didanosine, or dideoxycytidine) was given as dictated by best medical judgment. The patients were followed for the progression of retinitis, visual loss, and death. Results. Excess mortality in the ganciclovir group (as compared with the foscarnet group) led the Policy and Data Monitoring Board to recommend suspension of the treatment protocol 19 months after the trial started. As of that time, 65 of the patients assigned to ganciclovir had died, as compared with 36 of those assigned to foscarnet (51 percent vs. 34 percent, P = 0.007; relative risk, 1.79; 95 percent confidence interval, 1.17 to 2.73). The median survival was 8.5 months in the ganciclovir group and 12.6 months in the foscarnet group. Although the patients assigned to ganciclovir received less antiretroviral therapy on average than those assigned to foscarnet, the excess mortality could not be explained entirely by differences in exposure to antiretroviral drugs. In the foscarnet group, the only subgroup of patients identified as having excess mortality were those whose renal function was compromised at entry. There was no difference between the two treatment groups in the rate of progression of retinitis (relative risk, 0.95; P = 0.751). Conclusions. These results suggest that for patients with AIDS and- cytomegalovirus retinitis, treatment with foscarnet offers a survival advantage over treatment with ganciclovir, although the patients may not tolerate foscarnet as well as ganciclovir.			JABS, DA (corresponding author), STUDIES OCULAR COMPLICAT AIDS RES GRP, CHAIRMANS OFF, 550 N BROADWAY, SUITE 70, BALTIMORE, MD 21205 USA.				NEI NIH HHS [U10 EY 08052, U10 EY 08057, U10 EY 08067] Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY008067, U10EY008057, U10EY008052] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		CANNER PL, 1977, ESSAIS CONTROLES MUL, V76, P131; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; COX DR, 1972, J R STAT SOC B, V34, P187; ERIKSSON BFH, 1989, ANTIMICROB AGENTS CH, V33, P663, DOI 10.1128/AAC.33.5.663; FREEMAN WR, 1984, AM J OPHTHALMOL, V97, P133, DOI 10.1016/S0002-9394(14)76082-9; GIORGI JV, 1986, MANUAL CLIN LABORATO, P236; GROSS JG, 1990, OPHTHALMOLOGY, V97, P681; HARB GE, 1991, AIDS, V5, P959, DOI 10.1097/00002030-199108000-00006; HENDERLY DE, 1987, OPHTHALMOLOGY, V94, P425; HOCHSTER H, 1990, ANN INTERN MED, V113, P111, DOI 10.7326/0003-4819-113-2-111; HOLLAND GN, 1989, ARCH OPHTHALMOL-CHIC, V107, P1759, DOI 10.1001/archopht.1989.01070020841024; HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859; HOLLAND GN, 1990, OPHTHALMOLOGY, V97, P204; HOLLAND GN, 1987, OPHTHALMOLOGY, V94, P815; JABS DA, 1989, OPHTHALMOLOGY, V96, P1092; JABS DA, 1987, OPHTHALMOLOGY, V94, P824; JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031; Jackson A. L., 1986, MANUAL CLIN LABORATO, P226; JACOBSON MA, 1988, Q J MED, V67, P473; JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736; JACOBSON MA, 1991, J INFECT DIS, V163, P1219, DOI 10.1093/infdis/163.6.1219; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KONG XB, 1991, ANTIMICROB AGENTS CH, V35, P2003, DOI 10.1128/AAC.35.10.2003; KORETZ SH, 1986, NEW ENGL J MED, V314, P801, DOI 10.1056/NEJM198603273141301; LASKIN OL, 1987, AM J MED, V83, P201, DOI 10.1016/0002-9343(87)90685-1; LEHOANG P, 1989, OPHTHALMOLOGY, V96, P865; LIPSITZ SR, 1990, COMPUT BIOMED RES, V23, P268, DOI 10.1016/0010-4809(90)90021-4; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; NEWSOME DA, 1984, AM J OPHTHALMOL, V98, P590, DOI 10.1016/0002-9394(84)90245-9; ORELLANA J, 1987, OPHTHALMOLOGY, V94, P831; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; PALESTINE AG, 1986, AM J OPHTHALMOL, V101, P95, DOI 10.1016/0002-9394(86)90470-8; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; ROSENBERG PR, 1983, OPHTHALMOLOGY, V90, P874; ROYALL RM, 1986, INT STAT REV, V54, P221, DOI 10.2307/1403146; SCHUMAN JS, 1987, SURV OPHTHALMOL, V31, P384, DOI 10.1016/0039-6257(87)90031-2; WALMSLEY SL, 1988, J INFECT DIS, V157, P569, DOI 10.1093/infdis/157.3.569; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1991, SAS STAT SOFTWARE PH; 1987, MMWR S1, V36, pS1; IN PRESS CONTROLLED	47	251	257	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					213	220		10.1056/nejm199201233260401	http://dx.doi.org/10.1056/nejm199201233260401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1345799	Bronze			2022-12-28	WOS:A1992HA43100001
J	GORDON, C; BRADLEY, H; WARING, RH; EMERY, P				GORDON, C; BRADLEY, H; WARING, RH; EMERY, P			ABNORMAL SULFUR OXIDATION IN SYSTEMIC LUPUS-ERYTHEMATOSUS	LANCET			English	Note							DISEASE	S-carboxy-L-methylcysteine was used to assess the activity of the S-oxidation pathway of sulphur metabolism in 35 patients with systemic lupus erythematosus (SLE); 25 (71%) showed impaired sulphoxidation and 21 (60%) produced virtually no sulphoxides, compared with 17 (36%) and 2 (4%), respectively, of 47 healthy controls. The substrate/product ratio of cysteine oxygenase (plasma cysteine/sulphate) was significantly higher in SLE patients than in controls (median [interquartile range] 362 [224-588] vs 65 [44-111]; p < 0.00001). The alternative pathway of sulphur metabolism, S-methylation, catalysed by thiolmethyltransferase, was not impaired in the SLE patients. There is a biochemical difference in sulphur metabolism between SLE and rheumatoid arthritis, since both pathways are impaired in the latter disorder.	UNIV BIRMINGHAM,DEPT RHEUMATOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham			emery, paul/B-3560-2013	Gordon, Caroline/0000-0002-1244-6443				BRADLEY H, IN PRESS J RHEUMATOL; EMERY P, 1984, J RHEUMATOL, V11, P626; EMERY P, IN PRESS J RHEUMATOL; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; HEDMAN M, 1989, CLIN EXP RHEUMATOL, V7, P583; JACKSON SG, 1978, ANAL BIOCHEM, V90, P802, DOI 10.1016/0003-2697(78)90171-9; Mitchell S. C., 1989, SULPHUR CONTAINING A, V2A, P101; OLUMU AB, 1988, NEW ENGL J MED, V318, P1089; SIM E, 1989, COMPLEMENT INFLAMMAT, V6, P119, DOI 10.1159/000463084; WARING RH, 1989, LANCET, V2, P356	10	46	47	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					25	26		10.1016/0140-6736(92)90144-R	http://dx.doi.org/10.1016/0140-6736(92)90144-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345954				2022-12-28	WOS:A1992GY04300006
J	COSSON, P; BONIFACINO, JS				COSSON, P; BONIFACINO, JS			ROLE OF TRANSMEMBRANE DOMAIN INTERACTIONS IN THE ASSEMBLY OF CLASS-II MHC MOLECULES	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MEMBRANE-PROTEINS; RECEPTOR; EXPRESSION; PRODUCTS; DISTINCT; COMMON; GENES; MODEL; CLONE	Evidence is presented that suggests a role for transmembrane domain interactions in the assembly of class II major histocompatibility complex (MHC) molecules. Mutations in the transmembrane domains of the class II MHC alpha or beta chains resulted in proteins that did not generate complexes recognized by conformation-dependent antibodies and that were largely retained in the endoplasmic reticulum. Insertion of the alpha and beta transmembrane domains into other proteins allowed the chimeric proteins to assemble, suggesting a direct interaction of the alpha and beta transmembrane domains. The interactions were mediated by a structural motif involving several glycine residues on the same face of a putative alpha helix.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Bonifacino, Juan S./0000-0002-5673-6370				BISHOP GA, 1988, IMMUNOGENETICS, V28, P184, DOI 10.1007/BF00375858; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; COSSON P, UNPUB; CRESSWELL P, 1987, CRIT REV IMMUNOL, V7, P31; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ESTESS P, 1986, P NATL ACAD SCI USA, V83, P3594, DOI 10.1073/pnas.83.11.3594; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KABAT EA, 1991, SEQUENCES PROTEINS I, P816; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NIELSEN LK, 1990, J IMMUNOL, V144, P2915; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PIERRES M, 1980, EUR J IMMUNOL, V10, P950, DOI 10.1002/eji.1830101211; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SANT AJ, 1991, J EXP MED, V174, P799, DOI 10.1084/jem.174.4.799; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P79; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TRAVERS P, 1984, NATURE, V310, P235, DOI 10.1038/310235a0; VANDENELSEN P, 1985, NATURE, V314, P542, DOI 10.1038/314542a0; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	33	191	208	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					659	662		10.1126/science.1329208	http://dx.doi.org/10.1126/science.1329208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1329208				2022-12-28	WOS:A1992JU74500060
J	CHARO, RA				CHARO, RA			MANDATORY CONTRACEPTION	LANCET			English	Editorial Material														Charo, Robin Alta/0000-0003-3710-1043				POTTS N, 1991, LANCET, V338, P303; Shapiro Thomas, 1985, POPULATION CONTROL P; 1992, JAMA-J AM MED ASSOC, V267, P1812	3	1	1	2	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1104	1105						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349114				2022-12-28	WOS:A1992HR44600016
J	VANDERWALL, E; VERKOOYEN, RP; MINTJESDEGROOT, J; OOSTINGA, J; VANDIJK, A; HUSTINX, WNM; VERBRUGH, HA				VANDERWALL, E; VERKOOYEN, RP; MINTJESDEGROOT, J; OOSTINGA, J; VANDIJK, A; HUSTINX, WNM; VERBRUGH, HA			PROPHYLACTIC CIPROFLOXACIN FOR CATHETER-ASSOCIATED URINARY-TRACT INFECTION	LANCET			English	Article							FECAL FLORA; BACTERIURIA; PREVENTION; HYSTERECTOMY; TRIAL	Patients receiving antibiotics during bladder drainage have a lower incidence of urinary-tract infections compared with similar patients not on antibiotics. However, antibiotic prophylaxis in patients with a urinary catheter is opposed because of the fear of inducing resistant bacterial strains. We have done a double-blind, placebo-controlled trial of prophylactic ciprofloxacin in selected groups of surgical patients who had postoperative bladder drainage scheduled to last for 3 to 14 days. Patients were randomly assigned to receive placebo (n = 61), 250 mg ciprofloxacin per day (n = 59), or 500 mg ciprofloxacin twice daily (n = 64) from postoperative day 2 until catheter removal. 75% of placebo patients were bacteriuric at catheter removal compared with 16% of ciprofloxacin-treated patients (relative risk [RR] [95% Cl] 4.7 [3.0-7.4]). The prevalence of pyuria among placebo patients increased from 11% to 42% while the catheter was in place; by contrast, the rate of pyuria was 11 % or less in patients receiving ciprofloxacin (RR 4-0 [2.1-7-3]). 20% of placebo patients had symptomatic urinary-tract infections, including 3 with septicaemia, compared with 5% of the ciprofloxacin groups (RR 4-0 [1.6-10.2]). Bacteria isolated from urines of placebo patients at catheter removal were mostly species of enterobacteriaceae (37%), staphylococci (26%), and Enterococcus faecalis (20%), whereas species isolated from urines of ciprofloxacin patients were virtually all gram-positive. Ciprofloxacin-resistant mutants of normally sensitive gram-negative bacteria were not observed. Ciprofloxacin prophylaxis is effective and safe in the prevention of catheter-associated urinary tract infection and related morbidity in selected groups of patients requiring 3 to 14 days of bladder drainage.	DIAKONESSEN HOSP,DEPT MED MICROBIOL,1 BOSBOOMSTR,3182 KE UTRECHT,NETHERLANDS; DIAKONESSEN HOSP,DEPT MED,3182 KE UTRECHT,NETHERLANDS; DIAKONESSEN HOSP,DEPT HOSP PHARM,3182 KE UTRECHT,NETHERLANDS; OUDENRIJN HOSP,DEPT HOSP HYG,UTRECHT,NETHERLANDS; OUDENRIJN HOSP,DEPT HOSP PHARM,UTRECHT,NETHERLANDS	Diakonessenhuis; Diakonessenhuis; Diakonessenhuis								BALL P, 1986, J ANTIMICROB CHEMOTH, V18, P187, DOI 10.1093/jac/18.SD.187; BRUMFITT W, 1984, ANTIMICROB AGENTS CH, V26, P757, DOI 10.1128/AAC.26.5.757; BURKE JP, 1986, INFECT CONT HOSP EP, V7, P96, DOI 10.1017/S0195941700065553; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GIVENS CD, 1980, J UROLOGY, V124, P646, DOI 10.1016/S0022-5347(17)55596-2; GRABE M, 1987, EUR J CLIN MICROBIOL, V6, P11, DOI 10.1007/BF02097183; HOOPER DC, 1987, AM J MED, V82, P12; HUSTINX WNM, 1991, J HOSP INFECT, V18, P45, DOI 10.1016/0195-6701(91)90092-M; JAFFE R, 1985, CHEMOTHERAPY, V31, P476, DOI 10.1159/000238377; KUNIN CM, 1966, NEW ENGL J MED, V274, P1151; KUNIN CM, 1984, AM J MED, V73, P130; LITTLE PJ, 1974, J INFECT DIS, V129, pS241, DOI 10.1093/infdis/129.Supplement_2.S241; MACFARLANE DE, 1985, J INFECTION, V10, P96, DOI 10.1016/S0163-4453(85)91480-X; MARTINEZ OV, 1986, CRIT CARE MED, V14, P188, DOI 10.1097/00003246-198603000-00003; MOUNTOKALAKIS T, 1985, J UROLOGY, V134, P506, DOI 10.1016/S0022-5347(17)47262-4; MULHALL AB, 1988, J HOSP INFECT, V11, P253, DOI 10.1016/0195-6701(88)90103-X; PETERSDORF RG, 1957, NEW ENGL J MED, V21, P1001; PLATT R, 1983, LANCET, V1, P893; PLATT R, 1983, AM J MED, V75, P44, DOI 10.1016/0002-9343(83)90072-4; POLK BF, 1980, LANCET, V1, P437; ROZENBERGARSKA M, 1985, J INFECT DIS, V152, P104, DOI 10.1093/infdis/152.1.104; SANDERS WE, 1988, REV INFECT DIS, V10, P528; SHAPIRO M, 1984, INFECT CONT HOSP EP, V5, P525, DOI 10.1017/S019594170006104X; TURCK M, 1981, AM J MED, V70, P651, DOI 10.1016/0002-9343(81)90590-8; Verbrugh H A, 1990, Ned Tijdschr Geneeskd, V134, P490; VERBRUGH HA, 1988, EUR J CLIN MICROBIOL, V7, P490, DOI 10.1007/BF01962598; WENZEL RP, 1976, AM J EPIDEMIOL, V103, P251, DOI 10.1093/oxfordjournals.aje.a112223; 1986, SURVEILLANCE SUMMARI, V35, pSS17	28	70	72	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					946	951						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348797				2022-12-28	WOS:A1992HP03600002
J	ROSS, RK; BERNSTEIN, L; LOBO, RA; SHIMIZU, H; STANCZYK, FZ; PIKE, MC; HENDERSON, BE				ROSS, RK; BERNSTEIN, L; LOBO, RA; SHIMIZU, H; STANCZYK, FZ; PIKE, MC; HENDERSON, BE			5-ALPHA-REDUCTASE ACTIVITY AND RISK OF PROSTATE-CANCER AMONG JAPANESE AND UNITED-STATES WHITE AND BLACK-MALES	LANCET			English	Article							TESTOSTERONE; HORMONE; MEN; WOMEN; BLOOD	The incidence of prostate cancer varies widely between countries and ethnic groups. Black-Americans have the highest incidence rates world wide, whereas native Japanese have among the lowest. The reasons for this risk differential are unknown, although we have previously shown that higher circulating testosterone concentrations in young adult black men compared with young adult white men may explain the underlying differences in subsequent prostate cancer incidence between these two populations. We have now compared serum testosterone concentrations in young adult Japanese men with those of young adult whites and blacks, but found no significant differences. However, these white and black men had significantly higher values of 3-alpha, 17-beta androstanediol glucuronide (31% and 25% higher, respectively) and androsterone glucuronide (50% and 41% higher, respectively) than Japanese subjects. These two androgens are indices of 5-alpha-reductase activity. Our results raise the possibility that reduced 5-alpha-reductase activity has a role in producing the low prostate cancer incidence rates among Japanese. This finding may have important implications for prostate cancer prevention.	SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA; UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033; GIFU UNIV,SCH MED,GIFU 500,JAPAN	University of Southern California; Gifu University	ROSS, RK (corresponding author), UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,1441 EASTLAKE AVE,ROOM 803,LOS ANGELES,CA 90033, USA.				NCI NIH HHS [CA17054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA017054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLUWALIA B, 1981, CANCER, V48, P2267, DOI 10.1002/1097-0142(19811115)48:10<2267::AID-CNCR2820481023>3.0.CO;2-R; COFFEY DS, 1979, UICC TECH REP SER, V48, P4; FURUYAMA S, 1970, STEROIDS, V16, P415, DOI 10.1016/S0039-128X(70)80124-6; HENDERSON BE, 1988, BRIT J CANCER, V57, P216, DOI 10.1038/bjc.1988.46; HILL PB, 1979, CANCER LETT, V7, P273, DOI 10.1016/S0304-3835(79)80054-3; LOOKINGBILL DP, 1991, J CLIN ENDOCR METAB, V72, P1242, DOI 10.1210/jcem-72-6-1242; MATTERI RK, 1989, AM J OBSTET GYNECOL, V161, P1704, DOI 10.1016/0002-9378(89)90954-X; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; NANKIN HR, 1975, J CLIN ENDOCR METAB, V41, P271, DOI 10.1210/jcem-41-2-271; NOBLE RL, 1977, CANCER RES, V37, P1929; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; ROSS R, 1986, JNCI-J NATL CANCER I, V76, P45; ROSS RK, IN PRESS CANCER EPID; SHIMIZU H, 1991, JPN J CANCER RES, V82, P483, DOI 10.1111/j.1349-7006.1991.tb01874.x; SIITERI PK, 1986, CLIN ENDOCRINOL META, V15, P247, DOI 10.1016/S0300-595X(86)80023-8; STONER E, 1990, J STEROID BIOCHEM, V37, P375, DOI 10.1016/0960-0760(90)90487-6; 1984, SEER CANCER INCIDENC; 1990, CANCER FACTS FIGURES	19	386	394	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					887	889		10.1016/0140-6736(92)90927-U	http://dx.doi.org/10.1016/0140-6736(92)90927-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348296				2022-12-28	WOS:A1992HN48300002
J	STAAL, FJT; ELA, SW; ROEDERER, M; ANDERSON, MT; HERZENBERG, LA; HERZENBERG, LA				STAAL, FJT; ELA, SW; ROEDERER, M; ANDERSON, MT; HERZENBERG, LA; HERZENBERG, LA			GLUTATHIONE DEFICIENCY AND HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	LANCET			English	Review							TUMOR NECROSIS FACTOR; N-ACETYLCYSTEINE; KAPPA-B; ACTIVATION; METABOLISM; TRANSCRIPTION; EXPRESSION; CYSTEINE; PLASMA; CELLS		STANFORD UNIV, MED CTR, SCH MED, BECKMAN CTR B007, DEPT GENET, STANFORD, CA 94305 USA	Stanford University			Roederer, Mario/G-1887-2011		NCI NIH HHS [CA42509] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042509] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BUHL R, 1989, LANCET, V2, P1294; BURGUNDER JM, 1989, EUR J CLIN PHARMACOL, V36, P127, DOI 10.1007/BF00609183; CROSS CE, 1990, J LAB CLIN MED, V115, P396; DROGE W, 1986, IMMUNOBIOLOGY, V172, P151; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; FAZELY F, 1991, BLOOD, V77, P1653; HALLIWELL B, 1991, ARCH INTERN MED, V151, P29, DOI 10.1001/archinte.151.1.29; HAMILOS DL, 1985, J IMMUNOL, V135, P2740; HARAKEH S, 1991, AM J CLIN NUTR, V54, pS1231, DOI 10.1093/ajcn/54.6.1231s; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; PORTA P, 1991, J PHARMACOL EXP THER, V257, P331; ROEDERER M, 1991, AIDS RES HUM RETROV, V7, P563, DOI 10.1089/aid.1991.7.563; ROEDERER M, 1991, INT IMMUNOL, V3, P933, DOI 10.1093/intimm/3.9.933; ROEDERER M, 1992, AIDS RES HUM RETROV, V8, P209, DOI 10.1089/aid.1992.8.209; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; SCHEIB RG, 1987, AM J MED, V83, P608, DOI 10.1016/0002-9343(87)90794-7; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SMITH CV, 1990, 6TH INT C AIDS SAN F, V2, P368; STAAL FJT, 1992, AIDS RES HUM RETROV, V8, P305, DOI 10.1089/aid.1992.8.305; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STAAL FJT, IN PRESS J ACQUIR IM; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; Taniguchi N., 1989, GLUTATHIONE CENTENNI; YOSHIE O, 1989, J LEUKOCYTE BIOL, V45, P10, DOI 10.1002/jlb.45.1.10	36	407	423	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 11	1992	339	8798					909	912		10.1016/0140-6736(92)90939-Z	http://dx.doi.org/10.1016/0140-6736(92)90939-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348307				2022-12-28	WOS:A1992HN48300013
J	BRAHAMS, D				BRAHAMS, D			EYE MONITORING IN DIABETES	LANCET			English	Editorial Material																			0	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					863	864		10.1016/0140-6736(92)90297-G	http://dx.doi.org/10.1016/0140-6736(92)90297-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347868				2022-12-28	WOS:A1992HM44100016
J	NOBLEJAMIESON, G; THIRU, S; JOHNSTON, P; FRIEND, P; BARNES, ND				NOBLEJAMIESON, G; THIRU, S; JOHNSTON, P; FRIEND, P; BARNES, ND			GLOMERULONEPHRITIS WITH END-STAGE LIVER-DISEASE IN CHILDHOOD	LANCET			English	Note							CIRRHOSIS	Renal biopsies were done perioperatively in 18 children receiving liver grafts. All specimens showed glomerulonephritis, which was mesangial-proliferative in 15 and mesangio-capillary in 3. Of the 16 children who were alive four or more months after transplantation, only 1 showed progressive deterioration of renal function; 1 other had a subnormal but static glomerular filtration rate. In all 6 children who had proteinuria before operation, the urine became normal.	ADDENBROOKES HOSP, DEPT PATHOL, CAMBRIDGE CB2 2QQ, ENGLAND; ADDENBROOKES HOSP, DEPT SURG, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV CAMBRIDGE, CAMBRIDGE, ENGLAND	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	NOBLEJAMIESON, G (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, HILLS RD, CAMBRIDGE CB2 2QQ, ENGLAND.							[Anonymous], 1987, PEDIATRICS, V79, P1; BENE MC, 1988, AM J CLIN PATHOL, V89, P769, DOI 10.1093/ajcp/89.6.769; CHESNEY RW, 1987, PEDIATR CLIN N AM, V34, P609; EGIDO J, 1987, SEMIN NEPHROL, V7, P289; FISHER ER, 1959, AM J CLIN PATHOL, V32, P48; LAI KN, 1988, CLIN NEPHROL, V29, P229; LAMM ME, 1987, SEMIN NEPHROL, V7, P280; MOROZ SP, 1976, PEDIATRICS, V57, P232; MYERS BD, 1973, AM J CLIN PATHOL, V60, P222; PAPADAKIS MA, 1987, AM J MED, V82, P945, DOI 10.1016/0002-9343(87)90156-2	10	27	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	1992	339	8795					706	707		10.1016/0140-6736(92)90600-8	http://dx.doi.org/10.1016/0140-6736(92)90600-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347585				2022-12-28	WOS:A1992HK32000005
J	LOPEZ, A; MIRANDA, P; TEJADA, E; FISHBEIN, DB				LOPEZ, A; MIRANDA, P; TEJADA, E; FISHBEIN, DB			OUTBREAK OF HUMAN RABIES IN THE PERUVIAN JUNGLE	LANCET			English	Article								Transmission of rabies to man by vampire bats has been known for 60 years but there have been few reports of the features of rabies transmitted in this way. These aspects of the disease were investigated during an outbreak in Peru in early 1990. Between Jan 1 and April 30, 1990, 29 (5%) of 636 residents of the two rural communities in the Amazon Jungle in Peru acquired an illness characterised by hydrophobia, fever, and headache and died shortly thereafter. A census in one of the two towns revealed that the proportion affected was significantly higher for 5-14 year olds (17%) than for other age-groups (p < 10(-5)). Interviews conducted with 23 of the patients or their families revealed that 22 (96%) had a history of bat bite, compared with 66 (22%) of 301 community members who remained healthy (p < 10(-6)). A rabies virus strain identical to those isolated from vampire bats (Desmodus rotundus) was isolated from the brain of the only person on whom necropsy could be done. Because of the extreme isolation of this and other communities affected by bat-transmitted rabies, preventive measures should be directed at decreasing the risk of nocturnal exposure to bats by bat proofing dwellings or use of mosquito nets and at prompt wound care. Rabies pre-exposure or postexposure vaccination is clearly indicated, but may not be feasible in these isolated populations.	CTR DIS CONTROL, EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL, INT BRANCH,MAILSTOP C08, ATLANTA, GA 30333 USA; MINIST SALUD, PROGRAMA ENTRENAMIENTO & EPIDEMIOL CAMPO, OFICIANA GEN EPIDEMIOL, LIMA, PERU; CTR DIS CONTROL, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								Acha P N, 1967, Bull Off Int Epizoot, V67, P343; ARELLANOSOTA C, 1988, REV INFECT DIS, V10, pS707; Carini A, 1911, ANN I PASTEUR PARIS, V25, P843; Dean A. G., 1990, EPI INFO VERSION 5 W; GOLDWASSER RA, 1958, P SOC EXP BIOL MED, V98, P219, DOI 10.3181/00379727-98-23996; GUT H. JAMES, 1959, JOUR MAMMAL, V40, P534, DOI 10.2307/1376270; Hurst EW, 1931, LANCET, V2, P622; Hurst EW, 1932, J PATHOL BACTERIOL, V35, P301, DOI 10.1002/path.1700350302; Johnson H. N., 1971, Rabies. Proceedings of working conference on rabies, Tokyo, 1970., P237; LORD R D, 1975, Journal of Wildlife Diseases, V11, P210; MALAGAALBA A, 1954, AM J PUBLIC HEALTH, V44, P909, DOI 10.2105/AJPH.44.7.909; MCCARTHY TJ, 1989, AM J TROP MED HYG, V40, P320, DOI 10.4269/ajtmh.1989.40.320; NEHAUL BBG, 1955, AM J TROP MED HYG, V4, P550, DOI 10.4269/ajtmh.1955.4.550; NEHAUL BBG, 1965, AM J TROP MED HYG, V14, P295, DOI 10.4269/ajtmh.1965.14.295; SMITH JS, 1989, ADV VIRUS RES, V36, P215; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; VERLINDE JD, 1975, TROP GEOGR MED, V27, P137; WATERMAN J A, 1959, Caribb Med J, V21, P46; 1983, MMWR, V32, P494; 1987, WHORABIES89199	20	46	55	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					408	411						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346669				2022-12-28	WOS:A1992HD65900013
J	GOLDSMITH, R; YARBOUGH, PO; REYES, GR; FRY, KE; GABOR, KA; KAMEL, M; ZAKARIA, S; AMER, S; GAFFAR, Y				GOLDSMITH, R; YARBOUGH, PO; REYES, GR; FRY, KE; GABOR, KA; KAMEL, M; ZAKARIA, S; AMER, S; GAFFAR, Y			ENZYME-LINKED-IMMUNOSORBENT-ASSAY FOR DIAGNOSIS OF ACUTE SPORADIC HEPATITIS-E IN EGYPTIAN CHILDREN	LANCET			English	Article							NON-B-HEPATITIS; TRANSMITTED NON-A; VIRUS-LIKE PARTICLES; CYNOMOLGUS MACAQUES; POST-TRANSFUSION; EPIDEMIC; ETIOLOGY; TRANSMISSION; RECOVERY	Hepatitis E virus (HEV) is thought to be a cause of enterically transmitted non-A, non-B (ET-NANB) hepatitis. Waterborne epidemics have been recorded in many developing countries, mainly affecting young-to-middle-aged adults; sporadic infection and overt illness in children are rare. However, a convenient and sensitive diagnostic test for HEV infection is not yet available. We now report the use of a solid-phase enzyme-linked immunoassay (ELISA) that detects IgM and IgG antibody to HEV. In a prospective study of endemic acute hepatitis during 1986 in rural Benha, Egypt, 15 (42%) of 36 children with NANB hepatitis (from whom convalescent-phase sera were available every 3 months to 9 or 12 months) were positive for anti-HEV-IgG by ELISA. Of 20 sera from healthy Benha children (controls), 5 (25%) were also positive for anti-HEV-IgG. When evaluated for anti-HEV-IgM, 6 of the 15 IgG-positive children, but none of the controls, were IgM positive and were thus regarded as having confirmed acute HEV infections. These 6 cases together with 2 presumptive cases (IgM negative, IgG seroconversion from positive to negative) presented sporadically over 9 months. This ELISA is a convenient method for the diagnosis of HEV infection; we have shown that the disease is present in Egypt, that it can occur endemically as sporadic cases, and that children do have overt infection.	GENELABS INC,DEPT MOLEC VIROL,REDWOOD CITY,CA; BENHA UNIV,DEPT PEDIAT,BENHA,EGYPT; UNIV CAIRO,DEPT CLIN PATHOL,CAIRO,EGYPT; UNIV CAIRO,DEPT TROP MED,CAIRO,EGYPT; AIN SHAMS UNIV,DEPT MED,CAIRO,EGYPT	Egyptian Knowledge Bank (EKB); Benha University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Ain Shams University	GOLDSMITH, R (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143, USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1989, NEW ENGL J MED, V321, P1538, DOI 10.1056/NEJM198911303212208; ALTER MJ, 1989, ANN INTERN MED, V110, P583, DOI 10.7326/0003-4819-110-8-583; ARANKALLE VA, 1988, LANCET, V1, P550; ARANKALLE VA, 1988, LANCET, V2, P1199; BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRADLEY DW, 1987, P NATL ACAD SCI USA, V84, P6277, DOI 10.1073/pnas.84.17.6277; BRADLEY DW, 1986, SEMIN LIVER DIS, V6, P56, DOI 10.1055/s-2008-1040794; DECOCK KM, 1987, ANN INTERN MED, V106, P227, DOI 10.7326/0003-4819-106-2-227; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; KRAWCZYNSKI K, 1989, J INFECT DIS, V159, P1042, DOI 10.1093/infdis/159.6.1042; PANDA SK, 1989, HEPATOLOGY, V10, P466, DOI 10.1002/hep.1840100411; PURCELL RH, 1988, VIRAL HEPATITIS LIVE, P131; SKIDMORE SJ, 1991, LANCET, V337, P1541, DOI 10.1016/0140-6736(91)93227-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SREENIVASAN MA, 1984, J GEN VIROL, V65, P1005, DOI 10.1099/0022-1317-65-5-1005; TABOR E, 1985, LANCET, V1, P743; VELAZQUEZ O, 1990, JAMA-J AM MED ASSOC, V263, P3281, DOI 10.1001/jama.263.24.3281; WONG DC, 1980, LANCET, V2, P876; YARBOUGH PO, 1991, J VIROL, V65, P5790, DOI 10.1128/JVI.65.11.5790-5797.1991; ZAKARIA S, 1988, TROP GEOGR MED, V40, P285; ZUCKERMAN AJ, 1990, BRIT MED J, V300, P1475, DOI 10.1136/bmj.300.6738.1475; 1990, LANCET, P1158	24	192	204	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					328	331		10.1016/0140-6736(92)91647-Q	http://dx.doi.org/10.1016/0140-6736(92)91647-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346411				2022-12-28	WOS:A1992HC77100004
J	HARLEY, HG; BROOK, JD; RUNDLE, SA; CROW, S; REARDON, W; BUCKLER, AJ; HARPER, PS; HOUSMAN, DE; SHAW, DJ				HARLEY, HG; BROOK, JD; RUNDLE, SA; CROW, S; REARDON, W; BUCKLER, AJ; HARPER, PS; HOUSMAN, DE; SHAW, DJ			EXPANSION OF AN UNSTABLE DNA REGION AND PHENOTYPIC VARIATION IN MYOTONIC-DYSTROPHY	NATURE			English	Article							GENE	MYOTONIC dystrophy is the commonest adult form of muscular dystrophy, with an estimated incidence of 1 per 7,500, although this is likely to be an underestimate because of the difficulty of detecting minimally affected individuals. It is a multisystem autosomal dominant disorder of unknown biochemical basis 1. No case of new mutation has been proven. We have isolated a human genomic clone that detects novel restriction fragments specific to individuals with myotonic dystrophy. A two-allele EcoRI polymorphism is seen in normal individuals, but in most affected individuals one of the normal alleles is replaced by a larger fragment, which Varies in length both between unrelated affected individuals and within families. The unstable nature of this region may explain the characteristic variation in severity and age at onset of the disease. A second polymorphism at this locus is in almost complete linkage disequilibrium with myotonic dystrophy, strongly supporting our earlier results which indicated that most cases are descended from one original mutation 2.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	HARLEY, HG (corresponding author), UNIV WALES COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 6EJ,WALES.			Brook, John David/0000-0002-5946-6740	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; FU YH, 1991, CELL, V67, P1; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1991, HUM GENET, V87, P73, DOI 10.1007/BF01213096; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1972, LANCET, V2, P53; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; JANSEN G, 1991, AM J HUM GENET, V49, P82; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PENROSE LS, 1948, ANN EUGENIC, V14, P125; RICHARDS RI, 1991, J MED GENET, V28, P818, DOI 10.1136/jmg.28.12.818; Sambrook J, 1989, MOL CLONING LABORATO; SHUTLER, 1991, GENOMICS, V9, P500; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P; THIBAULT MC, IN PRESS CYTOGENET C; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; YULE GU, 1968, INTRO THEORY STATIST	24	694	714	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					545	546		10.1038/355545a0	http://dx.doi.org/10.1038/355545a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1346923				2022-12-28	WOS:A1992HC52600058
J	CHOWIENCZYK, PJ; LAWSON, CP; MORRIS, J; KERMANI, A; COCHRANE, GM				CHOWIENCZYK, PJ; LAWSON, CP; MORRIS, J; KERMANI, A; COCHRANE, GM			ELECTRONIC DIARY TO RECORD PHYSIOLOGICAL MEASUREMENTS	LANCET			English	Letter									GUYS HOSP,DEPT RESP MED,LONDON SE1 9RT,ENGLAND; MICRO MED,CHATHAM,KENT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust				Chowienczyk, Phil/0000-0003-4507-038X				GREEN M, 1986, BR J HEALTHCARE COMP, V3, P36; LISTER J, 1989, THORAX, V44, P343; TATTERSALL AB, 1989, J INT MED RES, V17, P185, DOI 10.1177/030006058901700212	3	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					251	251		10.1016/0140-6736(92)90061-7	http://dx.doi.org/10.1016/0140-6736(92)90061-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346213				2022-12-28	WOS:A1992HA58900053
J	SHAH, M; FOREMAN, DM; FERGUSON, MWJ				SHAH, M; FOREMAN, DM; FERGUSON, MWJ			CONTROL OF SCARRING IN ADULT WOUNDS BY NEUTRALIZING ANTIBODY TO TRANSFORMING GROWTH-FACTOR-BETA	LANCET			English	Note								Adult wounds heal with scar-tissue formation, whereas fetal wounds heal without scarring and with a lesser inflammatory and cytokine response. We injected the margins of healing dermal wounds in adult rats with neutralising antibody (NA) to transforming growth factor-beta (TGF-beta). All control wounds (irrelevant antibody, or TGF-beta, or no injection) healed with scarring, whereas the NA-treated wounds healed without scar-tissue formation; NA-treated wounds had fewer macrophages and blood vessels, lower collagen and fibronectin contents, but identical tensile strength and more normal dermal architecture than the other wounds. Early manipulation of the concentrations of selected cytokines may be a new approach to the control of scarring.	UNIV MANCHESTER, SCH BIOL SCI, DEPT CELL & STRUCT BIOL, STOPFORD BLDG, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; KRUMMEL TM, 1988, J PEDIATR SURG, V23, P647, DOI 10.1016/S0022-3468(88)80638-9; KSANDER GA, 1989, ANNU REP MED CHEM, V24, P223; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCartney-Francis N, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011007; MCGRATH MH, 1990, CLIN PLAST SURG, V17, P421; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; WHITBY DJ, 1991, DEVELOPMENT, V112, P651	10	517	570	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1992	339	8787					213	214		10.1016/0140-6736(92)90009-R	http://dx.doi.org/10.1016/0140-6736(92)90009-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346175				2022-12-28	WOS:A1992HA58900006
J	NONNASTDANIEL, B; MARTIN, RP; LINDERT, O; MUGGE, A; SCHAEFFER, J; SOCHTIG, E; GALANSKI, M; KOCH, KM; DANIEL, WG; VANDERLIETH, H				NONNASTDANIEL, B; MARTIN, RP; LINDERT, O; MUGGE, A; SCHAEFFER, J; SOCHTIG, E; GALANSKI, M; KOCH, KM; DANIEL, WG; VANDERLIETH, H			COLOR DOPPLER ULTRASOUND ASSESSMENT OF ARTERIOVENOUS HEMODIALYSIS FISTULAS	LANCET			English	Article							HEMODIALYSIS VASCULAR ACCESS; SONOGRAPHY; COMPLICATIONS	Satisfactory function of the arteriovenous fistula (AVF) is essential for adequate haemodialysis in patients with chronic renal failure. Existing methods to assess AVF function are imprecise (eg, clinical examination) or invasive (eg, angiography). We assessed the value of colour flow-doppler ultrasound (CFDU) in the investigation of clinically suspected AVF dysfunction. 51 patients with suspected impairment of AVF function were studied by CFDU, and 28 also underwent angiography. The findings were compared with the reference standard of the findings at reoperation. CFDU showed AVF stenoses in 1 8 patients, which were all confirmed at reoperation; the results of angiography in 13 of these 18 patients showed complete agreement with the findings of CFDU and surgery. CFDU showed partial or complete AVF thrombosis in 33 patients, confirmed in all patients at reoperation; 1 5 patients also underwent angiography, and thrombi were not found in 6 (in 4 because of technical failure). 7 patients had aneurysms on CFDU that were confirmed by surgery in all patients and by angiography in 2 of the 3 patients studied. CFDU enables reliable non-invasive assessment of AVF morphology and function and may become the procedure of choice for AVF assessment in patients with suspected AVF abnormalities.	HANOVER MED SCH,DEPT INTERNAL MED,DIV CARDIOL,W-3000 HANNOVER,GERMANY; HANOVER MED SCH,DEPT CARDIOVASC SURG,W-3000 HANNOVER,GERMANY; HANOVER MED SCH,DEPT RADIOL,W-3000 HANNOVER,GERMANY; EMORY UNIV,SCH MED,DIV CARDIOL,ATLANTA,GA 30322	Hannover Medical School; Hannover Medical School; Hannover Medical School; Emory University	NONNASTDANIEL, B (corresponding author), HANOVER MED SCH,DEPT INTERNAL MED,DIV NEPHROL,KONSTANTY GUTSCHOW STR 8,W-3000 HANNOVER,GERMANY.							BERGMANN H, 1982, WIEN MED WOCHENSCHR, V11, P245; BRESCIA MJ, 1966, NEW ENGL J MED, V275, P1089, DOI 10.1056/NEJM196611172752002; FORSBERG L, 1980, ACTA RADIOL DIAGN, V21, P465, DOI 10.1177/028418518002100406; KATHREIN H, 1989, ULTRASCHALL MED, V10, P33, DOI 10.1055/s-2007-1005958; MIDDLETON WD, 1989, AM J ROENTGENOL, V152, P633, DOI 10.2214/ajr.152.3.633; OREILLY RJ, 1978, AJR, V140, P1105; RIEDHAMMER HH, 1988, NIEREN HOCHDRUCK, V17, P85; SCHEIBLE W, 1980, AM J ROENTGENOL, V134, P1173, DOI 10.2214/ajr.134.6.1173; THOMAS ML, 1978, BRIT MED J, V2, P317, DOI 10.1136/bmj.2.6133.317; VILLEMARETTE PA, 1989, J VASC TECHNOL, V13, P164; WEISE A, 1987, NIEREN HOCHDRUCK, V16, P471	11	57	59	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					143	145		10.1016/0140-6736(92)90209-L	http://dx.doi.org/10.1016/0140-6736(92)90209-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346010				2022-12-28	WOS:A1992GZ96800003
J	WINSLOW, GM; SCHERER, MT; KAPPLER, JW; MARRACK, P				WINSLOW, GM; SCHERER, MT; KAPPLER, JW; MARRACK, P			DETECTION AND BIOCHEMICAL-CHARACTERIZATION OF THE MOUSE MAMMARY-TUMOR VIRUS-7 SUPERANTIGEN (MLS-1(A))	CELL			English	Article							RECEPTOR V-BETA; MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL RESPONSES; STAPHYLOCOCCAL ENTEROTOXIN-B; DISPARATE STIMULATOR CELLS; MLS-MODIFIED PRODUCTS; BONE-MARROW CHIMERAS; OPEN READING FRAME; CLONAL DELETION; DENDRITIC CELLS	Mouse mammary tumor viruses encode superantigens that bind to class II major histocompatibility complex proteins and engage T cells that bear particular V(beta)s. Among these superantigens is the long known, but previously uncharacterized, Mls-1a product, encoded by Mtv-7. Using a monoclonal antibody, we detect the Mtv-7 superantigen on the surface of activated B cells, but not on T cells or resting B cells. The superantigen is synthesized as a 45 kd transmembrane glycoprotein precursor, but is proteolytically processed to yield an 18.5 kd surface protein that we suggest is the functional form of the superantigen.	UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL & MED, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, DENVER, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WINSLOW, GM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DIV BASIC IMMUNOL, HOWARD HUGHES MED INST, DENVER, CO 80206 USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687	NIAID NIH HHS [AI 18785, AI 17134] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018785, R01AI018785, R01AI017134, R37AI017134, R56AI017134] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; ANDERSON GD, 1989, J IMMUNOL, V143, P3757; ARNOLD LW, 1983, J IMMUNOL, V131, P2064; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEUTNER U, 1992, P NATL ACAD SCI USA, V89, P5432, DOI 10.1073/pnas.89.12.5432; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BRANDTCARLSON C, 1991, J VIROL, V65, P6051, DOI 10.1128/JVI.65.11.6051-6060.1991; CHOI YW, 1992, J EXP MED, V175, P847, DOI 10.1084/jem.175.3.847; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DEKRUYFF RH, 1986, J IMMUNOL, V137, P1109; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FIRESTONE GL, 1982, NATURE, V300, P221, DOI 10.1038/300221a0; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GOLLOB KJ, 1991, J IMMUNOL, V147, P2447; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAINAUT P, 1990, CANCER RES, V50, P3754; HAMILOS DL, 1989, J IMMUNOL, V142, P1069; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HEDO JA, 1983, J BIOL CHEM, V258, P20; HELD W, 1992, J EXP MED, V175, P1623, DOI 10.1084/jem.175.6.1623; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; Herrmann T, 1991, Curr Top Microbiol Immunol, V174, P21; IGNATOWICZ L, 1992, J EXP MED, V175, P917, DOI 10.1084/jem.175.4.917; INABA M, 1991, J EXP MED, V173, P549, DOI 10.1084/jem.173.3.549; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JOUVINMARCHE E, 1992, P NATL ACAD SCI USA, V89, P3232, DOI 10.1073/pnas.89.8.3232; KAIN SR, 1992, J BIOL CHEM, V267, P8128; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KATZ ME, 1985, J IMMUNOL, V134, P2064; KING LB, 1990, MOL CELL BIOL, V10, P4211, DOI 10.1128/MCB.10.8.4211; KING LB, 1990, J IMMUNOL, V144, P3218; KIT S, 1963, EXP CELL RES, V31, P297, DOI 10.1016/0014-4827(63)90007-7; KNIGHT AM, 1992, EUR J IMMUNOL, V22, P879, DOI 10.1002/eji.1830220339; KORMAN AJ, 1992, EMBO J, V11, P1901, DOI 10.1002/j.1460-2075.1992.tb05242.x; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KUBO RT, 1983, MOL IMMUNOL, V20, P67, DOI 10.1016/0161-5890(83)90106-2; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSONSCIARD EL, 1990, EUR J IMMUNOL, V20, P1223, DOI 10.1002/eji.1830200605; LIEGLER TJ, 1986, J VIROL, V59, P159, DOI 10.1128/JVI.59.1.159-162.1986; LYNCH DH, 1985, J IMMUNOL, V134, P2071; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARCHEJOUVIN E, 1992, P NATL ACAD SCI USA, V89, P3232; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MAZDA O, 1991, J EXP MED, V173, P539, DOI 10.1084/jem.173.3.539; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; METLAY JP, 1989, J EXP MED, V169, P239, DOI 10.1084/jem.169.1.239; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NANDI S, 1972, J NATL CANCER I, V48, P1085; NICOLAS JF, 1987, EUR J IMMUNOL, V17, P1561, DOI 10.1002/eji.1830171106; OZATO K, 1980, J IMMUNOL, V124, P533; PAPIERNIK M, 1992, J EXP MED, V175, P453, DOI 10.1084/jem.175.2.453; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PULLEN AM, 1992, J EXP MED, V175, P41, DOI 10.1084/jem.175.1.41; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1990, J EXP MED, V171, P49, DOI 10.1084/jem.171.1.49; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; ROSS SR, 1985, P NATL ACAD SCI USA, V82, P5880, DOI 10.1073/pnas.82.17.5880; RUDY CK, 1992, J EXP MED, V175, P1613, DOI 10.1084/jem.175.6.1613; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; SINGER PA, 1990, EMBO J, V9, P3641, DOI 10.1002/j.1460-2075.1990.tb07575.x; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; SPEISER DE, 1989, J EXP MED, V170, P595, DOI 10.1084/jem.170.2.595; SPEISER DE, 1989, J EXP MED, V170, P2165, DOI 10.1084/jem.170.6.2165; TSUBURA A, 1988, CANCER RES, V48, P6555; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; VANKLAVEREN P, 1988, J VIROL, V62, P4410, DOI 10.1128/JVI.62.11.4410-4413.1988; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBB SR, 1990, SCIENCE, V248, P1643; WEBB SR, 1989, J EXP MED, V169, P1, DOI 10.1084/jem.169.1.1; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WOODLAND DL, 1991, J EXP MED, V174, P1255, DOI 10.1084/jem.174.5.1255; YAGI JJ, 1990, J IMMUNOL, V144, P892	102	103	105	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					719	730		10.1016/0092-8674(92)90549-R	http://dx.doi.org/10.1016/0092-8674(92)90549-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330323				2022-12-28	WOS:A1992JZ63300003
J	DELMAS, B; GELFI, J; LHARIDON, R; VOGEL, LK; SJOSTROM, H; NOREN, O; LAUDE, H				DELMAS, B; GELFI, J; LHARIDON, R; VOGEL, LK; SJOSTROM, H; NOREN, O; LAUDE, H			AMINOPEPTIDASE-N IS A MAJOR RECEPTOR FOR THE ENTEROPATHOGENIC CORONAVIRUS TGEV	NATURE			English	Article							INTESTINAL BRUSH-BORDER; TRANSMISSIBLE GASTROENTERITIS; VIRUS; EXPRESSION; SEQUENCE; CLONING; KIDNEY; GENE	CORONAVIRUSES, like many animal viruses, are characterized by a restricted host range and tissue tropism 1. Transmissible gastroenteritis virus (TGEV), a major pathogen causing a fatal diarrhoea in newborn pig, replicates selectively in the differentiated enterocytes covering the villi of the small intestine 2. To investigate the molecular determinants of the infection, we characterized the surface molecule used by the virus for binding and entry into host cells. Here we report that aminopeptidase N, an ectoenzyme abundantly expressed at the apical membrane of the enterocytes, serves as a receptor for TGEV. Monoclonal antibodies were selected for their ability to block infection by TGEV of porcine cell lines. They recognized a brush-border membrane protein of M(r) 150K, which was identified as aminopeptidase N by amino-terminal sequencing. Two lines of evidence supported the view that the peptidase itself acts as a receptor. First, virions bound specifically to aminopeptidase N that was purified to homogeneity. Second, recombinant expression of aminopeptidase N conferred infectivity by TGEV to an otherwise non-permissive cell line.	INRA,UNITE VIROL & IMMUNOL MOLEC,DOMAINE VILVERT,F-78350 JOUY EN JOSAS,FRANCE; PANUM INST,DEPT BIOCHEM,DK-2200 COPENHAGEN N,DENMARK	INRAE; UDICE-French Research Universities; Universite Paris Saclay				Vogel, Lotte K./0000-0001-9920-0982				DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; GORVEL JP, 1989, J CELL BIOL, V108, P2193, DOI 10.1083/jcb.108.6.2193; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HAELTERMAN EO, 1972, J AM VET MED ASSOC, V160, P534; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KRAMERS MTC, 1979, EUR J BIOCHEM, V99, P345, DOI 10.1111/j.1432-1033.1979.tb13262.x; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LAUDE H, 1986, J GEN VIROL, V67, P119, DOI 10.1099/0022-1317-67-1-119; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAROUX S, 1973, BIOCHIM BIOPHYS ACTA, V321, P282, DOI 10.1016/0005-2744(73)90083-1; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; PENSAERT M, 1970, ARCH GES VIRUSFORSCH, V31, P321, DOI 10.1007/BF01253767; SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761; SJOSTROM H, 1978, EUR J BIOCHEM, V88, P503, DOI 10.1111/j.1432-1033.1978.tb12476.x; SJOSTROM H, 1982, EUR J BIOCHEM, V122, P245, DOI 10.1111/j.1432-1033.1982.tb05873.x	21	504	549	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					417	420		10.1038/357417a0	http://dx.doi.org/10.1038/357417a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1350661	Green Published, Bronze			2022-12-28	WOS:A1992HX17200068
J	PATEL, NH; BALL, EE; GOODMAN, CS				PATEL, NH; BALL, EE; GOODMAN, CS			CHANGING-ROLE OF EVEN-SKIPPED DURING THE EVOLUTION OF INSECT PATTERN-FORMATION	NATURE			English	Article							EARLY EMBRYOGENESIS; EMBRYONIC PATTERN; DROSOPHILA EMBRYO; FUSHI-TARAZU; HOMEO BOX; EXPRESSION; SEGMENTATION; GRASSHOPPER; TRANSCRIPTS; GENE	THE development of Drosophila is typical of the so-called long germband mode of insect development, in which the pattern of segments is established by the end of the blastoderm stage 1,2. Short germband insects, such as the grasshopper Schistocerca americana, by contrast, generate all or most of their metameric pattern after the blastoderm stage by the sequential addition of segments during caudal elongation 3. This difference is discernible at the molecular level in the pattern of initiation of the segment polarity gene engrailed 4, and the homeotic gene abdominal-A (ref. 5). For example, in both types of insects, engrailed is expressed by the highly conserved germband stage 4,6 in a pattern of regularly spaced stripes, one stripe per segment 7-9. In Drosophila, the complete pattern is visible by the end of the blastoderm stage, although engrailed appears initially in alternate segments in a pair-rule pattern 9,10 that reflects its known control by pair-rule genes such as even-skipped 11-15. In contrast, in the grasshopper, the engrailed stripes appear one at a time after the blastoderm stage as the embryo elongates 4. To address the molecular basis for this difference, we have cloned the grasshopper homologue of the Drosophila pair-rule gene even-skipped and show that it does not serve a pair-rule function in early development, although it does have a similar function in both insects during neurogenesis later in development.	CARNEGIE INST WASHINGTON, BALTIMORE, MD 21210 USA; RES SCH BIOL SCI, MOLEC NEUROBIOL GRP, CANBERRA, ACT 2601, AUSTRALIA	Carnegie Institution for Science; Australian National University	PATEL, NH (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, 519 LSA, BERKELEY, CA 94720 USA.		Ball, Eldon E/C-9261-2009	Ball, Eldon E/0000-0002-6052-1495; Patel, Nipam/0000-0003-4328-654X				AKAM M, 1987, DEVELOPMENT, V101, P1; ALTABA ARI, 1990, TRENDS GENET, V6, P57; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DESPOSITO M, 1991, GENOMICS, V10, P43, DOI 10.1016/0888-7543(91)90482-T; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DUSH MK, IN PRESS DEV BIOL; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; FRASCH M, 1988, GENE DEV, V2, P1824, DOI 10.1101/gad.2.12b.1824; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; NILSSON B, 1990, METHOD ENZYMOL, V185, P144; PATEL NH, 1989, DEVELOPMENT, V107, P201; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; RUIZ IA, 1989, CELL, V57, P317; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; SANDER K, 1988, DEVELOPMENT, V104, P112; SNOW PM, 1988, P NATL ACAD SCI USA, V85, P5291, DOI 10.1073/pnas.85.14.5291; TEAR G, 1990, DEVELOPMENT, V110, P915; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; WEIR MP, 1985, NATURE, V318, P433, DOI 10.1038/318433a0	30	226	228	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1992	357	6376					339	342		10.1038/357339a0	http://dx.doi.org/10.1038/357339a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1350328				2022-12-28	WOS:A1992HW13200051
J	TURNER, G; ROBINSON, H; LAING, S; VANDENBERK, M; COLLEY, A; GODDARD, A; SHERMAN, S; PARTINGTON, M				TURNER, G; ROBINSON, H; LAING, S; VANDENBERK, M; COLLEY, A; GODDARD, A; SHERMAN, S; PARTINGTON, M			POPULATION SCREENING FOR FRAGILE-X	LANCET			English	Article							LINKED MENTAL-RETARDATION; LOCALIZATION	A screening programme to detect fragile X syndrome has been operating in New South Wales, Australia, since 1984. The aim of this programme is to find previously unidentified individuals with the syndrome so that their extended families can be properly informed of the risks before making decisions about childbearing. 14 225 individuals attending adult and child facilities for the intellectually handicapped have been screened, of whom 8172 have been offered testing for the fragile X syndrome with a 79% uptake of the service. 253 probands were found, and in the extended families 818 females at 25-100% risk of being carriers were interviewed and counselled. Continuing contact was maintained and prenatal diagnosis was offered. The effect of the programme was assessed in a subgroup of 90 individuals, most of whom were appreciative of the service and felt that they had been adequately informed. The influence of knowing the diagnosis and its genetic implications were also assessed, the main consequences being a 26% reduction in births and a 61% uptake of prenatal diagnosis. Improved techniques for diagnosis of fragile X have benefited the families identified and counselled, suggesting that systematic screening for fragile X should be an essential component of community genetic services.	EMORY UNIV,DEPT PEDIAT,DIV MED GENET,ATLANTA,GA 30322; WESTERN SUBURBS HOSP,NEWCASTLE & NO NEW S WALES GENET SERV,NEWCASTLE,NSW,AUSTRALIA	Emory University	TURNER, G (corresponding author), PRINCE WALES CHILDRENS HOSP,FRAGILE X PROGRAMME,SYDNEY,NSW 2031,AUSTRALIA.							COLLINS FA, 1990, CLIN GENET, V37, P18; FISHBURN J, 1983, AM J MED GENET, V14, P713, DOI 10.1002/ajmg.1320140413; GEDEON A, 1991, J MED GENET, V28, P372, DOI 10.1136/jmg.28.6.372; HEITZ D, IN PRESS AM J MED GE; LAING S, 1991, AM J MED GENET, V38, P256, DOI 10.1002/ajmg.1320380219; MODELL B, 1991, 8TH INT C HUM GEN WA; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PARTINGTON MW, 1988, AM J MED GENET, V30, P509, DOI 10.1002/ajmg.1320300153; PARTINGTON MW, 1988, AM J MED GENET, V30, P251, DOI 10.1002/ajmg.1320300127; PARTINGTON MW, 1988, AM J MED GENET, V29, P633, DOI 10.1002/ajmg.1320290322; PARTINGTON MW, IN PRESS AM J MED GE; PURVISSMITH SG, 1988, AM J MED GENET, V30, P337, DOI 10.1002/ajmg.1320300134; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SHERMAN SL, 1988, AM J MED GENET, V30, P633, DOI 10.1002/ajmg.1320300164; SUTHERS GK, 1988, AM J MED GENET, V30, P485, DOI 10.1002/ajmg.1320300151; THODE A, 1988, AM J MED GENET, V30, P239, DOI 10.1002/ajmg.1320300125; TURNER G, 1989, AM J MED GENET, V34, P463, DOI 10.1002/ajmg.1320340402; TURNER G, 1986, NEW ENGL J MED, V315, P607, DOI 10.1056/NEJM198609043151002; TURNER G, 1980, NEW ENGL J MED, V303, P662, DOI 10.1056/NEJM198009183031202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WILSON M, 1991, AM J MED GENET, V40, P406, DOI 10.1002/ajmg.1320400405; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	22	57	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1210	1213		10.1016/0140-6736(92)91142-U	http://dx.doi.org/10.1016/0140-6736(92)91142-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349946				2022-12-28	WOS:A1992HU68400012
J	GUTNIAK, M; ORSKOV, C; HOLST, JJ; AHREN, B; EFENDIC, S				GUTNIAK, M; ORSKOV, C; HOLST, JJ; AHREN, B; EFENDIC, S			ANTIDIABETOGENIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE IN NORMAL SUBJECTS AND PATIENTS WITH DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERFUSED RAT PANCREAS; SECONDARY FAILURE; INCRETIN CONCEPT; HUMAN-PLASMA; INSULIN; GLUCOSE; SOMATOSTATIN; RELEASE; RADIOIMMUNOASSAY; PROGLUCAGON	Background. Glucagon-like peptide-1 (7-36) amide (glucagon-like insulinotropic peptide, or GLIP) is a gastrointestinal peptide that potentiates the release of insulin in physiologic concentrations. Its effects in patients with diabetes mellitus are not known. Methods. We compared the effect of an infusion of GLIP that raised plasma concentrations of GLIP twofold with the effect of an infusion of saline, on the meal-related release of insulin, glucagon, and somatostatin in eight normal subjects, nine obese patients with non-insulin-dependent diabetes mellitus (NIDDM), and eight patients with insulin-dependent diabetes mellitus (IDDM). The blood glucose concentrations in the patients with diabetes were controlled by a closed-loop insulin-infusion system (artificial pancreas) during the infusion of each agent, allowing measurement of the meal-related requirement for exogenous insulin. In the patients with IDDM, normoglycemic-clamp studies were performed during the infusions of GLIP and saline to determine the effect of GLIP on insulin sensitivity. Results. In the normal subjects, the infusion of GLIP significantly lowered the meal-related increases in the blood glucose concentration (P < 0.01) and the plasma concentrations of insulin and glucagon (P < 0.05 for both comparisons). The insulinogenic index (the ratio of insulin to glucose) increased almost 10-fold, indicating that GLIP had an insulinotropic effect. In the patients with NIDDM, the infusion of GLIP reduced the mean (+/- SE) calculated isoglycemic meal-related requirement for insulin from 17.4 +/- 2.8 to 2.0 +/- 0.5 U (P < 0.001), so that the integrated area under the curve for plasma free insulin was decreased (P < 0.05) in spite of the stimulation of insulin release. In the patients with IDDM, the GLIP infusion decreased the calculated isoglycemic meal-related insulin requirement from 9.4 +/- 1.5 to 4.7 +/- 1.4 U. The peptide decreased glucagon and somatostatin release in both groups of patients. In the normoglycemic-clamp studies in the patients with IDDM, the GLIP infusion significantly increased glucose utilization (saline vs. GLIP, 7.2 +/- 0.5 vs. 8.6 +/- 0.4 mg per kilogram of body weight per minute; P < 0.01). Conclusions. GLIP has an antidiabetogenic effect, and it may therefore be useful in the treatment of patients with NIDDM.	UNIV COPENHAGEN,PANUM INST,INST MED PHYSIOL C,DEPT ENDOCRINOL,DK-2200 COPENHAGEN,DENMARK; UNIV LUND,DEPT PHARMACOL,S-22101 LUND,SWEDEN	University of Copenhagen; Lund University	GUTNIAK, M (corresponding author), KAROLINSKA INST,KAROLINSKA SJUKHUSET,DEPT ENDOCRINOL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN.		Holst, Jens/AAA-8022-2022	Orskov, Cathrine/0000-0002-7762-2372; Holst, Jens Juul/0000-0001-6853-3805				ARIMURA A, 1978, METABOLISM, V27, P1139, DOI 10.1016/0026-0495(78)90032-X; BROWN JC, 1979, CLIN ENDOCRINOL META, V8, P365, DOI 10.1016/S0300-595X(79)80047-X; CONLON JM, 1988, DIABETOLOGIA, V31, P563, DOI 10.1007/BF00264761; CREUTZFELDT W, 1985, DIABETOLOGIA, V28, P565, DOI 10.1007/BF00281990; CREUTZFELDT W, 1979, DIABETOLOGIA, V16, P75, DOI 10.1007/BF01225454; DEFRONZO RA, 1982, DIABETOLOGIA, V23, P313; DRUCKER DJ, 1990, PANCREAS, V5, P484, DOI 10.1097/00006676-199007000-00018; EBERT R, 1979, GASTROENTEROLOGY, V76, P515; EFENDIC S, 1978, FEBS LETT, V92, P33, DOI 10.1016/0014-5793(78)80715-7; EFENDIC S, 1980, FRONTIERS HORMONE RE, V7, P41; FALOONA GR, 1974, METHOD HORM RADIOIMM, P317; FEHMANN HC, 1991, FEBS LETT, V279, P335, DOI 10.1016/0014-5793(91)80182-3; FINEGOOD DT, 1988, DIABETES, V37, P1025, DOI 10.2337/diabetes.37.8.1025; GENNARO WD, 1975, CLIN CHEM, V21, P873; GUTNIAK M, 1987, DIABETES, V36, P802, DOI 10.2337/diabetes.36.7.802; GUTNIAK M, 1987, DIABETES CARE, V10, P545, DOI 10.2337/diacare.10.5.545; GUTNIAK M, 1990, AM J PHYSIOL, V258, pE805, DOI 10.1152/ajpendo.1990.258.5.E805; HANSEN IL, 1985, DIABETES, V34, P751, DOI 10.2337/diabetes.34.8.751; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HUGGETT ASG, 1957, LANCET, V2, P368; JOHANSSON C, 1981, DIGESTION, V22, P126, DOI 10.1159/000198619; KREJS GJ, 1980, GASTROENTEROLOGY, V78, P26; KREYMANN B, 1987, LANCET, V2, P1300; LABARRE J, 1930, AM J PHYSIOL, V91, P649; Lebovitz H E, 1978, Diabetes Care, V1, P189; MILLER LL, 1960, NATURE, V185, P248, DOI 10.1038/185248a0; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; Moore B, 1906, BIOCHEM J, V1, P28, DOI 10.1042/bj0010028; ORSKOV C, 1987, DIABETOLOGIA, V30, P874; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; ORSKOV C, 1988, ENDOCRINOLOGY, V123, P2009, DOI 10.1210/endo-123-4-2009; ORSKOV C, 1991, J CLIN INVEST, V87, P415, DOI 10.1172/JCI115012; PENMAN E, 1979, ANN CLIN BIOCHEM, V16, P15, DOI 10.1177/000456327901600103; POLONSKY KS, 1984, DIABETES, V33, P486, DOI 10.2337/diabetes.33.5.486; ROBERTSON DA, 1988, BAILLIERE CLIN ENDOC, V2, P407, DOI 10.1016/S0950-351X(88)80040-5; SARSON DL, 1984, DIABETES, V33, P389, DOI 10.2337/diabetes.33.4.389; SCHEEN AJ, 1989, DIABETES RES CLIN PR, V6, pS33, DOI 10.1016/0168-8227(89)90076-4; SIMON M, 1982, CLIN CHEM, V28, P9; SUTHERLAND EW, 1960, PHARMACOL REV, V12, P265; SUZUKI S, 1989, ENDOCRINOLOGY, V125, P3109, DOI 10.1210/endo-125-6-3109; TAKAHASHI H, 1990, BIOMED RES-TOKYO, V11, P99, DOI 10.2220/biomedres.11.99; VERDONK CA, 1980, HORM METAB RES, V12, P133, DOI 10.1055/s-2007-996224; WETTERGREN A, 1990, Digestion, V46, P120; 1979, DIABETES, V28, P1039	44	800	951	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1316	1322		10.1056/NEJM199205143262003	http://dx.doi.org/10.1056/NEJM199205143262003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT803	1348845				2022-12-28	WOS:A1992HT80300003
J	FACCHINI, FS; HOLLENBECK, CB; JEPPESEN, J; CHEN, YDI; REAVEN, GM				FACCHINI, FS; HOLLENBECK, CB; JEPPESEN, J; CHEN, YDI; REAVEN, GM			INSULIN RESISTANCE AND CIGARETTE-SMOKING	LANCET			English	Article							CORONARY-ARTERY DISEASE; RISK-FACTORS; DENSITY LIPOPROTEIN; GLUCOSE-TOLERANCE; HYPERTRIGLYCERIDEMIA; TRIGLYCERIDE; CHOLESTEROL; MEN	Cigarette smoking is associated with increases in plasma triglycerides and decreases in plasma high density-lipoprotein-cholesterol concentration. These changes not only increase risk of coronary heart disease but also are secondary to resistance to insulin-stimulated glucose uptake or hyperinsulinaemia. To see whether there is a relation between cigarette smoking and insulin-mediated glucose uptake we measured plasma lipid and lipoprotein concentrations, plasma glucose and insulin response to an oral glucose challenge, and insulin-mediated glucose uptake in 40 matched healthy volunteers (20 non-smokers, 20 smokers). Smokers had significantly higher mean (SEM) very-low-density-lipoprotein triglycerides (0.66 [0.10] vs 0.39 [0.03] mmol/l, p < 0.02) and cholesterol (0.45 [0.06] vs 0.23 [0.04] mmol/l, p < 0.005) concentrations and lower high-density-lipoprotein cholesterol concentrations (1.16 [0.05] vs l.51 [0.08]mmol/l, p < 0.001). Although plasma glucose concentrations in response to the oral glucose load were similar in the two groups, plasma insulin response of the smokers was significantly higher (p < 0.001). Finally, smokers had higher steady-state plasma glucose concentrations in response to a continuous infusion of glucose, insulin, and somatostatin (8.4 [0.2] vs 5.0 [0.3] mmol/l, p < 0.001), despite similar steady-state plasma insulin concentrations. The findings show that chronic cigarette smokers are insulin resistant, hyperinsulinaemic, and dyslipidaemic compared with a matched group of non-smokers, and may help to explain why smoking increases risk of coronary heart disease.	VET AFFAIRS MED CTR,GERIATR RES EDUC & CLIN CTR,PALO ALTO,CA 94304	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00070] Funding Source: Medline; NHLBI NIH HHS [HL 08506] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; CARLSON LA, 1979, ACTA MED SCAND, V206, P351; CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784; DEFRONZO RA, 1979, DIABETES, V28, P1095, DOI 10.2337/diab.28.12.1095; FREEDMAN DS, 1986, AM J EPIDEMIOL, V124, P207; HOFFMAN D, 1986, WHO IARC, P45; JANZON L, 1983, DIABETOLOGIA, V25, P86; KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6; LAWS A, 1989, J CLIN ENDOCR METAB, V69, P343, DOI 10.1210/jcem-69-2-343; MCGILL CG, 1991, ADV EXP MED BIOL, V273, P9; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; OLEFSKY JM, 1974, AM J MED, V57, P551, DOI 10.1016/0002-9343(74)90006-0; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSENTHAL M, 1983, DIABETES, V32, P408, DOI 10.2337/diabetes.32.5.408; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; SHEN SW, 1970, J CLIN INVEST, V49, P2151, DOI 10.1172/JCI106433; SHIRAISHI I, 1991, DIABETOLOGIA, V34, P737, DOI 10.1007/BF00401520; TOBEY TA, 1981, METABOLISM, V30, P165, DOI 10.1016/0026-0495(81)90167-0; WILLETT W, 1983, AM HEART J, V105, P417, DOI 10.1016/0002-8703(83)90358-7; WILLIAMS P, 1979, LANCET, V1, P72; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	22	549	566	1	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1128	1130		10.1016/0140-6736(92)90730-Q	http://dx.doi.org/10.1016/0140-6736(92)90730-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349365				2022-12-28	WOS:A1992HT23600002
J	TAYLOR, RFH; ALJARAD, N; JOHN, LME; CONROY, DM; BARNES, NC				TAYLOR, RFH; ALJARAD, N; JOHN, LME; CONROY, DM; BARNES, NC			BETEL-NUT CHEWING AND ASTHMA	LANCET			English	Article								Two Asian patients admitted to hospital with acute severe asthma had been chewing betel nut immediately before the attacks. Arecoline, a cholinergic alkaloid, is a major constituent of Areca catechu (betel) nut and causes the euphoric effects. We sought an association between betel-nut chewing and bronchoconstriction in asthmatic patients. In vitro, arecoline caused dose-related contraction of human bronchial smooth-muscle strips, with one-tenth the potency of methacholine. In a double-blind challenge study, inhalation of arecoline caused bronchoconstriction in six of seven asthmatic patients and one of six healthy subjects; methacholine caused bronchoconstriction in all the asthmatic patients and in five controls. The geometric mean concentrations of arecoline and methacholine that caused 20% falls in the forced expiratory volume in 1 s (PC20 FEV1,) in the asthmatic subjects were 5.2 mg/ml and 1.6 mg/ml, respectively. We then studied four Bengali asthmatic patients, regular users of betel nut, during a betel-nut challenge. Three showed no adverse effects, but one showed a 30% fall in FEV1, by 150 min after chewing; the effect was reproducible. In the UK, the rate of hospital admission for acute asthma is higher among Asians than among other groups in the population; betel-nut chewing may be one of several factors that affect asthma control and severity of attacks.	LONDON CHEST HOSP,LONDON,ENGLAND; ROYAL COLL SURG ENGLAND,LONDON WC2A 3PN,ENGLAND	University of London; Queen Mary University London; Royal College of Surgeons of England								AYRES JG, 1986, BRIT J DIS CHEST, V80, P242, DOI 10.1016/0007-0971(86)90059-8; BUSH RK, 1988, J ALLERGY CLIN IMMUN, V82, P251, DOI 10.1016/0091-6749(88)91007-X; COTES JE, 1979, LUNG FUNCTION ASSESS; FULLER RW, 1985, J APPL PHYSIOL, V58, P1080, DOI 10.1152/jappl.1985.58.4.1080; HOLMSTEDT B, 1967, ANN NY ACAD SCI, V142, P126, DOI 10.1111/j.1749-6632.1967.tb13719.x; JUPTNER H, 1968, TROP DIS B, V65, P1176; MUIR CS, 1967, PREVENTION CANCER, P75; MUIR CS, 1960, BRIT J CANCER, V14, P587; Nadkarni A.K., 1954, INDIAN MATERIA MED, VI; REYNOLDS JEF, 1989, MARTINDALE EXTRA PHA, P49; SAMHOUN MN, 1989, BRIT J PHARMACOL, V98, P1406; THOMAS KE, 1991, BRIT J IND MED, V48, P314; VOLLER RL, 1971, DRILLS PHARM MED, P591; 1978, HIGH TIMES ENCY RECR, P80	14	62	65	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1134	1136		10.1016/0140-6736(92)90732-I	http://dx.doi.org/10.1016/0140-6736(92)90732-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349367				2022-12-28	WOS:A1992HT23600004
J	HOOGENDIJK, JE; HENSELS, GW; GABREELSFESTEN, AAWM; GABREELS, FJM; JANSSEN, EAM; DEJONGHE, P; MARTIN, JJ; VAN BROECKHOVEN, C; VALENTIJN, LJ; BAAS, F; DEVISSER, M; BOLHUIS, PA				HOOGENDIJK, JE; HENSELS, GW; GABREELSFESTEN, AAWM; GABREELS, FJM; JANSSEN, EAM; DEJONGHE, P; MARTIN, JJ; VAN BROECKHOVEN, C; VALENTIJN, LJ; BAAS, F; DEVISSER, M; BOLHUIS, PA			DENOVO MUTATION IN HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE-1	LANCET			English	Note							DISEASE	Isolated cases of hereditary motor and sensory neuropathy type I (HMSN I, Charcot-Marie-Tooth disease type 1) have been thought to be most frequently autosomal recessive. We have found that a recently discovered duplication in chromosome 17, responsible for most cases of autosomal dominant HMSN I, is present as a de-novo mutation in 9 out of 10 sporadic patients. This finding has important implications for genetic counselling of isolated patients with HMSN I.	UNIV HOSP NIJMEGEN, INST NEUROL, NIJMEGEN, NETHERLANDS; UNIV INSTELLING ANTWERP, NEUROGENET LAB, B-2610 WILRIJK, BELGIUM	Radboud University Nijmegen; University of Antwerp	HOOGENDIJK, JE (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, DEPT NEUROL, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, NETHERLANDS.		Janssen, Emiel A.M./AAM-2357-2020; Baas, Frank/F-9574-2010; Van Broeckhoven, Christine/M-7853-2019; Van Broeckhoven, Christine/G-8362-2017	Baas, Frank/0000-0003-3912-5428; Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665				CHANCE PF, 1990, AM J HUM GENET, V47, P915; Dyck P.J., 1984, PERIPHERAL NEUROPATH, P1600; DYCK PJ, 1988, MUSCLE NERVE, V11, P21, DOI 10.1002/mus.880110106; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; HARDING AE, 1980, J MED GENET, V17, P329, DOI 10.1136/jmg.17.5.329; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; TANGSRUD SE, 1988, CLIN GENET, V34, P145; WAPENAAR MC, 1990, NUCLEIC ACIDS RES, V18, P384, DOI 10.1093/nar/18.2.384-a	9	163	167	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 2	1992	339	8801					1081	1082		10.1016/0140-6736(92)90668-S	http://dx.doi.org/10.1016/0140-6736(92)90668-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349106				2022-12-28	WOS:A1992HR44600007
J	GAILANI, MR; BALE, SJ; LEFFELL, DJ; DIGIOVANNA, JJ; PECK, GL; POLIAK, S; DRUM, MA; PASTAKIA, B; MCBRIDE, OW; KASE, R; GREENE, M; MULVIHILL, JJ; BALE, AE				GAILANI, MR; BALE, SJ; LEFFELL, DJ; DIGIOVANNA, JJ; PECK, GL; POLIAK, S; DRUM, MA; PASTAKIA, B; MCBRIDE, OW; KASE, R; GREENE, M; MULVIHILL, JJ; BALE, AE			DEVELOPMENTAL DEFECTS IN GORLIN SYNDROME RELATED TO A PUTATIVE TUMOR SUPPRESSOR GENE ON CHROMOSOME-9	CELL			English	Article							BASAL-CELL-CARCINOMA; NEVUS SYNDROME; CANCER; RETINOBLASTOMA; FIBROBLASTS; RADIATION; TISSUE	Gorlin syndrome is an autosomal dominant disorder that predisposes to basal cell carcinomas of the skin, ovarian fibromas, and medulloblastomas. Unlike other hereditary disorders associated with cancer, it features widespread developmental defects. To investigate the possibility that the syndrome is caused by mutation in a tumor suppressor gene, we searched for loss of heterozygosity in 16 sporadic basal cell carcinomas, 2 hereditary basal cell carcinomas, and 1 hereditary ovarian fibroma and performed genetic linkage studies in five Gorlin syndrome kindreds. Eleven sporadic basal cell carcinomas and all 3 hereditary tumors had allelic loss of chromosome 9q31, and all informative kindreds showed tight linkage between the Gorlin syndrome gene and a genetic marker in this region. Loss of heterozygosity at this chromosomal location, particularly in hereditary tumors, implies that the gene is homozygously inactivated and normally functions as a tumor suppressor. In contrast, hemizygous germline mutations lead to multiple congenital anomalies.	NIH, CTR CLIN, DEPT RADIOL, BETHESDA, MD 20892 USA; WESTAT CORP, ROCKVILLE, MD 20852 USA; YALE UNIV, SCH MED, DEPT DERMATOL, NEW HAVEN, CT 06510 USA; NCI, ENVIRONM EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; NIDR, CLIN INVEST & PATIENT CARE BRANCH, BETHESDA, MD 20892 USA; NCI, DERMATOL BRANCH, BETHESDA, MD 20892 USA; NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA; NCI, CLIN EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Westat; Yale University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	GAILANI, MR (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.			DiGiovanna, John J./0000-0002-2750-2313				ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; APPLEGATE LA, 1990, CANCER RES, V50, P637; BALE AE, 1989, CANCER GENET CYTOGEN, V42, P273, DOI 10.1016/0165-4608(89)90095-2; BALE SJ, 1991, AM J MED GENET, V40, P206, DOI 10.1002/ajmg.1320400217; BASSUKAS ID, 1990, LANCET, V336, P825, DOI 10.1016/0140-6736(90)93301-5; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN GL, 1983, AM J PATHOL, V111, P50; FEARS TR, 1982, JNCI-J NATL CANCER I, V69, P365; FEATHERSTONE T, 1983, AM J HUM GENET, V35, P58; FERGUSON-SMITH M A, 1971, Birth Defects Original Article Series, V7, P157; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GAO JS, 1985, CHINESE MED J-PEKING, V98, P538; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIBBS PM, 1986, CANCER GENET CYTOGEN, V20, P369, DOI 10.1016/0165-4608(86)90097-X; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GORLIN RJ, 1960, NEW ENGL J MED, V262, P908, DOI 10.1056/NEJM196005052621803; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; HAPPLE R, 1973, CLIN GENET, V4, P17; HOWELL JB, 1959, ARCH DERMATOL, V79, P67, DOI 10.1001/archderm.1959.01560130069008; JACOBS GH, 1982, CANCER, V49, P533, DOI 10.1002/1097-0142(19820201)49:3<533::AID-CNCR2820490322>3.0.CO;2-O; JUNG EG, 1982, ARCH DERMATOL RES, V272, P151; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KNUDSON AG, 1991, MUTAT RES, V247, P185, DOI 10.1016/0027-5107(91)90013-E; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LATHROP M, 1988, GENOMICS, V3, P361, DOI 10.1016/0888-7543(88)90128-0; LITTLE JB, 1989, CANCER RES, V49, P4705; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P161, DOI 10.1016/0190-9622(91)70022-T; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; Nagasawa H, 1984, Basic Life Sci, V29 Pt B, P775; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; POVEY S, 1990, CYTOGENET CELL GENET, V55, P136, DOI 10.1159/000133005; RINGBORG U, 1981, J INVEST DERMATOL, V76, P268, DOI 10.1111/1523-1747.ep12526102; ROMKE C, 1985, ARCH DERMATOL RES, V277, P370, DOI 10.1007/BF00509235; Sambrook J, 1989, MOL CLONING LABORATO; SARTO F, 1989, MUTAT RES, V225, P21, DOI 10.1016/0165-7992(89)90027-4; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRONG LC, 1977, CANCER, V40, P1861, DOI 10.1002/1097-0142(197710)40:4+<1861::AID-CNCR2820400815>3.0.CO;2-9; TROMOVITCH TA, 1978, CANCER-AM CANCER SOC, V41, P653, DOI 10.1002/1097-0142(197802)41:2<653::AID-CNCR2820410232>3.0.CO;2-X; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEITNAUER L, 1989, NUCLEIC ACIDS RES, V17, P10514, DOI 10.1093/nar/17.24.10514	46	360	364	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					111	117		10.1016/0092-8674(92)90122-S	http://dx.doi.org/10.1016/0092-8674(92)90122-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1348213				2022-12-28	WOS:A1992HM44500010
J	PONNIGHAUS, JM; FINE, PEM; STERNE, JAC; WILSON, RJ; MSOSA, E; GRUER, PJK; JENKINS, PA; LUCAS, SB; LIOMBA, NG; BLISS, L				PONNIGHAUS, JM; FINE, PEM; STERNE, JAC; WILSON, RJ; MSOSA, E; GRUER, PJK; JENKINS, PA; LUCAS, SB; LIOMBA, NG; BLISS, L			EFFICACY OF BCG VACCINE AGAINST LEPROSY AND TUBERCULOSIS IN NORTHERN MALAWI	LANCET			English	Article							TRIAL; DIAGNOSIS	Protection afforded by BCG (bacillus Calmette-Guerin) vaccines against tuberculosis and leprosy varies widely between different populations. In the only controlled trial which assessed protective efficacy of BCG (Danish and Pasteur strains) against both diseases, there was slightly more protection against leprosy than against tuberculosis. We have studied the protective efficacy of BCG (Glaxo, freeze dried) vaccine against these two diseases in Karonga District, northern Malawi. BCG vaccination was introduced into this population in 1974. Prior information about BCG scar status was available for 83 455 individuals followed up between 1979 and 1989. 414 new cases of leprosy and 180 new cases of tuberculosis were found in this population over that period. Protection was estimated at 50% or greater against leprosy, and there was no evidence for lower protection against multibacillary (84%; 95% confidence interval 26% to 97%) than against paucibacillary (51%; 30% to 66%) disease. There was no statistically significant protection by BCG against tuberculosis in this population. These findings add to the evidence that BCG vaccines afford greater protection against leprosy than against tuberculosis.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND; LEPRA,CHILUMBA,MALAWI; QUEEN ELIZABETH HOSP,BLANTYRE,MALAWI; UNIV COLL & MIDDLESEX SCH MED,LONDON,ENGLAND; UNIV HOSP WALES,PUBL HLTH LAB SERV,MYCOBACTERIUM REFERENCE UNIT,CARDIFF,WALES	University of London; London School of Hygiene & Tropical Medicine; University of Malawi; University of London; University College London; Cardiff University			Sterne, Jonathan/Z-3106-2019	Sterne, Jonathan/0000-0001-8496-6053				ABEL L, 1990, LANCET, V335, P1536, DOI 10.1016/0140-6736(90)93086-5; BAGSHAWE A, 1989, B WORLD HEALTH ORGAN, V67, P389; BLIN P, 1986, TUBERCLE, V67, P283, DOI 10.1016/0041-3879(86)90017-6; FINE PEM, 1988, BRIT MED BULL, V44, P691, DOI 10.1093/oxfordjournals.bmb.a072277; FINE PEM, 1988, T ROY SOC TROP MED H, V82, P810, DOI 10.1016/0035-9203(88)90003-X; FINE PEM, 1986, LANCET, V2, P499, DOI 10.1016/S0140-6736(86)90367-3; FINE PEM, 1982, EPIDEMIOL REV, V4, P161, DOI 10.1093/oxfordjournals.epirev.a036245; FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35; KAKLAMANI E, 1991, LANCET, P304; LWIN K, 1985, B WORLD HEALTH ORGAN, V63, P1069; MULIYIL J, 1991, INT J LEPROSY, V59, P229; PONNIGHAUS JM, 1988, T ROY SOC TROP MED H, V82, P803, DOI 10.1016/0035-9203(88)90002-8; PONNIGHAUS JM, 1991, INT J LEPROSY, V59, P221; PONNIGHAUS JM, 1987, INT J LEPROSY, V55, P454; PONNIGHAUS JM, 1987, LEPROSY REV, V58, P359; Rothman K, 1986, MODERN EPIDEMIOLOGY; SHAW MA, 1991, LEPROSY REV, V62, P87; STANLEY SJ, 1981, J HYG CAMB, V87, P223; TIDJANI O, 1986, TUBERCLE, V67, P269, DOI 10.1016/0041-3879(86)90016-4; TRIPATHY SP, 1983, ANN NATL ACAD MED SC, V19, P12; 1980, INDIAN J MED RES S, V72, P1	21	162	166	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					636	639		10.1016/0140-6736(92)90794-4	http://dx.doi.org/10.1016/0140-6736(92)90794-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347338				2022-12-28	WOS:A1992HH74300003
J	JACK, T; BROCKMAN, LL; MEYEROWITZ, EM				JACK, T; BROCKMAN, LL; MEYEROWITZ, EM			THE HOMEOTIC GENE APETALA3 OF ARABIDOPSIS-THALIANA ENCODES A MADS BOX AND IS EXPRESSED IN PETALS AND STAMENS	CELL			English	Article							SERUM RESPONSE ELEMENT; FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; FLORAL DEVELOPMENT; MORPHOGENESIS	Mutations in the APETALA3 (AP3) gene of A. thaliana result in homeotic transformations of petals to sepals and stamens to carpels. We have cloned the AP3 gene from Arabidopsis based on its homology to the homeotic flower gene deficiens (DEFA) from the distantly related plant Antirrhinum majus. The sequence of four ap3 mutant alleles and genetic mapping analysis prove that the DEFA homolog is AP3. Like several other plant homeotic genes, the AP3 gene contains a MADS box and likely acts as a transcription factor. The region-specific spatial expression pattern of AP3 rules out certain types of sequential models of flower development and argues in favor of a spatial model based on positional information. Since DEFA and AP3 have very similar protein products, mutant phenotypes, and spatial expression patterns, it is likely that these genes are cognate homologs.			JACK, T (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Meyerowitz, Elliot M/A-7118-2009		NIGMS NIH HHS [GM 13667-02] Funding Source: Medline; OHS HRSA HHS [ST32-GM07616] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1988, OXFORD SURV PLANT MO, V5, P57; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COX KH, 1988, PLANT MOL BIOL PRACT, P1; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; CRONQUIST A, 1981, INTEGRATED SYSTEM CL; Darwin C, 1903, MORE LETT C DARWIN, V2; DILCHER D, 1984, NAT HIST, V93, P57; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; Heslop-Harrison J., 1964, BROOKHAVEN SYM BIOL, V16, P109; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HOLDER N, 1979, J THEOR BIOL, V77, P195, DOI 10.1016/0022-5193(79)90307-2; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; Lord EM., 1991, FLOWERING NEWSLETTER, V11, P4; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MCHUGHEN A, 1980, BOT GAZ, V141, P389; MULLER J, 1981, BOT REV, V47, P1, DOI 10.1007/BF02860537; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PNUELI L, 1991, PLANT J, V1, P255, DOI 10.1111/j.1365-313X.1991.00255.x; Pruitt RE, 1987, GENETIC REGULATION D, P327; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; SOMMER H, 1991, DEVELOPMENT S, V1, P169; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	43	755	837	8	95	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					683	697		10.1016/0092-8674(92)90144-2	http://dx.doi.org/10.1016/0092-8674(92)90144-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1346756				2022-12-28	WOS:A1992HF44000009
J	GOLDSTEIN, AR; WHITE, RHR; AKUSE, R; CHANTLER, C				GOLDSTEIN, AR; WHITE, RHR; AKUSE, R; CHANTLER, C			LONG-TERM FOLLOW-UP OF CHILDHOOD HENOCH-SCHONLEIN NEPHRITIS	LANCET			English	Article							ANAPHYLACTOID PURPURA NEPHRITIS; PROGNOSTIC-SIGNIFICANCE; SCHOENLEIN NEPHRITIS; CHILDREN	A study of long-term outcome of 78 subjects who had had Henoch-Schonlein nephritis during childhood (at a mean of 23.4 years after onset) shows that severity of clinical presentation and initial findings on renal biopsy correlate well with outcome but have poor predictive value in individuals. 44% of patients who had nephritic, nephrotic, or nephritic/nephrotic syndromes at onset have hypertension or impaired renal function, whereas 82% of those who presented with haematuria (with or without proteinuria) are normal. 17 patients deteriorated clinically from an initial assessment in 1971; 7 of these had apparently completely recovered in 1976. 16 of 44 full-term pregnancies were complicated by proteinuria and/or hypertension, even in the absence of active renal disease. These findings indicate that childhood Henoch-Schonlein nephritis requires long-term follow-up, especially during pregnancy.	CHILDRENS HOSP,DEPT NEPHROL,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND; GUYS HOSP,DEPT PAEDIAT NEPHROL,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust								BOLD AM, 1975, CLIN CHEM CONVERSION, P20; BRENNER BM, 1983, KIDNEY INT, V23, P647, DOI 10.1038/ki.1983.72; BUNCHMAN TE, 1988, PEDIATR NEPHROL, V2, P393, DOI 10.1007/BF00853428; COUNAHAN R, 1977, BRIT MED J, V2, P11, DOI 10.1136/bmj.2.6078.11; Donckerwolcke R A, 1978, Proc Eur Dial Transplant Assoc, V15, P77; ELISES JS, 1988, CLIN NEPHROL, V30, P225; FARINE M, 1986, CLIN PEDIATR, V25, P257, DOI 10.1177/000992288602500505; HABIB R, 1973, CLIN PEDIATR, V12, P445, DOI 10.1177/000992287301200815; HURLEY RM, 1972, J PEDIATR-US, V81, P904, DOI 10.1016/S0022-3476(72)80541-9; KOSKIMIES O, 1981, ARCH DIS CHILD, V56, P482, DOI 10.1136/adc.56.6.482; KOSKIMIES O, 1974, ACTA PAEDIATR SCAND, V63, P357, DOI 10.1111/j.1651-2227.1974.tb04810.x; Levy M, 1976, Adv Nephrol Necker Hosp, V6, P183; MEADOW SR, 1978, CLIN NEPHROL, V9, P87; MEADOW SR, 1972, Q J MED, V41, P241; MOTAHERNANDEZ F, 1975, PEDIATRICIAN, V4, P452; SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P573; STEWART M, 1988, EUR J PEDIATR, V147, P113, DOI 10.1007/BF00442205; WALKER RJ, 1986, NZ MED J, V19, P534; WHITE RHR, 1991, SYSTEMIC VASCULITIDE, P203; YOSHIKAWA N, 1981, CLIN NEPHROL, V16, P223; 1978, WHO TECH REP SER, V628, P8	21	283	310	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					280	282		10.1016/0140-6736(92)91341-5	http://dx.doi.org/10.1016/0140-6736(92)91341-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346291				2022-12-28	WOS:A1992HB52900013
J	SFORZINI, S; LATINI, R; MINGARDI, G; VINCENTI, A; REDAELLI, B				SFORZINI, S; LATINI, R; MINGARDI, G; VINCENTI, A; REDAELLI, B			VENTRICULAR ARRHYTHMIAS AND 4-YEAR MORTALITY IN HEMODIALYSIS-PATIENTS	LANCET			English	Note							AMBULATORY PERITONEAL-DIALYSIS; HEMODIALYSIS; TRANSPLANTATION	127 randomly selected patients on haemodialysis showed a high prevalence of ventricular arrhythmias, the frequency of which rose significantly during and after dialysis. These patients have now been followed up for 4 years. Only age and ischaemic heart disease correlated independently with mortality. Although ventricular arrhythmias are often associated with cardiac disease in patients on chronic haemodialysis, they do not seem to predict overall mortality.	OSPED SAN GERARDO, DIV RENAL & DIALYSIS, MONZA, ITALY; OSPED RIUNITI BERGAMO, DIV RENAL & DIALYSIS, I-24100 BERGAMO, ITALY; MARIO NEGRI INST PHARMACOL RES, I-20157 MILAN, ITALY; OSPED SAN GERARDO, DIV CARDIOL, MONZA, ITALY	San Gerardo Hospital; Ospedali Riuniti di Bergamo; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; San Gerardo Hospital			Latini, Roberto/AAB-1410-2020	Latini, Roberto/0000-0002-3729-4650				BRADLEY JR, 1987, LANCET, V1, P295; BRUNNER FP, 1988, NEPHROL DIAL TRANSPL, V2, P109; BRYNGER H, 1980, 7TH P C EUR DIAL TRA, P36; BURTON PR, 1987, LANCET, V1, P1115; DEGOULET P, 1982, NEPHRON, V31, P103, DOI 10.1159/000182627; GOKAL R, 1987, LANCET, V2, P1105; KJELLSTRAND CM, 1990, AM J KIDNEY DIS, V15, P483, DOI 10.1016/S0272-6386(12)70365-7; LATINI R, 1988, LANCET, V2, P305	8	60	61	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1992	339	8787					212	213		10.1016/0140-6736(92)90008-Q	http://dx.doi.org/10.1016/0140-6736(92)90008-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346174				2022-12-28	WOS:A1992HA58900005
J	JAHR, CE				JAHR, CE			HIGH PROBABILITY OPENING OF NMDA RECEPTOR CHANNELS BY L-GLUTAMATE	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; ANTICONVULSANT MK-801; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; TIME COURSE; CURRENTS; DESENSITIZATION; POTENTIATION; ANTAGONIST; RESPONSES	Synaptic plasticity can be triggered by calcium flux into neurons through synaptically activated N-methyl-D-aspartate (NMDA) receptor channels. The amplitude and time course of the resulting intracellular calcium transient depend on the number of open NMDA receptor channels and the kinetics of their activation. Short applications of L-glutamate to outside-out patches from hippocampal neurons in the presence and absence of MK-801 revealed that about 30 percent of L-glutamate-bound channels are open at the peak of the current. This high probability of opening suggests that very few channels are required to guarantee a large, localized postsynaptic calcium transient.			JAHR, CE (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST L474, PORTLAND, OR 97201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021419] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21419] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; DALE N, 1985, J PHYSIOL-LONDON, V363, P35, DOI 10.1113/jphysiol.1985.sp015694; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GIBB AJ, 1991, P R SOC LONDON, V243, P34; HALLIWELL RF, 1989, BRIT J PHARMACOL, V96, P480, DOI 10.1111/j.1476-5381.1989.tb11841.x; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JAHR CE, UNPUB; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LESTER RAJ, IN PRESS J NEUROSCI; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MACDONALD JF, 1991, J PHYSIOL-LONDON, V432, P483, DOI 10.1113/jphysiol.1991.sp018396; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; RANDALL AD, 1990, NEUROSCI LETT, V114, P191, DOI 10.1016/0304-3940(90)90070-P; ROBINSON HPC, 1991, BIOPHYS J, V59, P295, DOI 10.1016/S0006-3495(91)82223-8; ROSENMUND C, 1991, Society for Neuroscience Abstracts, V17, P957; SATHER W, 1990, NEURON, V4, P725, DOI 10.1016/0896-6273(90)90198-O; VYKLICKY L, 1990, J PHYSIOL-LONDON, V428, P313, DOI 10.1113/jphysiol.1990.sp018214; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	28	124	124	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	1992	255	5043					470	472		10.1126/science.1346477	http://dx.doi.org/10.1126/science.1346477			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1346477				2022-12-28	WOS:A1992HA59000043
J	THORNTON, HM				THORNTON, HM			BREAST-CANCER TRIALS - A PATIENTS VIEWPOINT	LANCET			English	Editorial Material											THORNTON, HM (corresponding author), SAIONARA,31 REGENT ST,COLCHESTER CO5 7EA,ESSEX,ENGLAND.							Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; HAMILTON CR, 1990, BRIT MED J, V301, P224, DOI 10.1136/bmj.301.6745.224	2	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					44	45		10.1016/0140-6736(92)90157-X	http://dx.doi.org/10.1016/0140-6736(92)90157-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345963				2022-12-28	WOS:A1992GY04300016
J	EGGER, J; STOLLA, A; MCEWEN, LM				EGGER, J; STOLLA, A; MCEWEN, LM			CONTROLLED TRIAL OF HYPOSENSITIZATION IN CHILDREN WITH FOOD-INDUCED HYPERKINETIC SYNDROME	LANCET			English	Article							HAY-FEVER	Food intolerance seems to be an important cause of the hyperkinetic syndrome, but restricted diets are expensive, socially disruptive, and often nutritionally inadequate. Enzyme-potentiated desensitisation (EPD) may overcome some of these difficulties. EPD was tested in a double-blind placebo-controlled trial among 40 children with food-induced hyperkinetic behaviour disorder. A total of 185 children with established hyperkinetic syndrome underwent oligoantigenic dietary treatment for four weeks. 116 whose behaviour responded had provoking foods identified by sequential reintroduction. Foods that reproducibly provoked overactivity were avoided. 40 patients who were then invited to take part in the hyposensitisation trial were randomly assigned to treated and control groups. Treated patients received three doses of EPD (beta-glucuronidase and small quantities of food antigens) intradermally at two-monthly intervals. Controls received buffer only. Thereafter, patients were allowed to eat known provoking foods. Of 20 patients who received active treatment, 16 became tolerant towards provoking foods compared with 4 of 20 who received placebo (p < 0.001). Our results show that EPD permits children with food-induced hyperkinetic syndrome to eat foods that had previously been identified as responsible for their symptoms. These results also support the notion that food allergy is a possible mechanism of the hyperkinetic syndrome.	ALLERGY UNIT,LONDON W1M 7DE,ENGLAND		EGGER, J (corresponding author), UNIV MUNICH,KINDERKLIN,LINDWURMSTR 4,W-8000 MUNICH 2,GERMANY.							BROSTOFF J, 1969, LANCET, V2, P1269; COCA AF, 1943, FAMILIAL NONREAGINIC; CONNERS CK, 1973, PSYCHOPHARMACOLOGY B, P24; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EGGER J, 1985, LANCET, V1, P940; FELL P, 1990, EUR J CLIN PHARMACOL, V38, P77, DOI 10.1007/BF00314808; HUNTER JO, 1991, LANCET, V338, P495, DOI 10.1016/0140-6736(91)90557-6; KAPLAN BJ, 1989, PEDIATRICS, V83, P7; LATHI A, 1980, ALLERGY, V35, P297; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; MCALLEN MK, 1967, BMJ-BRIT MED J, V1, P22, DOI 10.1136/bmj.1.5531.22; MCEWEN LM, 1975, ANN ALLERGY, V34, P290; MCEWEN LM, 1975, ANN ALLERGY, V35, P98; MCEWEN LM, 1987, FOOD ALLERGY INTOLER, P985; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; PAGANELLI R, 1979, LANCET, V1, P1270; RUTTER M, 1975, GUIDE MULTIAXIAL CLA; SCADDING GK, 1988, BRIT MED J, V297, P105, DOI 10.1136/bmj.297.6641.105; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; URBANOVICZ M, UNPUB FEW FOODS DIET; WARNER JO, 1978, LANCET, V2, P912; 1987, DIAGNOSTIC STATISTIC	22	53	55	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1150	1153		10.1016/0140-6736(92)90742-L	http://dx.doi.org/10.1016/0140-6736(92)90742-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349376				2022-12-28	WOS:A1992HT23600013
J	KOSUNEN, TU; SEPPALA, K; SARNA, S; SIPPONEN, P				KOSUNEN, TU; SEPPALA, K; SARNA, S; SIPPONEN, P			DIAGNOSTIC-VALUE OF DECREASING IGG, IGA, AND IGM ANTIBODY-TITERS AFTER ERADICATION OF HELICOBACTER-PYLORI	LANCET			English	Article							CAMPYLOBACTER-PYLORI; GASTRIC-MUCOSA; SERUM IGG	Titres of antibody to Helicobacter pylori are known to fall with eradication of bacteria. To find out what degree of fall would reliably indicate eradication, 144 patients with Helicobacter pylori infection were given antimicrobial therapy for 2 weeks and then followed up at 6 weeks, 6 months, and 12 months with serological tests, bacterial cultures, and histological studies of gastric specimens. 6 weeks after treatment IgG titres had fallen by 20-30% irrespective of the success of bacterial eradication. In the 121 bacteria-negative patients the decrease continued. 6 and 1 2 months after treatment the titre was 50% or less of pretreatment value in 97% of these patients. In the 23 patients who remained infected, the initial drop of IgG titres, if any, was followed by unchanged or slightly rising titres. IgA and IgM titres, initially raised in 64% and 4% of the patients, respectively, showed similar trends. The high sensitivity (97%) of the IgG antibody tests and a consistent fall within 6 months after eradication of H pylori infection made IgG the most useful immunoglobulin class for follow-up of antimicrobial therapy in individual patients. IgA antibodies were valuable in the 2% patients who had raised titres in this immunoglobulin class only. The few patients (5-5%) who had raised IgM titres also had high IgG titres. Serological tests thus are a cheap and reliable means of monitoring success of eradication of H pylori.	JORVI HOSP,DEPT PATHOL,ESPOO,FINLAND; UNIV HELSINKI,DEPT MED 2,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,SF-00290 HELSINKI 29,FINLAND	University of Helsinki; University of Helsinki	KOSUNEN, TU (corresponding author), UNIV HELSINKI,DEPT BACTERIOL & IMMUNOL,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND.			Sarna, Seppo/0000-0003-3458-1627				BELL GD, 1987, LANCET, V1, P1367; BORODY TJ, 1987, MED J AUSTRALIA, V146, P450, DOI 10.5694/j.1326-5377.1987.tb120344.x; GOODWIN CS, 1985, J CLIN PATHOL, V38, P1127, DOI 10.1136/jcp.38.10.1127; GRAHAM DY, 1987, LANCET, V1, P1174; HIRSCHL AM, 1988, EUR J CLIN MICROBIOL, V7, P570, DOI 10.1007/BF01962618; JONES DM, 1986, J MED MICROBIOL, V22, P57, DOI 10.1099/00222615-22-1-57; JONES DM, 1984, J CLIN PATHOL, V37, P1002, DOI 10.1136/jcp.37.9.1002; KOSUNEN TU, 1989, SCAND J GASTROENTERO, V24, P110, DOI 10.3109/00365528909092247; MORRIS AJ, 1991, ANN INTERN MED, V114, P662, DOI 10.7326/0003-4819-114-8-662; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; ODERDA G, 1989, LANCET, V1, P690; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; VAIRA D, 1988, BMJ-BRIT MED J, V297, P397, DOI 10.1136/bmj.297.6645.397; VALLE J, 1991, SCAND J GASTROENTERO, V26, P1057, DOI 10.3109/00365529109003956; VANBOHEMEN CG, 1989, IMMUNOL LETT, V20, P59, DOI 10.1016/0165-2478(89)90069-2; VEENENDAAL RA, 1991, GUT, V32, P1291, DOI 10.1136/gut.32.11.1291; VILLAKO K, 1990, ENDOSCOPY, V22, P114, DOI 10.1055/s-2007-1012814	18	377	380	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					893	895		10.1016/0140-6736(92)90929-W	http://dx.doi.org/10.1016/0140-6736(92)90929-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348298				2022-12-28	WOS:A1992HN48300004
J	COOLEY, L; VERHEYEN, E; AYERS, K				COOLEY, L; VERHEYEN, E; AYERS, K			CHICKADEE ENCODES A PROFILIN REQUIRED FOR INTERCELLULAR CYTOPLASM TRANSPORT DURING DROSOPHILA OOGENESIS	CELL			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; MEDIATED ENHANCER DETECTION; ACTIN-BINDING PROTEINS; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; INSERTIONAL MUTAGENESIS; ACANTHAMOEBA PROFILIN; ANTERIOR PATTERN; GENE FAMILY; MELANOGASTER	The entire cytoplasmic contents of 15 highly polyploid nurse cells are transported rapidly to the oocyte near the end of Drosophila oogenesis, chickadee is one of a small group of genes whose mutant phenotype includes a disruption of this nurse cell cytoplasm transport. We have cloned the chickadee gene and found that cDNA clones encode a protein 40% identical to yeast and Acanthamoeba profilin. The nurse cells from chickadee egg chambers that lack ovary-specific profilin fail to synthesize cytoplasmic actin networks correctly. In addition, the nurse cell nuclei in chickadee egg chambers become displaced and often partially stretched through the channels leading into the oocyte, blocking the flow of cytoplasm. We suggest that the newly synthesized cytoplasmic actin networks are responsible for maintaining nuclear position in the nurse cells.			COOLEY, L (corresponding author), YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Verheyen, Esther/0000-0002-9795-5094	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043301] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD07149] Funding Source: Medline; NIGMS NIH HHS [GM43301] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BINETTE F, 1990, DNA CELL BIOL, V9, P323, DOI 10.1089/dna.1990.9.323; BOHRMANN J, 1987, DEVELOPMENT, V101, P279; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; COOLEY L, 1988, TRENDS GENET, V4, P254, DOI 10.1016/0168-9525(88)90032-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIMARIO P, 1986, CELL TISSUE RES, V246, P103; Engels W.R, 1989, MOBILE DNA, P437; FASANO L, 1988, DEVELOPMENT, V104, P245; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GONDOS B, 1987, INT J GYNECOL PATHOL, V6, P114, DOI 10.1097/00004347-198706000-00003; GONDOS B, 1973, Differentiation, V1, P177, DOI 10.1111/j.1432-0436.1973.tb00112.x; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; GUTZEIT HO, 1986, J CELL SCI, V80, P159; GUTZEIT HO, 1986, J EMBRYOL EXP MORPH, V93, P291; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; JAFFE LF, 1979, P NATL ACAD SCI USA, V76, P1328, DOI 10.1073/pnas.76.3.1328; JAFFE LF, 1969, DEVELOP BIOL       S, V3, P83; KIEHART DP, 1989, EMBO J, V8, P913, DOI 10.1002/j.1460-2075.1989.tb03452.x; King R. C., 1970, OVARIAN DEV DROSOPHI; KNIPPLE DC, 1984, MOL GEN GENET, V198, P75, DOI 10.1007/BF00328704; KNIPPLE DC, 1991, MOL GEN GENET, V226, P241, DOI 10.1007/BF00273609; KOTARSKI MA, 1983, GENETICS, V105, P371; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MARKEY F, 1981, CELL, V23, P145, DOI 10.1016/0092-8674(81)90279-8; MINDRINOS MN, 1985, EMBO J, V4, P147, DOI 10.1002/j.1460-2075.1985.tb02329.x; MLODZIK M, 1991, IN PRESS METHODS NEU, V9; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1991, CELL MOTIL CYTOSKEL, V20, P169, DOI 10.1002/cm.970200209; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; POPODI E, 1988, DEV BIOL, V127, P248, DOI 10.1016/0012-1606(88)90312-0; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1991, GENETICS, V129, P1119; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SPARDLING A, 1992, IN PRESS DROSOPHILA; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; SUN YA, 1992, IN PRESS DEV BIOL; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WARN RM, 1985, EXP CELL RES, V157, P355, DOI 10.1016/0014-4827(85)90120-X; WIDADA JS, 1989, NUCLEIC ACIDS RES, V17, P2855, DOI 10.1093/nar/17.7.2855; WOODRUFF RI, 1980, NATURE, V286, P84, DOI 10.1038/286084a0; WOODRUFF RI, 1988, ROUX ARCH DEV BIOL, V197, P231, DOI 10.1007/BF02439430; YOUNG PE, 1991, DEVELOPMENT, V111, P1; ZAMBONI L, 1968, J CELL BIOL, V36, P276, DOI 10.1083/jcb.36.1.276	70	322	330	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					173	184		10.1016/0092-8674(92)90128-Y	http://dx.doi.org/10.1016/0092-8674(92)90128-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1339308	hybrid			2022-12-28	WOS:A1992HM44500016
J	ABRAMOWICZ, D; PRADIER, O; MARCHANT, A; FLORQUIN, S; DEPAUW, L; VEREERSTRAETEN, P; KINNAERT, P; VANHERWEGHEM, JL; GOLDMAN, M				ABRAMOWICZ, D; PRADIER, O; MARCHANT, A; FLORQUIN, S; DEPAUW, L; VEREERSTRAETEN, P; KINNAERT, P; VANHERWEGHEM, JL; GOLDMAN, M			INDUCTION OF THROMBOSES WITHIN RENAL GRAFTS BY HIGH-DOSE PROPHYLACTIC OKT3	LANCET			English	Note							TUMOR-NECROSIS-FACTOR; TRANSPLANT RECIPIENTS; MONOCLONAL-ANTIBODY; INTERFERON; SERUM	Among 93 consecutive kidney-transplant patients who received prophylactic OKT3 10 mg/day for 2 weeks, 9 had intragraft thromboses within 2 weeks of transplantation. The thromboses were in graft artery in 1 patient and veins in 3. The other 5 had thromboses in glomerular capillaries and thrombotic microangiopathy similar to that of haemolyticuraemic syndrome. All attempted treatments failed, and the 9 grafts had to be removed. The finding that plasma concentrations of prothrombin fragment 1 and 2 were higher 4 h after the first OKT3 dose in OKT3 recipients than in transplant patients who received other prophylaxis (mean 5.88 [SEM 0.76] vs 2.25 [0.59] nmol/l, p < 0.01) confirms that OKT3 has procoagulant effects in vivo.	CLIN UNIV BRUXELLES,HOP ERASME,DEPT HAEMATOL,BRUSSELS,BELGIUM; CLIN UNIV BRUXELLES,HOP ERASME,DEPT PATHOL,BRUSSELS,BELGIUM; CLIN UNIV BRUXELLES,HOP ERASME,DEPT IMMUNOL,BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Universite Libre de Bruxelles	ABRAMOWICZ, D (corresponding author), CLIN UNIV BRUXELLES,HOP ERASME,DEPT NEPHROL,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.		Florquin, Sandrine/B-8242-2012					ABRAMOWICZ D, 1989, TRANSPLANTATION, V47, P606, DOI 10.1097/00007890-198904000-00008; ABRAMOWICZ D, IN PRESS TRANSPLANTA; CHATENOUD L, 1989, NEW ENGL J MED, V320, P1420; COLVIN RB, 1991, TRANSPL P, V23, P2052; COTRAN RS, 1989, KIDNEY INT, V35, P969, DOI 10.1038/ki.1989.80; KREIS H, 1991, TRANSPLANT REV, V5, P181; VANBUREN D, 1985, SURGERY, V98, P54; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302	8	85	86	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					777	778		10.1016/0140-6736(92)91897-H	http://dx.doi.org/10.1016/0140-6736(92)91897-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347805				2022-12-28	WOS:A1992HL50100005
J	BRAHAMS, D				BRAHAMS, D			MISSED DIAGNOSIS OF TESTICULAR CANCER	LANCET			English	Editorial Material																			0	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					734	735		10.1016/0140-6736(92)90618-D	http://dx.doi.org/10.1016/0140-6736(92)90618-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347594				2022-12-28	WOS:A1992HK32000016
J	MARION, MH; KLAP, P; PERRIN, A; COHEN, M				MARION, MH; KLAP, P; PERRIN, A; COHEN, M			STRIDOR AND FOCAL LARYNGEAL DYSTONIA	LANCET			English	Note							PARALYSIS	Fibreoptic laryngoscopy in 6 patients with laryngeal stridor showed immobile vocal cords in a paramedian position but no other local cause. Thus a diagnosis of Gerhardt's syndrome, usually ascribed to paralysis of vocal-cord abductor muscles, was made in 3 patients who had no other signs or symptoms of dystonia, and in 3 patients who had multifocal dystonia. Electromyography (EMG) showed evidence of overactivity of vocal-cord adductors, with no evidence of denervation in the abductor muscles. Botulinum toxin injection of the overactive thyroarytenoid muscles abolished stridor. These clinical and EMG findings indicate that Gerhardt's syndrome is not caused by paralysis of vocal-cord abductors, but represents a focal laryngeal dystonia which may be treatable by botulinum toxin injections of vocal-cord adductor muscles rather than by arytenoidopexy or tracheostomy.	FDN ADOLPHE DE ROTHSCHILD,DEPT OTORHINOLARYNGOL,F-75940 PARIS 19,FRANCE; FDN ADOLPHE DE ROTHSCHILD,NEUROPHYSIOL LAB,F-75940 PARIS 19,FRANCE									ALAJOUANINE T, 1953, Ann Otolaryngol, V70, P365; BANNISTER R, 1981, BRAIN, V104, P351, DOI 10.1093/brain/104.2.351; BLITZER A, 1991, ANN OTO RHINOL LARYN, V100, P85, DOI 10.1177/000348949110000201; Gerhardt C., 1863, VIRCHOWS ARCH, V27, P68; GERHARDT C, 1863, VIRCHOWS ARCH, V27, P296; LAPRESLE J, 1979, J NEUROPATHOL EXP NE, V28, P401; MARION MH, IN PRESS REV NERUOL; MARSDEN CD, 1982, NEUROLOGY, V32, P1202, DOI 10.1212/WNL.32.10.1202; ROTHWELL JC, 1987, MOVEMENT DISORD, V2, P313; WILLIAMS A, 1979, J NEUROL NEUROSUR PS, V42, P151, DOI 10.1136/jnnp.42.2.151; WOODMAN D, 1946, ARCH OTOLARYNGOL, V43, P63	11	44	46	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					457	458		10.1016/0140-6736(92)91060-L	http://dx.doi.org/10.1016/0140-6736(92)91060-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346820				2022-12-28	WOS:A1992HE93200005
J	REPINE, JE				REPINE, JE			SCIENTIFIC PERSPECTIVES ON ADULT RESPIRATORY-DISTRESS SYNDROME	LANCET			English	Article							LUNG INJURY; NEUTROPHILS; PERMEABILITY; RATS				REPINE, JE (corresponding author), UNIV COLORADO,HLTH SCI CTR,WEBB WARING LUNG INST,4200 E 9TH AVE,BOX C321,DENVER,CO 80262, USA.							ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; BAIRD BR, 1986, J APPL PHYSIOL, V61, P2224, DOI 10.1152/jappl.1986.61.6.2224; BERNARD G R, 1989, American Review of Respiratory Disease, V139, pA221; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERNARD GR, 1989, CHEST, V96, pA137; BONE RC, 1989, CHEST, V96, P114, DOI 10.1378/chest.96.1.114; Braquet P, 1989, Prog Clin Biol Res, V308, P425; BRIGHAM KL, 1979, CIRC RES, V45, P292, DOI 10.1161/01.RES.45.2.292; FERRARIBALIVIERA E, 1989, ARCH SURG-CHICAGO, V124, P1400; FLICK M R, 1986, Critical Care Clinics, V2, P455; KENNEDY TP, 1989, J CLIN INVEST, V83, P1326, DOI 10.1172/JCI114019; LEFF JA, IN PRESS CLIN RES; LINAS SL, 1988, AM J PHYSIOL, V24, P728; LYKENS M, 1988, CLIN RES, V36, pA508; MARTIN TR, 1989, J CLIN INVEST, V84, P1609, DOI 10.1172/JCI114338; MARTIN TR, 1991, AM REV RESPIR DIS, V144, P254, DOI 10.1164/ajrccm/144.2.254; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; REPINE JE, 1991, AM REV RESPIR DIS, V144, P251, DOI 10.1164/ajrccm/144.2.251; RINALDO JE, 1990, CLIN CHEST MED, V11, P621; RIVA CM, 1990, AM J RESP CELL MOL, V3, P301, DOI 10.1165/ajrcmb/3.4.301; SZNAJDER JI, 1989, CHEST, V96, P606, DOI 10.1378/chest.96.3.606; TERADA LS, 1989, CLIN RES, V37, pA145; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; WHITE CW, 1987, J CLIN INVEST, V79, P1868, DOI 10.1172/JCI113029; WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255; ZIMMERMAN GA, 1983, AM REV RESPIR DIS, V127, P290	26	205	216	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					466	469		10.1016/0140-6736(92)91067-I	http://dx.doi.org/10.1016/0140-6736(92)91067-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346826				2022-12-28	WOS:A1992HE93200012
J	DALTON, S; TREISMAN, R				DALTON, S; TREISMAN, R			CHARACTERIZATION OF SAP-1, A PROTEIN RECRUITED BY SERUM RESPONSE FACTOR TO THE C-FOS SERUM RESPONSE ELEMENT	CELL			English	Article							YEAST HO GENE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; TERNARY COMPLEX; CYC1 GENE; DNA; PROMOTER; EXPRESSION; BINDS; IDENTIFICATION	We used a yeast genetic screen to isolate cDNAs that encode a protein, SRF accessory protein-1 (SAP-1), that is recruited to the c-fos serum response element (SRE) as part of a ternary complex that includes serum response factor (SRF). SAP-1 requires DNA-bound SRF for ternary complex formation and makes extensive DNA contacts to the 5' side of SRF, but does not bind DNA autonomously. Ternary complex formation by SAP-1 requires only the DNA-binding domain of SRF, which can be replaced by that of the related yeast protein MCM1. We isolated cDNAs encoding two forms of SAP-1 protein, SAP-1a and SAP-1b, which differ at their C termini. Both SAP-1 proteins contain three regions of striking homology with the elk-1 protein, including an N-terminal ets domain. Ternary complex formation by SAP-1 requires both the ets domain and a second conserved region 50 amino acids to its C-terminal side. SAP-1 has similar DNA binding properties to the previously characterized HeLa cell protein p62/TCF.			DALTON, S (corresponding author), IMPERIAL CANC RES FUND, TRANSCRIPT LAB, LONDON WC2A 3PX, ENGLAND.			Treisman, Richard/0000-0002-9658-0067				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DOALN JW, 1991, BIOCH BIPOHYS ACTA, V1088, P155; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; FROHMAN MA, 1991, AMPLIFICATIONS, V1, P11; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GODING CR, 1989, VIROLOGY, V173, P363; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; Guthrie C, 1991, METHOD ENZYMOL, P194; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA J, 1988, CELL, V55, P443, DOI 10.1016/0092-8674(88)90030-X; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MOHUN TJ, 1989, DEVELOPMENT, V107, P835; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RUSSO P, 1989, P NATL ACAD SCI USA, V86, P8348, DOI 10.1073/pnas.86.21.8348; SAMBROOK J, 1990, MOL CLONING LABORATO; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIKORSKI RS, 1989, GENETICS, V122, P19; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; VIERA J, 1987, METHOD ENZYMOL, V2153, P3; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0	58	625	680	0	12	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					597	612		10.1016/0092-8674(92)90194-H	http://dx.doi.org/10.1016/0092-8674(92)90194-H			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1339307				2022-12-28	WOS:A1992HD39800018
J	BRAHAMS, D				BRAHAMS, D			ANESTHESIA AWARENESS - AN ORTHOPEDIC CASE	LANCET			English	Editorial Material																			0	1	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					116	116		10.1016/0140-6736(92)91016-2	http://dx.doi.org/10.1016/0140-6736(92)91016-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345832				2022-12-28	WOS:A1992GZ15600061
J	BRAHAMS, D				BRAHAMS, D			INFORMED CONSENT WHEN AN INVESTIGATION IS INTERRUPTED	LANCET			English	Editorial Material																			0	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					51	52		10.1016/0140-6736(92)90165-Y	http://dx.doi.org/10.1016/0140-6736(92)90165-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345964				2022-12-28	WOS:A1992GY04300020
J	ONEILL, D				ONEILL, D			PHYSICIANS, ELDERLY DRIVERS, AND DEMENTIA	LANCET			English	Article							AGE; MEDICINE	In western countries, the proportion of drivers who are elderly is increasing rapidly; over a quarter of the driving population will be 55 years of age or older by the year 2000. Although elderly drivers tend to drive less and may avoid night driving, the number of car accidents and the severity of injuries sustained in such accidents by distance driven increases strikingly after the age of 65. But how can doctors identify those elderly drivers who are a danger to themselves and others? And, once they are identified, how should clinicians balance the effects of removing a driving license, which may greatly affect a patient's lifestyle, against public safety and breach of confidentiality if the patient refuses to give up his or her license voluntarily? Medical decisions about illnesses that predispose to loss of consciousness are fairly clear-cut, but normal ageing processes and dementia can be much more difficult to identify and to assess; moreover, there seems little correlation between tests of mental performance and driving ability. Comparisons between practices in different countries may provide some answers, but the introduction of modified driving tests for elderly drivers with some evidence of mild impairment but who wish to retain their driving license should be considered.			ONEILL, D (corresponding author), FRENCHAY HOSP,DEPT CARE ELDERLY,BRISTOL BS16 1LE,AVON,ENGLAND.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				[Anonymous], 1990, LANCET, V336, P781; BETTS T, 1988, INT CLIN PSYCHOPH S1, V3, P88; CARR D, 1991, J AM GERIATR SOC, V39, pA62; CARTWRIGHT A, 1990, BRIT MED BULL, V46, P63, DOI 10.1093/oxfordjournals.bmb.a072395; COOPERSMITH HG, 1989, CAN MED ASSOC J, V140, P375; Donnelly R E, 1990, J Geriatr Psychiatry Neurol, V3, P67, DOI 10.1177/089198879000300203; DRACHMAN DA, 1988, ANN NEUROL, V24, P787, DOI 10.1002/ana.410240614; EVANS L, 1988, J GERONTOL, V43, pS186, DOI 10.1093/geronj/43.6.S186; Evans L., 1991, TRAFFIC SAFETY DRIVE; FIFE D, 1984, AM J PUBLIC HEALTH, V74, P473, DOI 10.2105/AJPH.74.5.473; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; HART S, 1991, NEUROPSYCHOLOGY DEME; HOLLAND CA, IN PRESS APPL COGNIT; HUTTON J, 1991, CARERS PROFESSIONALS, P279; KLAMM ER, 1985, DRIVERS 55 PLUS NEED, P87; LUCASBLAUSTEIN MJ, 1988, J AM GERIATR SOC, V36, P1087, DOI 10.1111/j.1532-5415.1988.tb04394.x; MALFETTI JL, 1985, DRIVERS 55 PLUS NEED; MCFARLAND RA, 1964, J GERONTOL, V19, P190, DOI 10.1093/geronj/19.2.190; OCONNOR DW, 1988, BMJ-BRIT MED J, V297, P1107, DOI 10.1136/bmj.297.6656.1107; ODENHEIMER G, 1991, J AM GERIATR SOC, V39, pA9; ONEILL D, IN PRESS J R SOC MED; PFEIFFER RI, 1987, AM J EPIDEMIOL, V125, P420; PONDS RWHM, 1988, J GERONTOL, V43, pP151, DOI 10.1093/geronj/43.6.P151; RAFFLE A, 1985, MED ASPECTS FITNESS, P92; RETCHIN SM, 1988, J AM GERIATR SOC, V36, P813, DOI 10.1111/j.1532-5415.1988.tb04265.x; REUBEN DB, 1988, J AM GERIATR SOC, V36, P1135, DOI 10.1111/j.1532-5415.1988.tb04403.x; SEIB H, 1990, Z GERONTOL, V23, P86; TAIRA ED, 1989, ASSESSING DRIVING AB; WALLER JA, 1967, J CHRON DIS, V20, P615, DOI 10.1016/0021-9681(67)90038-0; WALSH JB, 1980, J IRISH MED ASSOC, V73, P62; WILLIAMS AF, 1989, AM J PUBLIC HEALTH, V79, P326, DOI 10.2105/AJPH.79.3.326; WILLIAMS C, 1991, J AM GERIATR SOC, V39, pA72; 1985, TRAFFIC SAFETY ELDER; 1985, PROFESSIONAL CONDUCT, P19; 1988, MOTORING OLDER DRIVE, P40; 1990, MED ASPECTS FITNESS; 1983, JAMA-J AM MED ASSOC, V249, P3216; 1984, CALDMVRSS8292 CAL ST	39	38	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					41	43		10.1016/0140-6736(92)90155-V	http://dx.doi.org/10.1016/0140-6736(92)90155-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY043	1345962				2022-12-28	WOS:A1992GY04300015
J	ADAMS, DE; SHEKHTMAN, EM; ZECHIEDRICH, EL; SCHMID, MB; COZZARELLI, NR				ADAMS, DE; SHEKHTMAN, EM; ZECHIEDRICH, EL; SCHMID, MB; COZZARELLI, NR			THE ROLE OF TOPOISOMERASE-IV IN PARTITIONING BACTERIAL REPLICONS AND THE STRUCTURE OF CATENATED INTERMEDIATES IN DNA-REPLICATION	CELL			English	Article							ESCHERICHIA-COLI; TN3 RESOLVASE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; SALMONELLA-TYPHIMURIUM; NUCLEOID SEGREGATION; RECOMBINATION; MUTANTS; SITES; DECATENATION	Mutants in bacterial topoisomerase (topo) IV are deficient in chromosomal partitioning. To investigate the basis of this phenotype, we examined plasmid DNA topology in conditionally lethal topo IV mutants. We found that dimeric catenated plasmids accumulated in vivo after topo IV inhibition. The catenanes were supercoiled, contained from 2 to >32 nodes, and were the products of DNA synthesis. Electron microscopy and recombination tests proved that the catenanes have the unique structure predicted for replication intermediates. These data provide strong evidence for a model in which unlinking of the double helix can occur in two stages during DNA replication and for the critical role of topo IV in the second stage. The interlocks in the catenanes appear to be sequestered from DNA gyrase, perhaps by compartmentalization in an enzyme complex dedicated to partitioning.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University	ADAMS, DE (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.		Zechiedrich, Elizabeth Lynn/S-4720-2019	Zechiedrich, Lynn/0000-0003-0533-1637	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM14574-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, J MOL BIOL, V226, P661, DOI 10.1016/0022-2836(92)90623-R; BENJAMIN HW, 1990, J BIOL CHEM, V265, P6441; BENYAJATI C, 1976, CELL, V9, P393, DOI 10.1016/0092-8674(76)90084-2; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; CLEWELL DB, 1970, BIOCHEMISTRY-US, V9, P4428; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DROGE P, 1992, METHOD ENZYMOL, V212, P120; FIELDSBERRY SC, 1989, NUCLEIC ACIDS RES, V17, P3261, DOI 10.1093/nar/17.8.3261; GARRARD WT, 1990, NUCLEIC ACIDS MOL BI, V4, P163; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHII S, 1991, J BACTERIOL, V173, P5551, DOI 10.1128/jb.173.17.5551-5553.1991; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; Kornberg A., 1992, DNA REPLICATION; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; RYAN KA, 1988, P NATL ACAD SCI USA, V85, P5844, DOI 10.1073/pnas.85.16.5844; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID MB, 1990, J BACTERIOL, V172, P5416, DOI 10.1128/jb.172.9.5416-5424.1990; SHELINE C, 1989, MOL CELL BIOL, V9, P169, DOI 10.1128/MCB.9.1.169; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STECK TR, 1984, J BACTERIOL, V158, P397, DOI 10.1128/JB.158.2.397-403.1984; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	41	282	291	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					277	288		10.1016/0092-8674(92)90356-H	http://dx.doi.org/10.1016/0092-8674(92)90356-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1330320				2022-12-28	WOS:A1992JU39500013
J	SACHS, AB; DEARDORFF, JA				SACHS, AB; DEARDORFF, JA			TRANSLATION INITIATION REQUIRES THE PAB-DEPENDENT POLY(A) RIBONUCLEASE IN YEAST	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; PROTEIN-KINASE; REGULATORY SUBUNIT; TRANSFORMATION; DEADENYLATION; SEQUENCE; BINDING; SYSTEM; TAIL	Messenger RNA translation initiation and cytoplasmic poly(A) tail shortening require the poly(A)-binding protein (PAB) in yeast. The PAB-dependent poly(A) ribonuclease (PAN) has been purified to near homogeneity from S. cerevisiae based upon its PAB requirement, and its gene has been cloned. The essential PAN1 gene encodes a 161 kd protein organized into distinct domains containing repeated sequence elements. Deletion analysis of the gene revealed that only one-third of the protein is needed to maintain cell viability. Conditional mutations in PAN1 lead to an arrest of translation initiation and alterations in mRNA poly(A) tail lengths. These data suggest that PAN could mediate each of the PAB-dependent reactions within the cell, and they provide evidence for a direct relationship between translation initiation and mRNA metabolism.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute	SACHS, AB (corresponding author), UNIV CALIF BERKELEY,DEPT BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [R29 GM43164] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043164] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOEKE JD, 1987, 5 FLUOROOROTIC ACID; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; Guthrie C, 1991, GUIDE YEAST GENETICS; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNISAWA R, 1987, NUCLEIC ACIDS RES, V15, P368, DOI 10.1093/nar/15.1.368; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	32	184	190	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					961	973		10.1016/0092-8674(92)90246-9	http://dx.doi.org/10.1016/0092-8674(92)90246-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1339314				2022-12-28	WOS:A1992JN78100011
J	DUSTAN, HP				DUSTAN, HP			GROWTH-FACTORS AND RACIAL-DIFFERENCES IN SEVERITY OF HYPERTENSION AND RENAL DISEASES	LANCET			English	Note							WHITE PATIENTS; BLACK; FIBROBLASTS		UNIV ALABAMA, SCH MED, BIRMINGHAM, AL 35233 USA	University of Alabama System; University of Alabama Birmingham								[Anonymous], 1992, LANCET, V339, P28; BABU M, 1989, MOL CELL BIOL, V9, P1642, DOI 10.1128/MCB.9.4.1642; BERK BC, 1989, BIOCHEM PHARMACOL, V38, P219, DOI 10.1016/0006-2952(89)90030-0; CHOBANIAN AV, 1990, HYPERTENSION, V15, P666, DOI 10.1161/01.HYP.15.6.666; DATUBOBROWN DD, 1990, BRIT J PLAST SURG, V43, P70, DOI 10.1016/0007-1226(90)90047-4; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; DUSTAN HP, 1958, CIRCULATION, V18, P644, DOI 10.1161/01.CIR.18.4.644; FROHLICH ED, 1984, MINER ELECTROL METAB, V10, P173; HAMMOND IW, 1984, J NATL MED ASSOC, V76, P247; MESSERLI FH, 1979, AM J MED, V67, P27, DOI 10.1016/0002-9343(79)90065-2; MUIRHEAD EE, 1989, CLIN CARDIOL, V12, P58; PITCOCK JA, 1976, HUM PATHOL, V7, P333, DOI 10.1016/S0046-8177(76)80043-3; PITCOCK JA, 1975, CIRC RES, V36, P133, DOI 10.1161/01.RES.36.6.133; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; RUSSELL SB, 1988, P NATL ACAD SCI USA, V85, P587, DOI 10.1073/pnas.85.2.587; SAOUAF R, 1991, J CLIN INVEST, V88, P1182, DOI 10.1172/JCI115420; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; SMITH SR, 1991, KIDNEY INT, V40, P815, DOI 10.1038/ki.1991.281; 1990, USRDS1990 NIH US REN	21	22	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1992	339	8805					1339	1340		10.1016/0140-6736(92)91971-A	http://dx.doi.org/10.1016/0140-6736(92)91971-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1350001				2022-12-28	WOS:A1992HW83700013
J	ORRIOLS, R; ALIAGA, JL; RODRIGO, MJ; GARCIA, F; ROYO, L; MORELL, F				ORRIOLS, R; ALIAGA, JL; RODRIGO, MJ; GARCIA, F; ROYO, L; MORELL, F			LOCALIZED ALVEOLAR-SEPTAL AMYLOIDOSIS WITH HYPERSENSITIVITY PNEUMONITIS	LANCET			English	Note							BETA-FIBRILLOSES; DEPOSITS	Localised alveolar-septal amyloidosis has been thought irreversible. A woman exposed to the dust of sea-snail shells during the manufacture of nacre buttons had clinical and immunological features typical of hypersensitivity pneumonitis; however transbronchial lung biopsy showed alveolar-septal amyloidosis. There was no evidence of other diseases known to be associated with amyloidosis, nor were amyloid deposits found in other organs. After a year without exposure to the antigen there was no trace of either pneumonitis or amyloidosis.	HOSP GEN UNIV VALL HEBRON,SERV BIOQUIM,UNITAT IMMUNOL,E-08035 BARCELONA,SPAIN; HOSP GEN UNIV VALL HEBRON,SERV ANAT PATOL,E-08035 BARCELONA,SPAIN; MED OCUPAC,TARRAGONA,SPAIN	Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron	ORRIOLS, R (corresponding author), HOSP GEN UNIV VALL HEBRON,SERV PNEUMOL,PASSEIG VALL HEBRON S-N,E-08035 BARCELONA,SPAIN.			Morell Brotad, Ferran/0000-0002-7206-4543; ORRIOLS, RAMON/0000-0001-8498-5115				CORDIER JF, 1986, CHEST, V90, P827, DOI 10.1378/chest.90.6.827; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; HAWKINS PN, 1988, BLOOD REV, V2, P270, DOI 10.1016/0268-960X(88)90016-1; IWATANI Y, 1982, J IMMUNOL METHODS, V54, P31, DOI 10.1016/0022-1759(82)90110-7; METZGER WJ, 1981, CLIN ALLERGY, V11, P523, DOI 10.1111/j.1365-2222.1981.tb02170.x; ORRIOLS R, 1990, ANN INTERN MED, V113, P80, DOI 10.7326/0003-4819-113-1-80; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; ROCA J, 1990, AM REV RESPIR DIS, V141, P1026, DOI 10.1164/ajrccm/141.4_Pt_1.1026; WILBUR KM, 1972, MOLLUSKA, P103	10	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 23	1992	339	8804					1261	1262		10.1016/0140-6736(92)91595-Y	http://dx.doi.org/10.1016/0140-6736(92)91595-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349670				2022-12-28	WOS:A1992HV19100005
J	SHERMAN, MY; GOLDBERG, AL				SHERMAN, MY; GOLDBERG, AL			HEAT-SHOCK IN ESCHERICHIA-COLI ALTERS THE PROTEIN-BINDING PROPERTIES OF THE CHAPERONIN GROEL BY INDUCING ITS PHOSPHORYLATION	NATURE			English	Article								WHEN bacterial or eukaryotic cells are exposed to high temperatures or other harsh conditions, they respond by synthesis of a specific set of heat-shock proteins 1-3. Certain heat-shock proteins such as groEL, called 'chaperonins', can prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under harmful conditions 2,4. We report here a new aspect of the heat-shock response in Escherichia coli: at high temperatures a fraction of groEL becomes modified covalently, altering its interaction with unfolded proteins. The heat-modified form can be eluted with ATP from an unfolded protein more easily than normal groEL. The critical heat-induced modification seems to be phosphorylation, which is reversed on return to low temperature. Treatment of the modified groEL with phosphatases caused its apparent size, charge and binding properties to resemble those of the unmodified form. Thus during heat shock some groEL is reversibly phosphorylated, which allows its ATP-dependent release from protein substrates in the absence of its usual cofactor (groES), and probably promotes the repair of damaged polypeptides.			SHERMAN, MY (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115, USA.							ALTSCHULER M, 1982, HEAT SHOCK BACTERIA, P321; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HELLEBUST H, 1989, J BIOTECHNOL, V12, P275, DOI 10.1016/0168-1656(89)90047-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MACKEY BM, 1990, J APPL BACTERIOL, V69, P373, DOI 10.1111/j.1365-2672.1990.tb01527.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Morimoto RI, 1990, STRESS PROTEINS BIOL; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PHILLIPS TA, 1987, ESCHERICHIA COLI SAL, V2, P919; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHERMAN M, 1991, J BACTERIOL, V173, P4249; SHERMAN MY, 1992, EMBO J, V11, P71; SMITH BJ, 1991, P NATL ACAD SCI USA, V88, P11091, DOI 10.1073/pnas.88.24.11091; WATSON K, 1984, FEBS LETT, V169, P267	18	97	98	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					167	169		10.1038/357167a0	http://dx.doi.org/10.1038/357167a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1349729				2022-12-28	WOS:A1992HU12200061
J	FRASER, AG; ROSALKI, SB; POUNDER, RE				FRASER, AG; ROSALKI, SB; POUNDER, RE			EFFECTS OF H2-RECEPTOR ANTAGONISTS ON BLOOD-ALCOHOL LEVELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FRASER, AG (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND.							DIPADOVA C, 1992, JAMA-J AM MED ASSOC, V267, P83, DOI 10.1001/jama.267.1.83; FRASER AG, 1992, ALIMENT PHARM THERAP, V6, P267; FRASER AG, 1992, EUR J GASTROEN HEPAT, V4, P43; FRASER AG, 1991, ALIMENT PHARM THERAP, V5, P263	4	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2469	2469		10.1001/jama.1992.03480180055017	http://dx.doi.org/10.1001/jama.1992.03480180055017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349356				2022-12-28	WOS:A1992HT06800013
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WARNINGS ON USE OF ACE INHIBITORS IN 2ND AND 3RD TRIMESTER OF PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2445	2445		10.1001/jama.267.18.2445	http://dx.doi.org/10.1001/jama.267.18.2445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349355				2022-12-28	WOS:A1992HT06800005
J	DESILVA, HJ; WIJEWICKREMA, R; SENANAYAKE, N				DESILVA, HJ; WIJEWICKREMA, R; SENANAYAKE, N			DOES PRALIDOXIME AFFECT OUTCOME OF MANAGEMENT IN ACUTE ORGANOPHOSPHORUS POISONING	LANCET			English	Note							INSECTICIDES	Acute organophosphorus (OP) poisoning is usually treated with atropine plus cholinesterase reactivators such as oximes, but controlled trials to assess the efficacy of oximes in OP poisoning have not been done. A period when the acetyl cholinesterase reactivator pralidoxime chloride was not available in Sri Lanka gave us the opportunity to compare atropine alone for treatment of moderate to severe OP poisoning (21 patients) with atropine plus pralidoxime (24 patients). Outcome, as assessed clinically, was similar in the two groups. These results cast doubt on the necessity of cholinesterase reactivators for treatment of acute OP poisoning.			DESILVA, HJ (corresponding author), UNIV PERADENIYA,FAC MED,DEPT MED,KANDY,SRI LANKA.							DURHAM WF, 1962, ARCH ENVIRON HEALTH, V5, P21, DOI 10.1080/00039896.1962.10663237; FERNANDO R, 1989, Ceylon Medical Journal, V34, P139; HAYES WJ, 1975, TOXICOLOGY PESTICIDE, P410; KUSIC R, 1991, HUM EXP TOXICOL, V10, P113, DOI 10.1177/096032719101000204; LOTTI M, 1982, J TOXICOL-CLIN TOXIC, V19, P121, DOI 10.3109/15563658208990374; MILBY TH, 1971, J AMER MED ASSOC, V216, P2131, DOI 10.1001/jama.216.13.2131; NAMBA T, 1971, AM J MED, V50, P475, DOI 10.1016/0002-9343(71)90337-8; SANDERSON D, 1961, J PHARM PHARMACOL, V13, P435, DOI 10.1111/j.2042-7158.1961.tb11849.x; SENANAYAKE N, 1987, NEW ENGL J MED, V316, P761, DOI 10.1056/NEJM198703263161301; SENANAYAKE N, 1988, FORENSIC SCI INT, V36, P101, DOI 10.1016/0379-0738(88)90221-6	10	115	119	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1136	1138		10.1016/0140-6736(92)90733-J	http://dx.doi.org/10.1016/0140-6736(92)90733-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349368				2022-12-28	WOS:A1992HT23600005
J	NEWELL, ML; DUNN, D; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE				NEWELL, ML; DUNN, D; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE			RISK-FACTORS FOR MOTHER-TO-CHILD TRANSMISSION OF HIV-1	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION; TYPE-1; INFECTION; WOMEN; ANTIBODIES; INFANTS; BORN	Children born to women known to be infected with human immunodeficiency virus type 1 (HIV-1) before delivery were followed prospectively from birth in nineteen European centres. This analysis, encompassing the period end-December, 1984, to beginning-August, 1991, focuses on risk factors for mother-to-child transmission of HIV-1 infection. Rate of vertical transmission, based on 721 children born to 701 mothers more than 18 months before the time of analysis, was 14.4% (95% Cl 12.0-17.1%). Transmission was associated with maternal p24-antigenaemia and a CD4 count of less than 700/mu-l. In a multivariate analysis, odds ratios of transmission were: 2.25 (95% Cl 0.97-5.23) in breastfed children vs never-breastfed children; 3.80 (1.62-8.91) in children born before 34 weeks' gestation; and 0.56 (0.30-1.04) in children delivered by caesarean section. Transmission was higher with vaginal deliveries in which episiotomy, scalp electrodes, forceps, or vacuum extractors were used, but only in centres where these procedures were not routine. On the basis of these results, HIV-infected women contemplating pregnancy should be counselled according to their immunological findings and, if they have p24-antigenaemia or a low CD4 count, warned of an increased risk of viral transmission. Caesarean deliveries may have a protective effect, although it is premature to recommend routine operative delivery. The mechanism for the higher infection rate in children born before 34 weeks' gestation is unclear, but could reflect inadequate passive or active immunity at that age, combined with substantial transmission during labour or delivery. The balance of evidence suggests that mothers with established infection can transmit HIV infection through breastmilk, although the relative importance of this route remains to be defined.	INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; COORDINATING CTR,LONDON,ENGLAND; OSPED SAO PAOLO,MILAN,ITALY	University of London; University College London			Newell, Marie-Louise/AAE-8222-2019; De Rossi, A./L-3128-2015	Newell, Marie-Louise/0000-0002-1074-7699; De Rossi, A./0000-0001-6435-7509; Dunn, David/0000-0003-1836-4446; GIAQUINTO, CARLO/0000-0001-9365-0413				ANDIMAN WA, 1990, AM J DIS CHILD, V144, P758, DOI 10.1001/archpedi.1990.02150310026020; BIGGAR RJ, 1989, AM J OBSTET GYNECOL, V161, P1239, DOI 10.1016/0002-9378(89)90674-1; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CUMMINS LM, 1991, BLOOD, V77, P1111; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; HANSHAW GB, 1985, VIRAL DISEASE FETUS; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; MOK JYQ, 1989, ARCH DIS CHILD, V64, P1140, DOI 10.1136/adc.64.8.1140; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCARLATTI G, 1991, AIDS, V5, P1173, DOI 10.1097/00002030-199110000-00003; SCHULTZ R, 1991, BRIT MED J, V303, P1369, DOI 10.1136/bmj.303.6814.1369; SPRECHER S, 1986, LANCET, V2, P288; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VENET A, 1991, AIDS, V5, P283, DOI 10.1097/00002030-199103000-00006; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; ZAROU DM, 1964, AM J OBSTET GYNECOL, V88, P565, DOI 10.1016/0002-9378(64)90881-6; 1988, LANCET, V2, P1043; 1988, LANCET, V2, P1039; 1987, MMWR, V36, pS3; 1989, LANCET, V2, P36; 1991, LANCET, V337, P253; 1987, WEEKLY EPIDEMIOL REC, V33, P245; 1987, MMWR, V15, P225	34	266	272	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1007	1012						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349050				2022-12-28	WOS:A1992HQ43500002
J	CARNEY, DN				CARNEY, DN			BIOLOGY OF SMALL-CELL LUNG-CANCER	LANCET			English	Article							LINES; PHENOTYPE; INVITRO; GROWTH				CARNEY, DN (corresponding author), MATER MISERICORDIAE HOSP,ECCLES ST,DUBLIN 7,IRELAND.							BUNN PA, 1990, P NATL ACAD SCI USA, V87, P2162, DOI 10.1073/pnas.87.6.2162; CAPORASO NE, 1990, J NATL CANCER I, V82, P1264, DOI 10.1093/jnci/82.15.1264; CARMICHAEL J, 1988, BRIT J CANCER, V57, P540, DOI 10.1038/bjc.1988.125; CARNEY DN, 1988, SEMIN ONCOL, V15, P199; CARNEY DN, 1983, CANCER RES, V43, P2806; CARNEY DN, 1985, CANCER RES, V45, P2913; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; GAZDAR AF, 1990, JNCI-J NATL CANCER I, V82, P117, DOI 10.1093/jnci/82.2.117; GAZDAR AF, 1985, CANCER RES, V45, P2914; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; JOHNSON BE, 1991, P AN M AM SOC CLIN, V10, P240; LAI SL, 1989, J NATL CANCER I, V81, P1114; LAW MR, 1990, BRIT J CANCER, V61, P195, DOI 10.1038/bjc.1990.37; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; MABRY M, 1990, J CLIN INVEST, V85, P1740; MAHMOUD S, 1991, CANCER RES, V51, P1798; MINNA J, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P445; MULSHINE J, 1990, 2ND INT WORKSH SMALL; OIOPADE OI, 1991, P AACR, V32, P1814; PATEL K, 1989, INT J CANCER, V44, P573, DOI 10.1002/ijc.2910440402; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SOUHAMI RL, 1991, J NATL CANCER I, V83, P609, DOI 10.1093/jnci/83.9.609; STEVENSON HC, 1989, J CLIN ONCOL, V113, P923; TSAI CM, 1990, EUR J CANCER, V26, P1148, DOI 10.1016/0277-5379(90)90274-W; VALLENGA E, 1991, CANCER RES, V51, P73; WOLL PJ, 1990, CANCER RES, V50, P3968	26	44	44	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					843	846		10.1016/0140-6736(92)90286-C	http://dx.doi.org/10.1016/0140-6736(92)90286-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347864				2022-12-28	WOS:A1992HM44100011
J	ELLIOTT, P; HILLS, M; BERESFORD, J; KLEINSCHMIDT, I; JOLLEY, D; PATTENDEN, S; RODRIGUES, L; WESTLAKE, A; ROSE, G				ELLIOTT, P; HILLS, M; BERESFORD, J; KLEINSCHMIDT, I; JOLLEY, D; PATTENDEN, S; RODRIGUES, L; WESTLAKE, A; ROSE, G			INCIDENCE OF CANCERS OF THE LARYNX AND LUNG NEAR INCINERATORS OF WASTE SOLVENTS AND OILS IN GREAT-BRITAIN	LANCET			English	Article								The Small Area Health Statistics Unit (SAHSU) is a new independent facility for the investigation of disease near industrial installations in the UK. SAHSU analysed the incidence of cancers of the larynx and lung near the incinerator of waste solvents and oils at Charnock Richard, Coppull, Lancashire (which operated between 1972 and 1980) and nine other similar incinerators in Great Britain, after reports of a cluster of cases of cancer of the larynx near the Charnock Richard site. Postcoded cancer registration data were available for 1974-84 in England and Wales and 1975-87 in Scotland. Lag periods of 5 and 10 years were used between start-up (or first registration) of the incinerators and cancer incidence. Standardised observed/expected (O/E) ratios were assessed within 3 km and 3-10 km of each site and then aggregated over all sites. Expected values were based on national rates (regionally adjusted) with and without stratification by Carstairs' index, a measure of the socioeconomic profile of areas that uses census data for enumeration districts. Data were also assessed over a range of circles up to 10 km to test for trend in O/E ratios with distance. For Charnock Richard, none of the O/E ratios within 3 km or from 3-10 km differed significantly from unity, for either cancer or lag period. In the analysis of all sites with stratification by Carstairs' index, none of these O/E ratios differed significantly from unity for the two cancers. There was no evidence of decreasing risk with distance from the sites of either cancer. We conclude that the apparent cluster of cases of cancer of the larynx reported near Charnock Richard was unlikely to be due to its former incinerator.			ELLIOTT, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,ENVIRONM EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.							[Anonymous], 1986, MODERN EPIDEMIOLOGY, P58; AUSTIN DF, 1982, CANCER EPIDEMIOL, P554; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; DIGGLE PJ, 1990, J ROY STAT SOC A STA, V153, P349, DOI 10.2307/2982977; Doll R, 1981, THE CAUSES OF CANCER; EASTON DF, 1988, BRIT J IND MED, V45, P652; ELLIOTT P, IN PRESS J EPIDEMIOL; ELLIOTT P, IN PRESS GEOGRAPHICA; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FRAUMENI JF, 1982, CANCER EPIDEMIOL, P564; GATRELL AC, UNPUB CANCERS CHORLE; GATRELL AC, 1990, 9 LANC U NW REG RES; GATRELL AC, 1990, 8 LANC U NW REG RES; JOLLEY D, IN PRESS GEOGRAPHICA; KLEINSCHMIDT I, IN PRESS GEOGRAPHICA; Rothman K J, 1980, Epidemiol Rev, V2, P195; STONE RA, 1988, STAT MED, V7, P649, DOI 10.1002/sim.4780070604; SWERDLOW AJ, 1986, J ROY STAT SOC A STA, V149, P146, DOI 10.2307/2981527; WOODFIELD M, 1987, ENV IMPACT REFUSE IN; 1983, NIH832607 US NCI PUB; 1973, IARC MONOGRAPHS EVAL, V3; 1980, CANCER STATISTIC MB1; 1982, IARC MONOGRAPHS E S4, V1	23	74	75	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					854	858		10.1016/0140-6736(92)90290-J	http://dx.doi.org/10.1016/0140-6736(92)90290-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347867				2022-12-28	WOS:A1992HM44100014
J	FARLEY, TMM; ROSENBERG, MJ; ROWE, PJ; CHEN, JH; MEIRIK, O				FARLEY, TMM; ROSENBERG, MJ; ROWE, PJ; CHEN, JH; MEIRIK, O			INTRAUTERINE-DEVICES AND PELVIC INFLAMMATORY DISEASE - AN INTERNATIONAL PERSPECTIVE	LANCET			English	Article							INFECTION	The risk of pelvic inflammatory disease (PID) associated with use of an intrauterine device (IUD) has been an important concern that has dominated decisions on its use throughout the world, especially in the USA. Early research that suggested such an association led to both a dramatic decline in use of the method and its withdrawal from the US market by two manufacturers. However, factors other than use of an IUD are now thought to be major determinants of PID risk. To address these concerns, we have reviewed the World Health Organisation's IUD clinical trial data to explore the incidence and patterns of PID risk with use of an IUD. The overall rate of PID among 22 908 IUD insertions and during 51 399 woman-years of follow-up was 1.6 cases per 1 000 woman-years of use. After adjustment for confounding factors, PID risk was more than six times higher during the 20 days after insertion than during later times (unadjusted rates, 9.7 vs 1.4 per 1 000 woman-years, respectively); the risk was low and constant for up to eight years of follow-up. Rates varied according to geographical area (highest in Africa and lowest in China) and were inversely associated with age. PID rates were lower among women who had IUDs inserted more recently. Our findings indicate that PID among IUD users is most strongly related to the insertion process and to background risk of sexually transmissible disease. PID is an infrequent event beyond the first 20 days after insertion. Because of this increased risk with insertion, IUDs should be left in place up to their maximum lifespan and should not routinely be replaced earlier, provided there are no contraindications to continued use and the woman wishes to continue with the device.	HLTH DECIS INC,CHAPEL HILL,NC		FARLEY, TMM (corresponding author), WHO,SPECIAL PROGRAMME RES DEV & RES TRAINING HUMAN REPROD,CH-1211 GENEVA 27,SWITZERLAND.							BAKER RJ, 1978, GLIM SYSTEM; BISSET AM, 1987, BR J FAM PLANN, V13, P55; BUCHAN H, 1990, BRIT J OBSTET GYNAEC, V97, P780, DOI 10.1111/j.1471-0528.1990.tb02571.x; EDELMAN DA, 1990, BR J FAM PLAN, V16, P132; FARLEY TMM, 1986, STAT MED, V5, P475, DOI 10.1002/sim.4780050512; GARDNER MJ, 1989, BRIT MED J; KESSEL E, 1989, FERTIL STERIL, V51, P1; LEE NC, 1991, OBSTET GYNECOL, V77, P425; LEE NC, 1983, OBSTET GYNECOL, V62, P1; LISKIN L, 1982, POPUL REP B, V10, P101; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MISHELL DR, 1966, AM J OBSTET GYNECOL, V96, P119, DOI 10.1016/S0002-9378(16)34650-6; MOSHER WD, 1990, AM J PUBLIC HEALTH, V9, P1132; SINEI SKA, 1990, BRIT J OBSTET GYNAEC, V97, P412, DOI 10.1111/j.1471-0528.1990.tb01828.x; SIVIN I, 1991, CONTRACEPTION, V44, P473, DOI 10.1016/0010-7824(91)90149-A; SIVIN I, 1979, STUD FAMILY PLANN, V10, P263, DOI 10.2307/1965507; SNOWDEN R, 1984, BRIT MED J, V288, P1570, DOI 10.1136/bmj.288.6430.1570; TIETZE C, 1970, STUD FAM PLAN, V59, P1; TREIMAN K, 1988, POPUL REP B, V16, P1; VESSEY MP, 1981, BRIT MED J, V282, P855, DOI 10.1136/bmj.282.6267.855; WESTROM L, 1990, SEXUALLY TRANSMITTED, P593; 1982, CONTRACEPTION, V26, P1; 1990, CONTRACEPTION, V42, P141	23	445	457	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					785	788		10.1016/0140-6736(92)91904-M	http://dx.doi.org/10.1016/0140-6736(92)91904-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347812				2022-12-28	WOS:A1992HL50100012
J	GLENN, GM; LINEHAN, WM; HOSOE, S; LATIF, F; YAO, M; CHOYKE, P; GORIN, MB; CHEW, E; OLDFIELD, E; MANOLATOS, C; ORCUTT, ML; WALTHER, MM; WEISS, GH; TORY, K; JENSSON, O; LERMAN, MI; ZBAR, B				GLENN, GM; LINEHAN, WM; HOSOE, S; LATIF, F; YAO, M; CHOYKE, P; GORIN, MB; CHEW, E; OLDFIELD, E; MANOLATOS, C; ORCUTT, ML; WALTHER, MM; WEISS, GH; TORY, K; JENSSON, O; LERMAN, MI; ZBAR, B			SCREENING FOR VONHIPPEL-LINDAU DISEASE BY DNA POLYMORPHISM ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKAGE; MANIFESTATIONS; CHROMOSOME-3; MEMBERS; REGION; KIDNEY	Objective.-Von Hippel-Lindau (VHL) disease is a rare, inherited multisystem neoplastic disorder. There is no biochemical test available to distinguish VHL disease gene carriers from their healthy siblings. We evaluated DNA polymorphism analysis as a method for identifying disease gene carriers. Design.-Prospective comparison of the results of DNA analysis with a comprehensive clinical screening examination. Setting.-The Clinical Center of the National Institutes of Health. Patients.-Blood was collected from 182 members of 16 families with VHL disease. Forty-eight asymptomatic individuals, at risk of developing this hereditary illness (with an affected parent or sibling), were examined for occult disease at the Clinical Center of the National Institutes of Health and tested by DNA polymorphism analysis. Results.-DNA polymorphism analysis predicted nine disease gene carriers and 33 individuals with the wild-type (normal) allele among the 48 individuals at risk of developing VHL disease; the test was not informative in six individuals. All nine individuals predicted to carry the VHL gene had evidence of occult disease on clinical examination. There was no clinical evidence of VHL disease in 32 of 33 individuals predicted to carry the wild-type allele. Conclusions.-DNA polymorphism analysis can identify individuals likely to carry the VHL disease gene among asymptomatic members of disease families. This technique serves to focus attention on those individuals who require periodic medical examination and may help to alleviate the morbidity and mortality associated with this disease.	NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,BLDG 560,ROOM 12-71,FREDERICK,MD 21701; NCI,CANC DIAG BRANCH,FREDERICK,MD 21701; NCI,SURG BRANCH,FREDERICK,MD 21701; NEI,DEPT DIAGNOST RADIOL,BETHESDA,MD 20892; NEI,CTR CLIN,DEPT NURSING,BETHESDA,MD 20892; NEI,CLIN BRANCH,BETHESDA,MD 20892; NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892; EYE & EAR INST,PITTSBURGH,PA; PROGRAM RESOURCES INC,FREDERICK,MD; NATL UNIV HOSP REYKJAVIK,BLOOD BANK,REYKJAVIK,ICELAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Landspitali National University Hospital					Intramural NIH HHS [Z99 EY999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; CAVENEE WK, 1986, NEW ENGL J MED, V314, P1201, DOI 10.1056/NEJM198605083141901; CHOYKE PL, 1990, RADIOLOGY, V174, P815, DOI 10.1148/radiology.174.3.2305064; CHRISTOFERSON L, 1961, JAMA-J AM MED ASSOC, V178, P280, DOI 10.1001/jama.1961.03040420020005; DLUHY RG, 1991, NEW ENGL J MED, V324, P1119; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FILLINGKATZ MR, 1989, J COMPUT ASSIST TOMO, V13, P743, DOI 10.1097/00004728-198909000-00001; GLENN GM, 1991, HUM GENET, V87, P207, DOI 10.1007/BF00204184; GLENN GM, 1990, PROBL UROL, V4, P312; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; LAMIELL JM, 1989, MEDICINE, V68, P1; LANDER E, 1988, GENOME ANAL PRACTICA, P171; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LATIF F, 1990, NUCLEIC ACIDS RES, V18, P1088; LAUCKS SP, 1981, BRIT J RADIOL, V54, P12, DOI 10.1259/0007-1285-54-637-12; LERMAN MI, 1991, HUM GENET, V86, P567; LYNCH HT, 1985, CANCER GENET CYTOGEN, V16, P13, DOI 10.1016/0165-4608(85)90073-1; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MAHER ER, 1990, J NEUROL SCI, V100, P27, DOI 10.1016/0022-510X(90)90008-B; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MEISSEN GJ, 1988, NEW ENGL J MED, V318, P535, DOI 10.1056/NEJM198803033180903; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; OTT J, 1985, ANAL HUMAN GENETIC L; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SOBOL H, 1989, NEW ENGL J MED, V321, P996, DOI 10.1056/NEJM198910123211502; Thompson J. S., 1986, GENETICS MED; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; VANCE JM, 1990, GENOMICS, V6, P565, DOI 10.1016/0888-7543(90)90488-G	35	72	73	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1226	1231		10.1001/jama.267.9.1226	http://dx.doi.org/10.1001/jama.267.9.1226			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1347089	Green Submitted			2022-12-28	WOS:A1992HF43900024
J	SPITZER, WO; SUISSA, S; ERNST, P; HORWITZ, RI; HABBICK, B; COCKCROFT, D; BOIVIN, JF; MCNUTT, M; BUIST, AS; REBUCK, AS				SPITZER, WO; SUISSA, S; ERNST, P; HORWITZ, RI; HABBICK, B; COCKCROFT, D; BOIVIN, JF; MCNUTT, M; BUIST, AS; REBUCK, AS			THE USE OF BETA-AGONISTS AND THE RISK OF DEATH AND NEAR DEATH FROM ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRESCRIBED FENOTEROL; SALBUTAMOL; TERBUTALINE; ZEALAND	Background. Morbidity and mortality from asthma appear to be increasing, and it has been suggested that medications used to treat asthma are contributing to this trend. We investigated a possible association between death or near death from asthma and the regular use of beta-2-agonist bronchodilators. Methods. Using linked health insurance data bases from Saskatchewan, Canada, we conducted a matched case-control study of subjects drawn from a cohort of 12,301 patients for whom asthma medications had been prescribed between 1978 and 1987. We matched 129 case patients who had fatal or near-fatal asthma with 655 controls (who had received medications for asthma but had not had fatal or near-fatal events) with respect to region of residence, age, receipt of social assistance, and previous hospitalization for asthma. Results. The use of beta-agonists administered by a metered-dose inhaler was associated with an increased risk of death from asthma (odds ratio, 2.6 per canister per month; 95 percent confidence interval, 1.7 to 3.9) and of death or near death from asthma, considered together (odds ratio, 1.9; 95 percent confidence interval, 1.6 to 2.4). For death from asthma, use of the beta-agonist fenoterol was associated with an odds ratio of 5.4 per canister, as compared with 2.4 for the beta-agonist albuterol. On a microgram-equivalent basis, the odds ratio for this outcome with fenoterol was 2.3, as compared with 2.4 with albuterol. Conclusions. An increased risk of death or near death from asthma was associated with the regular use of inhaled beta-2-agonist bronchodilators, especially fenoterol. Regardless of whether beta-agonists are directly responsible for these adverse effects or are simply a marker for more severe asthma, heavy use of these agents should alert clinicians that it is necessary to reevaluate the patient's condition.	MCGILL UNIV,MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; UNIV SASKATCHEWAN,DEPT COMMUNITY HLTH & EPIDEMIOL,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; UNIV SASKATCHEWAN,DEPT MED,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; SASKATCHEWAN HLTH,LAB & DIS CONTROL SERV BRANCH,HE ROBERTSON LAB,REGINA,SASKATCHEWAN,CANADA; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PHYSIOL,PORTLAND,OR 97201; UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA; TORONTO HOSP,DIV RESP MED,TORONTO,ONTARIO,CANADA	McGill University; Yale University; University of Saskatchewan; University of Saskatchewan; Oregon Health & Science University; Oregon Health & Science University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	SPITZER, WO (corresponding author), MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,PURVIS HALL,1020 PINE AVE W,MONTREAL H3A 1A2,QUEBEC,CANADA.							ARAI Y, 1983, EUR J RESPIR DIS S, V128, P506; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CRANE J, 1989, LANCET, V1, P917; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; HOCKLEY B, 1983, POSTGRAD MED J, V59, P504, DOI 10.1136/pgmj.59.694.504; HORWITZ RI, 1991, CHEST, V100, P1586, DOI 10.1378/chest.100.6.1586; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LULICH KM, 1986, MED TOXICOL ADV DRUG, V1, P289; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; OLSSON OAT, 1979, ACTA PHARMACOL TOX, V44, P272; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; POYNTER D, 1987, J ALLERGY CLIN IMMUN, V80, P423, DOI 10.1016/0091-6749(87)90067-4; ROTHMAN KJ, 1986, MODERN EIDEMIOLOGY; SALOME CM, 1988, MECHANISMS ASTHMA PH, V263, P405; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPEIZER FE, 1975, NEW ENGL J MED, V292, P624, DOI 10.1056/NEJM197503202921207; STERK PJ, 1991, AM REV RESPIR DIS, V143, P1433, DOI 10.1164/ajrccm/143.6.1433; STORER BE, 1985, J AM STAT ASSOC, V80, P139, DOI 10.2307/2288064; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; TANG OT, 1984, POSTGRAD MED J, V60, P24; VANSHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P792; WEST R, 1987, AM J PREV MED S2, V4, P25; WONG CS, 1990, LANCET, V336, P1396, DOI 10.1016/0140-6736(90)93099-B; ZAAGSMA J, 1984, EUR J RESPIR DIS S, V135, P16; 1980, IARC SCI PUBLICATION, V32; 1980, DHHS PHS801260 PUBL	27	1011	1029	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					501	506		10.1056/NEJM199202203260801	http://dx.doi.org/10.1056/NEJM199202203260801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1346340				2022-12-28	WOS:A1992HD65800001
J	ZANOLARI, B; RATHS, S; SINGERKRUGER, B; RIEZMAN, H				ZANOLARI, B; RATHS, S; SINGERKRUGER, B; RIEZMAN, H			YEAST PHEROMONE RECEPTOR ENDOCYTOSIS AND HYPERPHOSPHORYLATION ARE INDEPENDENT OF G PROTEIN-MEDIATED SIGNAL TRANSDUCTION	CELL			English	Article							ALPHA-FACTOR RECEPTOR; BETA-ADRENERGIC-RECEPTOR; TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; SACCHAROMYCES-CEREVISIAE; PEPTIDE PHEROMONE; INSULIN-RECEPTOR; GAMMA-SUBUNITS; EGF RECEPTOR; S-CEREVISIAE	When alpha factor binds to the yeast alpha factor receptor a signal is transmitted via a tripartite G protein that prepares the cell for conjugation. As a result of alpha factor binding the receptor also undergoes a regulated internalization and hyperphosphorylation. Using cells that lack activity of this tripartite G protein, we show that G protein-mediated pheromone signal transduction is not necessary for regulation of receptor internalization or hyperphosphorylation. Therefore, the processes of signal transduction and down regulation can be uncoupled. We propose that binding of alpha factor to its receptor results in a receptor conformation change that permits receptor hyperphosphorylation and interaction with the endocytic machinery.			ZANOLARI, B (corresponding author), UNIV BASEL, BIOCTR, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND.			Riezman, Howard/0000-0003-4680-9422				BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DULIC V, 1990, J CELL SCI, V97, P517; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; GASSER SM, 1982, J BIOL CHEM, V257, P3034; HAGEN DC, 1984, J MOL BIOL, V178, P835, DOI 10.1016/0022-2836(84)90314-0; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARI J, 1987, J BIOL CHEM, V262, P15341; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUVARD D, 1983, EMBO J, V2, P1655, DOI 10.1002/j.1460-2075.1983.tb01640.x; Maniatis T., 1982, MOL CLONING; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; Sprague G F Jr, 1990, Adv Genet, V27, P33; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; TERNYNCK T, 1976, ANN INST PASTEUR IMM, VC127, P197; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; ZANOLARI B, 1991, MOL CELL BIOL, V11, P5251, DOI 10.1128/MCB.11.10.5251	49	70	70	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					755	763		10.1016/0092-8674(92)90552-N	http://dx.doi.org/10.1016/0092-8674(92)90552-N			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330324				2022-12-28	WOS:A1992JZ63300006
J	HOLMES, WE; SLIWKOWSKI, MX; AKITA, RW; HENZEL, WJ; LEE, J; PARK, JW; YANSURA, D; ABADI, N; RAAB, H; LEWIS, GD; SHEPARD, HM; KUANG, WJ; WOOD, WI; GOEDDEL, DV; VANDLEN, RL				HOLMES, WE; SLIWKOWSKI, MX; AKITA, RW; HENZEL, WJ; LEE, J; PARK, JW; YANSURA, D; ABADI, N; RAAB, H; LEWIS, GD; SHEPARD, HM; KUANG, WJ; WOOD, WI; GOEDDEL, DV; VANDLEN, RL			IDENTIFICATION OF HEREGULIN, A SPECIFIC ACTIVATOR OF P185ERBB2	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN-BREAST CANCER; ENDOMETRIAL CARCINOMA; ONCOGENE ALTERATIONS; ESCHERICHIA-COLI; CDNA SEQUENCE; EGF RECEPTOR; NEU ONCOGENE; EXPRESSION; GENE	The proto-oncogene designated erbB2 or HER2 encodes a 185-kilodalton transmembrane tyrosine kinase (p185erbB2), whose overexpression has been correlated with a poor prognosis in several human malignancies. A 45-kilodalton protein heregulin-alpha (HRG-alpha) that specifically induced phosphorylation of p185erbB2 Was purified from the conditioned medium of a human breast tumor cell line. Several complementary DNA clones encoding related HRGs were identified, all of which are similar to proteins in the epidermal growth factor family. Scatchard analysis of the binding of recombinant HRG to a breast tumor cell line expressing p185erbB2 showed a single high affinity binding site [dissociation constant (K(d)) = 105 +/- 15 picomolar]. Heregulin transcripts were identified in several normal tissues and cancer cell lines. The HRGs may represent the natural ligands for p185erbB2.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Mieszkowska, Magdalena/O-6753-2017	Henzel, William/0000-0003-2940-3797				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BORST MP, 1990, GYNECOL ONCOL, V38, P364, DOI 10.1016/0090-8258(90)90074-U; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; HENZEL WJ, 1989, J BIOL CHEM, V264, P15905; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JAIN S, 1991, INT J CANCER, V48, P668, DOI 10.1002/ijc.2910480506; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; Lee J.-S., UNPUB; LEMOINE NR, 1991, BRIT J CANCER, V64, P79, DOI 10.1038/bjc.1991.243; LEWIS GE, UNPUB; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; Marshall R D, 1974, Biochem Soc Symp, P17; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PRESS MF, 1990, ONCOGENE, V5, P953; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, UNPUB; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WINZLER RJ, 1973, HORMONAL PROTEINS PE, P1; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YOKOTA J, 1988, ONCOGENE, V2, P283; YONEMURA Y, 1991, CANCER RES, V51, P1034	46	993	1138	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1205	1210		10.1126/science.256.5060.1205	http://dx.doi.org/10.1126/science.256.5060.1205			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1350381				2022-12-28	WOS:A1992HV19200037
J	FALINI, B; BOLOGNESI, A; FLENGHI, L; TAZZARI, PL; BROE, MK; STEIN, H; DURKOP, H; AVERSA, F; CORNELI, P; PIZZOLO, G; BARBABIETOLA, G; SABATTINI, E; PILERI, S; MARTELLI, MF; STIRPE, F				FALINI, B; BOLOGNESI, A; FLENGHI, L; TAZZARI, PL; BROE, MK; STEIN, H; DURKOP, H; AVERSA, F; CORNELI, P; PIZZOLO, G; BARBABIETOLA, G; SABATTINI, E; PILERI, S; MARTELLI, MF; STIRPE, F			RESPONSE OF REFRACTORY HODGKINS-DISEASE TO MONOCLONAL ANTI-CD30 IMMUNOTOXIN	LANCET			English	Note							ANTIGEN	In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the antigen CD30. We investigated the possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody (Ber-H2) to saporin (SO6), a type-1 ribosome-inactivating protein. The immunotoxin (0.8 mg/kg in one or two doses) was given to four patients with advanced refractory Hodgkin's disease. In three, there was rapid and substantial reduction in tumour mass (50% to > 75%). Clinical responses were transient (6-10 weeks). In-vivo binding of the immunotoxin to tumour cells was shown by immunohistology in two patients. Antibodies to both parts of the immunotoxin developed in all patients.	FREE UNIV BERLIN,INST PATHOL,W-1000 BERLIN 33,GERMANY; UNIV VERONA,DEPT HAEMATOL,I-37100 VERONA,ITALY; UNIV BOLOGNA,DEPT EXPTL PATHOL,I-40126 BOLOGNA,ITALY; UNIV BOLOGNA,INST HAEMATOL,I-40126 BOLOGNA,ITALY; NATL INST CANC RES,GENOA,ITALY; UNIV PERUGIA,INST HAEMATOL,I-06100 PERUGIA,ITALY; UNIV PERUGIA,INST RADIOL,I-06100 PERUGIA,ITALY	Free University of Berlin; University of Verona; University of Bologna; University of Bologna; University of Genoa; IRCCS AOU San Martino IST; University of Perugia; University of Perugia			Sabattini, Elena/K-6720-2016; Bolognesi, Andrea/Q-6526-2017; TAZZARI, PIER LUIGI/HGC-8394-2022	Sabattini, Elena/0000-0002-4136-3591; TAZZARI, PIER LUIGI/0000-0002-8789-657X; Aversa, Franco/0000-0002-8871-6817; Bolognesi, Andrea/0000-0001-7497-4586; FALINI, Brunangelo/0000-0002-7198-5965				ENGERT A, 1990, CANCER RES, V50, P84; ENGERT A, 1990, CANCER RES, V50, P2929; FALINI B, 1991, EXP HEMATOL, V19, P545; PIZZOLO G, 1990, BRIT J HAEMATOL, V75, P282, DOI 10.1111/j.1365-2141.1990.tb02664.x; SCHWARTING R, 1989, BLOOD, V74, P1678; STEIN H, 1985, BLOOD, V66, P848; STIRPE F, 1986, FEBS LETT, V195, P1, DOI 10.1016/0014-5793(86)80118-1; STIRPE F, 1987, VIRCHOWS ARCH B, V53, P259, DOI 10.1007/BF02890252; TAZZARI PL, IN PRESS BR J HAEMAT; VITETTA ES, 1991, CANCER RES, V51, P4052	10	192	213	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1195	1196		10.1016/0140-6736(92)91135-U	http://dx.doi.org/10.1016/0140-6736(92)91135-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349939				2022-12-28	WOS:A1992HU68400005
J	OLSEN, SF; SORENSEN, JD; SECHER, NJ; HEDEGAARD, M; HENRIKSEN, TB; HANSEN, HS; GRANT, A				OLSEN, SF; SORENSEN, JD; SECHER, NJ; HEDEGAARD, M; HENRIKSEN, TB; HANSEN, HS; GRANT, A			RANDOMIZED CONTROLLED TRIAL OF EFFECT OF FISH-OIL SUPPLEMENTATION ON PREGNANCY DURATION	LANCET			English	Article							FATTY-ACIDS; BIRTH-WEIGHT; MARINE FAT; GROWTH	The high birthweights and long duration of pregnancy in the Faroe Islands led us to suggest that a high intake of marine-fat-derived n-3 fatty acids might prolong pregnancy by shifting the balance of production of prostaglandins involved in parturition. We have compared the effects on pregnancy duration, birthweight, and birth length of a fish-oil supplement, a control olive-oil supplement, and no supplementation. 533 healthy Danish women in week 30 of pregnancy were randomly assigned in a ratio of 2/1/1 to fish oil (four 1 g Pikasol capsules [containing 2.7 g n-3 fatty acids] per day), olive oil (four 1 g capsules per day), or no supplement. The three groups differed in mean length of gestation (p = 0.006), which was highest in the fish-oil group and lowest in the olive-oil group; the result was similar when the analysis was restricted to women with an estimate of gestation length based on early ultrasound findings (443 women). Pregnancies in the fish-oil group were on average 4.0 (95% confidence interval 1.5-6.4) days longer than those in the olive-oil group; the difference in birthweight was 107 (1-214) g. The effect of supplementation on length of gestation was influenced by intake of fish and of fish oil: the difference between fish-oil and other groups was increased by a low fish intake at baseline. Fish-oil supplementation in the third trimester seems to prolong pregnancy without detrimental effects on the growth of the fetus or on the course of labour.	AARHUS UNIV,PERINATAL EPIDEMIOL RES UNIT,DK-8000 AARHUS,DENMARK; ROYAL DANISH SCH PHARM,DEPT BIOL SCI,DK-2100 COPENHAGEN,DENMARK; NATL PERINATAL EPIDEMIOL UNIT,PERINATAL TRIALS SERV,OXFORD,ENGLAND	Aarhus University; Royal Danish School of Pharmacy; University of Oxford	OLSEN, SF (corresponding author), AARHUS UNIV,INST EPIDEMIOL & SOCIAL MED,HOEGHGULDBERGS GADE 8,DK-8000 AARHUS,DENMARK.			Olsen, Sjurdur/0000-0003-3017-7096; Hansen, Harald S./0000-0001-7360-7418				BAKKETEIG L, 1989, EFFECTIVE CARE PREGN, P765; ERIKSEN PS, 1985, ACTA OBSTET GYN SCAN, V64, P65, DOI 10.3109/00016348509154690; HANSENHS, 1988, PROG CLIN BIOL RES, V282, P305; HARALDSDOTTIR J, 1987, DIETARY HABITS DENMA, V2; KEIRSE MJN, 1989, EFFECTIVE CARE PREGN, P1270; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OLSEN SF, 1985, J EPIDEMIOL COMMUN H, V39, P27, DOI 10.1136/jech.39.1.27; OLSEN SF, 1986, LANCET, V2, P367; OLSEN SF, 1987, AGENTS ACTIONS, V22, P373, DOI 10.1007/BF02009084; OLSEN SF, 1990, BRIT J NUTR, V64, P599, DOI 10.1079/BJN19900063; OLSEN SF, 1991, AM J OBSTET GYNECOL, V164, P1203, DOI 10.1016/0002-9378(91)90683-I; PIPKIN FB, 1991, BRIT J OBSTET GYNAEC, V98, P737, DOI 10.1111/j.1471-0528.1991.tb13470.x; RADACK KL, 1988, ANN INTERN MED, V109, P81, DOI 10.7326/0003-4819-109-1-81; SECHER NJ, 1991, BRIT J OBSTET GYNAEC, V98, P738, DOI 10.1111/j.1471-0528.1991.tb13472.x; SECHER NJ, 1990, BRIT J OBSTET GYNAEC, V97, P1077, DOI 10.1111/j.1471-0528.1990.tb02493.x; VONSCHACKY C, 1987, ANN INTERN MED, V107, P890, DOI 10.7326/0003-4819-107-6-890; YUDKIN PL, 1987, LANCET, V1, P1192; 1942, LANCET, V2, P10	20	386	393	0	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1003	1007		10.1016/0140-6736(92)90533-9	http://dx.doi.org/10.1016/0140-6736(92)90533-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349049				2022-12-28	WOS:A1992HQ43500001
J	XI, YG; INGROSSO, L; LADOGANA, A; MASULLO, C; POCCHIARI, M				XI, YG; INGROSSO, L; LADOGANA, A; MASULLO, C; POCCHIARI, M			AMPHOTERICIN-B TREATMENT DISSOCIATES INVIVO REPLICATION OF THE SCRAPIE AGENT FROM PRP ACCUMULATION	NATURE			English	Article							INCUBATION PERIOD; MOUSE SCRAPIE; PROTEIN; HAMSTERS; PRION; STRAINS; FIBRILS; CURVES; BRAIN; ASSAY	SCRAPIE and related animal and human disorders are neurodegenerative diseases 1 characterized by the formation of a modified, partly proteinase-resistant protein (PrP) of the host 2,3, which tends to aggregate as amyloid fibrils 4 and accumulate in the brain of infected individuals 5. There is a general consensus that the pathological form of PrP (PrP(Sc)) is essential for the clinical appearance of the disease 6, but whether it is part of the scrapie agent 7 or a by-product of viral infection 8,9 is still controversial. Here we report that treatment of scrapie-infected hamsters with amphotericin B delays the accumulation in the brain of the proteinase-resistant portion of PrP(Sc) by about 30 days without affecting scrapie replication. The consequence is that hamsters treated with amphotericin B developed clinical signs of disease later than infected controls. We argue that the proteinase-resistant portion of PrP(Sc) is necessary for the development of the disease but that it is unlikely to be essential for scrapie replication.	IST SUPER SANITA, VIROL LAB, I-00161 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, IST NEUROL, I-00168 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, IST PATOL GEN, I-00168 ROME, ITALY	Istituto Superiore di Sanita (ISS); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			INGROSSO, LOREDANA/C-6487-2016; Ladogana, Anna/K-1415-2016; Pocchiari, Maurizio/J-8443-2018	Pocchiari, Maurizio/0000-0002-7269-2486; ladogana, Anna/0000-0002-7504-6906				BRAIG HR, 1985, EMBO J, V4, P2300; BRUNORI M, 1988, TRENDS BIOCHEM SCI, V13, P309, DOI 10.1016/0968-0004(88)90126-0; CASACCIA P, 1990, TRENDS IN NEUROIMMUNOLOGY, P135; CASACCIA P, 1991, ANTIMICROB AGENTS CH, V35, P1486, DOI 10.1128/AAC.35.7.1486; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; DICKINSON AG, 1988, CIBA F S, V135, P209; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; GAJDUSEK DC, 1990, VIROLOGY, P2289; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; HOPE J, 1988, EUR J BIOCHEM, V172, P271, DOI 10.1111/j.1432-1033.1988.tb13883.x; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANUELIDIS L, 1987, EMBO J, V6, P341, DOI 10.1002/j.1460-2075.1987.tb04760.x; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MEDOFF G, 1983, ANNU REV PHARMACOL, V23, P303, DOI 10.1146/annurev.pa.23.040183.001511; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; POCCHIARI M, 1989, J INFECT DIS, V160, P795, DOI 10.1093/infdis/160.5.795; POCCHIARI M, 1989, NEUROLOGIA SCI BASE, P571; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; REED L. J., 1938, AMER JOUR HYG, V27, P493; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	31	147	157	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					598	601		10.1038/356598a0	http://dx.doi.org/10.1038/356598a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1348570				2022-12-28	WOS:A1992HP03100047
J	BENIGNI, A; BOCCARDO, P; NORIS, M; REMUZZI, G; SIEGLER, RL				BENIGNI, A; BOCCARDO, P; NORIS, M; REMUZZI, G; SIEGLER, RL			URINARY-EXCRETION OF PLATELET-ACTIVATING-FACTOR IN HEMOLYTIC UREMIC SYNDROME	LANCET			English	Note							HEMOLYTIC-UREMIC SYNDROME	Since some of the features of haemolytic uraemic syndrome (HUS), such as platelet activation and glomerular injury, could be brought about by platelet-activating factor (PAF), we have studied the urinary excretion of PAF in 10 children with HUS and in 10 healthy age-matched controls. Urinary PAF concentrations, measured by radioimmunoassay, were significantly higher in acute-phase HUS patients than in controls (mean 2.04 [SD 1.66] vs 0.72 [0.43] ng/mg creatinine, p < 0.05) but were similar to those in controls in samples taken after recovery. High PAF concentrations during the acute phase of HUS may reflect platelet activation and glomerular injury, the lower values after recovery suggest that urinary PAF may be a marker of disease activity.	UNIV UTAH,DEPT PEDIAT,DIV NEPHROL & HYPERTENS,50 N MED DR,SALT LAKE CITY,UT 84132; OSPED RIUNITI BERGAMO,DIV NEPHROL,I-24100 BERGAMO,ITALY; MARIO NEGRI INST PHARMACOL RES,BERGAMO,ITALY	Utah System of Higher Education; University of Utah; Ospedali Riuniti di Bergamo; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			NORIS, MARINA/ABG-2219-2020; Boccardo, Paola/ABG-7647-2020; Ariela, Benigni/ABH-3492-2020; Remuzzi, Giuseppe/V-9766-2017	NORIS, MARINA/0000-0001-7651-5033; Boccardo, Paola/0000-0003-4969-6187; Ariela, Benigni/0000-0002-4721-5485; Remuzzi, Giuseppe/0000-0002-6194-3446				APPIANI AC, 1982, CLIN NEPHROL, V17, P195; CAMUSSI G, 1986, KIDNEY INT, V29, P469, DOI 10.1038/ki.1986.23; LEVY M, 1980, HEMOSTASIS PROSTAGLA, P383; MOAKE JL, 1984, BLOOD, V64, P592; NORIS M, 1990, J BIOL CHEM, V265, P19414; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; RICHARDSON SE, 1988, HUM PATHOL, V19, P1102, DOI 10.1016/S0046-8177(88)80093-5; WALTERS MDS, 1988, KIDNEY INT, V33, P107, DOI 10.1038/ki.1988.17	8	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					835	836		10.1016/0140-6736(92)90281-7	http://dx.doi.org/10.1016/0140-6736(92)90281-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347859				2022-12-28	WOS:A1992HM44100006
J	DENNIS, M				DENNIS, M			STROKE SERVICES	LANCET			English	Article							CONTROLLED TRIAL; MANAGEMENT				DENNIS, M (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; MORRIS AD, 1991, IN PRESS J NEUROL NE; RICCI S, 1991, J NEUROL NEUROSUR PS, V54, P695, DOI 10.1136/jnnp.54.8.695; STEVENS RS, 1984, AGE AGEING, V13, P65, DOI 10.1093/ageing/13.2.65; STONE SP, 1987, AGE AGEING, V16, P81, DOI 10.1093/ageing/16.1.81; WOODDAUPHINEE S, 1984, STROKE, V15, P864, DOI 10.1161/01.STR.15.5.864; 1988, BRIT MED J, V297, P126; 1991, LANCET, V337, P1235; 1988, BRIT MED J, V296, P320; 1991, NEW ENGL J MED, V325, P445	13	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					793	795		10.1016/0140-6736(92)91907-P	http://dx.doi.org/10.1016/0140-6736(92)91907-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347815				2022-12-28	WOS:A1992HL50100015
J	KAWASAKI, S; MAKUUCHI, M; ISHIZONE, S; MATSUNAMI, H; TERADA, M; KAWARAZAKI, H				KAWASAKI, S; MAKUUCHI, M; ISHIZONE, S; MATSUNAMI, H; TERADA, M; KAWARAZAKI, H			LIVER-REGENERATION IN RECIPIENTS AND DONORS AFTER TRANSPLANTATION	LANCET			English	Note							VOLUME; GRAFT	Reduced-size liver grafts from related donors may not be of an optimal size for adequate function in the recipient. Therefore, liver-graft regeneration is clinically important. We evaluated liver regeneration by liver-volume determinations with serial computed tomography scans in four recipients (aged 9 months to 12 years) and their donors (all fathers of the recipients) after living-related liver transplantation. Standard liver volume was calculated from the recipient's body-surface area. In each recipient, the size of the transplanted liver tended to converge to the standard liver volume with time, regardless of whether initial liver-graft volume was smaller or larger than standard liver volume. In addition, transplanted liver in the recipient regenerated much faster than remnant liver in the donor, even though both consisted of the same hepatocytes, which suggests that regeneration is regulated mainly by factors other than the hepatocytes themselves.	UNIV TOKYO,FAC MED,DEPT PAEDIAT SURG,TOKYO 113,JAPAN	University of Tokyo	KAWASAKI, S (corresponding author), SHINSHU UNIV,SCH MED,DEPT SURG 1,ASAHI 3-1-1,MATSUMOTO,NAGANO 390,JAPAN.							BISMUTH H, 1984, SURGERY, V95, P367; DEHEMPTINNE B, 1987, TRANSPLANT P, V19, P3317; HENDERSON JM, 1989, HEPATOLOGY, V10, P288, DOI 10.1002/hep.1840100306; HEYMSFIELD SB, 1979, ANN INTERN MED, V90, P185, DOI 10.7326/0003-4819-90-2-185; KAHAN D, 1988, TRANSPLANT P, V20, P850; KAM I, 1987, HEPATOLOGY, V7, P362, DOI 10.1002/hep.1840070225; KANEKO U, 1982, NIPPON HUMAN ANATOMY, V2; MAKUUCHI M, IN PRESS SURGERY; RAIA S, 1989, LANCET, V2, P497; STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106	10	170	178	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					580	581		10.1016/0140-6736(92)90867-3	http://dx.doi.org/10.1016/0140-6736(92)90867-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347095				2022-12-28	WOS:A1992HH07500005
J	PETERSON, CL; HERSKOWITZ, I				PETERSON, CL; HERSKOWITZ, I			CHARACTERIZATION OF THE YEAST SWI1, SWI2, AND SWI3 GENES, WHICH ENCODE A GLOBAL ACTIVATOR OF TRANSCRIPTION	CELL			English	Article							RNA POLYMERASE-II; MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; HO-GENE; BINDING-PROTEIN; DNA-BINDING; ALCOHOL-DEHYDROGENASE; MESSENGER-RNA; EXPRESSION; SUBUNIT	The yeast SWI1, SWI2 (SNF2), and SWI3 genes are required for transcription of HO and INO1 genes. We show that they are also required for transcription of ADH1, ADH2, SUC2, GAL1, and GAL10 and for function of simple UAS elements with binding sites for yeast GAL4 or Drosophila ftz proteins. SWI3 encodes a 99 kd nuclear protein containing a large, highly acidic N-terminal domain. SWI1 is identical to ADR6, which encodes a positive regulator of ADH1 and ADH2. Transcription of HO also requires SNF5 and SNF6. These and other observations suggest that SWI1, SWI2, SWI3, SNF5, and SNF6 may be components of a large multi-subunit complex. We propose that these products perform a general role in transcription by assisting gene-specific regulatory proteins.			PETERSON, CL (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA09270-16] Funding Source: Medline; NIAID NIH HHS [AI8738] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS E, 1986, MOL CELL BIOL, V6, P3643, DOI 10.1128/MCB.6.11.3643; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; DENIS CL, 1981, J MOL BIOL, V148, P355, DOI 10.1016/0022-2836(81)90181-9; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HAPPEL AM, 1991, GENETICS, V128, P69; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; KEMPHUES KJ, 1983, GENETICS, V105, P345; KLIED D, 1981, SCIENCE, V214, P1125; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; Miller J.H., 1972, EXPT MOL GENETICS; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NEIGEBORN L, 1984, GENETICS, V108, P845; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OHARA PJ, 1988, NUCLEIC ACIDS RES, V16, P10153, DOI 10.1093/nar/16.21.10153; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SPRAGUE GF, 1983, CELL, V32, P409, DOI 10.1016/0092-8674(83)90460-9; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERN M, 1985, THESIS U CALIFORNIA; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; TAGUCHI AKW, 1987, GENETICS, V116, P523; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	45	507	518	0	24	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					573	583		10.1016/0092-8674(92)90192-F	http://dx.doi.org/10.1016/0092-8674(92)90192-F			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1339306				2022-12-28	WOS:A1992HD39800016
J	BEWLEY, S; BEWLEY, TH				BEWLEY, S; BEWLEY, TH			DRUG-DEPENDENCE WITH ESTROGEN REPLACEMENT THERAPY	LANCET			English	Editorial Material							ESTRADIOL IMPLANTS; ESTROGEN DEFICIENCY; HORMONE IMPLANTS; SYMPTOMS; WOMEN	Dependence on some drugs can be hard to recognise. Hormone replacement therapy (HRT) has been widely prescribed only in the past two decades, and the indications for treatment and the risk/benefit ratio are still disputed. Oestrogens are psychoactive: they lift mood, can be given by injection, and their use has powerful psychological effects. Reports of women with supraphysiological oestradiol concentrations may represent tolerance and withdrawal. Dependence on substances occurring naturally in the body has been reported before. We propose that HRT dependence occurs.	ST GEORGE HOSP,SCH MED,DEPT ADDICT BEHAV,LONDON SW17,ENGLAND	St Georges University London	BEWLEY, S (corresponding author), UNIV COLL HOSP LONDON,DEPT OBSTET & GYNAECOL,LONDON WC1E 6HX,ENGLAND.			bewley, susan/0000-0001-8064-652X				APPLEBY L, 1991, PROGR OBSTETRICS GYN, V9, P289; BRINCAT M, 1984, LANCET, V1, P16; BROWER KJ, 1991, BRIT J ADDICT, V86, P759; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GANGAR K, 1991, BRIT J OBSTET GYNAEC, V98, P607, DOI 10.1111/j.1471-0528.1991.tb10383.x; GANGAR KF, 1990, BRIT MED J, V300, P436, DOI 10.1136/bmj.300.6722.436; GARNETT T, 1990, BRIT J OBSTET GYNAEC, V97, P917, DOI 10.1111/j.1471-0528.1990.tb02447.x; GINSBURG J, 1991, BRIT MED J, V302, P1601; LADER M, 1981, AUST NZ J PSYCHIAT, V15, P1, DOI 10.3109/00048678109159402; Magos AL, 1984, PROGR OBSTETRICS GYN, V4, P334; MONTGOMERY JC, 1987, LANCET, V1, P297; NOTT PN, 1976, BRIT J PSYCHIAT, V128, P379, DOI 10.1192/bjp.128.4.379; SHERWIN BB, 1985, PSYCHONEUROENDOCRINO, V10, P325, DOI 10.1016/0306-4530(85)90009-5; STUDD J, 1989, BRIT MED J, V299, P1400, DOI 10.1136/bmj.299.6712.1400-b; STUDD J, 1991, BRIT J OBSTET GYNAEC, V5, P502; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; 1987, DIAGNOSTIC STATISTIC, P167; 1990, MENTAL BEHAVIOURAL D, P54; 1988, HLTH CONSEQUENCES SM, V4, P177	20	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					290	291		10.1016/0140-6736(92)91344-8	http://dx.doi.org/10.1016/0140-6736(92)91344-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346294				2022-12-28	WOS:A1992HB52900016
J	CHIN, KV; UEDA, K; PASTAN, I; GOTTESMAN, MM				CHIN, KV; UEDA, K; PASTAN, I; GOTTESMAN, MM			MODULATION OF ACTIVITY OF THE PROMOTER OF THE HUMAN MDR1 GENE BY RAS AND P53	SCIENCE			English	Article							MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN; HUMAN-TUMORS; CELLS; EXPRESSION; TISSUES; PROTEIN; LIVER; DNA; TRANSFORMATION	Drug resistance in human cancer is associated with overexpression of the multidrug resistance (MDR1) gene, which confers cross-resistance to hydrophobic natural product cytotoxic drugs. Expression of the MDR1 gene can occur de novo in human cancers in the absence of drug treatment. The promoter of the human MDR1 gene was shown to be a target for the c-Ha-Ras-1 oncogene and the p53 tumor suppressor gene products, both of which are associated with tumor progression. The stimulatory effect of c-Ha-Ras-1 was not specific for the MDR1 promoter alone, whereas a mutant p53 specifically stimulated the MDR1 promoter and wild-type p53 exerted specific repression. These results imply that the MDR1 gene could be activated during tumor progression associated with mutations in Ras and p53.	NCI,CELL BIOL LAB,BLDG 37,ROOM 1B22,BETHESDA,MD 20892; KYOTO UNIV,DEPT AGR CHEM,KYOTO 606,JAPAN; NCI,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chin, Khew-Voon/F-2670-2013; pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Ueda, Kazumitsu/0000-0003-2980-6078				ARCECI RJ, 1990, MOL REPROD DEV, V25, P101, DOI 10.1002/mrd.1080250202; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIN KJ, UNPUB; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GORMAN CM, 1982, MOL CELL BIOL, V2, P10144; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P666; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1989, JPN J CANCER RES, V80, P1127, DOI 10.1111/j.1349-7006.1989.tb02269.x	43	806	840	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1992	255	5043					459	462		10.1126/science.1346476	http://dx.doi.org/10.1126/science.1346476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA590	1346476				2022-12-28	WOS:A1992HA59000039
J	Wejstal, R; Widell, A; Mansson, AS; Hermodsson, S; Norkrans, G				Wejstal, R; Widell, A; Mansson, AS; Hermodsson, S; Norkrans, G			Mother-to-Infant Transmission of Hepatitis-C Virus	ANNALS OF INTERNAL MEDICINE			English	Article						Hyponatremia; Encephalopathy, Hyponatremic; Postoperative Complications; Menstruation	POLYMERASE CHAIN-REACTION; NON-B HEPATITIS; CHRONIC NON-A; VERTICAL TRANSMISSION; RNA; INFECTION	Objective: To describe the rate of perinatal transmission of hepatitis C virus (HCV). Design: Follow-up study of newborn children of mothers with chronic HCV infection. Setting: A university hospital in Sweden. Participants: Fourteen women with chronic HCV infection and their 21 newly born children. Main Outcome Measures: Detection of HCV RNA in serum by the polymerase chain reaction and detection of anti-HCV antibody by second generation assays. Results: All mothers were found to be positive for anti-HCV antibody both by second-generation enzyme-linked immunosorbent assay (ELISA) and by second-generation recombinant immunoblot assay (RIBA-2); all also had detectable serum HCV RNA. Two children had long-lasting alanine aminotransferase (ALT) elevations, and one of them became HCV RNA positive. None of the other children developed biochemical hepatitis. However, two additional children had temporary viremia. Only the child with biochemical and biopsy-proven hepatitis and detectable HCV RNA in multiple blood samples actively produced anti-HCV antibody. Conclusions: Mother-to-infant transmission of HCV infection from chronically infected women without human immunodeficiency virus (HIV) infection seems to be uncommon.	Gothenburg Univ, Ostra Hosp, Dept Infect Dis, S-41685 Gothenburg, SWEDEN; Gothenburg Univ, Sahlgrens Hosp, S-41345 Gothenburg, SWEDEN; Malmo Gen Hosp, S-21401 Malmo, SWEDEN; Univ Lund, S-22101 Lund, SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Lund University	Wejstal, R (corresponding author), Gothenburg Univ, Ostra Hosp, Dept Infect Dis, S-41685 Gothenburg, SWEDEN.							[Anonymous], 1977, LANCET, V2, P914; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; BUSCH MP, 1992, NEW ENGL J MED, V326, P64, DOI 10.1056/NEJM199201023260114; CHEN DS, 1991, J INFECT DIS, V164, P428, DOI 10.1093/infdis/164.2.428; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAXI A, 1991, LANCET, V337, P1354, DOI 10.1016/0140-6736(91)93037-A; CRISTIANO K, 1991, HEPATOLOGY, V14, P51, DOI 10.1002/hep.1840140109; ERCILLA M G, 1991, Journal of Hepatology, V13, pS26, DOI 10.1016/0168-8278(91)91092-U; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FORTUNY C, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P418; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; KUROKI T, 1991, J INFECT DIS, V164, P427, DOI 10.1093/infdis/164.2.427; NOVATI R, 1991, Journal of Hepatology, V13, pS56, DOI 10.1016/0168-8278(91)91213-Z; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; REESINK HW, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92734-Y; ROUDOTTHORAVAL F, 1991, HEPATOLOGY, V14, pA130; STEVENS CE, 1991, PERINATAL SEXUAL TRA, P407; TAYLOR PE, 1991, POST TRANSFUSION HEP, P441; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; TONG MJ, 1981, GASTROENTEROLOGY, V80, P999; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; WEINTRUB PS, 1990, HEPATOLOGY, V12, P850; WEJSTAL R, 1989, SCAND J INFECT DIS, V21, P485, DOI 10.3109/00365548909037875; WEJSTAL R, 1990, J MED VIROL, V30, P178, DOI 10.1002/jmv.1890300306; WIDELL A, 1991, J MED VIROL, V35, P253, DOI 10.1002/jmv.1890350409	25	145	144	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					887	890		10.7326/0003-4819-117-11-887	http://dx.doi.org/10.7326/0003-4819-117-11-887			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1332562				2022-12-28	WOS:A1992JZ27600002
J	TAN, SL; ROYSTON, P; CAMPBELL, S; JACOBS, HS; BETTS, J; MASON, B; EDWARDS, RG				TAN, SL; ROYSTON, P; CAMPBELL, S; JACOBS, HS; BETTS, J; MASON, B; EDWARDS, RG			CUMULATIVE CONCEPTION AND LIVEBIRTH RATES AFTER INVITRO FERTILIZATION	LANCET			English	Article							MATERNAL AGE; FERTILIZATION; PREGNANCY; PROSPECTS; PROGRAM; EMBRYO	Cumulative conception and livebirth rates related to age and cause of infertility provide the most useful estimate of success after in-vitro fertilisation (IVF), but limited data are available. It is also uncertain whether the probability of pregnancy, livebirth, and pregnancy failure changes with repeated treatment cycles. To assess the effects of patients' age and cause of infertility on these outcomes, we studied the results of 5055 consecutive IVF cycles (773 clinical pregnancies, 518 livebirths) undertaken on 2735 patients in a single IVF unit. Cumulative conception and livebirth rates were analysed by the life-table approach and differences in rates between age-groups and between causes of infertility were measured by the log-rank test and logistic regression modelling. Both conception and livebirth rates per cycle declined with age (p < 0.001), and cumulative conception and livebirth rates after five treatment cycles were about 54% and 45%, respectively, at 20-34 years, compared with 38.7% and 28.9% at 35-39 years and 20.2% and 14.4% at greater-than-or-equal-to 40 years. The two rates were significantly different between causal groups (p < 0.001 and p = 0.02, respectively) and were lowest in patients with male infertility or multiple infertility factors. The pregnancy failure rate was higher (p = 0.006) in women over the age of 34 years and there was a significant decline in the chances of pregnancy and livebirth per cycle with successive treatment cycles. The success of IVF compares favourably with that of spontaneous conception in the natural menstrual cycle. For women up to the age of 34 years, almost 55% will become pregnant and 45% will have a livebirth within five cycles of treatment.	HALLAM MED CTR,LONDON,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED PHYS,LONDON W12 0HS,ENGLAND; MIDDLESEX HOSP,COBBOLD LABS,LONDON W1,ENGLAND	Imperial College London; University of London; University College London	TAN, SL (corresponding author), KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,DENMARK HILL,LONDON SE5 8RX,ENGLAND.		Jacobs, Howard/A-9845-2009; Tan, Seang Lin/I-7710-2012					COOKE ID, 1981, CLIN OBSTET GYNAECOL, V8, P531; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMER DW, 1979, FERTIL STERIL, V32, P80; DEMOUZON J, 1987, CONTRACEPT FERTIL S, V15, P740; GOSDEN RG, 1985, ANN NY ACAD SCI, V442, P45, DOI 10.1111/j.1749-6632.1985.tb37504.x; GUZICK DS, 1986, FERTIL STERIL, V46, P663; HUGHES EG, 1990, J CLIN ENDOCR METAB, V70, P358, DOI 10.1210/jcem-70-2-358; Kalbfleisch JD, 1980, STATISTICAL ANAL FAI, P14; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACS GT, 1986, MED J AUSTRALIA, V144, P682, DOI 10.5694/j.1326-5377.1986.tb113694.x; NAVOT D, 1991, LANCET, V337, P1375, DOI 10.1016/0140-6736(91)93060-M; PADILLA SL, 1989, FERTIL STERIL, V52, P270; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SCHWARTZ D, 1982, NEW ENGL J MED, V306, P404, DOI 10.1056/NEJM198202183060706; SHARMA V, 1988, FERTIL STERIL, V49, P468; STEPTOE PC, 1986, HUM REPROD, V1, P89, DOI 10.1093/oxfordjournals.humrep.a136366; STEPTOE PC, 1978, LANCET, V2, P366; TAN SL, IN PRESS AM J OBSTET; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361; 1991, 6TH REPORT INTERIM L; 1991, FERTIL STERIL, V55, P14	21	232	235	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1390	1394		10.1016/0140-6736(92)91205-M	http://dx.doi.org/10.1016/0140-6736(92)91205-M			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350813				2022-12-28	WOS:A1992HX63600012
J	WEIGEL, D; ALVAREZ, J; SMYTH, DR; YANOFSKY, MF; MEYEROWITZ, EM				WEIGEL, D; ALVAREZ, J; SMYTH, DR; YANOFSKY, MF; MEYEROWITZ, EM			LEAFY CONTROLS FLORAL MERISTEM IDENTITY IN ARABIDOPSIS	CELL			English	Article							POLYMORPHISM LINKAGE MAP; FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; GENETIC-CONTROL; THALIANA; AMPLIFICATION; MORPHOGENESIS; PRIMER; DNA	The first step in flower development is the generation of a floral meristem by the inflorescence meristem. We have analyzed how this process is affected by mutant alleles of the Arabidopsis gene LEAFY. We show that LEAFY interacts with another floral control gene, APETALA1, to promote the transition from inflorescence to floral meristem. We have cloned the LEAFY gene, and, consistent with the mutant phenotype, we find that LEAFY RNA is expressed strongly in young flower primordia. LEAFY expression precedes expression of the homeotic genes AGAMOUS and APETALA3, which specify organ identity within the flower. Furthermore, we demonstrate that LEAFY is the Arabidopsis homolog of the FLORICAULA gene, which controls floral meristem identity in the distantly related species Antirrhinum majus.	MONASH UNIV,DEPT GENET & DEV BIOL,CLAYTON,VIC 3168,AUSTRALIA	Monash University	WEIGEL, D (corresponding author), CALTECH,DIV BIOL 15629,PASADENA,CA 91125, USA.		Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/C-1418-2008; Meyerowitz, Elliot M/A-7118-2009; Smyth, David R/K-5993-2012; Weigel, Detlef/AAR-3312-2021	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Smyth, David R/0000-0003-0455-9699; 				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BATTEY NH, 1990, BOT REV, V56, P163; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1991, THESIS CALTECH PASAD; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gifford EM., 1988, MORPHOLOGY EVOLUTION; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KLEMM M., 1927, BOT ARCH, V20, P423; KOORNNEEF M, 1990, GENETIC MAPS; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; Muller A., 1961, KULTURPFLANZE, V9, P364, DOI [10.1007/BF02095757, DOI 10.1007/BF02095757]; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; OCHMAN H, 1990, PCR PROTOCOLS; POETHIG RS, 1988, GENETICS, V119, P959; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Stevens WL, 1939, J GENET, V39, P171, DOI 10.1007/BF02982823; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; Weberling F., 1981, MORPHOLOGIE BLUTEN B; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	38	1153	1310	1	138	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					843	859		10.1016/0092-8674(92)90295-N	http://dx.doi.org/10.1016/0092-8674(92)90295-N			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1350515	hybrid, Green Accepted			2022-12-28	WOS:A1992HW83800014
J	HUGHES, PH; BRANDENBURG, N; BALDWIN, DC; STORR, CL; WILLIAMS, KM; ANTHONY, JC; SHEEHAN, DV				HUGHES, PH; BRANDENBURG, N; BALDWIN, DC; STORR, CL; WILLIAMS, KM; ANTHONY, JC; SHEEHAN, DV			PREVALENCE OF SUBSTANCE USE AMONG UNITED-STATES PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							YOUTHFUL PRECURSORS; ALCOHOL-ABUSE; DRUG; STUDENTS	Objective.-To estimate the prevalence of substance use among US physicians. Design.-A mailed, anonymous, self-report survey that assessed use of 13 substances and permitted comparison with results of the National Household Survey on Drug Abuse. Rates of physician substance use were weighted to provide national prevalence estimates. Participants.-A national sample of 9600 physicians, stratified by specialty and career stage, and randomly selected from the American Medical Association master file. The response rate after three mailings was 59%. Demographic characteristics of respondents closely reflected those of the US physician population. Main Outcome Measures.-Subjects' self-reported use of 13 substances in their lifetime, the past year, and the past month; reasons for use; self-admitted substance abuse or dependence; and whether treatment was received. For controlled prescription substances, respondents were asked to report only use "not prescribed by another physician for a legitimate medical or psychiatric condition." Results.-Physicians were less likely to have used cigarettes and illicit substances, such as marijuana, cocaine, and heroin, in the past year than their age and gender counterparts in the National Household Survey on Drug Abuse. They were more likely to have used alcohol and two types of prescription medication-minor opiates and benzodiazepine tranquilizers. Prescription substances were used primarily for self-treatment, whereas illicit substances and alcohol were used primarily for recreation. Current daily use of illicit or controlled substances was rare. Conclusions.-Although physicians were as likely to have experimented with illicit substances in their lifetime as their age and gender peers in society, they were far less likely to be current users of illicit substances. The higher prevalence of alcohol use among respondents may be more a characteristic of their socioeconomic class than of their profession. A unique concern for physicians, however, is their high rate of self-treatment with controlled medications-a practice that could increase their risk of drug abuse or dependence. Uniform national guidelines are needed to sensitize medical students and physicians to the dangers of self-treatment with controlled prescription substances.	UNIV S FLORIDA, INST RES PSYCHIAT, TAMPA, FL 33620 USA; JAMES A HALEY VET HOSP, TAMPA, FL USA; UNIV S FLORIDA, COLL PUBL HLTH, TAMPA, FL 33620 USA; AMER MED ASSOC, DIV MED EDUC RES, CHICAGO, IL 60610 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21218 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; American Medical Association; Johns Hopkins University			Anthony, Jim/H-3637-2011; Sheehan, David V/L-6879-2013	Anthony, Jim/0000-0001-7176-0929; Sheehan, David V/0000-0002-5118-7050	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004877] Funding Source: NIH RePORTER; NIDA NIH HHS [1 RO1 DA04877] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1973, JAMA, V223, P684; [Anonymous], 1987, JAMA-J AM MED ASSOC, V257, P3110; BALDWIN DC, 1991, JAMA-J AM MED ASSOC, V265, P2074, DOI 10.1001/jama.265.16.2074; BALTER M, 1991, MAY ANN M AM PSYCH A; BISSELL L, 1989, American Pharmacy, V29, P19; Bissell L, 1984, ALCOHOLISM PROFESSIO; BREWSTER JM, 1986, JAMA-J AM MED ASSOC, V255, P1913, DOI 10.1001/jama.255.14.1913; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; COTTLER LB, 1987, AM J EPIDEMIOL, V125, P329, DOI 10.1093/oxfordjournals.aje.a114534; Du Pont R.L., 1988, AM J DRUG ALCOHOL S1, V14, P1; Fleiss JL, 1981, STAT METHODS RATES P; FRANKEL M, 1983, HDB SURVEY RES; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; HOLT D, 1979, J ROY STAT SOC A STA, V142, P33, DOI 10.2307/2344652; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; KNUPFER G, 1989, BRIT J ADDICT, V84, P1305; KRAKOWSKI AJ, 1984, PSYCHOTHER PSYCHOSOM, V42, P143, DOI 10.1159/000287838; LAPUMA J, 1991, NEW ENGL J MED, V325, P1290, DOI 10.1056/NEJM199110313251806; MADDUX JF, 1987, J MED EDUC, V62, P852; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; MCAULIFFE WE, 1991, AM J PUBLIC HEALTH, V81, P177, DOI 10.2105/AJPH.81.2.177; MOORE RD, 1990, AM J MED, V88, P332, DOI 10.1016/0002-9343(90)90485-V; MORSE RM, 1984, JAMA-J AM MED ASSOC, V251, P743, DOI 10.1001/jama.251.6.743; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V264, P1039, DOI 10.1001/jama.264.8.1039; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; ROBACK G, 1990, PHYSICIAN CHARACTERI; ROUSE B, 1985, RES MONOGRAPH NATION, V57; SHEIKH K, 1981, J EPIDEMIOL COMMUN H, V35, P293, DOI 10.1136/jech.35.4.293; TALBOTT GD, 1987, JAMA-J AM MED ASSOC, V257, P2927, DOI 10.1001/jama.257.21.2927; VAILLANT GE, 1970, NEW ENGL J MED, V282, P365, DOI 10.1056/NEJM197002122820705; 1989, NATIONAL HOUSEHOLD S; 1990, NATIONAL HOUSEHOLD S	32	240	244	2	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2333	2339		10.1001/jama.267.17.2333	http://dx.doi.org/10.1001/jama.267.17.2333			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1348789				2022-12-28	WOS:A1992HR01500025
J	CROOK, T; WREDE, D; TIDY, JA; MASON, WP; EVANS, DJ; VOUSDEN, KH				CROOK, T; WREDE, D; TIDY, JA; MASON, WP; EVANS, DJ; VOUSDEN, KH			CLONAL P53 MUTATION IN PRIMARY CERVICAL-CANCER - ASSOCIATION WITH HUMAN-PAPILLOMAVIRUS-NEGATIVE TUMORS	LANCET			English	Article							LUNG-CANCER; GENE; CARCINOMAS	Analyses of cancer cell lines and of anal cancers suggest an inverse correlation between infection with human papillomavirus (HPV) and somatic mutation of the p53 tumour-suppressor gene. We have investigated this association in primary cervical tumours. Tumour-tissue samples from 28 women with primary cancer of the cervix were analysed for presence of HPV sequences and for somatic mutations of the p53 gene. Southern blot analysis and the polymerase chain reaction (PCR) showed that 25 of the tumours contained HPV sequences; 20 were HPV16 positive and 5 HPV18 positive. 17 tumours subjected to restriction fragment length polymorphism analysis for the short arm of chromosome 17 showed no evidence of allelic deletion. Sequencing of the entire coding region of the p53 gene by asymmetric PCR detected heterozygous point mutations in only 3 HPV-negative tumours. By contrast, in 21 HPV-positive cancers the p53 sequence was wild-type throughout Our data indicate that loss of wild-type p53 function is important in the pathology of cervical cancer and that in the absence of an HPV-encoded gene product that mediates loss of p53 function, somatic mutation of the gene is required. This pattern of p53 mutation may partly explain the apparently worse prognosis of HPV-negative cervical cancers.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,DEPT HISTOPATHOL,LONDON W2 1PG,ENGLAND; SAMARITAN HOSP WOMEN,DEPT GYNAECOL ONCOL,LONDON,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London								AHERNE W., 1967, J ROY NUCROSC SOC, V87, P493; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; HAUSEN HZ, 1989, ADV VIRAL ONCOL, P1; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIGGINS GD, 1991, LANCET, V338, P910, DOI 10.1016/0140-6736(91)91773-N; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARKS JR, 1991, CANCER RES, V51, P2979; NELSON PH, 1989, EMBO J, V8, P3905; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RIOU G, 1990, LANCET, V335, P1171; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAW P, 1991, ONCOGENE, V6, P2121; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VANDENBRULE AJC, 1990, INT J CANCER, V45, P644, DOI 10.1002/ijc.2910450412; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHANG WH, 1988, J MED VIROL, V26, P163, DOI 10.1002/jmv.1890260208	27	325	329	2	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1070	1073		10.1016/0140-6736(92)90662-M	http://dx.doi.org/10.1016/0140-6736(92)90662-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349102				2022-12-28	WOS:A1992HR44600002
J	KIRBY, AJ; SPIEGELHALTER, DJ; DAY, NE; FENTON, L; SWANSON, K; MANN, EMF; MACGREGOR, JE				KIRBY, AJ; SPIEGELHALTER, DJ; DAY, NE; FENTON, L; SWANSON, K; MANN, EMF; MACGREGOR, JE			CONSERVATIVE TREATMENT OF MILD MODERATE CERVICAL DYSKARYOSIS - LONG-TERM OUTCOME	LANCET			English	Article							SMEARS	There is some controversy about the management of women with mild or moderate dyskaryotic cervical smears. To assess the strategy of an established cervical cytology screening programme (Grampian region, northeast Scotland) we identified 500 women who had had mild or moderate cervical dyskaryosis in 1978 or 1979, and 500, matched by age, who had had a normal smear at that time. Follow-up smear results and any subsequent investigation by colposcopy, cone biopsy, or hysterectomy, with biopsy result were recorded. Of the 500 women who initially had an abnormal smear, 300 (60%) had a smear that was normal or inflammatory at their last visit (after seven years' median follow-up). 184 (37%) had undergone biopsy, 97 (19%) of whom were cervical intraepithelial neoplasia grade III or worse. Survival curves for time to biopsy and ten-year biopsy rates show that women with an abnormal smear before their baseline year were the most likely to have a subsequent biopsy. Older women had a biopsy less often and at biopsy were more likely to have minor abnormalities. Mild or moderate dyskaryotic smears should not be an indication for immediate referral for colposcopy, since under a conservative management policy most women return to normal without needing treatment. Nevertheless, the increased risk associated with abnormal smears justifies rigorous surveillance.	MRC,BIOSTAT UNIT,5 SHAFTESBURY RD,CAMBRIDGE CB2 2BW,ENGLAND; UNIV ABERDEEN,HARRIS BIRTHRIGHT RES CTR,DEPT PATHOL,ABERDEEN AB9 1FX,SCOTLAND	MRC Biostatistics Unit; University of Aberdeen								CAMPION MJ, 1986, LANCET, V2, P237; FLETCHER A, 1990, BRIT MED J, V301, P641, DOI 10.1136/bmj.301.6753.641; FOX H, 1987, BRIT MED J, V294, P1307, DOI 10.1136/bmj.294.6583.1307; MACGREGOR JE, 1991, BRIT J OBSTET GYNAEC, V98, P6, DOI 10.1111/j.1471-0528.1991.tb10302.x; Matthews D.E., 2016, ACTA HAEMATOL-BASEL, V135, P194; Posner T, 1988, PREVENTION CERVICAL; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; WOODMAN CBJ, 1989, LANCET, V2, P88; 1990, GRAMPIAN HLTH BOARD	9	52	52	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					828	831		10.1016/0140-6736(92)90278-B	http://dx.doi.org/10.1016/0140-6736(92)90278-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347856				2022-12-28	WOS:A1992HM44100003
J	WADE, DT				WADE, DT			STROKE - REHABILITATION AND LONG-TERM CARE	LANCET			English	Article							THERAPY				WADE, DT (corresponding author), RIVERMEAD REHABIL CTR,OXFORD OX1 4XD,ENGLAND.			Wade, Derick/0000-0002-1188-8442				BARER DH, 1989, AGE AGEING, V18, P183, DOI 10.1093/ageing/18.3.183; Collen F M, 1991, Int Disabil Stud, V13, P50; Collin C, 1988, Int Disabil Stud, V10, P61; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P576, DOI 10.1136/jnnp.53.7.576; DAVIS AM, IN PRESS CLIN REHAB; Enderby P M, 1987, Int Rehabil Med, V8, P166; HALLIGAN PW, 1989, LANCET, V2, P908; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; HOUSE A, 1987, BMJ-BRIT MED J, V294, P76, DOI 10.1136/bmj.294.6564.76; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; MCGRATH JR, IN PRESS CLIN REHAB; SHEPHERD G, 1991, THEORY PRACTICE PSYC, pR13; SMITH ME, 1982, ARCH PHYS MED REHAB, V63, P21; WADE DT, 1992, BRIT MED J, V304, P609, DOI 10.1136/bmj.304.6827.609; WADE DT, 1990, RECENT ADV CLIN NEUR, V6, P133; WADE DT, 1989, HDB CLIN NEUROLOGY, V11, P233; WADE DT, 1990, CLIN REHABIL, V4, P147; Wade DT., 1992, MEASUREMENT NEUROLOG; WATTS FN, 1991, THEORY PRACTICE PSYC, P3; Young J, 1991, CLIN REHABIL, V5, P283	20	57	60	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					791	793		10.1016/0140-6736(92)91906-O	http://dx.doi.org/10.1016/0140-6736(92)91906-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347814				2022-12-28	WOS:A1992HL50100014
J	CHANG, SW; KATZ, MH; HERNANDEZ, SR				CHANG, SW; KATZ, MH; HERNANDEZ, SR			THE NEW AIDS CASE DEFINITION - IMPLICATIONS FOR SAN-FRANCISCO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HIV; INFECTION; COUNTS		UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	CHANG, SW (corresponding author), SAN FRANCISCO DEPT PUBL HLTH,AIDS OFF,25 VAN NESS AVE,SUITE 500,SAN FRANCISCO,CA 94102, USA.							ARNO PS, 1986, AM J PUBLIC HEALTH, V76, P1325, DOI 10.2105/AJPH.76.11.1325; BALL J, 1991, PHS910015 PUBL, V15, P1; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BROOKMEYER R, 1990, BIOMETRICS, V46, P1151, DOI 10.2307/2532455; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P92; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; HUTCHINSON CM, 1991, JAMA-J AM MED ASSOC, V266, P253, DOI 10.1001/jama.266.2.253; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; MCCARTHY RC, 1989, ARCH PATHOL LAB MED, V113, P658; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PAYNE SF, 1990, AIDS, V4, P335, DOI 10.1097/00002030-199004000-00008; PHILLIPS AN, 1991, LANCET, V337, P389; SHEPPARD HW, 1991, JAMA-J AM MED ASSOC, V266, P2221; STEINBERG C, 1989, JAMA-J AM MED ASSOC, V262, P1526; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; VALDISERRI RO, 1991, AM J PUBLIC HEALTH, V81, P491, DOI 10.2105/AJPH.81.4.491; 1991, MMWR, V40, P787; 1991, FED REG         1217, V56, P65498; 1987, MMWR, V36, pS3; [No title captured]; 1990, MMWR, V39, P1; 1988, ANN INTERN MED, V108, P470; 1985, MMWR, V34, P373	25	28	28	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					973	975		10.1001/jama.267.7.973	http://dx.doi.org/10.1001/jama.267.7.973			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1346406				2022-12-28	WOS:A1992HD15500033
J	LANE, DA; RYAN, K; IRELAND, H; CURTIS, JR; NURMOHAMED, MT; KREDIET, RT; ROGGEKAMP, MC; STEVENS, P; TENCATE, JW				LANE, DA; RYAN, K; IRELAND, H; CURTIS, JR; NURMOHAMED, MT; KREDIET, RT; ROGGEKAMP, MC; STEVENS, P; TENCATE, JW			DERMATAN SULFATE IN HEMODIALYSIS	LANCET			English	Note							HEPARIN	Experimental work suggests that dermatan sulphate has potential as an antithrombotic agent: it can inhibit venous thrombi yet has less effect upon bleeding than heparin. While heparin functions as an anticoagulant primarily by its ability to accelerate the action of the plasma protein inhibitor antithrombin III, dermatan sulphate acts selectively through a structurally related inhibitor, heparin co-factor II, to inhibit thrombin. We have done a series of dose-finding studies of the use of dermatan sulphate as an anticoagulant/antithrombotic agent in patients on maintenance haemodialysis. Dermatan sulphate proved to be an effective anticoagulant in this setting.	UNIV AMSTERDAM, ACAD MED CTR, CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT NEPHROL, 1105 AZ AMSTERDAM, NETHERLANDS; DIATEL AMSTERDAM, CTR DIALYSIS, AMSTERDAM, NETHERLANDS; CHARING CROSS & WESTMINSTER HOSP, DEPT HAEMATOL, LONDON, ENGLAND; CHARING CROSS & WESTMINSTER HOSP, DEPT MED, LONDON, ENGLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT MED, LONDON, ENGLAND	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Imperial College London; Imperial College London; Imperial College London	LANE, DA (corresponding author), CHARING CROSS & WESTMINSTER MED SCH, DEPT HAEMATOL, LONDON W6 8RF, ENGLAND.		Ireland, Helen A/B-9868-2008; Krediet, Raymond/GLT-2390-2022; Krediet, Raymond/AAP-3291-2021	Ireland, Helen A/0000-0002-7980-548X; Krediet, Raymond/0000-0002-9851-8507; Nurmohamed, Michael/0000-0002-6274-1934				BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; FERNANDEZ F, 1986, BRIT J HAEMATOL, V64, P309, DOI 10.1111/j.1365-2141.1986.tb04124.x; HIRSH J, 1990, ACTA CHIR SCAND, P42; MCKENNA JV, 1989, THROMB HAEMOSTASIS, V61, P7; OKWUSIDI J, 1990, THROMB HAEMORRH DISO, V1, P77; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713	7	29	29	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1992	339	8789					334	335		10.1016/0140-6736(92)91650-W	http://dx.doi.org/10.1016/0140-6736(92)91650-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346414				2022-12-28	WOS:A1992HC77100007
J	SOININEN, H; SYRJANEN, S; HEINONEN, O; NEITTAANMAKI, H; MIETTINEN, R; PALJARVI, L; SYRJANEN, K; BEYREUTHER, K; RIEKKINEN, P				SOININEN, H; SYRJANEN, S; HEINONEN, O; NEITTAANMAKI, H; MIETTINEN, R; PALJARVI, L; SYRJANEN, K; BEYREUTHER, K; RIEKKINEN, P			AMYLOID BETA-PROTEIN DEPOSITION IN SKIN OF PATIENTS WITH DEMENTIA	LANCET			English	Letter							ALZHEIMERS-DISEASE		UNIV KUOPIO,DEPT DERMATOL,SF-70211 KUOPIO,FINLAND; UNIV KUOPIO,DEPT PATHOL,SF-70211 KUOPIO,FINLAND; UNIV HEIDELBERG,CTR MOLEC BIOL,W-6900 HEIDELBERG,GERMANY	University of Eastern Finland; University of Eastern Finland; Ruprecht Karls University Heidelberg	SOININEN, H (corresponding author), UNIV KUOPIO,DEPT NEUROL,SF-70211 KUOPIO,FINLAND.			Syrjanen, Kari/0000-0001-7180-7491				ARAI H, 1991, ANN NEUROL, V30, P686, DOI 10.1002/ana.410300509; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; 1980, DIAGNOSTIC STATISTIC	5	46	49	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					245	245		10.1016/0140-6736(92)90046-6	http://dx.doi.org/10.1016/0140-6736(92)90046-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346198				2022-12-28	WOS:A1992HA58900036
J	DEKEYSER, J; HERROELEN, L; VERVAECK, M; BRUYLAND, M; EBINGER, G				DEKEYSER, J; HERROELEN, L; VERVAECK, M; BRUYLAND, M; EBINGER, G			IDIOPATHIC HEMIPARETIC PARKINSONISM, A SYNDROME DISTINCT FROM IDIOPATHIC PARKINSONISM	LANCET			English	Note							SPINAL-CORD; HEMIATROPHY; HEMIPARKINSONISM	Two women had a syndrome of progressive parkinsonism with ipsilateral rigidity, mild resting tremor, paresis, hyperreflexia, and an extensor plantar response. Symptoms had started 24 and 3 months after a surgical procedure in the affected limb. Neuroimaging studies were unhelpful. Both the parkinsonian features and the pyramidal tract signs responded well to dopaminergic drug treatment. We propose that the syndrome be called "idiopathic hemiparetic parkinsonism".			DEKEYSER, J (corresponding author), VRIJE UNIV BRUSSELS, ACAD ZIEKENHUIS, DEPT NEUROL, LAARBEEKLAAN 101, B-1090 BRUSSELS, BELGIUM.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				ADAMS RD, 1989, PRINCIPLES NEUROLOGY, P921; BARBEAU A, 1984, CLIN NEUROL NEUROSUR, V86, P164, DOI 10.1016/0303-8467(84)90193-8; BUCHMAN AS, 1988, NEUROLOGY, V38, P527, DOI 10.1212/WNL.38.4.527; DICK JPR, 1984, NATURE, V310, P407, DOI 10.1038/310407a0; GILADI N, 1990, NEUROLOGY, V40, P1731, DOI 10.1212/WNL.40.11.1731; GILBERT GJ, 1976, LANCET, V2, P442; JANKOVIC J, 1989, MOVEMENT DISORD, V4, pS95, DOI 10.1002/mds.870040512; KLAWANS HL, 1981, NEUROLOGY, V31, P625, DOI 10.1212/WNL.31.5.625; LINDVALL O, 1983, ANN NEUROL, V14, P255, DOI 10.1002/ana.410140302; MOUCHET P, 1986, J PHARMACOL-PARIS, V17, P523; POEWE WH, 1987, CLIN NEUROPHARMACOL, V10, P47, DOI 10.1097/00002826-198702000-00004; SCHOTT GD, 1986, LANCET, V2, P712; Thompson P D, 1986, Mov Disord, V1, P113, DOI 10.1002/mds.870010205; 1989, LANCET, V1, P759	14	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	1992	339	8786					149	150		10.1016/0140-6736(92)90213-M	http://dx.doi.org/10.1016/0140-6736(92)90213-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346013				2022-12-28	WOS:A1992GZ96800006
J	REINUS, JF; LEIKIN, EL; ALTER, HJ; CHEUNG, L; SHINDO, M; JETT, B; PIAZZA, S; SHIH, JWK				REINUS, JF; LEIKIN, EL; ALTER, HJ; CHEUNG, L; SHINDO, M; JETT, B; PIAZZA, S; SHIH, JWK			FAILURE TO DETECT VERTICAL TRANSMISSION OF HEPATITIS-C VIRUS	ANNALS OF INTERNAL MEDICINE			English	Article						MATERNAL-FETAL EXCHANGE; HEPATITIS-C; HEPATITIS ANTIBODIES; PREGNANCY COMPLICATIONS, INFECTIOUS	NON-B-HEPATITIS; MATERNAL-INFANT TRANSMISSION; CHRONIC NON-A; INFECTION; ANTIBODY; MOTHER; HIV	Objective: To search for transmission of hepatitis C virus (HCV) from infected mothers to their infants. Design: Prospective clinical, serologic, and molecular biologic follow-up (at least 3 months) of the infants of mothers with anti-HCV antibody. Setting: A county hospital providing primary and referral care in high-risk obstetrics (perinatology). Patients: Twenty-three mothers with anti-HCV antibody and their 24 infants. Methods: An enzyme-linked immunosorbent assay (EIA) and a four-antigen recombinant immunoblot assay (RIBA) were used to test for anti-HCV antibody; serum HCV RNA was measured in two independent laboratories by reverse transcription and polymerase chain reaction (PCR) using nested primers in the 5'-noncoding region. Infant samples were tested for HCV RNA by PCR at delivery and after 3 to 6 months of follow-up. Each sample was tested at least four times in two independent laboratories. Results: Twenty-nine of 648 mothers (4.5%; 95% CI, 3.0% to 6.4%) had anti-HCV antibody; these women had 30 babies. Twenty-three mothers and their 24 babies were followed at least 3 months (mean follow-up, 52 weeks). Of the 23 mothers, 21 (91%; CI, 72% to 99%) had a reactive RIBA; one woman had an indeterminate RIBA and was positive for HCV RNA by PCR. In 16 of 23 mothers (70%; CI, 47% to 87%), PCR yielded a positive result in both laboratories. The mean maternal alanine aminotransferase (ALT) level was 1.6 times the normal value. All the babies had anti-HCV antibody in cord-blood samples, but antibody disappeared or diminished in strength in interval samples, and no infant had evidence of active production of anti-HCV antibody. Only 1 of 24 (4%; CI, 0.1% to 21%) cord-blood samples was HCV RNA positive, and none of 24 (0%; CI, 0% to 14%) follow-up samples was positive for HCV RNA by PCR in either laboratory. Four mothers and one baby had antibody to HIV. Conclusions: Infant anti-HCV antibody is most likely acquired passively in utero, and vertical transmission of HCV is uncommon.			REINUS, JF (corresponding author), MONTEFIORE MED CTR, DIV GASTROENTEROL, 111 E 210TH ST, BRONX, NY 10467 USA.		Jett, Betsy/AAT-5154-2021					ALFORD CA, 1975, AM J DIS CHILD, V129, P455, DOI 10.1001/archpedi.1975.02120410043014; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; ALTER HJ, 1991, TRANSFUSION, V31, P771, DOI 10.1046/j.1537-2995.1991.31892023507.x; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P410; BUSCH MP, 1992, NEW ENGL J MED, V326, P64, DOI 10.1056/NEJM199201023260114; CHEN DS, 1991, J INFECT DIS, V164, P428, DOI 10.1093/infdis/164.2.428; ESTEBAN R, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P413; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FORTUNY C, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P418; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; JOUNG MK, 1991, 3RD P INT S HCV STRA, P96; KUROKI T, 1991, J INFECT DIS, V164, P427, DOI 10.1093/infdis/164.2.427; LEE SD, 1991, HEPATOLOGY, V13, P830, DOI 10.1016/0270-9139(91)90249-U; MCHUTCHISON JG, 1991, GASTROENTEROLOGY, V101, P1117, DOI 10.1016/0016-5085(91)90742-4; NOVATI R, 1992, J INFECT DIS, V165, P720, DOI 10.1093/infdis/165.4.720; ROUDOTTHORAVAL E, 1991, 3RD P INT S HCV STRA, P85; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SMOLEN P, 1983, J PEDIATR-US, V103, P917, DOI 10.1016/S0022-3476(83)80714-8; STEVENS CE, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P407; STEVENS CE, 1984, VIRAL HEPATITIS LIVE, P275; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; TONG MJ, 1981, GASTROENTEROLOGY, V80, P999; WEJSTAL R, 1990, J MED VIROL, V30, P178, DOI 10.1002/jmv.1890300306	26	139	138	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					881	886		10.7326/0003-4819-117-11-881	http://dx.doi.org/10.7326/0003-4819-117-11-881			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1332561				2022-12-28	WOS:A1992JZ27600001
J	HOWE, LR; LEEVERS, SJ; GOMEZ, N; NAKIELNY, S; COHEN, P; MARSHALL, CJ				HOWE, LR; LEEVERS, SJ; GOMEZ, N; NAKIELNY, S; COHEN, P; MARSHALL, CJ			ACTIVATION OF THE MAP KINASE PATHWAY BY THE PROTEIN-KINASE RAF	CELL			English	Article							C-MYC; ONCOGENE PRODUCT; GROWTH; PHOSPHORYLATION; REQUIREMENT; EXPRESSION; MUTANT; SUBSTRATE; CASCADE; INSULIN	Both MAP kinases and the protein kinase p74raf-1 are activated by many growth factors in a c-ras-dependent manner and by oncogenic p21ras. We were therefore interested in determining the relationship between MAP kinases and raf. The MAP kinase ERK2 is activated by expression of oncogenically activated raf, independently of cellular ras. Overexpressed p74raf-1 potentiates activation of ERK2 by EGF and TPA. MAP kinase kinase inactivated by phosphatase 2A treatment is phosphorylated and reactivated by incubation with p74raf-1 immunoprecipitated from phorbol ester-treated cells. We conclude that raf protein kinase is upstream of MAP kinases and is either a MAP kinase kinase kinase or a MAP kinase kinase kinase kinase.	UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	HOWE, LR (corresponding author), INST CANC RES,CHESTER BEATTY LABS,LONDON,ENGLAND.		Gomez, Nestor/I-2522-2015	Gomez, Nestor/0000-0002-1348-2737; Howe, Louise/0000-0002-1468-7136				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANCOCK JF, 1988, ONCOGENE, V3, P187; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORRIS JDH, 1989, ONCOGENE, V4, P27; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOZERI O, 1992, IN PRESS ONCOGENE; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	44	803	812	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					335	342		10.1016/0092-8674(92)90361-F	http://dx.doi.org/10.1016/0092-8674(92)90361-F			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1330321				2022-12-28	WOS:A1992JU39500018
J	ELLIS, JS; SEYMOUR, RA; MONKMAN, SC; IDLE, JR				ELLIS, JS; SEYMOUR, RA; MONKMAN, SC; IDLE, JR			GINGIVAL SEQUESTRATION OF NIFEDIPINE IN NIFEDIPINE-INDUCED GINGIVAL OVERGROWTH	LANCET			English	Note								The mechanism of gingival overgrowth associated with long-term use of nifedipine and of other drugs that affect calcium homoeostasis, such as cyclosporin and phenytoin, is unknown. With an ultrasensitive assay, we measured the pharmacokinetics of nifedipine in plasma and gingival crevicular fluid (GCF) of nine patients receiving this drug for angina and hypertension. In seven patients, the maximum nifedipine concentration was in the range 15-316 (mean 84 [SD 105]) times greater in GCF than in plasma. The two patients with low (undetectable) GCF nifedipine did not have overgrowth. We propose that gingival tissues sequester nifedipine and that the very high nifedipine concentrations predispose the tissues to overgrowth.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PHARMACOL SCI,PHARMACOGENET RES UNIT,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH DENT,DEPT OPERAT DENT,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK; Newcastle University - UK			Ellis, Janice/R-5300-2018	Ellis, Janice/0000-0002-4602-6674	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARCLAY S, 1992, J CLIN PERIODONTOL, V19, P311, DOI 10.1111/j.1600-051X.1992.tb00650.x; FERNER RE, 1990, HUM EXP TOXICOL, V9, P309, DOI 10.1177/096032719000900507; GELFAND EW, 1987, J IMMUNOL, V138, P1115; KAPUR RN, 1973, DEV MED CHILD NEUROL, V15, P483; MCGAW T, 1987, ORAL SURG ORAL MED O, V64, P293, DOI 10.1016/0030-4220(87)90007-7; SCHMID BJ, 1988, J CHROMATOGR-BIOMED, V425, P107, DOI 10.1016/0378-4347(88)80011-2; SEYMOUR RA, 1988, J CLIN PERIODONTOL, V15, P1, DOI 10.1111/j.1600-051X.1988.tb01549.x; SEYMOUR RA, 1991, BRIT DENT J, V170, P376, DOI 10.1038/sj.bdj.4807564; VATER W, 1972, ARZNEI-FORSCHUNG, V22, P1	9	39	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1382	1383		10.1016/0140-6736(92)91199-I	http://dx.doi.org/10.1016/0140-6736(92)91199-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350808				2022-12-28	WOS:A1992HX63600006
J	GLICK, BS; BRANDT, A; CUNNINGHAM, K; MULLER, S; HALLBERG, RL; SCHATZ, G				GLICK, BS; BRANDT, A; CUNNINGHAM, K; MULLER, S; HALLBERG, RL; SCHATZ, G			CYTOCHROMES-C1 AND CYTOCHROMES-B2 ARE SORTED TO THE INTERMEMBRANE SPACE OF YEAST MITOCHONDRIA BY A STOP-TRANSFER MECHANISM	CELL			English	Article							PRECURSOR PROTEINS; INNER MEMBRANE; C PEROXIDASE; NUCLEAR GENE; ENDOPLASMIC-RETICULUM; OUTER-MEMBRANE; CONTACT SITES; 2 STEPS; IMPORT; TRANSLOCATION	The pathway by which cytochromes c1 and b2 reach the mitochondrial intermembrane space has been controversial. According to the "conservative sorting" hypothesis, these proteins are first imported across both outer and inner membranes into the matrix, and then are retranslocated across the inner membrane. Our data argue against this model: import intermediates of cytochromes c1 and b2 were found only outside the inner membrane; maturation of these proteins was independent of the matrix-localized hsp60 chaperone; and dihydrofolate reductase linked to the presequence of either cytochrome was imported to the intermembrane space in the absence of ATP. We conclude that cytochromes c1 and b2 are sorted by a mechanism in which translocation through the inner membrane is arrested by a "stop-transfer" signal in the presequence. The arrested intermediates may be associated with a proteinaceous channel in the inner membrane.			GLICK, BS (corresponding author), UNIV BASEL, BIOCTR, CH-4056 BASEL, SWITZERLAND.			Muller, Sabina/0000-0002-4580-2758	NIGMS NIH HHS [2R01 GM 37803, GM 43885] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRANDT A, 1991, METHOD CELL BIOL, V34, P369; CASTELLOT JJ, 1980, INTRO MACROMOLECULES, P297; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAUM G, 1982, J BIOL CHEM, V257, P3075; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GLICK B, 1991, ANNU REV GENET, V25, P21; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; HWANG ST, 1991, J BIOL CHEM, V266, P21083; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KOZLOWSKI M, 1988, ANAL BIOCHEM, V172, P382; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; Margulis L., 1993, SYMBIOSIS CELL EVOLU; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NICHOLSON DW, 1988, PROTEIN TRANSFER ORG, P677; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1990, J BIOL CHEM, V265, P16324; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; PRATJE E, 1986, EMBO J, V5, P1312; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; REID GA, 1982, J BIOL CHEM, V257, P3068; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SCHERER P, 1988, THESIS U BASEL BASEL; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOMLO M, 1965, BIOCHIM BIOPHYS ACTA, V97, P183, DOI 10.1016/0304-4165(65)90083-8; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; TEINTZE M, 1982, J BIOL CHEM, V257, P364; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VANLOON APG, 1987, EMBO J, V8, P2433; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZIMMERMAN DL, 1990, J BIOL CHEM, V265, P4048	59	315	315	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					809	822		10.1016/0092-8674(92)90292-K	http://dx.doi.org/10.1016/0092-8674(92)90292-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1350514				2022-12-28	WOS:A1992HW83800011
J	BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; KNAPE, JTA; PIJLS, NHJ				BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; KNAPE, JTA; PIJLS, NHJ			VARIATION IN THE QUALITY OF CARDIOPULMONARY-RESUSCITATION	LANCET			English	Note								During instruction in basic cardiopulmonary resuscitation (CPR) skills, cardiac massage and mouth-to-mouth ventilation are applied without interruption for no longer than a few minutes. The aim of this study was to see if the quality of technique during the first 2 min of CPR reflects the resuscitators ability to perform CPR over a 15 min period. Assessments were done with a resuscitation mannequin from which recordings of several variables were made at 2, 5, 10, and 15 min after the start of CPR. 60 lay volunteers who had received CPR training were studied, and six variables that describe the quality of CPR technique were recorded and scored with a predefined scoring system. No deterioration in CPR skills was seen during 15 min. We conclude that the initial 2 min assessment reflects the resuscitators ability to perform CPR over a longer period.	CATHARINA HOSP,DEPT CARDIOL,POB 1350,5602 ZA EINDHOVEN,NETHERLANDS; DUTCH COLL GEN PRACTIONERS,UTRECHT,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,RADBOUD HOSP,DEPT CARDIOL,NIJMEGEN,NETHERLANDS; UNIV UTRECHT HOSP,DEPT ANAESTHESIA,3511 GV UTRECHT,NETHERLANDS	Catharina Hospital; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center			Berden, Hubert/GQB-0441-2022					BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BERDEN HJJM, 1992, RESUSCITATION, V23, P21, DOI 10.1016/0300-9572(92)90159-A; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; KALMTHOUT P, 1985, BRIT HEART J, V53, P562; KAYE W, 1991, RESUSCITATION, V21, P67, DOI 10.1016/0300-9572(91)90080-I; ROOS L, 1990, CARDIOLOGISCHE PATIE; SEFRIN P, 1987, ANASTH INTENSIVMED, V28, P129; SILVAST T, 1990, AM J EMERG MED, V8, P359; VANHOEYWEGHEN RJ, 1991, ANN EMERG MED, V20, P279, DOI 10.1016/S0196-0644(05)80940-0; 1986, JAMA-J AM MED ASSOC, V255, P2905	10	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1019	1020		10.1016/0140-6736(92)90539-F	http://dx.doi.org/10.1016/0140-6736(92)90539-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349054				2022-12-28	WOS:A1992HQ43500007
J	LEWIN, B; ROBERTSON, IH; CAY, EL; IRVING, JB; CAMPBELL, M				LEWIN, B; ROBERTSON, IH; CAY, EL; IRVING, JB; CAMPBELL, M			EFFECTS OF SELF-HELP POST-MYOCARDIAL-INFARCTION REHABILITATION ON PSYCHOLOGICAL ADJUSTMENT AND USE OF HEALTH-SERVICES	LANCET			English	Article							CARDIAC REHABILITATION; HEART-ATTACK; MORBIDITY; BEHAVIOR; RECOVERY; ILLNESS	A home-based exercise programme has been found to be as useful as a hospital-based one in improving cardiovascular fitness after an acute myocardial infarction. To find out whether a comprehensive home-based programme would reduce psychological distress, 176 patients with an acute myocardial infarction were randomly allocated to a self-help rehabilitation programme based on a heart manual or to receive standard care plus a placebo package of information and informal counselling. Psychological adjustment, as assessed by the Hospital Anxiety and Depression Scale, was better in the rehabilitation group at 1 year. They also had significantly less contact with their general practitioners during the following year and significantly fewer were readmitted to hospital in the first 6 months. The improvement was greatest among patients who were clinically anxious or depressed at discharge from hospital. The cost-effectiveness of the home-based programme has yet to be compared with that of a hospital-based programme, but the findings of this study indicate that it might be worth offering such a package to all patients with acute myocardial infarction.	ASTLEY AINSLIE HOSP,REHABIL MED UNIT,EDINBURGH EH9 2HL,SCOTLAND		LEWIN, B (corresponding author), ASTLEY AINSLIE HOSP,DEPT CLIN PSYCHOL,EDINBURGH EH9 2HL,SCOTLAND.							BERWICK DM, 1987, J CHRON DIS, V40, pS71, DOI 10.1016/S0021-9681(87)80035-8; BRYNE DG, 1978, J PSYCHOSOM RES, V22, P485; BYRNE DG, 1981, J PSYCHOSOM RES, V25, P97, DOI 10.1016/0022-3999(81)90096-9; CAY EL, 1972, J PSYCHOSOM RES, V16, P425, DOI 10.1016/0022-3999(72)90068-2; DEBUSK F, 1985, AM J CARDIOL, V85, P251; DELLIPIANI AW, 1976, BRIT HEART J, V38, P752; DOEHRMAN SR, 1977, SOC SCI MED, V11, P199, DOI 10.1016/0037-7856(77)90094-4; FRASURESMITH N, 1991, AM J CARDIOL, V67, P121, DOI 10.1016/0002-9149(91)90432-K; GLASGOW RE, 1978, PSYCHOL BULL, V85, P1, DOI 10.1037/0033-2909.85.1.1; GLOAG D, 1985, BRIT MED J, V290, P617, DOI 10.1136/bmj.290.6468.617; GOLDBERG DP, 1970, BMJ-BRIT MED J, V2, P439, DOI 10.1136/bmj.2.5707.439; GREEN V, 1988, PHYSIOTHERAPY, V74, P363; HEDBACK B, 1987, EUR HEART J, V8, P234, DOI 10.1093/oxfordjournals.eurheartj.a062265; HEDBACK B, 1985, J CARDIOPULM REHABIL, V5, P576; HOEPER EW, 1980, AM J PSYCHIAT, V137, P207; LLOYD GG, 1982, Q J MED, V51, P33; MAELAND JG, 1989, SCAND J SOC MED, V17, P93, DOI 10.1177/140349488901700114; MAYOU R, 1984, J PSYCHOSOM RES, V28, P17, DOI 10.1016/0022-3999(84)90036-9; MILLER NH, 1984, CIRCULATION, V4, P645; OBERMAN A, 1989, CIRCULATION, V80, P416, DOI 10.1161/01.CIR.80.2.416; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; Parmley W W, 1986, J Am Coll Cardiol, V7, P451; STERN MJ, 1977, ARCH INTERN MED, V137, P1680, DOI 10.1001/archinte.137.12.1680; Vieweg B. W., 1983, J OPER PSYCHIATR, V14, P74; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1988, ANN INTERN MED, V109, P671; 1975, J R COLL PHYSICIANS, V9, P281; 1981, BRIT MED J, V282, P894	29	211	214	2	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1036	1040		10.1016/0140-6736(92)90547-G	http://dx.doi.org/10.1016/0140-6736(92)90547-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ435	1349062				2022-12-28	WOS:A1992HQ43500015
J	PEREZ, A; LABBOK, MH; QUEENAN, JT				PEREZ, A; LABBOK, MH; QUEENAN, JT			CLINICAL-STUDY OF THE LACTATIONAL AMENORRHEA METHOD FOR FAMILY-PLANNING	LANCET			English	Article							CHILEAN WOMEN; OVULATION; MENSTRUATION; FERTILITY; PATTERNS	The effect of breastfeeding on fertility is well known; however, its use as a method of family planning was, until recently, untested. In 1988, the Bellagio Consensus Conference proposed guidelines that became the basis for a method of family planning called the lactational amenorrhoea method (LAM). The principle of LAM is that a woman who continues to fully or nearly fully breastfeed her infant and who remains amenorrhoeic during the first 6 months postpartum is protected from pregnancy during that time. We have assessed this method in the context of a breastfeeding support intervention study of 422 middle-class women in urban Santiago, Chile. The cumulative 6-month life-table pregnancy rate was 0.45% among women who relied on LAM as their only family planning method (1 woman pregnant in month 6). The findings indicate that LAM, with its high acceptance and efficacy, is a viable method of family planning and can safely serve as an introductory method for breastfeeding women.	GEORGETOWN UNIV,SCH MED,DEPT OBSTET & GYNECOL,3800 RESERVOIR RD,NW PHC3,WASHINGTON,DC 20007; CATHOLIC UNIV CHILE,SCH MED,DEPT OBSTET & GYNECOL,SANTIAGO,CHILE; GEORGETOWN UNIV,SCH MED,INST REPROD HLTH,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,DEPT OBSTET & GYNECOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,INST REPROD HLTH,WASHINGTON,DC 20007	Georgetown University; Pontificia Universidad Catolica de Chile; Georgetown University; Georgetown University; Georgetown University				Labbok, Miriam/0000-0001-9515-3963				BERMAN ML, 1972, AM J OBSTET GYNECOL, V114, P524, DOI 10.1016/0002-9378(72)90215-3; DIAZ S, 1988, CONTRACEPTION, V38, P37; DIAZ S, 1988, CONTRACEPTION, V38, P53, DOI 10.1016/0010-7824(88)90095-9; Ginneken J. K. van, 1977, Journal of Biosocial Science, P41, DOI 10.1017/S0021932000023828; GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; HOWIE PW, 1982, J REPROD FERTIL, V65, P545, DOI 10.1530/jrf.0.0650545; JAIN AK, 1981, STUD FAMILY PLANN, V12, P79, DOI 10.2307/1966370; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; LABBOK M, 1990, STUD FAMILY PLANN, V21, P226, DOI 10.2307/1966617; LABBOK M, 1990, GUIDELINES BREASTFEE; LABBOK MH, 1983, NEW ENGL J MED, V308, P51; PEREZ A, 1971, POP STUD-J DEMOG, V25, P491, DOI 10.1080/00324728.1971.10405820; PEREZ A, 1991, AM J OBSTET GYNECOL, V165, P2039, DOI 10.1016/S0002-9378(11)90576-6; RIVERA R, 1985, J BIOSOC SCI S, V9, P112; SAADEH R, 1990, B WORLD HEALTH ORGAN, V68, P625; SHORT RV, 1991, LANCET, V37, P715; VALDES V, IN PRESS J TROP PAED	17	92	97	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					968	970		10.1016/0140-6736(92)91538-J	http://dx.doi.org/10.1016/0140-6736(92)91538-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP036	1348806	hybrid			2022-12-28	WOS:A1992HP03600011
J	BOS, AP; BROERS, CJM; HAZEBROEK, FWJ; VANHEMEL, JO; TIBBOEL, D; WESBYVANSWAAY, E; MOLENAAR, JC				BOS, AP; BROERS, CJM; HAZEBROEK, FWJ; VANHEMEL, JO; TIBBOEL, D; WESBYVANSWAAY, E; MOLENAAR, JC			AVOIDANCE OF EMERGENCY-SURGERY IN NEWBORN-INFANTS WITH TRISOMY-18	LANCET			English	Article							DIE	Trisomy 18 (Edwards' syndrome) presents with characteristic external features as well as life-threatening abnormalities; many of these abnormalities require surgical correction during the neonatal period. Children with trisomy 18 have a very short life expectancy, and all long-term survivors have severe mental retardation. Difficult medical and ethical issues arise over whether or not to institute treatment when a newborn infant with suspected trisomy 18 has a life-threatening anomaly. We studied the policy of treatment in seven patients with clinical Edwards' syndrome. For three, the period of uncertainty was shortened because trisomy 18 was rapidly diagnosed by karyotyping of a bone-marrow aspirate. Four of the patients underwent surgery before the diagnosis of trisomy 18 was confirmed by routine karyotyping in lymphocytes; karyotyping in bone marrow might have allowed invasive treatment to be avoided in three of these. Rapid confirmation of clinically suspected Edwards' syndrome is very important because surgery may then be withheld. A newborn infant with trisomy 18 should be considered as a patient with a hopeless outlook who ought not to be subjected to invasive procedures. The decision to withdraw or withhold treatment should be discussed frankly with the parents. The period of uncertainty can be reduced to a minimum by the use of karyotyping in bone marrow.	ERASMUS UNIV,SCH MED,SOPHIA CHILDRENS HOSP,DEPT CLIN GENET,3000 LL ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital	BOS, AP (corresponding author), ERASMUS UNIV,SCH MED,SOPHIA CHILDRENS HOSP,DEPT PAEDIAT SURG,POB 70029,3000 LL ROTTERDAM,NETHERLANDS.							CARTER PE, 1985, CLIN GENET, V27, P59; EDWARDS JH, 1960, LANCET, V1, P787; MARION RW, 1988, J PEDIATR-US, V113, P45, DOI 10.1016/S0022-3476(88)80526-2; MIRAIE ED, 1988, J PEDIATR-US, V113, P262, DOI 10.1016/S0022-3476(88)80262-2; SAFAR P, 1990, CRIT CARE MED, V18, P788; SMITH DW, 1988, RECOGNIZABLE PATTERN, P16; TRUOG RD, 1990, CRIT CARE MED, V18, P790; VANDYKE DC, 1990, PEDIATRICS, V85, P753; WALDSTEIN G, 1987, ARCH PATHOL LAB MED, V111, P703; WALTERS JW, 1988, AM J DIS CHILD, V142, P825, DOI 10.1001/archpedi.1988.02150080031015	10	42	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					913	915		10.1016/0140-6736(92)90940-5	http://dx.doi.org/10.1016/0140-6736(92)90940-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348308				2022-12-28	WOS:A1992HN48300014
J	MURRAY, FE; STINCHCOMBE, SJ; HAWKEY, CJ				MURRAY, FE; STINCHCOMBE, SJ; HAWKEY, CJ			INDOMETHACIN AND POSTPRANDIAL GALLBLADDER EMPTYING	LANCET			English	Letter							ASPIRIN		UNIV NOTTINGHAM HOSP,DEPT RADIOL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	MURRAY, FE (corresponding author), UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND.							BROOMFIELD PH, 1988, NEW ENGL J MED, V319, P1567, DOI 10.1056/NEJM198812153192403; MURRAY FE, 1991, GUT, V32, pA1253; ODONNELL, 1992, LANCET, V339, P269; RHODES M, 1990, GUT, V31, pA1215	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					882	882		10.1016/0140-6736(92)90334-Y	http://dx.doi.org/10.1016/0140-6736(92)90334-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347903				2022-12-28	WOS:A1992HM44100056
J	SANDSON, TA; WEN, PY; LEMAY, M				SANDSON, TA; WEN, PY; LEMAY, M			REVERSED CEREBRAL ASYMMETRY IN WOMEN WITH BREAST-CANCER	LANCET			English	Note							HYPOTHESIS; HANDEDNESS	Altered intrauterine hormonal environment might predispose to both atypical cerebral asymmetry and breast cancer. We therefore investigated computed tomographic scans of 79 right-handed, white patients with breast cancer and 97 controls to assess the pattern of cerebral asymmetry. Women with breast cancer had a reversed pattern of cerebral asymmetry significantly more often than did controls (p < 0.0001) for both frontal and occipital width. Our findings suggest that an intrauterine or early life factor, probably hormonal, could predispose to breast cancer in adulthood.	BETH ISRAEL HOSP,DIV NEUROL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	SANDSON, TA (corresponding author), BETH ISRAEL HOSP,DEPT NEUROL,BEHAV NEUROL UNIT,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Wen, Patrick/AAE-3776-2022					BEAR D, 1986, ARCH NEUROL-CHICAGO, V43, P598, DOI 10.1001/archneur.1986.00520060060019; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; KELSEY JL, 1990, EPIDEMIOL REV, V12, P228, DOI 10.1093/oxfordjournals.epirev.a036056; KRAMER MA, 1985, NURS RES, V34, P333; LEMAY M, 1978, J COMPUT ASSIST TOMO, V2, P471; LeMay M., 1984, CEREBRAL DOMINANCE B, P26; LEMAY M, IN PRESS AM J NEUROR; MCCLUSKY NJ, 1981, SCIENCE, V211, P1294; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; WEINBERGER DR, 1982, ANN NEUROL, V11, P97, DOI 10.1002/ana.410110118	10	47	48	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					523	524		10.1016/0140-6736(92)90341-Y	http://dx.doi.org/10.1016/0140-6736(92)90341-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346881				2022-12-28	WOS:A1992HF63100006
J	DONNAN, GA				DONNAN, GA			INVESTIGATION OF PATIENTS WITH STROKE AND TRANSIENT ISCHEMIC ATTACKS	LANCET			English	Article							CAROTID ENDARTERECTOMY; CEREBRAL HEMATOMAS; ANGIOGRAPHY; INFARCTION; PHYSIOLOGY; DISEASE				DONNAN, GA (corresponding author), AUSTIN HOSP, DEPT NEUROL, HEIDELBERG, VIC 3084, AUSTRALIA.		DONNAN, GEOFFREY A/A-9947-2008	Donnan, Geoffrey/0000-0001-6324-3403				BARON JC, 1991, CEREBROVASC DIS, V1, P22, DOI 10.1159/000108877; BOZZAO L, 1989, AM J NEURORADIOL, V10, P1215; BROOKS RA, 1989, J COMPUT ASSIST TOMO, V13, P194, DOI 10.1097/00004728-198903000-00002; CUJEC B, 1991, STROKE, V22, P727, DOI 10.1161/01.STR.22.6.727; GUILEMANY JM, 1990, METALL TRANS A, V21, P895, DOI 10.1007/BF02656573; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; HENNERICI M, 1990, J NEUROSCI METH, V34, P169, DOI 10.1016/0165-0270(90)90055-K; HOMMEL M, 1990, STROKE, V21, P546, DOI 10.1161/01.STR.21.4.546; KASE CS, 1982, NEUROLOGY, V32, P1146, DOI 10.1212/WNL.32.10.1146; KERTESZ A, 1987, NEUROLOGY, V37, P1580, DOI 10.1212/WNL.37.10.1580; LENKINSKI RE, 1989, INVEST RADIOL, V24, P1034, DOI 10.1097/00004424-198912000-00025; LITT AW, 1991, AM J NEURORADIOL, V12, P149; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; PUJOL J, 1990, STROKE, V21, P404, DOI 10.1161/01.STR.21.3.404; ROSS JS, 1989, NEUROLOGY, V39, P1369, DOI 10.1212/WNL.39.10.1369; SPENCER MP, 1990, STROKE, V21, P415, DOI 10.1161/01.STR.21.3.415; STEINKE W, 1990, AM J NEURORADIOL, V11, P259; TEAGUE SM, 1991, STROKE, V22, P740, DOI 10.1161/01.STR.22.6.740; TEGELER C H, 1991, Current Concepts of Cerebrovascular Disease and Stroke, V26, P13; TSURUNDA JS, 1991, CIRCULATION, V83, P177; WEBSTER MWI, 1988, LANCET, V2, P11; WISE RJS, 1983, BRAIN, V106, P197, DOI 10.1093/brain/106.1.197; 1990, J R COLL PHYSICIANS, V24, P15	24	40	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 22	1992	339	8791					473	477		10.1016/0140-6736(92)91070-O	http://dx.doi.org/10.1016/0140-6736(92)91070-O			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346828				2022-12-28	WOS:A1992HE93200014
J	JOENSUU, H; KLEMI, PJ; TUOMINEN, J; RASANEN, O; PARVINEN, I				JOENSUU, H; KLEMI, PJ; TUOMINEN, J; RASANEN, O; PARVINEN, I			BREAST-CANCER FOUND AT SCREENING AND PREVIOUS DETECTION BY WOMEN THEMSELVES	LANCET			English	Letter									UNIV TURKU,DEPT PATHOL,SF-20520 TURKU 52,FINLAND; UNIV TURKU,DEPT BIOSTAT,SF-20520 TURKU 52,FINLAND; HLTH CTR TURKU,CANC SOC S W FINLAND,TURKU,FINLAND	University of Turku; University of Turku	JOENSUU, H (corresponding author), UNIV TURKU,CENT HOSP,DEPT ONCOL & RADIOTHERAPY,SF-20520 TURKU 52,FINLAND.							Shapiro S, 1985, Natl Cancer Inst Monogr, V67, P65; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; VERBEEK ALM, 1984, LANCET, V1, P1222	3	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					315	315		10.1016/0140-6736(92)91396-P	http://dx.doi.org/10.1016/0140-6736(92)91396-P			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346329				2022-12-28	WOS:A1992HB52900059
J	INGHAM, PW; ARIAS, AM				INGHAM, PW; ARIAS, AM			BOUNDARIES AND FIELDS IN EARLY EMBRYOS	CELL			English	Review							SEGMENT POLARITY GENE; DEVELOPING NERVOUS-SYSTEM; PAIR-RULE GENES; DROSOPHILA EMBRYO; FUSHI-TARAZU; HOMEOTIC GENES; CHICK-EMBRYO; CELL LINEAGE; CONTROLLING COMPARTMENT; EARLY EMBRYOGENESIS		UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	INGHAM, PW (corresponding author), UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,OXFORD OX1 3PS,ENGLAND.		Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/G-9903-2011; Ingham, Philip W/E-6710-2010; Martinez Arias, Alfonso/F-1966-2010	Ingham, Philip William/0000-0001-8224-9958; Ingham, Philip W/0000-0001-8224-9958; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AKAM M, 1988, DEVELOPMENT, V104, P123; AKAM ME, 1985, PHILOS T R SOC B, V312, P179, DOI 10.1098/rstb.1985.0187; ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1987, DEVELOPMENT, V100, P673; ARIAS AM, 1985, NATURE, V313, P639; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BATE CM, 1991, DEVELOPMENT, V112, P755; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BELLIDO A, 1973, NATURE, V45, P251; BELLIDO AG, 1977, AM ZOOL, V17, P613; BELLIDO AG, 1975, CIBA F S, V29, P161; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; CRICK FHC, 1975, SCIENCE, V189, P340, DOI 10.1126/science.806966; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Driesch H., 1892, Z WISS ZOOL, V53, P160; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; FRASCH M, 1988, GENE DEV, V2, P1824, DOI 10.1101/gad.2.12b.1824; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GARBER RL, 1983, EMBO J, V2, P2027, DOI 10.1002/j.1460-2075.1983.tb01696.x; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; Gould S. J., 1977, ONTOGENY PHYLOGENY; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GRUDON J, 1992, CELL, V68, P185; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; Harrison RG, 1918, J EXP ZOOL, V25, P413, DOI 10.1002/jez.1400250204; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; HOWARD K, 1988, GENE DEV, V2, P1037, DOI 10.1101/gad.2.8.1037; HOWARD KR, 1990, DEVELOPMENT, V110, P1223; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; Huxley J.S., 1934, ELEMENTS EXPT EMBRYO; INGHAM P, 1988, DEVELOPMENT, V104, P51; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1986, NATURE, V324, P592, DOI 10.1038/324592a0; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; JUNG KN, 1979, ROUX ARCH DEVEL BIOL, V186, P211; JUNG KN, 1977, ROUX ARCH DEVEL BIOL, V183, P17; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KAUFMAN TC, 1984, MOL ASPECTS EARLY DE, P189; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KEYNES RJ, 1984, NATURE, V310, P786, DOI 10.1038/310786a0; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KIMMEL CB, 1988, DEVELOPMENT, V104, P197; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE P, 1973, DEV SYSTEMS INSECTS, V12, P157; LAWRENCE PA, 1966, J EXP BIOL, V44, P607; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LAWRENCE PA, 1976, COMPARTMENT HYPOTHES; LEHMANN R, 1989, DEVELOPMENT, V107, P21; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Locke M., 1967, Advances in Morphogenesis, V6, P33; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MEINHARDT H, 1986, J CELL SCI S, V4, P357; Meinhardt H., 1982, MODELS BIOL PATTERN; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MORRISSEY D, 1991, GENE DEV, V5, P1684, DOI 10.1101/gad.5.9.1684; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PATEL NH, 1989, DEVELOPMENT, V107, P210; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; PRIMMETT DRN, 1989, DEVELOPMENT, V105, P119; RANSCHT B, 1991, DEVELOPMENT, V111, P15; RIDDIHOUGH G, 1991, GENE DEV, V5, P840, DOI 10.1101/gad.5.5.840; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Roux W., 1888, VIRCHOWS ARCHIV F R, V114, P113, DOI 10.1007/BF01935891; RUSSEL E, 1916, FORM FUNCTION; SAMPEDRO J, 1991, NATURE, V353, P187, DOI 10.1038/353187a0; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STERN CD, 1988, DEVELOPMENT, V104, P231; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STUMPF HF, 1966, NATURE, V212, P430, DOI 10.1038/212430a0; SZABAD J, 1979, DEV BIOL, V73, P256, DOI 10.1016/0012-1606(79)90066-6; TAM PPL, 1987, DEVELOPMENT, V99, P109; TEAR G, 1990, DEVELOPMENT, V110, P915; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, IN PRESS CELL; WARRIOR R, 1990, DEVELOPMENT, V110, P759; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0	115	226	229	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1992	68	2					221	235		10.1016/0092-8674(92)90467-Q	http://dx.doi.org/10.1016/0092-8674(92)90467-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1346367				2022-12-28	WOS:A1992HB35300005
J	MADAN, M; ALEXANDER, DJ; MCMAHON, MJ				MADAN, M; ALEXANDER, DJ; MCMAHON, MJ			INFLUENCE OF CATHETER TYPE ON OCCURRENCE OF THROMBOPHLEBITIS DURING PERIPHERAL INTRAVENOUS NUTRITION	LANCET			English	Article							PARENTERAL-NUTRITION; INFUSION THROMBOPHLEBITIS; COMPLICATIONS; PHLEBITIS; SUPPORT; HEPARIN; VEIN	To reduce the likelihood of thrombophlebitis during intravenous feeding through a peripheral vein, the osmolality of the solution is usually reduced by disproportionately raising the lipid content and lowering the carbohydrate, electrolyte, and aminoacid concentrations. The possibility that delivery system rather than feed is the main influence on the development of thrombophlebitis was examined in a randomised comparison of a fine-bore silicone catheter against a short 'Teflon' cannula. The nutrient solution given through a peripheral vein was a standard feed used for infusion into a central vein (osmolality 1250 mOsmol/kg, 13 g nitrogen, 200 g glucose [800 kcal], and lipid emulsion [1000 kcal]). 27 patients received the infusion through a fine-bore silicone rubber catheter (diameter 23 G, length 15 cm) and 23 through a teflon catheter (diameter 20 G, length 3.2 cm). The median duration of feeding was 5 days in each of the two groups. Thrombophlebitis developed in all patients in the teflon group but in only 2 (7%) of the silicone group. The first silicone catheter for a patient lasted a median of 128.5 h, compared with 40 h for the first teflon cannula (p < 0.001). The results show that when a nutrient solution of osmolality 1250 mOsmol/kg is delivered through a peripheral vein with an ultrafine-bore silicone catheter, the risk of thrombophlebitis is low. For many patients intravenous feeding may thus be given through a peripheral instead of a central vein without compromising the nutritional adequacy of the feed.	GEN INFIRM,DEPT SURG,NUTR SUPPORT SERV,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary								BAYERBERGER M, 1989, CLIN NUTR, V8, P181, DOI 10.1016/0261-5614(89)90071-X; BODOKY A, 1986, WORLD J SURG, V10, P47, DOI 10.1007/BF01656089; BUXTON AE, 1979, ANN INTERN MED, V90, P764, DOI 10.7326/0003-4819-90-5-764; CARTER J.F.B., 1951, LANCET, V2, P20; COLLIN J, 1975, LANCET, V2, P150; FONKALSRUD EW, 1971, SURG GYNECOL OBSTETR, V133, P253; FUGIWARA T, 1984, SURG GYNECOL OBSTET, V158, P57; GAZITUA R, 1979, ARCH SURG-CHICAGO, V114, P897; HANSELL DT, 1989, INTENSIVE THERAPY CL, V10, P184; HESSOV IB, 1985, ACTA ANAESTH SCAND, V29, P33, DOI 10.1111/j.1399-6576.1985.tb02339.x; JEEJEEBHOY KN, 1976, J CLIN INVEST, V57, P125, DOI 10.1172/JCI108252; JEEJEEHBOY KN, 1981, ACTA CHIR SCAND    S, V504, P419; KHAWAJA HT, 1988, BRIT J SURG, V75, P1212, DOI 10.1002/bjs.1800751223; KOHLHARDT SR, 1989, BRIT MED J, V299, P1380, DOI 10.1136/bmj.299.6712.1380; LEE B, 1989, CLIN NUTR, V8, P187, DOI 10.1016/0261-5614(89)90072-1; LODGE JPA, 1987, BRIT J CLIN PRACT, V41, P816; MADAN M, 1990, Gastroenterology, V98, pA421; MESSING B, 1986, CLIN NUTR, V5, P57, DOI 10.1016/0261-5614(86)90043-9; MUGHAL MM, 1989, BRIT J SURG, V76, P15, DOI 10.1002/bjs.1800760107; PAYNEJAMES J, 1990, BRIT MED J, V301, P1, DOI 10.1136/bmj.301.6742.1; Reid I, 1990, SURG RES COMMUN, V9, P69; RUDIN C, 1990, EUR J PEDIATR, V150, P119, DOI 10.1007/BF02072053; TANNER WA, 1980, BRIT J SURG, V67, P311, DOI 10.1002/bjs.1800670503; WELCH GW, 1974, SURG GYNECOL OBSTET, V138, P421; WOLFE BM, 1986, AM J SURG, V152, P93, DOI 10.1016/0002-9610(86)90153-4	25	54	54	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					101	103		10.1016/0140-6736(92)91007-U	http://dx.doi.org/10.1016/0140-6736(92)91007-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345826				2022-12-28	WOS:A1992GZ15600011
J	MAKIIKOLA, O; GRANFORS, K				MAKIIKOLA, O; GRANFORS, K			SALMONELLA-TRIGGERED REACTIVE ARTHRITIS	LANCET			English	Review							SYNOVIAL-FLUID; MACROPHAGES; INFECTIONS; LIPOPOLYSACCHARIDE; IDENTIFICATION; ANTIGENS; ENZYME; CELLS		NATL PUBL HLTH INST,SF-20520 TURKU,FINLAND; UNIV TURKU,DEPT MED MICROBIOL,SF-20500 TURKU 50,FINLAND	Finland National Institute for Health & Welfare; University of Turku								BAIRDPARKER AC, 1990, LANCET, V336, P1231, DOI 10.1016/0140-6736(90)92844-8; BREWERTON DA, 1988, LANCET, V2, P1063; CALIN A, 1987, ARTHRITIS RHEUM, V30, P1197, DOI 10.1002/art.1780301021; DUNCAN RL, 1984, J IMMUNOL, V132, P1416; GASTON JSH, 1989, CLIN EXP IMMUNOL, V76, P348; GRANFORS K, 1989, NEW ENGL J MED, V320, P216, DOI 10.1056/NEJM198901263200404; GRANFORS K, 1989, J INFECT DIS, V159, P1142, DOI 10.1093/infdis/159.6.1142; GRANFORS K, 1990, LANCET, V335, P685, DOI 10.1016/0140-6736(90)90804-E; GRANFORS K, IN PRESS 2ND P INT S; HAMMER M, 1990, ARTHRITIS RHEUM, V33, P1795, DOI 10.1002/art.1780331206; HERMANN E, 1990, SCAND J RHEUMATOL, V19, P350, DOI 10.3109/03009749009096790; INMAN RD, 1989, J IMMUNOL, V142, P4256; ISOMAKI O, 1989, LANCET, V1, P1411; JALKANEN S, 1989, SPRINGER SEMIN IMMUN, V11, P187; KEAT A, 1987, LANCET, V1, P72; LAHESMAARANTALA R, 1987, ANN RHEUM DIS, V46, P510, DOI 10.1136/ard.46.7.510; MAKELA PH, 1988, IMMUNOL LETT, V19, P217, DOI 10.1016/0165-2478(88)90145-9; MAKIIKOLA O, 1991, RHEUMATOL INT, V10, P231, DOI 10.1007/BF02274884; MAKIIKOLA O, 1991, J INFECT DIS, V164, P1141, DOI 10.1093/infdis/164.6.1141; MAKIIKOLA O, 1990, LANCET, V336, P1387, DOI 10.1016/0140-6736(90)92949-I; MAKIIKOLA O, 1992, BRIT J RHEUMATOL, V31, P25; MAKIIKOLA O, IN PRESS BR J RHEUMA; MAKIIKOLA O, 1991, THESIS TURKU U TURKU; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; REPO H, 1984, ANN CLIN RES, V16, P47; SCHUMACHER HR, 1988, ARTHRITIS RHEUM, V31, P937; STIEGLITZ H, 1989, ARTHRITIS RHEUM, V32, P937, DOI 10.1002/anr.1780320802; TAGGART AJ, 1989, BRIT MED J, V298, P674, DOI 10.1136/bmj.298.6674.674-a; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; VIITANEN AM, 1991, ARTHRITIS RHEUM, V34, P89, DOI 10.1002/art.1780340114; VINER NJ, 1991, ARTHRITIS RHEUM, V34, P1151, DOI 10.1002/art.1780340911; WORDSWORTH BP, 1990, BRIT J RHEUMATOL, V29, P208	32	61	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1096	1098		10.1016/0140-6736(92)90675-S	http://dx.doi.org/10.1016/0140-6736(92)90675-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349113				2022-12-28	WOS:A1992HR44600014
J	MALIK, IA; ABBAS, Z; KARIM, M				MALIK, IA; ABBAS, Z; KARIM, M			RANDOMIZED COMPARISON OF ORAL OFLOXACIN ALONE WITH COMBINATION OF PARENTERAL ANTIBIOTICS IN NEUTROPENIC FEBRILE PATIENTS	LANCET			English	Article							GRANULOCYTOPENIC CANCER-PATIENTS; EMPIRIC TREATMENT; PLUS AMIKACIN; SINGLE-AGENT; THERAPY; CEFTAZIDIME; CIPROFLOXACIN; INFECTIONS; FEVER; TRIAL	Prompt treatment with empirical antibiotics in neutropenic febrile patients reduces morbidity and mortality. Most patients have been treated with parenteral combination antibiotics, but newer antibiotics with broad-spectrum bactericidal activity have made monotherapy feasible. Ofloxacin, a broad-spectrum fluoroquinolone, has the additional advantage that bactericidal concentrations can be achieved with oral administration. We have compared ofloxacin as an oral single agent with standard parenteral combination antibiotics for the management of neutropenic febrile patients in a prospective, randomised trial. Patients with severe neutropenia (absolute neutrophil count less-than-or-equal-to 0.5 x 10(9)/l), fever above 38-degrees-C, and ability to take drugs by mouth were eligible for the study. After initial investigations, 60 patients were randomly assigned to oral ofloxacin 400 mg twice daily and 62 to parenteral combination antibiotic therapy (amikacin 15 mg/kg daily, plus, at various times in the trial, carbenicillin, cloxacillin, or piperacillin). Patients were examined 72 h and 7 days after the start of treatment and when neutropenia resolved. 24 (40%) ofloxacin-treated and 26 (42%) combination-treated patients had pyrexia of unknown origin (PUO). In both treatment groups, the treatment success rate was higher for such patients than for those with clinically or microbiologically documented infections (92% vs 67% [p < 0.05] for ofloxacin; 85% vs 64% for combination). There were no significant differences in success rates of ofloxacin and combination treatment for these subgroups or overall (77% vs 73%). Patients with neutropenia for less than 1 week had better responses to both treatments than patients with longer-lasting neutropenia. There were 4 (7%) deaths in the ofloxacin group and 6 (10%) in the combination group. Both regimens were well tolerated. We conclude that oral single-agent ofloxacin is as effective as parenteral combination antibiotic therapy in neutropenic febrile patients, especially those expected to have short durations of neutropenia.	UNIV CALIF IRVINE,MED CTR,DEPT MED,DIV HEMATOL ONCOL,IRVINE,CA 92717	University of California System; University of California Irvine	MALIK, IA (corresponding author), AGA KHAN UNIV HOSP,DEPT MED,STADIUM RD,POB 3500,KARACHI 74800,PAKISTAN.							ANDERSON ET, 1978, CHEMOTHERAPY, V24, P45, DOI 10.1159/000237759; BAYSTON K, 1988, 5TH P INT S INF IMM, P7; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; CHAN CC, 1989, ANTIMICROB AGENTS CH, V33, P87, DOI 10.1128/AAC.33.1.87; DEJONGH CA, 1986, AM J MED S5C, V80, P36; ELLIOTT CR, 1988, CLIN INVEST MED, V11, P327; FAINSTEIN V, 1983, J ANTIMICROB CHEMOTH, V12, P101, DOI 10.1093/jac/12.suppl_A.101; FLAHERTY JP, 1989, AM J MED, V87, pS278, DOI 10.1016/0002-9343(89)90080-6; HATHORN JW, 1987, ANTIMICROB AGENTS CH, V31, P971, DOI 10.1128/AAC.31.7.971; ISSELL BF, 1980, ANTIMICROB AGENTS CH, V17, P1008, DOI 10.1128/AAC.17.6.1008; Karim M, 1991, J Pak Med Assoc, V41, P35; KELSEY SM, 1989, AM J MED, V87, pS274, DOI 10.1016/0002-9343(89)90079-X; KIBBLER CC, 1987, 3RD P EUR C CLIN MIC; KLASTERSKY J, 1972, ANTIMICROB AGENTS CH, V2, P470, DOI 10.1128/AAC.2.6.470; MORGAN G, 1983, J ANTIMICROB CHEMOTH, V12, P347, DOI 10.1093/jac/12.suppl_A.347; PATER JL, 1986, J CLIN ONCOL, V4, P346, DOI 10.1200/JCO.1986.4.3.346; PICCART M, 1984, ANTIMICROB AGENTS CH, V26, P870, DOI 10.1128/AAC.26.6.870; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; REILLY JT, 1983, J ANTIMICROB CHEMOTH, V12, P89, DOI 10.1093/jac/12.suppl_A.89; RUBIN RH, 1988, ANN INTERN MED, V108, P134, DOI 10.7326/0003-4819-108-1-134; SANDERS CC, 1988, REV INFECT DIS, V10, P516; SANDERS CC, 1982, ANTIMICROB AGENTS CH, V21, P968, DOI 10.1128/AAC.21.6.968; VANLAETHEM Y, 1983, ANTIMICROB AGENTS CH, V23, P435, DOI 10.1128/AAC.23.3.435; WADE JC, 1985, AM J MED, V78, P62, DOI 10.1016/0002-9343(85)90103-2; WADE JC, 1982, ANN INTERN MED, V97, P503, DOI 10.7326/0003-4819-97-4-503; WADE JC, 1981, AM J MED, V71, P983, DOI 10.1016/0002-9343(81)90324-7; WADE JC, 1986, AM J MED, V80, P85; WADE JC, 1982, INFECTIONS CANCER PA, P105; 1978, J INFECT DIS, V137, P14	29	98	101	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1092	1096		10.1016/0140-6736(92)90674-R	http://dx.doi.org/10.1016/0140-6736(92)90674-R			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349112				2022-12-28	WOS:A1992HR44600013
J	CUZICK, J; TERRY, G; HO, L; HOLLINGWORTH, T; ANDERSON, M				CUZICK, J; TERRY, G; HO, L; HOLLINGWORTH, T; ANDERSON, M			HUMAN PAPILLOMAVIRUS TYPE-16 DNA IN CERVICAL SMEARS AS PREDICTOR OF HIGH-GRADE CERVICAL-CANCER	LANCET			English	Note							COLPOSCOPY	The management of women with mild to moderately dyskaryotic cervical smears would benefit from a non-invasive test that predicts which women have high-grade cervical intraepithelial neoplasia. Detection of human papillomavirus type 16 (HPV16) DNA in cervical smears may be such a test. With the polymerase chain reaction (PCR), we estimated the amount of HPV16 DNA in cervical smears from 85 women referred for colposcopy because of abnormal cytology. An intermediate or high amount of HPV16 DNA predicted the presence of high-grade cervical intraepithelial neoplasia in a subsequent biopsy in almost 90% of patients irrespective of the cytological grade of the referral smear. This technique may allow early identification of those women with low-grade cytological abnormalities who have high-grade underlying cervical disease	UNIV LONDON UNIV COLL,DEPT CHEM PATHOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT MED MICROBIOL,LONDON WC1E 6BT,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT OBSTET,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT PATHOL,NOTTINGHAM NG7 2UH,ENGLAND	University of London; University College London; University of London; University College London; University of Nottingham; University of Nottingham	CUZICK, J (corresponding author), IMPERIAL CANC RES FUND,POB 123,LONDON WC2A 3PX,ENGLAND.							FUCHS PG, 1988, INT J CANCER, V41, P41, DOI 10.1002/ijc.2910410109; JOHNSON MA, 1990, J GEN VIROL, V71, P1473, DOI 10.1099/0022-1317-71-7-1473; KOCHEL HG, 1990, INT J GYNECOL OBSTET, V31, P145, DOI 10.1016/0020-7292(90)90712-T; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; NUOVO GJ, 1991, AM J PATHOL, V138, P53; NUOVO GJ, 1990, OBSTET GYNECOL, V75, P1006; NUOVO GJ, 1989, OBSTET GYNECOL, V74, P673; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; VANDENBRULE AJC, 1991, INT J CANCER, V48, P404, DOI 10.1002/ijc.2910480317	10	134	135	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					959	960		10.1016/0140-6736(92)91532-D	http://dx.doi.org/10.1016/0140-6736(92)91532-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348800				2022-12-28	WOS:A1992HP03600005
J	LOOAREESUWAN, S; VIRAVAN, C; VANIJANONTA, S; WILAIRATANA, P; SUNTHARASAMAI, P; CHAROENLARP, P; ARNOLD, K; KYLE, D; CANFIELD, C; WEBSTER, K				LOOAREESUWAN, S; VIRAVAN, C; VANIJANONTA, S; WILAIRATANA, P; SUNTHARASAMAI, P; CHAROENLARP, P; ARNOLD, K; KYLE, D; CANFIELD, C; WEBSTER, K			RANDOMIZED TRIAL OF ARTESUNATE AND MEFLOQUINE ALONE AND IN SEQUENCE FOR ACUTE UNCOMPLICATED FALCIPARUM-MALARIA	LANCET			English	Article							PLASMODIUM-FALCIPARUM; QINGHAOSU ARTEMISININ; ANTIMALARIAL DRUG; PYRIMETHAMINE; SULFADOXINE; THAILAND	The increasing frequency of therapeutic failures in falciparum malaria in Thailand shows an urgent need for effective drugs or drug combinations. Artesunate, a qinghaosu derivative, is effective in clearing parasitaemia rapidly, but the recrudescence rate can be as high as 50%. We have compared artesunate followed by mefloquine with each drug alone in acute, uncomplicated falciparum malaria. 127 patients were randomly assigned treatment with artesunate (600 mg over 5 days), mefloquine (750 mg then 500 mg 6 h later), or artesunate followed by mefloquine. All patients were admitted to hospital for 28 days to exclude reinfection. Cure was defined as no recrudescence during the 28 days' follow-up. The cure rates for mefloquine and artesunate alone were 81% (30/37 patients) and 88% (35/40); the combination was effective in all of 39 patients. Fever and parasite clearance times were significantly shorter in the groups that received artesunate than in the mefloquine-only group. The frequency of nausea and vomiting was slightly, but not significantly, higher among patients who received both drugs than in the other groups. The combination of artesunate followed by mefloquine is highly effective and well tolerated in patients with acute, uncomplicated falciparum malaria in Thailand.	ROCHE ASIAN RES FDN, HONG KONG, HONG KONG; USA, MED COMPONENT, ARMED FORCES RES INST MED SCI, BANGKOK, THAILAND; PHARMACEUT SYST INC, GAITHERSBURG, MD USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	LOOAREESUWAN, S (corresponding author), MAHIDOL UNIV, BANGKOK HOSP TROP DIS, FAC TROP MED, 4206 RAJVITHI RD, BANGKOK 10400, THAILAND.			Kyle, Dennis/0000-0002-0238-965X				[Anonymous], 1979, CHINESE MED J-PEKING, V92, P811; ARNOLD K, 1990, T ROY SOC TROP MED H, V84, P499, DOI 10.1016/0035-9203(90)90012-4; BUNNAG D, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P380; CHAWIRA AN, 1987, J TROP MED HYG, V90, P1; CHAWIRA AN, 1987, T ROY SOC TROP MED H, V81, P554, DOI 10.1016/0035-9203(87)90404-4; CHONGSUPHAJAISIDDHI T, 1983, Southeast Asian Journal of Tropical Medicine and Public Health, V14, P357; CHONGSUPHAJAISIDDHI T, 1987, B WORLD HEALTH ORGAN, V65, P223; HARINASUTA T, 1987, B WORLD HEALTH ORGAN, V65, P363; JIANG JB, 1982, LANCET, V2, P285; KARBWANG J, 1991, B WORLD HEALTH ORGAN, V69, P207; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; LI GQ, 1984, LANCET, V2, P1360; NAING UT, 1988, T ROY SOC TROP MED H, V82, P530, DOI 10.1016/0035-9203(88)90493-2; NOEYPATIMANOND S, 1983, T ROY SOC TROP MED H, V77, P338, DOI 10.1016/0035-9203(83)90158-X; NOSTEN F, 1987, B WORLD HEALTH ORGAN, V65, P891; NOSTEN F, 1991, LANCET, V337, P1140, DOI 10.1016/0140-6736(91)92798-7; REACHER M, 1981, LANCET, V2, P1066, DOI 10.1016/S0140-6736(81)91274-5; SHANKS GD, 1991, AM J TROP MED HYG, V45, P488, DOI 10.4269/ajtmh.1991.45.488; SHWE T, 1989, T ROY SOC TROP MED H, V83, P489, DOI 10.1016/0035-9203(89)90261-7; SHWE T, 1988, T ROY SOC TROP MED H, V82, P665, DOI 10.1016/0035-9203(88)90187-3; WEBSTER HK, 1985, AM J TROP MED HYG, V34, P228, DOI 10.4269/ajtmh.1985.34.228; [No title captured]; 1973, WHO TECHN REP SER, V529, P30	23	133	135	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	1992	339	8797					821	824		10.1016/0140-6736(92)90276-9	http://dx.doi.org/10.1016/0140-6736(92)90276-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347854				2022-12-28	WOS:A1992HM44100001
J	KROHN, K; UIBO, R; AAVIK, E; PETERSON, P; SAVILAHTI, K				KROHN, K; UIBO, R; AAVIK, E; PETERSON, P; SAVILAHTI, K			IDENTIFICATION BY MOLECULAR-CLONING OF AN AUTOANTIGEN ASSOCIATED WITH ADDISONS-DISEASE AS STEROID 17-ALPHA-HYDROXYLASE	LANCET			English	Article							AUTOIMMUNE HEPATITIS; AUTOANTIBODIES; EXPRESSION; ANTIGEN; GENES	Idiopathic Addison's disease is characterised by a progressive failure in the synthesis of all classes of steroid hormones and by an immune response against the steroid-producing cells of the adrenal cortex; the nature of the adrenal autoantigens is not known. We have used molecular cloning and sequencing to identify the target antigens. We screened a human fetal adrenal cDNA expression library in lambda-gt11 vector with serum samples from patients with Addison's disease as part of the type 1 polyendocrine autoimmunity syndrome. Samples from 3 patients, which had precipitating antibodies against two adrenal proteins detected by immunodiffusion and against five adrenal proteins of molecular mass 55, 48, 43, 39, and 19 kDa as judged by immunoblotting, were used to identify 60 immunoreactive clones 39 of these were subcloned, inserted into the M13mp10 vector, and sequenced by the dideoxy method or identified by Southern and dot-blot hybridisation. All but 1 of the inserts showed more than 98.8% homology with the published sequence of steroid 17-alpha-hydroxylase. This protein was expressed by insertion of 1 of the clones into the pGEMEX-1 vector. Only serum from patients with Addison's disease and type 1 polyendocrine autoimmunity syndrome that reacted with the 55 kDa adrenal protein recognised the recombinant 17-alpha-hydroxylase protein on immunoblotting. Our results show that one of the key enzymes in steroid biosynthesis, 17-alpha-hydroxylase, is an autoantigen involved in the pathogenesis of adrenocortical failure.	TARTU STATE UNIV, INST GEN & MOLEC PATHOL, TARTU, ESTONIA, USSR; TARTU STATE UNIV, INST CELLULAR & MOLEC BIOL, TARTU, ESTONIA, USSR	University of Tartu; University of Tartu	KROHN, K (corresponding author), UNIV TAMPERE, INST BIOMED SCI, POB 607, SF-33101 TAMPERE, FINLAND.		Peterson, Pärt/A-5788-2009	Peterson, Pärt/0000-0001-6755-791X; Uibo, Raivo/0000-0002-2298-1300				ANDERSON J. R., 1968, CLIN EXP IMMUNOL, V3, P107; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BLIZZARD RM, 1963, J CLIN INVEST, V42, P1653, DOI 10.1172/JCI104851; BRIGHT GM, 1990, J CLIN ENDOCR METAB, V70, P95, DOI 10.1210/jcem-70-1-95; CHUNG BC, 1987, P NATL ACAD SCI USA, V84, P407, DOI 10.1073/pnas.84.2.407; CZAZNOCKA B, 1985, FEBS LETT, V190, P147; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HEINONEN E, 1977, MED BIOL, V55, P48; HEINONEN E, 1976, ACTA U TAMPERENSIS, V81, P92; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KROHN K, 1974, CLIN IMMUNOL IMMUNOP, V3, P59, DOI 10.1016/0090-1229(74)90023-3; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; MACLAREN NK, 1985, AUTOIMMUNE DISEASES, P201; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MEESE E, 1990, NUCLEIC ACIDS RES, V18, P1923, DOI 10.1093/nar/18.7.1923; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OUCHTERLONY O, 1948, ACTA PATHOL MIC SC, V25, P186; Sambrook J, 1989, MOL CLONING LABORATO; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VOUTILAINEN R, 1991, J CLIN ENDOCR METAB, V72, P761, DOI 10.1210/jcem-72-4-761; WADSWORTH C, 1957, INT ARCH ALLER A IMM, V10, P355, DOI 10.1159/000228394; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256	27	158	162	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1992	339	8796					770	773		10.1016/0140-6736(92)91894-E	http://dx.doi.org/10.1016/0140-6736(92)91894-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347802				2022-12-28	WOS:A1992HL50100002
J	TASAKI, T; OHTO, H; HASHIMOTO, C; ABE, R; SAITOH, A; KIKUCHI, S				TASAKI, T; OHTO, H; HASHIMOTO, C; ABE, R; SAITOH, A; KIKUCHI, S			RECOMBINANT-HUMAN-ERYTHROPOIETIN FOR AUTOLOGOUS BLOOD DONATION - EFFECTS ON PERIOPERATIVE RED-BLOOD-CELL AND SERUM ERYTHROPOIETIN PRODUCTION	LANCET			English	Article							TRANSFUSION; ANTIBODY; VIRUS	To speed collection of blood for autologous transfusion during elective surgery, patients may be given recombinant human erythropoietin (r-HuEPO). In a controlled trial, we evaluated the effects of r-HuEPO on perioperative red-blood-cell and serum erythropoietin (s-EPO) production in patients, donating blood before elective orthopaedic surgery. Patients were assigned randomly to receive no r-HuEPO (1 2 patients), or 3000 U (4), 6000 U (5), or 9000 U (4) of r-HuEPO intravenously twice a week from the time of the first blood donation. All patients received iron sulphate. 1200 ml blood was collected from each patient in three weekly donations of 400 ml. The 3000, 6000, and 9000 U treatment groups produced 284, 350, and 383 ml, respectively, of red cells during donation, and the untreated controls produced 211 ml. s-EPO concentrations were within the normal range during donation. After surgery, s-EPO concentrations peaked on postoperative day 1 in untreated patients and on day 7 in treated patients; therefore, r-HuEPO may suppress endogenous erythropoietin secretion. Although administration of r-HuEPO increases production of red blood cells, the preoperative anaemia induced by repeated phlebotomy without r-HuEPO may accelerate the postoperative secretion of endogenous erythropoietin.	FUKUSHIMA MED SCH,DEPT ORTHOPAED SURG,FUKUSHIMA 96012,JAPAN	Fukushima Medical University	TASAKI, T (corresponding author), FUKUSHIMA MED SCH,BLOOD TRANSFUS SERV,HIKARIGA OKA,FUKUSHIMA 96012,JAPAN.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; CUMMING PD, 1989, NEW ENGL J MED, V321, P914; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; HOWARD JE, 1978, TRANSFUSION, V18, P496, DOI 10.1046/j.1537-2995.1978.18478251250.x; INABA S, 1989, TRANSFUSION, V29, P7, DOI 10.1046/j.1537-2995.1989.29189101168.x; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; KICKLER TS, 1988, JAMA-J AM MED ASSOC, V260, P65, DOI 10.1001/jama.260.1.65; LEVINE E, 1990, TRANSFUSION, V30, P295, DOI 10.1046/j.1537-2995.1990.30490273433.x; MAEDA H, 1989, LANCET, V2, P284; NADLER SB, 1962, SURGERY, V51, P224; OWINGS DV, 1989, JAMA-J AM MED ASSOC, V262, P1963	13	47	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					773	775		10.1016/0140-6736(92)91895-F	http://dx.doi.org/10.1016/0140-6736(92)91895-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347803				2022-12-28	WOS:A1992HL50100003
J	ENGELBERG, H				ENGELBERG, H			LOW SERUM-CHOLESTEROL AND SUICIDE	LANCET			English	Note							LIPID FLUIDITY; MEMBRANES; SEROTONIN; BEHAVIOR; MICROVISCOSITY; PARAMETERS; MORTALITY; BINDING	Primary prevention trials which have shown that the lowering of serum cholesterol concentrations in middle-aged subjects by diet, drugs, or both leads to a decrease in coronary heart disease have also reported an increase in deaths due to suicide or violence. There has been no adequate explanation for this association. I have reviewed the relevant published work and describe a physiological mechanism that might account for this curious finding. One of the functions of serotonin in the central nervous system is the suppression of harmful behavioural impulses. When mouse brain synaptosomal membrane cholesterol is increased there is a pronounced increase in the number of serotonin receptors. Low membrane cholesterol decreases the number of serotonin receptors. Since membrane cholesterol exchanges freely with cholesterol in the surrounding medium, a lowered serum cholesterol concentration may contribute to a decrease in brain serotonin, with poorer suppression of aggressive behaviour.	CEDARS SINAI MED CTR, DEPT MED, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center								ASBERG M, 1976, ARCH GEN PSYCHIAT, V33, P1193; BOROCHOV H, 1976, P NATL ACAD SCI USA, V73, P4526, DOI 10.1073/pnas.73.12.4526; COOPER RA, 1978, J SUPRAMOL STR CELL, V8, P413, DOI 10.1002/jss.400080404; HERON DS, 1980, P NATL ACAD SCI-BIOL, V77, P7463, DOI 10.1073/pnas.77.12.7463; HERSHKOWITZ M, 1982, PROG BRAIN RES, V56, P419; HORROBIN DF, 1990, BRIT MED J, V301, P554, DOI 10.1136/bmj.301.6751.554-b; JENKINS CD, 1969, PSYCHOSOM MED, V31, P115; JOHNSON DA, 1979, MOL PHARMACOL, V15, P739; KAPLAN JR, 1990, PSYCHOSOM MED, V52, P226; MCLOUGHLIN I, 1989, BRIT J PSYCHIAT, V154, P275, DOI 10.1192/S0007125000226275; MULDOON MF, 1990, BRIT MED J, V301, P554, DOI 10.1136/bmj.301.6751.554-a; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V433, P133, DOI 10.1016/0005-2736(76)90183-8; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SLAP GB, 1989, PEDIATRICS, V84, P762; SLETTEN IW, 1964, PSYCHOSOM MED, V26, P261, DOI 10.1097/00006842-196405000-00005; SMITH GD, 1990, BRIT MED J, V301, P552; SOUBRIE P, 1986, BEHAV BRAIN SCI, V9, P319, DOI 10.1017/S0140525X00022871; THILO L, 1977, BIOCHEMISTRY-US, V16, P1283, DOI 10.1021/bi00626a007; VIKKUNEN M, 1983, NEUROPSYCHOBIOLOGY, V10, P65; VIKKUNEN M, 1984, NEUROPSYCHOBIOLOGY, V19, P435; VIKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27; 1987, LANCET, V2, P949	25	393	401	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	1992	339	8795					727	729		10.1016/0140-6736(92)90609-7	http://dx.doi.org/10.1016/0140-6736(92)90609-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347593				2022-12-28	WOS:A1992HK32000014
J	DENNY, T; YOGEV, R; GELMAN, R; SKUZA, C; OLESKE, J; CHADWICK, E; CHENG, SC; CONNOR, E				DENNY, T; YOGEV, R; GELMAN, R; SKUZA, C; OLESKE, J; CHADWICK, E; CHENG, SC; CONNOR, E			LYMPHOCYTE SUBSETS IN HEALTHY-CHILDREN DURING THE 1ST 5 YEARS OF LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CONTROLLED TRIAL; CELL SUBSETS; INFECTION; ZIDOVUDINE	Objective. - To assess whether relative and absolute values of CD4 and CD8 lymphocytes and CD4/CD8 ratio change in relation to age, and to estimate the fifth and 95th percentiles for these values in children of various ages. Patients and Methods. - Phenotypic analysis of lymphocyte subsets was performed on blood samples from 208 healthy children, aged 1 through 59 months, using standard flow cytometric techniques. Results. - Regression analysis demonstrated that CD4 and CD8 lymphocyte counts declined significantly with advancing age (P < .000001 and P = .03, respectively). Since CD4 and CD8 counts depend on total lymphocyte count, the percentage of total lymphocytes of each phenotype was also analyzed and demonstrated that the CD4 percentage was highly age dependent (P < .000001). The CD8 percentage increased with age (P = .0001) but not as much as the CD4 percentage decreased. Median CD4 counts (fifth and 95th percentiles) for children 2 through 3, 4 through 8, 12 through 23, and 24 through 59 months of age were 2.83 (1.46 to 5.11), 2.95 (1.69 to 4.61), 2.07 (1.02 to 3.60), and 1.80 (0.90 to 2.86) x 10(9)/L, respectively. Conclusion. - Healthy children's CD4 lymphocyte counts are considerably higher than previously established adult values. These data demonstrate that age is an important consideration in interpretation of lymphocyte subsets in children. This may be especially relevant in children who are infected with the human immunodeficiency virus, where CD4 lymphocyte values play a central role in monitoring disease progression and determining thresholds for medical interventions.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PEDIAT,185 S ORANGE AVE,NEWARK,NJ 07103; CHILDRENS HOSP NEW JERSEY,NEWARK,NJ; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,AIDS CLIN TRIALS UNIT,NEWARK,NJ 07103; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT PEDIAT,CHICAGO,IL 60614; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,AIDS CLIN TRIALS UNIT,CHICAGO,IL 60614; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Brugnara, Carlo/A-8041-2010; Oleske, James/C-1951-2016	Brugnara, Carlo/0000-0001-8192-8713; Oleske, James/0000-0003-2305-5605; Denny, Thomas/0000-0002-7364-8276	NIAID NIH HHS [N01-AI-95030, 5UO1-AI27559, 1UO1-AI25883] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025883, N01AI095030, U01AI027559] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASCHER DP, 1991, 31ST INT C ANT AG CH; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; Breiman L., 1982, CLASSIFICATION REGRE; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; CULVER KW, 1987, J PEDIATR-US, V111, P230, DOI 10.1016/S0022-3476(87)80073-2; DALLMAN PR, 1978, AM J CLIN NUTR, V31, P377, DOI 10.1093/ajcn/31.3.377; DANGOSTINO RB, 1986, GOODNESS FIT TECHNIQ; DEMARTINO M, 1991, J PEDIATR-US, V119, P702, DOI 10.1016/S0022-3476(05)80283-5; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GIORGI JV, 1986, MANUAL CLIN LABORATO, P236; JACKSON A, 1986, MANUAL CLIN LABORATO, P236; JOHNSON L, 1986, CONTINUOUS UNIVARIAT, P73; KARAYALCIN G, 1972, NEW YORK STATE J MED, V72, P1815; KENDALL M, 1977, ADV THEORY STAT, V1, P258; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P52; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; LIEBOVITZ E, 1990, NEW ENGL J MED, V323, P531; MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881; TOLLERUD DJ, 1989, J CLIN IMMUNOL, V9, P214, DOI 10.1007/BF00916817; TOLLERUD DJ, 1990, CLIN IMMUNOL IMMUNOP, V56, P88, DOI 10.1016/0090-1229(90)90172-M; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1989, MMWR S5, V38, P1; 1991, MMWR, V40, P1	25	189	191	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1484	1488		10.1001/jama.267.11.1484	http://dx.doi.org/10.1001/jama.267.11.1484			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1347086				2022-12-28	WOS:A1992HH48800028
J	VAHAKANGAS, KH; SAMET, JM; METCALF, RA; WELSH, JA; BENNETT, WP; LANE, DP; HARRIS, CC				VAHAKANGAS, KH; SAMET, JM; METCALF, RA; WELSH, JA; BENNETT, WP; LANE, DP; HARRIS, CC			MUTATIONS OF P53 AND RAS GENES IN RADON-ASSOCIATED LUNG-CANCER FROM URANIUM MINERS	LANCET			English	Article							POINT MUTATIONS; RISK; CARCINOMA; EXPOSURE; FREQUENT; CELLS	Radon increases the risk of lung cancer in smoking and non-smoking underground miners. To investigate the mutational spectrum associated with exposure to high levels of radon, we sequenced exons 5-9 of the p53 tumour suppressor gene and codons 12-13 of the Ki-ras protooncogene in 19 lung cancers from uranium miners exposed to radon and tobacco smoke. Mutations were not found in Ki-ras, but 9 p53 mutations, including 2 deletions, were found in 7 patients by direct DNA sequencing after polymerase chain reaction amplification of DNA from formalin-fixed, paraffin-embedded tissue. In tumours from 5 patients, the mutation produced an aminoacid change and an increased nuclear content of p53 protein. The tumours with either a stop codon or frame-shift deletion in the p53 gene were negative by immunohistochemistry. None of the mutations were G:C to T:A transversions in the coding strand of the p53 gene, which are the most frequent base substitutions associated with tobacco smoking, and none were found at the hotspot codons described in lung cancer. The observed differences from the usual lung cancer mutational spectrum may reflect the genotoxic effects of radon.	NCI, HUMAN CARCINOGENESIS LAB, BLDG 37, ROOM 2C05, BETHESDA, MD 20892 USA; UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND; UNIV NEW MEXICO, MED CTR, CTR CANC, NEW MEXICO TUMOR REGISTRY, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, MED CTR, DEPT MED, ALBUQUERQUE, NM 87131 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Dundee; University of New Mexico; University of New Mexico			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545	NCI NIH HHS [N01 CN-55426] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN055426] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT WP, 1991, ONCOGENE, V6, P1779; BOS JL, 1989, CANCER RES, V49, P4682; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRENNAN J, 1991, CANCER RES, V51, P1708; BRIDGES BA, 1991, LANCET, V337, P1187, DOI 10.1016/0140-6736(91)92859-Z; CHIBA I, 1990, ONCOGENE, V5, P1603; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; GROSOVSKY AJ, 1988, P NATL ACAD SCI USA, V85, P185, DOI 10.1073/pnas.85.1.185; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HARLEY NH, 1990, CA-CANCER J CLIN, V40, P265, DOI 10.3322/canjclin.40.5.265; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SAMESHIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P697, DOI 10.1016/S0006-291X(05)80091-9; SAMET JM, 1989, HEALTH PHYS, V56, P415, DOI 10.1097/00004032-198904000-00002; SAMET JM, 1991, HEALTH PHYS, V61, P745, DOI 10.1097/00004032-199112000-00005; SAMET JM, 1990, RISK ANAL, V10, P65, DOI 10.1111/j.1539-6924.1990.tb01021.x; SCHWARTZ JL, 1990, ENVIRON MOL MUTAGEN, V16, P178; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; 1988, HLTH RISKS RADON OTH	30	298	304	2	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1992	339	8793					576	580		10.1016/0140-6736(92)90866-2	http://dx.doi.org/10.1016/0140-6736(92)90866-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347094				2022-12-28	WOS:A1992HH07500004
J	VALLANCE, P; LEONE, A; CALVER, A; COLLIER, J; MONCADA, S				VALLANCE, P; LEONE, A; CALVER, A; COLLIER, J; MONCADA, S			ACCUMULATION OF AN ENDOGENOUS INHIBITOR OF NITRIC-OXIDE SYNTHESIS IN CHRONIC-RENAL-FAILURE	LANCET			English	Article							NG-METHYLARGININE; BLOOD-PRESSURE; L-ARGININE; NG,NG-DIMETHYLARGININE; PURIFICATION; INVIVO	Nitric oxide (NO), synthesised from L-arginine, contributes to the regulation of blood pressure and to host defence. We describe in-vitro and in-vivo evidence that NO synthesis can be inhibited by an endogenous compound, N(G),N(G)-dimethylarginine (asymmetrical dimethylarginine, ADMA). In man, this inhibitor is found in plasma and more than 1 0 mg is excreted in urine over 24 h. However, in patients with end-stage chronic renal failure, who have little or no urine output, elimination is blocked and circulating concentrations of the inhibitor rise sufficiently to inhibit NO synthesis. Accumulation of endogenous ADMA, leading to impaired NO synthesis, might contribute to the hypertension and immune dysfunction associated with chronic renal failure.	WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & TOXICOL,LONDON SW17,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; St Georges University London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CARNEGIE PR, 1977, METABOLISM, V26, P531, DOI 10.1016/0026-0495(77)90097-X; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; ESCHBACH JW, 1991, KIDNEY, P2019; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; GRANGER DL, 1991, J IMMUNOL, V146, P1294; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIRSCHBERG RR, 1988, KIDNEY INT, V33, P1147, DOI 10.1038/ki.1988.123; KAKIMOTO Y, 1970, J BIOL CHEM, V245, P5751; KEANE WF, 1983, REPLACEMENT RENAL FU, P646; LIEW FY, 1990, J IMMUNOL, V144, P4794; LOU MF, 1979, SCIENCE, V203, P668, DOI 10.1126/science.760213; MCDERMOTT JR, 1976, BIOCHEM J, V154, P179, DOI 10.1042/bj1540179; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V230, P212; NAKAMURA T, 1991, HYPERTENSION, V17, P875, DOI 10.1161/01.HYP.17.6.875; OGAWA T, 1990, J BIOL CHEM, V265, P20938; OGAWA T, 1989, J BIOL CHEM, V264, P10205; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PARK KS, 1988, J CHROMATOGR, V440, P225, DOI 10.1016/S0021-9673(00)94526-6; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; SADASIVUDU B, 1974, CLINICIAN, V38, P114; TOLINS JP, 1991, HYPERTENSION, V17, P1045, DOI 10.1161/01.HYP.17.6.1045; TOLKOFFRUBIN NE, 1990, NEW ENGL J MED, V322, P770, DOI 10.1056/NEJM199003153221109; VALLANCE P, 1989, LANCET, V2, P997; WALDER CE, 1991, BRIT J PHARMACOL, V102, P967, DOI 10.1111/j.1476-5381.1991.tb12285.x	28	1893	1960	1	42	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					572	575						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347093				2022-12-28	WOS:A1992HH07500003
J	WATTS, GF; LEWIS, B; BRUNT, JNH; LEWIS, ES; COLTART, DJ; SMITH, LDR; MANN, JI; SWAN, AV				WATTS, GF; LEWIS, B; BRUNT, JNH; LEWIS, ES; COLTART, DJ; SMITH, LDR; MANN, JI; SWAN, AV			EFFECTS ON CORONARY-ARTERY DISEASE OF LIPID-LOWERING DIET, OR DIET PLUS CHOLESTYRAMINE, IN THE ST-THOMAS-ATHEROSCLEROSIS-REGRESSION-STUDY (STARS)	LANCET			English	Article							MYOCARDIAL-INFARCTION; HEART-DISEASE; PROGRESSION; THERAPY; HYPERLIPEMIA; RELAXATION	To assess the effect of dietary reduction of plasma cholesterol concentrations on coronary atherosclerosis, we set up a randomised, controlled, end-point-blinded trial based on quantitative image analysis of coronary angiograms in patients with angina or past myocardial infarction. Another intervention group received diet and cholestyramine, to determine the effect of a greater reduction in circulating cholesterol concentrations. 90 men with coronary heart disease (CHD), who had a mean (SD) plasma cholesterol of 7.23 (0.77) mmol/l were randomised to receive usual care (U, controls), dietary intervention (D), or diet plus cholestyramine (DC), with angiography at baseline and at 39 (SD 3-5) months. Mean plasma cholesterol during the trial period was 6.93 (U), 6.l7 (D), and 5-56 (DC) mmol/l. The proportion of patients who showed overall progression of coronary narrowing was significantly reduced by both interventions (U 46%, D 15%, DC 12%), whereas the proportion who showed an increase in luminal diameter rose significantly (U 40%, D 38%, DC 33%). The mean absolute width of the coronary segments (MAWS) studied decreased by 0.201 mm in controls increased by 0.003 mm in group D, and increased 0.103 mm in group DC (p < 0.05), with improvement also seen in the minimum width of segments, percentage diameter stenosis, and edge-irregularity index in intervention groups. The change in MAWS was independently and significantly correlated with LDL cholesterol concentration and LDL/HDL cholesterol ratio during the trial period. Both interventions significantly reduced the frequency of total cardiovascular events. Dietary change alone retarded overall progression and increased overall regression of coronary artery disease, and diet plus cholestyramine was additionally associated with a net increase in coronary lumen diameter. These findings support the use of a lipid-lowering diet, and if necessary of appropriate drug treatment, in men with CHD who have even mildly raised serum cholesterol concentrations.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,RAYNE INST,LONDON,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT CARDIOL,LONDON,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON,ENGLAND; UNIV MANCHESTER,SCH MED,DEPT MED BIOPHYS,MANCHESTER M13 9PL,LANCS,ENGLAND; UNIV OTAGO,DEPT HUMAN NUTR,DUNEDIN,NEW ZEALAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Manchester; University of Otago	WATTS, GF (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT ENDOCRINOL & CHEM PATHOL,LONDON SE1 7EH,ENGLAND.			Watts, Gerald/0000-0003-2276-1524				AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; AMITZENIUS AC, 1985, NEW ENGL J MED, V312, P805; ARMSTRONG ML, 1976, ATHEROSCLER REV, V1, P137; ASTLEY SM, 1987, COMPUT CARDIOL, V13, P579; Austen W. G., 1975, CIRCULATION, V51, P7; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1991, CIRCULATION, V83, P438, DOI 10.1161/01.CIR.83.2.438; BLANKENHORN DH, 1990, JAMA-J AM MED ASSOC, V263, P1646, DOI 10.1001/jama.263.12.1646; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN BG, 1982, ARTERIOSCLEROSIS, V2, P2, DOI 10.1161/01.ATV.2.1.2; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BRUNT JNH, 1989, 3RD INT S COR ART RO, P32; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHOUDHURY S, 1984, ATHEROSCLEROSIS, V50, P93, DOI 10.1016/0021-9150(84)90011-X; COLCHESTER ACF, 1983, J CEREBRAL BLOOD FLO, V3, pS640; CRAWFORD DW, 1977, J LAB CLIN MED, V89, P378; DUFFIELD RGM, 1983, LANCET, V2, P639; HABIB JB, 1984, CIRCULATION, V70, P123; HACKETT D, 1989, AM J CARDIOL, V63, P1517, DOI 10.1016/0002-9149(89)90018-0; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P1007; LAVILLE AE, 1989, ATHEROSCLEROSIS, V78, P205, DOI 10.1016/0021-9150(89)90224-4; LEWIS B, 1981, LANCET, V2, P1310; LEWIS B, 1974, BMJ-BRIT MED J, V3, P489, DOI 10.1136/bmj.3.5929.489; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; REIBER JHC, 1991, QUANTITATIVE CORONAR, P55; ROUSSOUW JE, 1990, NEW ENGL J MED, V323, P1112; VARTIAINEN I, 1947, ANN MED INTERN FIN, V34, P705; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WISSLER RW, 1976, ANN NY ACAD SCI, V275, P363, DOI 10.1111/j.1749-6632.1976.tb43368.x; 1947, AM J PATHOL, V33, P793; 1981, JAMA-J AM MED ASSOC, V251, P351; 1988, EUR HEART J, V8, P277	34	723	728	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					563	569		10.1016/0140-6736(92)90863-X	http://dx.doi.org/10.1016/0140-6736(92)90863-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347091				2022-12-28	WOS:A1992HH07500001
J	FAYAD, IM; HIRSCHHORN, N; ABUZIKRY, M; KAMEL, M				FAYAD, IM; HIRSCHHORN, N; ABUZIKRY, M; KAMEL, M			HYPERNATREMIA SURVEILLANCE DURING A NATIONAL DIARRHEAL DISEASES CONTROL PROJECT IN EGYPT	LANCET			English	Article							ORAL REHYDRATION SOLUTION; INFANTILE DIARRHEA; CHILDREN	The nationwide introduction of oral rehydration therapy to Egypt has led to improvement in diarrhoea case management and a fall in infant and child mortality. With the wider use of oral rehydration solution (ORS) prepared from packets, the incidence of hypernatraemia (serum sodium > 150 mmol/l) in inpatients with dehydration seen at Abu El-Reeche Hospital, Cairo, increased between 1980 and 1984. Systematic surveillance of hypernatraemia in the outpatient rehydration unit began in late 1984, and we report trends in hypernatraemia and analyses of key variables affecting its incidence in dehydrated children. In 1980, 17 of 100 children sampled had hypernatraemia and 2 had severe hypernatraemia (ie, serum sodium > 165 mmol/l). The frequency in inpatients peaked at 49% of 222 children in 1984 (19% with severe hypernatraemia). Between 1 986 and 1 989, at least 1 000 dehydrated outpatients were surveyed each year; by 1989 the incidence of hypernatraemia had fallen to around 10% (2% severe hypernatraemia). The rise and decline coincided with increasing use of ORS and then increasing ability of mothers to mix the solution correctly. Hypernatraemia was positively related to the quantity of ORS taken, severity of dehydration, nutritional status, and the cooler season, and negatively related to age and duration of diarrhoea. Explanations for our findings include improved use of ORS and better case-management. Good practice promoted through the mass media has facilitated these changes, if the standard of ORS use is not maintained, there may be a case for reducing the sodium content of ORS.	JOHN SNOW INC, BOSTON, MA USA; MINIST HLTH CAIRO, NATL CONTROL DIARRHEAL DIS PROJECT, CAIRO, EGYPT	Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt	FAYAD, IM (corresponding author), UNIV CAIRO, CHILDRENS HOSP, ABU EL REECHE HOSP, FAC MED, GASTROENTERITIS UNIT, CAIRO, EGYPT.							BLACK RE, 1984, PEDIATRICS, V73, P799; CLEARY TG, 1981, J PEDIATR-US, V99, P739, DOI 10.1016/S0022-3476(81)80397-6; ELMOUGI M, 1989, J TROP PEDIATRICS, V35, P230, DOI 10.1093/tropej/35.5.230; ELRAFIE M, 1990, LANCET, V335, P334; FARTHING MJG, 1988, DRUGS, V36, P80, DOI 10.2165/00003495-198800364-00011; FORTIN J, 1978, J TROP PED ENV CH H, V24, P110, DOI 10.1093/tropej/24.3.110; HELMY N, 1988, J PEDIATR GASTR NUTR, V7, P417, DOI 10.1097/00005176-198805000-00018; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; PANETH N, 1980, AM J DIS CHILD, V134, P785, DOI 10.1001/archpedi.1980.02130200053017; PIZARRO D, 1984, J PEDIATR-US, V104, P316, DOI 10.1016/S0022-3476(84)81023-9; SANTOSHAM M, 1990, J PEDIATR-US, V116, P868, DOI 10.1016/S0022-3476(05)80642-0; 1988, LANCET, V2, P145; 1977, B WORLD HEALTH ORGAN, V55, P87	13	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					389	393		10.1016/0140-6736(92)90079-I	http://dx.doi.org/10.1016/0140-6736(92)90079-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346660				2022-12-28	WOS:A1992HD65900004
J	LANDI, G				LANDI, G			CLINICAL-DIAGNOSIS OF TRANSIENT ISCHEMIC ATTACKS	LANCET			English	Article							ISCHEMIC ATTACKS; INTEROBSERVER AGREEMENT; STROKE; RELIABILITY; COMMUNITY; RIND				LANDI, G (corresponding author), OSPED POLICLIN, NEUROL CLIN, VIA F SFORZA 35, I-20122 MILAN, ITALY.							BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; CALANCHINI PR, 1977, JAMA-J AM MED ASSOC, V238, P2029, DOI 10.1001/jama.238.19.2029; CAPLAN LR, 1983, STROKE, V14, P431, DOI 10.1161/01.STR.14.3.431; DENNIS M, 1990, J NEUROL, V237, P257, DOI 10.1007/BF00314630; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DENNIS MS, 1989, LANCET, V1, P185; FISHER CM, 1986, STROKE, V17, P1033, DOI 10.1161/01.STR.17.5.1033; FISHER CM, 1982, NEUROLOGY, V32, P871, DOI 10.1212/WNL.32.8.871; HANKEY GJ, 1991, LANCET, V337, P335, DOI 10.1016/0140-6736(91)90953-M; HODGES JR, 1990, BRAIN, V113, P639, DOI 10.1093/brain/113.3.639; KAPPELLE LJ, 1991, ANCET, V337, P339; KOUDSTAAL PJ, 1986, STROKE, V17, P723, DOI 10.1161/01.STR.17.4.723; KRAAIJEVELD CL, 1984, STROKE, V15, P723, DOI 10.1161/01.STR.15.4.723; LANDI G, IN PRESS CEREBROVASC; LARSEN BH, 1990, J NEUROL NEUROSUR PS, V53, P1029, DOI 10.1136/jnnp.53.12.1029; LEE H, 1990, NEUROLOGY, V40, P165, DOI 10.1212/WNL.40.1.165; MEISSNER I, 1986, NEUROLOGY, V36, P1029, DOI 10.1212/WNL.36.8.1029; PORTENOY RK, 1984, STROKE, V15, P1009, DOI 10.1161/01.STR.15.6.1009; SHINAR D, 1987, ARCH NEUROL-CHICAGO, V44, P149, DOI 10.1001/archneur.1987.00520140021012; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOMASELLO F, 1982, STROKE, V13, P32, DOI 10.1161/01.STR.13.1.32; WAXMAN SG, 1983, STROKE, V14, P433, DOI 10.1161/01.STR.14.3.433; WIEBERS DO, 1982, NEUROLOGY, V32, P459, DOI 10.1212/WNL.32.5.459; YANAGIHARA T, 1985, ANN NEUROL, V18, P244, DOI 10.1002/ana.410180212	24	39	41	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					402	405		10.1016/0140-6736(92)90086-I	http://dx.doi.org/10.1016/0140-6736(92)90086-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346667				2022-12-28	WOS:A1992HD65900011
J	TABAR, L; FAGERBERG, G; DAY, NE; DUFFY, SW; KITCHIN, RM				TABAR, L; FAGERBERG, G; DAY, NE; DUFFY, SW; KITCHIN, RM			BREAST-CANCER-TREATMENT AND NATURAL-HISTORY - NEW INSIGHTS FROM RESULTS OF SCREENING	LANCET			English	Editorial Material							COMPARING TOTAL MASTECTOMY; TRIAL		MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; LINKOPING UNIV HOSP,DEPT DIAGNOST RADIOL,S-58185 LINKOPING,SWEDEN	MRC Biostatistics Unit; Linkoping University	TABAR, L (corresponding author), CENT HOSP FALUN,DEPT MAMMOG,S-79182 FALUN,SWEDEN.		Tabar, Laszlo Kornel/AGT-3287-2022					CHITTOOR SR, 1991, AM FAM PHYSICIAN, V44, P453; DUFFY SW, 1991, BRIT J CANCER, V64, P1133, DOI 10.1038/bjc.1991.477; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FISHER B, 1980, CANCER RES, V40, P3863; FISHER ER, 1988, CONTROVERSIES BREAST, P151; MEYER JS, 1991, INT J CANCER, V47, P213, DOI 10.1002/ijc.2910470209; ROSNER D, 1990, CANCER, V66, P199, DOI 10.1002/1097-0142(19900715)66:2<199::AID-CNCR2820660202>3.0.CO;2-L; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; TABAR L, IN PRESS RADIOL CLIN; TUBIANA M, 1991, BREAST CANCER RES TR, V18, P125, DOI 10.1007/BF01990028; 1992, LANCET, V339, P71	14	139	140	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					412	414		10.1016/0140-6736(92)90090-P	http://dx.doi.org/10.1016/0140-6736(92)90090-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346670				2022-12-28	WOS:A1992HD65900014
J	ALEXANDER, AG; BARNES, NC; KAY, AB				ALEXANDER, AG; BARNES, NC; KAY, AB			TRIAL OF CYCLOSPORINE IN CORTICOSTEROID-DEPENDENT CHRONIC SEVERE ASTHMA	LANCET			English	Article							LYMPHOCYTE-T ACTIVATION; DRUG-THERAPY; PREDNISOLONE; DISEASE	The treatment of chronic severe asthma is unsatisfactory for many patients. In a randomised, double-blind, placebo-controlled, crossover trial we have tested whether cyclosporin, which is thought to act primarily by inhibition of T lymphocyte activation, improves lung function in corticosteroid-dependent asthmatics. After a 4-week run-in period, 33 patients with longstanding asthma (mean duration 27 years), and who had required continuous oral corticosteroids for a mean of 9.3 years, were randomised to receive either cyclosporin (initial dose 5 mg/kg per day) or placebo for 12 weeks, crossing over after a 2-week washout period. Mean baseline forced expiratory volume in 1 s (FEV1) was 60.1% of the predicted value. 2 patients failed to complete the protocol and 1 withdrew because of hypertrichosis. Cyclosporin therapy resulted in a mean increase above placebo of 12.0% in morning peak expiratory flow rate (PEFR; p < 0.004) and 17.6% in FEV1 (p < 0.001). The frequency of disease exacerbations requiring an increased prednisolone dose was reduced by 48% in patients on cyclosporin compared with placebo (p < 0.02). Diurnal variation in PEFR decreased by a mean of 27.6% (p = 0.04). Cyclosporin for 12 weeks was well tolerated by this group of chronic asthmatics, in whom the mean whole-blood trough concentration was 152-mu-g/l. These findings provide further evidence of a role for activated T lymphocytes in the pathogenesis of asthma. Specific pharmacological targeting of this cell could form the basis of a novel approach to the treatment of asthma.	NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND; ROYAL BROMPTON HOSP,LONDON SW3,ENGLAND; LONDON CHEST HOSP,LONDON E2,ENGLAND	Imperial College London; Royal Brompton Hospital								AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; CIRILLO R, 1990, J IMMUNOL, V144, P3891; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1988, LANCET, V1, P1129; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026, DOI 10.1164/ajrccm/144.5.page; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; FISHER M, 1975, BRIT MED J, V2, P542, DOI 10.1136/bmj.2.5970.542; FREY FJ, 1987, TRANSPLANTATION, V43, P494, DOI 10.1097/00007890-198704000-00007; GRANELLIPIPERNO A, 1988, TRANSPLANTATION, V46, pS53; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; MACLEOD MA, 1977, UROL RES, V5, P71, DOI 10.1007/BF00256844; MIHATSCH MJ, 1988, J AUTOIMMUN, V1, P533, DOI 10.1016/0896-8411(88)90046-7; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P116; ROCCI ML, 1988, TRANSPLANTATION, V45, P656, DOI 10.1097/00007890-198803000-00032; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; THOMSON AW, 1991, BRIT MED J, V302, P4, DOI 10.1136/bmj.302.6767.4; VONGRAFFENRIED B, 1989, CYCLOSPORIN MODE ACT, P213	22	329	341	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					324	328		10.1016/0140-6736(92)91646-P	http://dx.doi.org/10.1016/0140-6736(92)91646-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346410				2022-12-28	WOS:A1992HC77100003
J	ADVANI, R; CHAO, NJ; HORNING, SJ; BLUME, KG; AHN, DK; LAMBORN, KR; FLEMING, NC; BONNEM, EM; GREENBERG, PL				ADVANI, R; CHAO, NJ; HORNING, SJ; BLUME, KG; AHN, DK; LAMBORN, KR; FLEMING, NC; BONNEM, EM; GREENBERG, PL			GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AS AN ADJUNCT TO AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR LYMPHOMA	ANNALS OF INTERNAL MEDICINE			English	Article						GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; TRANSPLANTATION, AUTOLOGOUS; HODGKINS DISEASE; LYMPHOMA, NON-HODGKIN	BONE-MARROW TRANSPLANTATION; NON-HODGKINS LYMPHOMA; LEUKEMIA; CHEMOTHERAPY; THERAPY; DISEASE; GROWTH; LINE	Objective: To determine the hemopoietic effects of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients having autologous hemopoietic stem cell transplantation for Hodgkin or non-Hodgkin lymphoma. Design: Placebo or GM-CSF was administered after bone marrow or peripheral blood stem cell transplantation or both in a randomized, double-blind phase III trial by daily intravenous infusion (10-mu-g/kg body weight) until absolute neutrophil counts reached greater-than-or-equal-to 1000/mm3 on 3 consecutive days. Setting: Bone marrow transplantation unit in a university hospital. Patients: Sixty-nine consecutive patients with Hodgkin or non-Hodgkin lymphoma received GM-CSF (36 patients) or placebo (33 patients). Measurements and Main Results: Patients who received GM-CSF achieved absolute neutrophil counts greater-than-or-equal-to 500/mm3 (median, 12 compared with 16 days, P = 0.02) and absolute neutrophil counts greater-than-or-equal-to 1000/mm3 (median, 15 compared with 24 days, P < 0.001) more quickly than patients who received placebo. Multivariate analysis indicated that use of GM-CSF, peripheral blood stem cells, and unpurged bone marrow were the strongest predictors for early neutrophil recovery > 500/mm3. Bacterial infections were significantly reduced in the GM-CSF group (P = 0.04). Delayed engraftment (neutrophils < 500/mm3 at day 30) occurred in 26% and 17% of the placebo and GM-CSF groups, respectively, and correlated with the absence of detectable myeloid progenitor cells (colony-forming units-granulocyte macrophage, CFU-GM) (P < 0.001) in marrow aspirate specimens obtained on day 15. Time to platelet independence, duration of hospital stay, severe adverse reactions, relapse, and disease-free survival rates did not differ significantly between the two groups. Conclusions: Administration of GM-CSF after autologous hemopoietic stem cell transplantation in patients with lymphoma resulted in accelerated myeloid recovery, particularly in patients who received peripheral blood stem cells and nonpurged bone marrow, and was associated with a decreased incidence of bacterial infections.	STANFORD UNIV, MED CTR, DIV HEMATOL 161, STANFORD, CA 94305 USA; NO CALIF CANC CTR, BELMONT, CA USA; SCHERING PLOUGH CORP, KENILWORTH, NJ USA	Stanford University; Merck & Company; Schering Plough Corporation				Advani, Ranjana/0000-0002-3219-2292				ADVANI R, 1990, BLOOD S, V76, pA525; APPELBAUM FR, 1978, BLOOD, V52, P85; BENNETT CL, 1990, BLOOD S, V76, pA132; BLAZAR BR, 1989, BLOOD, V73, P849; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; DEVITA VT, 1985, PRINCIPLES PRACTICE, P67; HERRMANN F, 1989, J CLIN ONCOL, V7, P159, DOI 10.1200/JCO.1989.7.2.159; HORNING SJ, 1991, ANN ONCOL, V2, P47, DOI 10.1093/annonc/2.suppl_1.47; KESSINGER A, 1988, BLOOD, V71, P723; KIRK JL, 1988, CANCER-AM CANCER SOC, V62, P2445, DOI 10.1002/1097-0142(19881201)62:11<2445::AID-CNCR2820621133>3.0.CO;2-I; KORBLING M, 1990, J CLIN ONCOL, V8, P978; KUPPER T, 1987, J IMMUNOL, V138, P4288; METCALF D, 1975, SCIENCE, V220, P16; MONROY RL, 1987, BLOOD, V70, P1696; NAGLER A, 1990, BLOOD, V76, P1299; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NEMUNAITIS J, 1988, BLOOD, V72, P834; NEMUNAITIS J, 1990, P AN M AM SOC CLIN, V9, pA10; NIENHUIS AW, 1987, J CLIN INVEST, V80, P573, DOI 10.1172/JCI113106; OKUNEWICK JP, 1985, EXP HEMATOL, V13, P23; PARK LS, 1986, J EXP MED, V164, P251, DOI 10.1084/jem.164.1.251; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; SKETTINO S, 1988, BLOOD, V71, P907; TAKVORIAN T, 1987, NEW ENGL J MED, V316, P1499, DOI 10.1056/NEJM198706113162402; VADHANRAJ S, 1990, AM J HEMATOL, V33, P189, DOI 10.1002/ajh.2830330307; VALTIERI M, 1987, J IMMUNOL, V138, P4042; WALKER F, 1985, EMBO J, V4, P933, DOI 10.1002/j.1460-2075.1985.tb03721.x	27	124	126	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1992	116	3					183	189		10.7326/0003-4819-116-3-183	http://dx.doi.org/10.7326/0003-4819-116-3-183			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB356	1345803				2022-12-28	WOS:A1992HB35600002
J	ROWE, BR; THORPE, J; BARNETT, A				ROWE, BR; THORPE, J; BARNETT, A			SAFETY OF FLUCONAZOLE IN WOMEN TAKING ORAL HYPOGLYCEMIC AGENTS	LANCET			English	Letter											ROWE, BR (corresponding author), UNIV BIRMINGHAM,E BIRMINGHAM HOSP,DEPT MED,BIRMINGHAM B9 5ST,ENGLAND.							BRAMMER KW, 1989, INT C S SER ROY SOC, V160, P29; LAZAR JD, 1991, REV INFECT DIS S3, V12, P328; 1989, BRIT J OBSTET GYNAEC, V96, P226	3	9	9	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					255	256		10.1016/0140-6736(92)90072-B	http://dx.doi.org/10.1016/0140-6736(92)90072-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346224				2022-12-28	WOS:A1992HA58900067
J	BRAEGGER, CP; NICHOLLS, S; MURCH, SH; STEPHENS, S; MACDONALD, TT				BRAEGGER, CP; NICHOLLS, S; MURCH, SH; STEPHENS, S; MACDONALD, TT			TUMOR-NECROSIS-FACTOR-ALPHA IN STOOL AS A MARKER OF INTESTINAL INFLAMMATION	LANCET			English	Article							BOWEL-DISEASE	Measurement of disease activity in patients with inflammatory bowel disease is difficult. The best available methods are complex and time consuming, but it may be possible to use tumour necrosis factor alpha (TNF-alpha) concentration in stool as a marker of disease activity. We measured TNF-alpha concentrations in stool samples from normal children, infants with diarrhoea, and children with inflammatory bowel disease in active and inactive phases of the disease. In 10 normal children and 14 children with diarrhoea, median stool TNF-alpha concentrations were 58 and 45 pg/g stool, respectively. Compared with diarrhoeal controls, stool TNF-alpha concentrations were significantly increased in children with active Crohn's disease (n = 13, median 994 pg/g, p < 0.0002) and active ulcerative colitis (n = 4, range 276-5982 pg/g, p < 0.003). In patients with inactive disease, either as a result of surgery or treatment with steroids, the concentration of stool TNF-alpha fell to those of controls. Measurement of stool TNF-alpha concentations may provide a simple way to monitor disease activity in inflammatory bowel disease.	ST BARTHOLOMEWS HOSP,DEPT PAEDIAT GASTROENTEROL,LONDON EC1A 7BE,ENGLAND; CELLTECH LTD,SLOUGH,BERKS,ENGLAND	University of London; Queen Mary University London; Celltech Group Ltd			Braegger, Christian Peter/ABC-9884-2021	Braegger, Christian/0000-0001-8069-9875	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHONG SKF, 1984, BRIT MED J, V284, P101; DONNELLAN WL, 1966, GASTROENTEROLOGY, V50, P519; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; ELIAKIM R, 1988, GASTROENTEROLOGY, V95, P1176; LAURITSEN K, 1988, GASTROENTEROLOGY, V95, P11, DOI 10.1016/0016-5085(88)90284-3; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P351; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; SAVERYMUTTU SH, 1983, GASTROENTEROLOGY, V85, P1333; ZIFRONI A, 1983, GUT, V24, P659, DOI 10.1136/gut.24.7.659	10	600	626	1	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					89	91		10.1016/0140-6736(92)90999-J	http://dx.doi.org/10.1016/0140-6736(92)90999-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345871				2022-12-28	WOS:A1992GZ15600003
J	OCKENHOUSE, CF; BETAGERI, R; SPRINGER, TA; STAUNTON, DE				OCKENHOUSE, CF; BETAGERI, R; SPRINGER, TA; STAUNTON, DE			PLASMODIUM FALCIPARUM-INFECTED ERYTHROCYTES BIND ICAM-1 AT A SITE DISTINCT FROM LFA-1, MAC-1, AND HUMAN RHINOVIRUS	CELL			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; MEMBRANE GLYCOPROTEIN; ENDOTHELIAL-CELLS; RECEPTOR; LIGAND; IDENTIFICATION; IMMUNOGLOBULIN; INTERFERON; ACTIVATION; ADHERENCE	The attachment of erythrocytes infected with P. falciparum to human venular endothelium is the primary step leading to complications from severe and cerebral malaria. Intercellular adhesion molecule-1 (ICAM-1, CD54) has been implicated as a cytoadhesion receptor for P. falciparum-infected erythrocytes. Characterization of domain deletion, human/murine chimeric ICAM-1 molecules, and amino acid substitution mutants localized the primary binding site for parasitized erythrocytes to the first amino-terminal immunoglobulin-like domain of ICAM-1. The ICAM-1 binding site is distinct f rom those recognized by LFA-1, Mac-1, and the human major-type rhinoviruses. Synthetic peptides encompassing the binding site on ICAM-1 inhibited malaria-infected erythrocyte adhesion to ICAM-1-coated surfaces with a K(i) of 0.1-0.3 mM, whereas the K(i) for soluble ICAM-1 is 0.15-mu-M. These findings have implications for the therapeutic reversal of malaria-infected erythrocyte sequestration in the host microvasculature.	WALTER REED ARMY MED CTR,DEPT MED,WASHINGTON,DC 20307; BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Boehringer Ingelheim; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	OCKENHOUSE, CF (corresponding author), WALTER REED ARMY MED CTR,INST RES,WASHINGTON,DC 20307, USA.				NCI NIH HHS [CA31798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031798, R37CA031798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIKAWA M, 1990, AM J TROP MED HYG, V43, P30, DOI 10.4269/ajtmh.1990.43.30; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1986, J IMMUNOL, V137, P245; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MAIO M, 1989, J IMMUNOL, V143, P181; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POBER JS, 1986, J IMMUNOL, V137, P1893; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; SCHNORRENBERG G, 1989, TETRAHEDRON, V45, P7759, DOI 10.1016/S0040-4020(01)85791-4; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAKEI F, 1985, J IMMUNOL, V134, P1403; TANDON NN, 1989, J BIOL CHEM, V264, P7576; UDEINYA IJ, 1983, NATURE, V303, P429, DOI 10.1038/303429a0	29	144	153	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1992	68	1					63	69		10.1016/0092-8674(92)90206-R	http://dx.doi.org/10.1016/0092-8674(92)90206-R			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ583	1346257				2022-12-28	WOS:A1992GZ58300009
J	HOLM, K; MAKI, M; SAVILAHTI, E; LIPSANEN, V; LAIPPALA, P; KOSKIMIES, S				HOLM, K; MAKI, M; SAVILAHTI, E; LIPSANEN, V; LAIPPALA, P; KOSKIMIES, S			INTRAEPITHELIAL GAMMA-DELTA-T-CELL-RECEPTOR LYMPHOCYTES AND GENETIC SUSCEPTIBILITY TO CELIAC-DISEASE	LANCET			English	Article							CELIAC-DISEASE; HETERODIMER	Although the proportion of gamma-delta T-cell-receptor (TCR)-bearing intraepithelial lymphocytes is increased in the jejunum of patients with active coeliac disease, an abnormality thought to be specific among those with gluten-sensitive enteropathy, the factors influencing gamma-delta TCR expression remain uncertain. We examined the relation between genetic factors associated with coeliac disease and intraepithelial gamma-delta T lymphocyte distribution in both coeliac patients and their healthy first-degree relatives. 41% (45/109) of healthy relatives had an increased density of gamma-delta T cells in their mucosa and 66% had an increased density of alpha-beta T cells. By contrast with alpha-beta T cells, the density of gamma-delta cells was significantly associated with genetic markers for coeliac disease susceptiblity (DR3, DQA, and DQB). We also found a dose effect of DQA and DQB genes on the number of intraepithelial gamma-delta T cells. An increased density of gamma-delta T cells in normal jejunal mucosa of a healthy individual with appropriate genetic determinants might be necessary for the development of the typical lesions of coeliac disease. Routine jejunal histological studies should include gamma-delta T-cell counts, thus allowing early detection of coeliac disease latency.	UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND; UNIV TAMPERE,DEPT PUBL HLTH,BIOMETRY UNIT,TAMPERE,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,BLOOD TRANSFUS SERV,HELSINKI,FINLAND	University of Helsinki; Tampere University	HOLM, K (corresponding author), UNIV TAMPERE,DEPT CLIN SCI,TEISKONTIE 35,POB 607,SF-33101 TAMPERE,FINLAND.							BAND H, 1987, SCIENCE, V238, P6824; BOSNES V, 1990, EUR J IMMUNOL, V20, P1429, DOI 10.1002/eji.1830200704; CUENOD B, 1990, GASTROENTEROLOGY, V99, P1037, DOI 10.1016/0016-5085(90)90624-A; FAURE F, 1988, J IMMUNOL, V141, P3357; HALL MA, 1991, GUT, V32, P487, DOI 10.1136/gut.32.5.487; HALSTENSEN TS, 1989, SCAND J IMMUNOL, V30, P665, DOI 10.1111/j.1365-3083.1989.tb02474.x; KOSKIMIES S, 1991, COELIAC DISEASE 40 Y, P10; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MAKI M, 1991, LANCET, V337, P763, DOI 10.1016/0140-6736(91)91375-5; MAKI M, 1991, LANCET, V338, P1350, DOI 10.1016/0140-6736(91)92234-S; MAKI M, 1991, GUT, V32, P1412, DOI 10.1136/gut.32.11.1412; MAKI M, 1988, LANCET, V1, P479; PASTERNACK A, 1990, CLIN NEPHROL, V34, P56; RAJASEKAR R, 1990, P NATL ACAD SCI USA, V87, P1767, DOI 10.1073/pnas.87.5.1767; SAVILAHTI E, 1990, PEDIATR RES, V28, P579, DOI 10.1203/00006450-199012000-00005; SAVILAHTI E, 1992, GUT, V33, P206, DOI 10.1136/gut.33.2.206; SPENCER J, 1989, EUR J IMMUNOL, V19, P1335, DOI 10.1002/eji.1830190728; SPURKLAND A, 1990, HUM IMMUNOL, V29, P157, DOI 10.1016/0198-8859(90)90111-2; TRIEBEL F, 1989, IMMUNOL TODAY, V10, P186, DOI 10.1016/0167-5699(89)90321-6; WRAY D, 1981, DIGEST DIS SCI, V26, P737, DOI 10.1007/BF01316864	20	114	117	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1500	1503		10.1016/0140-6736(92)91262-7	http://dx.doi.org/10.1016/0140-6736(92)91262-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351185				2022-12-28	WOS:A1992HZ17500003
J	SIMONS, FER; GILLESPIE, CA; SIMONS, KJ				SIMONS, FER; GILLESPIE, CA; SIMONS, KJ			LOCAL-ANESTHETIC CREAMS AND INTRADERMAL SKIN-TESTS	LANCET			English	Letter							HISTAMINE; ANESTHESIA; FLARE				SIMONS, FER (corresponding author), UNIV MANITOBA,FAC MED,DEPT PEDIAT & CHILD HLTH,WINNIPEG R3A 1S1,MANITOBA,CANADA.							BJERRING P, 1990, BRIT J ANAESTH, V64, P173, DOI 10.1093/bja/64.2.173; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; HARPER EI, 1989, AGENTS ACTIONS, V28, P192, DOI 10.1007/BF01967400; PIPKORN U, 1987, CLIN ALLERGY, V17, P307, DOI 10.1111/j.1365-2222.1987.tb02019.x; SHUTTLEWORTH D, 1988, BRIT J DERMATOL, V119, P535, DOI 10.1111/j.1365-2133.1988.tb03259.x; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540	6	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1351	1352		10.1016/0140-6736(92)91994-J	http://dx.doi.org/10.1016/0140-6736(92)91994-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1350007				2022-12-28	WOS:A1992HW83700026
J	BUCHWALD, H				BUCHWALD, H			CHOLESTEROL INHIBITION, CANCER, AND CHEMOTHERAPY	LANCET			English	Note							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; PLASMA-CHOLESTEROL; MORTALITY; SUPPRESSION; MEVALONATE; LOVASTATIN; MORBIDITY; MEVINOLIN; PROGRAM	An important feature of malignant transformation is loss of the cholesterol feedback inhibition mechanism that regulates cholesterol synthesis. Cancer cells seem to require an increase in the concentrations of cholesterol and of cholesterol precursors. Therefore, a reasonable assumption is that prevention of tumour-cell growth can be achieved by restricting either cholesterol availability or cholesterol synthesis. In-vivo and cell-culture experiments have shown that lowering the plasma cholesterol concentration or intervening in the mevalonate pathway with 3-hydroxy-3-methylglutaryl (HMG) CoA reductase inhibitors decreases tumour growth. Currently prescribed doses of HMG-CoA reductase inhibitors given orally or continuously by an implantable infusion pump could achieve tumour therapeutic tissue concentrations of these agents. My hypothesis is that cholesterol inhibition can inhibit tumour cell growth, can act as an adjuvant to cancer chemotherapy, and, possibly, can prevent carcinogenesis.			BUCHWALD, H (corresponding author), UNIV MINNESOTA,DEPT SURG,BOX 290 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.							ADDLEMAN W, 1972, NEW ENGL J MED, V287, P1047; BLAU L, 1978, J BIOL CHEM, V253, P8366; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUCHWALD H, 1989, INTERN MED SPECIALIS, V10, P182; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen H W, 1978, Prog Exp Tumor Res, V22, P275; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; DUGGAN DE, 1989, DRUG METAB DISPOS, V17, P166; FAIRBANKS KP, 1986, J CELL PHYSIOL, V127, P216, DOI 10.1002/jcp.1041270205; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORE IRENE YOUHOTSKY, 1962, BIOCHEM JOUR, V84, P93; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; KORT WJ, 1989, CLIN EXP METASTAS, V7, P517, DOI 10.1007/BF01753812; LITTMAN M. L., 1966, CANCER CHEMOTHERAP REP, V50, P25; MACDONALD JS, 1988, AM J CARDIOL, V62, pJ16, DOI 10.1016/0002-9149(88)90003-3; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MORRIS PJ, 1992, EFFECT LOVASTATIN AD; MORRIS T J, 1991, Surgical Forum (Chicago), V42, P452; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROSE G, 1980, LANCET, V1, P523; SALONEN JT, 1982, AM J EPIDEMIOL, V116, P622, DOI 10.1093/oxfordjournals.aje.a113445; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHNEIDER PD, 1980, SURGERY, V87, P409; SIPERSTEIN MD, 1964, CANCER RES, V24, P1108; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VATTEN LJ, 1990, CANCER RES, V50, P2341; WINGARD DL, 1984, J CHRON DIS, V37, P401, DOI 10.1016/0021-9681(84)90107-3	27	118	120	2	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1154	1156		10.1016/0140-6736(92)90744-N	http://dx.doi.org/10.1016/0140-6736(92)90744-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349377				2022-12-28	WOS:A1992HT23600014
J	ISLES, CG; HOLE, DJ; HAWTHORNE, VM; LEVER, AF				ISLES, CG; HOLE, DJ; HAWTHORNE, VM; LEVER, AF			RELATION BETWEEN CORONARY RISK AND CORONARY MORTALITY IN WOMEN OF THE RENFREW AND PAISLEY SURVEY - COMPARISON WITH MEN	LANCET			English	Article							HEART-DISEASE; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; FOLLOW-UP	Most epidemiological and intervention studies in patients with coronary artery disease have focused on men, the assumption being that such data can be extrapolated to women. However, there is little evidence to support this belief. We have completed a fifteen-year follow-up of 15 399 adults, including 8262 women, who lived in Renfrew and Paisley and were aged 45-64 years when screened between 1972 and 1976. We identified 490 deaths from coronary heart disease (CHD) in women and 878 in men. Women were more likely to have high cholesterol, to be obese, and to come from lower social classes than men, but they smoked less and had similar blood pressures. The relative risk-top to bottom quintile (95% Cl) - of cholesterol for coronary death after adjustment for all other risk markers was slightly greater in women (1.77 [1.45,2.16]) than in men (1.56 [1.32,1.85]), but absolute and attributable risk were lower. Thus, women in the top quintile for cholesterol had lower coronary mortality (6.1 deaths per thousand patient years) than men in the bottom quintile (6.8 deaths per thousand patient years). Moreover, it was estimated that there would have been only 103 (21%) fewer CHD deaths in women, yet 211 (24%) fewer in men, if mortality had been the same for women and men in the lowest quintiles of cholesterol. Trends showing similar relative risks in these women, but lower absolute and attributable risks than in men, were present for smoking, diastolic blood pressure, and social class. There was no relation between obesity and coronary death after adjustment for other risks. Our results suggest that some other factors protect women against CHD. The potential for women to reduce their risk of CHD by changes in lifestyle may be less than for men.	RUCHILL HOSP,CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,SCOTLAND; UNIV MICHIGAN,DEPT EPIDEMIOL,ANN ARBOR,MI 48109; WESTERN INFIRM & ASSOCIATED HOSP,MRC,BLOOD PRESSURE UNIT,GLASGOW G11 6NT,SCOTLAND	University of Michigan System; University of Michigan	ISLES, CG (corresponding author), DUMFRIES & GALLOWAY ROYAL INFIRM,DUMFRIES DG1 4AP,SCOTLAND.							ALDERSON MR, 1983, BMJ-BRIT MED J, V287, P444, DOI 10.1136/bmj.287.6390.444; AUSTIN MA, 1989, AM J EPIDEMIOL, V129, P249, DOI 10.1093/oxfordjournals.aje.a115130; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1987, CORONARY HEART DISEA, P106; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DONAHUE RP, 1987, LANCET, V1, P821; Garrow JS., 1981, TREAT OBESITY SERIOU; HAWTHORNE VM, 1974, BMJ-BRIT MED J, V3, P600, DOI 10.1136/bmj.3.5931.600; HIGGINS M, 1987, CORONARY HEART DISEA, P83; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PERLMAN JA, 1988, AM J OBSTET GYNECOL, V158, P1568, DOI 10.1016/0002-9378(88)90192-5; ROSENBERG L, 1990, NEW ENGL J MED, V322, P213, DOI 10.1056/NEJM199001253220401; SILMAN AJ, 1984, BRIT MED J, V289, P1021, DOI 10.1136/bmj.289.6451.1021; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; THOMPSON SG, 1989, BRIT HEART J, V61, P403; Tunstall-Pedoe H, 1986, Health Bull (Edinb), V44, P153; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; 1985, BRIT MED J, V2, P97; 1977, INT CLASSIFICATION D; [No title captured]	26	226	227	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					702	706		10.1016/0140-6736(92)90599-X	http://dx.doi.org/10.1016/0140-6736(92)90599-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347584	Green Submitted			2022-12-28	WOS:A1992HK32000004
J	BERENGUER, J; MORENO, S; LAGUNA, F; VICENTE, T; ADRADOS, M; ORTEGA, A; GONZALEZLAHOZ, J; BOUZA, E				BERENGUER, J; MORENO, S; LAGUNA, F; VICENTE, T; ADRADOS, M; ORTEGA, A; GONZALEZLAHOZ, J; BOUZA, E			TUBERCULOUS MENINGITIS IN PATIENTS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADENOSINE-DEAMINASE; AIDS	Background and Methods. Tuberculosis is a frequent complication of human immunodeficiency virus (HIV) infection. We describe the clinical manifestations and outcomes of tuberculous meningitis in patients with HIV infection, and compare them with those in non-HIV-infected patients. We reviewed the records from 1985 through 1990 at two large referral hospitals in Madrid for patients who had Mycobacterium tuberculosis isolated from cerebrospinal fluid. Results. Of 2205 patients with tuberculosis, 455 (21 percent) also had HIV infection, of whom 45 had M. tuberculosis isolated from the cerebrospinal fluid. Of the 37 HIV-infected patients with tuberculous meningitis for whom records were available, 24 (65 percent) had clinical or radiologic evidence of extrameningeal tuberculosis at the time of admission. In 18 of 26 patients (69 percent), a CT scan of the head was abnormal. In most patients, analysis of cerebrospinal fluid showed pleocytosis (median white-cell count, 0.234 x 10(9) per liter) and hypoglycorrhachia (median glucose level, 1.3 mmol per liter), but in 43 percent (15 of 35), the level of protein in cerebrospinal fluid was normal. In four patients with HIV infection, tuberculosis was only discovered after their deaths. Of the 33 patients who received antituberculous treatment, 7 died (in-hospital mortality, 21 percent). Illness lasting more than 14 days before admission and a CD4+ cell count of less than 0.2 x 10(9) per liter (200 per cubic millimeter) were associated with a poor prognosis. Comparison with tuberculous meningitis in patients without HIV infection showed that the presentation, clinical manifestations, cerebrospinal fluid findings, and mortality were generally similar in the two groups. However, of the 1750 patients without HIV infection, only 2 percent (38 patients) had tuberculous meningitis, as compared with 10 percent of the HIV-infected patients (P < 0.001). Conclusions. HIV-infected patients with tuberculosis are at increased risk for meningitis, but infection with HIV does not appear to change the clinical manifestations or the outcome of tuberculous meningitis.	INST SALUD CARLOS 3,CTR NACL INVEST,DEPT INFECT DIS,MADRID,SPAIN; INST SALUD CARLOS 3,CTR NACL INVEST,DEPT MICROBIOL,MADRID,SPAIN	Instituto de Salud Carlos III; Instituto de Salud Carlos III	BERENGUER, J (corresponding author), HOSP GEN GREGORIO MARANON,DEPT CLIN MICROBIOL & INFECT DIS,SERV MICROBIOL CLIN,DR ESQUERDO 46,E-28007 MADRID,SPAIN.		Van de Perre, Philippe/B-9692-2008; Berenguer, Juan/A-1347-2009; Adrados, Magdalena/H-8123-2015; Bouza, Emilio/D-8661-2014	Van de Perre, Philippe/0000-0002-3912-0427; Berenguer, Juan/0000-0001-8541-8200; Adrados, Magdalena/0000-0003-3317-670X; Bouza, Emilio/0000-0001-6967-9267				BISHBURG E, 1986, ANN INTERN MED, V105, P210, DOI 10.7326/0003-4819-105-2-210; BOUZA E, 1988, EUR J CLIN MICROBIOL, V7, P785, DOI 10.1007/BF01975050; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; DYLEWSKI J, 1990, J INFECT DIS, V162, P778, DOI 10.1093/infdis/162.3.778; FISCHL MA, 1985, JAMA-J AM MED ASSOC, V253, P3428, DOI 10.1001/jama.253.23.3428; Leonard J M, 1990, Infect Dis Clin North Am, V4, P769; OGAWA SK, 1987, MEDICINE, V66, P317, DOI 10.1097/00005792-198707000-00004; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; RIBERA E, 1987, J INFECT DIS, V155, P603, DOI 10.1093/infdis/155.4.603; SLAATS EH, 1985, J CLIN CHEM CLIN BIO, V23, P677; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; TEOH R, 1987, Q J MED, V63, P449; 1948, LANCET, V1, P582; 1989, MMWR, V38, P236; 1989, MMWR, V38, P243; 1987, MMWR S1, V36, pS1	17	317	323	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					668	672		10.1056/NEJM199203053261004	http://dx.doi.org/10.1056/NEJM199203053261004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1346547				2022-12-28	WOS:A1992HG11700004
J	BALLARD, RA; BALLARD, PL; CREASY, RK; PADBURY, J; POLK, DH; BRACKEN, M; MOYA, FR; GROSS, I				BALLARD, RA; BALLARD, PL; CREASY, RK; PADBURY, J; POLK, DH; BRACKEN, M; MOYA, FR; GROSS, I			RESPIRATORY-DISEASE IN VERY-LOW-BIRTH-WEIGHT INFANTS AFTER PRENATAL THYROTROPIN-RELEASING-HORMONE AND GLUCOCORTICOID	LANCET			English	Article							FETAL RABBIT LUNG; PITUITARY-THYROID AXIS; PREMATURE-INFANTS; SURFACTANT; MATURATION; CORTICOSTEROIDS; STIMULATION; PREVENTION; THERAPY; TRH	Although prenatal glucocorticoid treatment reduces neonatal respiratory morbidity, respiratory distress syndrome and chronic lung disease (CLD) develop in many very-low-birthweight infants despite therapy. To investigate the effect of additional prenatal treatment with thyrotropin-releasing hormone (TRH), we did a multicentre, blinded, randomised trial. 404 women with threatened preterm delivery at less than 32 weeks' gestation received betamethasone plus TRH (4 doses of 400-mu-g 8-hourly) or betamethasone plus placebo. 103 infants who were fully treated and of less than 1500 g birthweight were evaluated during the neonatal period. TRH treatment (55 infants) did not affect the total incidence of respiratory distress syndrome (47% vs 58% in controls) or of severe respiratory distress syndrome (13% vs 25% in controls, p = 0.11). CLD (defined as requirement for supplemental oxygen at 28 days after birth) developed in significantly fewer TRH-treated infants (18% vs 44% of controls, p < 0.01). The unadjusted relative risk of CLD with TRH therapy was 0.40 (95% Cl 0.26-0-80, p < 0.05), and this was not materially changed after adjustment for potentially modifying variables. There were significantly fewer adverse outcomes, defined as death or continuing oxygen requirement, in the TRH group than in the steroid-alone group both at 28 days and when infants reached 36 weeks' postconceptional age. The incidence of other complications of prematurity was similar in the two groups. Prenatal TRH reduces the incidence of chronic lung disease among betamethasone-treated infants.	MT ZION HOSP & MED CTR,DEPT PEDIAT,SAN FRANCISCO,CA 94120; MT ZION HOSP & MED CTR,DEPT OBSTET & GYNECOL,SAN FRANCISCO,CA 94120; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; YALE UNIV,SCH EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06520; UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,TORRANCE,CA 90509	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco; Yale University; Yale University; University of Texas System; University of Texas Health Science Center Houston; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425, M01RR000125] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024075] Funding Source: NIH RePORTER; NCRR NIH HHS [GCRC-RR-00425, M01 RR00125] Funding Source: Medline; NHLBI NIH HHS [HL-24075] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTHABE F, 1991, PEDIATR RES, V29, pA200; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BALLARD PL, 1984, J CLIN INVEST, V74, P898, DOI 10.1172/JCI111507; BALLARD PL, 1991, PEDIATR RES, V29, pA307; BALLARD PL, 1986, MONOGR ENDOCRINOL, V28, P197; BALLARD RA, 1991, PEDIATR RES, V29, pA307; BALLARD RA, 1986, MONOGRAPHS ENDOCRINO, V28, P173; BARKER PM, 1990, PEDIATR RES, V27, P588, DOI 10.1203/00006450-199006000-00010; BAUER CR, 1984, PEDIATRICS, V73, P682; Bracken M. B., 1992, EFFECTIVE CARE NEWBO; CLYMAN RI, 1981, J PEDIATR-US, V98, P123, DOI 10.1016/S0022-3476(81)80557-4; CROWLEY P, 1989, EFFECTIVE CARE PREGN, V1, P746; DEVASKAR U, 1987, AM J OBSTET GYNECOL, V157, P460, DOI 10.1016/S0002-9378(87)80195-3; GONZALES LW, 1986, J CLIN ENDOCR METAB, V62, P687; IKEGAMI M, 1987, AM REV RESPIR DIS, V136, P892, DOI 10.1164/ajrccm/136.4.892; JIKIHARA H, 1990, 6TH P C FED AS OC PE; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIGGINS GC, 1972, PEDIATRICS, V50, P515; MANTEL N, 1959, J NATL CANCER I, V22, P719; MORALES WJ, 1989, OBSTET GYNECOL, V73, P111; MOYA F, 1986, PEDIATR RES, V20, P982, DOI 10.1203/00006450-198610000-00018; MOYA FR, 1990, PEDIATR RES, V27, pA81; OHLSSON A, 1989, AM J OBSTET GYNECOL, V160, P890, DOI 10.1016/0002-9378(89)90306-2; OULTON M, 1989, AM J OBSTET GYNECOL, V160, P961, DOI 10.1016/0002-9378(89)90317-7; ROTI E, 1981, J CLIN ENDOCR METAB, V53, P813, DOI 10.1210/jcem-53-4-813; SHELLENBERG JC, 1988, J APPL PHYSIOL, V65, P94; SHENNAN AT, 1988, PEDIATRICS, V82, P527; VANMARTER LJ, 1990, PEDIATRICS, V86, P331; WARBURTON D, 1988, PEDIATR RES, V24, P166, DOI 10.1203/00006450-198808000-00005	29	102	103	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					510	515		10.1016/0140-6736(92)90337-3	http://dx.doi.org/10.1016/0140-6736(92)90337-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346877				2022-12-28	WOS:A1992HF63100002
J	BALDWIN, CT; HOTH, CF; AMOS, JA; DASILVA, EO; MILUNSKY, A				BALDWIN, CT; HOTH, CF; AMOS, JA; DASILVA, EO; MILUNSKY, A			AN EXONIC MUTATION IN THE HUP2 PAIRED DOMAIN GENE CAUSES WAARDENBURG SYNDROME	NATURE			English	Article							SYNDROME TYPE-I; MOUSE; DNA; BOX	HERE We report the identification and characterization of a gene defect causing Waardenburg's syndrome with hearing loss in a large Brazilian family. This demonstrates a mutation causing Waardenburg's syndrome as well as a mutation causing a form of congenital deafness. The mutation was found in the HuP2 gene, a member of the paired domain family of proteins that bind DNA and regulate gene expression 1. The mutation occurred in 100% of the cases with the disease in this family and was absent in a random sample of 50 unrelated control subjects. Identification of the Waardenburg's syndrome gene and future characterization of its gene product is likely to increase our understanding of the pathogenesis of this disorder and may allow prevention of deafness of this type.	BOSTON UNIV, SCH MED, CTR HUMAN GENET, 80 E CONCORD ST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02118 USA; FED UNIV PUERNAMBUCO, INST MATERNOINFANTIL PERNAMBUCO, RECIFE, PE, BRAZIL; FED UNIV PUERNAMBUCO, DEPT GENET, RECIFE, PE, BRAZIL	Boston University; Boston University				Milunsky, Aubrey/0000-0003-2114-4823; Baldwin, Clinton/0000-0002-3275-9463				ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; DASILVA EO, 1991, AM J MED GENET, V40, P65, DOI 10.1002/ajmg.1320400113; EPSTEIN D, 1991, CELL, V67, P1; FOY C, 1990, AM J HUM GENET, V46, P1017; GANGULY A, 1991, J BIOL CHEM, V266, P12035; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HAGEMAN MJ, 1977, AM J HUM GENET, V29, P468; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; ISHIKIRIYAMA S, 1989, AM J MED GENET, V33, P505, DOI 10.1002/ajmg.1320330419; PROCKOP DJ, 1990, ADV HUM GENET, V19, P105; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALKI RK, 1966, SCIENCE, V80, P222; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; Tsui LC, 1991, CURR OPIN GENET DEV, V1, P4, DOI 10.1016/0959-437X(91)80032-H; WAARDENBURG PJ, 1951, AM J HUM GENET, V3, P195; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; White R, 1991, CURR OPIN GENET DEV, V1, P15, DOI 10.1016/0959-437X(91)80034-J	22	428	434	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1992	355	6361					637	638		10.1038/355637a0	http://dx.doi.org/10.1038/355637a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1347149				2022-12-28	WOS:A1992HD54700055
J	PARRY, A				PARRY, A			TAKING HEROIN MAINTENANCE SERIOUSLY - THE POLITICS OF TOLERANCE	LANCET			English	Editorial Material											PARRY, A (corresponding author), ATLANTIC PROJECT,20 FIR RD,LIVERPOOL L22 4QL,ENGLAND.							FAZEY C, 1990, STUDY DRUG PATIENTS	1	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					350	351		10.1016/0140-6736(92)91661-Q	http://dx.doi.org/10.1016/0140-6736(92)91661-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HC771	1346423				2022-12-28	WOS:A1992HC77100018
J	BIRNBAUMER, L				BIRNBAUMER, L			RECEPTOR-TO-EFFECTOR SIGNALING THROUGH G-PROTEINS - ROLES FOR BETA-GAMMA-DIMERS AS WELL AS ALPHA-SUBUNITS	CELL			English	Review							ADENYLYL CYCLASE; PHOSPHOLIPASE-C; HL-60 CELLS; HYDROLYSIS; TRANSDUCTION; ACTIVATION; MEMBRANES; THROMBIN; 5-HT1A				BIRNBAUMER, L (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1993, CELL S, V72; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CAMPS M, 1992, IN PRESS NATURE; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; EASON MG, 1992, J BIOL CHEM, V267, P15795; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HEIN J, 1990, METHOD ENZYMOL, V183, P626; KATZ A, 1992, IN PRESS NATURE; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1992, IN PRESS SCIENCE; LEE CH, 1992, J BIOL CHEM, V267, P16044; PARK D, 1992, J BIOL CHEM, V267, P16048; RAYMOND JR, 1991, J BIOL CHEM, V266, P372; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUPRENANT A, 1992, SCIENCE, V257, P977; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WU DQ, 1992, J BIOL CHEM, V267, P1811	37	431	443	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1069	1072		10.1016/S0092-8674(05)80056-X	http://dx.doi.org/10.1016/S0092-8674(05)80056-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335363				2022-12-28	WOS:A1992KE60400002
J	LARKMAN, A; HANNAY, T; STRATFORD, K; JACK, J				LARKMAN, A; HANNAY, T; STRATFORD, K; JACK, J			PRESYNAPTIC RELEASE PROBABILITY INFLUENCES THE LOCUS OF LONG-TERM POTENTIATION	NATURE			English	Article							QUANTAL ANALYSIS; HIPPOCAMPAL SLICES; SYNAPTIC TRANSMISSION; LTP; NEURONS	THE quantal hypothesis proposes that chemical synaptic transmission involves the probabilistic release of multimolecular packets of transmitter1. Analysis of the resulting trial-to-trial fluctuations in postsynaptic response can provide estimates both of the number of quanta released and of the size of their postsynaptic effect. This in turn permits the quantification of the relative contributions of pre- and postsynaptic factors to the strength of a given synapse. Quantal analysis of excitatory synapses in the hippocampus has proved difficult2-6 and has led to contradictory conclusions when applied to long-term potentiation7-14. Here we report the use of a combination of quantal analysis procedures to provide evidence that both pre- and postsynaptic changes can contribute substantially to the maintenance of long-term potentiation in the CA1 region of the hippocampus. The initial setting of the presynaptic release mechanism seems to determine their relative importance.			LARKMAN, A (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.			Hannay, Timo/0000-0002-5941-3390	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; CLEMENTS J, 1991, NATURE, V353, P396, DOI 10.1038/353396a0; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KORN H, 1991, NATURE, V350, P282, DOI 10.1038/350282a0; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LARKMAN A, 1991, NATURE, V353, P396, DOI 10.1038/353396b0; MAGLEBY KL, 1981, J PHYSIOL-LONDON, V311, P267, DOI 10.1113/jphysiol.1981.sp013584; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; VORONIN LL, 1983, NEUROSCIENCE, V10, P1051, DOI 10.1016/0306-4522(83)90099-4	20	193	193	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					70	73		10.1038/360070a0	http://dx.doi.org/10.1038/360070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1331808				2022-12-28	WOS:A1992JW71700057
J	SHUB, DA; GOODRICHBLAIR, H				SHUB, DA; GOODRICHBLAIR, H			PROTEIN INTRONS - A NEW HOME FOR ENDONUCLEASES	CELL			English	Review							ADENOSINE-TRIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; SUBUNIT		SUNY ALBANY,CTR MOLEC GENET,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany	SHUB, DA (corresponding author), SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222, USA.			Goodrich-Blair, Heidi/0000-0003-1934-2636				BELFORT M, 1991, CELL, V64, P9, DOI 10.1016/0092-8674(91)90201-9; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CUMMINGS DJ, 1989, CURR GENET, V16, P381, DOI 10.1007/BF00340719; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DAVIS EO, 1991, J BACTERIOL, V173, P5653, DOI 10.1128/jb.173.18.5653-5662.1991; DUJON B, 1989, GENE, V82, P115, DOI 10.1016/0378-1119(89)90035-8; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GOGUEL V, 1992, MOL CELL BIOL, V12, P695; HIRATA R, 1990, J BIOL CHEM, V265, P6726; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; NAKAGAWA K, 1992, EMBO J, V11, P2707, DOI 10.1002/j.1460-2075.1992.tb05336.x; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; WARING RB, 1982, P NATL ACAD SCI-BIOL, V79, P6332, DOI 10.1073/pnas.79.20.6332; WERNETTE CM, 1990, J BIOL CHEM, V265, P18976; WONG SC, 1990, J BACTERIOL, V172, P630, DOI 10.1128/jb.172.2.630-642.1990	16	78	80	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					183	186		10.1016/0092-8674(92)90345-D	http://dx.doi.org/10.1016/0092-8674(92)90345-D			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1330319				2022-12-28	WOS:A1992JU39500002
J	PALACE, J; SHAH, R; CLOUGH, C				PALACE, J; SHAH, R; CLOUGH, C			FLECAINIDE INDUCED PERIPHERAL NEUROPATHY	BRITISH MEDICAL JOURNAL			English	Letter							DEBRISOQUINE; OXIDATION		BROOK GEN HOSP,DEPT NEUROL,LONDON SE18 4LW,ENGLAND		PALACE, J (corresponding author), GUYS HOSP,DEPT NEUROL,LONDON SE1 9RT,ENGLAND.							BECKMANN J, 1988, BRIT MED J, V297, P1316, DOI 10.1136/bmj.297.6659.1316; EVANS DAP, 1980, J MED GENET, V17, P102, DOI 10.1136/jmg.17.2.102; Gentzkow GD, 1984, AM J CARDIOL, V53, p101B; MIKUS G, 1989, CLIN PHARMACOL THER, V45, P562, DOI 10.1038/clpt.1989.73; SHAH RR, 1982, BRIT MED J, V284, P295, DOI 10.1136/bmj.284.6312.295	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					810	810		10.1136/bmj.305.6857.810	http://dx.doi.org/10.1136/bmj.305.6857.810			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1330141	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JT25600024
J	COWELL, R				COWELL, R			AFTER ISIS-3	LANCET			English	Letter											COWELL, R (corresponding author), HAREFIELD HOSP,DEPT CARDIOL,HAREFIELD UB9 6JH,ENGLAND.							URBAN, 1992, LANCET, V339, P817	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1227	1227						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349952				2022-12-28	WOS:A1992HU68400024
J	SOBEL, BE; COLLEN, D				SOBEL, BE; COLLEN, D			AFTER ISIS-3	LANCET			English	Letter							TISSUE PLASMINOGEN-ACTIVATOR; ACUTE MYOCARDIAL-INFARCTION; HEPARIN; THROMBOLYSIS		WASHINGTON UNIV,SCH MED,CTR CARDIOVASC RES,ST LOUIS,MO 63110; CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,B-3000 LOUVAIN,BELGIUM	Washington University (WUSTL); KU Leuven	SOBEL, BE (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,ST LOUIS,MO 63110, USA.							BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; BRAUNWALD E, 1987, J AM COLL CARDIOL, V9, P467, DOI 10.1016/S0735-1097(87)80407-2; CHESEBRO JH, 1988, NEW ENGL J MED, V319, P1544; DEBONO DP, 1992, BRIT HEART J, V67, P122; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; WHITE HD, 1989, NEW ENGL J MED, V320, P817, DOI 10.1056/NEJM198903303201301; 1990, LANCET, V336, P71	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1225	1226						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349951				2022-12-28	WOS:A1992HU68400022
J	PORTENOY, RK				PORTENOY, RK			CANCER PAIN - PATHOPHYSIOLOGY AND SYNDROMES	LANCET			English	Article							PLEXOPATHY; RADIATION				PORTENOY, RK (corresponding author), MEM SLOAN KETTERING CANC CTR, PAIN SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.							ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; BONICA JJ, 1985, ADV PAIN RES THER, V9, P589; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; DEVOR M, 1991, NEW PHARM PAIN, P417; DUBNER R, 1991, 6TH P WORLD C PAIN A, P263; DUGGAN AW, 1991, NEW PHARMACOTHERAPY, P35; ELLIOTT K, 1989, NEUROL CLIN, V7, P333, DOI 10.1016/S0733-8619(18)30817-X; EVANS CJ, 1988, OPIATE RECEPTORS, P23; FOLEY KM, 1980, ANN NEUROL, V7, P311, DOI 10.1002/ana.410070405; GONZALES GR, IN PRESS PAIN; GREENBERG HS, 1981, NEUROLOGY, V31, P530, DOI 10.1212/WNL.31.5.530; HILL HF, 1990, PAIN, V40, P121, DOI 10.1016/0304-3959(90)90062-I; JAECKLE KA, 1985, NEUROLOGY, V35, P8, DOI 10.1212/WNL.35.1.8; Jensen T. S, 1989, TXB PAIN, P508; JORGENSEN L, 1990, Pain Clinic, V3, P83; KANNER R, 1982, P AN M AM SOC CLIN, V1, P152; KORI SH, 1981, NEUROLOGY, V31, P45, DOI 10.1212/WNL.31.1.45; LOESER JD, 1989, MANAGING CHRONIC PAI, P3; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; NESS TJ, 1990, PAIN, V41, P167, DOI 10.1016/0304-3959(90)90021-5; Portenoy R.K., 1991, NEW PHARMACOTHERAPY, P393; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; PORTENOY RK, IN PRESS OXFORD TXB; REDMOND J, 1988, J CLIN ONCOL, V6, P154, DOI 10.1200/JCO.1988.6.1.154; Saunders C, 1984, MANAGEMENT TERMINAL, P232; SCHAIBLE HG, 1985, J NEUROPHYSIOL, V54, P1109, DOI 10.1152/jn.1985.54.5.1109; STJERNSWARD J, 1990, ADV PAIN RES THER, V16, P7; THOMAS JE, 1985, NEUROLOGY, V35, P1; TWYCROSS RG, 1990, R SOC MED SERV INT C, V146, P1; VENTAFRIDDA V, 1989, PAIN, V36, P137, DOI 10.1016/0304-3959(89)90018-3; VONROENN JH, 1991, P AN M AM SOC CLIN, V10, P326; WATSON CPN, 1989, PAIN, V38, P177, DOI 10.1016/0304-3959(89)90236-4; Willis W.D, 1985, PAIN SYSTEM NEURAL B	33	83	84	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 25	1992	339	8800					1026	1031		10.1016/0140-6736(92)90545-E	http://dx.doi.org/10.1016/0140-6736(92)90545-E			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349060				2022-12-28	WOS:A1992HQ43500013
J	OXNER, RBG; SIMMONDS, NJ; GERTNER, DJ; NIGHTINGALE, JMD; BURNHAM, WR				OXNER, RBG; SIMMONDS, NJ; GERTNER, DJ; NIGHTINGALE, JMD; BURNHAM, WR			CONTROLLED TRIAL OF ENDOSCOPIC INJECTION TREATMENT FOR BLEEDING FROM PEPTIC-ULCERS WITH VISIBLE VESSELS	LANCET			English	Article							UPPER GASTROINTESTINAL-TRACT; THERAPY; HEMORRHAGE; SCLEROSIS; NECROSIS	Controlled trials have shown that bleeding peptic ulcers can be successfully treated by endoscopy and injection of adrenaline, with or without sclerosant. However, these trials have been done in major research centres, and endoscopic treatment of upper gastrointestinal bleeding has not yet become routine in general hospitals. We have done a prospective, randomised, controlled trial of injection treatment for bleeding peptic ulcers in a district general hospital. Between April, 1989, and June, 1991, all patients with acute upper gastrointestinal bleeding (n = 555) underwent endoscopy by an experienced endoscopist within 24 h of admission. 98 patients were found to have an ulcer with a visible vessel, of whom 93 were randomised to injection (n = 48) or standard treatment alone (n = 45). Injection treatment consisted of 1-2 ml of 1 in 10000 adrenaline injected at four to six sites around the ulcer. Adrenaline and 5% ethanolamine oleate (1-2 ml) were then injected directly into the vessel. The medical team managing the patient was unaware of the endoscopic treatment given. The two groups were similar for age, initial haemoglobin concentration, shock, and ulcer site. Rebleeding (injected 8 [16.7%] vs control 21 [46.7%], p = 0.011) was significantly reduced in treated patients. The treated group also had lower mortality (4 [8.3%] vs 9 [20%]), requirement for surgery (4 [8.3%] vs 8 [17.8%]), and mean blood-transfusion requirement (5 vs 7.5 units). Endoscopic injection treatment in our patients significantly reduced rebleeding rate and may have other benefits. This cheap and widely applicable treatment can be used routinely in the management of patients with bleeding peptic ulcers who are at high risk of rebleeding.	OLDCHURCH HOSP,DEPT GASTROENTEROL,ROMFORD RM7 0BE,ESSEX,ENGLAND									BLANZO J, 1988, ENDOSCOPY, V20, P289; CHESTER JF, 1990, ENDOSCOPY, V22, P287, DOI 10.1055/s-2007-1012873; DIFELICE G, 1987, ENDOSCOPY, V19, P185, DOI 10.1055/s-2007-1018278; HENRY D, 1991, GASTROENTEROLOGY, V100, P1481; HIRAO M, 1985, GASTROINTEST ENDOSC, V31, P313, DOI 10.1016/S0016-5107(85)72213-4; LOPERFIDO S, 1990, ENDOSCOPY, V22, P285, DOI 10.1055/s-2007-1010728; PANES J, 1987, LANCET, V2, P1292; RAJGOPAL C, 1991, GUT, V32, P727, DOI 10.1136/gut.32.7.727; RUTGEERTS P, 1989, LANCET, V1, P1164; SACKS HS, 1990, JAMA-J AM MED ASSOC, V264, P494, DOI 10.1001/jama.264.4.494; SOEHENDRA N, 1985, ENDOSCOPY, V17, P129, DOI 10.1055/s-2007-1018481; Steele R J, 1989, J R Coll Surg Edinb, V34, P133; SWAIN C P, 1991, Gastroenterology, V100, pA170	13	75	76	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					966	968		10.1016/0140-6736(92)91537-I	http://dx.doi.org/10.1016/0140-6736(92)91537-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348805				2022-12-28	WOS:A1992HP03600010
J	MILLER, DM; SHEN, MM; SHAMU, CE; BURGLIN, TR; RUVKUN, G; DUBOIS, ML; GHEE, M; WILSON, L				MILLER, DM; SHEN, MM; SHAMU, CE; BURGLIN, TR; RUVKUN, G; DUBOIS, ML; GHEE, M; WILSON, L			C-ELEGANS UNC-4 GENE ENCODES A HOMEODOMAIN PROTEIN THAT DETERMINES THE PATTERN OF SYNAPTIC INPUT TO SPECIFIC MOTOR NEURONS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; TRANSPOSABLE ELEMENT; NERVOUS-SYSTEM; CELL LINEAGES; DROSOPHILA; HOMEOBOX; EXPRESSION; PRODUCT	THE creation of neural circuits depends on the formation of synapses between specific sets of neurons. Little is known, however, of the molecular mechanisms governing synaptic choice. A mutation in the unc-4 gene alters the pattern of synaptic input to one class of motor neurons in the Caenorhabditis elegans ventral nerve cord. In unc-4(e120), the presynaptic partners of VA motor neurons are replaced with interneurons appropriate to motor neurons of the VB class. This change in neural specificity is not accompanied by any detectable effects on neuronal morphology or process extension 1,2. We show that the absence of a functional unc-4 gene product accounts for the mutant phenotype. The unc-4 gene encodes a homeodomain protein and thus is likely to function as a transcription factor. The limited effect of the unc-4 null mutation on cell fate may mean that unc-4 regulates the expression of a small number of target genes and that the products of these genes are directly involved in the choice of synaptic partners.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	MRC Laboratory Molecular Biology; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	MILLER, DM (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710, USA.		Shen, Michael M/C-7546-2009	Shen, Michael M/0000-0002-4042-1657				AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BABU P, 1981, MUTAT RES, V82, P269, DOI 10.1016/0027-5107(81)90156-1; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1990, NATURE, V355, P184; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DURBIN R, 1987, THESIS CAMBRIDGE U; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; EMMONS SW, 1988, NEMATODE CAENORHABDI, P47; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HAWKINS NC, 1990, NUCLEIC ACIDS RES, V18, P6101, DOI 10.1093/nar/18.20.6101; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERMAN RK, 1978, GENETICS, V88, P49; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; LIAO LW, 1983, P NATL ACAD SCI-BIOL, V80, P3585, DOI 10.1073/pnas.80.12.3585; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAMU CE, 1989, THESIS CAMBRIDGE U; SHEN MM, 1988, CELL, V54, P1019, DOI 10.1016/0092-8674(88)90117-1; SHEN MM, 1988, THESIS CAMBRIDGE U; SIGURDSON DC, 1984, GENETICS, V108, P331; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, COLD SPRING HARB SYM, V48, P443, DOI 10.1101/SQB.1983.048.01.049; SUZUKI DT, 1970, SCIENCE, V170, P695, DOI 10.1126/science.170.3959.695; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1992, NATURE, V355, P838, DOI 10.1038/355838a0; [No title captured]	40	156	158	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					841	845		10.1038/355841a0	http://dx.doi.org/10.1038/355841a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1347150				2022-12-28	WOS:A1992HF63600061
J	ATKINSON, MA; KAUFMAN, DL; CAMPBELL, L; GIBBS, KA; SHAH, SC; BU, DF; ERLANDER, MG; TOBIN, AJ; MACLAREN, NK				ATKINSON, MA; KAUFMAN, DL; CAMPBELL, L; GIBBS, KA; SHAH, SC; BU, DF; ERLANDER, MG; TOBIN, AJ; MACLAREN, NK			RESPONSE OF PERIPHERAL-BLOOD MONONUCLEAR-CELLS TO GLUTAMATE-DECARBOXYLASE IN INSULIN-DEPENDENT DIABETES	LANCET			English	Note								Insulin-dependent diabetes is characterised by autoantibodies to several pancreatic-islet-cell antigens, including glutamate decarboxylase. We measured the proliferative responses to this antigen of peripheral-blood mononuclear cells from patients with newly diagnosed insulin-dependent diabetes, relatives of diabetic patients, and healthy controls. The likelihood of a positive response was substantially greater among the diabetic patients and relatives positive for islet-cell autoantibodies (ICA) than among subjects at low risk of diabetes (controls and ICA-negative relatives). Glutamate decarboxylase may have a pathogenetic role in insulin-dependent diabetes.	UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV S FLORIDA,DEPT PEDIAT,TAMPA,FL 33620	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University System of Florida; University of South Florida	ATKINSON, MA (corresponding author), UNIV FLORIDA,DEPT PATHOL,POB 100275,GAINESVILLE,FL 32610, USA.		Kaufman, Daniel/AAU-1228-2021; Campbell, Lesley V/B-2271-2008	Kaufman, Daniel/0000-0002-9844-5918; 				ATKINSON MA, 1990, SCI AM, V263, P62, DOI 10.1038/scientificamerican0790-62; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BU DF, IN PRESS P NATL ACAD; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GEPTS W, 1981, AM J MED, V70, P105, DOI 10.1016/0002-9343(81)90417-4; JAMES SP, 1990, CURRENT PROTOCOLS IM; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROEP BO, 1991, LANCET, V337, P1439, DOI 10.1016/0140-6736(91)93127-U	10	279	286	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					458	459		10.1016/0140-6736(92)91061-C	http://dx.doi.org/10.1016/0140-6736(92)91061-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346821				2022-12-28	WOS:A1992HE93200006
J	PATEL, V; ARAYA, R				PATEL, V; ARAYA, R			TRAINED OVERSEAS, UNABLE TO RETURN HOME - PLIGHT OF DOCTORS FROM DEVELOPING-COUNTRIES	LANCET			English	Editorial Material											PATEL, V (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 8AZ,ENGLAND.			Araya, Ricardo/0000-0002-0420-5148				Anwar M., 1987, OVERSEAS DOCTORS EXP; HALSTEAD SB, 1991, J CLIN EPIDEMIOL, V44, P579, DOI 10.1016/0895-4356(91)90222-U; HOLDEN N, 1989, PSYCHIATRIC B, V13, P558; LEFF J, 1980, BRIT J PSYCHIAT, V137, P288, DOI 10.1192/bjp.137.3.288; LISTER J, 1986, NEW ENGL J MED, V315, P1038, DOI 10.1056/NEJM198610163151630; ORLEY J, 1990, SOC PSYCH PSYCH EPID, V25, P65; PANDYA SK, 1990, BRIT MED J, V301, P333, DOI 10.1136/bmj.301.6747.333; TANTAM D, 1990, PSYCHIATRIC B, V14, P406; WHITE P, 1986, B R COLL PSYCHIATR, V10, P59; KAROLINSKA I NOBEL C; 1990, LANCET, V336, P1415; 1987, LANCET, V2, P1064; 1987, LANCET, V2, P1076	13	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					110	111		10.1016/0140-6736(92)91010-6	http://dx.doi.org/10.1016/0140-6736(92)91010-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ156	1345829				2022-12-28	WOS:A1992GZ15600014
J	MARGULIES, M; PEREZ, GC; VOTO, LS				MARGULIES, M; PEREZ, GC; VOTO, LS			MISOPROSTOL TO INDUCE LABOR	LANCET			English	Letter									UNIV AUSTRAL CHILE, VALDIVIA, CHILE	Universidad Austral de Chile	MARGULIES, M (corresponding author), UNIV BUENOS AIRES, JA FERNANDEZ HOSP, RA-1119 BUENOS AIRES, ARGENTINA.		Pérez, Gabriela/GYA-2894-2022; Voto, Liliana Susana/AAC-4923-2020					MARGULIES M, 1991, PRENSA MED ARGENT, V78, P9; PEREZ GAC, 1991, 2ND P EUR C PROST RE	2	67	74	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					64	64		10.1016/0140-6736(92)90194-8	http://dx.doi.org/10.1016/0140-6736(92)90194-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345991				2022-12-28	WOS:A1992GY04300054
J	LI, L; JAMES, G; HELLERHARRISON, R; CZECH, MP; OLSON, EN				LI, L; JAMES, G; HELLERHARRISON, R; CZECH, MP; OLSON, EN			FGF INACTIVATES MYOGENIC HELIX-LOOP-HELIX PROTEINS THROUGH PHOSPHORYLATION OF A CONSERVED PROTEIN-KINASE-C SITE IN THEIR DNA-BINDING DOMAINS	CELL			English	Article							MUSCLE-SPECIFIC ENHANCER; FIBROBLAST GROWTH-FACTOR; H-RAS ONCOGENE; GENE-EXPRESSION; MYC HOMOLOGY; ACTIVATION; MYOD1; DIFFERENTIATION; SEQUENCE; REGION	Myogenin belongs to a family of myogenic helix-loop-helix (HLH) proteins that activate muscle transcription through binding to a conserved DNA sequence associated with numerous muscle-specific genes. Fibroblast growth factor (FGF) inhibits myogenesis by inactivating myogenic HLH proteins. We show that activated protein kinase C (PKC) can substitute for FGF and inhibit transcriptional activity of myogenic HLH proteins. In transfected cells, FGF induces phosphorylation of a conserved site in the DNA-binding domain of myogenin. This site is phosphorylated by PKC in vivo and in vitro and mediates repression of the myogenic program through a loss in DNA binding activity. A myogenin mutant lacking the PKC phosphorylation site is not repressed by FGF, confirming this site as a molecular target for FGF-dependent repression of muscle transcription. These results establish a direct link between the signal transduction pathways that inhibit myogenesis and the transcription factors directly activating muscle-specific genes.	UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	LI, L (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030, USA.				NIAMS NIH HHS [AR 39849, AR 40339] Funding Source: Medline; NIDDK NIH HHS [DK 30648] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039849, R01AR040339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUANNO S, 1990, CANCER RES, V50, P3377; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COHEN R, 1977, NATURE, V266, P538, DOI 10.1038/266538a0; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIAS P, 1990, AM J PATHOL, V137, P1283; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Gorman C., 1985, DNA CLONING, V2; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIM SJ, 1992, J BIOL CHEM, V267, P15140; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; MARTIN JF, 1992, J BIOL CHEM, V267, P10956; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; OLSON EN, 1992, IN PRESS DEV BIOL; RAPP UR, 1991, ONCOGENE, V6, P495; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TONIN PN, 1991, CANCER RES, V51, P5100; TSUDA T, 1985, FEBS LETT, V191, P205, DOI 10.1016/0014-5793(85)80009-0; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; VINSON CR, 1992, NEW BIOL, V4, P396; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZHU YY, 1991, J CELL BIOL, V115, P745, DOI 10.1083/jcb.115.3.745	66	321	324	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1181	1194		10.1016/S0092-8674(05)80066-2	http://dx.doi.org/10.1016/S0092-8674(05)80066-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335366				2022-12-28	WOS:A1992KE60400012
J	PELLETIER, H; KRAUT, J				PELLETIER, H; KRAUT, J			CRYSTAL-STRUCTURE OF A COMPLEX BETWEEN ELECTRON-TRANSFER PARTNERS, CYTOCHROME-C PEROXIDASE AND CYTOCHROME-C	SCIENCE			English	Article							SITE-DIRECTED MUTANTS; FERROCYTOCHROME-C; COMPOUND-I; 3-DIMENSIONAL STRUCTURE; PARAMAGNETIC RESONANCE; CHEMICAL MODIFICATION; ESCHERICHIA-COLI; BINDING DOMAINS; RADICAL SITE; RESOLUTION	The crystal structure of a 1:1 complex between yeast cytochrome c peroxidase and yeast iso-1-cytochrome c was determined at 2.3 angstrom resolution. This structure reveals a possible electron transfer pathway unlike any previously proposed for this extensively studied redox pair. The shortest straight line between the two hemes closely follows the peroxidase backbone chain of residues Ala194, Ala193, Gly192, and finally Trp191, the indole ring of which is perpendicular to, and in van der Waals contact with, the peroxidase heme. The crystal structure at 2.8 angstrom of a complex between yeast cytochrome c peroxidase and horse heart cytochrome c was also determined. Although crystals of the two complexes (one with cytochrome c from yeast and the other with cytochrome c from horse) grew under very different conditions and belong to different space groups, the two complex structures are closely similar, suggesting that cytochrome c interacts with its redox partners in a highly specific manner.			PELLETIER, H (corresponding author), UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA.				NIDDK NIH HHS [DK07233] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAND P, 1991, STRUCT BOND, V75, P1; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BOSSHARD HR, 1991, PEROXIDASES CHEM BIO, V2, pCH3; BRUNGER AT, 1990, XPLOR MANUAL; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CORIN AF, 1991, BIOCHEMISTRY-US, V30, P11585, DOI 10.1021/bi00113a014; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GEREN L, 1991, BIOCHEMISTRY-US, V30, P9450, DOI 10.1021/bi00103a009; HAHM S, 1992, BIOCHEMISTRY-US, V31, P3472, DOI 10.1021/bi00128a022; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HILDEBRANDT P, 1992, BIOCHEMISTRY-US, V31, P2384, DOI 10.1021/bi00123a025; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; KANG CH, 1978, J BIOL CHEM, V253, P6502; Keilin D, 1929, P R SOC LOND B-CONTA, V104, P206, DOI 10.1098/rspb.1929.0009; Keilin D, 1925, P R SOC LOND B-CONTA, V98, P312, DOI 10.1098/rspb.1925.0039; KIM KL, 1990, BIOCHEMISTRY-US, V29, P9150, DOI 10.1021/bi00491a008; LEONARD JJ, 1974, BIOCHEMISTRY-US, V13, P1465, DOI 10.1021/bi00704a023; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; LUM VR, 1987, PROTEIN STRUCTURE FO, V2, P143; MATHEWS FS, 1991, BIOCHEMISTRY-US, V30, P238, DOI 10.1021/bi00215a034; MAUK AG, 1991, STRUCT BOND, V75, P131; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MCLENDON G, 1991, STRUCT BOND, V75, P159; MILLER MA, 1988, BIOCHEMISTRY-US, V27, P9081, DOI 10.1021/bi00426a003; MILLER MA, 1992, BIOCHEMISTRY-US, V31, P2789, DOI 10.1021/bi00125a020; MOCHAN E, 1971, BIOCHEM J, V121, P69, DOI 10.1042/bj1210069; MOENCH SJ, 1992, BIOCHEMISTRY-US, V31, P3661, DOI 10.1021/bi00129a015; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; OCHI H, 1983, J MOL BIOL, V166, P407, DOI 10.1016/S0022-2836(83)80092-8; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; PELLETIER H, 1992, THESIS U CALIFORNIA; POULOS TL, 1980, J BIOL CHEM, V255, P322; POULOS TL, 1987, J BIOL CHEM, V262, P13881; SALEMME FR, 1973, J BIOL CHEM, V248, P7701; SCHOLES CP, 1989, ISRAEL J CHEM, V29, P85; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SMITH L, 1965, BIOCHIM BIOPHYS ACTA, V105, P1, DOI 10.1016/S0926-6593(65)80170-9; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; YONETANI T, COMMUNICATION; [No title captured]; 1988, MERLOT MANUAL	47	720	723	1	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1992	258	5089					1748	1755		10.1126/science.1334573	http://dx.doi.org/10.1126/science.1334573			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1334573				2022-12-28	WOS:A1992KB96400026
J	TROELSTRA, C; VANGOOL, A; DEWIT, J; VERMEULEN, W; BOOTSMA, D; HOEIJMAKERS, JHJ				TROELSTRA, C; VANGOOL, A; DEWIT, J; VERMEULEN, W; BOOTSMA, D; HOEIJMAKERS, JHJ			ERCC6, A MEMBER OF A SUBFAMILY OF PUTATIVE HELICASES, IS INVOLVED IN COCKAYNES-SYNDROME AND PREFERENTIAL REPAIR OF ACTIVE GENES	CELL			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; NUCLEOTIDE EXCISION REPAIR; 7TH COMPLEMENTATION GROUP; STRAND-SPECIFIC REPAIR; CHINESE-HAMSTER CELLS; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; ESCHERICHIA-COLI; CDNA CLONING	Cells from patients with the UV-sensitive nucleotide excision repair disorder Cockayne's syndrome (CS) have a specific defect in preferential repair of lesions from the transcribed strand of active genes. This system permits quick resumption of transcription after UV exposure. Here we report the characterization of ERCC6, a gene involved in preferential repair in eukaryotes. ERCC6 corrects the repair defect of CS complementation group B (CS-B). It encodes a protein of 1493 amino acids, containing seven consecutive domains conserved between DNA and RNA helicases. The entire helicase region bears striking homology to segments in recently discovered proteins involved in transcription regulation, chromosome stability, and DNA repair. Mutation analysis of a CS-B patient indicates that the gene is not essential for cell viability and is specific for preferential repair of transcribed sequences.			TROELSTRA, C (corresponding author), ERASMUS UNIV, CTR MED GENET, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS.		van Gool, Alain J/G-3806-2010; Hoeijmakers, Jan/AAX-6972-2021; van Gool, Alain J./L-4328-2015; Vermeulen, Wim/W-8708-2019	Vermeulen, Wim/0000-0003-3616-734X; van Gool, Alain/0000-0003-0010-5286				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; [Anonymous], 1985, DNA REPAIR; ARLETT CF, 1982, INDUCED MUTAGENESIS, P249; BANG DD, 1992, IN PRESS NUCL ACIDS; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BUDD M, 1982, MUTAT RES, V103, P19, DOI 10.1016/0165-7992(82)90080-X; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DEWEERDK.EA, 1972, NATURE-NEW BIOL, V238, P80, DOI 10.1038/newbio238080a0; DOMINSKI Z, 1992, MOL CELL BIOL, V12, P2108, DOI 10.1128/MCB.12.5.2108; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FRYNS JP, 1991, AM J MED GENET, V40, P343, DOI 10.1002/ajmg.1320400320; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HENDERSON EE, 1981, VIROLOGY, V115, P237, DOI 10.1016/0042-6822(81)90107-0; HIGGINS DR, 1983, P NATL ACAD SCI-BIOL, V80, P5680, DOI 10.1073/pnas.80.18.5680; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LEHMANN A R, 1987, Cancer Reviews, V7, P82; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; LOMMEL L, 1991, MUTAT RES, V255, P183, DOI 10.1016/0921-8777(91)90052-Q; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NAUMOVSKI L, 1983, P NATL ACAD SCI-BIOL, V80, P4818, DOI 10.1073/pnas.80.15.4818; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1992, J BIOL CHEM, V267, P780; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUBY SW, 1991, TRENDS GENET, V7, P79; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SAEKI T, 1980, MUTAT RES, V73, P251, DOI 10.1016/0027-5107(80)90192-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHILD D, 1992, YEAST, V8, P385, DOI 10.1002/yea.320080506; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIMPSON NE, 1990, CYTOGENET CELL GENET, V55, P142, DOI 10.1159/000133006; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1981, SOMAT CELL GENET, V7, P445, DOI 10.1007/BF01542989; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; TERLETH C, 1990, MOL CELL BIOL, V10, P4678, DOI 10.1128/MCB.10.9.4678; THOMPSON LH, 1989, MUTAGENESIS, V4, P140, DOI 10.1093/mutage/4.2.140; THOMPSON LH, 1988, SOMAT CELL MOLEC GEN, V14, P605, DOI 10.1007/BF01535314; TROELSTRA C, 1992, GENOMICS, V12, P745, DOI 10.1016/0888-7543(92)90304-B; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANDUIN M, 1989, MUTAT RES, V217, P83, DOI 10.1016/0921-8777(89)90059-1; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VANZEELAND AA, 1981, MUTAT RES, V82, P173, DOI 10.1016/0027-5107(81)90148-2; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, THESIS STATE U LEIDE; VERMEULEN W, 1986, MUTAT RES, V165, P199, DOI 10.1016/0167-8817(86)90055-6; VERMEULEN W, 1991, MUTAT RES, V255, P201, DOI 10.1016/0921-8777(91)90054-S; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WOOD CM, 1987, EXP CELL RES, V169, P543, DOI 10.1016/0014-4827(87)90214-X; YAGI T, 1983, MUTAT RES, V112, P59, DOI 10.1016/0167-8817(83)90024-X; YE RD, 1987, J BIOL CHEM, V262, P3718; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P165, DOI 10.1016/0167-8817(88)90018-1; ZELLE B, 1980, MUTAT RES, V72, P491, DOI 10.1016/0027-5107(80)90121-9	93	631	646	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					939	953		10.1016/0092-8674(92)90390-X	http://dx.doi.org/10.1016/0092-8674(92)90390-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1339317	Green Published			2022-12-28	WOS:A1992KB99000007
J	REGNERY, RL; OLSON, JG; PERKINS, BA; BIBB, W				REGNERY, RL; OLSON, JG; PERKINS, BA; BIBB, W			SEROLOGICAL RESPONSE TO ROCHALIMAEA-HENSELAE ANTIGEN IN SUSPECTED CAT-SCRATCH DISEASE	LANCET			English	Note							ANGIOMATOSIS; AGENT	There are no generally accepted diagnostic tests for cat-scratch disease (CSD), the cause of which is unknown. During the development of an indirect fluorescence antibody (IFA) test for detection of antibodies to "Rochalimaea henselae", sera from patients with CSD were found to have high titres to R henselae antigens. Further tests with this assay showed that 36 (88%) of 41 patients with suspected CSD had serum titres of 64 or more to R henselae antigen, that there was a low prevalence (3%) of substantial titres to R henselae in healthy controls (n = 107), and that the immune responses to R henselae antigens were specific. These data suggest that the R henselae IFA test, or other serological assays based on R henselae, may be useful for diagnosis of CSD.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	REGNERY, RL (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333, USA.							BRENNER DJ, 1991, J CLIN MICROBIOL, V29, P2450, DOI 10.1128/JCM.29.11.2450-2460.1991; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; ENGLISH CK, 1988, JAMA-J AM MED ASSOC, V259, P1347, DOI 10.1001/jama.259.9.1347; KEMPER CA, 1990, AM J MED, V89, P216, DOI 10.1016/0002-9343(90)90301-S; LEBOIT PE, 1988, LANCET, V1, P960; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1991, NEW ENGL J MED, V324, P1514; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; TEPPERO JW, 1991, 7 INT C AIDS FLOR, P340; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992	10	470	487	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1443	1445		10.1016/0140-6736(92)92032-B	http://dx.doi.org/10.1016/0140-6736(92)92032-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351130				2022-12-28	WOS:A1992HY31700005
J	CHENG, KK; DAY, NE; DUFFY, SW; LAM, TH; FOK, M; WONG, J				CHENG, KK; DAY, NE; DUFFY, SW; LAM, TH; FOK, M; WONG, J			PICKLED VEGETABLES IN THE ETIOLOGY OF ESOPHAGEAL CANCER IN HONG-KONG CHINESE	LANCET			English	Article							HIGH-RISK POPULATION; ESOPHAGEAL CANCER; PRECURSOR LESIONS; IRAN	Oesophageal cancer is common in Chinese populations, but individual-based epidemiological studies have provided little explanation. A case control study with 400 cases and 1598 controls (800 hospital and 798 general practice) was conducted among Hong Kong Chinese. In multivariate analyses, statistically significant effects on risk were detected for several potentially preventable exposures with high attributable risks (ARs). These included preference for consuming drinks or soups at high temperature (AR = 14%), infrequent consumption of green leafy vegetables (AR = 15%) and citrus fruits (AR = 26%), ingestion of pickled vegetables (AR = 29%), tobacco smoking (AR = 44%), and alcohol drinking (AR = 48%). On the assumption of multiplicative risk, the combined AR due to these exposures was 89%. This is the first case control study to show an association between pickled vegetable consumption and oesophageal cancer risk. The finding considerably strengthens the evidence for carcinogenicity of N-nitroso compounds in man and helps to explain the very high risk among Chinese.	ADDENBROOKES HOSP,DEPT COMMUNITY MED,LEVEL 5,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV HONG KONG,DEPT COMMUNITY MED,HONG KONG,HONG KONG; UNIV CAMBRIDGE,DEPT COMMUNITY MED,CAMBRIDGE,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; UNIV HONG KONG,QUEEN MARY HOSP,DEPT SURG,HONG KONG,HONG KONG	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Hong Kong; University of Cambridge; MRC Biostatistics Unit; University of Hong Kong			Lam, Tai Hing/C-4317-2009	Lam, Tai Hing/0000-0002-2033-9971				BENICHOU J, 1991, STAT MED, V10, P1753, DOI 10.1002/sim.4780101113; Breslow N, 1980, STATISTICAL METHODS, V32; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CHANGCLAUDE JC, 1990, CANCER RES, V50, P2268; CHEN J, 1987, IARC SCI PUBL, V84, P503; COOKMOZAFFARI PJ, 1979, BRIT J CANCER, V39, P293, DOI 10.1038/bjc.1979.54; DEJONG UW, 1974, INT J CANCER, V13, P291, DOI 10.1002/ijc.2910130304; LEE HP, 1988, IARC SCI PUBL, V91; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; Li M H, 1986, Nutr Cancer, V8, P63, DOI 10.1080/01635588609513877; Lu S H, 1991, IARC Sci Publ, P11; Lu S H, 1987, IARC Sci Publ, P538; LU SH, 1986, CANCER RES, V46, P1485; MARTINEZ I, 1969, J NATL CANCER I, V42, P1069; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; MUNOZ N, 1982, LANCET, V1, P876; MUNOZ N, IN PRESS CANCER EPID; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; VASSALLO A, 1985, J NATL CANCER I, V75, P1005; VICTORA CG, 1987, INT J CANCER, V39, P710, DOI 10.1002/ijc.2910390610; WAHRENDORF J, 1989, LANCET, V2, P1239, DOI 10.1016/S0140-6736(89)91850-3; YANG CS, 1980, CANCER RES, V40, P2633; Yu M C, 1991, IARC Sci Publ, P39	24	112	119	3	22	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1314	1318		10.1016/0140-6736(92)91960-G	http://dx.doi.org/10.1016/0140-6736(92)91960-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349991				2022-12-28	WOS:A1992HW83700003
J	CABANES, PA; SALMON, RJ; VILCOQ, JR; DURAND, JC; FOURQUET, A; GAUTIER, C; ASSELAIN, B				CABANES, PA; SALMON, RJ; VILCOQ, JR; DURAND, JC; FOURQUET, A; GAUTIER, C; ASSELAIN, B			VALUE OF AXILLARY DISSECTION IN ADDITION TO LUMPECTOMY AND RADIOTHERAPY IN EARLY BREAST-CANCER	LANCET			English	Article							LYMPH-NODE; MASTECTOMY; PROGNOSIS; THERAPY; AGE	Axillary dissection in early breast cancer remains controversial because of its substantial side-effects and because its value with respect to recurrence or survival has not been unequivocally proven. Between 1982 and 1987, 658 patients were included in a prospective randomised comparison of lumpectomy alone with lumpectomy plus axillary dissection. All patients had a unilateral breast tumour not exceeding 3 cm in diameter and lymph-node involvement or metastases. Radiation therapy was given to both groups. The two groups of patients were similar with respect to mean age, TNM stage, and presence of hormonal receptors. Median follow-up was 54 months. 5-year survival of the patients was 94.2% (95% Cl: 92.1-96.4). There was a significant advantage in survival in the axillary dissection group (p = 0.014). Recurrence of tumour in the breast was similar in the two groups but visceral metastases, supraclavicular metastases, and lymph-node recurrences were less frequent in the axillary dissection group. Survival was related to the age of the patients (p = 0.005), the presence of positive nodes (p = 0.006), the histological grading (p < 0.0001), and the presence of hormonal receptors (progesterone p = 0.0008, oestrogen p < 0.0001). Treatment-adjusted relative risk was 2.4 (95% Cl: 1.3-4.2). The findings show that axillary dissection is justified for treatment of small breast cancers, although whether the better survival is due to axillary clearance itself or to adjuvant treatment for lymph-node involvement is unclear.	INST CURIE,DEPT CHIRURG,26 RUE ULM,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; AMALRIC R, 1982, CANCER-AM CANCER SOC, V49, P30, DOI 10.1002/1097-0142(19820101)49:1<30::AID-CNCR2820490107>3.0.CO;2-L; BERTHOUX L, 1960, J CHIR-PARIS, V127, P1; BONADONNA G, 1988, CANCER RES, V48, P2314; BONADONNA G, 1986, J CLIN ONCOL, V4, P451, DOI 10.1200/JCO.1986.4.4.451; CLARK RS, 1983, PHOTON SPECTRA, V17, P91; DURAND JC, 1984, CANCER, V53, P2439, DOI 10.1002/1097-0142(19840601)53:11<2439::AID-CNCR2820531113>3.0.CO;2-8; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FENTIMAN IS, 1991, LANCET, V337, P221, DOI 10.1016/0140-6736(91)92172-X; FISHER B, 1971, CANCER, V27, P1001, DOI 10.1002/1097-0142(197105)27:5<1001::AID-CNCR2820270502>3.0.CO;2-U; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FISHER B, 1970, SURG GYNECOL OBSTETR, V131, P79; HOST H, 1986, CANCER-AM CANCER SOC, V57, P2217, DOI 10.1002/1097-0142(19860601)57:11<2217::AID-CNCR2820571124>3.0.CO;2-T; LALANNE CM, 1981, DIAGNOSIS TREATMENT, P29; MONTAGUE ED, 1983, CONSERVATIVE MANAGEM, P53; ROSEN PP, 1981, ANN SURG, V194, P585, DOI 10.1097/00000658-198111000-00006; Salmon R. J., 1989, CANCER J, V2, P476; SANT M, 1991, EUR J CANCER, V27, P981, DOI 10.1016/0277-5379(91)90263-D; SARRAZIN D, 1991, BREAST COMPREHENSIVE, P808; VERONESI U, 1986, EUR J CANCER CLIN ON, V22, P1085, DOI 10.1016/0277-5379(86)90011-8; VERONESI U, 1983, ANN SURG, V198, P681, DOI 10.1097/00000658-198312000-00002; 1988, NEW ENGL J MED, V319, P1681; 1992, LANCET, V339, P71	23	229	233	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 23	1992	339	8804					1245	1248		10.1016/0140-6736(92)91591-U	http://dx.doi.org/10.1016/0140-6736(92)91591-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349666				2022-12-28	WOS:A1992HV19100001
J	HANNAFORD, PC; KAY, CR				HANNAFORD, PC; KAY, CR			AFTER ISIS-3	LANCET			English	Letter											HANNAFORD, PC (corresponding author), ROYAL COLL GEN PRACTIT,MANCHESTER RES UNIT,MANCHESTER M20 0TR,ENGLAND.		Hannaford, Philip C/B-7867-2012					1992, LANCET, V339, P753	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1225	1225		10.1016/0140-6736(92)91161-Z	http://dx.doi.org/10.1016/0140-6736(92)91161-Z			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349950				2022-12-28	WOS:A1992HU68400021
J	LEFF, RL; LOVE, LA; MILLER, FW; GREENBERG, SJ; KLEIN, EA; DALAKAS, MC; PLOTZ, PH				LEFF, RL; LOVE, LA; MILLER, FW; GREENBERG, SJ; KLEIN, EA; DALAKAS, MC; PLOTZ, PH			VIRUSES IN IDIOPATHIC INFLAMMATORY MYOPATHIES - ABSENCE OF CANDIDATE VIRAL GENOMES IN MUSCLE	LANCET			English	Article							INCLUSION-BODY MYOSITIS; POLYMYOSITIS; DERMATOMYOSITIS; RNA; AMPLIFICATION; PICORNAVIRUS; MYOCARDITIS; POLYMERASE; RETROVIRUS; MODEL	There is indirect evidence that various viruses have aetiological roles in the idiopathic inflammatory myopathies. By means of a sensitive and specific method based on the polymerase chain reaction (PCR), we sought direct evidence for the presence in affected muscle of nucleic acid sequences from Coxsackie virus, mumps virus, encephalomyocarditis virus, adenovirus, human T-lymphotropic virus types I and II, and human immunodeficiency virus. RNA was extracted from muscle biopsy samples obtained from 44 patients with idiopathic inflammatory myopathies a mean of 45 (range 0-216) months after disease onset. All the subjects were older than 16 years at disease onset. The integrity of the mRNA extracted was confirmed by the successful PCR amplification of insulin receptor mRNA in all samples. The PCR method was able to detect between 1 and 20 molecules of added viral nucleic acid for the picornaviruses sought. No detectable virus sequences were found, however, in any of the patients' muscle samples or in samples from 13 controls. We tested for retroviral DNA in 22 samples (17 patients, 5 controls) that met our criterion for adequate DNA extraction (detectable beta-actin DNA by PCR); again no virus sequences were found. Persistence in muscle of these or closely related viruses is unlikely to be a continuing stimulus for disease in the idiopathic inflammatory myopathies.	ROSWELL PK CANC INST,DEPT NEUROL,BUFFALO,NY; SUNY BUFFALO,BUFFALO,NY 14260; NINCDS,BETHESDA,MD 20892	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	LEFF, RL (corresponding author), NIAMS,ARTHRIT & RHEUMATISM BRANCH,BLDG 10,ROOM 9N228,BETHESDA,MD 20892, USA.		Miller, Frederick/D-2431-2019	Miller, Frederick/0000-0003-2831-9593				BOWLES NE, 1987, LANCET, V1, P1004; CHOU SM, 1970, NEUROLOGY, V20, P205, DOI 10.1212/WNL.20.3.205; CHOU SM, 1986, HUM PATHOL, V17, P765, DOI 10.1016/S0046-8177(86)80197-6; CHRISTENSEN ML, 1986, ARTHRITIS RHEUM, V29, P1365, DOI 10.1002/art.1780291109; CRENNAN JM, 1986, AM J MED, V81, P35, DOI 10.1016/0002-9343(86)90179-8; CRONIN ME, 1988, J EXP MED, V168, P1639, DOI 10.1084/jem.168.5.1639; DALAKAS MC, 1986, JAMA-J AM MED ASSOC, V256, P2381, DOI 10.1001/jama.256.17.2381; DALAKAS MC, 1986, NEUROLOGY, V36, P569, DOI 10.1212/WNL.36.4.569; DENMAN AM, 1988, POLYMYOSITIS DERMATO, P97; EHRLICH GD, 1991, NEUROLOGY, V41, P335, DOI 10.1212/WNL.41.3.335; EHRLICH GD, 1990, PCR PROTOCOLS GUIDE, P325; JIN O, 1990, CIRCULATION, V82, P8, DOI 10.1161/01.CIR.82.1.8; KALLAJOKI M, 1991, HUM PATHOL, V22, P29, DOI 10.1016/0046-8177(91)90057-V; LEFF RL, 1991, ARTHRITIS RHEUM, V11, P1391; LINDLEY IJD, 1977, J GEN VIROL, V34, P177, DOI 10.1099/0022-1317-34-1-177; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MIKOL J, 1982, ANN NEUROL, V11, P576, DOI 10.1002/ana.410110605; MURPHY BR, 1990, VIROLOGY, P1109; NISHINO H, 1989, ANN NEUROL, V25, P260, DOI 10.1002/ana.410250309; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; ROSENBERG NL, 1989, ANN NEUROL, V26, P204, DOI 10.1002/ana.410260204; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON R, 1974, NATURE, V249, P32, DOI 10.1038/249032a0; STRONGWATER SL, 1984, ARTHRITIS RHEUM, V27, P433, DOI 10.1002/art.1780270411; TANG TT, 1975, NEW ENGL J MED, V292, P608, DOI 10.1056/NEJM197503202921203; WILEY CA, 1989, NEW ENGL J MED, V320, P992, DOI 10.1056/NEJM198904133201507; YOUSEF GE, 1990, ANN RHEUM DIS, V49, P310, DOI 10.1136/ard.49.5.310	28	107	107	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1192	1195		10.1016/0140-6736(92)91134-T	http://dx.doi.org/10.1016/0140-6736(92)91134-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349938				2022-12-28	WOS:A1992HU68400004
J	SCAMBLER, PJ; KELLY, D; LINDSAY, E; WILLIAMSON, R; GOLDBERG, R; SHPRINTZEN, R; WILSON, DI; GOODSHIP, JA; CROSS, IE; BURN, J				SCAMBLER, PJ; KELLY, D; LINDSAY, E; WILLIAMSON, R; GOLDBERG, R; SHPRINTZEN, R; WILSON, DI; GOODSHIP, JA; CROSS, IE; BURN, J			VELO-CARDIO-FACIAL SYNDROME ASSOCIATED WITH CHROMOSOME-22 DELETIONS ENCOMPASSING THE DIGEORGE LOCUS	LANCET			English	Note								The large clinical overlap between DiGeorge syndrome and velo-cardio-facial syndrome suggests an aetiological connection. DiGeorge syndrome is associated with microdeletions of chromosome 22q11 and is therefore likely to be caused by reduced dosage of genes within this region. We present preliminary data that velocardiofacial syndrome patients have similar chromosome deletions, a finding consistent with the hypothesis that these disorders represent part of a spectrum of abnormalities seen with monosomy for 22q11.	MONTEFIORE MED CTR,CTR CRANIOFACIAL DISORDERS,BRONX,NY 10467; UNIV NEWCASTLE UPON TYNE,DIV HUMAN GENET & CYTOGENET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Newcastle University - UK	SCAMBLER, PJ (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND.		Scambler, Peter/AAZ-6026-2020; Wilson, David/A-6264-2010; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Wilson, David/0000-0001-8779-2060; Scambler, Peter J/0000-0002-1487-4628				CAREY AH, 1990, GENOMICS, V7, P299, DOI 10.1016/0888-7543(90)90161-M; CAREY AH, 1991, THESIS U LONDON UK; CAREY AH, IN PRESS MAMMAL GENO; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; McKusick VA, 1990, MENDELIAN INHERITANC; SCAMBLER PJ, 1991, GENOMICS, V10, P201, DOI 10.1016/0888-7543(91)90501-5; SHARKEY AM, IN PRESS HUM GENET; SHPRINTZEN RJ, 1990, BIRTH DEFECTS ENCY, P1744; STEVENS CA, 1990, PEDIATRICS, V85, P526; WILSON DI, 1991, BRIT HEART J, V66, P308	10	366	372	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1138	1139		10.1016/0140-6736(92)90734-K	http://dx.doi.org/10.1016/0140-6736(92)90734-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349369				2022-12-28	WOS:A1992HT23600006
J	DOOREN, MC; KUIJPERS, RWAM; JOEKES, EC; HUISKES, E; GOLDSCHMEDING, R; OVERBEEKE, MAM; VONDEMBORNE, AEGK; ENGELFRIET, CP; OUWEHAND, WH				DOOREN, MC; KUIJPERS, RWAM; JOEKES, EC; HUISKES, E; GOLDSCHMEDING, R; OVERBEEKE, MAM; VONDEMBORNE, AEGK; ENGELFRIET, CP; OUWEHAND, WH			PROTECTION AGAINST IMMUNE HEMOLYTIC-DISEASE OF NEWBORN-INFANTS BY MATERNAL MONOCYTE-REACTIVE IGG ALLOANTIBODIES (ANTI-HLA-DR)	LANCET			English	Article							HUMAN-SERA; ANTIBODIES	The extent to which maternal anti-Rh(D) antibodies support lysis of erythrocytes by monocytes in the antibody-dependent cell-mediated cytotoxicity (ADCC) assay is closely correlated with the severity of Rh(D) haemolytic disease of the newborn infant (HDN). However, in some cases HDN is much milder than would be predicted from the ADCC value. We postulated that maternal ADCC-blocking alloantibodies against paternal antigens on monocytes can protect these infants against severe haemolysis. We studied 13 severely Rh(D)-alloimmunised mothers whose infants showed unexpectedly mild HDN (group I) and 14 women with similar ADCC values but whose infants had severe HDN (group II), 7 group-I women had monocyte-reactive IgG alloantibodies that inhibited lysis by paternal monocYtes in the ADCC. No such antibodies were found in group II (p < 0.01). In 6 of the 7 serum samples with monocyte-reactive antibodies, the antibodies had HLA-DR specificity. Our findings suggest that Rh(D)-positive children of some severely Rh(D)-alloimmunised women may be protected from severe HDN by maternal non-HLA-class-I, IgG alloantibodies against paternal monocyte blood-group antigens. These antibodies may inhibit the mononuclear phagocyte system of the fetus.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT IMMUNOHAEMATOL,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,CLIN & EXPTL IMMUNOL LAB,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT HAEMATOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT TRANSFUS MED,CAMBRIDGE CB2 2QQ,ENGLAND	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			kuijpers, robert/AAD-5194-2019; Goldschmeding, Roel/I-1723-2014					BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P385; DEBOER M, 1981, J IMMUNOL METHODS, V43, P225, DOI 10.1016/0022-1759(81)90027-2; Engelfriet C P, 1990, Baillieres Clin Haematol, V3, P321, DOI 10.1016/S0950-3536(05)80053-8; Engelfriet CP, 1981, SEMINAR IMMUNE MEDIA, P93; FLEER A, 1978, SCAND J IMMUNOL, V8, P515, DOI 10.1111/j.1365-3083.1978.tb00551.x; KUIJPERS RWAM, 1991, BLOOD, V78, P2150; KURLANDER RJ, 1983, J IMMUNOL, V131, P140; MUELLERECKHARDT G, 1989, HUM IMMUNOL, V25, P125, DOI 10.1016/0198-8859(89)90076-1; NEPPERT J, 1986, VOX SANG, V51, P122, DOI 10.1111/j.1423-0410.1986.tb00227.x; OUWEHAND WH, 1984, THESIS RODOPI AMSTER, P19; OUWEHAND WH, 1984, THESIS AMSTERDAM, P87; Roos D, 1986, Methods Enzymol, V132, P225; SHULMAN NR, 1964, PROG HEMATOL, V4, P222; TERASAKI PI, 1982, DHEW NIH77545 PUBL, P92; URBANIAK SJ, 1991, VOX SANG, V60, P225	15	38	40	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1067	1070		10.1016/0140-6736(92)90661-L	http://dx.doi.org/10.1016/0140-6736(92)90661-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349101				2022-12-28	WOS:A1992HR44600001
J	FITZPATRICK, VD; PERCIVALSMITH, A; INGLES, CJ; KRAUSE, HM				FITZPATRICK, VD; PERCIVALSMITH, A; INGLES, CJ; KRAUSE, HM			HOMEODOMAIN-INDEPENDENT ACTIVITY OF THE FUSHI-TARAZU POLYPEPTIDE IN DROSOPHILA EMBRYOS	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; ULTRABITHORAX PROTEINS; ANTENNAPEDIA; REPRESSION; EXPRESSION; CELLS; EMBRYOGENESIS; MELANOGASTER; LOCALIZATION; SITE	THE Drosophila segmentation gene fushi tarazu (ftz) encodes a homeodomain-containing protein, ftz, that can act as a DNA-binding activator of transcription 1-5. In the developing embryo, ftz is expressed in seven stripes 6 which correspond to the even-numbered parasegments 7. These parasegments are missing in ftz- embryos 8. When ftz is expressed throughout blastoderm embryos under the control of a heat-shock promoter, the odd-numbered parasegments are lost 9. This 'anti-ftz' phenotype has been attributed to autoactivation of the endogenous ftz gene by the ectopically expressed protein 10. Here we show that the same phenotype is induced by ectopic expression of a ftz polypeptide containing a deletion in the homeodomain. Thus, ftz can alter gene expression without binding directly to DNA.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto				Krause, Henry/0000-0002-6182-7074				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CONDE BG, 1990, MOL CELLB IOL, V7, P3376; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRAUSE HM, 1989, EMBO J, V8, P1197, DOI 10.1002/j.1460-2075.1989.tb03492.x; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MURPHY P, 1991, DEVELOPMENT, V111, P61; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; WEISCHAUS E, 1986, DROSOPHILA PRACTICAL, P199; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1; WRIGHT CVE, 1987, EMBO J, V6, P4083, DOI 10.1002/j.1460-2075.1987.tb02754.x	27	85	85	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					610	612		10.1038/356610a0	http://dx.doi.org/10.1038/356610a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1348571				2022-12-28	WOS:A1992HP03100051
J	SALONEN, JT; YLAHERTTUALA, S; YAMAMOTO, R; BUTLER, S; KORPELA, H; SALONEN, R; NYYSSONEN, K; PALINSKI, W; WITZTUM, JL				SALONEN, JT; YLAHERTTUALA, S; YAMAMOTO, R; BUTLER, S; KORPELA, H; SALONEN, R; NYYSSONEN, K; PALINSKI, W; WITZTUM, JL			AUTOANTIBODY AGAINST OXIDIZED LDL AND PROGRESSION OF CAROTID ATHEROSCLEROSIS	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; HERITABLE HYPERLIPIDEMIC RABBIT; OXIDATIVE MODIFICATION; PROTEIN ADDUCTS; VITAMIN-E; LESIONS; PLASMA; MALONDIALDEHYDE; ANTIBODIES	Oxidative modification of LDL renders it immunogenic and autoantibodies to epitopes of oxidised LDL, such as malondialdehyde (MDA) -lysine, are found in serum and recognise material in atheromatous tissue. However, there has been no prospective study to assess the importance of oxidised LDL among patients with vascular disease. We compared the titre of autoantibodies to MDA-modified LDL and native LDL in baseline serum samples of 30 eastern Finnish men with accelerated two-year progression of carotid atherosclerosis and 30 age-matched controls without progression. Neither group had specific antibody binding to native LDL. A titre was defined as a ratio of antibody binding to MDA-LDL/binding to native LDL. Cases had a significantly higher titre to MDA-LDL (2.67 vs 2.06, p = 0.003). Cases also had a greater proportion of smokers (37% vs 3%), higher LDL cholesterol (4.2 mmol/l vs 3.6 mmol/l), and higher serum copper concentration (1.14 mg/l vs 1.04 mg/l). Even after adjusting for these variables and the severity of baseline atherosclerosis, the difference in antibody titre remained significant in a multifactorial logistic model (p = 0.031). Thus, the titre of autoantibodies to MDA-LDL was an independent predictor of the progression of carotid atherosclerosis in these Finnish men. Our data provide further support for a role of oxidatively modified LDL in atherogenesis.	UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,DEPT MED 0613D,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV KUOPIO,PUBL HLTH RES INST,SF-70101 KUOPIO 10,FINLAND; UNIV TAMPERE,DEPT BIOMED SCI,SF-33101 TAMPERE 10,FINLAND	University of California System; University of California San Diego; University of Eastern Finland; Tampere University			Palinski, Wulf/AAW-8032-2021	Yla-Herttuala, Seppo/0000-0001-7593-2708; Palinski, Wulf/0000-0002-5113-0169				BOYD HC, 1989, AM J PATHOL, V135, P815; ESTERBAUER H, 1987, J LIPID RES, V28, P495; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HARATS D, 1990, ATHEROSCLEROSIS, V85, P47, DOI 10.1016/0021-9150(90)90181-H; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOUGLUM K, 1990, J CLIN INVEST, V86, P1991, DOI 10.1172/JCI114934; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; OREKHOV VN, 1991, ARTERIOSCLER THROMB, V11, P316; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PALINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325, DOI 10.1161/01.ATV.10.3.325; PARUMS DV, 1990, ARCH PATHOL LAB MED, V114, P383; PARVIAINEN MT, 1986, J LIQ CHROMATOGR, V9, P2185, DOI 10.1080/01483918608074142; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SALONEN JT, 1991, BRIT MED J, V302, P756, DOI 10.1136/bmj.302.6779.756; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SALONEN R, 1991, ULTRASOUND MED BIOL, V17, P225, DOI 10.1016/0301-5629(91)90043-V; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YLAHERTTUALA S, 1991, ARTERIOSCLEROSIS, V11, pA1426	22	1172	1210	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					883	887		10.1016/0140-6736(92)90926-T	http://dx.doi.org/10.1016/0140-6736(92)90926-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348295	Green Submitted			2022-12-28	WOS:A1992HN48300001
J	FARIZO, KM; BUEHLER, JW; CHAMBERLAND, ME; WHYTE, BM; FROELICHER, ES; HOPKINS, SG; REED, CM; MOKOTOFF, ED; COHN, DL; TROXLER, S; PHELPS, AF; BERKELMAN, RL				FARIZO, KM; BUEHLER, JW; CHAMBERLAND, ME; WHYTE, BM; FROELICHER, ES; HOPKINS, SG; REED, CM; MOKOTOFF, ED; COHN, DL; TROXLER, S; PHELPS, AF; BERKELMAN, RL			SPECTRUM OF DISEASE IN PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS DRUG-USERS; NEW-YORK-CITY; NON-HODGKINS LYMPHOMA; SYNDROME AIDS; HOMOSEXUAL MEN; HIV INFECTION; RISK; EPIDEMIC; TUBERCULOSIS; BACTERIAL	Objective. - To describe the spectrum of disease in persons with human immunodeficiency virus (HIV) infection. Design. - Retrospective survey of medical records. Setting. - More than 50 clinics, hospitals, and private medical practices in nine US cities. Patients. - A total of 626 women and 7008 men 13 years of age or older with HIV infection who received medical care from January 1990 through March 1991 were consecutively enrolled. Main Outcome Measures. - Any history of diseases in the 1987 case definition for the acquired immunodeficiency syndrome (AIDS), and during the 12-month period preceding enrollment (baseline period), the occurrence of other major diseases, hospitalizations, and results of CD4+ lymphocyte counts. Results. - Thirty-two percent of persons met the 1987 case definition for AIDS. The occurrence of an AIDS-indicator disease during the baseline period ranged from 3% (33/1011) to 46% (1254/2748) among persons with CD4+ lymphocyte counts of 0.50 x 10(9)/L or greater and fewer than 0.20 x 10(9)/L (greater-than-or-equal-to 500 and < 200 CD4+ lymphocytes per microliter), respectively, and, at comparable CD4+ lymphocyte levels, was similar among women compared with men, and among persons who reported intravenous drug use compared with men who reported male-to-male sex. The frequency of one or more other major infectious diseases (eg, other pneumonias, bacterial sepsis, pulmonary tuberculosis) ranged from 6% to 16% among persons with CD4+ lymphocyte counts of 0.50 x 10(9)/L or greater and fewer than 0.20 x 10(9)/L, respectively; these illnesses were also associated with a history of intravenous drug use. Among persons who did not meet the 1987 AIDS case definition, 30% of those with an available CD4+ lymphocyte count had fewer CD4+ cells than 0.20 x 10(9)/L, 8% had one or more major infectious diseases, and 14% had one or more hospital admissions. Conclusions.-For every person with AIDS at these sites, two additional persons with HIV infection were receiving medical care, many of whom had severe immunosuppression and a broad spectrum of serious HIV-related disease.	LOS ANGELES CTY DEPT HLTH,LOS ANGELES,CA; GEORGIA DEPT HUMAN RESOURCES,ATLANTA,GA; SEATTLE KING CTY DEPT PUBL HLTH,SEATTLE,WA 98104; TEXAS DEPT HLTH,AUSTIN,TX; MICHIGAN DEPT PUBL HLTH,DETROIT,MI; DENVER DEPT HLTH & HOSP,DENVER,CO; LOUISIANA DEPT HLTH & HOSP,NEW ORLEANS,LA; HLTH & HUMAN SERV DEPT,HOUSTON,TX	Texas Department of State Health Services; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	FARIZO, KM (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,SURVEILLANCE BRANCH,ATLANTA,GA 30333, USA.		Hopkins, Sharon E E/GYV-4926-2022; Buehler, James/B-8419-2014	Hopkins, Sharon E E/0000-0002-2175-4202; 				AMES ED, 1991, HEMATOL ONCOL CLIN N, V5, P343, DOI 10.1016/S0889-8588(18)30446-5; BIGGAR RJ, 1987, AM J EPIDEMIOL, V126, P578, DOI 10.1093/oxfordjournals.aje.a114697; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P92; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; CARPENTER CCJ, 1991, MEDICINE, V70, P307, DOI 10.1097/00005792-199109000-00003; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Cohn D L, 1991, Infect Dis Clin North Am, V5, P485; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FELS AOS, 1988, CLIN CHEST MED, V9, P449; FERNANDEZCRUZ E, 1990, AIDS, V4, P987, DOI 10.1097/00002030-199010000-00007; FRIESE K, 1989, GEBURTSH FRAUENHEILK, V49, P385, DOI 10.1055/s-2008-1026605; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GREENBERG AE, 1991, 7TH P INT C AIDS FLO; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; HARNLY ME, 1988, AM J EPIDEMIOL, V128, P261, DOI 10.1093/oxfordjournals.aje.a114966; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P15; IMAM N, 1990, AM J MED, V89, P142, DOI 10.1016/0002-9343(90)90291-K; KRISTAL AR, 1988, AM J EPIDEMIOL, V128, P711, DOI 10.1093/oxfordjournals.aje.a115024; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; NICHOLSON JKA, 1989, AIDS RES HUM RETROV, V5, P205, DOI 10.1089/aid.1989.5.205; PALEFSKY J, 1991, HEMATOL ONCOL CLIN N, V5, P357, DOI 10.1016/S0889-8588(18)30447-7; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SCHAFER A, 1991, AM J OBSTET GYNECOL, V164, P593, DOI 10.1016/S0002-9378(11)80029-3; SCHRAGER LK, 1988, AIDS, V2, pS183, DOI 10.1097/00002030-198800001-00027; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; STEIN J, 1991, 7TH P INT C AIDS FLO; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P1141; TIRELLI U, 1988, CANCER DETECT PREV, V12, P267; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WILKINSON M, 1990, J UROLOGY, V144, P1157, DOI 10.1016/S0022-5347(17)39680-5; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; 1986, MMWR, V35, P587; 1987, MMWR, V36, P785; 1992, HIV AIDS SURVEILLANC, P1; 1987, MMWR, V36, pS3; 1991, 1992 REVISED CLASSIF; 1987, MMWR, V36, P133; 1990, MMWR, V39, P846	47	272	274	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1798	1805		10.1001/jama.267.13.1798	http://dx.doi.org/10.1001/jama.267.13.1798			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1347573				2022-12-28	WOS:A1992HK67200030
J	TAM, JY; BLUME, KG; PROBER, CG				TAM, JY; BLUME, KG; PROBER, CG			PROPHYLACTIC FLUCONAZOLE AND CANDIDA-KRUSEI INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											TAM, JY (corresponding author), STANFORD UNIV,MED CTR,STANFORD,CA 94305, USA.			Solary, Eric/0000-0002-8629-1341				WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803	1	15	15	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					891	891						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK523	1343806				2022-12-28	WOS:A1992HK52300015
J	KUEHN, MJ; HEUSER, J; NORMARK, S; HULTGREN, SJ				KUEHN, MJ; HEUSER, J; NORMARK, S; HULTGREN, SJ			P PILI IN UROPATHOGENIC ESCHERICHIA-COLI ARE COMPOSITE FIBERS WITH DISTINCT FIBRILLAR ADHESIVE TIPS	NATURE			English	Article							CLATHRIN LATTICE MORPHOLOGY; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CYTOPLASMIC ACIDIFICATION; RECEPTOR-BINDING; PAP PILI; SUBUNIT; PROTEIN; LOCALIZATION; BIOGENESIS	ESCHERICHIA coli is a frequent cause of several common bacterial infections in humans and animals, including urinary tract infections, bacteraemia and bacteria-related diarrhoea and is also the main cause of neonatal meningitis 1. Microbial attachment to surfaces is a key event in colonization and infection and results mainly from a stereochemical fit between microbial adhesins and complementary receptors on host cells. Bacterial adhesins required for, extracellular colonization by Gram-negative bacteria are often minor components of heteropolymeric fibres called pili which must be oriented in an accessible manner in these structures to be able to bind to specific receptor architectures. P pili mediate the binding of uropathogenic E. coli to a digalactoside receptor determinant present in the urinary tract epithelium. We report here that the adhesin is a component of distinct fibrillar structures present at the tips of the pili. These virulence-associated tip fibrillae are thin, flexible polymers composed mostly of repeating subunits of PapE that frequently terminate with the alpha-D-galactopyranosyl-(1-4)-beta-D-galactopyranose or Gal-alpha(1-4)Gal binding PapG adhesin.	WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, BOX 8230, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Kuehn, Meta/AAL-2950-2021	Kuehn, Meta/0000-0003-0519-3019				BAGA M, 1987, CELL, V49, P241, DOI 10.1016/0092-8674(87)90565-4; BAGA M, 1984, J BACTERIOL, V157, P330; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; DEGRAAF FK, 1986, ADV MICROB PHYSIOL, V28, P65; DEGRAAF FK, 1981, INFECT IMMUN, V33, P877, DOI 10.1128/IAI.33.3.877-883.1981; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOLMGREN A, IN PRESS EMBO J; HOSCHUTZKY H, 1989, INFECT IMMUN, V57, P76; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; Hultgren SJ, 1991, CURR OPIN GENET DEV, V1, P313, DOI 10.1016/S0959-437X(05)80293-X; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; JACOBS AAC, 1987, J BACTERIOL, V169, P735, DOI 10.1128/jb.169.2.735-741.1987; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LINDBERG F, 1986, P NATL ACAD SCI USA, V83, P1891, DOI 10.1073/pnas.83.6.1891; LINDBERG F, 1987, THESIS UMEA U; LINDBERG FP, 1984, EMBO J, V3, P1167, DOI 10.1002/j.1460-2075.1984.tb01946.x; NORGREN M, 1987, MOL MICROBIOL, V1, P169, DOI 10.1111/j.1365-2958.1987.tb00509.x; RIEDE I, 1987, J MOL BIOL, V194, P23, DOI 10.1016/0022-2836(87)90712-1; ROOSENDAAL B, 1984, FEMS MICROBIOL LETT, V22, P253; WARD S, 1970, J MOL BIOL, V54, P15, DOI 10.1016/0022-2836(70)90443-2; WESTERLUND B, 1991, MOL MICROBIOL, V5, P2965, DOI 10.1111/j.1365-2958.1991.tb01856.x	28	269	282	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1992	356	6366					252	255		10.1038/356252a0	http://dx.doi.org/10.1038/356252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1348107				2022-12-28	WOS:A1992HJ94400062
J	PRANDONI, P; LENSING, AWA; BULLER, HR; CARTA, M; COGO, A; VIGO, M; CASARA, D; RUOL, A; TENCATE, JW				PRANDONI, P; LENSING, AWA; BULLER, HR; CARTA, M; COGO, A; VIGO, M; CASARA, D; RUOL, A; TENCATE, JW			COMPARISON OF SUBCUTANEOUS LOW-MOLECULAR-WEIGHT HEPARIN WITH INTRAVENOUS STANDARD HEPARIN IN PROXIMAL DEEP-VEIN THROMBOSIS	LANCET			English	Article							VENOUS THROMBOSIS; INITIAL TREATMENT; DIAGNOSIS; WARFARIN		UNIV AMSTERDAM, ACAD MED CTR, CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, F4-237, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV HOSP PADUA, DEPT INTERNAL MED 2, PADUA, ITALY; UNIV HOSP PADUA, SERV RADIOL 2, PADUA, ITALY; UNIV HOSP PADUA, SERV NUCL MED, PADUA, ITALY	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; Azienda Ospedaliera - Universita di Padova			Carta, Mariarosa/ABF-9677-2021	Carta, Mariarosa/0000-0002-7143-4928				ALBADA J, 1989, CIRCULATION, V80, P935, DOI 10.1161/01.CIR.80.4.935; BRANDJES DPM, 1991, THROMB HAEMOSTASIS, V65, P703; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; BRIANT L, 1989, THROMB HAEMOSTASIS, V61, P348; DUROUX P, 1991, THROMB HAEMOSTASIS, V65, P251; FRYDMAN AM, 1988, J CLIN PHARMACOL, V28, P609, DOI 10.1002/j.1552-4604.1988.tb03184.x; GALLUS A, 1986, LANCET, V2, P1293; GALLUS AS, 1989, SEMIN THROMB HEMOST, V15, P99, DOI 10.1055/s-2007-1002692; GITEL SN, 1979, J LAB CLIN MED, V94, P481; HANDELAND GF, 1990, EUR J CLIN PHARMACOL, V39, P107, DOI 10.1007/BF00280041; HIRSH J, 1992, BLOOD, V79, P1; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HIRSH J, 1990, ACTA CHIR SCAND, P42; HIRSH J, 1987, HEMOSTASIS THROMBOSI, P1266; HOLM HA, 1986, HAEMOSTASIS, V16, P30; HOMANS J, 1973, AM J SURG, V38, P316; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; LENSING AWA, 1992, THROMB HAEMOSTASIS, V67, P8; LENSING AWA, 1990, ANN INTERN MED, V113, P9, DOI 10.7326/0003-4819-113-1-9; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1991, THROMB HAEMOSTASIS, V65, P1171; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; MARDER VJ, 1977, J LAB CLIN MED, V89, P1018; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P229; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; SALZMAN EW, 1986, NEW ENGL J MED, V315, P957, DOI 10.1056/NEJM198610093151509; THOMAS DG, 1977, J AM STAT ASSOC, V72, P73, DOI 10.2307/2286908	29	556	565	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 22	1992	339	8791					441	445		10.1016/0140-6736(92)91054-C	http://dx.doi.org/10.1016/0140-6736(92)91054-C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346817				2022-12-28	WOS:A1992HE93200001
J	OS, I; BRATLAND, B; DAHLOF, B; GISHOLT, K; SYVERTSEN, JO; TRETLI, S				OS, I; BRATLAND, B; DAHLOF, B; GISHOLT, K; SYVERTSEN, JO; TRETLI, S			FEMALE SEX AS AN IMPORTANT DETERMINANT OF LISINOPRIL-INDUCED COUGH	LANCET			English	Letter							ENALAPRIL		GRANGARDEN MED CTR,ARENDAL,NORWAY; OSTRA HOSP,S-41685 GOTHENBURG,SWEDEN; OREASEN MED CTR,MOSS,NORWAY	Sahlgrenska University Hospital	OS, I (corresponding author), ULLEVAL HOSP,DEPT NEPHROL,OSLO 1,NORWAY.							COULTER DM, 1987, BRIT MED J, V294, P1521, DOI 10.1136/bmj.294.6586.1521; GIBSON GR, 1989, ARCH INTERN MED, V149, P2701, DOI 10.1001/archinte.149.12.2701; OS I, 1991, J HYPERTENS, V9, P1097; YEO WW, 1991, BRIT J CLIN PHARMACO, V31, P356, DOI 10.1111/j.1365-2125.1991.tb05544.x	4	56	59	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					372	372		10.1016/0140-6736(92)91694-4	http://dx.doi.org/10.1016/0140-6736(92)91694-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346451				2022-12-28	WOS:A1992HC77100053
J	BUXTON, J; SHELBOURNE, P; DAVIES, J; JONES, C; VANTONGEREN, T; ASLANIDIS, C; DEJONG, P; JANSEN, G; ANVRET, M; RILEY, B; WILLIAMSON, R; JOHNSON, K				BUXTON, J; SHELBOURNE, P; DAVIES, J; JONES, C; VANTONGEREN, T; ASLANIDIS, C; DEJONG, P; JANSEN, G; ANVRET, M; RILEY, B; WILLIAMSON, R; JOHNSON, K			DETECTION OF AN UNSTABLE FRAGMENT OF DNA SPECIFIC TO INDIVIDUALS WITH MYOTONIC-DYSTROPHY	NATURE			English	Article							CHROMOSOME-19; REGION; LOCUS; GENE; IDENTIFICATION; LINKAGE; MARKERS; MAP; 19Q	MYOTONIC dystrophy (DM) is the most common form of adult muscular dystrophy, with a prevalence of 2-14 per 100,000 individuals 1. The disease is characterized by progressive muscle weakness and sustained muscle contraction, often with a wide range of accompanying symptoms. The age at onset and severity of the disease show extreme variation, both within and between families. Despite its clinical variability, this dominant condition segregates as a single locus at chromosome 19q13.3 in every population studied 1. It is flanked by the tightly linked genetic markers ERCC1 proximally 2,3 and D19S51 distally 4,5; these define the DM critical region. We report the isolation of an expressed sequence from this region which detects a DNA fragment that is larger in affected individuals than in normal siblings or unaffected controls. The size of this fragment varies between affected siblings, and increases in size through generations in parallel with increasing severity of the disease. We postulate that this unstable DNA sequence is the molecular feature that underlies DM.	CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,FULHAM PALACE RD,LONDON W6 8RF,ENGLAND; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,LIVERMORE,CA 94550; CATHOLIC UNIV NIJMEGEN,FAC MED SCI,DEPT CELL BIOL & HISTOL,6500 HB NIJMEGEN,NETHERLANDS; KAROLINSKA HOSP,DEPT CLIN GENET,S-10401 STOCKHOLM 60,SWEDEN; ST MARYS HOSP,IMPERIAL COLL,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND	Imperial College London; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Radboud University Nijmegen; Karolinska Institutet; Karolinska University Hospital; Imperial College London			Buxton, Jessica L/I-4033-2014; Buxton, Jessica/L-9849-2019; Jansen, Gert/HCI-8852-2022	Buxton, Jessica L/0000-0002-0918-9335; Jansen, Gert/0000-0002-7524-171X; johnson, keith/0000-0002-8578-5921				ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BROOK JD, 1986, CYTOGENET CELL GENET, V41, P30, DOI 10.1159/000132192; BROOK JD, 1991, J MED GENET, V28, P84, DOI 10.1136/jmg.28.2.84; BROOK JD, IN PRESS GENOMICS; BRUNNER HG, 1989, GENOMICS, V5, P589, DOI 10.1016/0888-7543(89)90027-X; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; FU YH, 1991, CELL, V67, P1; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; JOHNSON K, 1989, GENOMICS, V5, P746, DOI 10.1016/0888-7543(89)90116-X; KOCH MC, 1991, AM J HUM GENET, V48, P1084; KORNELUK RG, 1989, GENOMICS, V5, P596, DOI 10.1016/0888-7543(89)90028-1; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; SCHONK D, 1989, GENOMICS, V4, P384, DOI 10.1016/0888-7543(89)90346-7; SHUTLER, 1991, GENOMICS, V9, P500; SMEETS H, 1990, AM J HUM GENET, V46, P492; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; STALLINGS RL, 1988, AM J HUM GENET, V43, P144; TSILFIDIS C, 1991, AM J HUM GENET, V49, P961; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	27	584	606	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					547	548		10.1038/355547a0	http://dx.doi.org/10.1038/355547a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1346924				2022-12-28	WOS:A1992HC52600059
J	GARDOSI, J; CHANG, A; KALYAN, B; SAHOTA, D; SYMONDS, EM				GARDOSI, J; CHANG, A; KALYAN, B; SAHOTA, D; SYMONDS, EM			CUSTOMIZED ANTENATAL GROWTH CHARTS	LANCET			English	Article							GESTATIONAL AGE INFANTS; BIRTH-WEIGHT; FETAL GROWTH; ULTRASOUND; STANDARDS; MORTALITY; WHITE	Charts for fetal growth do not take physiological variables into account. We have therefore designed a computer-generated antenatal chart that can be easily "customised" for each individual pregnancy, taking the mother's characteristics and birthweights from previous pregnancies into consideration. The adjusted birthweight range expected at 40 weeks' gestation is combined with a standard, longitudinal ultrasound-derived curve for intrauterine weight gain. Review at the Queen's Medical Centre, Nottingham, UK, of 4179 pregnancies with ultrasound-confirmed dates showed that, in addition to gestation and sex, maternal weight at first antenatal-clinic visit, height, ethnic group, and parity were significant determinants of birthweight in our population. Correction factors were calculated for each of these variables and entered into a computer program to adjust the normal birthweight centile limits. With adjusted centiles we found that 28% of babies conventionally designated small for gestational age (< 10th centile) and 22% of those designated large (> 90th centile) were in fact within normal limits for the pregnancy. Conversely, 24% and 26% of babies identified as small or large, respectively, with adjusted centiles were "missed" by conventional unadjusted centile assessment. Adjustment for physiological variables will make assessment of fetal growth more precise and reduce unnecessary investigations, interventions, and parental anxiety.			GARDOSI, J (corresponding author), QUEENS MED CTR,DEPT OBSTET & GYNAECOL,PERINATAL RES & MONITORING UNIT,NOTTINGHAM NG7 2UH,ENGLAND.		Gardosi, Jason/GXN-1375-2022; Chang, Allan M/B-1882-2009	Gardosi, Jason/0000-0002-3230-1292				ALBERMAN E, 1991, J ROY SOC MED, V84, P257, DOI 10.1177/014107689108400505; ALTMAN DG, 1980, BRIT J OBSTET GYNAEC, V87, P81, DOI 10.1111/j.1471-0528.1980.tb04498.x; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; CAMPBELL S, 1975, BRIT J OBSTET GYNAEC, V82, P689, DOI 10.1111/j.1471-0528.1975.tb00708.x; DAWSON I, 1982, BRIT J OBSTET GYNAEC, V89, P896, DOI 10.1111/j.1471-0528.1982.tb05053.x; DETER RL, 1982, J CLIN ULTRASOUND, V10, P365, DOI 10.1002/jcu.1870100804; DETER RL, 1989, J CLIN ULTRASOUND, V17, P83, DOI 10.1002/jcu.1870170203; EVANS T, 1990, CLIN APPLICATION ULT; GRUNDY MFB, 1978, BRIT J OBSTET GYNAEC, V85, P481, DOI 10.1111/j.1471-0528.1978.tb15618.x; HILL LM, 1986, J CLIN ULTRASOUND, V14, P171, DOI 10.1002/jcu.1870140303; MATHAI M, 1987, BRIT J OBSTET GYNAEC, V94, P217, DOI 10.1111/j.1471-0528.1987.tb02357.x; MCFADYEN IR, 1984, BRIT J OBSTET GYNAEC, V91, P968, DOI 10.1111/j.1471-0528.1984.tb03672.x; MEIRE HB, 1981, BRIT J OBSTET GYNAEC, V88, P260, DOI 10.1111/j.1471-0528.1981.tb00979.x; NORTH AF, 1977, J PEDIATR-US, V90, P809, DOI 10.1016/S0022-3476(77)81258-4; PEARCE JM, 1987, BRIT J OBSTET GYNAEC, V94, P100, DOI 10.1111/j.1471-0528.1987.tb02333.x; THOMSON A M, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P903; TUCK SM, 1983, BRIT J OBSTET GYNAEC, V90, P892, DOI 10.1111/j.1471-0528.1983.tb06759.x; WILCOX AJ, 1981, AM J OBSTET GYNECOL, V139, P863, DOI 10.1016/0002-9378(81)90950-9; YUDKIN PL, 1983, BRIT J OBSTET GYNAEC, V90, P291, DOI 10.1111/j.1471-0528.1983.tb08912.x	19	600	605	0	22	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					283	287		10.1016/0140-6736(92)91342-6	http://dx.doi.org/10.1016/0140-6736(92)91342-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346292				2022-12-28	WOS:A1992HB52900014
J	HORINA, JH; HOLZER, H; REISINGER, EC; KREJS, GJ; NEUGEBAUER, JS				HORINA, JH; HOLZER, H; REISINGER, EC; KREJS, GJ; NEUGEBAUER, JS			ELDERLY PATIENTS AND CHRONIC-HEMODIALYSIS	LANCET			English	Letter									KRANKENHAUS WIENER NEUSTADT,WIENER NEUSTADT,GERMANY		HORINA, JH (corresponding author), GRAZ UNIV,DEPT MED,A-8036 GRAZ,AUSTRIA.							HORINA JH, 1991, NEPHRON, V58, P407, DOI 10.1159/000186471; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; KILNER JF, 1990, AM J KIDNEY DIS, V15, P218, DOI 10.1016/S0272-6386(12)80766-9; Kjellstrand C M, 1988, Acta Med Scand Suppl, V725, P1; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; 1984, LANCET, V1, P717	6	16	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					183	183		10.1016/0140-6736(92)90251-W	http://dx.doi.org/10.1016/0140-6736(92)90251-W			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346036				2022-12-28	WOS:A1992GZ96800039
J	THANOS, D; MANIATIS, T				THANOS, D; MANIATIS, T			THE HIGH MOBILITY GROUP PROTEIN HMG-I(Y) IS REQUIRED FOR NF-KAPPA-B-DEPENDENT VIRUS INDUCTION OF THE HUMAN IFN-BETA GENE	CELL			English	Article							DNA-BINDING PROTEIN; INTERFERON GENE; HMG-I; NUCLEAR FACTOR; CHROMOSOMAL-PROTEINS; REGULATORY ELEMENTS; INDUCIBLE ENHANCER; ESCHERICHIA-COLI; MAMMALIAN-CELLS; RNA-POLYMERASE	In this paper, we show that both NF-kappaB and the high mobility group protein I(Y) (HMG I(Y)) are required for virus induction of the human interferon-beta (IFN-beta) gene. NF-kappaB binds to the terminal regions of a 10 bp regulatory sequence through contacts in the major groove, while HMG I(Y) recognizes the central region of the same sequence through contacts in the minor groove. Mutations that interfere with binding of either protein decrease the level of virus induction, and activation of the gene can be blocked by either NF-kappaB or HMG I(Y) antisense RNA. HMG I(Y) stimulates the binding of NF-kappaB to the IFN-beta promoter, and it may also function as a promoter-specific accessory factor for NF-kappaB transcriptional activity.			THANOS, D (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Thanos, Dimitris/AAE-5720-2019		NIAID NIH HHS [AI20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020642, R37AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1990, HORMONAL CONTROL REG, P423; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Demaeyer E., 1988, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FASHENA ST, 1991, MOL CELL BIOL, V12, P894; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1992, IN PRESS INT REV EXP; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEHN DA, 1988, BIOCHEM INT, V16, P963; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Maniatis T., 1982, MOL CLONING; MANIATIS T, 1992, IN PRESS TRANSCRIPTI; MAUXION F, 1991, P NATL ACAD SCI USA, V88, P2141, DOI 10.1073/pnas.88.6.2141; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOLITOR JA, 1991, NEW BIOL, V3, P987; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; REEVES R, 1990, J BIOL CHEM, V265, P8573; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URBAN MB, 1991, NEW BIOL, V3, P279; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VILCEK J, 1990, HDB EXPT PHARM, V95, P1; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEGNER M, 1989, NUCLEIC ACIDS RES, V17, P9909, DOI 10.1093/nar/17.23.9909; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406; ZABEL U, 1991, J BIOL CHEM, V266, P252	65	609	613	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 27	1992	71	5					777	789		10.1016/0092-8674(92)90554-P	http://dx.doi.org/10.1016/0092-8674(92)90554-P			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330326				2022-12-28	WOS:A1992JZ63300008
J	INOSTROZA, JA; MERMELSTEIN, FH; HA, I; LANE, WS; REINBERG, D				INOSTROZA, JA; MERMELSTEIN, FH; HA, I; LANE, WS; REINBERG, D			DR1, A TATA-BINDING PROTEIN ASSOCIATED PHOSPHOPROTEIN AND INHIBITOR OF CLASS-II GENE-TRANSCRIPTION	CELL			English	Article								We have discovered a protein termed Dr1 that interacts with the TATA-binding protein, TBP. The association of Dr1 with TBP results in repression of both basal and activated levels of transcription. The interaction of Dr1 with TBP precludes the formation of a transcription-competent complex by inhibiting the association of TFIIA and/or TFIIB with TBP. Dr1 activity is associated with a 19 kd protein. A cDNA clone encoding Dr1 was isolated. Dr1 is phosphorylated in vivo and phosphorylation of Dr1 affected its interaction with TBP. Our results suggest a regulatory role for Dr1 in repression of transcription mediated via phosphorylation.			INOSTROZA, JA (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA.			Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037120, R37GM037120] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FLORES O, 1992, J BIOL CHEM, V267, P2786; GILL G, 1992, IN PRESS CURR OPIN G; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; ZAWEL L, 1992, IN PRESS PROG NUCL A	45	338	342	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					477	489						13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1339312				2022-12-28	WOS:A1992JH12400013
J	LIFSON, AR; HESSOL, NA; BUCHBINDER, SP; OMALLEY, PM; BARNHART, L; SEGAL, M; KATZ, MH; HOLMBERG, SD				LIFSON, AR; HESSOL, NA; BUCHBINDER, SP; OMALLEY, PM; BARNHART, L; SEGAL, M; KATZ, MH; HOLMBERG, SD			SERUM BETA-2-MICROGLOBULIN AND PREDICTION OF PROGRESSION TO AIDS IN HIV-INFECTION	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; BISEXUAL MEN; ACTIVATION; MARKERS; ANTIGEN; FOLLOW; COHORT; TYPE-1; COUNT; LEVEL	Identification of laboratory tests that can help predict progression to acquired immunodeficiency syndrome (AIDS) in people infected with human immunodeficiency virus (HIV) is important for clinical management and counselling. We have assessed the usefulness of CD4 lymphocyte count, serum beta-2-microglobulin concentration, and the presence of p24 antigen as predictors of AIDS. We studied 214 homosexual and bisexual men with well-defined dates of HIV seroconversion. For each participant we defined the baseline date as the earliest date before the development of AIDS on which the three laboratory tests were done. beta-2-microglobulin concentration at baseline was in all analyses an independent predictor of AIDS, even after stratification by baseline CD4 count, duration of HIV infection, or use of zidovudine before or at baseline. For example, among men with at least 0.5 x 10(9)/l CD4 cells who were negative for p24 antigen, the risks of AIDS at 12 months and 24 months were 1% and 5%, respectively, for those whose beta-2-microglobulin concentrations were below 4.0 mg/l, compared with 17% and 27%, respectively for those with beta-2-microglobulin concentrations above that cut-off point (p<0.001). Among men with an estimated duration of infection of 5 years or less, beta-2-microglobulin concentration was the strongest independent predictor of AIDS. Measurement of serum beta-2-microglobulin adds important prognostic information to CD4 count in determining the risk of progression to AIDS in HIV-infected subjects, including those whose CD4 cell count has not yet fallen.	DEPT PUBL HLTH,AIDS PROGRAM,SAN FRANCISCO,CA; CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	LIFSON, AR (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,BOX 0560,SAN FRANCISCO,CA 94143, USA.				PHS HHS [U62/CCU900523-03-5] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; BASS HZ, 1992, J ACQ IMMUN DEF SYND, V5, P215; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FLEGG PJ, 1991, AIDS, V5, P1021, DOI 10.1097/00002030-199108000-00015; GALLO D, 1986, J CLIN MICROBIOL, V23, P1049, DOI 10.1128/JCM.23.6.1049-1051.1986; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; HESSOL NA, 1992, AM J PUBLIC HEALTH, V82, P561, DOI 10.2105/AJPH.82.4.561; HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005; JACOBSON MA, 1989, J INFECT DIS, V159, P1029, DOI 10.1093/infdis/159.6.1029; JACOBSON MA, 1991, BRIT MED J, V302, P73, DOI 10.1136/bmj.302.6768.73; JORGENSEN AF, 1990, AIDS, V4, P1168; KIN K, 1979, IMMUNOLOGY, V36, P47; LAURENCE J, 1990, J INFECT DIS, V162, P338, DOI 10.1093/infdis/162.2.338; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PEDERSEN C, 1987, BRIT MED J, V295, P567, DOI 10.1136/bmj.295.6598.567; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZANGERLE R, 1991, AIDS, V5, P985, DOI 10.1097/00002030-199108000-00010; 1989, MMWR, V38, P1	25	83	88	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1436	1440		10.1016/0140-6736(92)92030-J	http://dx.doi.org/10.1016/0140-6736(92)92030-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351128				2022-12-28	WOS:A1992HY31700003
J	HALL, A; ANWAR, KS; TOMKINS, AM				HALL, A; ANWAR, KS; TOMKINS, AM			INTENSITY OF REINFECTION WITH ASCARIS-LUMBRICOIDES AND ITS IMPLICATIONS FOR PARASITE CONTROL	LANCET			English	Article							HELMINTH INFECTIONS; SCHISTOSOMA-MANSONI; PREDISPOSITION; HEALTH; HUMANS	Intestinal helminths are among the most common and widespread of human infections. Because it is typical to find that most worms are aggregated in a few potential hosts it has been suggested that some individuals are predisposed to heavy infections and that morbidity could be controlled by the treatment of heavily infected individuals only. We have studied the prevalence and intensity of reinfection with the intestinal nematode Ascaris lumbricoides among people living in Dhaka, Bangladesh. 880 people were treated with pyrantel pamoate three times at six month intervals, and on each occasion they collected all their stools for 48 h after treatment. Worms expelled by each subject were counted and weighed. The prevalence of infection at round 1 of treatment was 89% and the mean burden was 18.5 worms. Reinfection was rapid and at rounds 2 and 3 the prevalence was 82% and 80%, respectively, with mean burdens of 14.0 and 11.5 worms. The intensity of reinfection was not random more subjects than expected became heavily reinfected (greater-than-or-equal-to 15 worms) and more subjects than expected remained lightly infected (less-than-or-equal-to 14 worms) (p < 0.001). Worms were highly aggregated at each round of treatment but although just over 10% of all subjects were heavily infected at each and every round of treatment, over 60% of all subjects were heavily infected at least once. The findings show that some individuals seem to be susceptible to heavy infection whereas others are not, that deworming has a greater effect on the intensity of infection than on the prevalence, and that mass chemotherapy is likely to be a more effective means to control morbidity than is selective treatment of heavily infected individuals only.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL,PRINCE CONSORT RD, LONDON SW7 2BB, ENGLAND; INT CTR DIARRHOEL DIS RES, DHAKA 1000, BANGLADESH; INST PUBL HLTH, DHAKA 1212, BANGLADESH; INST CHILD HLTH, CTR INT CHILD HLTH, LONDON WC1N 1EH, ENGLAND	Imperial College London; International Centre for Diarrhoeal Disease Research (ICDDR); University of London; University College London				Anwar, Kazi Selim/0000-0002-6001-6616; Selim Anwar, Kazi/0000-0002-3437-4014				Anderson R.M., 1982, P204; ANDERSON R M, 1991; ANDERSON RM, 1985, PARASITOLOGY, V90, P629, DOI 10.1017/S0031182000052288; ANDERSON RM, 1982, NATURE, V297, P557, DOI 10.1038/297557a0; BENSTEDSMITH R, 1987, T ROY SOC TROP MED H, V81, P651, DOI 10.1016/0035-9203(87)90442-1; Gustafsson LL, 1987, HDB DRUGS TROPICAL P; HALL A, 1981, T ROY SOC TROP MED H, V75, P682, DOI 10.1016/0035-9203(81)90148-6; HASWELLELKINS MR, 1987, PARASITOLOGY, V95, P323, DOI 10.1017/S0031182000057772; James DM, 1985, HUMAN ANTIPARASITIC; KEYMER A, 1990, HOOKWORM DISEASE : CURRENT STATUS AND NEW DIRECTIONS, P177; Pawlowski Z. S., 1990, Tropical and Geographical Medicine., P369; SINNIAH B, 1981, ANN TROP MED PARASIT, V75, P315, DOI 10.1080/00034983.1981.11687445; THIENHLAING, 1985, ASCARIASIS ITS PUBLI, P83; TINGLEY GA, 1988, T ROY SOC TROP MED H, V82, P448, DOI 10.1016/0035-9203(88)90159-9; WAKELIN D, 1984, IMMUNITY PARASITES; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; Warren K. S., 1990, Tropical and Geographical Medicine., P110; WARREN KS, 1991, LANCET, V338, P686, DOI 10.1016/0140-6736(91)91251-O; 1990, WHO MODEL PRESCRIBIN	19	68	72	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	1992	339	8804					1253	1257		10.1016/0140-6736(92)91593-W	http://dx.doi.org/10.1016/0140-6736(92)91593-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349668				2022-12-28	WOS:A1992HV19100003
J	PAN, MG; FLORIO, T; STORK, PJS				PAN, MG; FLORIO, T; STORK, PJS			G-PROTEIN ACTIVATION OF A HORMONE-STIMULATED PHOSPHATASE IN HUMAN TUMOR-CELLS	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; MIA PACA-2; DEPHOSPHORYLATION	The growth-inhibiting peptide hormone somatostatin stimulates phosphotyrosine phosphatase activity in the human pancreatic cell line MIA PaCa-2. This hormonal activation was mediated by a pertussis toxin-sensitive guanosine 5'-triphosphate-binding protein (G protein) in the membranes of these cells. Activation of this G protein by somatostatin stimulated the dephosphorylation of exogenous epidermal growth factor receptor prepared from A-431 cells in vitro. This pathway may mediate the antineoplastic action of somatostatin in these cells and in human tumors and could represent a general mechanism of G protein coupling Mat is utilized by normal cells in the hormonal control of cell growth.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, L474, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			FLORIO, TULLIO/ABG-3182-2020; Florio, Tullio/A-2211-2012	Florio, Tullio/0000-0002-2394-996X				BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; CIRILLO D, 1988, MOL CELL BIOL, V6, P4641; COHEN S, 1982, J BIOL CHEM, V257, P1523; CUI Z, 1991, J BIOL CHEM, V266, P20276; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HIEROWSKI MT, 1985, FEBS LETT, V179, P252, DOI 10.1016/0014-5793(85)80529-9; INGEBRITSEN TS, 1989, J BIOL CHEM, V264, P7754; JARVIS MF, 1991, 21ST ANN M SOC NEUR, P45; KARLUND JK, 1985, CELL, V41, P707; LIEBOW C, 1991, P NATL ACAD SCI USA, V88, P2244, DOI 10.1073/pnas.88.6.2244; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; Pan M.-L., UNPUB; STORK PJS, UNPUB; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; YUNIS AA, 1977, INT J CANCER, V19, P128, DOI 10.1002/ijc.2910190118; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	21	232	235	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1992	256	5060					1215	1217		10.1126/science.256.5060.1215	http://dx.doi.org/10.1126/science.256.5060.1215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1350382				2022-12-28	WOS:A1992HV19200040
J	ROSS, RK; YUAN, JM; YU, MC; WOGAN, GN; QIAN, GS; TU, JT; GROOPMAN, JD; GAO, YT; HENDERSON, BE				ROSS, RK; YUAN, JM; YU, MC; WOGAN, GN; QIAN, GS; TU, JT; GROOPMAN, JD; GAO, YT; HENDERSON, BE			URINARY AFLATOXIN BIOMARKERS AND RISK OF HEPATOCELLULAR-CARCINOMA	LANCET			English	Article							HEPATITIS-B VIRUS; PRIMARY LIVER-CANCER; FREQUENCY; EXPOSURE; CHINA	Aflatoxins have long been suspected to be human hepatic carcinogens but no direct study was feasible until assays to measure individual aflatoxin exposure became available. We have used assays for urinary aflatoxin B1, its metabolites AFP1 and AFM1, and DNA-adducts (AFB1-N7-Gua) to assess the relation between aflatoxin exposure and liver cancer, as part of an ongoing prospective study of 18 244 middle-aged men in Shanghai, People's Republic of China. After 35 299 person-years of follow-up, 22 cases of liver cancer had been identified. For each case, 5 or 10 controls were randomly selected from cohort members without liver cancer on the date the disorder was diagnosed in the case and matched to within 1 year for age, within 1 month for sample collection, and for neighbourhood of residence. Subjects with liver cancer were more likely than were controls to have detectable concentrations of any of the aflatoxin metabolites (relative risk 2.4, 95% confidence interval 1.0-5.9). The highest relative risk was for aflatoxin P1 (6.2, 1.8-21.5). In an analysis adjusting for the effects of hepatitis B surface antigen seropositivity, level of education, cigarette smoking, and alcohol consumption, the relative risk for the presence of aflatoxin metabolites was 3-8 (1.2-12.2). There was a strong interaction between serological markers of chronic hepatitis B infection and aflatoxin exposure in liver-cancer risk. Reduction of aflatoxin exposure may be a useful intermediate goal in prevention of liver cancer, since the benefits of wide-scale hepatitis B vaccination will not be apparent for many years.	SHANGHAI CANC INST,SHANGHAI,PEOPLES R CHINA; MIT,DIV TOXICOL,CAMBRIDGE,MA 02139; JOHNS HOPKINS UNIV,DIV ENVIRONM CHEM & BIOL,BALTIMORE,MD 21218	Shanghai Jiao Tong University; Massachusetts Institute of Technology (MIT); Johns Hopkins University	ROSS, RK (corresponding author), UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,1441 EASTLAKE AVE,ROOM 803,LOS ANGELES,CA 90033, USA.		/X-4205-2019; Gao, Yu/HGE-1937-2022	/0000-0003-4690-2133; Yuan, Jian-Min/0000-0002-4620-3108	NCI NIH HHS [KO4 CA01517, R01 CA043092-20, CA 43092, R01 CA043092] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001517, R01CA043092] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALPERT ME, 1971, CANCER, V28, P253, DOI 10.1002/1097-0142(197107)28:1&lt;253::AID-CNCR2820280151&gt;3.0.CO;2-G; BLUMBERG BS, 1985, JNCI-J NATL CANCER I, V74, P267; Breslow N, 1980, STATISTICAL METHODS, V32; BULATAOJAYME J, 1982, INT J EPIDEMIOL, V11, P112, DOI 10.1093/ije/11.2.112; Busby W. F., 1985, CHEM CARCINOGENS, P945; CAMPBELL TC, 1990, CANCER RES, V50, P6882; CAMPBELL TC, 1991, CANCER RES, V51, P3826; GROOPMAN JD, 1985, P NATL ACAD SCI USA, V82, P6492, DOI 10.1073/pnas.82.19.6492; GROOPMAN JD, 1992, CANCER EPIDEM BIOMAR, V1, P221; GROOPMAN JD, 1992, CANCER RES, V52, P45; GROOPMAN JD, 1984, P NATL ACAD SCI-BIOL, V81, P7728, DOI 10.1073/pnas.81.24.7728; GROOPMAN JD, IN PRESS ENV HLTH PE; Groopman JD, 1991, MOL DOSIMETRY HUMAN, P303; LAM KC, 1982, CANCER RES, V42, P5246; LI J, 1979, ATLAS CANCER MORTALI, P39; MUIR C, 1987, CANCER 5 CONTINENTS, V5; NEWBERNE PM, 1969, CANCER RES, V29, P236; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PEERS F, 1987, INT J CANCER, V39, P545, DOI 10.1002/ijc.2910390502; WOGAN GN, 1967, CANCER RES, V27, P2370; Yeh F S, 1985, Natl Cancer Inst Monogr, V69, P47; YEH FS, 1989, CANCER RES, V49, P2506; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; 1987, IARC MONOGRAPHS EV S, V7, P83; 1983, LANCET, V1, P463	25	552	581	1	59	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					943	946		10.1016/0140-6736(92)91528-G	http://dx.doi.org/10.1016/0140-6736(92)91528-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348796				2022-12-28	WOS:A1992HP03600001
J	LEMOUELLIC, H; LALLEMAND, Y; BRULET, P				LEMOUELLIC, H; LALLEMAND, Y; BRULET, P			HOMEOSIS IN THE MOUSE INDUCED BY A NULL MUTATION IN THE HOX-3.1 GENE	CELL			English	Article							STEM-CELL LINES; HOMEOBOX GENE; HOMOLOGOUS RECOMBINATION; EXPRESSION PATTERN; HOMEOTIC GENES; SOMITIC MESODERM; MAMMALIAN-CELLS; FUSHI-TARAZU; DROSOPHILA; EMBRYO	We have replaced the Hox-3.1 coding sequence with the E. coli lacZ gene by means of homologous recombination in embryonic stem cells and thus produced null mutant mice. Homozygous mice were born alive, but most of them died within a few days. In the trunk region of homozygotes, several skeletal segments were transformed into the likeness of more anterior ones, as observed in Drosophila with loss-of-function homeotic mutations. The most obvious transformations were the attachment of the 8th pair of ribs to the sternum and the appearance of a 14th pair of ribs on the 1st lumbar vertebra. The pattern of beta-galactosidase activity was identical in heterozygotes and homozygotes and reflected faithfully the Hox-3.1 expression pattern. Thus, the mutation modified the identity, rather than the position, of embryonic cells that would normally express Hox-3.1.	INST PASTEUR,CNRS,URA 1148,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LEMOUELLIC, H (corresponding author), COLL FRANCE,UNITE GENET CELLULAIRE,25 RUE DOCTEUR ROUX,F-75231 PARIS 05,FRANCE.							AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AKAM M, 1988, DEVELOPMENT, V104, P123; AWGULEWITSCH A, 1990, P NATL ACAD SCI USA, V87, P6428, DOI 10.1073/pnas.87.16.6428; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BREIER G, 1988, EMBO J, V7, P1329, DOI 10.1002/j.1460-2075.1988.tb02948.x; CARROLL SB, 1988, GENE DEV, V2, P350, DOI 10.1101/gad.2.3.350; CHEN JM, 1953, J ANAT, V87, P130; CHEN JM, 1952, J ANAT, V86, P387; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COULY G, 1990, DEVELOPMENT, V108, P543; DALGLEISH AE, 1985, ACTA ANAT, V122, P91; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GRUNEBERG H, 1952, GENETICS MOUSE; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HOGAN B, 1986, MANIPULATING MOUSE E; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIENY M, 1972, DEV BIOL, V28, P142, DOI 10.1016/0012-1606(72)90133-9; KIMMEL CB, 1987, NATURE, V327, P234, DOI 10.1038/327234a0; LANCEJONES C, 1988, DEV BIOL, V126, P408, DOI 10.1016/0012-1606(88)90150-9; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MAUGER A, 1972, J EMBRYOL EXP MORPH, V28, P343; NODEN DM, 1988, DEVELOPMENT, V103, P121; OUDEJANS CBM, 1990, DEVELOPMENT, V108, P471; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918	57	316	321	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					251	264		10.1016/0092-8674(92)90406-3	http://dx.doi.org/10.1016/0092-8674(92)90406-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1348969				2022-12-28	WOS:A1992HQ18300005
J	MENDALL, MA; GOGGIN, PM; MOLINEAUX, N; LEVY, J; TOOSY, T; STRACHAN, D; NORTHFIELD, TC				MENDALL, MA; GOGGIN, PM; MOLINEAUX, N; LEVY, J; TOOSY, T; STRACHAN, D; NORTHFIELD, TC			CHILDHOOD LIVING-CONDITIONS AND HELICOBACTER-PYLORI SEROPOSITIVITY IN ADULT LIFE	LANCET			English	Note							INFECTION	Infection with Helicobacter pylori increases an individual's risk of peptic ulceration and gastric cancer. In the developed world, prevalence of infection rises with age and varies with social class. We used a cross-sectional study design to test the hypothesis that H pylori infection would be more closely associated with childhood living conditions than with current socioeconomic status. Prevalence of IgG antibodies against H pylori was determined with an enzyme-linked immunosorbent assay in 21 5 subjects (median age 46 years, range 18-82) attending a health-screening clinic in London. Seropositivity varied from 9% (age < 30) to 67% (greater-than-or-equal-to 70). Subjects were asked about their living conditions at present and when they were aged 8 years. Absence of a fixed hot-water supply (p = 0.0005) and domestic crowding (p = 0.0005) in childhood were powerful independent risk factors for current infection with H pylori. Among current living conditions, only the number of children living in the household was independently associated with H pylori infection (p = 0.004). Most British adults infected with H pylori probably became infected by household contact in childhood.	ST GEORGE HOSP,SCH MED,DEPT MED,DIV BIOCHEM MED,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND; THE PRACTICE,WALLINGTON,SURREY,ENGLAND	St Georges University London; St Georges University London								BACKETT EM, 1957, LANCET, V1, P778; BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; BARKER RJ, 1978, GLIM SYSTEM; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; JONES DM, 1987, BRIT MED J, V294, P615, DOI 10.1136/bmj.294.6572.615-a; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; SITAS F, 1991, GUT, V32, P25, DOI 10.1136/gut.32.1.25; SIURALA M, 1985, SCAND J GASTROENTERO, V20, P69, DOI 10.3109/00365528509103939	9	440	449	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					896	897		10.1016/0140-6736(92)90931-R	http://dx.doi.org/10.1016/0140-6736(92)90931-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348299				2022-12-28	WOS:A1992HN48300005
J	BERAL, V; BULL, D; DARBY, S; WELLER, I; CARNE, C; BEECHAM, M; JAFFE, H				BERAL, V; BULL, D; DARBY, S; WELLER, I; CARNE, C; BEECHAM, M; JAFFE, H			RISK OF KAPOSIS-SARCOMA AND SEXUAL PRACTICES ASSOCIATED WITH FECAL CONTACT IN HOMOSEXUAL OR BISEXUAL MEN WITH AIDS	LANCET			English	Article								The causal agent of Kaposi's sarcoma is unknown. That the disorder is ten times more common in homosexual or bisexual men with the acquired immunodeficiency syndrome (AIDS) than in other human immunodeficiency virus (HIV) transmission groups suggests that a certain aspect of their behaviour exposes them to the agent or facilitates its spread. We therefore assessed social and demographic characteristics, including sexual behaviour, of 65 homosexual or bisexual men with AIDS from London. Sexual practices in which there was contact with partner's faeces before AIDS developed were the main determinants of Kaposi's sarcoma risk. Risk increased with frequency of insertive "rimming" (oral-anal contact): Kaposi's sarcoma developed in 18% of the men with AIDS who reported never having practised insertive rimming compared with 50% who practised it less than once a month, 73% between once a week and once a month, and 75% or more once a week (two-sided exact p-value for trend < 0.001 ). 45 men had been interviewed about their sexual practices before AIDS developed, and 20 were interviewed at the time the syndrome developed. The findings were similar and statistically significant when each group was analysed separately. The men with Kaposi's sarcoma also tended to be more sexually active and were more likely to engage in other sexual activities that entailed contact with faeces than were the men who had other features of AIDS only. Other behaviours and exposures, including the use of "poppers" (nitrite inhalants), were not related to Kaposi's sarcoma risk, after taking into account whether the subjects had practised insertive rimming. The data suggest that faecal-oral contact is the main route of transmission of the agent of Kaposi's sarcoma in homosexual or bisexual men with AIDS.	UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON,ENGLAND	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	BERAL, V (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCHIBALD CP, 1990, J ACQ IMMUN DEF SYND, V3, pS18; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; CARNE CA, 1987, LANCET, V1, P656; DARROW WW, 1992, LANCET, P685; HAVERKOS HW, 1985, SEX TRANSM DIS, V12, P203, DOI 10.1097/00007435-198510000-00007; JACOBSEN L, 1990, 6TH INT C AIDS SAN F; JACOBSENLP, 1990, J ACQUIR IMMUNE D S1, V3, pS24; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; MOSS AR, 1987, AM J EPIDEMIOL, V125, P1035, DOI 10.1093/oxfordjournals.aje.a114619; 1986, ANN INTERN MED, V105, P231	12	178	185	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					632	635		10.1016/0140-6736(92)90793-3	http://dx.doi.org/10.1016/0140-6736(92)90793-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH743	1347337				2022-12-28	WOS:A1992HH74300002
J	JACOBSON, SJ; JONES, K; JOHNSON, K; CEOLIN, L; KAUR, P; SAHN, D; DONNENFELD, AE; RIEDER, M; SANTELLI, R; SMYTHE, J; PASTUSZAK, A; EINARSON, T; KOREN, G				JACOBSON, SJ; JONES, K; JOHNSON, K; CEOLIN, L; KAUR, P; SAHN, D; DONNENFELD, AE; RIEDER, M; SANTELLI, R; SMYTHE, J; PASTUSZAK, A; EINARSON, T; KOREN, G			PROSPECTIVE MULTICENTER STUDY OF PREGNANCY OUTCOME AFTER LITHIUM EXPOSURE DURING 1ST TRIMESTER	LANCET			English	Article								Lithium carbonate is an effective drug for prophylaxis and treatment of major affective disorders. In-utero exposure to lithium during the first trimester of pregnancy might be associated with an increased risk of cardiac malformations, especially the rare Ebstein's anomaly. We prospectively recruited and followed 148 women (mean age 30 years, SD 5 range 15-40) using lithium during the first trimester of pregnancy, who consulted four teratogen information centres in the USA and Canada. Pregnancy outcome was compared with that of controls matched for maternal age. We had complete follow-up of pregnancy outcome in 138 of 148 patients recruited. In the other 10, fetal echocardiograms were available but postnatal follow-up was not done. Mean daily dose of lithium was 927 mg (SD 340). Rates of major congenital malformations did not differ between the lithium (2.8%) and control (2.4%) groups. 1 patient in the lithium group chose to terminate pregnancy after Ebstein's anomaly was detected by a prenatal echocardiogram. There was 1 ventricular septal defect in the controls. Birthweight was significantly higher in the lithium-exposed infants than in the controls despite identical gestational ages (3475 [660] g vs 3383 [566] g, p = 0.02). The true difference in birthweight might have been even larger, since significantly more women using lithium than controls were cigarette smokers (31.8% vs 15.5%, p = 0.002). These results indicate that lithium is not an important human teratogen. Women with major affective disorders who wish, to have children may continue lithium therapy, provided that adequate screening tests, including level II ultrasound and fetal echocardiography, are done.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT PEDIAT & PHARMACOL,DIV CLIN PHARMACOL,MOTHERISK PROGRAM,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV CALIF SAN DIEGO,DEPT PEDIAT,CALIF TERATOGEN INFORMAT SERV,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PEDIAT,CLIN RES PROGRAM,LA JOLLA,CA 92093; UNIV PENN,DEPT PEDIAT,PHILADELPHIA PREGNANCY HEALTHLINE,PHILADELPHIA,PA 19104; UNIV WESTERN ONTARIO,CHILDRENS HOSP,DEPT PEDIAT,FRAME,LONDON N6A 3K7,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of California System; University of California San Diego; University of California System; University of California San Diego; University of Pennsylvania; Western University (University of Western Ontario)			Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				BELIK J, 1983, PEDIATR RES, V17, pA304; FRANKENBURG FR, 1983, NEW ENGL J MED, V309, P311; FRIES H, 1970, LANCET, V1, P1233; GOODMAN L, 1985, PHARM BASIS THERPEUT, P429; GRALLA EJ, 1972, TOXICOL APPL PHARM, V21, P428, DOI 10.1016/0041-008X(72)90163-9; KALLEN B, 1988, TERATOLOGY, V38, P597, DOI 10.1002/tera.1420380608; KALLEN B, 1983, ACTA PSYCHIAT SCAND, V68, P134, DOI 10.1111/j.1600-0447.1983.tb06991.x; KOREN G, 1986, NEW ENGL J MED, V315, P262; KOREN G, 1990, MATERNAL FETAL TOXIC, P373; KOREN G, 1990, MATERNAL FETAL TOXIC, P17; Long W A, 1984, Am J Perinatol, V1, P182, DOI 10.1055/s-2007-999999; MARDEN PM, 1964, J PEDIATR-US, V64, P357, DOI 10.1016/S0022-3476(64)80188-8; MCEVOY GK, 1989, AM SOC HOSPITAL PHAR, P1245; NORA JJ, 1974, LANCET, V2, P594; ROSA FW, 1991, NEW ENGL J MED, V324, P674, DOI 10.1056/NEJM199103073241006; SCHOU M, 1976, ACTA PSYCHIAT SCAND, V54, P193, DOI 10.1111/j.1600-0447.1976.tb00112.x; SMITHBERG M, 1982, TERATOLOGY, V26, P239, DOI 10.1002/tera.1420260304; YODER MC, 1984, PEDIATR RES, V18, pA404; ZALSTEIN K, 1990, AM J CARDIOL, V65, P817	19	228	231	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					530	533		10.1016/0140-6736(92)90346-5	http://dx.doi.org/10.1016/0140-6736(92)90346-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346886				2022-12-28	WOS:A1992HF63100011
J	BONITA, R				BONITA, R			EPIDEMIOLOGY OF STROKE	LANCET			English	Article							CEREBROVASCULAR-DISEASE; COMMUNITY; PROJECT; SURVIVAL; DECLINE; RATES				BONITA, R (corresponding author), UNIV AUCKLAND,N SHORE HOSP,DEPT MED,GERIATR UNIT,PRIVATE BAG 93-503,AUCKLAND 9,NEW ZEALAND.							ALLEN CMC, 1983, Q J MED, V52, P515; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P824, DOI 10.1136/jnnp.53.10.824; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BONITA R, 1988, STROKE, V19, P669, DOI 10.1161/01.STR.19.6.669; BONITA R, 1987, AGE AGEING, V16, P29; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; BONITA R, 1984, AM J EPIDEMIOL, V120, P236, DOI 10.1093/oxfordjournals.aje.a113885; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; CHRISTIE D, 1981, MED J AUSTRALIA, V2, P182, DOI 10.5694/j.1326-5377.1981.tb100891.x; GARRAWAY WM, 1983, MAYO CLIN PROC, V58, P520; MALMGREN R, 1987, LANCET, V2, P1196; MALMGREN R, 1989, BRIT MED J, V298, P656, DOI 10.1136/bmj.298.6674.656; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; TERENT A, 1988, STROKE, V19, P598, DOI 10.1161/01.STR.19.5.598; TERENT A, 1989, STROKE, V20, P1320, DOI 10.1161/01.STR.20.10.1320; TUOMILEHTO J, 1991, STROKE, V22, P7, DOI 10.1161/01.STR.22.1.7; UEDA K, 1981, STROKE, V12, P154, DOI 10.1161/01.STR.12.2.154; WARD G, 1988, STROKE, V19, P1501, DOI 10.1161/01.STR.19.12.1501; 1988, J CLIN EPIDEMIOL, V41, P105; 1989, WORLD HLTH STATISTIC	20	638	687	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					342	344		10.1016/0140-6736(92)91658-U	http://dx.doi.org/10.1016/0140-6736(92)91658-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346420				2022-12-28	WOS:A1992HC77100015
J	JACOBSON, MA; BESCH, CL; CHILD, C; HAFNER, R; MATTS, JP; MUTH, K; WENTWORTH, DN; DEYTON, L				JACOBSON, MA; BESCH, CL; CHILD, C; HAFNER, R; MATTS, JP; MUTH, K; WENTWORTH, DN; DEYTON, L			TOXICITY OF CLINDAMYCIN AS PROPHYLAXIS FOR AIDS-ASSOCIATED TOXOPLASMIC ENCEPHALITIS	LANCET			English	Note							NERVOUS-SYSTEM TOXOPLASMOSIS	A double-blind, placebo-controlled trial was set up to compare clindamycin and pyrimethamine as prophylaxis for toxoplasmic encephalitis (TE) in HIV-infected patients at risk of the disorder. Interim analysis showed that clindamycin-treated patients were 4.4 (95% confidence interval 1.3-15.2) times more likely to experience an adverse effect that necessitated withdrawal of the study drug than those who received placebo. Diarrhoea and rash were reported in 16 (31%) and 11 (21%), respectively, of 52 patients treated with clindamycin (300 mg twice daily) compared with 2 (6%; p = 0.06) and none (p = 0.01) of the 32 placebo-treated patients. The clindamycin arm of the trial was prematurely terminated, although recruitment to the pyrimethamine arm continues.	NIAID,DIV AIDS,6003 EXECUT BLVD,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; SAN FRANCISCO COMMUNITY CONSORTIUM AIDS,SAN FRANCISCO,CA; TULANE UNIV,NEW ORLEANS,LA 70118; UNIV MINNESOTA,DIV BIOSTAT,MINNEAPOLIS,MN 55455; ROW SCI,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Tulane University; University of Minnesota System; University of Minnesota Twin Cities								DANNEMANN BR, 1990, 30TH INT C ANT AG CH; ELIASZEWICZ M, 1990, 6TH INT C AIDS SAN F; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; LEPORT C, 1989, J INFECT DIS, V160, P557, DOI 10.1093/infdis/160.3.557; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; MATHERSON S, 1990, 6TH INT C AIDS SAN F; PEDROL E, 1990, AIDS, V4, P511, DOI 10.1097/00002030-199006000-00003; TOMA E, 1989, LANCET, V1, P1046, DOI 10.1016/S0140-6736(89)92446-X	8	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					333	334		10.1016/0140-6736(92)91649-S	http://dx.doi.org/10.1016/0140-6736(92)91649-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346413				2022-12-28	WOS:A1992HC77100006
J	JAMIESON, C; SMITH, SE				JAMIESON, C; SMITH, SE			SALT TRIAL	LANCET			English	Letter									ST THOMAS HOSP,DEPT CLIN PHARMACOL,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	JAMIESON, C (corresponding author), ST THOMAS HOSP,DEPT SURG,LONDON SE1 7EH,ENGLAND.							MAJERUS PW, 1983, J CLIN INVEST, V72, P1521, DOI 10.1172/JCI111110; YU TF, 1959, J CLIN INVEST, V38, P1298, DOI 10.1172/JCI103905	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					377	377						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346462				2022-12-28	WOS:A1992HC77100065
J	ASLANIDIS, C; JANSEN, G; AMEMIYA, C; SHUTLER, G; MAHADEVAN, M; TSILFIDIS, C; CHEN, C; ALLEMAN, J; WORMSKAMP, NGM; VOOIJS, M; BUXTON, J; JOHNSON, K; SMEETS, HJM; LENNON, GG; CARRANO, AV; KORNELUK, RG; WIERINGA, B; DEJONG, PJ				ASLANIDIS, C; JANSEN, G; AMEMIYA, C; SHUTLER, G; MAHADEVAN, M; TSILFIDIS, C; CHEN, C; ALLEMAN, J; WORMSKAMP, NGM; VOOIJS, M; BUXTON, J; JOHNSON, K; SMEETS, HJM; LENNON, GG; CARRANO, AV; KORNELUK, RG; WIERINGA, B; DEJONG, PJ			CLONING OF THE ESSENTIAL MYOTONIC-DYSTROPHY REGION AND MAPPING OF THE PUTATIVE DEFECT	NATURE			English	Article							VECTORS; DNA	MYOTONIC dystrophy is a common dominant disorder (global incidence of 1:8,000) with variable onset and a protean nature of symptoms mainly involving progressive muscle wasting, myotonia and cataracts 1. To define the molecular defect, we have cloned the essential region of chromosome 19q13.3, including proximal and distal markers 2-7 in a 700-kilobase contig formed by overlapping cosmids and yeast artificial chromosomes (YACs). The central part of the contig bridges an area of about 350 kilobases between two new flanking crossover borders 4,5. This segment has been extensively characterized through the isolation of five YAC clones and the subsequent subcloning in cosmids from which a detailed EcoRI, HindIII, MluI and NotI restriction map has been derived. Two genomic probes and two homologous complementary DNA probes were isolated using the cosmids. These probes are all situated within approximately 10 kilobases of genomic DNA and detect an unstable genomic segment in myotonic dystrophy patients. The length variation in this segment shows similarities to the instability seen at the fragile X locus 8. The physical map location and the genetic characteristics of the length polymorphism is compatible with a direct role in the pathogenesis of myotonic dystrophy.	UNIV CALIF LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,DIV BIOMED SCI,L-452,LIVERMORE,CA 94550; CATHOLIC UNIV NIJMEGEN,FAC MED SCI,DEPT CELL BIOL & HISTOL,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,FAC MED SCI,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; CHILDRENS HOSP EASTERN ONTARIO,DIV GENET,OTTAWA K1H 8L1,ONTARIO,CANADA; UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA K1N 6N5,ONTARIO,CANADA; CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Radboud University Nijmegen; Radboud University Nijmegen; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Imperial College London			Buxton, Jessica/L-9849-2019; Jansen, Gert/HCI-8852-2022; Buxton, Jessica L/I-4033-2014; Vooijs, Marc/K-3522-2019; Lennon, Greg/T-4717-2019; Wieringa, Berend/A-5346-2011	Buxton, Jessica L/0000-0002-0918-9335; Wieringa, Berend/0000-0001-9192-8020; Jansen, Gert/0000-0002-7524-171X; johnson, keith/0000-0002-8578-5921				BRANSCOMB E, 1990, GENOMICS, V8, P351, DOI 10.1016/0888-7543(90)90293-4; BROOK JD, 1991, J MED GENET, V28, P84, DOI 10.1136/jmg.28.2.84; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; BUXTON J, IN PRESS GENOMICS; CARRANO AV, 1989, GENOMICS, V4, P129, DOI 10.1016/0888-7543(89)90291-7; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; GRIGGS RC, 1989, NEUROLOGY, V39, P420, DOI 10.1212/WNL.39.3.420; HARLEY HG, 1991, AM J HUM GENET, V49, P68; Harper P.S., 1989, MYOTONIC DYSTROPHY; HERMENS R, 1991, NUCLEIC ACIDS RES, V19, P1726, DOI 10.1093/nar/19.7.1726; JANSEN G, IN PRESS GENOMICS; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KORNELUK RG, 1991, NUCLEIC ACIDS RES, V19, P1157, DOI 10.1093/nar/19.5.1157; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LENNON GG, IN PRESS HUM MOL GEN; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; SHUTLER, 1991, GENOMICS, V9, P500; SHUTLER G, IN PRESS NUCLEIC ACI; SHUTLER G, IN PRESS GENOMICS; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; TSILFIDIS C, 1991, AM J HUM GENET, V49, P961; TSILFIDIS C, 1991, NUCLEIC ACIDS RES, V19, P1157, DOI 10.1093/nar/19.5.1157-a; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	25	476	486	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					548	551		10.1038/355548a0	http://dx.doi.org/10.1038/355548a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1346925				2022-12-28	WOS:A1992HC52600060
J	GUTIERREZ, G; PALIZAS, F; DOGLIO, G; WAINSZTEIN, N; GALLESIO, A; PACIN, J; DUBIN, A; SCHIAVI, E; JORGE, M; PUSAJO, J; KLEIN, F; ROMAN, ES; DORFMAN, B; SHOTTLENDER, J; GINIGER, R				GUTIERREZ, G; PALIZAS, F; DOGLIO, G; WAINSZTEIN, N; GALLESIO, A; PACIN, J; DUBIN, A; SCHIAVI, E; JORGE, M; PUSAJO, J; KLEIN, F; ROMAN, ES; DORFMAN, B; SHOTTLENDER, J; GINIGER, R			GASTRIC INTRAMUCOSAL PH AS A THERAPEUTIC INDEX OF TISSUE OXYGENATION IN CRITICALLY ILL PATIENTS	LANCET			English	Article							SURGICAL PATIENTS; INTRAMURAL PH; ORGAN FAILURE; SEPTIC SHOCK; DOBUTAMINE; DELIVERY; CONSUMPTION; INFUSION; SYSTEM; PIGS	Falls in gastric intramucosal pH (pH(i)) are associated with morbidity and mortality in patients admitted to intensive-care units (ICU). We tested the hypothesis that ICU outcome can be improved by therapy guided by changes in pH(i) and aimed at improving systemic oxygen availability. We studied 260 patients admitted to ICUs with APACHE II scores of 15-25. After insertion of a gastric tonometer, each patient was randomly assigned to a control or protocol group within the admission pH(i) category (normal = 7.35 or higher, low = below 7.35). The control groups were treated according to standard ICU practices. The protocol groups received, in addition, treatment to increase systemic oxygen transport or to reduce oxygen demand, whenever the pH(i) fell below 7.35 or by more than 0.10 units from the previous measurement. The protocol was used, because pH(i) fell, in 67 (85%) of the protocol group with normal pH(i) on admission. There were no significant differences between protocol and control groups in demographic characteristics, admission blood gases or haemoglobin concentration, number or type of organ system failures, or the intensity of ICU care. For patients admitted with low pH(i), survival was similar in the protocol and control groups (37% vs 36%), whereas for those admitted with normal pH(i), survival was significantly greater in the protocol than in the control group (58% vs 42%; p < 0.01). Therapy guided by pH(i) measurements improved survival in patients whose pH(i) on admission to ICU was normal. pH(i)-guided resuscitation may help improve outcome in such patients by preventing splanchnic organ hypoxia and the development of a systemic oxygen deficit.	HOSP CLIN SAN MARTIN,DEPT CRIT CARE MED,BUENOS AIRES,ARGENTINA; UNIV BUENOS AIRES,HOSP ISRAELITA,DEPT CRIT CARE MED,BUENOS AIRES,ARGENTINA; HOSP SAN MARTIN,DEPT CRIT CARE MED,LA PLATA,ARGENTINA; HOSP ITALIANO BUENOS AIRES,DEPT CRIT CARE MED,BUENOS AIRES,ARGENTINA; SANATORIO BAZTERRICA,DEPT CRIT CARE MED,BUENOS AIRES,ARGENTINA; SANATORIO GUEMES HOSP PRIVADO,DEPT CRIT CARE MED,BUENOS AIRES,ARGENTINA; HOSP FERRER,DEPT CRIT CARE MED,BUENOS AIRES,ARGENTINA; POLICLIN BANCARIA,DEPT CRIT CARE MED,BUENOS AIRES,ARGENTINA	University of Buenos Aires; University of Buenos Aires; Hospital Italiano de Buenos Aires; University of Buenos Aires	GUTIERREZ, G (corresponding author), UNIV TEXAS,HLTH SCI CTR,DIV PULM & CRIT CARE MED,6431 FANNIN,MSMB 1274,HOUSTON,TX 77030, USA.		Gutierrez, Guillermo/ABC-1894-2020	Gutierrez, Guillermo/0000-0001-7754-5816				ANTONSSON JB, 1990, AM J PHYSIOL, V259, pG519, DOI 10.1152/ajpgi.1990.259.4.G519; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BLACKWELDER WC, 1984, CONTROL CLIN TRIALS, V5, P97, DOI 10.1016/0197-2456(84)90116-8; CLARKE C, 1991, CRIT CARE MED, V19, P497, DOI 10.1097/00003246-199104000-00007; DANEK SJ, 1980, AM REV RESPIR DIS, V122, P387; DOGLIO GR, 1991, CRIT CARE MED, V19, P1037, DOI 10.1097/00003246-199108000-00011; FIDDIANGREEN RG, 1991, CRIT CARE MED, V19, P141, DOI 10.1097/00003246-199102000-00004; FIDDIANGREEN RG, 1987, CRIT CARE MED, V15, P153, DOI 10.1097/00003246-198702000-00015; FINK MP, 1989, CRIT CARE MED, V17, P641, DOI 10.1097/00003246-198907000-00009; GILBERT EM, 1986, AM REV RESPIR DIS, V134, P873, DOI 10.1164/arrd.1986.134.5.873; GRUM CM, 1984, J APPL PHYSIOL, V56, P1065, DOI 10.1152/jappl.1984.56.4.1065; GUTIERREZ G, 1986, Journal of Critical Care, V1, P45, DOI 10.1016/S0883-9441(86)80116-2; GYS T, 1988, CRIT CARE MED, V16, P1222, DOI 10.1097/00003246-198812000-00009; HARTMANN M, 1991, CRIT CARE MED, V19, P205, DOI 10.1097/00003246-199102000-00016; HAUPT MT, 1985, AM REV RESPIR DIS, V131, P912; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1989, CRIT CARE CLIN, V5, P221; MARSHALL JC, 1988, ARCH SURG-CHICAGO, V123, P309; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1986, CRIT CARE MED, V14, P1032, DOI 10.1097/00003246-198612000-00008; STEFFES CP, 1991, CRIT CARE MED, V19, P512, DOI 10.1097/00003246-199104000-00010; VINCENT JL, 1990, AM REV RESPIR DIS, V142, P2, DOI 10.1164/ajrccm/142.1.2; VINCENT JL, 1990, CRIT CARE MED, V18, P689, DOI 10.1097/00003246-199007000-00001; WONG DT, 1991, CAN J ANAESTH, V38, P374, DOI 10.1007/BF03007629	26	625	650	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					195	199		10.1016/0140-6736(92)90002-K	http://dx.doi.org/10.1016/0140-6736(92)90002-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346170				2022-12-28	WOS:A1992HA58900001
J	VOLTA, U; BIANCHI, FB				VOLTA, U; BIANCHI, FB			IGA ANTIBODIES TO ENDOMYSIUM, GLIADIN, AND RETICULIN IN SILENT CELIAC-DISEASE	LANCET			English	Letter							CHILDHOOD CELIAC-DISEASE				VOLTA, U (corresponding author), UNIV BOLOGNA,IST CLIN MED,CATTEDRA SEMEIOT MED,I-40138 BOLOGNA,ITALY.							DIAS J, 1987, LANCET, V2, P157; MAKI, 1991, LANCET, V338, P1350; MAKI M, 1984, J PEDIATR-US, V105, P901, DOI 10.1016/S0022-3476(84)80074-8; UNSWORTH DJ, 1983, LANCET, V1, P874; UNSWORTH DJ, 1981, ARCH DIS CHILD, V56, P864, DOI 10.1136/adc.56.11.864; VOLTA U, 1985, GUT, V26, P667, DOI 10.1136/gut.26.7.667; VOLTA U, 1991, DIGEST DIS SCI, V36, P752, DOI 10.1007/BF01311232	7	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					242	242		10.1016/0140-6736(92)90040-A	http://dx.doi.org/10.1016/0140-6736(92)90040-A			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346192				2022-12-28	WOS:A1992HA58900030
J	SALSER, SJ; KENYON, C				SALSER, SJ; KENYON, C			ACTIVATION OF A C-ELEGANS ANTENNAPEDIA HOMOLOG IN MIGRATING CELLS CONTROLS THEIR DIRECTION OF MIGRATION	NATURE			English	Article							CAENORHABDITIS-ELEGANS; TRANSGENIC MICE; GENE; EXPRESSION; HOMEOBOX; NEMATODE	ANTERIOR-POSTERIOR patterning in insects, vertebrates and nematodes involves members of conserved Antennapedia-class homeobox gene clusters (HOM-C) that are thought to give specific body regions their identities 1-5. The effects of these genes on region-specific body structures have been described extensively, particularly in Drosophila, but little is known about how HOM-C genes affect the behaviours of cells that migrate into their domains of function. In Caenorhabditis elegans, the Antennapedia-like HOM-C gene mab-5 not only specifies postembryonic fates of cells in a posterior body region, but also influences the migration of mesodermal and neural cells that move through this region 5-7. Here we show that as one neuroblast migrates into this posterior region, it switches on mab-5 gene expression; mab-5 then acts as a developmental switch to control the migratory behaviour of the neuroblast descendants. HOM-C genes can therefore not only direct region-specific patterns of cell division and differentiation, but can also act within migrating cells to programme region-specific migratory behaviour.			SALSER, SJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CHALFIE M, 1983, SCIENCE, V221, P61, DOI 10.1126/science.6857263; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; DAMSKY CH, IN PRESS J CLIN INVE; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HUNT P, 1991, DEVELOPMENT, V112, P43; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; MELLO C, IN PRESS EMBO J; REID L, 1990, CELL, V63, P875, DOI 10.1016/0092-8674(90)90491-V; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; STRINGHAM EG, IN PRESS MOL BIOL CE; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0	27	144	147	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1992	355	6357					255	258		10.1038/355255a0	http://dx.doi.org/10.1038/355255a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ694	1346230				2022-12-28	WOS:A1992GZ69400069
J	GRUNDER, S; THIEMANN, A; PUSCH, M; JENTSCH, TJ				GRUNDER, S; THIEMANN, A; PUSCH, M; JENTSCH, TJ			REGIONS INVOLVED IN THE OPENING OF CIC-2 CHLORIDE CHANNEL BY VOLTAGE AND CELL-VOLUME	NATURE			English	Article							INACTIVATION; MECHANISMS; EXPRESSION	REGULATION of cell volume is essential for every cell and is accomplished by the regulated loss or gain of intracellular ions or other osmolytes1-4. Regulatory volume decrease often involves the parallel activation of potassium and chloride channels5-10. Overexpression of P-glycoprotein leads to volume-activated Cl-currents11,12 but its physiological importance for volume regulation is unclear13. ClC-2 is a ubiquitously expressed Cl- channel14 activatable by non-physiologically strong hyperpolarization. We now show that ClC-2 can be activated by extracellular hypotonicity, which suggests that it has a widespread role in volume regulation. Domains necessary for activation by both voltage and volume are localized to the amino terminus. Mutations in an 'essential' region lead to constitutively open channels unresponsive to medium tonicity, whereas deletions in a 'modulating' region produce partially opened channels responsive to both hypo- and hypertonicity. These domains can be transplanted to different regions of the protein without loss of function.	UNIV HAMBURG,ZMNH,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	University of Hamburg	JENTSCH, TJ (corresponding author), UNIV HAMBURG,ZMNH,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883; Pusch, Michael/0000-0002-8644-8847; Jentsch, Thomas/0000-0002-3509-2553				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; CHAN HC, 1992, SCIENCE, V257, P669, DOI 10.1126/science.1379742; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHRISTENSEN O, 1992, J MEMBRANE BIOL, V129, P13; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DUBINSKY WP, 1992, P NATL ACAD SCI USA, V89, P1770, DOI 10.1073/pnas.89.5.1770; FOSTER CD, 1992, NEURON, V9, P229, DOI 10.1016/0896-6273(92)90162-7; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KUNZELMANN K, 1992, PFLUG ARCH EUR J PHY, V421, P238, DOI 10.1007/BF00374833; MCEWAN GTA, 1992, FEBS LETT, V304, P233, DOI 10.1016/0014-5793(92)80626-R; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; PIERCE SK, 1990, ANNU REV PHYSIOL, V52, P27, DOI 10.1146/annurev.ph.52.030190.000331; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TORO L, 1992, NEURON, V9, P237, DOI 10.1016/0896-6273(92)90163-8; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WEISS H, 1992, J MEMBRANE BIOL, V126, P109; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	28	381	390	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					759	762		10.1038/360759a0	http://dx.doi.org/10.1038/360759a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1334533				2022-12-28	WOS:A1992KE47200040
J	LIN, CJ; LIN, SC; CHANG, CP; ROSENFELD, MG				LIN, CJ; LIN, SC; CHANG, CP; ROSENFELD, MG			PIT-1-DEPENDENT EXPRESSION OF THE RECEPTOR FOR GROWTH-HORMONE RELEASING-FACTOR MEDIATES PITUITARY CELL-GROWTH	NATURE			English	Article							PANCREATIC-ISLET TUMOR; SOMATOSTATIN GENE; MESSENGER-RNA; TRANSCRIPTION; MICE; CREB; PHOSPHORYLATION; HYPERPLASIA; MUTATIONS; DWARFISM	IN Snell (dw) and Jackson (dw(J)) dwarf mice, mutations in the gene encoding Pit-1, a tissue-specific POU-domain transcription factor, lead to the absence of somatotroph, lactotroph and thyrotroph cells1-6. Pre-somatotroph proliferation is stimulated by increased intracellular levels of cyclic AMP, normally induced by growth hormone releasing factor (GRF; refs 7-17). Here we report the cloning of mouse and rat complementary DNAs encoding a new member of the seven-transmembrane-helix, G-protein-coupled receptor family restricted to the pituitary gland, which mediates increases in intracellular cAMP and cAMP-dependent gene transcription in response to GRF. The receptor is expressed in a spatial and temporal pattern corresponding precisely to growth hormone gene expression, and neither is expressed in dw/dw mice. The pituitary hypoplasia in these mice thus appears to be due, at least in part, to the absence of GRF receptor, which is in turn due to the absence of functional Pit-1.	UNIV CALIF SAN DIEGO,SCH & DEPT MED,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego	LIN, CJ (corresponding author), UNIV CALIF SAN DIEGO,SCH & DEPT MED,HOWARD HUGHES MED INST,9500 GILMAN DR,LA JOLLA,CA 92093, USA.		Lin, SC/G-4666-2010					BAIRD A, 1984, REGUL PEPTIDES, V10, P23, DOI 10.1016/0167-0115(84)90049-1; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; EICHER EM, 1976, J HERED, V67, P87, DOI 10.1093/oxfordjournals.jhered.a108682; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; FROHMAN LA, 1986, ENDOCR REV, V7, P236; GICK GG, 1984, P NATL ACAD SCI-BIOL, V81, P1553, DOI 10.1073/pnas.81.5.1553; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUILLEMIN R, 1982, SCIENCE, V218, P585, DOI 10.1126/science.6812220; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; ISHIHARA T, 1992, NEURON, V8, P815; ISHIKAWA K, 1986, NEUROENDOCRINOLOGY, V43, P537, DOI 10.1159/000124579; JUPPNER H, 1991, SCIENCE, P1022; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; RIVIER J, 1982, NATURE, V300, P276, DOI 10.1038/300276a0; ROUSE M, 1982, CELL TISSUE RES, V223, P415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFERT H, 1985, NATURE, V313, P487, DOI 10.1038/313487a0; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; THORNER MO, 1982, J CLIN INVEST, V70, P965, DOI 10.1172/JCI110708; WILSON DB, 1986, ANAT EMBRYOL, V174, P277, DOI 10.1007/BF00824343; YASHIRO T, 1988, CELL TISSUE RES, V251, P249, DOI 10.1007/BF00215832	35	287	300	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					765	768		10.1038/360765a0	http://dx.doi.org/10.1038/360765a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1334535				2022-12-28	WOS:A1992KE47200042
J	ROCA, J; WANG, JC				ROCA, J; WANG, JC			THE CAPTURE OF A DNA DOUBLE HELIX BY AN ATP-DEPENDENT PROTEIN CLAMP - A KEY STEP IN DNA TRANSPORT BY TYPE-II DNA TOPOISOMERASES	CELL			English	Article							NUCLEOTIDE-SEQUENCE; YEAST; GYRASE; SITE; COMPLEXES; HOMOLOGY; CLEAVAGE; MITOSIS; GENE	The binding of linear and circular forms of DNA to yeast DNA topoisomerase II or its complex with AMPPNP, the nonhydrolyzable beta,gamma-imido analog of ATP, was carried out to probe the ATP analog-induced conformational change of the enzyme. Binding of the ATP analog is shown to convert the enzyme to a circular clamp with an annulet, through which only a linear DNA can pass; subsequent circularization of the bound linear DNA forms a salt-stable catenane between the protein circular clamp and the DNA ring. Analysis of catenane formation between a small DNA ring originally bound to the topoisomerase and a large DNA ring subsequently added, under conditions such that the two do not exchange, supports a model in which a second DNA double-helix can enter the open jaws of a DNA-bound protein clamp, and the closure of the jaws upon ATP-binding traps the second duplex and transports it through an enzyme-operated gate in the first DNA duplex.			ROCA, J (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.		Roca, Joaquim/AAP-1077-2020	Roca, Joaquim/0000-0003-1462-954X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24544] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; CARON PR, 1992, IN PRESS 1991 INT S; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; GOTO T, 1982, J BIOL CHEM, V257, P5866; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOROWITZ DS, 1987, J BIOL CHEM, V262, P5339; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; HUANG WM, 1990, DNA TOPOLOGY ITS BIO, P265; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MIZZUUCHI K, 1980, PNAS, V77, P1847; MORRISON A, 1980, J BIOL CHEM, V255, P2211; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; TAMURA JK, 1992, J BIOL CHEM, V267, P9214; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1980, MECHANISTIC STUDIES, P769; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YANAGIDA M, 1987, NUCLEIC ACIDS MOL BI, V1, P196; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	36	297	305	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					833	840		10.1016/0092-8674(92)90558-T	http://dx.doi.org/10.1016/0092-8674(92)90558-T			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330327				2022-12-28	WOS:A1992JZ63300012
J	JOHNSON, SW; SEUTIN, V; NORTH, RA				JOHNSON, SW; SEUTIN, V; NORTH, RA			BURST FIRING IN DOPAMINE NEURONS INDUCED BY N-METHYL-D-ASPARTATE - ROLE OF ELECTROGENIC SODIUM-PUMP	SCIENCE			English	Article							VENTRAL TEGMENTAL AREA; FREELY MOVING RATS; PARKINSONS-DISEASE; ELECTROPHYSIOLOGICAL PROPERTIES; IMPULSE FLOW; INVITRO; SYSTEM; INVIVO; MIDBRAIN; DRUGS	Dopamine-containing neurons of the mammalian midbrain are required for normal behavior and movements. In vivo they fire action potentials in bursts, but in vitro they discharge regularly spaced action potentials. Burst firing in vitro has now been shown to be robustly induced by the glutamate agonist N-methyl-D-aspartate (NMDA) although not by the non-NMDA agonists kainate or quisqualate. The hyperpolarization between bursts of action potentials results from electrogenic sodium ion extrusion by a ouabain-sensitive pump. This mechanism of burst generation in mammalian neurons may be important in the pathophysiology of schizophrenia and Parkinson's disease.	OREGON HLTH SCI UNIV, DEPT NEUROL, PORTLAND, OR 97201 USA	Oregon Health & Science University	JOHNSON, SW (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.		North, Richard/GQA-6156-2022					ADAMS WB, 1985, J PHYSIOL-LONDON, V360, P69, DOI 10.1113/jphysiol.1985.sp015604; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; Bjorklund A., 1984, HDB CHEM NEUROANAT 1, V2, P55; CHARLETY PJ, 1991, ACTA PHYSIOL SCAND, V142, P105, DOI 10.1111/j.1748-1716.1991.tb09134.x; CHRISTIE MJ, 1985, BRAIN RES, V333, P169, DOI 10.1016/0006-8993(85)90140-4; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COOK NS, 1985, J PHYSIOL-LONDON, V358, P373, DOI 10.1113/jphysiol.1985.sp015556; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; FREEMAN AS, 1985, LIFE SCI, V36, P1983, DOI 10.1016/0024-3205(85)90448-5; GONON FG, 1988, NEUROSCIENCE, V24, P19, DOI 10.1016/0306-4522(88)90307-7; GONON FG, 1985, NEUROSCIENCE, V14, P765, DOI 10.1016/0306-4522(85)90141-1; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRACE AA, 1984, J NEUROSCI, V4, P2877; GRACE AA, 1989, J NEUROSCI, V9, P3463; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P227, DOI 10.1113/jphysiol.1984.sp015154; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; KRAMER RH, 1985, J PHYSIOL-LONDON, V362, P131, DOI 10.1113/jphysiol.1985.sp015667; LACEY MG, 1988, J PHYSIOL-LONDON, V406, pP18; LACEY MG, 1989, J NEUROSCI, V9, P1233; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; Luria A.R., 1969, HDB CLIN NEUROLOGY V, P725; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; OADES RD, 1987, BRAIN RES REV, V12, P117, DOI 10.1016/0165-0173(87)90011-7; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; ROMO R, 1990, J NEUROPHYSIOL, V63, P592, DOI 10.1152/jn.1990.63.3.592; ROSS ED, 1981, NEUROLOGY, V31, P1435, DOI 10.1212/WNL.31.11.1435; RUSSELL WR, 1948, LANCET, V254, P356; SANGHERA MK, 1984, NEUROSCIENCE, V12, P793, DOI 10.1016/0306-4522(84)90171-4; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHULTZ W, 1986, J NEUROPHYSIOL, V56, P1439, DOI 10.1152/jn.1986.56.5.1439; SEEMAN P, 1975, SCIENCE, V188, P1217, DOI 10.1126/science.1145194; SHEPARD PD, 1991, EXP BRAIN RES, V86, P141, DOI 10.1007/BF00231048; SMITH TG, 1975, NATURE, V253, P450, DOI 10.1038/253450a0; SNYDER SH, 1976, AM J PSYCHIAT, V133, P197; STRECKER RE, 1985, BRAIN RES, V361, P339, DOI 10.1016/0006-8993(85)91304-6; SVENSSON TH, 1989, ACTA PHYSIOL SCAND, V136, P135, DOI 10.1111/j.1748-1716.1989.tb08640.x; WHITTAM R, 1962, BIOCHEM J, V82, P205, DOI 10.1042/bj0820205; WISE RA, 1988, ANN NY ACAD SCI, V537, P228; YUNG WH, 1991, J PHYSIOL-LONDON, V436, P643, DOI 10.1113/jphysiol.1991.sp018571	44	378	386	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					665	667		10.1126/science.1329209	http://dx.doi.org/10.1126/science.1329209			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1329209				2022-12-28	WOS:A1992JU74500062
J	REIBNEGGER, G; FUCHS, D; JUDMAIER, G; WEISS, G; WERNERFELMAYER, G; WACHTER, H				REIBNEGGER, G; FUCHS, D; JUDMAIER, G; WEISS, G; WERNERFELMAYER, G; WACHTER, H			CRITICAL-STUDY OF CONSENSUS ANALYSIS	LANCET			English	Article							RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; NEOPTERIN; TESTS	Consensus analysis has been proposed as a statistical method by which the efficacy of clinical and laboratory tests of inflammatory activity can be assessed. This technique is claimed to overcome the need for an external "gold standard" as a reference method; instead, the consensus of all tests is used as the gold standard. We have evaluated the reliability of consensus analysis using data collected from patients with Crohn's disease. Our results demonstrate that the technique depends strongly on the correlation structure underlying the set of measures of disease used for analysis. This observation was supported by a series of conventional cluster analyses of the same set of variables. Furthermore, slight modifications of the algorithm had profound effects on the final result. We conclude that for the evaluation of tests of inflammatory activity, an external reference method, albeit an imperfect one, remains indispensable.	UNIV INNSBRUCK,DEPT INTERNAL MED,A-6020 INNSBRUCK,AUSTRIA	University of Innsbruck	REIBNEGGER, G (corresponding author), UNIV INNSBRUCK,INST MED CHEM & BIOCHEM,FRITZ PREGL STR 3,A-6020 INNSBRUCK,AUSTRIA.		Reibnegger, Gilbert/H-5742-2012; Fuchs, Dietmar/AAL-8011-2021	Reibnegger, Gilbert/0000-0001-7202-2426; Fuchs, Dietmar/0000-0003-1627-9563; Weiss, Guenter/0000-0003-0709-2158; Werner-Felmayer, Gabriele/0000-0002-2340-8063				BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BULL BS, 1986, LANCET, V2, P377; BULL BS, 1989, LANCET, V2, P965; DAWES PT, 1989, LANCET, V2, P1219; DUCLOS B, 1990, GASTROEN CLIN BIOL, V14, P22; LOBO AJ, 1991, EUR J GASTROEN HEPAT, V3, P663; PAWLOTSKY Y, 1989, LANCET, V2, P1532; PRIOR C, 1986, CLIN CHIM ACTA, V155, P11, DOI 10.1016/0009-8981(86)90094-X; PULLAR T, 1989, LANCET, V2, P1532; SCOTT DL, 1989, LANCET, V2, P1531	10	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1394	1397		10.1016/0140-6736(92)91206-N	http://dx.doi.org/10.1016/0140-6736(92)91206-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350814				2022-12-28	WOS:A1992HX63600013
J	MONYER, H; SPRENGEL, R; SCHOEPFER, R; HERB, A; HIGUCHI, M; LOMELI, H; BURNASHEV, N; SAKMANN, B; SEEBURG, PH				MONYER, H; SPRENGEL, R; SCHOEPFER, R; HERB, A; HIGUCHI, M; LOMELI, H; BURNASHEV, N; SAKMANN, B; SEEBURG, PH			HETEROMERIC NMDA RECEPTORS - MOLECULAR AND FUNCTIONAL DISTINCTION OF SUBTYPES	SCIENCE			English	Article							AMINO-ACID RECEPTORS; LONG-TERM POTENTIATION; MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; GLUTAMATE RECEPTOR; DEPENDENT BLOCK; NERVOUS-SYSTEM; BRAIN NEURONS; ION CHANNELS; CLONED CDNAS	The N-methyl D-aspartate (NMDA) receptor subtype of glutamate-gated ion channels possesses high calcium permeability and unique voltage-dependent sensitivity to magnesium and is modulated by glycine. Molecular cloning identified three complementary DNA species of rat brain, encoding NMDA receptor subunits NMDAR2A (NR2A), NR2B, and NR2C, which are 55 to 70% identical in sequence. These are structurally related, with less than 20% sequence identity to other excitatory amino acid receptor subunits, including the NMDA receptor subunit NMDAR1 (NR1). Upon expression in cultured cells, the new subunits yielded prominent, typical glutamate- and NMDA-activated currents only when they were in heteromeric configurations with NR1. NR1-NR2A and NR1-NR2C channels differed in gating behavior and magnesium sensitivity. Such heteromeric NMDA receptor subtypes may exist in neurons, since NR1 messenger RNA is synthesized throughout the mature rat brain, while NR2 messenger RNA show a differential distribution.	UNIV HEIDELBERG, CTR MOLEC BIOL, NEUENHEIMER FELD 282, W-6900 HEIDELBERG, GERMANY; MAX PLANCK INST MED RES, W-6900 HEIDELBERG 1, GERMANY	Ruprecht Karls University Heidelberg; Max Planck Society			Burnashev, Nail/G-4056-2013	Monyer, Hannah/0000-0002-9332-5749; Lomeli, Hilda/0000-0001-9659-0102				ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; GONZALES RA, 1992, J NEUROCHEM, V58, P579, DOI 10.1111/j.1471-4159.1992.tb09758.x; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JAHR CE, 1992, SCIENCE, V255, P470, DOI 10.1126/science.1346477; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LESTER RAJ, 1992, J NEUROSCI, V12, P635; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MACDONALD JF, 1987, J NEUROPHYSIOL, V58, P251, DOI 10.1152/jn.1987.58.2.251; MARAGOS WF, 1988, J NEUROSCI, V8, P493; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONAGHAN DT, 1988, P NATL ACAD SCI USA, V85, P9836, DOI 10.1073/pnas.85.24.9836; MONAGHAN DT, 1991, EUR J PHARMACOL, V194, P123, DOI 10.1016/0014-2999(91)90134-C; MONAGHAN DT, 1991, NEUROSCI LETT, V122, P21, DOI 10.1016/0304-3940(91)90183-T; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PERKINS MN, 1983, BRAIN RES, V259, P172, DOI 10.1016/0006-8993(83)91084-3; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIGUCHI M, 1990, J NEUROSCI, V10, P2148; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WADA K, 1991, NATURE, V351, P742; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205	54	2297	2381	1	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1992	256	5060					1217	1221		10.1126/science.256.5060.1217	http://dx.doi.org/10.1126/science.256.5060.1217			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1350383				2022-12-28	WOS:A1992HV19200041
J	OLIVER, MF				OLIVER, MF			CORONARY ATHEROMA REGRESSION TRIALS	LANCET			English	Letter											OLIVER, MF (corresponding author), WYNN INST METAB RES, LONDON NW8 9SQ, ENGLAND.		Seed, Paul T/C-4435-2008	Seed, Paul T/0000-0001-7904-7933; Yeo, Wilfred/0000-0001-9554-5203; Watts, Gerald/0000-0003-2276-1524				1992, LANCET, V339, P563	1	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	1992	339	8803					1241	1241		10.1016/0140-6736(92)91189-F	http://dx.doi.org/10.1016/0140-6736(92)91189-F			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349983				2022-12-28	WOS:A1992HU68400055
J	OBOYLE, CA; MCGEE, H; HICKEY, A; OMALLEY, K; JOYCE, CRB				OBOYLE, CA; MCGEE, H; HICKEY, A; OMALLEY, K; JOYCE, CRB			INDIVIDUAL QUALITY-OF-LIFE IN PATIENTS UNDERGOING HIP-REPLACEMENT	LANCET			English	Article							IMPACT	Quality of life (QoL) assessment is becoming increasingly important for measuring the impact of illnesses, diseases, and their treatment and for deciding priorities when allocating resources. We developed a novel method to measure QoL from the perspective of the individual patient. The schedule for the evaluation of individual qualitY of life (SEIQoL) was devised from the technique known as judgment analysis to measure patients' level of functioning in five self-nominated facets of life and the relative weight or importance attached to these areas. We applied this method, together with traditional measures of health status, in a prospective intervention study of 20 patients undergoing unilateral total hip-replacement surgery with six-month follow-up by comparison with matched, non-patient controls. Health status was significantly improved by hip replacement on the McMaster health index questionnaire (p < 0.001) and the arthritis impact measurement scales (p < 0.001). Individually measured QoL was significantly increased after surgery when measured by SEIQoL (p < 0.02). The individual nature of QoL was reflected in the variety of life areas nominated as important by individual patients, the differences in relative weights attached to these areas, and the complex nature of the changes that occurred postoperatively. Our data not only highlight such individuality but also show that SEIQoL provides a means by which this can be assessed scientifically.	ROYAL COLL SURG IRELAND,DEPT CLIN PHARMACOL,DUBLIN 2,IRELAND; UNIV BERN,PSYCHIAT POLICLIN,CH-3000 BERN,SWITZERLAND	Royal College of Surgeons - Ireland; University of Bern	OBOYLE, CA (corresponding author), ROYAL COLL SURG IRELAND,DEPT PSYCHOL,ST STEPHENS GREEN,DUBLIN 2,IRELAND.		McGee, Hannah M/D-6480-2012	McGee, Hannah M/0000-0003-1417-993X; O'Boyle, Ciaran/0000-0003-0254-8603				CHAMBERS LW, 1982, J RHEUMATOL, V9, P780; EVANS RW, 1991, LANCET, V338, P636, DOI 10.1016/0140-6736(91)90649-A; HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623-196951040-00012; McDowell I, 1987, MEASURING HLTH GUIDE; MCGEE HM, 1991, PSYCHOL MED, V21, P749, DOI 10.1017/S0033291700022388; MEENAN RF, 1980, ARTHRITIS RHEUM, V23, P146, DOI 10.1002/art.1780230203; OBOYLE CA, 1989, BR J CLIN PHARM, V27, pP155; SARASON IG, 1978, J CONSULT CLIN PSYCH, V46, P932, DOI 10.1037/0022-006X.46.5.932; Stewart T.R., 1988, HUMAN JUDGEMENT SJT, P41, DOI [DOI 10.1016/S0166-4115(08)62170-6, 10.1016/S0166-4115(08)62170-6]; 1986, POLICY PC SOFTWARE J	10	313	317	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1088	1091		10.1016/0140-6736(92)90673-Q	http://dx.doi.org/10.1016/0140-6736(92)90673-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349111				2022-12-28	WOS:A1992HR44600012
J	SABOOR, SA; JOHNSON, NM; MCFADDEN, J				SABOOR, SA; JOHNSON, NM; MCFADDEN, J			DETECTION OF MYCOBACTERIAL DNA IN SARCOIDOSIS AND TUBERCULOSIS WITH POLYMERASE CHAIN-REACTION	LANCET			English	Article							DIAGNOSIS	The cause of sarcoidosis is unknown. However, the histological similarity between the disorder and tuberculosis suggests that mycobacteria might contribute to the pathogenesis of sarcoidosis. We have used the polymerase chain reaction (PCR) to detect mycobacterial DNA in clinical samples from patients with sarcoidosis. 104 patients were included in the study (62 referred for possible tuberculosis and 20 for possible sarcoidosis, and 22 control patients who had undergone bronchoscopy for other reasons). Bronchoalveolar lavage samples, bronchial washings, and tissue specimens (1 from each patient) underwent assay by PCR as well as bacteriological, histological, and cytological examination. We used two PCR reactions: in the first the complex-specific insertion sequence IS986/IS6110 was used to specifically detect DNA from Mycobacterium tuberculosis complex bacteria; in the second, conserved sequences of the mycobacterial groEL gene were used to detect DNA from mycobacteria other than M tuberculosis. The PCR was more sensitive than culture for diagnosis of tuberculosis. However, the false-positive PCR rate for M tuberculosis was 9%. M tuberculosis DNA was found in half the sarcoidosis patients, and non-tuberculosis mycobacterial DNA in a further 20%. The findings that a significant proportion of the sarcoidosis patients in this study have mycobacteria in their lungs and that most of these mycobacteria belong to M tuberculosis complex suggest an aetiological role for mycobacteria in sarcoidosis.	UNIV SURREY,SCH BIOL SCI,MOLEC MICROBIOL GRP,GUILDFORD GU2 5XH,SURREY,ENGLAND; UNIV LONDON UNIV COLL,UNIV COLL & MIDDLESEX SCH MED,LONDON WC1E 6BT,ENGLAND; WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,LONDON N19 5NF,ENGLAND	University of Surrey; University of London; University College London; University of London; University College London				McFadden, Johnjoe/0000-0003-2145-0046				BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRISSONNOEL A, 1991, LANCET, V338, P364, DOI 10.1016/0140-6736(91)90492-8; BURNET FM, 1959, CLONAL SELECTION THE, P160; DEWIT MYL, 1991, J CLIN MICROBIOL, V29, P906, DOI 10.1128/JCM.29.5.906-910.1991; HANCE AJ, 1989, MOL MICROBIOL, V3, P843, DOI 10.1111/j.1365-2958.1989.tb00233.x; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; Higuchi R., 1989, PCR TECHNOLOGY, P61; MANJUNATH N, 1991, TUBERCLE, V72, P21, DOI 10.1016/0041-3879(91)90020-S; MITCHELL DN, 1983, 9TH INT C SARC OTH G, P132; MUSCOVIC EA, 1978, PATHOL ANNU, V13, P69; Sambrook J, 1989, MOL CLONING LABORATO; SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987; THIERRY D, 1990, J CLIN MICROBIOL, V28, P2668, DOI 10.1128/JCM.28.12.2668-2673.1990; VANEK J, 1970, AM REV RESPIR DIS, V101, P395; WALTERS EH, 1991, THORAX, V46, P613, DOI 10.1136/thx.46.9.613; WARRING FC, 1970, AM REV RESPIR DIS, V102, P714	16	225	228	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1012	1015		10.1016/0140-6736(92)90535-B	http://dx.doi.org/10.1016/0140-6736(92)90535-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349051				2022-12-28	WOS:A1992HQ43500003
J	KLEIN, G; NEFF, H; KULLICH, W; PHLEPS, W; KOLLENZ, CJ				KLEIN, G; NEFF, H; KULLICH, W; PHLEPS, W; KOLLENZ, CJ			S(+) VERSUS RACEMIC IBUPROFEN	LANCET			English	Letter							ENANTIOMERS; INVERSION		LUDWIG BOLTZMANN INST REHABIL INTERNAL DIS,SAALFELDEN,AUSTRIA; GEBRO FIEBERBRUNN,DEPT MED,A-6391 FIEBERBRUNN,AUSTRIA	Ludwig Boltzmann Institute	KLEIN, G (corresponding author), REHABIL CTR RHEUMAT DIS,SAALFELDEN,AUSTRIA.							ADAMS SS, 1976, J PHARM PHARMACOL, V28, P256, DOI 10.1111/j.2042-7158.1976.tb04144.x; EVANS AM, 1990, BIOPHARM DRUG DISPOS, V11, P507, DOI 10.1002/bdd.2510110605; HUTT AJ, 1983, J PHARM PHARMACOL, V35, P693, DOI 10.1111/j.2042-7158.1983.tb02874.x; KEAN, 1991, LANCET, V338, P1565; LEE EJD, 1985, BRIT J CLIN PHARMACO, V19, P669, DOI 10.1111/j.1365-2125.1985.tb02694.x; WAGENER HH, 1991, AKTUEL RHEUMATOL, V16, P65, DOI 10.1055/s-2008-1047384	6	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					681	681		10.1016/0140-6736(92)90842-Q	http://dx.doi.org/10.1016/0140-6736(92)90842-Q			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347370				2022-12-28	WOS:A1992HH74300043
J	HART, RG				HART, RG			CARDIOGENIC EMBOLISM TO THE BRAIN	LANCET			English	Article							MYOCARDIAL-INFARCTION; ATRIAL-FIBRILLATION; NATURAL-HISTORY; STROKE; TRIAL; THROMBOSIS; WARFARIN				HART, RG (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MED NEUROL, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.							ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; [Anonymous], 1988, LANCET, V2, P349; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; BELKIN RN, 1990, AM HEART J, V120, P948, DOI 10.1016/0002-8703(90)90214-I; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; BOGOUSSLAVSKY J, 1990, NEUROLOGY, V40, P1046, DOI 10.1212/WNL.40.7.1046; BOGOUSSLAVSKY J, 1991, NEUROLOGY, V41, P855, DOI 10.1212/WNL.41.6.855; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; CUJEC B, 1991, STROKE, V22, P727, DOI 10.1161/01.STR.22.6.727; EZEKOWITZ MD, 1991, CIRCULATION S2, V84, P450; FALK RH, 1990, AM J CARDIOL, V65, P914, DOI 10.1016/0002-9149(90)91436-A; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P71; HOFMANN T, 1990, LANCET, V336, P1421; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOUVARAS G, 1990, AM HEART J, V119, P73, DOI 10.1016/S0002-8703(05)80084-5; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; MAGGIONI A, 1991, BMJ-BRIT MED J, V302, P1428, DOI 10.1136/bmj.302.6790.1428; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; NIHOYANNOPOULOS P, 1989, J AM COLL CARDIOL, V14, P903, DOI 10.1016/0735-1097(89)90463-4; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; PETERSEN P, 1989, LANCET, V1, P175; PETERSEN P, 1990, NEW ENGL J MED, V323, P482; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; SACCO RL, 1991, STROKE, V22, P305, DOI 10.1161/01.STR.22.3.305; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; TAVAZZI L, 1989, LANCET, V2, P182; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VECCHIO C, 1991, CIRCULATION, V84, P512, DOI 10.1161/01.CIR.84.2.512; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; 1987, ARCH INTERN MED, V174, P636	36	142	147	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1992	339	8793					589	594		10.1016/0140-6736(92)90873-2	http://dx.doi.org/10.1016/0140-6736(92)90873-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347101				2022-12-28	WOS:A1992HH07500011
J	KYLE, WS				KYLE, WS			SIMIAN RETROVIRUSES, POLIOVACCINE, AND ORIGIN OF AIDS	LANCET			English	Editorial Material																		ESSEX M, 1988, SCI AM, V259, P64, DOI 10.1038/scientificamerican1088-64; LINCOLN C, 1976, SCHOH LETT, V26, P1; MILSTIEN JB, 1975, J CLIN MICROBIOL, V1, P353, DOI 10.1128/JCM.1.4.353-358.1975; TAGER A, 1974, DERMATOLOGICA, V149, P253, DOI 10.1159/000251529; 1982, NEW ENGL J MED, V306, P252; 1980, FED REGISTER, V45, P25652; 1959, 1ST INT C LIV POL VA, P324; 1961, DEV RESPECT MANUFACT, P317	8	17	18	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					600	601		10.1016/0140-6736(92)90876-5	http://dx.doi.org/10.1016/0140-6736(92)90876-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347104				2022-12-28	WOS:A1992HH07500014
J	MACNAUGHTON, PD; EVANS, TW				MACNAUGHTON, PD; EVANS, TW			MANAGEMENT OF ADULT RESPIRATORY-DISTRESS SYNDROME	LANCET			English	Article							INTENSIVE-CARE UNIT; VENTILATION; FAILURE; ARDS; RISK		ROYAL BROMPTON NATL HEART & LUNG HOSP,NATL HEART & LUNG INST,LONDON SW3 6NP,ENGLAND	Imperial College London								ALEXANDER JW, 1990, JPEN-PARENTER ENTER, V14, pS170, DOI 10.1177/014860719001400505; ASHBAUGH DG, 1967, LANCET, V2, P319; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; CARLON GC, 1983, CHEST, V84, P551, DOI 10.1378/chest.84.5.551; DANTZKER DR, 1991, AM REV RESPIR DIS, V143, P675, DOI 10.1164/ajrccm/143.3.675; DOWNS JB, 1987, CRIT CARE MED, V15, P459; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; GATTINONI L, 1984, INTENS CARE MED, V10, P121, DOI 10.1007/BF00265800; HICKLING KG, 1990, INTENS CARE MED, V16, P219, DOI 10.1007/BF01705155; HUNTER DN, 1990, INTENS CARE MED, V16, P363, DOI 10.1007/BF01735173; KALLIS P, 1991, LANCET, V337, P549, DOI 10.1016/0140-6736(91)91329-S; KEOGH BF, 1990, EUROPEAN RESPIRA S10, V3, pS62; MACNAUGHTON PD, 1990, RESP MED, V84, P437, DOI 10.1016/S0954-6111(08)80106-0; MACNAUGHTON PD, IN PRESS THORAX; MEDURI GU, 1991, CHEST, V100, P943, DOI 10.1378/chest.100.4.943; MOHSENIFAR Z, 1983, CHEST, V84, P267, DOI 10.1378/chest.84.3.267; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MORGAN JM, 1988, INT J CARDIOL, V21, P259, DOI 10.1016/0167-5273(88)90103-9; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; RADERMACHER P, 1990, INTENS CARE MED, V16, P227, DOI 10.1007/BF01705156; ROCKER GM, 1989, LANCET, V1, P120; SCHULLER D, 1991, CHEST, V100, P1068, DOI 10.1378/chest.100.4.1068; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; THARRATT RS, 1988, CHEST, V94, P755, DOI 10.1378/chest.94.4.755; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; VINCENT JL, 1990, AM REV RESPIR DIS, V142, P2, DOI 10.1164/ajrccm/142.1.2; ZEIGLER EJ, 1991, NEW ENGL J MED, V324, P429	30	46	46	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					469	472		10.1016/0140-6736(92)91068-J	http://dx.doi.org/10.1016/0140-6736(92)91068-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346827				2022-12-28	WOS:A1992HE93200013
J	UCHIGATA, Y; KUWATA, S; TOKUNAGA, K; EGUCHI, Y; TAKAYAMAHASUMI, S; MIYAMOTO, M; OMORI, Y; JUJI, T; HIRATA, Y				UCHIGATA, Y; KUWATA, S; TOKUNAGA, K; EGUCHI, Y; TAKAYAMAHASUMI, S; MIYAMOTO, M; OMORI, Y; JUJI, T; HIRATA, Y			STRONG ASSOCIATION OF INSULIN AUTOIMMUNE SYNDROME WITH HLA-DR4	LANCET			English	Note								Insulin autoimmune syndrome is characterised by spontaneous hypoglycaemia without evidence of exogenous insulin administration, a high serum concentration of total immunoreactive insulin, and the presence of insulin autoantibodies in high titre. HLA typing of 27 patients with insulin autoimmune syndrome showed that all had DR4, which was present in only 43% of 51 healthy controls (odds ratio 72.1, p < 2 x l0(-6), and 19 (70%) of the patients were positive for the allelic combination, Cw4, Bw62, and DR4. Analysis of the nucleotide sequences of the DRB1, DQA1, and DQB1 genes showed that all the patients had DRB1*0406, DQA1*0301, and DQB1*0302, compared with only 14% of the controls (odds ratio 281, p < 1 x 10(-10)). We conclude that the development of insulin autoimmune syndrome is associated with a strong genetic predisposition.	UNIV TOKYO,FAC MED,DEPT TRANSFUS MED & IMMUNOHEMATOL,TOKYO 113,JAPAN	University of Tokyo	UCHIGATA, Y (corresponding author), TOKYO WOMENS MED COLL,CTR DIABET,8-1 KAWADA CHO,SHINJUKU KU,TOKYO 162,JAPAN.							BRONSTEIN I, 1989, NATURE, V338, P599, DOI 10.1038/338599a0; EGUCHI Y, 1989, Journal of the Japan Diabetes Society, V32, P887; HIRATA Y, 1983, LANCET, V2, P1037; Hirata Y., 1987, HYPOGLYCEMIA, P105; Hirata Y, 1970, J JPN DIABET SOC, V13, P312; PALMER JP, 1987, DIABETES METAB REV, V3, P1005, DOI 10.1002/dmr.5610030409; TOKUNAGA K, 1985, IMMUNOGENETICS, V22, P359, DOI 10.1007/BF00430919; WILKIN TJ, 1987, HYPOGLYCEMIA, P119; ZIEGLER R, 1991, DIABETES, V40, P709, DOI 10.2337/diabetes.40.6.709	9	83	97	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					393	394		10.1016/0140-6736(92)90080-M	http://dx.doi.org/10.1016/0140-6736(92)90080-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346661				2022-12-28	WOS:A1992HD65900005
J	HAMILTON, JD; HARTIGAN, PM; SIMBERKOFF, MS; DAY, PL; DIAMOND, GR; DICKINSON, GM; DRUSANO, GL; EGORIN, MJ; GEORGE, WL; GORDIN, FM; HAWKES, CA; JENSEN, PC; KLIMAS, NG; LABRIOLA, AM; LAHART, CJ; OBRIEN, WA; OSTER, CN; WEINHOLD, KJ; WRAY, NP; ZOLLAPAZNER, SB				HAMILTON, JD; HARTIGAN, PM; SIMBERKOFF, MS; DAY, PL; DIAMOND, GR; DICKINSON, GM; DRUSANO, GL; EGORIN, MJ; GEORGE, WL; GORDIN, FM; HAWKES, CA; JENSEN, PC; KLIMAS, NG; LABRIOLA, AM; LAHART, CJ; OBRIEN, WA; OSTER, CN; WEINHOLD, KJ; WRAY, NP; ZOLLAPAZNER, SB			A CONTROLLED TRIAL OF EARLY VERSUS LATE TREATMENT WITH ZIDOVUDINE IN SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - RESULTS OF THE VETERANS AFFAIRS COOPERATIVE STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; DOUBLE-BLIND; AZIDOTHYMIDINE AZT; CLINICAL-TRIALS; EFFICACY; TOXICITY; PATIENT; HIV	Background. Zidovudine is recommended for asymptomatic and early symptomatic human immunodeficiency virus (HIV) infection. The best time to initiate zidovudine treatment remains uncertain, however, and whether early treatment improves survival has not been established. Methods. We conducted a multicenter, randomized, double-blind trial that compared early zidovudine therapy (beginning at 1500 mg per day) with late therapy in HIV-infected patients who were symptomatic and had CD4+ counts between 0.2 x 10(9) and 0.5 x 10(9) cells per liter (200 to 500 per cubic millimeter) at entry. Those assigned to late therapy initially received placebo and began zidovudine when their CD4+ counts fell below 0.2 x 10(9) per liter (200 per cubic millimeter) or when the acquired immunodeficiency syndrome (AIDS) developed. Results. During a mean follow-up period of more than two years, there were 23 deaths in the early-therapy group (n = 170) and 20 deaths in the late-therapy group (n = 168) (P = 0.48; relative risk [late vs. early], 0.81; 95 percent confidence interval, 0.44 to 1.59). In the early-therapy group, 28 patients progressed to AIDS, as compared with 48 in the late-therapy group (P = 0.02; relative risk, 1.76; 95 percent confidence interval, 1.1 to 2.8). Early therapy increased the time until CD4+ counts fell below 0.2 x l0(9) per liter (200 per cubic millimeter), and it produced more conversions from positive to negative for serum p24 antigen. Early therapy was associated with more anemia, leukopenia, nausea, vomiting, and diarrhea, whereas late therapy was associated with more skin rash. Conclusions. In symptomatic patients with HIV infection, early treatment with zidovudine delays progression to AIDS, but in this controlled study it did not improve survival, and it was associated with more side effects.	DEPT VET AFFAIRS MED CTR,BALTIMORE,MD; DEPT VET AFFAIRS MED CTR,HOUSTON,TX; DEPT VET AFFAIRS MED CTR,LOS ANGELES,CA; DEPT VET AFFAIRS MED CTR,MIAMI,FL; DEPT VET AFFAIRS MED CTR,NEW YORK,NY; DEPT VET AFFAIRS MED CTR,SAN FRANCISCO,CA; DEPT VET AFFAIRS MED CTR,WASHINGTON,DC; VET AFFAIRS COORDINATING CTR,W HAVEN,CT; VET AFFAIRS COORDINATING CTR,ALBUQUERQUE,NM; DUKE UNIV,DURHAM,NC 27706; WALTER REED ARMY MED CTR,WASHINGTON,DC	US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Duke University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	HAMILTON, JD (corresponding author), DEPT VET AFFAIRS MED CTR,508 FULTON ST,DURHAM,NC 27705, USA.		Zolla-Pazner, Susan/S-1864-2019	Zolla-Pazner, Susan/0000-0002-0750-2666				[Anonymous], 1991, NEUROLOGY, V41, P778; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; GITTERMAN SR, 1990, CLIN PHARMACOL THER, V48, P161, DOI 10.1038/clpt.1990.131; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PRICE RW, 1988, J INFECT DIS, V158, P1079, DOI 10.1093/infdis/158.5.1079; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1987, MMWR S1S, V36, pS1; 1989, MMWR SS5, V38, P1	18	335	335	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1992	326	7					437	443		10.1056/NEJM199202133260703	http://dx.doi.org/10.1056/NEJM199202133260703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD164	1346337				2022-12-28	WOS:A1992HD16400003
J	MICHEL, G; RITTER, A; GERKEN, G; ZUMBUSCHENFELDE, KHM; DECKER, R; MANNS, MP				MICHEL, G; RITTER, A; GERKEN, G; ZUMBUSCHENFELDE, KHM; DECKER, R; MANNS, MP			ANTI-GOR AND HEPATITIS-C VIRUS IN AUTOIMMUNE LIVER-DISEASES	LANCET			English	Article							AUTOANTIBODIES; ANTIBODIES	Anti-GOR is an autoantibody found in hepatitis C virus (HCV) infection. We have studied the specificity of this antibody for HCV infection in various groups of autoimmune liver diseases. Anti-HCV was detected by a second generation HCV enzyme-linked immunosorbent assay in 14 of 29 patients with liver-kidney-microsomal (LKM-1) -antibody-positive autoimmune hepatitis type 2 and in all 6 control patients with HCV-RNA-positive chronic hepatitis C. Anti-HCV was not found in those with antinuclear-antibody-positive autoimmune hepatitis type 1 (10 patients), with soluble-liver-protein-antibody-positive autoimmune hepatitis type 3 (8), with primary biliary cirrhosis (9), with systemic lupus erythematosus (SLE) (10), or in healthy controls (13). Anti-GOR was detected in 11 of 14 patients with autoimmune hepatitis type 2 who were all positive for anti-HCV but only in 1 of 15 LKM-1 patients who were negative for anti-HCV. We did not find anti-GOR in any other group of autoimmune liver disease, SLE, or control sera, but this antibody was detected in 3 of 6 patients with chronic hepatitis C. Autoimmune hepatitis type 2 patients who were anti-GOR positive and anti-HCV positive were less likely to be female, were older (p < 0.001), and had lower LKM-1 antibody titres (p < 0.001), lower disease activity, and responded less effectively to immuno- suppression than did those who were anti-HCV negative/anti-GOR negative. The findings show that anti-GOR reflects HCV-specific autoimmunity. HCV seems to induce autoimmunity to both GOR (an HCV-specific autoepitope) and LKM-1 (an epitope that is also recognised by autoimmune hepatitis sera of a different cause). Anti-GOR and LKM-1 antibodies contribute to a better differentiation of chronic hepatitis, a finding that has therapeutic implications.	MED HSCH HANNOVER,ZENTRUM INNERE MED,DEPT GASTROENTEROL & HEPATOL,KONSTANTY GUTSCHOW STR 8,W-3000 HANNOVER 61,GERMANY; ABBOTT LABS,EUROPEAN RES & DEV,WIESBADEN,GERMANY; UNIV MAINZ,DEPT MED 1,W-6500 MAINZ,GERMANY	Hannover Medical School; Johannes Gutenberg University of Mainz								ESTEBAN JI, 1989, LANCET, V2, P294; FUSCONI M, 1990, LANCET, V336, P823, DOI 10.1016/0140-6736(90)93297-3; HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; MANNS M, 1989, J HEPATOL, V9, P272, DOI 10.1016/0168-8278(89)90063-9; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; VENTO S, 1989, LANCET, V2, P926; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256	11	193	192	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					267	269		10.1016/0140-6736(92)91332-3	http://dx.doi.org/10.1016/0140-6736(92)91332-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346282				2022-12-28	WOS:A1992HB52900004
J	DRUMMOND, MF; CRUMP, BJ; LITTLE, VA				DRUMMOND, MF; CRUMP, BJ; LITTLE, VA			FUNDING RESEARCH-AND-DEVELOPMENT IN THE NHS	LANCET			English	Editorial Material									S BIRMINGHAM HLTH AUTHOR,DEPT PUBL HLTH,BIRMINGHAM,ENGLAND; UNIV BIRMINGHAM,CTR HLTH SERV MANAGEMENT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	DRUMMOND, MF (corresponding author), UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND.							COGHLAN A, 1990, NEW SCI         0505, P21; KINGMAN S, 1990, NEW SCI         0127, P25; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; SELBY P, 1991, YORKSHIRE MED    AUT, P18; SHELDON TA, 1991, J MANAGEMENT MED, V5, P6; 1989, NEW SCI         0603, P25; 1991, RES HLTH RES DEV STR	7	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					230	231		10.1016/0140-6736(92)90019-Y	http://dx.doi.org/10.1016/0140-6736(92)90019-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346184				2022-12-28	WOS:A1992HA58900016
J	IINO, M; ENDO, M				IINO, M; ENDO, M			CALCIUM-DEPENDENT IMMEDIATE FEEDBACK-CONTROL OF INOSITOL 1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE	NATURE			English	Article							SMOOTH-MUSCLE CELLS; CHANNELS; TRISPHOSPHATE; OSCILLATIONS; PHOSPHATES; CEREBELLUM	THE temporal and spatial distribution of increases in intracellular Ca2+ concentration is an important factor in cellular signal transduction1. Inositol 1,4,5-trisphosphate (InsP3) plays a key part in agonist-induced Ca2+ release1, which can take place abruptly2 and in a confined space3 by a mechanism that is not fully understood. Here we analyse the kinetics of InsP3-induced Ca2+ release following flash photolysis4-7 of Caged InsP3 or caged Ca2+, and demonstrate that Ca2+-dependent immediate feedback control is an important determinant of the time course of Ca2+ release. The positive feedback mechanism is also important for the 'loading dependence' of InsP3-induced Ca2+ release8. Furthermore, our results support the operation of positive cooperativity in channel opening9 and feedback control augments the steep InsP3 concentration-Ca2+ release relation. These inherent properties of InsP3-induced Ca2+ release are expected to give rise to temporally abrupt and/or spatially confined Ca2+ release within the cell.			IINO, M (corresponding author), UNIV TOKYO, FAC MED, DEPT PHARMACOL, BUNKYO KU, TOKYO 113, JAPAN.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLATT MR, 1990, NATURE, V346, P766, DOI 10.1038/346766a0; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KAPLAN JH, 1990, ANNU REV PHYSIOL, V52, P897; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; SOMLYO AP, 1990, REV PHYSL, V52, P857; WATRAS J, 1991, J NEUROSCI, V11, P3239	24	266	269	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1992	360	6399					76	78		10.1038/360076a0	http://dx.doi.org/10.1038/360076a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1331809				2022-12-28	WOS:A1992JW71700059
J	RAY, CA; BLACK, RA; KRONHEIM, SR; GREENSTREET, TA; SLEATH, PR; SALVESEN, GS; PICKUP, DJ				RAY, CA; BLACK, RA; KRONHEIM, SR; GREENSTREET, TA; SLEATH, PR; SALVESEN, GS; PICKUP, DJ			VIRAL INHIBITION OF INFLAMMATION - COWPOX VIRUS ENCODES AN INHIBITOR OF THE INTERLEUKIN-1-BETA CONVERTING ENZYME	CELL			English	Article							VACCINIA VIRUS; REACTIVE SITE; STRUCTURAL EVIDENCE; EXPRESSION SYSTEM; MESSENGER-RNA; CLEAVAGE SITE; DNA-SEQUENCE; PROTEASE; PURIFICATION; GENERATION	Cowpox virus effectively inhibits inflammatory responses against viral infection in the chick embryo. This study demonstrates that one of the viral genes necessary for this inhibition, the crmA gene (a cytokine response modifier gene), encodes a serpin that is a specific inhibitor of the interleukin-1-beta converting enzyme. This serpin can prevent the proteolytic activation of interleukin-1-beta, thereby suppressing an interleukin-1-beta response to infection. However, the modification of this single cytokine response is not sufficient to inhibit inflammatory responses. This suggests that cowpox virus encodes several cytokine response modifiers that act together to inhibit the release of pro-inflammatory cytokines in response to infection. These viral counter measures to host defenses against infection may contribute significantly to the pathology associated with poxvirus infections.	DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; IMMUNEX CORP, DEPT PROT CHEM, SEATTLE, WA 98101 USA	Duke University; Immunex Corporation	RAY, CA (corresponding author), DUKE UNIV, MED CTR, DEPT MICROBIOL & IMMUNOL, DURHAM, NC 27710 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023886] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI23886] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CERRETTI DP, 1992, IN PRESS SCIENCE; CHUA TP, 1990, IMMUNOLOGY, V69, P202; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1988, INFLAMMATION BASIC P, P195; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Fenner F., 1989, MONKEYPOX VIRUS ORTH, P227; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; FREDRICKSON TN, 1992, IN PRESS VIROLOGY; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Goebel S.J., 1990, VIROLOGY, V179, P517; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; JORNVALL H, 1979, FEBS LETT, V106, P358, DOI 10.1016/0014-5793(79)80532-3; KISO U, 1988, FEBS LETT, V230, P51, DOI 10.1016/0014-5793(88)80640-9; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOTWAL GJ, 1989, J VIROL, V63, P600, DOI 10.1128/JVI.63.2.600-606.1989; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MORII M, 1983, J BIOL CHEM, V258, P2749; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PATEL DD, 1988, P NATL ACAD SCI USA, V85, P9431, DOI 10.1073/pnas.85.24.9431; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; PICKUP DJ, 1984, P NATL ACAD SCI-BIOL, V81, P6817, DOI 10.1073/pnas.81.21.6817; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SALVESEN GS, 1985, J BIOL CHEM, V260, P2432; SAMBHI SK, 1991, P NATL ACAD SCI USA, V88, P4025, DOI 10.1073/pnas.88.9.4025; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1991, SCIENCE, V72, P1349; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; TABOR S, 1990, J BIOL CHEM, V265, P8322; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; [No title captured]	50	921	976	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					597	604		10.1016/0092-8674(92)90223-Y	http://dx.doi.org/10.1016/0092-8674(92)90223-Y			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1339309				2022-12-28	WOS:A1992HV08900004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW REQUIREMENT FOR MANUFACTURERS TO TRACK CERTAIN MEDICAL DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2445	2445		10.1001/jama.267.18.2445	http://dx.doi.org/10.1001/jama.267.18.2445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349355				2022-12-28	WOS:A1992HT06800004
J	LANGER, T; LU, C; ECHOLS, H; FLANAGAN, J; HAYER, MK; HARTL, FU				LANGER, T; LU, C; ECHOLS, H; FLANAGAN, J; HAYER, MK; HARTL, FU			SUCCESSIVE ACTION OF DNAK, DNAJ AND GROEL ALONG THE PATHWAY OF CHAPERONE-MEDIATED PROTEIN FOLDING	NATURE			English	Article							HEAT-SHOCK PROTEINS; RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; STRESS PROTEINS; RNA-POLYMERASE; ATP HYDROLYSIS; GENE; PRECURSOR; RHODANESE	The main stress proteins of Escherichia coli function in an ordered protein-folding reaction. DnaK (heat-shock protein 70) recognizes the folding polypeptide as an extended chain and cooperates with DnaJ in stabilizing an intermediate conformational state lacking ordered tertiary structure. Dependent on GrpE and ATP hydrolysis, the protein is then transferred to GroEL (heat-shock protein 60) which acts catalytically in the production of the native state. This sequential mechanism of chaperone action may represent an important pathway for the folding of newly synthesized polypeptides.	SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LABS,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Memorial Sloan Kettering Cancer Center; University of California System; University of California Berkeley; Yale University			Hayer-Hartl, Manajit/V-8078-2017; Hartl, F. Ulrich/Y-8206-2019	Hayer-Hartl, Manajit/0000-0001-8213-6742; Langer, Thomas/0000-0003-1250-1462				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; BADCOE, 1991, BIOCHEMISTRY-US, V30, P9195; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLUMBERG RP, 1991, NATURE, V349, P627; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CRAIG EA, 1987, P NATL ACAD SCI USA, V84, P4156, DOI 10.1073/pnas.84.12.4156; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2206; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; NORTH G, 1991, NATURE, V354, P434, DOI 10.1038/354434a0; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OSTOASALOMA P, 1990, BIOCHIM BIOPHYS ACTA, V1041, P140; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1990, J BIOL CHEM, V265, P5967; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	68	874	892	1	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					683	689		10.1038/356683a0	http://dx.doi.org/10.1038/356683a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1349157				2022-12-28	WOS:A1992HQ14600050
J	CUMANO, A; PAIGE, CJ; ISCOVE, NN; BRADY, G				CUMANO, A; PAIGE, CJ; ISCOVE, NN; BRADY, G			BIPOTENTIAL PRECURSORS OF B-CELLS AND MACROPHAGES IN MURINE FETAL LIVER	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; LYMPHOCYTE PRECURSORS; EXPRESSION; ANTIBODIES; FAMILY; MOUSE; DIFFERENTIATION; PURIFICATION; CLONING; GENES	LYMPHOCYTES (B and T cells) derive continuously from the same multipotential stem cells that produce myeloid cells, including erythrocytes, granulocytes and macrophages 1,2. Tri- and bipotential myeloid intermediates between the multipotential stem cells and later unipotential cells have been identified using clonal methods in culture. Although similar methods have detected committed pre-B cells in mouse fetal liver 3, earlier progenitors with additional non-B lineage options have not been demonstrated in normal tissues. We report the characterization and purification of fetal liver cells that generate clones containing both macrophages and B cells, identified biochemically and morphologically. The common origin of the two cell types was shown by culture of single precursor cells. Their dual potential and unrearranged immunoglobulin loci place the precursors before exclusive B-lineage commitment in the haematopoietic hierarchy. The availability of such cells in purified form will allow direct study of lineage choice in cells having both lymphoid and non-lymphoid options.			CUMANO, A (corresponding author), ONTARIO CANC INST, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA.			Cumano, Ana/0000-0002-4578-959X				BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; COLLINS LS, 1987, J IMMUNOL, V138, P1082; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; CUMANO A, 1990, EUR J IMMUNOL, V20, P2183, DOI 10.1002/eji.1830201006; CUMANO A, 1992, EMBO J, V11, P590; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRISON DE, 1980, BLOOD, V55, P77; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KINCADE PW, 1981, J IMMUNOL, V127, P2262; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LECLAIR KP, 1986, EMBO J, V5, P3227, DOI 10.1002/j.1460-2075.1986.tb04633.x; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MELCHERS F, 1976, COLD SPRING HARB SYM, V41, P147; MONK RJ, 1981, CELL, V24, P301, DOI 10.1016/0092-8674(81)90319-6; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OHARA A, 1991, INT IMMUNOL, V3, P703, DOI 10.1093/intimm/3.7.703; PAIGE CJ, 1983, NATURE, V302, P711, DOI 10.1038/302711a0; RAFF MC, 1976, NATURE, V259, P224, DOI 10.1038/259224a0; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STALL AM, 1984, J IMMUNOL, V132, P787; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	30	315	318	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1992	356	6370					612	615		10.1038/356612a0	http://dx.doi.org/10.1038/356612a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1348572				2022-12-28	WOS:A1992HP03100052
J	HAN, R; BREITBURD, F; MARCHE, PN; ORTH, G				HAN, R; BREITBURD, F; MARCHE, PN; ORTH, G			LINKAGE OF REGRESSION AND MALIGNANT CONVERSION OF RABBIT VIRAL PAPILLOMAS TO MHC CLASS-II GENES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; EPIDERMODYSPLASIA VERRUCIFORMIS; CERVICAL DYSPLASIA	HUMAN papillomaviruses associated with cutaneous 1 and anogenital 2 cancers induce intraepithelial precursor lesions which may regress spontaneously or progress into invasive carcinomas 3,4. Cell mediated immune responses are probably involved in regression of precancerous lesions 1,5-8 and the polymorphism of the genes responsible may thus have a key role in the variability of the host response. Skin warts and cancers induced in rabbits by Shope papillomavirus 9-12 provide a model to test this hypothesis. We analysed a restriction-fragment-length polymorphism of major histocompatibility complex class I and class II genes 13,14 and T-cell receptor beta-chain genes 15 in infected domestic rabbits. We found a strong linkage between wart regression and a DR-alpha EcoRI fragment, and an increased relative risk of malignant transformation associated with a DQ-alpha PvuII fragment. This indicates a genetic control of wart evolution, involving genes in the class II region of the major histocompatibility complex.	INST PASTEUR, INSERM, U190, UNITE PAPILLOMAVIRUS, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE; INST PASTEUR, CNRS, URA 359, UNITE IMMUNOCHIM ANALYT, F-75724 PARIS 15, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			ORTH, Gérard C/C-2518-2009; Marche, Patrice N/K-5060-2013	Marche, Patrice N/0000-0002-8930-9340				Beard JW, 1934, J EXP MED, V60, P723, DOI 10.1084/jem.60.6.723; BEUTLER B, 1990, J INVEST DERMATOL, V95, pS81, DOI 10.1111/1523-1747.ep12874797; BOURKER GF, 1985, INTERPRETATION USES; CARMICHAEL JA, 1989, AM J OBSTET GYNECOL, V160, P916, DOI 10.1016/0002-9378(89)90310-4; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; COOPER KD, 1990, J INVEST DERMATOL, V94, P769, DOI 10.1111/1523-1747.ep12874631; FAVRE M, 1975, J VIROL, V15, P1239, DOI 10.1128/JVI.15.5.1239-1247.1975; GEORGES E, 1984, J VIROL, V51, P530, DOI 10.1128/JVI.51.2.530-538.1984; HAUSEN HZ, 1989, CANCER RES, V49, P4677; Hurst EW, 1933, J EXP MED, V58, P607, DOI 10.1084/jem.58.5.607; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KREIDER JW, 1981, ADV CANCER RES, V35, P81, DOI 10.1016/S0065-230X(08)60909-4; MAJEWSKI S, 1990, J AM ACAD DERMATOL, V22, P423, DOI 10.1016/0190-9622(90)70058-P; MALEJCZYK J, 1991, CELL IMMUNOL, V136, P155, DOI 10.1016/0008-8749(91)90390-W; MARCHE PN, 1986, J IMMUNOL, V137, P1729; MARCHE PN, 1989, IMMUNOGENETICS, V29, P273, DOI 10.1007/BF00717913; MENEGUZZI G, 1991, VIROLOGY, V181, P62, DOI 10.1016/0042-6822(91)90470-V; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; NASSERI M, 1984, J VIROL, V51, P706, DOI 10.1128/JVI.51.3.706-712.1984; ORTH G, 1987, PAPOVAVIRIDAE, V2, P199; PAYAMI H, 1989, AM J HUM GENET, V45, P541; Rous P, 1935, J EXP MED, V62, P523, DOI 10.1084/jem.62.4.523; SITTISOMBUT N, 1989, J IMMUNOGENET, V16, P63; Tagami H, 1985, Clin Dermatol, V3, P170, DOI 10.1016/0738-081X(85)90062-8; WANK R, 1991, NATURE, V352, P723, DOI 10.1038/352723a0; YOSHIKAWA T, 1990, IMMUNOGENETICS, V32, P398, DOI 10.1007/BF00241633	26	129	132	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					66	68						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1347151				2022-12-28	WOS:A1992HG60200057
J	BEARD, K; BULPITT, C; MASCIETAYLOR, H; OMALLEY, K; SEVER, P; WEBB, S				BEARD, K; BULPITT, C; MASCIETAYLOR, H; OMALLEY, K; SEVER, P; WEBB, S			MANAGEMENT OF ELDERLY PATIENTS WITH SUSTAINED HYPERTENSION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; TRIAL	Objective - To assess the clinical benefits of treating hypertension in elderly patients and to derive practical guidelines regarding indications, goals, and forms of treatment. Design - Review of six published randomised trials. Results - Active treatment of hypertension in elderly patients was associated with significant improvements in several indices of cardiovascular morbidity and mortality, particularly the incidence of fatal and non-fatal strokes. On the basis of the trial data, combined systolic and diastolic hypertension was defined as a sustained systolic pressure > 160 mm Hg and diastolic pressure > 90 mm Hg. There is convincing evidence that efforts should be made to reduce both systolic and diastolic pressures to below these levels in patients up to the age of 80 years. Isolated systolic hypertension was defined as a systolic pressure > 160 mm Hg in the presence of a diastolic pressure < 90 mm Hg. Two trials reported benefit from the treatment of isolated systolic hypertension in patients up to the age of 80, and further trials are underway to support or refute this recommendation. Diuretics have an established role in the management of hypertension in elderly patients; beta adrenoceptor antagonists have given variable results, and the benefits are less impressive than with diuretic based regimens. Newer agents show promise in the treatment of elderly patients, particularly in the presence of coexisting disease, but their effects on morbidity and mortality have not been evaluated in large randomised trials. Conclusions - Diuretics rather than beta-blockers are the treatment of choice for patients with uncomplicated hypertension, but combinations of drugs may be required in as many as 50% of patients.	ST CHARLES HOSP, LONDON W10 6DZ, ENGLAND; SEACROFT HOSP, DEPT GERIATR MED, LEEDS LS14 6UH, W YORKSHIRE, ENGLAND; ST MARYS HOSP, SCH MED, LONDON W2 1PG, ENGLAND; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT MED, LONDON W12 0HS, ENGLAND; ROYAL COLL SURG IRELAND, CLIN PHARMACOL, DUBLIN 2, IRELAND; VICTORIA INFIRM, GLASGOW G42 9TY, SCOTLAND	Imperial College London; Imperial College London; Imperial College London; Royal College of Surgeons - Ireland								AMERY A, 1985, LANCET, V1, P1349; AMERY A, 1986, LANCET, V2, P589; Amery A, 1991, Aging (Milano), V3, P287; [Anonymous], 1991, JAMA, V265, P3255; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; PETRIE J, 1989, BLOOD PRESSURE MEASU; POTTER JF, 1989, HDB HYPERTENSION, V12, P352; STAESSEN J, 1989, HDB HYPERTENSION, V2, P320; 1981, MED J AUSTRALIA, V2, P398	12	107	109	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	1992	304	6824					412	416		10.1136/bmj.304.6824.412	http://dx.doi.org/10.1136/bmj.304.6824.412			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1347711	Green Published, Bronze			2022-12-28	WOS:A1992HE38900018
J	DEBONO, DP; SAMANI, NJ; SPYT, TJ; HARTSHORNE, T; THRUSH, AJ; EVANS, DH				DEBONO, DP; SAMANI, NJ; SPYT, TJ; HARTSHORNE, T; THRUSH, AJ; EVANS, DH			TRANSCUTANEOUS ULTRASOUND MEASUREMENT OF BLOOD-FLOW IN INTERNAL MAMMARY ARTERY TO CORONARY-ARTERY GRAFTS	LANCET			English	Article								Transcutaneous doppler ultrasound was used to examine internal-mammary-artery (IMA) blood-flow in 26 patients with IMA coronary bypass grafts. The ungrafted right IMA could be seen in all of 19 patients, the grafted left IMA in 16 of 26, and the grafted right IMA in 3 of 7. The velocity profile recorded from the proximal part of the grafted IMA is distinct from that of an ungrafted artery, with a systolic peak which reflects graft capacitance in the face of high intramyocardial resistance, and a diastolic peak which represents graft conductance when intramyocardial resistance is low. Total graft blood-flow can be estimated from the mean velocity and the measured vessel diameter, resting flows ranged from 22 to 79 ml/min. In recently grafted patients, resting graft blood-flow correlated with myocardial "run-off" estimated from preoperative arteriograms; graft blood-flow increased appropriately with exercise. This simple, non-invasive technique to measure IMA graft blood-flow may find applications for routine postoperative follow-up of patients with IMA grafts and for studies on the physiology and pharmacology of coronary artery blood-flow.	UNIV LEICESTER,DEPT CARDIOL,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT SURG,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT MED PHYS,LEICESTER LE1 7RH,ENGLAND	University of Leicester; University of Leicester; University of Leicester								BARNER HB, 1982, ANN THORAC SURG, V34, P408, DOI 10.1016/S0003-4975(10)61402-6; BRANDT PWT, 1977, CLIN RADIOL, V28, P261; CANVER CC, 1991, J VASC SURG, V13, P294, DOI 10.1016/0741-5214(91)90222-G; Evans DH, 1989, DOPPLER ULTRASOUND P, P233; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; MILLS NL, 1989, J THORAC CARDIOV SUR, V98, P73; SONS H, 1989, European Heart Journal, V10, P304	7	77	79	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					379	381		10.1016/0140-6736(92)90076-F	http://dx.doi.org/10.1016/0140-6736(92)90076-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346657				2022-12-28	WOS:A1992HD65900001
J	PADFIELD, PL; TEELUCKSINGH, S; GOUGH, KJ; HOLT, P; TIBI, L				PADFIELD, PL; TEELUCKSINGH, S; GOUGH, KJ; HOLT, P; TIBI, L			BECLOMETHASONE AND OSTEOCALCIN	LANCET			English	Letter							RADIOIMMUNOASSAY		FISONS PHARMACEUT,LOUGHBOROUGH,ENGLAND; ROYAL INFIRM,DEPT CLIN CHEM,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh	PADFIELD, PL (corresponding author), WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							MEERAN K, 1991, American Review of Respiratory Disease, V143, pA625; PERETZ, 1991, LANCET, V338, P1340; POWER MJ, 1989, CLIN CHEM, V35, P1408; PRICE PA, 1980, P NATL ACAD SCI-BIOL, V77, P2234, DOI 10.1073/pnas.77.4.2234; 1991, LANCET, V338, P60	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					369	370		10.1016/0140-6736(92)91691-Z	http://dx.doi.org/10.1016/0140-6736(92)91691-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346446				2022-12-28	WOS:A1992HC77100048
J	WHITE, NJ; WALLER, D; CRAWLEY, J; NOSTEN, F; CHAPMAN, D; BREWSTER, D; GREENWOOD, BM				WHITE, NJ; WALLER, D; CRAWLEY, J; NOSTEN, F; CHAPMAN, D; BREWSTER, D; GREENWOOD, BM			COMPARISON OF ARTEMETHER AND CHLOROQUINE FOR SEVERE MALARIA IN GAMBIAN CHILDREN	LANCET			English	Article							FALCIPARUM-MALARIA; QUININE	Artemether is an oil-soluble methyl ether of artemesinin (qinghaosu). It has been studied extensively in China, where it has been shown to be rapidly effective in severe falciparum malaria. Nearly all the patients studied previously were adults. We have investigated the efficacy of artemether in children with moderate or severe falciparum malaria. In the preliminary study of moderately severe malaria, 30 Gambian children were randomised in pairs to receive either intramuscular artemether (4 mg/kg loading dose followed by 2 mg/kg daily) or intramuscular chloroquine ('Nivaquine') 3.5 mg base/kg every 6 h. Both drugs were well tolerated and rapidly effective. The times to parasite clearance were significantly shorter in the artemether recipients (mean 36.7 [SD 11.3] vs 48.4 [16.8] h, p < 0.05). 43 children with severe malaria were then randomised to receive intramuscular treatment with the same regimens of artemether (n = 21) or chloroquine (n = 22) as used in the preliminary study. 8 children (19%) died. There were no significant differences between the two groups in the clinical, haematological, biochemical, or parasitological measures of therapeutic response in survivors and there was no evidence of local or systemic toxicity. Despite similar parasite counts on admission, clearance times overall were longer in severe malaria than in moderate malaria. Artemether is a well tolerated and rapidly effective parenteral treatment for severe malaria in children, and would be especially valuable in areas with chloroquine-resistant P falciparum.	CHO QUAN HOSP, WELLCOME CLIN RES UNIT, HO CHI MINH CITY, VIETNAM; ROYAL VICTORIA HOSP, DEPT PAEDIAT, BANJUL, SENEGAMBIA; UNIV OXFORD, JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND; MRC LABS, FAJARA, SENEGAMBIA	University of Oxford	WHITE, NJ (corresponding author), MAHIDOL UNIV, FAC TROP MED, 420-6 RAJVITHI RD, BANGKOK 10400, THAILAND.		White, Nicholas J/I-4629-2012; Nosten, Francois/AAC-5509-2019; White, Nick/AAC-6527-2019	Nosten, Francois/0000-0002-7951-0745; White, Nick/0000-0002-1897-1978	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1979, CHINESE MED J-PEKING, V92, P811; ARNOLD K, 1990, T ROY SOC TROP MED H, V84, P499, DOI 10.1016/0035-9203(90)90012-4; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; LI Q, 1982, J TRADIT CHIN MED, V2, P125; MOLYNEUX ME, 1989, Q J MED, V71, P441; MURRAY CJL, 1990, T ROY SOC TROP MED H, V84, P1, DOI 10.1016/0035-9203(90)90364-K; Pe Than Myint, 1986, Southeast Asian J Trop Med Public Health, V17, P19; WHITE NJ, 1988, NEW ENGL J MED, V319, P1493, DOI 10.1056/NEJM198812083192301; WHITE NJ, 1989, T ROY SOC TROP MED H, V83, P767, DOI 10.1016/0035-9203(89)90322-2; WHITE NJ, 1988, EUR J CLIN PHARMACOL, V34, P1, DOI 10.1007/BF01061409; WHITE NJ, 1989, LANCET, V2, P1313, DOI 10.1016/S0140-6736(89)91918-1	11	62	65	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1992	339	8789					317	321		10.1016/0140-6736(92)91644-N	http://dx.doi.org/10.1016/0140-6736(92)91644-N			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346408				2022-12-28	WOS:A1992HC77100001
J	BIECHE, I; CHAMPEME, MH; MATIFAS, F; HACENE, K; CALLAHAN, R; LIDEREAU, R				BIECHE, I; CHAMPEME, MH; MATIFAS, F; HACENE, K; CALLAHAN, R; LIDEREAU, R			LOSS OF HETEROZYGOSITY ON CHROMOSOME-7Q AND AGGRESSIVE PRIMARY BREAST-CANCER	LANCET			English	Article							SHORT ARM; CELL CARCINOMA; ALLELE LOSS; GENES; DELETIONS; LUNG; 11P; ADENOCARCINOMA; METASTASIS; ONCOGENE	Genetic alterations are believed to be important in the origin and dissemination of breast cancer. Cytogenetic rearrangements on chromosome 7 are common in breast tumours. We used the c-met proto-oncogene probe, which detects sequences on chromosome 7q31, to analyse tumour and blood leucocyte DNA samples from 245 patients with primary breast cancers. The pmetH polymorphic probe detected a high frequency of allele loss (40.5%) among the 121 informative (heterozygous) patients. This genetic alteration was not significantly associated with standard prognostic features including tumour size, histopathological grade, and lymph-node or steroid receptor status. However, patients with loss of heterozygosity on chromosome 7q31 in primary tumour DNA had significantly shorter metastasis-free survival (p = 0.00022) and overall survival (p = 0.0036) after surgery than patients without this alteration. These findings indicate that this region of chromosome 7 might be the site of a breast tumour or metastasis suppressor gene.	CTR RENE HUGUENIN,ONCOVIROL LAB,5 RUE GASTON LATOUCHE,F-92211 ST CLOUD,FRANCE; CTR RENE HUGUENIN,DEPT MED STAT,F-92211 ST CLOUD,FRANCE; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	Rene Huguenin Hospital; Rene Huguenin Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429				ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BIECHE I, 1990, INT J CANCER, V46, P1136, DOI 10.1002/ijc.2910460632; BIECHE I, 1990, HUM GENET, V85, P101; BLOOM HJG, 1957, BRIT J CANCER, V11, P35; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; COLLARD JG, 1987, CANCER RES, V47, P6666; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; EHLEN T, 1990, ONCOGENE, V5, P219; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEY MF, 1989, BRIT J CANCER, V59, P750, DOI 10.1038/bjc.1989.157; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; LEISTER I, 1990, CANCER RES, V50, P7232; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LUNBERG C, 1987, P NATL ACAD SCI USA, V84, P2372; MACKAY J, 1988, LANCET, V2, P1384; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; Maniatis T., 1982, MOL CLONING; MERLO GR, 1989, CANCER RES, V49, P6966; MOTOMURA K, 1988, Genomics, V2, P180, DOI 10.1016/0888-7543(88)90101-2; OLUMI AF, 1990, CANCER RES, V50, P7081; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SKINNER MA, 1990, CANCER RES, V50, P2303; SOBEL ME, 1990, JNCI-J NATL CANCER I, V82, P267, DOI 10.1093/jnci/82.4.267; TRENT JM, 1990, NEW ENGL J MED, V322, P1508, DOI 10.1056/NEJM199005243222107; TRENT JM, 1985, BREAST CANCER RES TR, V5, P221, DOI 10.1007/BF01806017; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; 1989, CYTOGENET CELL GENET, V51, P713; 1980, EUR J CANCER, V16, P1513	40	185	185	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					139	143		10.1016/0140-6736(92)90208-K	http://dx.doi.org/10.1016/0140-6736(92)90208-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346009				2022-12-28	WOS:A1992GZ96800002
J	BRAHAMS, D				BRAHAMS, D			LEGAL STATUS OF DEAD PATIENTS	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					173	174		10.1016/0140-6736(92)90227-T	http://dx.doi.org/10.1016/0140-6736(92)90227-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346022				2022-12-28	WOS:A1992GZ96800017
J	ZUCKERMAN, M; COX, R; OXFORD, J; TAYLOR, J; WOOD, J; HAAHEIM, L				ZUCKERMAN, M; COX, R; OXFORD, J; TAYLOR, J; WOOD, J; HAAHEIM, L			ACTIVITY OF INFLUENZA VACCINE AGAINST VIRUS-STRAINS NOW CIRCULATING	LANCET			English	Letter									NATL INST BIOL STAND & CONTROLS,S MIMMS,ENGLAND; UNIV BERGEN,DEPT MICROBIOL & IMMUNOL,N-5014 BERGEN,NORWAY	National Institute for Biological Standards & Control; University of Bergen	ZUCKERMAN, M (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,LONDON E1 2AD,ENGLAND.							OXFORD JS, 1990, TOPLEY WILSONS PRINC, P291; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; ZUCKERMAN MA, 1991, J MED VIROL, V33, P133, DOI 10.1002/jmv.1890330213; 1991, WKLY EPIDEMIOL  1129, P357; 1991, COMMUNICAB DIS REP, V1, P6	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					118	118		10.1016/0140-6736(92)91021-Y	http://dx.doi.org/10.1016/0140-6736(92)91021-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345833				2022-12-28	WOS:A1992GZ15600020
J	SPRENGER, F; NUSSLEINVOLHARD, C				SPRENGER, F; NUSSLEINVOLHARD, C			TORSO RECEPTOR ACTIVITY IS REGULATED BY A DIFFUSIBLE LIGAND PRODUCED AT THE EXTRACELLULAR TERMINAL REGIONS OF THE DROSOPHILA EGG	CELL			English	Article							FEMALE STERILE MUTATIONS; TYROSINE KINASE-ACTIVITY; DORSAL-VENTRAL POLARITY; TOLL GENE-PRODUCT; SIGNAL TRANSDUCTION; TRUNCATED RECEPTOR; CONSERVED FEATURES; EMBRYONIC TERMINI; RNA-POLYMERASE; 2ND CHROMOSOME	torso encodes a receptor tyrosine kinase (torso) required for anterior and posterior terminal development of the Drosophila embryo. Injecting eggs with in vitro synthesized torso mRNAs revealed that torso activation is governed by an extracellular molecule, presumably the torso ligand, produced at terminal regions of the egg during early embryogenesis. In the absence of torso, the ligand shows no apparent localization, indicating that it is diffusible and normally bound by an excess of torso receptor at the egg poles. Mutant ligand-binding torso proteins can suppress telson formation in a dominant negative manner, suggesting that the ligand is limited in amount. Analysis of torso mutations indicates that torso functions as a tyrosine kinase and that gain-of-function mutations causing ligand-independent activation are located in the extracellular domain.	MAX PLANCK INST ENTWICKLUNGSBIOL, GENET ABT, W-7400 TUBINGEN, GERMANY	Max Planck Society								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BERGER SL, 1987, GUIDE MOL CLONING TE, V152; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; DICKSON B, 1992, IN PRESS GENES DEV, V6; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEINE G, 1981, EUR J BIOCHEM, V116, P419; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PERRIMON N, 1986, GENETICS, V113, P695; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PIGNONI F, 1992, DEV BIOL, V115, P221; Roberts D.B., 1986, P1; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1989, GENETICS, V121, P101; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEVENS LM, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P145; STJOHNSTON D, 1992, CELL, V68, P201; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SZABAD J, 1989, GENETICS, V122, P823; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARN RM, 1982, DEV BIOL, V89, P540, DOI 10.1016/0012-1606(82)90344-X; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WHITTAKER J, 1990, DIABETES CARE, V13, P576, DOI 10.2337/diacare.13.6.576; Wieschaus E., 1986, P199; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	55	137	137	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					987	1001		10.1016/0092-8674(92)90394-R	http://dx.doi.org/10.1016/0092-8674(92)90394-R			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1333890				2022-12-28	WOS:A1992KB99000011
J	HORMIGO, A; ALVES, M				HORMIGO, A; ALVES, M			PERIPHERAL NEUROPATHY IN A PATIENT RECEIVING ENALAPRIL	BRITISH MEDICAL JOURNAL			English	Letter							CAPTOPRIL				HORMIGO, A (corresponding author), INST PORTUGUES ONCOL FRANCISCO GENTIL,LISBON,PORTUGAL.							ATKINSON AB, 1980, LANCET, V2, P36; CHAKRABORTY TK, 1987, POSTGRAD MED J, V63, P221, DOI 10.1136/pgmj.63.737.221; INMAN WHW, 1988, BRIT MED J, V297, P826, DOI 10.1136/bmj.297.6652.826; SAMANTA A, 1985, BRIT MED J, V291, P1172	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1332	1332		10.1136/bmj.305.6865.1332-a	http://dx.doi.org/10.1136/bmj.305.6865.1332-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1336423	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992KA77300025
J	ZIEGELSTEIN, RC; CHENG, L; CAPOGROSSI, MC				ZIEGELSTEIN, RC; CHENG, L; CAPOGROSSI, MC			FLOW-DEPENDENT CYTOSOLIC ACIDIFICATION OF VASCULAR ENDOTHELIAL-CELLS	SCIENCE			English	Article							DEPOLARIZATION-INDUCED ALKALINIZATION; INTRACELLULAR PH REGULATION; LYMPHOCYTE VOLUME REGULATION; ACTIVATING FACTOR PRODUCTION; ESTER INDUCED ACTIVATION; BOVINE AORTIC-CELLS; CHICK HEART-CELLS; NA+-H+ EXCHANGE; SHEAR-STRESS; PROXIMAL TUBULES	Hemodynamic shear stress affects endothelial cell structure and function, but little is known about the signal transduction mechanisms involved in these processes. The effect of laminar shear stress on cytosolic pH (pH(i)) was examined in rat aortic endothelial cells cultured in glass capillary tubes. Shear stress forces led to a rapid decrease in pH(i) (maximal effect 0.09 pH unit at 13.4 dynes per square centimeter). Removal of specific ions or addition of exchange inhibitors suggests that in vascular endothelial cells shear stress forces activate both an alkali extruder, sodium ion-independent chloride-bicarbonate ion exchange, and an acid extruder, sodium-hydrogen ion exchange; the net effect in physiologic buffer with the bicarbonate ion is a decrease in pH(i).	NIA,FAMILY PRACTICE RES CTR,CARDIOVASC SCI LAB,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,DIV CARDIOL,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLANK PS, 1992, AM J PHYSIOL, V263, pH276, DOI 10.1152/ajpheart.1992.263.1.H276; BLANK PS, AM J PHYSL; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; CAPOGROSSI MC, UNPUB; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLE OF, 1986, CELL BIOL INT REP, V10, P399, DOI 10.1016/0309-1651(86)90034-2; COOKE JP, 1991, J CLIN INVEST, V88, P1663, DOI 10.1172/JCI115481; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; DAVIES PF, 1984, J CLIN INVEST, V73, P1121, DOI 10.1172/JCI111298; DULL RO, 1991, AM J PHYSIOL, V261, pH149, DOI 10.1152/ajpheart.1991.261.1.H149; ESCOBALES N, 1990, AM J PHYSIOL, V259, pC640, DOI 10.1152/ajpcell.1990.259.4.C640; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; GHIGO D, 1988, J BIOL CHEM, V263, P19437; GLEESON D, 1990, AM J PHYSIOL, V258, pG299, DOI 10.1152/ajpgi.1990.258.2.G299; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HSIEH HJ, 1992, J CELL PHYSIOL, V150, P552, DOI 10.1002/jcp.1041500316; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; KITAZONO T, 1988, BIOCHEM BIOPH RES CO, V152, P1304, DOI 10.1016/S0006-291X(88)80427-3; LANSMAN JB, 1988, NATURE, V331, P481, DOI 10.1038/331481a0; LIU S, 1990, J GEN PHYSIOL, V96, P1247, DOI 10.1085/jgp.96.6.1247; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; NAKACHE M, 1988, P NATL ACAD SCI USA, V85, P1841, DOI 10.1073/pnas.85.6.1841; NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF342, DOI 10.1152/ajprenal.1989.256.2.F342; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF354, DOI 10.1152/ajprenal.1989.256.2.F354; THOMAS RC, 1989, NATURE, V337, P601, DOI 10.1038/337601a0; VAUGHANJONES RD, 1983, NATURE, V301, P522, DOI 10.1038/301522a0; WHITAKER JE, 1991, ANAL BIOCHEM, V194, P330, DOI 10.1016/0003-2697(91)90237-N; ZIEGELSTEIN RC, UNPUB; ZIEGELSTEIN RC, 1991, AM J PHYSIOL, V260, pH1698	34	110	111	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					656	659		10.1126/science.1329207	http://dx.doi.org/10.1126/science.1329207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1329207				2022-12-28	WOS:A1992JU74500059
J	BOCK, T; PEDERSEN, CR; JOSEFSEN, K; BOTTAZZO, GF; PALMER, JP; BUSCHARD, K				BOCK, T; PEDERSEN, CR; JOSEFSEN, K; BOTTAZZO, GF; PALMER, JP; BUSCHARD, K			NO RISK OF DIABETES AFTER INSULIN-SHOCK TREATMENT	LANCET			English	Article							ISLET-CELL ANTIBODIES; AUTOANTIBODIES; MELLITUS	Prophylactic insulin treatment is effective in preventing diabetes in animal models of insulin-dependent diabetes mellitus (IDDM) but the safety of such preventive treatment in prediabetic human subjects remains unclear; insulin is a potential autoantigen that could accelerate beta-cell decompensation and onset of IDDM. We have investigated whether insulin treatment of non-diabetic diabetic subjects increases the risk of subsequent development of diabetes in a retrospective study of Danish patients who received insulin-shock treatment for psychiatric disorders. Mean age of the 481 patients at insulin-shock treatment was 32.6 (range 12.9-69.6) years. The patients received 59 (6-200) injections of 78 (16-261) IU bovine/porcine insulin. Hospital records provided an average of 22.0 (0.6-51.2) years' observation. During the observation time, IDDM developed in only 1 patient; 1.3 cases would be expected from Danish incidence data (p=0.75). Similarly, there was no significant difference between the observed number of cases of non-insulin-dependent diabetes mellitus (NIDDM) and the number expected from Danish prevalence data (12 vs 10.2; p=0.45). We collected blood samples from 27 of the patients. All but 2 (who had previously diagnosed NIDDM) had normal fasting blood glucose and plasma insulin concentrations, none had islet-cell antibodies, and only 2 had detectable insulin antibodies. Thus, the risk of diabetes was not increased by the use of many insulin injections in these non-diabetic subjects. We conclude that clinical trials on prevention of IDDM by prophylactic insulin treatment can be regarded as safe.	UNIV LONDON LONDON HOSP,COLL MED,DEPT IMMUNOL,LONDON E1 1BB,ENGLAND; UNIV WASHINGTON,VET AFFAIRS MED CTR,SEATTLE,WA 98195	University of London; University College London; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BOCK, T (corresponding author), KOMMUNE HOSP COPENHAGEN,BARTHOLIN INST,DK-1399 COPENHAGEN K,DENMARK.			Buschard, Karsten/0000-0002-0126-7423	NIDDK NIH HHS [DK 02456] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASPLIN CM, 1981, DIABETES CARE, V4, P337, DOI 10.2337/diacare.4.3.337; ATKINSON MA, 1990, DIABETES, V39, P933, DOI 10.2337/diabetes.39.8.933; ATKINSON MA, 1986, DIABETES, V35, P894, DOI 10.2337/diabetes.35.8.894; Beck-Nielsen H, 1990, Ugeskr Laeger, V152, P2; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BERSON SA, 1964, DIABETES, V13, P247; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BOTTAZZO GF, 1991, ANN MED, V23, P453, DOI 10.3109/07853899109148089; BOTTAZZO GF, 1980, LANCET, V1, P668; CHRISTAU B, 1982, DIABETOLOGIA, V23, P160; Christy M, 1979, Diabetes Care, V2, P127, DOI 10.2337/diacare.2.2.127; DAMSGAARD EM, 1987, DIABETES CARE, V10, P26, DOI 10.2337/diacare.10.1.26; DEAN BM, 1986, DIABETOLOGIA, V29, P339, DOI 10.1007/BF00452073; GOTFREDSEN CF, 1985, DIABETOLOGIA, V28, P933, DOI 10.1007/BF00703140; KLOPPEL G, 1976, ACTA ENDOCRINOL-COP, V83, P107; KUHL C, 1975, ACTA ENDOCRINOL-COP, V79, P7409; KURTZ AB, 1980, DIABETOLOGIA, V18, P147, DOI 10.1007/BF00290492; LACY PE, 1965, DIABETES, V14, P634, DOI 10.2337/diab.14.10.634; LIKE AA, 1986, DIABETES, V35, pA74; MCGRATH D, 1950, J MENT SCI, V96, P285; MORGAN CR, 1965, ANAT REC, V153, P49, DOI 10.1002/ar.1091530107; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; SUTTON M, 1988, METABOLISM, V37, P1005, DOI 10.1016/0026-0495(88)90058-3; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	24	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1504	1506		10.1016/0140-6736(92)91264-9	http://dx.doi.org/10.1016/0140-6736(92)91264-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351186				2022-12-28	WOS:A1992HZ17500004
J	MALGAROLI, A; TSIEN, RW				MALGAROLI, A; TSIEN, RW			GLUTAMATE-INDUCED LONG-TERM POTENTIATION OF THE FREQUENCY OF MINIATURE SYNAPTIC CURRENTS IN CULTURED HIPPOCAMPAL-NEURONS	NATURE			English	Article							PROTEIN KINASE-C; FROG NEUROMUSCULAR-JUNCTION; EXCITATORY AMINO-ACIDS; CENTRAL NERVOUS-SYSTEM; PRESYNAPTIC ENHANCEMENT; TRANSMITTER RELEASE; QUANTAL ANALYSIS; RAT HIPPOCAMPUS; PERFORANT PATH; TRANSMISSION	Glutamate application at synapses between hippocampal neurons in culture produces long-term potentiation of the frequency of spontaneous miniature synaptic currents, together with long-term potentiation of evoked synaptic currents. The mini frequency potentiation is initiated postsynaptically and requires activity of NMDA receptors. Although the frequency of unitary quantal responses increases strongly, their amplitude remains little changed with potentiation. Tests of postsynaptic responsiveness rule out recruitment of latent glutamate receptor clusters. Thus, postsynaptic induction can lead to enhancement of presynaptic transmitter release. The sustained potentiation of mini frequency is expressed even in the absence of Ca2+ entry into presynaptic terminals.	STANFORD UNIV, MED CTR, BECKMAN CTR, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University			Malgaroli, Antonio/I-5090-2013	Malgaroli, Antonio/0000-0003-3758-7477				AMARAL DG, 1990, PROG BRAIN RES, V83, P1; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; BAXTER D, 1985, P NATL ACAD SCI USA, V80, P7347; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS T V P, 1988, P3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BROWN TH, 1979, BRAIN RES, V177, P194, DOI 10.1016/0006-8993(79)90931-4; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CHERNEVSKAYA NI, 1991, NATURE, V349, P418, DOI 10.1038/349418a0; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CLEMENTS J, 1991, NATURE, V353, P396, DOI 10.1038/353396a0; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; FINCH DM, 1990, BRAIN RES, V518, P269, DOI 10.1016/0006-8993(90)90979-L; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; HUBBARD JI, 1968, J PHYSIOL-LONDON, V197, P639, DOI 10.1113/jphysiol.1968.sp008579; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KORN H, 1991, NATURE, V350, P282, DOI 10.1038/350282a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LEVTOV A, 1980, J PHYSIOL-LONDON, V309, P247, DOI 10.1113/jphysiol.1980.sp013507; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LONGENEC.HE, 1970, NATURE, V225, P701, DOI 10.1038/225701a0; Lynch G, 1991, Hippocampus, V1, P9, DOI 10.1002/hipo.450010103; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MARTIN AR, 1977, HDB PHYSL          1, V1, P329; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SEGAL M, 1989, NEUROSCI LETT, V101, P169, DOI 10.1016/0304-3940(89)90525-9; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; VORONIN LL, 1991, NEUROSCI RES COMMUN, V8, P87	55	341	343	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					134	139		10.1038/357134a0	http://dx.doi.org/10.1038/357134a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1349728				2022-12-28	WOS:A1992HU12200049
J	NIGHTINGALE, SL				NIGHTINGALE, SL			2 NEW THERAPIES AVAILABLE UNDER TREATMENT IND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2445	2445		10.1001/jama.267.18.2445	http://dx.doi.org/10.1001/jama.267.18.2445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349355				2022-12-28	WOS:A1992HT06800006
J	CALVERT, GM; HORNUNG, RW; SWEENEY, MH; FINGERHUT, MA; HALPERIN, WE				CALVERT, GM; HORNUNG, RW; SWEENEY, MH; FINGERHUT, MA; HALPERIN, WE			HEPATIC AND GASTROINTESTINAL EFFECTS IN AN OCCUPATIONAL COHORT EXPOSED TO 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCARIC ACID EXCRETION; HUMAN HEALTH; P-DIOXIN; SEVESO; TCDD; WORKERS; CHILDREN; AREA	Objective. - To examine the effect of occupational exposure to substances contaminated with 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) on the liver and gastrointestinal system. Design. - A medical survey. Participants. - The exposed participants were employed at two chemical plants more than 15 years earlier in the manufacture of sodium trichlorophenol and its derivatives. The reference group consisted of individuals with no occupational exposure to phenoxy herbicides and who lived within the communities of the workers. A total of 281 workers and 260 unexposed referents participated in the medical study. Measurements and Main Results. - The workers had substantial exposure to substances contaminated with TCDD, as evidenced by a mean serum TCDD level, lipid adjusted, of 220 pg per gram of lipid compared with a mean of 7 pg per gram of lipid in the referents. Compared with the unexposed reference group, workers had a statistically significantly elevated risk for an out-of-range gamma-glutamyltransferase (GGT) level (odds ratio, 2.27; 95% confidence interval, 1.17 to 4.39 [unadjusted for confounders]). In multivariate analyses run with logistic regression, a statistically significant interaction was found between TCDD exposure and lifetime alcohol consumption, indicating that the elevated risk for an out-of-range GGT was confined to those workers with a history of alcohol consumption and that the risk among the alcohol-consuming workers for an out-of-range GGT increased with increasing TCDD level. No difference was found between workers and referents for any of the other liver and gastrointestinal outcomes of interest. Conclusions. - This study found no evidence of an elevated risk for clinical hepatic or gastrointestinal disease in a group of workers with high exposure to TCDD. However, TCDD-exposed workers with a history of sufficient alcohol consumption were found to have a statistically significantly elevated risk for an out-of-range GGT compared with referents.			CALVERT, GM (corresponding author), NIOSH,DIV SURVEILLANCE HAZARD EVALUAT & FIELD STUDIES,INDUSTRWIDE,CINCINNATI,OH 45226, USA.							BONACCORSI A, 1978, AMBIO, V7, P234; BOND GG, 1983, BRIT J IND MED, V40, P318; CALVERT G, IN PRESS CHEMOSPHERE; CALVERT GM, 1991, AM REV RESPIR DIS, V144, P1302, DOI 10.1164/ajrccm/144.6.1302; FINGERHUT M, 1990, PB91125971; GOLDBERG DM, 1979, CLIN ENZYMOL, P123; GOLDMANN PJ, 1973, HAUTARZT, V24, P149; GUZELIAN PS, 1985, ENVIRON HEALTH PERSP, V60, P159, DOI 10.2307/3429958; HOFFMAN RE, 1986, JAMA-J AM MED ASSOC, V255, P2031, DOI 10.1001/jama.255.15.2031; HOOK GER, 1975, CHEM-BIOL INTERACT, V10, P199; IDEO G, 1982, CLIN CHIM ACTA, V120, P273, DOI 10.1016/0009-8981(82)90368-0; IDEO G, 1985, ENVIRON HEALTH PERSP, V60, P151, DOI 10.2307/3429957; LATHROP GD, 1987, ADA188262; LATHROP GD, 1984, ADA138340; MARTIN JV, 1984, BRIT J IND MED, V41, P254; MAY G, 1982, BRIT J IND MED, V39, P128; MOCARELLI P, 1986, JAMA-J AM MED ASSOC, V256, P2687, DOI 10.1001/jama.256.19.2687; MOSES M, 1984, AM J IND MED, V5, P161, DOI 10.1002/ajim.4700050303; NILSSEN O, 1990, AM J EPIDEMIOL, V132, P318, DOI 10.1093/oxfordjournals.aje.a115661; PAZDEROVAVEJLUPKOVA J, 1981, ARCH ENVIRON HEALTH, V36, P5, DOI 10.1080/00039896.1981.10667598; REGGIANI G, 1980, J TOXICOL ENV HEALTH, V6, P27, DOI 10.1080/15287398009529828; SCHECTER A, 1986, CHEMOSPHERE, V15, P1273, DOI 10.1016/0045-6535(86)90401-7; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; SUSKIND RR, 1984, JAMA-J AM MED ASSOC, V251, P2372, DOI 10.1001/jama.251.18.2372; SUSKIND RR, 1978, JOINT C NATIONAL I E, P7; SWEENEY MH, 1989, CHEMOSPHERE, V19, P973, DOI 10.1016/0045-6535(89)90443-8; SWEENEY MH, 1990, THESIS U MICHIGAN AN; WOLFE WH, 1991, ADA241874; 1987, SAS STAT GUIDE PERSO	29	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2209	2214		10.1001/jama.267.16.2209	http://dx.doi.org/10.1001/jama.267.16.2209			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1348289				2022-12-28	WOS:A1992HN84100031
J	HUNTER, CA; JENNINGS, FW; ADAMS, JH; MURRAY, M; KENNEDY, PGE				HUNTER, CA; JENNINGS, FW; ADAMS, JH; MURRAY, M; KENNEDY, PGE			SUBCURATIVE CHEMOTHERAPY AND FATAL POSTTREATMENT REACTIVE ENCEPHALOPATHIES IN AFRICAN TRYPANOSOMIASIS	LANCET			English	Article							GAMBIENSE SLEEPING SICKNESS; ARSENICAL ENCEPHALOPATHY; TRIAL; DNA	The treatment of late-stage African sleeping sickness in man is often complicated by a post-treatment reactive encephalopathy. The basis of this pathological reaction was investigated in a mouse model of African trypanosomiasis. Subcurative treatment with diminazene aceturate, which did not clear parasites from the central nervous system, resulted in a post-treatment meningoencephalitis similar to that seen in man. By contrast, a curative regimen of melaminylthioarsenite and 5-nitroimidazole, which cleared parasites from the central nervous system, did not cause any pathological reaction in the mice. This result indicates that subcurative treatment leads to the development of the post-treatment encephalopathy. Evidence that this may also be the case in man was provided by the detection of trypanosome DNA with the polymerase chain reaction in the brains of 9 patients who had died as the result of a post-treatment reaction. Our findings suggest that more aggressive treatment regimens, which ensure the elimination of trypanosomes from the central nervous system, may prevent post-treatment reactions in patients.	UNIV GLASGOW,DEPT VET MED,GLASGOW G61 1QH,SCOTLAND; UNIV GLASGOW,DEPT VET PARASITOL,GLASGOW G61 1QH,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROL,GLASGOW G51 4TF,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow			Hunter, Christopher/H-1970-2011					ADAMS JH, 1986, NEUROPATH APPL NEURO, V12, P81, DOI 10.1111/j.1365-2990.1986.tb00682.x; AROZ JOL, 1987, T R SOC TROP MED HYG, V81, P192; FOULKES JR, 1975, J TROP MED HYG, V78, P72; HALLER L, 1986, AM J TROP MED HYG, V35, P94, DOI 10.4269/ajtmh.1986.35.94; HUNTER CA, 1991, INFECT IMMUN, V59, P4636, DOI 10.1128/IAI.59.12.4636-4640.1991; HURST EW, 1959, J PATHOL BACTERIOL, V77, P523, DOI 10.1002/path.1700770224; Jennings F W, 1983, Contrib Microbiol Immunol, V7, P147; JENNINGS FW, 1991, TROP MED PARASITOL, V42, P157; LAMBERT PH, 1981, J CLIN INVEST, V67, P77, DOI 10.1172/JCI110035; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; MURRAY PK, 1974, IMMUNOLOGY, V27, P825; ORMEROD WE, 1971, AFRICAN TRYPANOSOMIA, P588; PEPIN J, 1989, LANCET, V1, P1246, DOI 10.1016/S0140-6736(89)92340-4; PEPIN J, 1991, T ROY SOC TROP MED H, V85, P222, DOI 10.1016/0035-9203(91)90032-T; POLTERA AA, 1980, T ROY SOC TROP MED H, V74, P706, DOI 10.1016/0035-9203(80)90183-2; SLOOF P, 1983, NUCLEIC ACIDS RES, V11, P3889, DOI 10.1093/nar/11.12.3889; VANNIEUWENHOVE S, 1985, T ROY SOC TROP MED H, V79, P692, DOI 10.1016/0035-9203(85)90195-6; VEEKEN HJGM, 1989, TROP GEOGR MED, V41, P113; 1986, WHO TECH REP SER, V739	19	42	42	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					956	958		10.1016/0140-6736(92)91531-C	http://dx.doi.org/10.1016/0140-6736(92)91531-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348799				2022-12-28	WOS:A1992HP03600004
J	ROTH, A; KALUSKI, E; FELNER, S; HELLER, K; LANIADO, S				ROTH, A; KALUSKI, E; FELNER, S; HELLER, K; LANIADO, S			CLONIDINE FOR PATIENTS WITH RAPID ATRIAL-FIBRILLATION	ANNALS OF INTERNAL MEDICINE			English	Article								Objective: To determine whether clonidine can slow ventricular rate in patients with rapid atrial fibrillation. Design: Randomized, controlled trial, with a 4-hour follow-up period. Setting: Emergency room of a university hospital. Patients: A consecutive sample of 18 hemodynamically stable patients who were evaluated or treated for rapid atrial fibrillation. Exclusion criteria included acute or terminal illness; current use of antiarrhythmic agents, calcium-channel blockers, or beta-blockers; excessive hypertension; pulmonary, valvular, or pericardial disease; and electrolyte imbalance. Interventions: Patients were randomly assigned to receive either "no treatment" (control group) or clonidine, 0.075 mg orally, at baseline and after 2 hours if heart rate did not decrease by at least 20%. Measurements: Blood pressure was measured by the same nurse in the same arm for 4 consecutive hours, and a full 12-lead electrocardiographic evaluation was done. Main Results: Heart rate decreased to below 100 beats/min in eight of nine patients receiving clonidine compared with two of nine patients in the control group. The difference in the mean decreases in heart rate was 38 beats/min (95% CI, 20 to 56 beats/min). Six patients who were treated with clonidine and one patient in the control group reverted to normal sinus rhythm. Systolic blood pressure decreased slightly in both groups, without significant differences. Clinical follow-up was uneventful. Conclusion: Low-dose clonidine was an easy, efficient, and effective treatment for patients with rapid atrial fibrillation who were hemodynamically stable.	SACKLER SCH MED, TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	ROTH, A (corresponding author), TEL AVIV SOURASKY MED CTR, DEPT CARDIOL, 6 WEIZMANN, IL-64239 TEL AVIV, ISRAEL.		Kaluski, Edo/Q-1972-2019	Kaluski, Edo/0000-0002-1400-3988				AHLQUIST RP, 1948, AM J PHYSIOL, V153, P586, DOI 10.1152/ajplegacy.1948.153.3.586; FLACKE JW, 1987, ANESTHESIOLOGY, V67, P11, DOI 10.1097/00000542-198707000-00003; LANGER SZ, 1980, HYPERTENSION, V2, P372, DOI 10.1161/01.HYP.2.4.372; MEIJLER FL, 1985, J AM COLL CARDIOL, V5, pA60, DOI 10.1016/S0735-1097(85)80464-2; ROTH A, 1986, CIRCULATION, V73, P316, DOI 10.1161/01.CIR.73.2.316; SCHWARTZ PJ, 1991, CARDIAC ELECTROPHYSI, P330; STRUTHERS AD, 1985, BRIT J CLIN PHARMACO, V19, P311, DOI 10.1111/j.1365-2125.1985.tb02649.x; WAXMAN HL, 1981, ANN INTERN MED, V94, P1, DOI 10.7326/0003-4819-94-1-1	8	26	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					388	390		10.7326/0003-4819-116-5-388	http://dx.doi.org/10.7326/0003-4819-116-5-388			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1346564				2022-12-28	WOS:A1992HF26800007
J	PULSINELLI, W				PULSINELLI, W			PATHOPHYSIOLOGY OF ACUTE ISCHEMIC STROKE	LANCET			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; GLUTAMATE NEUROTOXICITY; CEREBRAL-ISCHEMIA; BRAIN-DAMAGE; THRESHOLDS				PULSINELLI, W (corresponding author), CORNELL UNIV,MED CTR,COLL MED,CEREBROVASC DIS RES CTR,DEPT NEUROL & NEUROSCI,1300 YORK AVE,NEW YORK,NY 10021, USA.							ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BRIERLEY JB, 1976, GREENFIELDS NEUROPAT, P43; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1987, J NEUROSCI, V7, P369; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; GINSBERG MD, 1990, CEREBROVAS BRAIN MET, V2, P58; HOSSMANN KA, 1973, ARCH NEUROL-CHICAGO, V29, P375, DOI 10.1001/archneur.1973.00490300037004; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KAPLAN B, 1991, STROKE, V22, P1032, DOI 10.1161/01.STR.22.8.1032; KRAIG RP, 1990, J CEREBR BLOOD F MET, V10, P104, DOI 10.1038/jcbfm.1990.13; LEVY DE, 1975, J NEUROL NEUROSUR PS, V38, P1197, DOI 10.1136/jnnp.38.12.1197; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; OBRENOVITCH TP, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P97; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; PULSINELLI W, IN PRESS PROG BRAIN; PULSINELLI WA, 1983, J NEUROCHEM, V40, P1500, DOI 10.1111/j.1471-4159.1983.tb13599.x; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165	22	256	265	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					533	536		10.1016/0140-6736(92)90347-6	http://dx.doi.org/10.1016/0140-6736(92)90347-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346887	hybrid			2022-12-28	WOS:A1992HF63100012
J	DURRINGTON, PN; BHATNAGAR, D				DURRINGTON, PN; BHATNAGAR, D			WRONG LESSON FROM FINNISH TRIAL OF CARDIOVASCULAR-DISEASE PREVENTION	LANCET			English	Letter							DRUGS				DURRINGTON, PN (corresponding author), UNIV MANCHESTER,MANCHESTER ROYAL INFIRM,DEPT MED,MANCHESTER M13 9WL,LANCS,ENGLAND.							AMES RP, 1986, DRUGS, V32, P260, DOI 10.2165/00003495-198632030-00003; DURRINGTON PN, 1985, ATHEROSCLEROSIS, V55, P187, DOI 10.1016/0021-9150(85)90097-8; Durrington PN, 1989, HYPERLIPIDAEMIA DIAG; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MILLER NE, 1987, AM J CARDIOL, V60, pE17; OGLESBY P, 1991, JAMA-J AM MED ASSOC, V266, P1267; STEINBERG D, 1989, CIRCULATION, V80, P1070, DOI 10.1161/01.CIR.80.4.1070; STRANDBERG TE, 1991, JAMA-J AM MED ASSOC, V266, P1225, DOI 10.1001/jama.266.9.1225	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					488	488		10.1016/0140-6736(92)91089-Q	http://dx.doi.org/10.1016/0140-6736(92)91089-Q			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346833				2022-12-28	WOS:A1992HE93200022
J	SAI, FT; MEASHAM, DM				SAI, FT; MEASHAM, DM			SAFE MOTHERHOOD INITIATIVE - GETTING OUR PRIORITIES STRAIGHT	LANCET			English	Editorial Material									FAMILY CARE INT,588 BROADWAY,SUITE 510,NEW YORK,NY 10012; UNIV GHANA,SCH MED,DEPT COMMUNITY HLTH,ACCRA,GHANA	University of Ghana								FAUVEAU V, 1991, LANCET, P1183; FORGY L, 1992, WORLD BANK WORKING P, V846; HUQUE ZAA, 1991, NOV WORLD BANK MOTH; Maine D, 1991, SAFE MOTHERHOOD PROG; MEASHAM DM, IN PRESS DEV SAFE MO; ROONEY C, 1991, NOV WORLD BANK MOTH; 1990, SEMINAR REASSESSMENT	7	17	17	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					478	480		10.1016/0140-6736(92)91072-G	http://dx.doi.org/10.1016/0140-6736(92)91072-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE932	1346829				2022-12-28	WOS:A1992HE93200015
J	LUCAS, A; MORLEY, R; COLE, TJ; LISTER, G; LEESONPAYNE, C				LUCAS, A; MORLEY, R; COLE, TJ; LISTER, G; LEESONPAYNE, C			BREAST-MILK AND SUBSEQUENT INTELLIGENCE QUOTIENT IN CHILDREN BORN PRETERM	LANCET			English	Article							BIRTH-WEIGHT INFANTS; MOTHERS CHOICE; DIET	There is considerable controversy over whether nutrition in early life has a long-term influence on neurodevelopment. We have shown previously that, in preterm infants, mother's choice to provide breast milk was associated with higher developmental scores at 18 months. We now report data on intelligence quotient (IQ) in the same children seen at 7 1/2-8 years. IQ was assessed in 300 children with an abbreviated version of the Weschler Intelligence Scale for Children (revised Anglicised). Children who had consumed mother's milk in the early weeks of life had a significantly higher IQ at 7 1/2-8 years than did those who received no maternal milk. An 8.3 point advantage (over half a standard deviation) in IQ remained even after adjustment for differences between groups in mother's education and social class (p < 0.0001). This advantage was associated with being fed mother's milk by tube rather than with the process of breastfeeding. There was a dose-response relation between the proportion of mother's milk in the diet and subsequent IQ. Children whose mothers chose to provide milk but failed to do so had the same IQ as those whose mothers elected not to provide breast milk. Although these results could be explained by differences between groups in parenting skills or genetic potential (even after adjustment for social and educational factors), our data point to a beneficial effect of human milk on neurodevelopment.	UNIV CAMBRIDGE,DEPT PAEDIAT,CAMBRIDGE,ENGLAND; NORFOLK & NORWICH HOSP,DEPT COMMUNITY CHILD HLTH,NORWICH NR1 3SR,NORFOLK,ENGLAND; JESSOP HOSP WOMEN,DEPT PAEDIAT,SHEFFIELD S3 7RE,S YORKSHIRE,ENGLAND	University of Cambridge; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	LUCAS, A (corresponding author), MRC,DUNN NUTR UNIT,DOWNHAMS LANE,MILTON RD,CAMBRIDGE CB4 1XJ,ENGLAND.		Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200				BROAD B, 1972, NZ MED J, V76, P28; LUCAS A, 1989, ARCH DIS CHILD, V64, P1570, DOI 10.1136/adc.64.11.1570; LUCAS A, 1984, ARCH DIS CHILD, V59, P722, DOI 10.1136/adc.59.8.722; LUCAS A, 1990, LANCET, V335, P1477, DOI 10.1016/0140-6736(90)93026-L; LUCAS A, 1988, ARCH DIS CHILD, V63, P48, DOI 10.1136/adc.63.1.48; McNemar Q, 1974, J CONSULT CLIN PSYCH, V42, P145, DOI DOI 10.1037/H0035842; MORLEY R, 1988, ARCH DIS CHILD, V63, P1382, DOI 10.1136/adc.63.11.1382; POLLOCK JI, 1989, ARCH DIS CHILD, V64, P763, DOI 10.1136/adc.64.5.763; READ LC, 1988, FETAL NEONATAL GROWT, P131; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; Rogerson BCF, 1939, J MENT SCI, V85, P1163, DOI 10.1192/bjp.85.359.1163; SACK J, 1980, HUMAN MILK ITS BIOL, P56; SILVA PA, 1978, AUST PAEDIATR J, V14, P265; TAYLOR B, 1977, NEW ZEAL MED J, V85, P235; [No title captured]; 1974, ANGLICIZED REVISED E; [No title captured]	17	825	861	2	100	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					261	264		10.1016/0140-6736(92)91329-7	http://dx.doi.org/10.1016/0140-6736(92)91329-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346280				2022-12-28	WOS:A1992HB52900002
J	PEERLINCK, K; ARNOUT, J; VERMYLEN, J				PEERLINCK, K; ARNOUT, J; VERMYLEN, J			FACTOR-VIII SOLUTIONS IN PREFILLED SYRINGES	LANCET			English	Letter											PEERLINCK, K (corresponding author), CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,CAMPUS GASTHUISBERG,B-3000 LOUVAIN,BELGIUM.							BURNOUF T, 1991, VOX SANG, V60, P8, DOI 10.1111/j.1423-0410.1991.tb00864.x; HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x; MATUCCI M, 1985, SCAND J HAEMATOL, V34, P22; MORFINI M, 1991, THROMB DIATH HAEMO, V66, P381; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; SCHWINN H, 1989, ARZNEIMITTEL-FORSCH, V39-2, P1302	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					303	304		10.1016/0140-6736(92)91371-E	http://dx.doi.org/10.1016/0140-6736(92)91371-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346301				2022-12-28	WOS:A1992HB52900030
J	KJELDSENKRAGH, J; HAUGEN, M; FFORRE, O				KJELDSENKRAGH, J; HAUGEN, M; FFORRE, O			DIET THERAPY IN RHEUMATOID-ARTHRITIS	LANCET			English	Letter									OSLO SANITETSFORENING REUMATISM HOSP,OSLO,NORWAY		KJELDSENKRAGH, J (corresponding author), NATL HOSP,INST IMMUNOL & RHEUMATOL,N-0172 OSLO,NORWAY.		Kjeldsen-Kragh, Jens/A-4472-2008; Haugen, Margaretha/H-7007-2016	Haugen, Margaretha/0000-0001-5924-5000				OFARRELLY, 1992, LANCET, V339, P68	1	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					250	250		10.1016/0140-6736(92)90059-C	http://dx.doi.org/10.1016/0140-6736(92)90059-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346210				2022-12-28	WOS:A1992HA58900051
J	JONES, EA; BERGASA, NV				JONES, EA; BERGASA, NV			THE PRURITUS OF CHOLESTASIS AND THE OPIOID SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VISUAL ANALOG SCORE; ORAL NALMEFENE; APPRAISAL				JONES, EA (corresponding author), NIDDKD,DIGEST DIS BRANCH,LIVER UNIT,LIVER DIS SECT,BLDG 10,ROOM 4D-52,BETHESDA,MD 20892, USA.							BERGASA NV, 1992, J HEPATOL, V15, P220, DOI 10.1016/0168-8278(92)90040-V; BERGASA NV, 1992, GASTROENTEROLOGY, V102, P544, DOI 10.1016/0016-5085(92)90102-5; BERGASA NV, 1992, HEPATOLOGY, V16, pA152; BERGASA NV, 1991, AM J GASTROENTEROL, V86, P1404; BERGASA NV, 1991, HEPATOLOGY, V14, pA154; BERGASA NV, 1990, HEPATOLOGY, V12, P887; BERNSTEIN J E, 1979, Archives of Dermatology, V115, P1366, DOI 10.1001/archderm.115.11.1366; BLANCHARD SG, 1988, OPIATE RECEPTORS, P425; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DIXON R, 1986, CLIN PHARMACOL THER, V39, P49, DOI 10.1038/clpt.1986.9; DOMONKOS AN, 1982, ANDREWS DISEASES SKI, P56; GAL TJ, 1986, CLIN PHARMACOL THER, V40, P537, DOI 10.1038/clpt.1986.220; KOENIGSTEIN H, 1948, ARCH DERMATOL SYPH, V57, P828, DOI 10.1001/archderm.1948.01520180045006; MCCORMACK HM, 1988, PSYCHOL MED, V18, P1007, DOI 10.1017/S0033291700009934; OLIVERAS JL, 1986, J NEUROSCI, V6, P3086; SUMMERFIELD JA, 1980, BRIT J CLIN PHARMACO, V10, P180, DOI 10.1111/j.1365-2125.1980.tb01742.x; SUMMERFIELD JA, 1980, BRIT J DERMATOL, V102, P275; SWAIN MG, 1992, GASTROENTEROLOGY, V103, P630, DOI 10.1016/0016-5085(92)90857-U; TALBOT T L, 1991, Biomedical Instrumentation and Technology, V25, P400; TAO PL, 1987, J PHARMACOL EXP THER, V240, P809; THOMAS DA, 1992, BRAIN RES, V585, P315, DOI 10.1016/0006-8993(92)91227-6; THORNTON JR, 1988, BRIT MED J, V297, P1501, DOI 10.1136/bmj.297.6662.1501	22	60	61	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3359	3362		10.1001/jama.268.23.3359	http://dx.doi.org/10.1001/jama.268.23.3359			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB732	1333541				2022-12-28	WOS:A1992KB73200030
J	MURAKAMI, Y; MATSUFUJI, S; KAMEJI, T; HAYASHI, S; IGARASHI, K; TAMURA, T; TANAKA, K; ICHIHARA, A				MURAKAMI, Y; MATSUFUJI, S; KAMEJI, T; HAYASHI, S; IGARASHI, K; TAMURA, T; TANAKA, K; ICHIHARA, A			ORNITHINE DECARBOXYLASE IS DEGRADED BY THE 26S-PROTEASOME WITHOUT UBIQUITINATION	NATURE			English	Article							RETICULOCYTE LYSATE; PEST HYPOTHESIS; MOUSE KIDNEY; 26S COMPLEX; DEGRADATION; PROTEINS; CELLS; PROTEASE; PURIFICATION; TURNOVER	ORNITHINE decarboxylase (ODC), a key enzyme in polyamine biosynthesis, is the most rapidly turned over mammalian enzyme1. We have shown that its degradation is accelerated by ODC antizyme2,3, an inhibitory protein induced by polyamines4,5. This is a new type of enzyme regulation and may be a model for selective protein degradation. Here we report the identification of the protease responsible for ODC degradation. Using a cell-free degradation system, we demonstrate that immunodepletion of proteasomes from cell extracts causes almost complete loss of ATP- and antizyme-dependent degradation of ODC. In addition, purified 26S proteasome complex, but not the 20S proteasome, catalyses ODC degradation in the absence of ubiquitin. These results strongly suggest that the 26S proteasome, widely viewed as specific for ubiquitin-conjugated proteins, is the main enzyme responsible for ODC degradation. The 26S proteasome may therefore have a second role in ubiquitin-independent proteolysis.	CHIBA UNIV,FAC PHARMACEUT SCI,CHIBA 260,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Chiba University; Tokushima University	MURAKAMI, Y (corresponding author), JIKEI UNIV,DEPT NUTR,MINATO KU,TOKYO 105,JAPAN.		Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556; Igarashi, Kazuei/0000-0003-3751-3187				ARMON T, 1990, J BIOL CHEM, V265, P20723; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V205, P9; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KAMEJI T, IN PRESS BIOCH J; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; LI X, 1992, MOL CELL BIOL, V12, P3356; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; NISHIYAMA M, 1988, PREP BIOCHEM, V18, P227, DOI 10.1080/00327488808062524; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROGRES S, 1986, SCIENCE, V234, P20; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V196, P647, DOI 10.1111/j.1432-1033.1991.tb15861.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEELY JE, 1982, J BIOL CHEM, V257, P7549; SHERMAN MY, 1992, EMBO J, V11, P71; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J BIOL CHEM, V263, P16209	31	690	700	2	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					597	599		10.1038/360597a0	http://dx.doi.org/10.1038/360597a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1334232				2022-12-28	WOS:A1992KB95900089
J	RANDHAWA, PS; JAFFE, R; DEMETRIS, AJ; NALESNIK, M; STARZL, TE; CHEN, YY; WEISS, LM				RANDHAWA, PS; JAFFE, R; DEMETRIS, AJ; NALESNIK, M; STARZL, TE; CHEN, YY; WEISS, LM			EXPRESSION OF EPSTEIN-BARR VIRUS-ENCODED SMALL RNA (BY THE EBER-1 GENE) IN LIVER SPECIMENS FROM TRANSPLANT RECIPIENTS WITH POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSITU HYBRIDIZATION; DISORDERS; EBV; LYMPHOMAS; TISSUES; INDIVIDUALS; LYMPHOCYTES; PATHOLOGY; HEPATITIS; THERAPY	Background. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disease (PTLD) develops in 1 to 10 percent of transplant recipients, in whom it can be treated by a reduction in the level of immunosuppression. We postulated that the tissue expression of the small RNA transcribed by the EBER-1 gene during latent EBV infection would identify patients at risk for PTLD. Methods. We studied EBER-1 gene expression in liver specimens obtained from 24 patients 2 days to 22 months before the development of PTLD, using in situ hybridization with an oligonucleotide probe. Control specimens were obtained from 20 recipients of allografts with signs of injury due to organ retrieval, acute graft rejection, or viral hepatitis in whom PTLD had not developed 9 to 71 months after the biopsy. Results. Of the 24 patients with PTLD, 17 (71 percent) had specimens in which 1 to 40 percent of mononuclear cells were positive for the EBER-1 gene. In addition, 10 of these 17 patients (59 percent) had specimens with histopathological changes suggestive of EBV hepatitis. In every case, EBER-1-positive cells were found within the lymphoproliferative lesions identified at autopsy. Only 2 of the 20 controls (10 percent) had specimens with EBER-1-positive cells (P<0.001), and such cells were rare. Conclusions. EBER-1 gene expression in liver tissue precedes the occurrence of clinical and histologic PTLD. The possibility of identifying patients at risk by the method we describe here and preventing the occurrence of PTLD by a timely reduction of immunosuppression needs to be addressed by future prospective studies.	UNIV PITTSBURGH, DIV TRANSPLANTAT BIOL, PITTSBURGH, PA 15260 USA; PRESBYTERIAN UNIV HOSP, PITTSBURGH TRANSPLANT INST, PITTSBURGH, PA USA; PRESBYTERIAN UNIV HOSP, DEPT SURG, PITTSBURGH, PA USA; CHILDRENS HOSP PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA USA; CITY HOPE NATL MED CTR, DEPT PATHOL, DUARTE, CA 91010 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; City of Hope			Randhawa, Parmjeet/H-4285-2019		NCI NIH HHS [CA-50341] Funding Source: Medline; NHLBI NIH HHS [HL-13108] Funding Source: Medline; NIAAA NIH HHS [A-3176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA050341] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAMBER M, 1981, GUT, V22, P854, DOI 10.1136/gut.22.10.854; BUSH JL, 1989, LAB MED, V20, P318, DOI 10.1093/labmed/20.5.318; CROUSE CA, 1990, J CLIN MICROBIOL, V28, P1026, DOI 10.1128/JCM.28.5.1026-1032.1990; DEMETRIS AJ, 1987, PATHOL ANNU, V22, P347; Gowing N F, 1975, Pathol Annu, V10, P1; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; KATZ BZ, 1989, J INFECT DIS, V160, P589, DOI 10.1093/infdis/160.4.589; KIKUTA H, 1988, NATURE, V333, P455, DOI 10.1038/333455a0; LOCKER J, 1989, AM J PATHOL, V135, P977; LUKES RJ, 1958, AM J PATHOL, V34, P586; MARKIN RS, 1987, GASTROENTEROLOGY, V93, P1210, DOI 10.1016/0016-5085(87)90246-0; NALESNIK MA, 1988, AM J PATHOL, V133, P173; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; RANDHAWA PS, 1990, AM J SURG PATHOL, V14, P538, DOI 10.1097/00000478-199006000-00004; RANDHAWA PS, 1991, AM J PATHOL, V138, P1027; ROONEY C, 1989, J VIROL, V63, P1531, DOI 10.1128/JVI.63.4.1531-1539.1989; SCHUURMAN HJ, 1989, AM J CLIN PATHOL, V91, P461, DOI 10.1093/ajcp/91.4.461; Sheibani K, 1984, Semin Diagn Pathol, V1, P235; SHIBATA D, 1991, BLOOD, V77, P1527; STARZL TE, 1984, LANCET, V1, P583; STRAUCH B, 1974, LANCET, V1, P234; SU IJ, 1991, BLOOD, V77, P799; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; WEISS LM, 1990, AM J PATHOL, V137, P979; WEISS LM, 1991, AM J PATHOL, V139, P1259; WEISS LM, 1991, J HISTOCHEM CYTOCHEM, V39, P1237, DOI 10.1177/39.9.1918942; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	30	160	161	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1710	1714		10.1056/NEJM199212103272403	http://dx.doi.org/10.1056/NEJM199212103272403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1331789	Green Accepted			2022-12-28	WOS:A1992KA89700003
J	MEZEY, E; PALKOVITS, M				MEZEY, E; PALKOVITS, M			LOCALIZATION OF TARGETS FOR ANTIULCER DRUGS IN CELLS OF THE IMMUNE-SYSTEM	SCIENCE			English	Article							ACETYLCHOLINE-RECEPTOR GENES; GASTRIC-ACID SECRETION; DUODENAL-ULCER; DOPAMINE AGONISTS; MOLECULAR-CLONING; PARIETAL-CELLS; RAT; CYSTEAMINE; PROPIONITRILE; EXPRESSION	The gastric mucosa consists of the epithelium, which lines the lumen, the lamina propria, and the muscularis mucosae. The targets of drugs used to treat stomach and duodenal ulcers are thought to be the acid-secreting parietal cells of the epithelium. However, immune cells in the lamina propria are the only cells that showed detectable messenger RNAs for histamine, muscarinic, gastrin, and dopamine receptors by in situ hybridization histochemistry. None of the epithelial cells expressed any of these messenger RNAs. Thus, the targets of antiulcer drugs seem to be cells of the immune system in the gut and not parietal cells, as generally believed. This conclusion may revise the thinking about ulcer formation and may shed light on the etiology of such chronic small intestinal diseases as Crohn's disease.	NIMH,CELL BIOL LAB,BETHESDA,MD 20892; NINCDS,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	MEZEY, E (corresponding author), SEMMELWEIS UNIV MED,SCH MED,NEUROMORPHOL LAB,H-1085 BUDAPEST 8,HUNGARY.		Palkovits, Miklos/F-2707-2013; Mezey, Eva/A-8105-2008	Palkovits, Miklos/0000-0003-0578-0387; Mezey, Eva/0000-0002-5907-4691				BIENENSTOCK J, 1980, IMMUNOLOGY, V41, P249; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRANDBORG LL, 1969, GASTROENTEROLOGY, V57, P191; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BRIMBLECOMBE RW, 1975, J INT MED RES, V3, P86, DOI 10.1177/030006057500300205; BRUNTON LL, 1990, PHARM BASE THERAPEUT, V1, P897; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHUANG CN, 1991, SCAND J GASTROENTERO, V26, P95, DOI 10.3109/00365529109093184; CRABBE PA, 1966, GASTROENTEROLOGY, V51, P305; CRABBE PA, 1965, LAB INVEST, V14, P235; FIOCCHI C, 1990, IMMUNOLOGY IMMUNOPAT, P107; GALLAGHER G, 1987, J PHARMACOL EXP THER, V240, P883; GLAVIN GB, 1989, J PHARMACOL EXP THER, V251, P726; GLAVIN GB, 1990, DIGEST DIS SCI, V35, P1153, DOI 10.1007/BF01537589; GLAVIN GB, 1991, BRAIN RES REV, V16, P301, DOI 10.1016/0165-0173(91)90012-W; GLAVIN GB, 1987, LIFE SCI, V41, P1397, DOI 10.1016/0024-3205(87)90615-1; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUTH PH, 1966, GASTROENTEROLOGY, V50, P562; GUYTON AC, 1980, TXB MED PHYSL; HERNANDEZ DE, 1987, LIFE SCI, V41, P2717, DOI 10.1016/0024-3205(87)90464-4; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LAMOROUX A, 1987, EMBO J, V6, P3921; LETH R, 1987, AM J PHYSIOL, V253, pG497, DOI 10.1152/ajpgi.1987.253.4.G497; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MEZEY E, 1989, NUCLEIC ACIDS RES, V17, P2125, DOI 10.1093/nar/17.5.2125; MEZEY E, UNPUB; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; OISHI T, 1987, J PHARMACOL EXP THER, V240, P879; Roitt I.M., 1988, ESSENTIAL IMMUNOLOGY; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; SIKIRIC P, 1991, DIGEST DIS SCI, V36, P905, DOI 10.1007/BF01297139; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SOLL AH, 1984, AM J PHYSIOL, V247, pG715, DOI 10.1152/ajpgi.1984.247.6.G715; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; SZABO S, 1979, LANCET, V2, P880; SZABO S, 1987, J PHARMACOL EXP THER, V240, P871; SZABO S, 1988, TOXICOL PATHOL, V16, P205, DOI 10.1177/019262338801600213; SZABO S, 1987, CHRONOBIOL INT, V4, P31, DOI 10.3109/07420528709078506; SZABO S, 1979, DIGEST DIS SCI, V24, P471, DOI 10.1007/BF01299831; SZABO S, 1979, Gastroenterology, V76, P1257; SZABO S, 1982, ADV DOPAMINE RES, V37, P165; TOMASI TB, 1968, NEW ENGL J MED, V279, P1327, DOI 10.1056/NEJM196812122792408; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; YOUNG WS, 1986, MOL BRAIN RES, V1, P231, DOI 10.1016/0169-328X(86)90029-X	48	83	88	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1662	1665		10.1126/science.1333642	http://dx.doi.org/10.1126/science.1333642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1333642				2022-12-28	WOS:A1992KA89600041
J	JONES, DJ; GOORNEY, BP				JONES, DJ; GOORNEY, BP			ABC OF COLORECTAL DISEASES - SEXUALLY-TRANSMITTED DISEASES AND ANAL PAPILLOMAS	BRITISH MEDICAL JOURNAL			English	Article									HOPE HOSP,DEPT SURG,SALFORD M6 8HD,LANCS,ENGLAND		JONES, DJ (corresponding author), HOPE HOSP,DEPT GENITOURINARY MED,SALFORD M6 8HD,LANCS,ENGLAND.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					820	823		10.1136/bmj.305.6857.820	http://dx.doi.org/10.1136/bmj.305.6857.820			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1330142	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JT25600032
J	NIRUTHISARD, S; RODDY, RE; CHUTIVONGSE, S				NIRUTHISARD, S; RODDY, RE; CHUTIVONGSE, S			USE OF NONOXYNOL-9 AND REDUCTION IN RATE OF GONOCOCCAL AND CHLAMYDIAL CERVICAL INFECTIONS	LANCET			English	Article							SEXUALLY-TRANSMITTED DISEASES; CLINICAL-TRIAL; SPERMICIDES; GONORRHEA	The spermicide nonoxynol-9 (N-9) has been used as a contraceptive for over 30 years, but the use of a vaginal spermicide and condoms for the prevention of sexually transmitted infections has not been examined in randomised studies. We report a single-blind randomised field trial to assess the effect of N-9 film on the rate of gonococcal and chlamydial cervical infection in women at high risk of these diseases. 343 women were randomly assigned to use either condoms and N-9 (186 women) or condoms and a placebo (157). Compliance with condom use was much the same in the two groups. Overall, N-9 reduced the rate of cervical infection by 25% (rate ratio [RR] 0.75, 95% confidence interval [CI] 0.5-1.1); in women who used N-9 for more than 75%of their coital acts the infection rate was reduced by 40% (RR 95% CI 0.3-1.0). The rate of yeast vulvovaginitis or genital ulcers was not higher in N-9 users than in placebo users, but the rate of symptomatic irritation was increased by 700% (RR 95% CI 1.1-2.6) among N-9 users. Condom use was more protective against cervical infection than N-9 use. The rate of infection was 50% (RR 95% CI 0.3-0.7) lower with 75% than with 0-50% condom compliance. The use of a vaginal N-9 spermicide with condoms whenever possible seems to be a better strategy than the use of condoms only for prevention of gonococcal and chlamydial cervical infection.	FAMILY HLTH INT,POB 13950,RES TRIANGLE PK,NC 27709; QUEEN SAOVBHA MEM INST,DIV SCI,BANGKOK,THAILAND; THAI RED CROSS SOC,BANGKOK,THAILAND; CHULALONGKORN UNIV,DEPT OBSTET & GYNECOL,BANGKOK 5,THAILAND	Thai Red Cross Society; Chulalongkorn University								AUSTIN H, 1984, JAMA-J AM MED ASSOC, V251, P2822, DOI 10.1001/jama.251.21.2822; COLE CH, 1980, BRIT J VENER DIS, V56, P314; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER S J, 1958, J Chronic Dis, V8, P699, DOI 10.1016/0021-9681(58)90126-7; EDDY DM, 1991, FAST STAR PRO SOFTWA; FELDBLUM PJ, 1986, N C MED J, V47, P569; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; JICK H, 1982, JAMA-J AM MED ASSOC, V248, P1619, DOI 10.1001/jama.248.13.1619; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KREISS J, 1989, 5TH INT C AIDS MONTR; LOUV WC, 1988, J INFECT DIS, V158, P518, DOI 10.1093/infdis/158.3.518; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; NIRUTHISARD S, 1991, SEX TRANSM DIS, V18, P176, DOI 10.1097/00007435-199107000-00010; REKART ML, 1990, 6TH INT C AIDS SAN F; ROSENBERG MJ, 1987, JAMA-J AM MED ASSOC, V257, P2308, DOI 10.1001/jama.257.17.2308; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P171; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; STONE KM, 1986, AM J OBSTET GYNECOL, V155, P180, DOI 10.1016/0002-9378(86)90108-0	18	92	93	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1371	1375		10.1016/0140-6736(92)91195-E	http://dx.doi.org/10.1016/0140-6736(92)91195-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350804				2022-12-28	WOS:A1992HX63600002
J	COURTNEY, MG; NUNES, DP; BERGIN, CF; ODRISCOLL, M; TRIMBLE, V; KEELING, PWN; WEIR, DG				COURTNEY, MG; NUNES, DP; BERGIN, CF; ODRISCOLL, M; TRIMBLE, V; KEELING, PWN; WEIR, DG			RANDOMIZED COMPARISON OF OLSALAZINE AND MESALAZINE IN PREVENTION OF RELAPSES IN ULCERATIVE-COLITIS	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; 5-AMINOSALICYLIC ACID; MAINTENANCE TREATMENT; AZODISAL SODIUM; DOUBLE-BLIND; SULPHASALAZINE; SULFASALAZINE; TRIAL; METABOLISM; EXCRETION	Sulphasalazine extends remissions and lessens disease activity during relapses of ulcerative colitis, but it also causes many adverse side-effects. The adverse reactions are mostly attributable to the sulphapyridine carrier moiety rather than the active principle 5-aminosalicylic acid (5-ASA), so agents to deliver 5-ASA to the colon by other means have been designed. We have compared the efficacy and tolerability of two such agents, olsalazine and mesalazine, in maintenance therapy of ulcerative colitis. 100 patients with ulcerative colitis in remission were recruited at one centre and assigned randomly to treatment with olsalazine (Dipentum; 1.0 g daily) or mesalazine (Asacol, with Eudragit-S coating; 1.2 g daily). Compliance, biochemical and haematological variables, and clinical evidence of disease activity were assessed every 3 months for 12 months by observers unaware of treatment allocation. In intention-to-treat analysis, which included as treatment failures patients withdrawn for protocol violations, adverse reactions, intercurrent illness, or non-compliance as well as those with relapses of ulcerative colitis, the olsalazine group had a significantly lower rate of treatment failure than the mesalazine group (12/49 [24%] vs 23/50 [46%]; p = 0.025). Analysis restricted to 64 patients still in remission at 1 year and 18 with relapses also showed a significant difference in relapse rate (olsalazine 5/42 [12%] vs mesalazine 13/40 [33%]; p = 0.024). Both drugs were well tolerated; only 9 patients reported substantial side-effects. Olsalazine was clearly superior to mesalazine in prevention of relapses in ulcerative colitis, especially in patients with left-sided disease.	ST JAMES HOSP,DEPT CLIN MED,DUBLIN 8,IRELAND; UNIV DUBLIN TRINITY COLL,DUBLIN 2,IRELAND	Trinity College Dublin; Trinity College Dublin				Nunes, David/0000-0002-6808-2247				AZADKHAN AK, 1977, LANCET, V2, P892; BARON JH, 1962, LANCET, V1, P1094; CAMPIERI M, 1981, LANCET, V2, P270; CELLO JP, 1983, GASTROINTESTINAL DIS, P1122; DAS KM, 1973, NEW ENGL J MED, V289, P491, DOI 10.1056/NEJM197309062891001; DEW MJ, 1982, BRIT J CLIN PHARMACO, V14, P405, DOI 10.1111/j.1365-2125.1982.tb01999.x; DICK AP, 1964, GUT, V5, P437, DOI 10.1136/gut.5.5.437; DISSANAYAKE AS, 1973, GUT, V14, P923, DOI 10.1136/gut.14.12.923; GOLDMAN P, 1982, GASTROENTEROLOGY, V83, P1138; IRELAND A, 1988, GUT, V29, P835, DOI 10.1136/gut.29.6.835; JARNEROT G, 1989, DRUGS, V37, P73; LAURITSEN K, 1984, GASTROENTEROLOGY, V86, P1496; LAURSEN LS, 1990, GUT, V31, P1271, DOI 10.1136/gut.31.11.1271; MEYERS S, 1987, GASTROENTEROLOGY, V93, P1255, DOI 10.1016/0016-5085(87)90253-8; MISIEWICZ JJ, 1965, LANCET, V1, P185; PEPPERCORN MA, 1984, ANN INTERN MED, V101, P377, DOI 10.7326/0003-4819-101-3-377; PEPPERCORN MA, 1990, ANN INTERN MED, V112, P50, DOI 10.7326/0003-4819-112-1-50; RASKMADSEN J, 1976, INTESTINAL ION TRANS, P381; RILEY SA, 1988, GUT, V29, P669, DOI 10.1136/gut.29.5.669; RILEY SA, 1988, GASTROENTEROLOGY, V94, P1383, DOI 10.1016/0016-5085(88)90677-4; RYDE M, 1988, SCAND J GASTROENTERO, V23, P104, DOI 10.3109/00365528809101562; SANDBERGGERTZEN H, 1986, GUT, V27, P1306, DOI 10.1136/gut.27.11.1306; SANDBERGGERTZEN H, 1986, GASTROENTEROLOGY, V90, P1024, DOI 10.1016/0016-5085(86)90882-6; SANDBERGGERTZEN H, 1983, SCAND J GASTROENTERO, V18, P107, DOI 10.3109/00365528309181568; VANHEES PAM, 1980, GUT, V21, P632, DOI 10.1136/gut.21.7.632; WILLOUGHBY CP, 1988, SCAND J GASTROENTERO, V23, P40, DOI 10.3109/00365528809101546; 1990, DRUG THER B, V28, P57	27	70	70	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 23	1992	339	8804					1279	1281		10.1016/0140-6736(92)91601-4	http://dx.doi.org/10.1016/0140-6736(92)91601-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349676				2022-12-28	WOS:A1992HV19100011
J	[Anonymous]				[Anonymous]			LOW-DOSE INTERFERON-ALPHA AND HIV-INFECTION	LANCET			English	Editorial Material																		1990, LANCET, V336, P935; INTERIM REPORT LOW D	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1106	1106						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349115				2022-12-28	WOS:A1992HR44600018
J	SHIVJI, MKK; KENNY, MK; WOOD, RD				SHIVJI, MKK; KENNY, MK; WOOD, RD			PROLIFERATING CELL NUCLEAR ANTIGEN IS REQUIRED FOR DNA EXCISION REPAIR	CELL			English	Article							XERODERMA PIGMENTOSUM CELLS; SINGLE-STRAND BREAKS; HUMAN-FIBROBLASTS; POLYMERASE-DELTA; AUXILIARY PROTEIN; CYCLIN PCNA; REPLICATION; COMPLEMENTATION; ALPHA; INHIBITION	Fractionation of extracts from human cell lines allows nucleotide excision repair of damaged DNA to be resolved into discrete incision and polymerization stages. Generation of incised intermediates depends on the XP-A protein, a polypeptide that recognizes sites of damaged DNA, and on the human single-stranded DNA-binding protein HSSB. The proliferating cell nuclear antigen (PCNA) is required for the DNA synthesis that converts the nicked intermediates to completed repair events. This need for PCNA implies that repair synthesis is carried out by DNA polymerase-delta or epsilon. The ability to visualize repair intermediates in the absence of PCNA facilitates dissection of the multiprotein reaction that leads to incision of damaged DNA in a major pathway of cellular defense against mutagens.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	SHIVJI, MKK (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892				BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEJONGE AJR, 1985, MUTAT RES, V150, P99, DOI 10.1016/0027-5107(85)90106-X; DRESLER SL, 1984, J BIOL CHEM, V259, P3947; DRESLER SL, 1986, NUCLEIC ACIDS RES, V14, P7093, DOI 10.1093/nar/14.17.7093; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FORNACE AJ, 1976, P NATL ACAD SCI USA, V73, P39, DOI 10.1073/pnas.73.1.39; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HOEIJMAKERS JHJ, 1991, J CELL SCI, V100, P687; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JONES CJ, 1989, CARCINOGENESIS, V10, P1197, DOI 10.1093/carcin/10.7.1197; KAUFMANN WK, 1990, CARCINOGENESIS, V11, P15, DOI 10.1093/carcin/11.1.15; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TANAKA K, 1977, P NATL ACAD SCI USA, V74, P2958, DOI 10.1073/pnas.74.7.2958; THIELMANN HW, 1991, CANCER RES, V51, P3456; THNG JPH, 1985, MUTAT RES, V165, P139; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WASEEM NH, 1990, J CELL SCI, V96, P121; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; ZUBER M, 1989, MOL CELL BIOL, V9, P57, DOI 10.1128/MCB.9.1.57	39	773	785	14	118	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					367	374		10.1016/0092-8674(92)90416-A	http://dx.doi.org/10.1016/0092-8674(92)90416-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1348971				2022-12-28	WOS:A1992HQ18300015
J	LI, ZW; TAUBE, H				LI, ZW; TAUBE, H			USE OF A DIHYDROGEN OSMIUM COMPLEX AS A VERSATILE H-1-NMR RECOGNITION PROBE	SCIENCE			English	Article								A new recognition probe for biomolecules, [en2OS(eta-2-H-2)]2+ (1; en, ethylenediamine), is reported. In aqueous solution, 1 binds readily to a variety of biomolecules, including nucleotides, RNA, amino acids, peptides, and phospholipids. In each case, binding leads to a characteristic proton nuclear magnetic resonance (H-1 NMR) for the dihydrogen that appears in a spectral window in the range delta = 0 to -20 parts per million, and as well to characteristic values of the coupling J(HD) and of the relaxation time T1. Small structural differences in molecules such as DGMP (2'-deoxyguanosine 5'-monophosphate) and IMP (inosine 5'-monophosphate) or Asp and Glu can readily be distinguished, such as when 1 binds to the N-7 position of the nucleobase of DGMP or IMP and when 1 binds to the carboxylate of Asp or Glu. Upon one-electron oxidation of the metal center, diamagnetic 1 is converted to a paramagnetic probe.	STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013638, R37GM013638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13638-24] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRABTREE RH, 1990, ACCOUNTS CHEM RES, V23, P95, DOI 10.1021/ar00172a001; ISIED S, 1974, INORG CHEM, V13, P1545, DOI 10.1021/ic50137a001; Jardetzky O., 1981, NMR MOL BIOL; KUBAS GJ, 1988, ACCOUNTS CHEM RES, V21, P120, DOI 10.1021/ar00147a005; LaMar G. N., 1973, NMR PARAMAGNETIC MOL; Li Z.B., UNPUB; LI ZW, 1991, J AM CHEM SOC, V113, P8946, DOI 10.1021/ja00023a052; LIM HS, 1972, INORG CHEM, V11, P1460, DOI 10.1021/ic50113a003; Mildvan A S, 1978, Methods Enzymol, V49, P322; PYLE AM, 1990, PROG INORG CHEM, V38, P413; Stryer L, 1981, BIOCHEMISTRY; TAUBE H, 1973, SURV PROG CHEM, V6, P1; WISHART JF, 1984, INORG CHEM, V23, P2997, DOI 10.1021/ic00187a020; Wuthrich K., 1986, NMR PROTEINS NUCL AC; [No title captured]	15	32	34	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					210	213		10.1126/science.1348872	http://dx.doi.org/10.1126/science.1348872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1348872				2022-12-28	WOS:A1992HM89600025
J	RAYMOND, M; GROS, P; WHITEWAY, M; THOMAS, DY				RAYMOND, M; GROS, P; WHITEWAY, M; THOMAS, DY			FUNCTIONAL COMPLEMENTATION OF YEAST-STE6 BY A MAMMALIAN MULTIDRUG RESISTANCE MDR-GENE	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; BACTERIAL TRANSPORT PROTEINS; HORMONE A-FACTOR; CLASS-II REGION; SACCHAROMYCES-CEREVISIAE; P-GLYCOPROTEIN; IDENTIFICATION; FAMILY; HOMOLOGY; PRODUCT	Multidrug resistance in mammalian tumor cells is associated with the overexpression of mdr genes encoding P-glycoproteins, which function as drug efflux pumps. A yeast homolog of mdr, STE6, mediates export of a-factor mating peptide. Yeast MATa cells carrying a ste6 deletion produce no extracellular a-factor and therefore are defective in mating. Expression of a complementary DNA for the mouse mdr3 gene in a yeast ste6 deletion strain restored ability to export a-factor and to mate. A mutation (a serine to phenylalanine substitution at amino acid 939) known to affect the activity of the mdr3 gene product abolished its ability to complement the yeast ste6 deletion. Thus, functions of P-glyco-proteins in normal mammalian cells may include the transmembrane export of endogenous peptides.	MCGILL UNIV, DEPT BIOL, MONTREAL H3A 1B1, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3A 1B1, QUEBEC, CANADA	McGill University; McGill University	RAYMOND, M (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL H4P 2R2, QUEBEC, CANADA.		Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPRAGUE GF, 1981, J MOL BIOL, V153, P305, DOI 10.1016/0022-2836(81)90280-1; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEDEN M, 1989, MOL GEN GENET, V219, P439, DOI 10.1007/BF00259617; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TOHE A, 1981, J BACTERIOL, V145, P1421, DOI 10.1128/JB.145.3.1421-1424.1981; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P83; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713	38	207	219	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					232	234		10.1126/science.1348873	http://dx.doi.org/10.1126/science.1348873			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1348873				2022-12-28	WOS:A1992HM89600032
J	HOCH, M; GERWIN, N; TAUBERT, H; JACKLE, H				HOCH, M; GERWIN, N; TAUBERT, H; JACKLE, H			COMPETITION FOR OVERLAPPING SITES IN THE REGULATORY REGION OF THE DROSOPHILA GENE KRUPPEL	SCIENCE			English	Article							HORMONE RECEPTOR SUPERFAMILY; BICOID PROTEIN; DNA-BINDING; GAP GENES; GLUCOCORTICOID RECEPTOR; ANTERIOR PATTERN; FUSHI-TARAZU; C-JUN; EMBRYO; EXPRESSION	A 730-base pair element regulates expression of the Drosophila gap gene Kruppel (Kr) in response to the fly anterior morphogen bicoid (bcd). Two hormone receptor-like proteins, encoded by the genes knirps (kni) and tailless (tll), bind specifically to the element. In vitro, kni protein competes with the homeodomain-containing bcd protein in binding to a 16-base pair target sequence. In vivo experiments suggest that both kni and tll act as competitive repressors of bcd-mediated activation of Kr. These results suggest a mechanism by which developmental genes can be regulated in response to an activating morphogen gradient antagonized by repressors.			HOCH, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,W-3400 GOTTINGEN,GERMANY.							AKAM M, 1987, DEVELOPMENT, V101, P1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MAHONEY PA, 1987, DEV BIOL, V122, P464, DOI 10.1016/0012-1606(87)90310-1; MANGELSDORF KK, 1991, NATURE, V345, P224; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STRECKER TR, 1988, DEVELOPMENT, V102, P721; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	60	111	112	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					94	97		10.1126/science.1348871	http://dx.doi.org/10.1126/science.1348871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1348871				2022-12-28	WOS:A1992HL82200034
J	SLETNES, KE; SMITH, P; ABDELNOOR, M; ARNESEN, H; WISLOFF, F				SLETNES, KE; SMITH, P; ABDELNOOR, M; ARNESEN, H; WISLOFF, F			ANTIPHOSPHOLIPID ANTIBODIES AFTER MYOCARDIAL-INFARCTION AND THEIR RELATION TO MORTALITY, REINFARCTION, AND NONHEMORRHAGIC STROKE	LANCET			English	Article							ANTICARDIOLIPIN ANTIBODIES; LUPUS ANTICOAGULANT; ANTICEPHALIN; CARDIOLIPIN	Antiphospholipid antibodies have been suggested as markers for a high risk of recurrent cardiovascular events in young survivors of an acute myocardial infarction. However, there are few data to confirm or refute this hypothesis. In a cohort study, we have measured anticephalin (aCEPHA) and anticardiolipin (aCL) antibodies in a group of patients surviving an acute infarct. Of 597 patients studied, 13.2% were IgG or IgM aCEPHA positive compared with 4.4% of a reference population (n = 158; p = 0.002). In a multivariate analysis, adjusted for major cardiovascular risk factors, neither aCEPHA (IgG or IgM) nor aCL (IgG or IgM) was an independent risk factor for mortality, reinfarction, or non-haemorrhagic stroke. Although an increased proportion of survivors of a myocardial infarction have antiphospholipid antibodies, the presence of such antibodies is not a risk factor for subsequent coronary or cerebrovascular thrombosis.	UNIV OSLO,ULLEVAL HOSP,CLIN RES UNIT,OSLO 1,NORWAY	University of Oslo	SLETNES, KE (corresponding author), ULLEVAL UNIV HOSP,DEPT MED,HAEMATOL RES LAB,N-0407 OSLO 4,NORWAY.		Wisloff, Ulrik/K-2899-2012; abdelnoor, michael/K-4248-2019					ASHERSON RA, 1986, BRIT HEART J, V56, P190; ASHERSON RA, 1989, Q J MED, V73, P1103; CHASTANG C, 1984, THESIS U P M CURIE P; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; GIGASE PL, 1988, J IMMUNOL METHODS, V107, P93, DOI 10.1016/0022-1759(88)90014-2; HAMSTEN A, 1986, LANCET, V1, P113; HARRIS EN, 1990, BRIT J HAEMATOL, V74, P1, DOI 10.1111/j.1365-2141.1990.tb02530.x; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; HARRIS EN, 1990, J RHEUMATOL, V17, P733; Miller R. G., 1981, SURVIVAL ANAL; MORTON KE, 1986, LANCET, V2, P1353; Nomenclature and criteria for diagnosis of ischemic heart disease, 1979, CIRCULATION, V59, P607; SHI W, 1990, AUST NZ J MED, V20, P231, DOI 10.1111/j.1445-5994.1990.tb01025.x; SLETNES KE, 1990, THROMB RES, V57, P235, DOI 10.1016/0049-3848(90)90323-5; SLETNES KE, 1990, THROMB RES, V59, P675, DOI 10.1016/0049-3848(90)90427-E; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SMITH P, 1990, J INTERN MED, V228, P253, DOI 10.1111/j.1365-2796.1990.tb00227.x	17	119	121	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					451	453		10.1016/0140-6736(92)91057-F	http://dx.doi.org/10.1016/0140-6736(92)91057-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346819				2022-12-28	WOS:A1992HE93200003
J	HADDAD, J; DENY, P; MUNZGOTHEIL, C; AMBROSINI, JC; TRINCHET, JC; PATERON, D; MAL, F; CALLARD, P; BEAUGRAND, M				HADDAD, J; DENY, P; MUNZGOTHEIL, C; AMBROSINI, JC; TRINCHET, JC; PATERON, D; MAL, F; CALLARD, P; BEAUGRAND, M			LYMPHOCYTIC SIALADENITIS OF SJOGRENS-SYNDROME ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS LIVER-DISEASE	LANCET			English	Article							SALIVARY-GLAND BIOPSIES	Viral infection has often been suggested as a possible cause of Sjogren's syndrome or chronic lymphocytic sialadenitis, and Epstein-Barr virus has been found in the salivary glands of patients with this condition. After we had noted Sjogren's syndrome in several patients infected with hepatitis C virus (HCV), a virus also excreted in saliva, we set up a prospective study to investigate the association of chronic lymphocytic sialadenitis, with or without symptoms, to chronic HCV liver disease. The histological appearances of labial salivary glands in patients with proven HCV hepatitis or cirrhosis were compared with those in dead controls. Histological changes characteristic of Sjogren's syndrome were significantly more common in HCV-infected patients (16 of 28, 57%) compared with controls (1 of 20, 5%). Focal lymphocytic sialadenitis characteristic of Sjogren's syndrome (though only 10 patients had xerostomia and none complained of xerophthalmia) appears to be common in patients with chronic HCV liver disease; if this association is confirmed, identification of the underlying mechanism may improve our understanding of both disorders.	HOP JEAN VERDIER, DEPT HEPATOGASTROENTEROL, SERV HEPATOGASTROENTEROL, AVE 14 JUILLET, F-93143 BONDY, FRANCE; HOP AVICENNE, DEPT MICROBIOL, BOBIGNY, FRANCE; HOP JEAN VERDIER, DEPT PATHOL, F-93140 BONDY, FRANCE; HOP JEAN VERDIER, DEPT ORAL MED, F-93140 BONDY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP			Deny, Paul/C-6099-2011					ABE K, 1987, J INFECT DIS, V155, P1078, DOI 10.1093/infdis/155.5.1078; BLOCH KJ, 1965, MEDICINE, V44, P187, DOI 10.1097/00005792-196505000-00001; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; DUSHEIKO GM, 1990, LANCET, V336, P503, DOI 10.1016/0140-6736(90)92049-N; FLESCHER E, 1991, AM J MED, V90, P283, DOI 10.1016/0002-9343(91)80006-8; FOX RI, 1986, J IMMUNOL, V137, P3162; GOLDING PL, 1970, BRIT MED J, V4, P340, DOI 10.1136/bmj.4.5731.340; GREENSPAN JS, 1974, ORAL SURG ORAL MED O, V37, P217, DOI 10.1016/0030-4220(74)90417-4; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KOJIMA A, 1980, Experimental Animals (Tokyo), V29, P409; MAGRIN S, 1991, J HEPATOL, V13, P56, DOI 10.1016/0168-8278(91)90864-8; MARIETTE X, 1991, AM J MED, V90, P286, DOI 10.1016/0002-9343(91)80007-9; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; Moutsopoulos H. M., 1987, SJOGRENS SYNDROME CL, P258; SCOTT J, 1980, J BIOL BUCCALE, V8, P187; TAKAMATSU K, 1990, LANCET, V336, P1515, DOI 10.1016/0140-6736(90)93229-I; TODROS L, 1991, J HEPATOL, V13, P128, DOI 10.1016/0168-8278(91)90874-B; VENTO S, 1989, LANCET, V2, P926	19	479	487	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1992	339	8789					321	323		10.1016/0140-6736(92)91645-O	http://dx.doi.org/10.1016/0140-6736(92)91645-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346409	Green Published			2022-12-28	WOS:A1992HC77100002
J	GLUPCZYNSKI, Y; BURETTE, A				GLUPCZYNSKI, Y; BURETTE, A			ERADICATING HELICOBACTER-PYLORI	LANCET			English	Letter									NOUVELLE CLIN BASILIQUE,GASTROENTEROL UNIT,BRUSSELS,BELGIUM		GLUPCZYNSKI, Y (corresponding author), BRUGMANN UNIV HOSP,DEPT MICROBIOL,B-1020 BRUSSELS,BELGIUM.							GLUPCZYNSKI Y, 1991, MICROB ECOL HLTH D S, V4, P184; 1990, LANCET, V336, P779	2	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					54	55						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345966				2022-12-28	WOS:A1992GY04300027
J	MIRALLES, GD; OFALLON, JR; TALLEY, NJ				MIRALLES, GD; OFALLON, JR; TALLEY, NJ			PLASMA-CELL DYSCRASIA WITH POLYNEUROPATHY - THE SPECTRUM OF POEMS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; PERIPHERAL-NERVE MYELIN; MONOCLONAL GAMMOPATHY; OSTEOSCLEROTIC MYELOMA; SKIN CHANGES; NEUROPATHY; PARAPROTEINEMIA; FEATURES; ANTIBODY; TISSUE	Background. The POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome and osteosclerotic myeloma (polyneuropathy and sclerotic bone lesions) may both be manifestations of plasma-cell dyscrasia, but the interrelation of these diseases is not clear. We therefore set out to define the clinical spectrum of disease in patients with plasma-cell dyscrasia and polyneuropathy who have the complete or incomplete form of the POEMS syndrome or osteosclerotic myeloma. Methods. Among 2714 patients with plasma-cell dyscrasia who were identified between 1973 and 1989, we reviewed the cases of those with polyneuropathy and plasma-cell dyscrasia who fulfilled the criteria for the POEMS syndrome or osteosclerotic myeloma. Results. Thirty-eight patients (1.4 percent) with a median age of 51 years were identified, 22 of whom were male. By definition, all had polyneuropathy (37 combined sensorimotor, and 1 primarily motor). Other findings included osteosclerotic bone lesions (82 percent), skin abnormalities (58 percent), lymphadenopathy (42 percent), papilledema (37 percent), peripheral edema (29 percent), hepatomegaly (24 percent), splenomegaly (21 percent), and ascites (11 percent). Thirty-three patients (87 percent) had an abnormal M protein in serum or urine (17 had IgA-lambda and 12 IgG-lambda). Five patients fulfilled all the criteria for the POEMS syndrome. The estimated five-year survival in the 38 patients was 60 percent, which was significantly better than the 20 percent survival in 869 patients with multiple myeloma (P<0.05). The clinical course was similar among the patients with the complete form of the POEMS syndrome and those with the incomplete form. Conclusions. Plasma-cell dyscrasia with polyneuropathy is a rare multisystem disease that often presents with osteosclerotic bone lesions. The differentiation of the POEMS syndrome from so-called osteosclerotic myeloma with peripheral neuropathy appears to have no clinical value.	MAYO CLIN & MAYO FDN, DIV GASTROENTEROL & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, CANC STAT UNIT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic			Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092				AGUAYO A, 1964, J NEUROL NEUROSUR PS, V27, P562, DOI 10.1136/jnnp.27.6.562; BARDWICK PA, 1980, MEDICINE, V59, P311, DOI 10.1097/00005792-198007000-00006; BESINGER UA, 1981, SCIENCE, V213, P1027, DOI 10.1126/science.7268405; BRAUN PE, 1982, J NEUROCHEM, V39, P1261, DOI 10.1111/j.1471-4159.1982.tb12563.x; CROW RS, 1956, BRIT MED J, V2, P802, DOI 10.1136/bmj.2.4996.802; DRIEDGER H, 1980, MEDICINE, V59, P301, DOI 10.1097/00005792-198007000-00005; DYCK PJ, 1991, NEW ENGL J MED, V325, P1482, DOI 10.1056/NEJM199111213252105; EVISON G, 1967, BRIT J RADIOL, V40, P81, DOI 10.1259/0007-1285-40-470-81; HAFLER DA, 1986, NEUROLOGY, V36, P75, DOI 10.1212/WNL.36.1.75; JULIEN J, 1978, ARCH NEUROL-CHICAGO, V35, P423, DOI 10.1001/archneur.1978.00500310025005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLY JJ, 1981, NEUROLOGY, V31, P24, DOI 10.1212/WNL.31.1.24; KELLY JJ, 1983, NEUROLOGY, V33, P202, DOI 10.1212/WNL.33.2.202; KOJIMA M, 1983, JPN J CLIN ONCOL, V13, P557; KYLE RA, 1975, MAYO CLIN PROC, V50, P29; KYLE RA, 1976, MONOCLONAL GAMMOPATH; LATOV N, 1980, NEW ENGL J MED, V303, P618, DOI 10.1056/NEJM198009113031105; LATOV N, 1981, NEUROLOGY, V31, P1530, DOI 10.1212/WNL.31.12.1530; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mayo C M, 1968, Trans Am Neurol Assoc, V93, P240; MEIER C, 1985, J NEUROL, V232, P204, DOI 10.1007/BF00313781; MONACO S, 1990, NEW ENGL J MED, V322, P649, DOI 10.1056/NEJM199003083221002; MORLEY JB, 1967, J NEUROL NEUROSUR PS, V30, P432, DOI 10.1136/jnnp.30.5.432; MYERS BM, 1991, AM J MED, V90, P646; NAKANISHI T, 1984, NEUROLOGY, V34, P712, DOI 10.1212/WNL.34.6.712; ODELBERGJOHNSON O, 1959, ACTA RADIOL, V52, P139, DOI 10.3109/00016925909171139; REITAN JB, 1980, ACTA MED SCAND, V208, P137; REULECKE M, 1988, NEUROLOGY, V38, P614, DOI 10.1212/WNL.38.4.614; SEMBLE EL, 1986, ARTHRITIS RHEUM, V29, P286, DOI 10.1002/art.1780290218; SHELLEY WB, 1987, ARCH DERMATOL, V123, P85, DOI 10.1001/archderm.123.1.85; Shimpo S, 1968, Nihon Rinsho, V26, P2444; Silberstein L E, 1985, J Clin Apher, V2, P253, DOI 10.1002/jca.2920020309; TAKATSUKI K, 1983, JPN J CLIN ONCOL, V13, P543; TRENTHAM DE, 1976, ANN INTERN MED, V84, P271, DOI 10.7326/0003-4819-84-3-271; WALDENSTROM JG, 1978, ACTA MED SCAND, V203, P297; WIERNIK PH, 1991, NEOPLASTIC DISEASES	36	216	222	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1919	1923		10.1056/NEJM199212313272705	http://dx.doi.org/10.1056/NEJM199212313272705			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1333569				2022-12-28	WOS:A1992KE50500005
J	SPRIGGS, MK; HRUBY, DE; MALISZEWSKI, CR; PICKUP, DJ; SIMS, JE; BULLER, RML; VANSLYKE, J				SPRIGGS, MK; HRUBY, DE; MALISZEWSKI, CR; PICKUP, DJ; SIMS, JE; BULLER, RML; VANSLYKE, J			VACCINIA AND COWPOX VIRUSES ENCODE A NOVEL SECRETED INTERLEUKIN-1-BINDING PROTEIN	CELL			English	Article							INVERTED TERMINAL REPEAT; EPIDERMAL GROWTH-FACTOR; OPEN READING FRAME; B-CELL GROWTH; IMMUNOGLOBULIN SUPERFAMILY; EXPRESSION VECTORS; INFLUENZA-VIRUS; IL-1 RECEPTOR; T-CELLS; INFECTION	Supernatants from vaccinia virus (VV)-infected CV-1 cells were examined and found to contain a 33 kd protein capable of binding murine interleukin-1beta (mIL-1beta). A VV open reading frame (ORF) that exhibits 30% amino acid identity to the type II IL-1 receptor was expressed in CV-1-EBNA cells and shown specifically to bind mIL-1beta. A similar ORF from cowpox virus was expressed and also specifically bound mIL-1beta. A recombinant VV was constructed in which this ORF was disrupted (vB15RKO). Supernatants from vB15RKO-infected cells did not contain an IL-1-binding protein. Supernatants from VV-infected CV-1 cells were capable of inhibiting IL-1-induced murine lymphocyte proliferation in vitro while supernatants from vB15RKO infected cells did not. Intracranial inoculation of mice with vB15RKO suggests that this ORF is involved in VV virulence. The possible role of a virus-encoded IL-1-binding protein in the pathology of a poxvirus infection and its relationship to other poxvirus-encoded immune modulators is discussed.	IMMUNEX RES & DEV CORP,DEPT IMMUNOL,SEATTLE,WA 98101; OREGON STATE UNIV,DEPT MICROBIOL,CORVALLIS,OR 97331; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	Oregon State University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	SPRIGGS, MK (corresponding author), IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101, USA.			Sims, John/0000-0002-5667-9185	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021335] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21335-06] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCAMI A, 1992, CELL, V71; BECKER S, 1991, J IMMUNOL, V147, P4307; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BLANDEN RV, 1975, NATURE, V254, P269, DOI 10.1038/254269a0; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BOOTH RJ, 1984, J IMMUNOL, V133, P1346; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BULLER RML, 1985, NATURE, V317, P813, DOI 10.1038/317813a0; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEYERLE KL, 1992, IN PRESS J IMMUNOL; DOWER SK, 1990, CELLULAR MOL MECHANI, V1, P137; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; ELANGO N, 1986, P NATL ACAD SCI USA, V83, P1906, DOI 10.1073/pnas.83.6.1906; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FARRAR WL, 1987, J IMMUNOL, V139, P459; Fenner F., 1989, MONKEYPOX VIRUS ORTH, P227; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; FRANKE CA, 1985, MOL CELL BIOL, V5, P1918, DOI 10.1128/MCB.5.8.1918; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HOWARD M, 1983, J EXP MED, V157, P1529, DOI 10.1084/jem.157.5.1529; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HRUBY DE, 1990, CLIN MICROBIOL REV, V3, P153, DOI 10.1128/CMR.3.2.153-170.1990; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; LAW KM, 1992, J GEN VIROL, V73, P549, DOI 10.1099/0022-1317-73-3-549; LUGMAN M, 1992, EUR J IMMUNOL, V22, P95; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MARTIN M, 1988, TRENDS PHARMACOL SCI, V9, P171, DOI 10.1016/0165-6147(88)90033-8; McFadden G., 1988, Virus diseases in laboratory and captive animals, P37; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; OLIFF A, 1988, CELL, V54, P141, DOI 10.1016/0092-8674(88)90543-0; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; PICKUP DJ, 1984, P NATL ACAD SCI-BIOL, V81, P6817, DOI 10.1073/pnas.81.21.6817; PIKE BL, 1985, P NATL ACAD SCI USA, V82, P8153, DOI 10.1073/pnas.82.23.8153; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REISNER AH, 1985, NATURE, V313, P801, DOI 10.1038/313801a0; Sambrook J, 1989, MOL CLONING LABORATO; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VACHERON F, 1990, J GEN VIROL, V71, P477, DOI 10.1099/0022-1317-71-2-477	53	294	303	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					145	152		10.1016/0092-8674(92)90273-F	http://dx.doi.org/10.1016/0092-8674(92)90273-F			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1339315				2022-12-28	WOS:A1992JQ62300014
J	SAITOH, H; TOMKIEL, J; COOKE, CA; RATRIE, H; MAURER, M; ROTHFIELD, NF; EARNSHAW, WC				SAITOH, H; TOMKIEL, J; COOKE, CA; RATRIE, H; MAURER, M; ROTHFIELD, NF; EARNSHAW, WC			CENP-C, AN AUTOANTIGEN IN SCLERODERMA, IS A COMPONENT OF THE HUMAN INNER KINETOCHORE PLATE	CELL			English	Article							MAMMALIAN KINETOCHORE; CENTROMERE PROTEINS; AUTO-ANTIGEN; ANTICENTROMERE ANTIBODIES; CHROMOSOME CONDENSATION; ELECTRON-MICROSCOPY; AUTOIMMUNE SERA; DNA; FAMILY; CELLS	We have isolated and characterized a set of overlapping cDNA clones that encode the human centromere autoantigen centromere protein C (CENP-C). The identity of these clones has been established using several criteria. First, they were shown to encode a polypeptide that migrates at the expected position for CENP-C on SDS-polyacrylamide gel electrophoresis. Second, we have demonstrated that this polypeptide shares at least two epitopes with human CENP-C. Polyclonal antibodies were raised to fusion proteins encoded by nonoverlapping regions of the cDNA clones. These antibodies were shown to recognize a protein at a position appropriate for CENP-C on immunoblots of human chromosomal proteins. In addition, we used indirect immunofluorescence to demonstrate that these antibodies recognize centromeres of HeLa chromosomes in the expected pattern for CENP-C. Localization of CENP-C by immunoelectron microscopy reveals that this protein is a component of the inner kinetochore plate.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV RHEUMAT DIS,FARMINGTON,CT 06032	University of Connecticut	SAITOH, H (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035212] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37986] Funding Source: Medline; NIGMS NIH HHS [GM35212] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; COMINGS DE, 1971, EXP CELL RES, V67, P97, DOI 10.1016/0014-4827(71)90625-2; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; DARLINGTON CD, 1936, CYTOLOGIA, V7, P242; EARNSHAW W, 1986, J CLIN INVEST, V77, P426, DOI 10.1172/JCI112320; EARNSHAW WC, 1987, P NATL ACAD SCI USA, V84, P4979, DOI 10.1073/pnas.84.14.4979; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; HATTORI M, 1985, NUCLEIC ACIDS RES, V13, P7813, DOI 10.1093/nar/13.21.7813; JOKELAINEN PT, 1967, J ULTRA MOL STRUCT R, V19, P19, DOI 10.1016/S0022-5320(67)80058-3; KINGWELL B, 1987, CHROMOSOMA, V95, P403, DOI 10.1007/BF00333991; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LUYKX P, 1965, EXP CELL RES, V39, P643, DOI 10.1016/0014-4827(65)90068-6; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MITCHISON TJ, 1985, J CELL BIOL, V101, P776; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; RATTNER JB, 1987, CHROMOSOMA, V95, P175, DOI 10.1007/BF00330348; REIDER CL, 1982, INT REV CYTOL, V79, P1; REIDER CL, 1990, J CELL BIOL, V110, P81; RIJHSINGHANI AG, 1988, OBSTET GYNECOL, V71, P991; RIS H, 1981, CHROMOSOMA, V82, P153, DOI 10.1007/BF00286101; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; ROTHFIELD N, 1987, ARTHRITIS RHEUM, V30, P1416, DOI 10.1002/art.1780301214; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA V, 1991, NUCLEIC ACIDS RES, V19, P1168, DOI 10.1093/nar/19.5.1168-a; Sharp LW., 1934, INTRO CYTOLOGY; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN L, 1984, NUCLEIC ACIDS RES, V12, P2669, DOI 10.1093/nar/12.6.2669; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAN EM, 1988, CLIN IMMUNOL IMMUNOP, V47, P121, DOI 10.1016/0090-1229(88)90066-9; WITT PL, 1980, CHROMOSOMA, V81, P483, DOI 10.1007/BF00368158; WORDEMAN L, 1991, J CELL BIOL, V114, P285, DOI 10.1083/jcb.114.2.285	50	312	322	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					115	125		10.1016/0092-8674(92)90538-N	http://dx.doi.org/10.1016/0092-8674(92)90538-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1339310				2022-12-28	WOS:A1992JC95700013
J	TALASZ, H; GENSER, N; MAIR, J; DWORZAK, EA; FRIEDRICH, G; MOES, N; MUHLBERGER, V; PUSCHENDORF, B				TALASZ, H; GENSER, N; MAIR, J; DWORZAK, EA; FRIEDRICH, G; MOES, N; MUHLBERGER, V; PUSCHENDORF, B			SIDE-BRANCH OCCLUSION DURING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY	LANCET			English	Note							RELEASE; DAMAGE	Concentrations of creatine kinase (CK) MB mass and cardiac troponin T were measured in serial peripheral venous blood samples from 21 patients who underwent percutaneous transluminal coronary angioplasty (PTCA). Angiography showed side-branch occlusion during PTCA without clinical signs of myocardial injury in 5 patients. After PTCA, CKMB mass concentrations were substantially higher than normal in all 5 patients with side-branch occlusion, and troponin T concentrations were high in 3. By contrast, only 2 patients and 1 patient, respectively, without side-branch occlusion had slight rises in CKMB and troponin T. Release of the contractile protein troponin T reflects more severe damage to myocytes than simple leakage of CKMB. Therefore, myocardial damage induced by side-branch occlusion can be graded by measurement of troponin T in plasma.	UNIV INNSBRUCK,SCH MED,DEPT MED CHEM & BIOCHEM,FRITZ PREGLSTR 3,A-6020 INNSBRUCK,AUSTRIA; UNIV INNSBRUCK,SCH MED,DEPT INTERNAL MED,A-6020 INNSBRUCK,AUSTRIA	University of Innsbruck; University of Innsbruck			Mair, Johannes/J-5822-2019					DUNCAN CJ, 1987, J CELL SCI, V87, P183; GERHARDT W, 1991, CLIN CHEM, V37, P1405; HEYNDRICKX GR, 1985, J AM COLL CARDIOL, V6, P1299, DOI 10.1016/S0735-1097(85)80216-3; HUNT AC, 1991, EUR HEART J, V12, P690; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1991, AM J CARDIOL, V67, P1360, DOI 10.1016/0002-9149(91)90466-X; KLEIN LW, 1991, J AM COLL CARDIOL, V17, P621, DOI 10.1016/S0735-1097(10)80174-3; MAIR J, 1991, AM J CARDIOL, V68, P1545, DOI 10.1016/0002-9149(91)90307-7; MORIMOTO S, 1990, AM HEART J, V120, P864, DOI 10.1016/0002-8703(90)90202-9; PIPER HM, 1984, J MOL CELL CARDIOL, V16, P385, DOI 10.1016/S0022-2828(84)80609-4	10	65	68	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1380	1382		10.1016/0140-6736(92)91198-H	http://dx.doi.org/10.1016/0140-6736(92)91198-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350807				2022-12-28	WOS:A1992HX63600005
J	LANCE, JW				LANCE, JW			TREATMENT OF MIGRAINE	LANCET			English	Article							MENSTRUAL MIGRAINE; NAPROXEN SODIUM; AMITRIPTYLINE; PROPHYLAXIS; ESTRADIOL; ATTACKS; THERAPY; DRUG				LANCE, JW (corresponding author), PRINCE WALES HOSP, INST NEUROL SCI, RANDWICK, NSW 2031, AUSTRALIA.							ADLER CS, 1987, PSYCHIATRIC ASPECTS; AMERY WK, 1983, HEADACHE, V23, P70, DOI 10.1111/j.1526-4610.1983.hed2302070.x; [Anonymous], 1991, Eur Neurol, V31, P314; ANTHONY M, 1969, ARCH NEUROL-CHICAGO, V21, P263, DOI 10.1001/archneur.1969.00480150053007; ANTHONY M, 1967, ARCH NEUROL-CHICAGO, V16, P544, DOI 10.1001/archneur.1967.00470230096013; BLAU JN, 1980, BRIT MED J, V281, P658, DOI 10.1136/bmj.281.6241.658; BROWN EG, 1991, EUR NEUROL, V31, P339, DOI 10.1159/000116762; CLEAL A, 1991, EUR NEUROL, V31, P323; COPPEN A, 1978, LANCET, V1, P63; Curran D.A., 1967, RESEARCH CLINICAL ST, V1, P74; DELIGNIERES B, 1986, BMJ-BRIT MED J, V293, P1540, DOI 10.1136/bmj.293.6561.1540; GOADSBY PJ, 1991, LANCET, V338, P782, DOI 10.1016/0140-6736(91)90666-D; GOMERSALL JD, 1973, J NEUROL NEUROSUR PS, V36, P684, DOI 10.1136/jnnp.36.4.684; GRAHAM AN, 1984, PROGR MIGRAINE RES, V2, P283; HIRT D, 1989, CEPHALALGIA S10, V9, P410; JOHNSON ES, 1985, CEPHALALGIA, V5, P5, DOI 10.1046/j.1468-2982.1985.0501005.x; KIMBALL RW, 1960, NEUROLOGY, V10, P107, DOI 10.1212/WNL.10.2.107; Lance J. W, 1986, MIGRAINE OTHER HEADA; LANCE JW, 1964, LANCET, V1, P1236; LITTLEWOOD JT, 1987, CURR PROBLEMS NEUROL, V4, P123; MAGOS AL, 1983, J NEUROL NEUROSUR PS, V46, P1044, DOI 10.1136/jnnp.46.11.1044; MCQUEEN J, 1989, ADV HEADACHE RES, P235; MELLOR C, 1991, EUR NEUROL, V31, P306; MEYER JS, 1983, HEADACHE, V23, P266, DOI 10.1111/j.1526-4610.1983.hed2306266.x; PRADALIER A, 1985, CEPHALALGIA, V5, P107, DOI 10.1046/j.1468-2982.1985.0502107.x; RASKIN NH, 1986, NEUROLOGY, V36, P995, DOI 10.1212/WNL.36.7.995; RASKIN NH, 1988, HEADACHE, P176; SORENSEN KV, 1988, ACTA NEUROL SCAND, V78, P346, DOI 10.1111/j.1600-0404.1988.tb03667.x; TFELTHANSEN P, 1980, J NEUROL NEUROSUR PS, V43, P369, DOI 10.1136/jnnp.43.4.369; 1988, CEPHALALGIA S7, V8, P13	30	20	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	1992	339	8803					1207	1209		10.1016/0140-6736(92)91141-T	http://dx.doi.org/10.1016/0140-6736(92)91141-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349945				2022-12-28	WOS:A1992HU68400011
J	HERCBERGS, A; BROKSIMONI, F; HOLTZMAN, F; BARAM, J; LEITH, JT; BRENNER, HJ				HERCBERGS, A; BROKSIMONI, F; HOLTZMAN, F; BARAM, J; LEITH, JT; BRENNER, HJ			ERYTHROCYTE GLUTATHIONE AND TUMOR RESPONSE TO CHEMOTHERAPY	LANCET			English	Article							METABOLISM; CANCER; CELLS; INVITRO	There is much evidence that tumour glutathione (GSH) concentration is an important factor in resistance to cancer chemotherapy. Since measurement of tumour GSH would require an, invasive procedure in every patient, we have tried to find out whether GSH concentrations in peripheral-blood erythrocytes are related to the response to chemotherapy and thus whether they reflect those in tumour cells. Erythrocyte GSH concentrations were measured by spectrophotometry in peripheral blood from 28 patients with advanced breast cancer and 40 patients with other tumours before and after treatment with various conventional chemotherapeutic regimens. The mean pretreatment GSH concentration was lower in patients who showed a complete or partial response to chemotherapy than in those with stable or progressive disease in both the breast-cancer group (8.69 [95% confidence interval 5.99-11.39] vs 2.32 [1.23-3.41] mu-mol/g haemoglobin; p < 0.01) and the group with other tumours (5.94 [4.14-7.74) vs 2.83 [1.71-3.95] mu-mol/g; p < 0.01 ). The correlation of erythrocyte GSH concentration with response rate suggests that this measurement may be helpful in prediction of response to therapy.	SHEBA MED CTR,DEPT HEMATOL,RAMAT GAN,ISRAEL; SHEBA MED CTR,DEPT ONCOL,RAMAT GAN,ISRAEL; BROWN UNIV,DEPT RADIAT MED,RADIAT SERV,PROVIDENCE,RI 02912	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Brown University	HERCBERGS, A (corresponding author), CLEVELAND CLIN FDN,DEPT RADIAT THERAPY,DESK T18,1 CLIN CTR,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							ARRICK BA, 1984, CANCER RES, V44, P4224; ATKINS MB, 1988, NEW ENGL J MED, V318, P1557, DOI 10.1056/NEJM198806163182401; Beutler E., 1984, RED CELL METABOLISM, P131; BUMP EA, 1990, PHARMACOL THERAPEUT, V47, P117, DOI 10.1016/0163-7258(90)90048-7; CIMINO JA, 1987, P SOC EXP BIOL MED, V184, P151, DOI 10.3181/00379727-184-42459; DETHLEFSEN LA, 1986, INT J RADIAT ONCOL, V12, P1157, DOI 10.1016/0360-3016(86)90248-8; HAYWARD JL, 1977, BRIT J CANCER, V35, P292, DOI 10.1038/bjc.1977.42; HENDERSON IC, 1987, BREAST DISEASES, P428; HERCBERGS A, 1989, NEW ENGL J MED, V319, P1351; HERCBERGS A, 1988, P AN M AM SOC CLIN, V7, P20; LACRETA F, 1991, P AN M AM SOC CLIN, V10, P104; LEE FYF, 1989, CANCER RES, V49, P5244; MEIJER C, 1990, CANCER TREAT REV, V17, P389, DOI 10.1016/0305-7372(90)90081-P; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MENENDEZ CE, 1974, AM J PHYSIOL, V226, P1480, DOI 10.1152/ajplegacy.1974.226.6.1480; MITCHELL JB, 1989, INT J RADIAT ONCOL, V16, P1289, DOI 10.1016/0360-3016(89)90301-5; Ozols R F, 1986, Important Adv Oncol, P129; REID I, 1991, BRIT J CANCER, V64, P915, DOI 10.1038/bjc.1991.426; RIVLIN RS, FLAVINS FLAVOPROTEIN; Rosenberg SA., CANC PRINCIPLES PRAC, Ved, P895; SHOEMAKER JP, 1979, J NATL CANCER I, V62, P1575; Tate M. W., 1957, NONPARAMETRIC SHORTC; WEISENTHAL LM, 1985, CANCER TREAT REP, V69, P615	23	53	54	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1074	1076		10.1016/0140-6736(92)90664-O	http://dx.doi.org/10.1016/0140-6736(92)90664-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349103				2022-12-28	WOS:A1992HR44600003
J	SUGITANI, M; INCHAUSPE, G; SHINDO, M; PRINCE, AM				SUGITANI, M; INCHAUSPE, G; SHINDO, M; PRINCE, AM			SENSITIVITY OF SEROLOGICAL ASSAYS TO IDENTIFY BLOOD-DONORS WITH HEPATITIS-C VIREMIA	LANCET			English	Note							NON-B HEPATITIS; NON-A	Blood donors at high risk of hepatitis C virus (HCV) infection were tested for viraemia by the polymerase chain reaction (PCR). PCR results were accepted as positive only if reactive in 3 of 4 tests and if confirmed in an independent laboratory. The sera were also tested by 6 different assays to determine the ability of current serological assays to detect viraemic blood donors. Of 19 PCR-positive sera, only 13 (68%) were detected by the most sensitive of the serological assays. If these results are confirmed, automated PCR assays may be required for blood-donor screening to prevent transmission of HCV.	NEW YORK BLOOD CTR,VIROL & PARASITOL LAB,310 E 67TH ST,NEW YORK,NY 10021; NIHON UNIV,SCH MED,DEPT PATHOL 1,TOKYO 173,JAPAN; NIH,LIVER DIS SECT,BETHESDA,MD 20892	New York Blood Center; Nihon University; National Institutes of Health (NIH) - USA								AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; HOSEIN B, 1991, P NATL ACAD SCI USA, V88, P3647, DOI 10.1073/pnas.88.9.3647; INCHAUSPE G, 1991, HEPATOLOGY, V14, P595, DOI 10.1016/0270-9139(91)90044-V; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; NASOFF MS, 1991, P NATL ACAD SCI USA, V88, P5462, DOI 10.1073/pnas.88.12.5462; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; ZANETTI AR, 1990, LANCET, V336, P448, DOI 10.1016/0140-6736(90)92003-Z	9	147	150	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1018	1019		10.1016/0140-6736(92)90538-E	http://dx.doi.org/10.1016/0140-6736(92)90538-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349053				2022-12-28	WOS:A1992HQ43500006
J	MISTRY, PK; SMITH, SJ; ALI, M; HATTON, CSR; MCINTYRE, N; COX, TM				MISTRY, PK; SMITH, SJ; ALI, M; HATTON, CSR; MCINTYRE, N; COX, TM			GENETIC DIAGNOSIS OF GAUCHERS-DISEASE	LANCET			English	Article							HUMAN GLUCOCEREBROSIDASE GENE; MUTATION; DNA; HETEROGENEITY; PSEUDOGENE; SEQUENCE; CLONING; TYPE-1; LEVEL	The inherited disorder Gaucher's disease can be caused by various mutations in the glucocerebrosidase gene. Some mutations may be associated with greater severity, and there is a need for methods of gene analysis that would facilitate screening and diagnosis. We have studied the molecular basis of Gaucher's disease in twelve unrelated patients of diverse ethnic origin by means of the amplification refractory mutation system (ARMS). Primers for the polymerase chain reaction were designed to discriminate between mutant and wild-type alleles of glucocerebrosidase and to allow separation from products of the related pseudogene. The nucleotide 1226 mutation (asparagine 370 --> serine) and 84GG (an insertional frameshift mutation) were found exclusively in five patients of Ashkenazi Jewish descent (7 and 2 of the 1 0 disease alleles, respectively). Two point mutations, at nucleotides 1448 (leucine 444 --> proline) and 1504 (arginine 463 --> cysteine), were found in 4 and 3 alleles, respectively; they were associated with rapidly progressive disease and neurological involvement in non-Jewish patients. The ARMS procedure for direct detection of common mutations in glucocerebrosidase will facilitate genetic counselling and screening programmes for individuals at risk of Gaucher's disease.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND; WEXHAM PK HOSP,DEPT HAEMATOL,SLOUGH,BERKS,ENGLAND; UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT MED,LONDON,ENGLAND	Addenbrooke's Hospital; University of Cambridge; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School				Smith, Stuart/0000-0001-7266-6790	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1991, NEW ENGL J MED, V325, P1354; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; BEUTLER E, 1991, NEW ENGL J MED, V325, P1809; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; DAHL N, 1990, AM J HUM GENET, V47, P275; GINNS EI, 1985, P NATL ACAD SCI USA, V82, P7101, DOI 10.1073/pnas.82.20.7101; GRAVES PN, 1988, DNA-J MOLEC CELL BIO, V7, P521, DOI 10.1089/dna.1.1988.7.521; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HONG CM, 1990, DNA CELL BIOL, V9, P233, DOI 10.1089/dna.1990.9.233; HOROWITZ M, 1989, GENOMICS, V4, P87, DOI 10.1016/0888-7543(89)90319-4; JOHN SWM, 1991, NUCLEIC ACIDS RES, V19, P408, DOI 10.1093/nar/19.2.408; KAWAME H, 1991, AM J HUM GENET, V49, P1378; LATHAM TE, 1991, DNA CELL BIOL, V10, P15, DOI 10.1089/dna.1991.10.15; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; OHASHI T, 1991, J BIOL CHEM, V266, P3661; PERBAL B, 1988, PRACTICAL GUIDE MOL, P340; SORGE J, 1990, J CLIN INVEST, V86, P1137, DOI 10.1172/JCI114818; THEOPHILUS B, 1989, AM J HUM GENET, V45, P212; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; WIGDERSON M, 1989, AM J HUM GENET, V44, P365; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1991, AM J HUM GENET, V49, P855	25	45	46	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					889	892		10.1016/0140-6736(92)90928-V	http://dx.doi.org/10.1016/0140-6736(92)90928-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348297				2022-12-28	WOS:A1992HN48300003
J	FARNDON, PA; DELMASTRO, RG; EVANS, DGR; KILPATRICK, MW				FARNDON, PA; DELMASTRO, RG; EVANS, DGR; KILPATRICK, MW			LOCATION OF GENE FOR GORLIN SYNDROME	LANCET			English	Note							CELL CARCINOMA SYNDROME	The Gorlin (naevoid-basal-cell-carcinoma) syndrome is an autosomal dominant disorder characterised by multiple naevoid basal-cell carcinomas, recurrent odontogenic keratocysts, skeletal anomalies, intracranial calcification, and developmental malformations. Characterisation of the gene that causes the syndrome may improve our understanding of the pathogenesis of other basal-cell carcinomas. By linkage analysis, we have shown that the gene is located on chromosome 9q22.3-q31; the most likely position is between DNA markers D9S12 and D9S53. Location of the gene for Gorlin syndrome offers the possibility that DNA markers can be used in risk estimation and presymptomatic identification of patients for surveillance.	ST MARYS HOSP,DEPT MED GENET,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Manchester	FARNDON, PA (corresponding author), UNIV BIRMINGHAM,BIRMINGHAM MATERN HOSP,DEPT CLIN GENET,BIRMINGHAM B15 2TG,ENGLAND.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		EVANS DGR, 1991, BRIT J CANCER, V64, P959, DOI 10.1038/bjc.1991.435; FARNDON P, 1988, J MED GENET, V25, P638; FARNDON PA, 1991, CYTOGENET CELL GENET, V58, P2112; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; OTT J, 1974, AM J HUM GENET, V26, P588; Ott J., 1991, ANAL HUMAN GENETIC L; SPRINGATE JE, 1986, J PEDIATR SURG, V21, P908, DOI 10.1016/S0022-3468(86)80023-9; WEBER JL, 1989, AM J HUM GENET, V44, P388	8	303	307	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					581	582		10.1016/0140-6736(92)90868-4	http://dx.doi.org/10.1016/0140-6736(92)90868-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347096				2022-12-28	WOS:A1992HH07500006
J	KENNEDY, KI; VISNESS, CM				KENNEDY, KI; VISNESS, CM			CONTRACEPTIVE EFFICACY OF LACTATIONAL AMENORRHEA	LANCET			English	Article							OVULATION; RETURN; FERTILITY	Pregnancy is rare among breastfeeding women with lactational amenorrhoea. The lactational amenorrhoea method (LAM) is the informed use of breastfeeding as a contraceptive method by a woman who is still amenorrhoeic, and who is not feeding her baby with supplements, for up to 6 months after delivery. Under these three conditions, LAM users are thought to have 98% protection from pregnancy. It can be difficult, however, to determine when supplementation of the baby's diet begins. We have analysed data from nine studies of the recovery of fertility in breastfeeding women to assess the effectiveness of lactational amenorrhoea alone, irrespective of whether supplements have been introduced, as a fertility regulation method post partum. Cumulative probabilities of ovulation during lactational amenorrhoea were 30.9 and 67.3 per 100 women at 6 and 12 months, respectively, compared with 27.2 at 6 months when all three criteria of the LAM were met. Cumulative pregnancy rates during lactational amenorrhoea were 2.9 and 5.9 per 100 women at 6 and 12 months, compared with 0.7 at 6 months for the LAM. The probability of pregnancy during lactational amenorrhoea calculated from these studies is similar to that of other modern contraceptive methods, and it seems reasonable for a woman to rely on lactational amenorrhoea without regard to whether she is fully or partly breastfeeding. So that amenorrhoea and fertility suppression can be maintained, counselling about good breastfeeding and weaning practices remains important.			KENNEDY, KI (corresponding author), FAMILY HLTH INT,RES TRIANGLE PK,NC 27709, USA.							BENITEZ I, IN PRESS J BIOSCI SC; BONGAARTS J, 1983, DETERMINANTS FERTILI, P103; Brown J B, 1988, Prog Clin Biol Res, V285, P119; DIAZ S, 1991, CONTRACEPTION, V43, P335, DOI 10.1016/0010-7824(91)90072-N; GOLDZIEHER JW, 1962, ACTA ENDOCRINOL-COP, V41, P371, DOI 10.1530/acta.0.0410371; GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; HOWIE PW, 1982, CLIN ENDOCRINOL, V17, P323, DOI 10.1111/j.1365-2265.1982.tb01597.x; HOWIE PW, 1982, CLIN ENDOCRINOL, V17, P609; ISRANGKURA B, 1989, INT J GYNECOL OBSTET, V30, P335, DOI 10.1016/0020-7292(89)90820-5; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; KHAN T, 1989, CONTRACEPTION, V40, P365, DOI 10.1016/0010-7824(89)90099-1; LABBOCK M, 1990, LACTATIONAL ED HLTH, P70; RIVERA R, 1988, FERTIL STERIL, V49, P780; Rolland R., 1976, Bibliography of Reproduction, V28, P1; SAVINA G, 1989, STUD FAMILY PLANN, V20, P203, DOI 10.2307/1966838; SHAABAN MM, 1990, J BIOSOC SCI, V22, P19, DOI 10.1017/S0021932000018344; SHORT RV, 1991, LANCET, V337, P715, DOI 10.1016/0140-6736(91)90288-Z; SIMPSONHEBERT M, 1981, STUD FAMILY PLANN, V12, P125, DOI 10.2307/1965593; TRUSSELL J, 1990, STUD FAMILY PLANN, V21, P51, DOI 10.2307/1966591; Trussell J, 1991, Health Transit Rev, V1, P105; VANGINNE.JK, 1974, STUD FAMILY PLANN, V5, P201, DOI 10.2307/1965371; WOOD JW, 1989, OXFORD REV REPROD B, V11, P61; 1989, LIFETAB PROGRAM LIFE; 1988, LANCET, V2, P1204; 1985, SAS USERS GUIDE STAT	25	122	127	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					227	230		10.1016/0140-6736(92)90018-X	http://dx.doi.org/10.1016/0140-6736(92)90018-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346183				2022-12-28	WOS:A1992HA58900015
J	MACLENNAN, ICM; CHAPMAN, C; DUNN, J; KELLY, K				MACLENNAN, ICM; CHAPMAN, C; DUNN, J; KELLY, K			COMBINED CHEMOTHERAPY WITH ABCM VERSUS MELPHALAN FOR TREATMENT OF MYELOMATOSIS	LANCET			English	Article							ALTERNATING COMBINATION CHEMOTHERAPY; REQUIRING PROLONGED OBSERVATION; BONE-MARROW TRANSPLANTATION; SOUTHWEST-ONCOLOGY-GROUP; MULTIPLE-MYELOMA; PREDNISONE; SURVIVAL; TRIALS; LEUKEMIA; FEATURES	Both melphalan and cyclophosphamide increase life expectancy in patients with myelomatosis, but few large randomised studies have compared combination chemotherapy regimens with these single agents. In the Vth MRC myelomatosis trial, the survival of 314 patients randomised to receive ABCM (adriamycin, BCNU, cyclophosphamide, and melphalan) as first-line treatment was significantly longer than that of 316 patients given intermittent melphalan (M7) (p = 0.0003). The 75%, median, and 25% survivals were 7, 24, and 42 months, respectively, with M7 and 10, 32, and 56 months, respectively, with ABCM. Stable disease with few symptoms (plateau) was achieved by 61% of patients given ABCM and 49% of those given M7 (p = 0.004). Myelotoxicity was comparable between regimens. Cross-trial analysis suggests that M7 is comparable to melphalan and prednisone or melphalan, prednisone, and vincristine; that the efficacy of ABCM in the Vth trial and VIth MRC trials is comparable; and that ABCM gave better survival than intermittent melphalan regimens in the prognostic groups analysed. The results indicate that ABCM is an acceptable regimen that is more effective than melphalan, with or without prednisone, for first-line treatment of myelomatosis.	UNIV BIRMINGHAM,SCH MED,CRC TRIALS UNIT,BIRMINGHAM B15 2SZ,ENGLAND	University of Birmingham	MACLENNAN, ICM (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,MRC,MYELOMATOSIS TRIALS OFF,POB 1894,VINCENT DR,BIRMINGHAM B15 2SZ,ENGLAND.							ALBERTS DS, 1975, LANCET, V1, P926; BERGSAGEL DE, 1988, HEMATOL ONCOL, V6, P159, DOI 10.1002/hon.2900060216; BLADE J, 1990, BLUT, V60, P319, DOI 10.1007/BF01737844; BOCCADORO M, 1991, J CLIN ONCOL, V9, P444, DOI 10.1200/JCO.1991.9.3.444; BRANDES LJ, 1982, CANCER TREAT REP, V66, P1413; CUZICK J, 1985, BRIT J CANCER, V52, P1, DOI 10.1038/bjc.1985.140; CUZICK J, 1980, BRIT J CANCER, V43, P831; DIXON WJ, 1985, BMDP STATISTICAL SOF; DURIE BGM, 1986, J CLIN ONCOL, V4, P1227, DOI 10.1200/JCO.1986.4.8.1227; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; GAHRTON G, 1989, EUR J HAEMATOL, V43, P182; HJORTH M, 1990, BRIT J HAEMATOL, V74, P185, DOI 10.1111/j.1365-2141.1990.tb02564.x; JAGANNATH S, 1990, BLOOD, V76, P1860; KELLY KA, 1988, HEMATOL ONCOL, V6, P131, DOI 10.1002/hon.2900060213; MACLENNAN ICM, 1988, HEMATOL ONCOL, V6, P145, DOI 10.1002/hon.2900060215; OSGOOD EE, 1960, CANCER CHEMOTH REP, V9, P1; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; SALMON SE, 1983, J CLIN ONCOL, V1, P453, DOI 10.1200/JCO.1983.1.8.453; SELBY PJ, 1987, BRIT J HAEMATOL, V66, P55, DOI 10.1111/j.1365-2141.1987.tb06890.x; 1985, BRIT J CANCER, V52, P153; 1980, BRIT J CANCER, V42, P813; 1971, BRIT MED J, V1, P640	23	123	123	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					200	205		10.1016/0140-6736(92)90004-M	http://dx.doi.org/10.1016/0140-6736(92)90004-M			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346171				2022-12-28	WOS:A1992HA58900002
J	TUFFNELL, DJ; LILFORD, RJ; BUCHAN, PC; PRENDIVILLE, VM; TUFFNELL, AJ; HOLGATE, MP; JONES, MDG				TUFFNELL, DJ; LILFORD, RJ; BUCHAN, PC; PRENDIVILLE, VM; TUFFNELL, AJ; HOLGATE, MP; JONES, MDG			RANDOMIZED CONTROLLED TRIAL OF DAY-CARE FOR HYPERTENSION IN PREGNANCY	LANCET			English	Article								Our aim was to assess the effect of the introduction of a day-care unit on the care of women with non-proteinuric hypertension in pregnancy. A randomised controlled trial was carried out on 54 women who presented at 26 weeks of pregnancy or later with non-proteinuric hypertension (systolic blood pressure 150-170 mm Hg and/or diastolic pressure 90-105 mm Hg on two occasions at least 15 min apart). 30 women were allocated to care by the day unit and 24 were managed according to the established practice of their clinicians without access to the day unit (control group). Women in the control group spent on average 4.6 times longer as inpatients (difference in mean stay 4.0 days [95% confidence interval 2.1-5.9 days]) than the day-unit group and were 8.8 times (95% Cl 3.0-25.8) more likely to be admitted to hospital. Induction of labour was 4.9 times (95% Cl 1.6-13.8) more likely in the control than in the day-unit group and the development of proteinuria 11.4 times (95% Cl 1.8-71.4) more likely. The control group had a mean of 1.5 fewer hospital outpatient visits (95% Cl 0.36-2.64). The groups did not differ in their use of antihypertensive drugs. Day-unit care for hypertension in pregnancy significantly reduced the need for and the length of antenatal inpatient admissions and the number of medical interventions, at the cost of an increase in outpatient attendances. Our results are further evidence that inpatient care does not improve outcomes or prevent the development of proteinuria in this disorder.			TUFFNELL, DJ (corresponding author), ST JAMES UNIV HOSP, DEPT OBSTET & GYNAECOL, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND.		Steen, Mary/E-7567-2015	Steen, Mary/0000-0002-0362-5693				BURNELL I, 1982, J OBSTET GYNAECOL, V3, P43, DOI 10.3109/01443618209083086; CARTWRIGHT A, 1986, STAT MED, V5, P607, DOI 10.1002/sim.4780050608; CARTWRIGHT A, 1988, MILBANK Q, V66, P172, DOI 10.2307/3349989; CROWTHER CA, 1989, EFFECTIVE CARE PREGN, V1, P624; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; DAWSON AJ, 1989, BRIT J OBSTET GYNAEC, V96, P1319, DOI 10.1111/j.1471-0528.1989.tb03230.x; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; HAMLIN RHJ, 1952, LANCET, V262, P64; JOHNSON N, 1991, SCI F OBSTETRICS GYN, P723; LILFORD RJ, 1987, BRIT MED J, V295, P1298, DOI 10.1136/bmj.295.6609.1298; LILFORD RJ, 1989, LANCET, V2, P112; MATHEWS DD, 1977, BRIT J OBSTET GYNAEC, V84, P108, DOI 10.1111/j.1471-0528.1977.tb12535.x; MATHEWS DD, 1971, J OBSTET GYN BR COMM, V78, P610; THORNTON JG, 1989, J OBSTET GYNAECOL, V9, P283, DOI 10.3109/01443618909151065; THORNTON JG, 1990, MED DECIS MAKING, V10, P288, DOI 10.1177/0272989X9001000407; WALKER JJ, 1986, HYPERTENSION PREGNAN; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	17	47	47	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1992	339	8787					224	227		10.1016/0140-6736(92)90017-W	http://dx.doi.org/10.1016/0140-6736(92)90017-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346182				2022-12-28	WOS:A1992HA58900014
J	BRODIE, MJ				BRODIE, MJ			LAMOTRIGINE	LANCET			English	Article							ADD-ON TRIAL; PARTIAL SEIZURES; EPILEPSY; ANTICONVULSANT				BRODIE, MJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,DEPT MED & THERAPEUT,EPILEPSY RES UNIT,GLASGOW G11 6NT,SCOTLAND.							BETTS T, 1991, EPILEPSIA, V32, pS17, DOI 10.1111/j.1528-1157.1991.tb05881.x; BINNIE CD, 1989, EPILEPSY RES, V4, P222, DOI 10.1016/0920-1211(89)90007-7; BINNIE CD, 1986, EPILEPSIA, V27, P248, DOI 10.1111/j.1528-1157.1986.tb03536.x; BRODIE MJ, 1990, LANCET, V336, P350, DOI 10.1016/0140-6736(90)91886-F; CHADWICK D, 1990, LANCET, V336, P291, DOI 10.1016/0140-6736(90)91815-R; COHEN AF, 1987, CLIN PHARMACOL THER, V42, P535, DOI 10.1038/clpt.1987.193; DEPOT M, 1990, CLIN PHARMACOL THER, V48, P346, DOI 10.1038/clpt.1990.162; JAWAD S, 1986, BRIT J CLIN PHARMACO, V22, P191, DOI 10.1111/j.1365-2125.1986.tb05249.x; JAWAD S, 1989, EPILEPSIA, V30, P356, DOI 10.1111/j.1528-1157.1989.tb05309.x; JAWAD S, 1987, EPILEPSY RES, V1, P196; Lamb RJ, 1985, BRIT J PHARMACOL, V86, P765; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; LOISEAU P, 1990, EPILEPSY RES, V7, P136, DOI 10.1016/0920-1211(90)90099-H; MELDRUM BS, 1991, EPILEPSIA, V32, pS1, DOI 10.1111/j.1528-1157.1991.tb05879.x; MILLER AA, 1986, EPILEPSIA, V27, P483, DOI 10.1111/j.1528-1157.1986.tb03572.x; PECK AW, 1991, EPILEPSIA, V32, pS9, DOI 10.1111/j.1528-1157.1991.tb05883.x; RAMSAY RE, 1991, EPILEPSY RES, V10, P191, DOI 10.1016/0920-1211(91)90012-5; RICHENS A, 1991, EPILEPSIA, V32, pS13, DOI 10.1111/j.1528-1157.1991.tb05880.x; RISNER ME, 1990, EPILEPSIA, V31, P619; ROGAWSKI MA, 1990, PHARMACOL REV, V42, P223; SANDER JWAS, 1990, EPILEPSY RES, V6, P221, DOI 10.1016/0920-1211(90)90077-9; SHORVON SD, 1990, LANCET, V336, P93, DOI 10.1016/0140-6736(90)91603-8; WHEATLEY PL, 1989, EPILEPSIA, V30, P34, DOI 10.1111/j.1528-1157.1989.tb05277.x	23	196	199	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1397	1400		10.1016/0140-6736(92)91207-O	http://dx.doi.org/10.1016/0140-6736(92)91207-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350815				2022-12-28	WOS:A1992HX63600014
J	JADAD, AR; CARROLL, D; GLYNN, CJ; MOORE, RA; MCQUAY, HJ				JADAD, AR; CARROLL, D; GLYNN, CJ; MOORE, RA; MCQUAY, HJ			MORPHINE RESPONSIVENESS OF CHRONIC PAIN - DOUBLE-BLIND RANDOMIZED CROSSOVER STUDY WITH PATIENT-CONTROLLED ANALGESIA	LANCET			English	Article								There is controversy about whether the lack of response of some chronic pain to opioid treatment is absolute or relative. It is widely believed that nociceptive pain is responsive to opioids whereas neuropathic pain tends not to be. We have used a method of patient-controlled analgesia (PCA) with simultaneous nurse-observer measurement of analgesia, mood, and adverse effects to address these issues. Ten patients with chronic pain were given morphine at two concentrations (10 and 30 mg/ml) by PCA in two separate sessions in a double-blind randomised crossover study. Before the study a clinical judgment was made as to whether each pain was nociceptive or neuropathic. Seven patients showed good analgesic responses (more than 70 mm pain relief on a visual-analogue scale) of pain at rest, two patients poor responses (less than 30 mm pain relief), and one a moderate response with both concentrations (30-70 mm pain relief). The response to morphine was consistent (greater and faster relief with the higher concentration) in nine patients. Two patients had pain on movement that responded moderately to low-concentration morphine and well to the higher concentration. All patients with pains judged to be nociceptive showed good analgesic responses compared with half of those with neuropathic pain. There was no evidence that analgesic responses in patients with neuropathic pain were due to changes in mood. This PCA method is a quick and efficient tool to determine the consistency of the analgesic response. Such consistency can guide the clinician as to whether continued or higher-dose opioid treatment will produce good analgesia. An inconsistent response points to the use of other pain-relieving strategies.	UNIV OXFORD,NUFFIELD DEPT ANAESTHET,OXFORD,ENGLAND; DIAGNOST PROD CORP,EUROPEAN RES INST,OXFORD,ENGLAND	University of Oxford								ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; BRENA SF, 1991, CLIN J PAIN, V7, P342, DOI 10.1097/00002508-199112000-00015; BRUERA E, 1991, PAIN, V44, P167, DOI 10.1016/0304-3959(91)90132-H; COOPER SA, 1991, DESIGN ANALGESIC CLI, V18, P117; GLYNN CJ, 1991, CLIN J PAIN, V7, P346, DOI 10.1097/00002508-199112000-00016; HARDY PAJ, 1991, BRIT J HOSP MED, V45, P257; HILL CS, 1989, ADV PAIN RES THERAPY, V11; JACOBS OLR, 1985, AUTOMATICA, V21, P349, DOI 10.1016/0005-1098(85)90072-X; KEERISZANTO M, 1979, PAIN, V6, P217, DOI 10.1016/0304-3959(79)90129-5; KUPERS RC, 1991, PAIN, V47, P5, DOI 10.1016/0304-3959(91)90004-H; MCQUAY HJ, IN PRESS ANAESTHESIA; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; TASKER RR, 1983, ADV PAIN RES THER, V5, P713	14	154	157	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1367	1371		10.1016/0140-6736(92)91194-D	http://dx.doi.org/10.1016/0140-6736(92)91194-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350803				2022-12-28	WOS:A1992HX63600001
J	ANDERSON, DJ; OBRIEN, TR; POLITCH, JA; MARTINEZ, A; SEAGE, GR; PADIAN, N; HORSBURGH, CR; MAYER, KH				ANDERSON, DJ; OBRIEN, TR; POLITCH, JA; MARTINEZ, A; SEAGE, GR; PADIAN, N; HORSBURGH, CR; MAYER, KH			EFFECTS OF DISEASE STAGE AND ZIDOVUDINE THERAPY ON THE DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN SEMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV INFECTION; RISK-FACTORS; TRANSMISSION; AIDS; QUANTITATION; ANTIBODY; CELLS; BLOOD; MEN	Objective.-To determine the prevalence and temporal expression of infectious human immunodeficiency virus type 1 (HIV-1) in the semen of HIV-1 seropositive men and to determine whether the detection of HIV-1 in semen is associated with disease stage, zidovudine treatment status, or other clinical factors. Design.-A microculture technique was used to detect infectious HIV-1 in semen from a cohort of 95 seropositive men. In addition, semen cultures were performed monthly for at least 6 months for 14 of the men. information was obtained by interview and extracted from medical records to identify clinical variables associated with HIV-1 in semen. Patients.-Sixty HIV-1 seropositive homosexual men participating in clinical studies at the Fenway Community Health Center, Boston, Mass, and 35 HIV seropositive bisexual or heterosexual men participating in the California Partner Study of the University of California, San Francisco. Main Outcome Measures.-Semen HIV-1 culture results, seminal leukocyte counts, Centers for Disease Control (CDC) disease stage, peripheral CD4+ cell counts, zidovudine therapy, HIV risk category. Results.-In the cross-sectional study, HIV-1 was cultured from the semen of nine (9%) of 95 men. Factors associated with detection of HIV-1 in semen were peripheral CD4+ cell counts of 0.20 X 10(9)/L (200/mu-L) or less (adjusted odds ratio [OR], 23.33; 95% confidence interval [CI], 2.89 to 175.63); symptomatic (CDC class IV) disease (adjusted OR, 6.56; 95% CI, 1.02 to 66.76); and seminal leukocytosis (> 1 x 10(9) white blood cells per liter of semen) (adjusted OR, 7.02; 95% CI, 1.28 to 39.29). Zidovudine therapy was associated with decreased detection of HIV-1 in semen (adjusted OR, 0.04; 95% Cl, 0.00 to 0.63). In the longitudinal study of 14 men who had neither peripheral CD4+ cells counts of 0.20 X 10(9)/L or less nor seminal leukocytosis, seminal HIV-1 was detected in at least one sample from six men (43%). Conclusion.-HIV-1 is more commonly found in semen from men with advanced HIV-1 infection and seminal leukocytosis but can also be cultured from semen of men with neither of these conditions. Zidovudine therapy may decrease the prevalence and/or titer of seminal HIV-1. However, all HIV-1-infected persons should continue to assume that they are potentially infectious through sexual contact.	CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; BOSTON DEPT HLTH & HOSP,INST URBAN HLTH RES,BOSTON,MA; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; MEM HOSP,INFECT DIS BRANCH,PAWTUCKET,RI 02860; FENWAY COMMUNITY HLTH CTR,BOSTON,MA	Centers for Disease Control & Prevention - USA; Boston University; University of California System; University of California San Francisco	ANDERSON, DJ (corresponding author), HARVARD UNIV,SCH MED,DEPT OBSTET GYNECOL & REPROD BIOL,FEARING RES LAB,ROOM 204,BOSTON,MA 02115, USA.			Anderson, Deborah/0000-0002-2848-7290; Horsburgh, C./0000-0001-6838-7895; Politch, Joseph/0000-0002-7022-0135	NIAID NIH HHS [AI25305] Funding Source: Medline; PHS HHS [U62/CCU100607, CCR903266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025305] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER NJ, 1987, FERTIL STERIL, V47, P192; ANDERESON DJ, 1990, 6TH P C AIDS, V1, P263; ANDERSON DJ, 1990, HETEROSEXUAL TRANSMI, P167; ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0; CASTRO BA, 1988, J CLIN MICROBIOL, V26, P2371, DOI 10.1128/JCM.26.11.2371-2376.1988; CLUMECK N, 1989, NEW ENGL J MED, V321, P1460, DOI 10.1056/NEJM198911233212107; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEVINCENZI I, 1989, 5TH INT C ACQ IMM SY, P115; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GUPTA P, 1989, J VIROL, V63, P2361, DOI 10.1128/JVI.63.5.2361-2365.1989; HENRY K, 1988, JAMA-J AM MED ASSOC, V259, P3023, DOI 10.1001/jama.259.20.3023; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLMBERG SD, 1989, J INFECT DIS, V160, P116, DOI 10.1093/infdis/160.1.116; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P68, DOI 10.2105/AJPH.78.1.68; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; OSHEA S, 1990, J MED VIROL, V31, P291, DOI 10.1002/jmv.1890310409; OSMOND D, 1988, AM J PUBLIC HEALTH, V78, P944, DOI 10.2105/AJPH.78.8.944; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PUDNEY J, 1991, AM J PATHOL, V39, P149; SEAGE GR, 1989, AM J PUBLIC HEALTH, V79, P1638, DOI 10.2105/AJPH.79.12.1638; VANVOORHIS BJ, 1991, FERTIL STERIL, V55, P588; WOLFF H, 1992, J ACQ IMMUN DEF SYND, V5, P65; WOLFF H, 1988, FERTIL STERIL, V49, P497; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607; 1987, WHO LABORATORY MANUA, P27; [No title captured]	31	183	185	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2769	2774		10.1001/jama.267.20.2769	http://dx.doi.org/10.1001/jama.267.20.2769			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1349654				2022-12-28	WOS:A1992HV26500025
J	TOVO, PA; DEMARTINO, M; GABIANO, C; CAPPELLO, N; DELIA, R; LOY, A; PLEBANI, A; ZUCCOTTI, GV; DALLACASA, P; FERRARIS, G; CASELLI, D; FUNDARO, C; DARGENIO, P; GALLI, L; PRINCIPI, N; STEGAGNO, M; RUGA, E; PALOMBA, E				TOVO, PA; DEMARTINO, M; GABIANO, C; CAPPELLO, N; DELIA, R; LOY, A; PLEBANI, A; ZUCCOTTI, GV; DALLACASA, P; FERRARIS, G; CASELLI, D; FUNDARO, C; DARGENIO, P; GALLI, L; PRINCIPI, N; STEGAGNO, M; RUGA, E; PALOMBA, E			PROGNOSTIC FACTORS AND SURVIVAL IN CHILDREN WITH PERINATAL HIV-1 INFECTION	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; REGRESSION-MODELS; INFANTS; MOTHERS; TYPE-1; EXPRESSION; BLOOD; BORN	The signs that may arise after perinatal infection with human immunodeficiency virus type 1 (HIV-1) have been classified by the Centers for Disease Control, but the clinical usefulness of the classification system and the prognostic importance of each disease pattern have not been established. We sought to address these issues by analysing data from the italian Register for HIV infection in children. We studied 1887 children born to HIV-1-seropositive mothers. 1045 were identified at birth and the others were registered later (median age 4.8 [range 0.4-72] months). HIV-1-associated signs developed in 433 (81.8%) of 529 seropositive infected children at a median age of 5 (0.03-84) months. These signs appeared significantly earlier in the 102 children who died of HIV-1-related illness than in those who are still alive (median 3 [0.03-55] vs 6 [0.03-84] months; p < 0.001). The cumulative proportion surviving at age 9 years was 49.5% (95% confidence interval 27-65%) and the median survival time was 96.2 months. Separate analysis of the 112 seropositive infected children followed from birth and older than 15 months gave similar results. Hepatomegaly, splenomegaly, lymphadenopathy, parotitis, skin diseases, and recurrent respiratory tract infections formed the mildest disease pattern. Lymphoid interstitial pneumonitis and thrombocytopenia were signs of intermediate disease. By contrast, in multivariate analysis specific secondary infectious diseases, severe bacterial infections, progressive neurological disease, anaemia, and fever were significant and independent negative predictors of survival. Growth failure, persistent oral candidosis, hepatitis, and cardiopathy were associated in univariate analysis with significantly shorter survival. Our findings suggest that the outlook for children with perinatal HIV-1 infection is better than previously thought and that a new clinical staging system of single disease patterns is needed.	UNIV FLORENCE, DEPT PAEDIAT, I-50121 FLORENCE, ITALY; UNIV TURIN, DEPT GENET BIOL & MED CHEM, I-10124 TURIN, ITALY; UNIV PADUA, DEPT PAEDIAT, I-35100 PADUA, ITALY; UNIV GENOA, G GASLINI INST, DEPT INFECT DIS 1, I-16126 GENOA, ITALY; UNIV MILAN, DEPT PEDIAT 1, I-20122 MILAN, ITALY; UNIV MILAN, DEPT PAEDIAT 5, I-20122 MILAN, ITALY; UNIV BOLOGNA, INST CHILD HLTH & NEONATOL, I-40126 BOLOGNA, ITALY; INFANT & MATERNAL CTR DRUG DEPENDENT RELATED ILLNE, MILAN, ITALY; UNIV PAVIA, DEPT PAEDIAT, I-27100 PAVIA, ITALY; UNIV CATTOLICA SACRO CUORE, DEPT PAEDIAT, I-00168 ROME, ITALY; BAMBINO GESU PEDIAT HOSP, ROME, ITALY; UNIV MILAN, DEPT PAEDIAT 4, I-20122 MILAN, ITALY; UNIV ROME LA SAPIENZA, DEPT CHILD HLTH, I-00185 ROME, ITALY	University of Florence; University of Turin; University of Padua; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Milan; University of Milan; University of Bologna; University of Pavia; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Bambino Gesu; University of Milan; Sapienza University Rome	TOVO, PA (corresponding author), UNIV TURIN, DEPT PAEDIAT, PIAZZA POLONIA 94, I-10126 TURIN, ITALY.		Plebani, Alessandro/C-8593-2011; Cappello, Nazario/D-9530-2012; D'Argenio, Patrizia/ABA-3852-2021; Zuccotti, Gianvincenzo/H-8572-2017	Zuccotti, Gianvincenzo/0000-0002-2795-9874; Tovo, Pier Angelo/0000-0002-0192-3240; Guarino, Alfredo/0000-0003-0199-0336				ARICO M, 1991, CANCER, V68, P2473, DOI 10.1002/1097-0142(19911201)68:11<2473::AID-CNCR2820681125>3.0.CO;2-L; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; COX DR, 1972, J R STAT SOC B, V34, P187; DEMARTINO M, 1991, J PEDIATR-US, V119, P702, DOI 10.1016/S0022-3476(05)80283-5; DEMARTINO M, 1991, ARCH DIS CHILD, V66, P1235, DOI 10.1136/adc.66.10.1235; FALLOON J, 1989, J PEDIATR-US, V114, P1, DOI 10.1016/S0022-3476(89)80596-7; FERRIS S, 1990, 6TH INT C AIDS SAN F, V1, P261; GABIANO C, IN PRESS PEDIATRICS; HAUGER S B, 1991, Journal of Pediatrics, V119, pS25, DOI 10.1016/S0022-3476(05)81450-7; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRASINSKI K, 1989, PEDIATR INFECT DIS J, V8, P216; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; LAMPERT R, 1986, PEDIATR INFECT DIS J, V5, P374, DOI 10.1097/00006454-198605000-00020; LAURE F, 1988, LANCET, V2, P538; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PAWHA S, 1986, JAMA-J AM MED ASSOC, V225, P2299; PECKHAM CS, 1991, LANCET, V337, P253; PEDUZZI PN, 1980, BIOMETRICS, V36, P511, DOI 10.2307/2530219; ROGERS MF, 1987, PEDIATRICS, V79, P1008; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; TOVO PA, 1987, LANCET, V1, P1201; TOVO PA, 1988, LANCET, V2, P1043; TOVO PA, 1985, RIV ITAL PED, V11, P885; WAHN V, 1990, EUR J PEDIATR, V149, P330, DOI 10.1007/BF02171559; 1987, MMWR, V36, P225; 1987, MMWR, V36, P1	30	300	304	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	1992	339	8804					1249	1253		10.1016/0140-6736(92)91592-V	http://dx.doi.org/10.1016/0140-6736(92)91592-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349667				2022-12-28	WOS:A1992HV19100002
J	BRAHAMS, D				BRAHAMS, D			RETRACTOR DESIGN AND THE LINGUAL NERVE	LANCET			English	Editorial Material																			0	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					801	801		10.1016/0140-6736(92)91915-U	http://dx.doi.org/10.1016/0140-6736(92)91915-U			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347817				2022-12-28	WOS:A1992HL50100018
J	SUPHIOGLU, C; SINGH, MB; TAYLOR, P; BELLOMO, R; HOLMES, P; PUY, R; KNOX, RB				SUPHIOGLU, C; SINGH, MB; TAYLOR, P; BELLOMO, R; HOLMES, P; PUY, R; KNOX, RB			MECHANISM OF GRASS-POLLEN-INDUCED ASTHMA	LANCET			English	Article							EXTRACT	Many asthmatics are sensitive to rye-grass pollen, but pollen grains are too large to penetrate the lower airways. Our aim was to investigate the mechanism by which rye-grass pollen causes asthma. A major allergen of rye-grass pollen, Lol pIX, is located in intracellular starch granules within pollen grains. In-vitro tests showed that pollen grains are ruptured in rainwater by osmotic shock, each grain releasing about 700 starch granules into the environment. These granules are small enough to enter the airways (< 3-mu-m in diameter). The starch granules were present in atmospheric samples taken during the pollen season, and showed a 50-fold increase in atmospheric concentration on days following rainfall. Isolated granules elicited IgE-mediated responses in asthmatic patients, and 4 patients with rainfall-associated asthma who underwent an inhalation challenge test had striking bronchial constriction after exposure to starch granules. Starch granules released from rye-grass pollen seem to be capable of causing asthma.	UNIV MELBOURNE,SCH BOT,PARKVILLE,VIC 3052,AUSTRALIA; MONASH MED CTR,DEPT RESP MED,CLAYTON,VIC,AUSTRALIA; ALFRED HOSP,ALLERGY & RESP IMMUNOL UNIT,PRAHRAN,VIC 3181,AUSTRALIA	University of Melbourne; Monash University; Florey Institute of Neuroscience & Mental Health			Puy, Robert/AAU-6374-2020	Puy, Robert/0000-0001-7001-6313; Singh, Mohan/0000-0001-9427-8975				BELLOMO R, IN PRESS MED J AUST; HILL DJ, 1979, MED J AUSTRALIA, V1, P426, DOI 10.5694/j.1326-5377.1979.tb127014.x; ONG EK, 1990, INT ARCH ALLER A IMM, V93, P338, DOI 10.1159/000235263; PACKE GE, 1985, LANCET, V2, P199; PAGGIARO PL, 1990, RESPIRATION, V57, P51; SALVAGGIO JE, 1967, J ALLERGY, V30, P227; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; STEWART GA, 1985, MED J AUSTRALIA, V143, P426, DOI 10.5694/j.1326-5377.1985.tb123117.x; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006	10	295	301	0	34	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					569	572		10.1016/0140-6736(92)90864-Y	http://dx.doi.org/10.1016/0140-6736(92)90864-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347092				2022-12-28	WOS:A1992HH07500002
J	CLEARY, PP; KAPLAN, EL; HANDLEY, JP; WLAZLO, A; KIM, MH; HAUSER, AR; SCHLIEVERT, PM				CLEARY, PP; KAPLAN, EL; HANDLEY, JP; WLAZLO, A; KIM, MH; HAUSER, AR; SCHLIEVERT, PM			CLONAL BASIS FOR RESURGENCE OF SERIOUS STREPTOCOCCUS-PYOGENES DISEASE IN THE 1980S	LANCET			English	Article							SHOCK-LIKE SYNDROME; GROUP-A; INFECTION; EPIDEMIC; EXOTOXIN; STRAINS	During the 1980s there was a resurgence of serious Streptococcus pyogenes infections with complications, including rheumatic fever, sepsis, severe soft-tissue invasion, and toxic-shock-like syndrome (TSLS). We have investigated the suggested association between expression of a scarlet fever toxin, SPE A, and systemic toxicity, and the possibility that a new highly virulent clone of S pyogenes has emerged and spread world wide. We studied serotype M1 strains, the serotype most commonly associated with serious complications. 19 isolates from patients with sepsis, with or without TSLS, and 48 from patients with uncomplicated pharyngitis or superficial skin infection were subjected to restriction-enzyme digestion and electrophoresis, 56 isolates (19 serious, 37 uncomplicated disease) were then examined by hybridisation to an speA gene probe. 17 (90%) of the 19 serious-disease isolates had a characteristic ("invasive", I) restriction-fragment profile and were positive for the speA gene. Significantly lower proportions of the isolates from patients with uncomplicated disease had the I profile-(21/48 [44%]; p = 0.0035) and speA (20/37 [54%]; p < 0.001). These findings suggest that the strains from patients with serious disease are a unique clone, which became the predominant cause of severe streptococcal infections in the United States and elsewhere in the late 1980s.	UNIV MINNESOTA,WHO,COLLABORATING CTR REFERENCE & RES STREPTOCOCCI,DEPT PEDIAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; World Health Organization	CLEARY, PP (corresponding author), UNIV MINNESOTA,DEPT MICROBIOL,BOX 196,UMHC,MINNEAPOLIS,MN 55455, USA.			Schlievert, Patrick/0000-0001-8314-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036611, R55HL036611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016722] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36611] Funding Source: Medline; NIAID NIH HHS [AI16722] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atwater RM, 1927, AM J HYG, V7, P343, DOI 10.1093/oxfordjournals.aje.a120418; BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; BEGOVAC J, 1990, PEDIATR INFECT DIS J, V9, P369, DOI 10.1097/00006454-199005000-00013; BELANI K, 1991, PEDIATR INFECT DIS J, V10, P351, DOI 10.1097/00006454-199105000-00001; CLEARY PP, 1988, J INFECT DIS, V158, P1317, DOI 10.1093/infdis/158.6.1317; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; GAWORZEWSKA ET, 1988, EPIDEMIOL INFECT, V3100, P257; HAUSER AR, 1991, J CLIN MICROBIOL, V29, P1562, DOI 10.1128/JCM.29.8.1562-1567.1991; HRIBALOVA V, 1988, ANN INTERN MED, V108, P772, DOI 10.7326/0003-4819-108-5-772_2; JOHNSON DR, 1990, IN PRESS 11TH P LANC; JOHNSON LP, 1986, J BACTERIOL, V166, P623, DOI 10.1128/jb.166.2.623-627.1986; LEE PK, 1989, J CLIN MICROBIOL, V27, P1890, DOI 10.1128/JCM.27.8.1890-1892.1989; MARSHALL GS, 1991, PEDIATR INFECT DIS J, V10, P339, DOI 10.1097/00006454-199104000-00018; MARTIN NJ, 1990, J CLIN MICROBIOL, V28, P1881, DOI 10.1128/JCM.28.9.1881-1886.1990; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; MUSSER JM, 1991, P NATL ACAD SCI USA, V88, P2668, DOI 10.1073/pnas.88.7.2668; SCHLIEVERT PM, 1979, J INFECT DIS, V140, P676, DOI 10.1093/infdis/140.5.676; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STOLLERMAN GH, 1975, MOD CONC CARDIOV DIS, V44, P35; YU CE, 1989, INFECT IMMUN, V57, P3715, DOI 10.1128/IAI.57.12.3715-3719.1989	21	270	275	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					518	521		10.1016/0140-6736(92)90339-5	http://dx.doi.org/10.1016/0140-6736(92)90339-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346879				2022-12-28	WOS:A1992HF63100004
J	FRIEDLAND, IR; KLUGMAN, KP				FRIEDLAND, IR; KLUGMAN, KP			FAILURE OF CHLORAMPHENICOL THERAPY IN PENICILLIN-RESISTANT PNEUMOCOCCAL MENINGITIS	LANCET			English	Article							ANTIBIOTICS; ORGANISM	First-line therapy for meningitis is often penicillin plus chloramphenicol. Penicillin-resistant Streptococcus pneumoniae (PRSP) infections are increasing world wide, but the efficacy of chloramphenicol for PRSP meningitis is unknown. We therefore prospectively assessed children with pneumococcal meningitis treated with penicillin plus chloramphenicol over 27 months to compare outcome of penicillin-susceptible S pneumoniae (PSSP) meningitis with that of PRSP meningitis. 68 children with pneumococcal meningitis who survived 24 hours were evaluated, of whom 25 had chloramphenicol-susceptible PRSP meningitis that was treated initially with chloramphenicol. 20 (80%) of these 25 children had an unsatisfactory outcome (death, serious neurological deficit, or poor clinical response). By contrast, 14 (33%) of 43 children with PSSP meningitis (treated with benzylpenicillin) had an adverse outcome (p < 0.001). Despite similar zone sizes on antibiotic disc testing (indicating chloramphenicol susceptibility) the chloramphenicol minimum bactericidal concentrations (MBCs) of PRSP isolates were significantly higher than those of PSSP isolates. The higher chloramphenicol MBCs resulted in borderline cerebrospinal-fluid bactericidal activity in many cases of PRSP meningitis and frequent treatment failure. Current definitions of chloramphenicol susceptibility of S pneumoniae may be inappropriate for management of pneumococcal meningitis. We suggest that chloramphenicol should not be used for the management of PRSP meningitis, alternative agents, such as third-generation cephalosporins, are more appropriate.	S AFRICAN INST MED RES,MRC,EMERGENT PATHOGEN RES UNIT,JOHANNESBURG 2000,SOUTH AFRICA; BARAGWANATH HOSP,DEPT PAEDIAT,JOHANNESBURG 2013,SOUTH AFRICA; BARAGWANATH HOSP,DEPT CLIN MICROBIOL,JOHANNESBURG 2013,SOUTH AFRICA; UNIV WITWATERSRAND,JOHANNESBURG 2001,SOUTH AFRICA	University of Witwatersrand								CAPUTO GM, 1983, ANN INTERN MED, V98, P416, DOI 10.7326/0003-4819-98-3-416_2; Facklam RR, 1985, MANUAL CLIN MICROBIO, V4th, P154; FRIEDLAND IR, 1991, PEDIATR INFECT DIS J, V10, P705, DOI 10.1097/00006454-199109000-00018; IZER PV, 1978, PEDIATRICS, V61, P157; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; MCCRACKEN GH, 1985, ANTIMICROB AGENTS CH, V27, P141, DOI 10.1128/AAC.27.2.141; MOELLERING RC, 1989, J ANTIMICROB CHEMOTH, V24, P1; NARAQI S, 1974, J PEDIATR-US, V85, P671, DOI 10.1016/S0022-3476(74)80513-5; PAREDES A, 1976, PEDIATRICS, V58, P378; VILADRICH PF, 1991, ANTIMICROB AGENTS CH, V35, P2467, DOI 10.1128/AAC.35.12.2467; VILADRICH PF, 1988, AM J MED, V84, P839, DOI 10.1016/0002-9343(88)90061-7; WONG UK, 1991, PEDIATR INFECT DIS J, V10, P122; 1990, NCCLS M7A2 NAT COMM	13	150	154	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					405	408		10.1016/0140-6736(92)90087-J	http://dx.doi.org/10.1016/0140-6736(92)90087-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346668				2022-12-28	WOS:A1992HD65900012
J	TASSABEHJI, M; READ, AP; NEWTON, VE; HARRIS, R; BALLING, R; GRUSS, P; STRACHAN, T				TASSABEHJI, M; READ, AP; NEWTON, VE; HARRIS, R; BALLING, R; GRUSS, P; STRACHAN, T			WAARDENBURG SYNDROME PATIENTS HAVE MUTATIONS IN THE HUMAN HOMOLOG OF THE PAX-3 PAIRED BOX GENE	NATURE			English	Article							CONSERVATION; DOMAIN; MOUSE	WAARDENBURG'S syndrome (WS) is an autosomal dominant combination of deafness and pigmentary disturbances, probably caused by defective function of the embryonic neural crest 1,2. We have mapped one gene for WS to the distal part of chromosome 2 (ref. 3). On the basis of their homologous chromosomal location, their close linkage to an alkaline phosphatase gene, and their related phenotype, we suggested that WS and the mouse mutant Splotch 4,5 might be homologous. Splotch is caused by mutation in the mouse Pax-3 gene 6,7. This gene is one of a family of eight Pax genes known in mice which are involved in regulating embryonic development; each contains a highly conserved transcription control sequence, the paired box 8. Here we show that some families with WS have mutations in the human homologue 9 of Pax-3. Mutations in a related gene, Pax-6, which, like Pax-3, has both a paired box and a paired-type homeobox sequence, cause the Small-eye mutation in mice 10 and aniridia in man 11. Thus mutations in the Pax genes are important causes of human developmental defects.	UNIV MANCHESTER,ST MARYS HOSP,DEPT MED GENET,MANCHESTER M13 0JH,LANCS,ENGLAND; MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY; UNIV MANCHESTER,CTR AUDIOL,MANCHESTER M13 9PL,LANCS,ENGLAND; MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY	University of Manchester; Max Planck Society; University of Manchester; Max Planck Society			Balling, Rudi/E-9680-2010	Balling, Rudi/0000-0003-2902-5650	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARIAS S, 1971, Birth Defects Original Article Series, V7, P87; ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; COLLIER S, 1989, EMBO J, V8, P1393, DOI 10.1002/j.1460-2075.1989.tb03520.x; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; EPSTEIN DJ, 1991, GENOMICS, V10, P89, DOI 10.1016/0888-7543(91)90488-Z; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FOY C, 1990, AM J HUM GENET, V46, P1017; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; KEEN J, 1991, TRENDS GENET, V7, P5; STEEL KP, 1983, ARCH OTOLARYNGOL, V109, P22; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WAARDENBURG PJ, 1951, AM J HUM GENET, V3, P195; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4	18	591	602	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1992	355	6361					635	636		10.1038/355635a0	http://dx.doi.org/10.1038/355635a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD547	1347148				2022-12-28	WOS:A1992HD54700054
J	ANGELUCCI, E; MARIOTTI, E; LUCARELLI, G; BARONCIANI, D; CESARONI, P; DURAZZI, SMT; GALIMBERTI, M; GIARDINI, C; MURETTO, P; POLCHI, P; SGARBI, E				ANGELUCCI, E; MARIOTTI, E; LUCARELLI, G; BARONCIANI, D; CESARONI, P; DURAZZI, SMT; GALIMBERTI, M; GIARDINI, C; MURETTO, P; POLCHI, P; SGARBI, E			SUDDEN CARDIAC-TAMPONADE AFTER CHEMOTHERAPY FOR MARROW TRANSPLANTATION IN THALASSEMIA	LANCET			English	Article							THALASSEMIA; HEART	Published work suggests that cardiac tamponade occurs only occasionally after bone-marrow transplantation (BMT) but the worrying number of cases encountered in the transplant programme in Pesaro, Italy, has led to an analysis of this complication. Cardiac tamponade occurred in 8 (2%) of 400 consecutive thalassaemic patients during conditioning for or within a month of BMT. 6 cases were fatal; these represented 9% of all causes of death and 29% of those occurring between start of conditioning regimen and 30 days post transplant. The syndrome was characterised by sudden onset of circulatory shock and cardiac arrest. The only effective treatment was immediate fluid removal. The absence of myocardial lesions and the complete resolution of the syndrome after pericardiocentesis suggest that the pericardial membranes played the main part in the pathogenesis of the syndrome. Since irradiation was not part of the conditioning regimen and since 3 of the affected patients had bacteraemia, the triggering factor for the syndrome could have been the drugs used for conditioning, acting alone or together with bacteraemia and trauma. The frequency with which we encountered the syndrome, and the similarity among our patients in clinical picture, and in characteristics of the effusion, indicate that cardiac tamponade occurring in thalassaemic patients after start of chemotherapy as conditioning for BMT is a specific syndrome requiring rapid treatment.	OSPED SAN SALVATORE PESARO,DIV CARDIOL,PESARO,ITALY; OSPED SAN SALVATORE PESARO,SERV ANAT PATOL,PESARO,ITALY; OSPED PESARO,CTR TRAPIANTI MIDOLLO OSSEO,I-61100 PESARO,ITALY		ANGELUCCI, E (corresponding author), OSPED PESARO,DIV EMATOL MURAGLIA,I-61100 PESARO,ITALY.		Angelucci, Emanuele/AAC-1855-2021	Angelucci, Emanuele/0000-0002-6512-6080; Baronciani, Donatella/0000-0001-6087-2431				APPELBAUM FR, 1976, LANCET, V1, P58; BEARMAN SI, 1990, BONE MARROW TRANSPL, V5, P173; BUJA LM, 1976, HUM PATHOL, V7, P15; CAZIN B, 1986, CANCER, V57, P2061, DOI 10.1002/1097-0142(19860515)57:10<2061::AID-CNCR2820571031>3.0.CO;2-H; GOTTDIENER JS, 1981, ARCH INTERN MED, V141, P758, DOI 10.1001/archinte.141.6.758; KUPARI M, 1990, BONE MARROW TRANSPL, V5, P91; LUCARELLI G, 1991, HEMATOL ONCOL CLIN N, V5, P549, DOI 10.1016/S0889-8588(18)30430-1; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; LUCARELLI G, 1987, NEW ENGL J MED, V316, P1050, DOI 10.1056/NEJM198704233161703; MILLS BA, 1979, CANCER, V43, P2223, DOI 10.1002/1097-0142(197906)43:6<2223::AID-CNCR2820430610>3.0.CO;2-Y; SAHASAKUL Y, 1985, J MED ASSOC THAILAND, V68, P517; SMITH CH, 1955, AMA AM J DIS CHILD, V90, P587; SMITH CH, 1975, AM J MED, V22, P390; THEOLOGIDES A, 1978, SEMIN ONCOL, V5, P181; ZIPF RE, 1972, CHEST, V62, P592	15	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					287	289		10.1016/0140-6736(92)91343-7	http://dx.doi.org/10.1016/0140-6736(92)91343-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346293				2022-12-28	WOS:A1992HB52900015
J	PERGOLIZZI, RG; ERSTER, SH; GOONEWARDENA, P; BROWN, WT				PERGOLIZZI, RG; ERSTER, SH; GOONEWARDENA, P; BROWN, WT			DETECTION OF FULL FRAGILE-X MUTATION	LANCET			English	Note								In fragile X syndrome, the most common inherited cause of mental deficiency, the underlying mutation is a large increase in the number of CGG repeats in a gene on chromosome X. We have developed a polymerase chain reaction (PCR) method to amplify across the full mutation in affected individuals. In this report, a fragile X family including a positive prenatally diagnosed fetus was analysed by PCR, and the results are consistent with direct genomic Southern blot analysis. Genetic screening of at-risk populations for fragile X can now be achieved by PCR rapidly, inexpensively, and on small samples.	CORNELL UNIV,N SHORE UNIV HOSP,COLL MED,DEPT RES,MANHASSET,NY 11030; CORNELL UNIV,N SHORE UNIV HOSP,COLL MED,DEPT PEDIAT,MANHASSET,NY 11030	Cornell University; Northwell Health; North Shore University Hospital; Cornell University; Northwell Health; North Shore University Hospital			Brown, William/GXN-2777-2022					BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN WT, 1990, AM J HUM GENET, V47, P175; DOBKIN CS, 1991, LANCET, V338, P957; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LATIMER LJP, 1991, J BIOL CHEM, V266, P13849; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P1; TEMPLE IK, 1990, LANCET, V336, P1131, DOI 10.1016/0140-6736(90)92608-K; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H	10	78	81	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					271	272		10.1016/0140-6736(92)91334-5	http://dx.doi.org/10.1016/0140-6736(92)91334-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346284	hybrid			2022-12-28	WOS:A1992HB52900006
J	HENTER, JI; ELINDER, G				HENTER, JI; ELINDER, G			CEREBROMENINGEAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	LANCET			English	Article							FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS; NERVOUS-SYSTEM	We describe 3 children with a progressive encephalopathy that was characterised by irritability, convulsions, cranial nerve palsies, ataxia, nystagmus, walking difficulties, delayed psychomotor development, hemiplegia/tetraplegia, visual disturbance, vomiting, neck stiffness, and non-specific signs of raised intracranial pressure. A final diagnosis was made in all 3 patients from necropsy material. The clinical features were ascribed to multiple inflammatory, predominantly lymphocytic, reactions and raised intracranial pressure. This condition is an atypical form of haemophagocytic lymphohistiocytosis, which normally presents with fever, hepatosplenomegaly, and cytopenias. By contrast, the disease pattern in our 3 children was dominated by cerebromeningeal involvement which can precede the typical systemic symptoms of haemophagocytic lymphohistiocytosis. An awareness of this condition is important because treatments are available.	SACHS CHILDRENS HOSP, STOCKHOLM, SWEDEN		HENTER, JI (corresponding author), KAROLINSKA INST, ST GORANS CHILDRENS HOSP, DEPT PAEDIAT, S-11281 STOCKHOLM, SWEDEN.							AKIMA M, 1984, HUM PATHOL, V15, P161, DOI 10.1016/S0046-8177(84)80057-X; BLANCHE S, 1991, BLOOD, V78, P51; BOUTIN B, 1991, SEMIN ONCOL, V18, P29; BRITTON S, 1978, NEW ENGL J MED, V298, P89, DOI 10.1056/NEJM197801122980208; CREAVEN PJ, 1982, CANCER CHEMOTH PHARM, V7, P133; HENTER JI, 1991, ACTA PAEDIATR SCAND, V80, P428, DOI 10.1111/j.1651-2227.1991.tb11878.x; HENTER JI, 1991, BLOOD, V78, P2918, DOI 10.1182/blood.V78.11.2918.2918; HENTER JI, 1991, ACTA PAEDIATR SCAND, V80, P269, DOI 10.1111/j.1651-2227.1991.tb11849.x; HENTER JI, 1991, SEMIN ONCOL, V18, P29; HOWELLS DW, 1990, PEDIATR RES, V28, P116; JANKA GE, 1983, EUR J PEDIATR, V140, P221, DOI 10.1007/BF00443367; PRICE DL, 1971, ARCH NEUROL-CHICAGO, V24, P270, DOI 10.1001/archneur.1971.00480330098010; PURTILO DT, 1981, CANCER RES, V41, P4226; RETTWITZ W, 1983, BRAIN DEV-JPN, V5, P322, DOI 10.1016/S0387-7604(83)80027-8	14	70	71	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 11	1992	339	8785					104	107		10.1016/0140-6736(92)91008-V	http://dx.doi.org/10.1016/0140-6736(92)91008-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345827				2022-12-28	WOS:A1992GZ15600012
J	PILLAY, D; PATOU, G; HURT, S; KIBBLER, CC; GRIFFITHS, PD				PILLAY, D; PATOU, G; HURT, S; KIBBLER, CC; GRIFFITHS, PD			PARVOVIRUS-B19 OUTBREAK IN A CHILDRENS WARD	LANCET			English	Article							INFECTION; B19; SCHOOL; ANEMIA	Parvovirus B19 infection can cause severe complications in pregnant women, individuals with haemolytic anaemia, and those who are immunocompromised. In a hospital outbreak of this infection, a balance should be struck between protection of these individuals and the maintenance of medical services. The index case of an outbreak of parvovirus B19 infection among staff and patients of a paediatric ward was not identified. 58 members of staff were screened for B19 markers and 4 of the 6 susceptible men and 6 of the 24 susceptible women became infected (p = 0.05) as defined by serum IgM and viraemia. 1 of the 11 adults (10 members of staff and 1 parent) infected remained symptom-free. 12 immunocompromised patients were also assessed, and symptom-free infection developed in 2 of these. During the outbreak staff with symptoms were put on sick leave, immunocompromised patients (there were none with haemolytic anaemia) were given normal human immunoglobulin and nursed in single rooms by B19 IgG-positive, IgM-negative staff, and the ward was closed to B19 IgG-negative pregnant women. However, the limitation of spread of infection cannot be attributed with certainty to the measures taken.	UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,LONDON,ENGLAND; UNIV LONDON ROYAL FREE HOSP,OCCUPAT HLTH UNIT,LONDON NW3 2PF,ENGLAND	University of London; University College London; University of London; University College London	PILLAY, D (corresponding author), UNIV LONDON ROYAL FREE HOSP,DIV COMMUNICABLE DIS,LONDON NW3 2PF,ENGLAND.							ANDERSON MJ, 1985, J INFECT DIS, V152, P257, DOI 10.1093/infdis/152.2.257; ANDERSON MJ, 1985, J MED VIROL, V15, P163, DOI 10.1002/jmv.1890150209; [Anonymous], 1990, BRIT MED J, V300, P1166; BELL LM, 1989, NEW ENGL J MED, V321, P485, DOI 10.1056/NEJM198908243210801; BLAND M, 1987, INTRO MED STATISTICS; COHEN BJ, 1983, J HYG-CAMBRIDGE, V91, P113, DOI 10.1017/S0022172400060095; Cohen BJ, 1986, PUBLIC HLTH VIROLOGY, P130; FRICKHOFEN N, 1990, ANN INTERN MED, V113, P926, DOI 10.7326/0003-4819-113-12-926; GILLESPIE SM, 1990, JAMA-J AM MED ASSOC, V263, P2061, DOI 10.1001/jama.263.15.2061; GRILLI EA, 1989, EPIDEMIOL INFECT, V103, P359, DOI 10.1017/S0950268800030697; KURTZMAN GJ, 1988, LANCET, V2, P1159; KURTZMAN GJ, 1987, NEW ENGL J MED, V317, P287, DOI 10.1056/NEJM198707303170506; MORGANCAPNER P, 1987, LANCET, V2, P98, DOI 10.1016/S0140-6736(87)92758-9; PATTISON JR, 1990, VIROLOGY, P1765; PILLAY D, 1991, PEDIATR INFECT DIS J, V10, P623, DOI 10.1097/00006454-199108000-00015; WOOLF AD, 1989, ARCH INTERN MED, V149, P1153, DOI 10.1001/archinte.149.5.1153	16	49	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					107	109		10.1016/0140-6736(92)91009-W	http://dx.doi.org/10.1016/0140-6736(92)91009-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345828				2022-12-28	WOS:A1992GZ15600013
J	COUPLAND, RM; HOIKKA, V; SJOEKLINT, OG; CUENOD, P; CAUDERAY, GC; DOSWALDBECK, L				COUPLAND, RM; HOIKKA, V; SJOEKLINT, OG; CUENOD, P; CAUDERAY, GC; DOSWALDBECK, L			ASSESSMENT OF BULLET DISRUPTION IN ARMED-CONFLICTS	LANCET			English	Article								Under international humanitarian law, the Hague Declaration of 1899 forbids the use of small arms ammunition that disrupts in the body after impact. However, assessment of whether bullets have undergone disruption is subjective and accusations that one or both sides of a conflict have used such ammunition cannot be substantiated. We describe a method by which disruption of bullets after impact can be assessed objectively. We reviewed 1287 wound radiographs of 1201 patients in four International Committee of the Red Cross hospitals. Radiographs were scored according to the F (fracture) and M (presence of metallic bodies) variables of the Red Cross would classification; bullet disruption is evidenced by metallic fragments on the radiograph. One hospital had a significantly higher proportion of patients wounded by bullets that disrupted after impact, these wounds were associated with comminuted fractures. The findings show that the presence of metallic fragments on a radiograph is a reliable indicator of wound severity and bullet disruption. The study has important implications for the upholding of international humanitarian law, because with our method the use and manufacture of bullets that contravene the Hague Declaration can be identified.			COUPLAND, RM (corresponding author), INT COMM RED CROSS, DIV MED, 17 AVE PAIX, CH-1202 GENEVA, SWITZERLAND.							BERLIN RH, 1988, J TRAUMA, V28, pS58, DOI 10.1097/00005373-198801001-00013; BERLIN RH, 1982, ACTA CHIR SCAND, P11; CAUDERAY GC, 1990, J TRAUMA S, V6, P88; COOPER GJ, 1990, BRIT J SURG, V77, P606, DOI 10.1002/bjs.1800770604; COUPLAND RM, 1991, IN PRESS WORLD J SUR; Davis H J, 1897, Br Med J, V2, P1789; DEVETH C, 1982, ACTA CHIR SCAND, P129; EZZ EA, 1988, J TRAUMA, V28, pS1, DOI 10.1097/00005373-198801001-00002; FACKLER ML, 1984, J TRAUMA, V24, P35, DOI 10.1097/00005373-198401000-00005; FACKLER ML, 1988, J TRAUMA, V28, pS21, DOI 10.1097/00005373-198801001-00007; FACKLER ML, 1984, J TRAUMA, V24, P263, DOI 10.1097/00005373-198403000-00014; FACKLER ML, 1989, INT DEFENSE REV, V8, P1091; Ogston A, 1898, Br Med J, V2, P813; Ogston Alex, 1899, BMJ, V2, P278; RAGSDALE BD, 1988, J TRAUMA, V28, pS109, DOI 10.1097/00005373-198801001-00024; SMITH MSO, 1981, HIGH VELOCITY MISSIL; 1989, INT LAW CONDUCT HOST; 1973, WEAPONS MAY CAUSE UN	18	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 4	1992	339	8784					35	37		10.1016/0140-6736(92)90152-S	http://dx.doi.org/10.1016/0140-6736(92)90152-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345960				2022-12-28	WOS:A1992GY04300013
J	MANABE, T; RENNER, P; NICOLL, RA				MANABE, T; RENNER, P; NICOLL, RA			POSTSYNAPTIC CONTRIBUTION TO LONG-TERM POTENTIATION REVEALED BY THE ANALYSIS OF MINIATURE SYNAPTIC CURRENTS	NATURE			English	Article							FROG NEUROMUSCULAR JUNCTION; HIPPOCAMPAL SLICES; RAT HIPPOCAMPUS; PERFORANT PATH; NEURONS; TRANSMISSION; INDUCTION; RELEASE; TRANSMITTER	Miniature excitatory synaptic currents were recorded from CA1 pyramidal cells in hippocampal slices to study the site of the persistent change in synaptic efficacy during long-term potentiation. Induction of long-term potentiation produced a large increase in the amplitude of these currents. Such a change in amplitude suggests an increase in postsynaptic transmitter sensitivity.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ASZTELY F, 1991, BRAIN RES, V558, P153, DOI 10.1016/0006-8993(91)90734-D; BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P691, DOI 10.1113/jphysiol.1972.sp010054; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T V P, 1988, P3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; ELMQVIST D, 1965, J PHYSIOL-LONDON, V177, P463, DOI 10.1113/jphysiol.1965.sp007605; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; Katz B., 1966, NERVE MUSCLE SYNAPSE; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; RAHAMIMOFF R, 1973, J PHYSIOL-LONDON, V228, P241, DOI 10.1113/jphysiol.1973.sp010084; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; THIBAULT O, 1989, BRAIN RES, V476, P170, DOI 10.1016/0006-8993(89)91553-9; VANDERKLOOT W, 1991, PROG NEUROBIOL, V36, P93, DOI 10.1016/0301-0082(91)90019-W; VORONIN LL, 1990, NEUROPHYSIOLOGY+, V22, P341; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x	34	301	303	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1992	355	6355					50	55		10.1038/355050a0	http://dx.doi.org/10.1038/355050a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY228	1346229				2022-12-28	WOS:A1992GY22800045
J	WRANA, JL; ATTISANO, L; CARCAMO, J; ZENTELLA, A; DOODY, J; LAIHO, M; WANG, XF; MASSAGUE, J				WRANA, JL; ATTISANO, L; CARCAMO, J; ZENTELLA, A; DOODY, J; LAIHO, M; WANG, XF; MASSAGUE, J			TGF-BETA SIGNALS THROUGH A HETEROMERIC PROTEIN-KINASE RECEPTOR COMPLEX	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MOLECULAR-WEIGHT RECEPTOR; MEMBRANE PROTEOGLYCAN; CELL-PROLIFERATION; EXPRESSION CLONING; FIBROBLAST GROWTH; BINDING-PROTEINS; ACTIVIN RECEPTOR; IDENTIFICATION; TRANSDUCTION	Transforming growth factor beta (TGFbeta) binds with high affinity to the type II receptor, a transmembrane protein with a cytoplasmic serine/threonine kinase domain. We show that the type II receptor requires both its kinase activity and association with another TGFbeta-binding protein, the type I receptor, to signal growth inhibition and early gene responses. Receptors I and II associate as interdependent components of a heteromeric complex: receptor I requires receptor II to bind TGFbeta, and receptor II requires receptor I to signal. This mode of operation points to fundamental differences between this receptor and the protein-tyrosine kinase cytokine receptors.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Duke University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Wrana, Jeffrey/F-8857-2013	Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA-34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRANDES ME, 1991, J BIOL CHEM, V266, P19697; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEBKOWSKI JS, 1986, MOL CELL BIOL, V6, P1838, DOI 10.1128/MCB.6.5.1838; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MACKAY K, 1991, J BIOL CHEM, V266, P9907; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELOCHE, 1992, MOL BIOL CELL, V3, P63; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; PARALKAR VM, 1991, P NATL ACAD SCI USA, V88, P3397, DOI 10.1073/pnas.88.8.3397; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WRANA JL, 1991, BIOCHEM J, V273, P523, DOI 10.1042/bj2730523; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	1453	1503	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1003	1014		10.1016/0092-8674(92)90395-S	http://dx.doi.org/10.1016/0092-8674(92)90395-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1333888				2022-12-28	WOS:A1992KB99000012
J	CHAPUY, MC; ARLOT, ME; DUBOEUF, F; BRUN, J; CROUZET, B; ARNAUD, S; DELMAS, PD; MEUNIER, PJ				CHAPUY, MC; ARLOT, ME; DUBOEUF, F; BRUN, J; CROUZET, B; ARNAUD, S; DELMAS, PD; MEUNIER, PJ			VITAMIN-D(3) AND CALCIUM TO PREVENT HIP-FRACTURES IN ELDERLY WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARATHYROID-HORMONE; PHYSICAL-ACTIVITY; D SUPPLEMENTATION; DIETARY CALCIUM; AGE; OSTEOPOROSIS; INCREASE; PEOPLE; RISK	Background. Hypovitaminosis D and a low calcium intake contribute to increased parathyroid function in elderly persons. Calcium and vitamin D supplements reduce this secondary hyperparathyroidism, but whether such supplements reduce the risk of hip fractures among elderly people is not known. Methods. We studied the effects of supplementation with vitamin D3 (cholecalciferol) and calcium on the frequency of hip fractures and other nonvertebral fractures, identified radiologically, in 3270 healthy ambulatory women (mean [+/-SD] age, 84+/-6 years). Each day for 18 months, 1634 women received tricalcium phosphate (containing 1.2 g of elemental calcium) and 20 mug (800 IU) of vitamin D3, and 1636 women received a double placebo. We measured serial serum parathyroid hormone and 25-hydroxyvitamin D (25(OH)D) concentrations in 142 women and determined the femoral bone mineral density at base line and after 18 months in 56 women. Results. Among the women who completed the 18-month study, the number of hip fractures was 43 percent lower (P = 0.043) and the total number of nonvertebral fractures was 32 percent lower (P = 0.015) among the women treated with vitamin D3 and calcium than among those who received placebo. The results of analyses according to active treatment and according to intention to treat were similar. In the vitamin D3-calcium group, the mean serum parathyroid hormone concentration had decreased by 44 percent from the base-line value at 18 months (P<0.001) and the serum 25(OH)D concentration had increased by 162 percent over the base-line value (P<0.001). The bone density of the proximal femur increased 2.7 percent in the vitamin D3-calcium group and decreased 4.6 percent in the placebo group (P<0.001). Conclusions. Supplementation with vitamin D3 and calcium reduces the risk of hip fractures and other nonvertebral fractures among elderly women.			CHAPUY, MC (corresponding author), HOP EDOUARD HERRIOT, INSERM, U234, PAVILLON F, F-69437 LYON, FRANCE.			francois, duboeuf/0000-0002-7819-0153				ALBANESE AA, 1975, NEW YORK STATE J MED, V75, P326; ALEVIZAKI CC, 1973, J NUCL MED, V14, P760; BOYCE WJ, 1985, LANCET, V1, P150; CHAPUY MC, 1987, AM J CLIN NUTR, V46, P324, DOI 10.1093/ajcn/46.2.324; CHAPUY MC, 1983, J GERONTOL, V38, P19, DOI 10.1093/geronj/38.1.19; Chevalley T, 1991, Osteoporos Int, V1, P147, DOI 10.1007/BF01625444; DEDEUXCHAISNES CN, 1988, CALCIFIED TISSUE INT, V42, P201, DOI 10.1007/BF02556335; Duboeuf F, 1991, Osteoporos Int, V1, P242; FORERO MS, 1987, J BONE MINER RES, V2, P363; HEANEY RP, 1990, CLIN BIOCH NEWS REV, V7, P54; HIMMELSTEIN S, 1990, AM J CLIN NUTR, V52, P701, DOI 10.1093/ajcn/52.4.701; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LEE CJ, 1981, AM J CLIN NUTR, V34, P819, DOI 10.1093/ajcn/34.5.819; LIPS P, 1982, METAB BONE DIS RELAT, V4, P85, DOI 10.1016/0221-8747(82)90021-2; LIPS P, 1988, J CLIN ENDOCR METAB, V67, P644, DOI 10.1210/jcem-67-4-644; MARTIN AD, 1991, CLIN ORTHOP RELAT R, V266, P111; MCKENNA MJ, 1985, AM J CLIN NUTR, V41, P101, DOI 10.1093/ajcn/41.1.101; MELTON LJ, 1987, BONE MINER, V2, P321; NORDIN BEC, 1980, BRIT MED J, V280, P451, DOI 10.1136/bmj.280.6212.451; NYDEGGER V, 1991, OSTEOPOROSIS INT, V2, P42, DOI 10.1007/BF01627078; PAK CYC, 1989, J BONE MINER RES, V4, P119; PRIER A, 1985, ANN MED INTERNE, V136, P27; SEBERT JL, 1988, REV RHUM, V55, P693; SEBERT JL, 1991, J BONE MINER RES S, V1, pS123; SLOVIK DM, 1981, NEW ENGL J MED, V305, P372, DOI 10.1056/NEJM198108133050704; SMITH EL, 1981, MED SCI SPORT EXER, V13, P60; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; TJELLESEN L, 1986, BONE MINER, V1, P407; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; YOUNG G, 1987, J BONE MINER RES, V2, P367	31	2215	2275	2	134	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1992	327	23					1637	1642		10.1056/NEJM199212033272305	http://dx.doi.org/10.1056/NEJM199212033272305			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA260	1331788				2022-12-28	WOS:A1992KA26000005
J	SCHIAVO, G; BENFENATI, F; POULAIN, B; ROSSETTO, O; DELAURETO, PP; DASGUPTA, BR; MONTECUCCO, C				SCHIAVO, G; BENFENATI, F; POULAIN, B; ROSSETTO, O; DELAURETO, PP; DASGUPTA, BR; MONTECUCCO, C			TETANUS AND BOTULINUM-B NEUROTOXINS BLOCK NEUROTRANSMITTER RELEASE BY PROTEOLYTIC CLEAVAGE OF SYNAPTOBREVIN	NATURE			English	Article							INTEGRAL MEMBRANE-PROTEIN; SMALL SYNAPTIC VESICLES; CHROMAFFIN CELLS; DISTINCT SITES; SYNAPSIN-I; EXOCYTOSIS; TOXIN; CHAINS; GENES; BIND	CLOSTRIDIAL neurotoxins, including tetanus toxin and the seven serotypes of botulinum toxin (A-G), are produced as single chains and cleaved to generate toxins with two chains joined by a single disulphide bond (Fig. 1). The heavy chain (M(r) 100,000 (100K)) is responsible for specific binding to neuronal cells and cell penetration of the light chain (50K), which blocks neurotransmitter release1-9. Several lines of evidence have recently suggested that clostridial neurotoxins could be zinc endopeptidases2,10-14. Here we show that tetanus and botulinum toxins serotype B are zinc endopeptidases, the activation of which requires reduction of the interchain disulphide bond. The protease activity is localized on the light chain and is specific for synaptobrevin, an integral membrane protein of small synaptic vesicles. The rat synaptobrevin-2 isoform is cleaved by both neurotoxins at the same single site, the peptide bond Gln 76-Phe 77, but the isoform synaptobrevin-1, which has a valine at the corresponding position, is not cleaved. The blocking of neurotransmitter release of Aplysia neurons injected with tetanus toxin or botulinum toxin serotype B is substantially delayed by peptides containing the synaptobrevin-2 cleavage site. These results indicate that tetanus and botulinum B neurotoxins block neurotransmitter release by cleaving synaptobrevin2, a protein that, on the basis of our results, seems to play a key part in neurotransmitter release.	UNIV PADUA,CRIBI,I-35131 PADUA,ITALY; UNIV MODENA,INST FISIOL UMANA,I-41100 MODENA,ITALY; CNRS,NEUROBIOL MOLEC & CELLULAIRE LAB,F-91118 GIF SUR YVETTE,FRANCE; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706	University of Padua; Universita di Modena e Reggio Emilia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Wisconsin System; University of Wisconsin Madison	SCHIAVO, G (corresponding author), UNIV PADUA,CNR,CTR BIOMEMBRANE,DIPARTIMENTO SCI BIOMED,75 VIA TRIESTE,I-35131 PADUA,ITALY.		rossetto, ornella/AAC-3866-2022	rossetto, ornella/0000-0002-6113-3857; Schiavo, Giampietro/0000-0002-4319-8745	Telethon [170] Funding Source: Medline	Telethon(Fondazione Telethon)		ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DECAMILLI P, REV PHYSL, V52, P625; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FONTANA A, 1983, METHOD ENZYMOL, V91, P311; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KOCHWESER J, 1982, NEW ENGL J MED, V306, P214; MOLGO J, 1990, J PHYSIOLOGY PARIS, V84, P152; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; PENNER R, 1986, NATURE, V324, P76, DOI 10.1038/324076a0; POULAIN B, 1990, J PHYSIOL-PARIS, V84, P247; POULAIN B, 1992, J BIOL CHEM, V11, P3577; POULAIN B, 1991, J BIOL CHEM, V266, P1; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHIAVO G, IN PRESS J BIOL CHEM; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1991, REV NEUROSCI, V14, P93; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WRIGHT JF, 1992, J BIOL CHEM, V267, P9053; [No title captured]; [No title captured]	31	1410	1469	3	123	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					832	835		10.1038/359832a0	http://dx.doi.org/10.1038/359832a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1331807				2022-12-28	WOS:A1992JV77700065
J	SMITH, WC; HARLAND, RM				SMITH, WC; HARLAND, RM			EXPRESSION CLONING OF NOGGIN, A NEW DORSALIZING FACTOR LOCALIZED TO THE SPEMANN ORGANIZER IN XENOPUS EMBRYOS	CELL			English	Article							MESSENGER-RNA; LAEVIS; AXIS; MESODERM; PATTERN; EMBRYOGENESIS; INDUCTION; ACTIVIN; XWNT-8; GENE	We have cloned a cDNA encoding a novel polypeptide capable of inducing dorsal development in Xenopus embryos. RNA transcripts from this clone rescue normal development when injected into ventralized embryos and result in excessive head development at high doses. Therefore, we have named the cDNA nog. gin. noggin cDNA contains a single reading frame encoding a 26 kd protein with a hydrophobic amino-terminal sequence, suggesting that it is secreted. In Northern blot analysis this cDNA hybridizes to two mRNAs that are expressed both maternally and zygotically. Although noggin transcript is not localized in the oocyte and cleavage stage embryo, zygotic transcripts are initially restricted to the presumptive dorsal mesoderm and reach their highest levels at the gastrula stage in the dorsal lip of the blastopore (Spemann organizer). In the neurula, noggin is transcribed in the notochord and prechordal mesoderm. The activity of exogenous noggin RNA in embryonic axis induction and the localized expression of endogenous noggin transcripts suggest that noggin plays a role in normal dorsal development.			SMITH, WC (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.							ALTABA ARI, 1992, IN PRESS DEVELOPMENT; BLUMBERG B, 1991, NATURE, V253, P194; BOLCE ME, 1992, DEVELOPMENT, V115, P681; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CONDIE BG, 1987, DEVELOPMENT, V101, P93; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FRANK D, 1992, DEVELOPMENT, V115, P439; FRANK D, 1991, DEVELOPMENT, V113, P1387; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; KAGEURA H, 1990, DEV BIOL, V142, P432, DOI 10.1016/0012-1606(90)90365-P; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1992, DEVELOPMENT, V114, P261; KIMELMAN D, 1992, IN PRESS DEVELOPMENT; KLOC M, 1989, DEVELOPMENT, V107, P899; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PENG HB, 1991, METHOD CELL BIOL, V36, P661; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	37	989	1027	0	52	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					829	840		10.1016/0092-8674(92)90316-5	http://dx.doi.org/10.1016/0092-8674(92)90316-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1339313				2022-12-28	WOS:A1992JL66300014
J	ARSHAD, SH; MATTHEWS, S; GANT, C; HIDE, DW				ARSHAD, SH; MATTHEWS, S; GANT, C; HIDE, DW			EFFECT OF ALLERGEN AVOIDANCE ON DEVELOPMENT OF ALLERGIC DISORDERS IN INFANCY	LANCET			English	Article							COWS MILK; ATOPIC DISEASE; BREAST-MILK; HIGH-RISK; IGE; HYPERSENSITIVITY; PREDICTION; LACTATION; CHILDREN; PROTEIN	There is much evidence that the development of allergic disorders may be related to early exposure of allergens, including those in breastmilk. We have tried to find out whether avoidance of food and inhaled allergens in infancy protects against the development of allergic disorders in high-risk infants. In a prenatally randomised, controlled study 120 infants with family history of atopy and high (>0.5 kU/I) cord-blood concentrations of total IgE were allocated randomly to prophylactic and control groups. In the prophylactic group (n=58), lactating mothers avoided allergenic foods (milk, egg, fish, and nuts) and avoided feeding their infants these foods and soya, wheat, and orange up to the age of 12 months; the infants' bedrooms and living rooms were treated with an acaricidal powder and foam every 3 months, and concentrations of Dermatophagoides pteronyssinus antigen (Der p I) in dust samples were measured by enzyme-linked immunosorbent assay. In the control group (n=62), the diet of mothers and infants was unrestricted; no acaricidal treatment was done and Der p I concentrations were measured at birth and at 9 months. A paediatric allergy specialist unaware of group assignment examined the infants for allergic disorders at 10-12 months. Odds ratios were calculated by logistic regression analysis for various factors with control for other confounding variables. At 12 months, allergic disorders had developed in 25 (40%) control infants and in 8 (13%) of the prophylactic group (odds ratio 6.34, 95% confidence intervals 2.0-20.1 ). The prevalences at 12 months of asthma (4.13,1.1-15.5) and eczema (3.6,1.0-12.5) were also significantly greater in the control group. Parental smoking was a significant risk factor for total allergy at 12 months whether only one parent smoked (3.97,1.2-13.6) or both parents smoked (4.72,1.2-18.2). Reduced exposure of infants to allergens in food and in housedust lowered the frequency of allergic disorders in the first years of life. Passive smoking is an important risk factor that should be addressed in any prophylactic programme.	ST MARYS HOSP,CLIN ALLERGY RES UNIT,NEWPORT PO30 5TG,WIGHT,ENGLAND									ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; BURR ML, 1983, ARCH DIS CHILD, V58, P561, DOI 10.1136/adc.58.7.561; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; CANT A, 1985, BRIT MED J, V291, P932, DOI 10.1136/bmj.291.6500.932; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228, DOI 10.1136/bmj.299.6693.228; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P868, DOI 10.1016/S0091-6749(87)80279-8; GLASER J, 1953, JAMA-J AM MED ASSOC, V153, P620, DOI 10.1001/jama.1953.02940240012003; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; LAUSCHADENDORF S, 1991, J ALLERGY CLIN IMMUN, V87, P41, DOI 10.1016/0091-6749(91)90211-6; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; SAARINEN UM, 1980, LANCET, V1, P166; SMITH JM, 1979, CLIN ALLERGY, V9, P153, DOI 10.1111/j.1365-2222.1979.tb01536.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STUART CA, 1984, CLIN ALLERGY, V14, P533, DOI 10.1111/j.1365-2222.1984.tb02240.x; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WILSON NM, 1989, ARCH DIS CHILD, V64, P1194, DOI 10.1136/adc.64.8.1194; WILSON NM, 1980, ARCH DIS CHILD, V1, P166	26	401	407	1	32	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1493	1497		10.1016/0140-6736(92)91260-F	http://dx.doi.org/10.1016/0140-6736(92)91260-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351183				2022-12-28	WOS:A1992HZ17500001
J	NISHINO, T; SUGIYAMA, A; TANAKA, A; ISHIKAWA, T				NISHINO, T; SUGIYAMA, A; TANAKA, A; ISHIKAWA, T			EFFECTS OF TOPICAL NASAL ANESTHESIA ON SHIFT OF BREATHING ROUTE IN ADULTS	LANCET			English	Article							RESPIRATORY ACTIVITY; MUSCLE-ACTIVITY; ANESTHESIA; PRESSURE; OBSTRUCTION; RECEPTORS; INFANTS; HUMANS; LAMBS; SLEEP	The position of the soft palate is known to determine the breathing route, but the physiological mechanisms that bring about a shift from nasal to oral breathing are unclear. To test the hypothesis that activation of receptors in the nasal passage may be involved in reflex initiation of oral breathing after nasal obstruction, we investigated respiratory responses to nasal occlusion before and after topical lignocaine anaesthesia of the nasal passages. Eleven volunteers were fitted with custom-made partitioned face masks, which separated nasal and oral passages. Air flow through each passage was detected by changes in airway pressure and carbon dioxide concentration. Nine subjects were habitual nasal breathers both before and after topical anaesthesia with 4% lignocaine. Among these subjects, the time to initiate oral breathing in response to nasal occlusion was significantly shorter before anaesthesia than afterwards (mean 4.4 [SD 2.5] vs 10.8 [7.4] s, p<0.01). Similarly, the time to resume nasal breathing after release of nasal occlusion was significantly shorter before topical anaesthesia than afterwards (6.9 [4.9] vs 12.1 [7.8] s, p<0.01). Topical anaesthesia did not affect respiration rate, end-tidal carbon dioxide concentration, or arterial oxygen saturation. These findings suggest that in human beings sensory information from receptors in the nasal passage has an important role in controlling the shift of breathing route.			NISHINO, T (corresponding author), NATL CANC CTR,DEPT ANESTHESIOL,TSUKIJI 5-1-1,CHUO KU,TOKYO 104,JAPAN.							DEWEESE EL, 1988, J APPL PHYSIOL, V64, P1346, DOI 10.1152/jappl.1988.64.4.1346; HARDING R, 1990, RESP PHYSIOL, V80, P71, DOI 10.1016/0034-5687(90)90007-L; HARDING R, 1987, RESP PHYSIOL, V68, P177, DOI 10.1016/S0034-5687(87)80004-X; HARDING R, 1991, J APPL PHYSIOL, V71, P1574, DOI 10.1152/jappl.1991.71.4.1574; KUNA ST, 1988, AM REV RESPIR DIS, V137, P656, DOI 10.1164/ajrccm/137.3.656; MATHEW OP, 1982, J APPL PHYSIOL, V52, P438, DOI 10.1152/jappl.1982.52.2.438; MATHEW OP, 1984, RESP PHYSIOL, V58, P41, DOI 10.1016/0034-5687(84)90043-4; MATHEW OP, 1984, J APPL PHYSIOL, V56, P500, DOI 10.1152/jappl.1984.56.2.500; MCBRIDE B, 1981, J APPL PHYSIOL, V51, P1189, DOI 10.1152/jappl.1981.51.5.1189; MILLER MJ, 1985, J PEDIATR-US, V107, P465, DOI 10.1016/S0022-3476(85)80535-7; RODENSTEIN DO, 1985, AM REV RESPIR DIS, V131, P343; RODENSTEIN DO, 1984, J APPL PHYSIOL, V57, P651, DOI 10.1152/jappl.1984.57.3.651; SANTAMBROGIO FB, 1985, J APPL PHYSIOL, V58, P1298, DOI 10.1152/jappl.1985.58.4.1298; SANTAMBROGIO G, 1983, RESP PHYSIOL, V54, P317, DOI 10.1016/0034-5687(83)90075-0; SANTAMBROGIO G, 1985, RESPIR PHYSL, V59, P34; Swift DL., 1977, RESPIRATORY DEFENSE, V5, P63; WHITE DP, 1985, AM REV RESPIR DIS, V132, P972; WOLFSDORF J, 1969, PEDIATRICS, V43, P799	18	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1497	1500		10.1016/0140-6736(92)91261-6	http://dx.doi.org/10.1016/0140-6736(92)91261-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351184				2022-12-28	WOS:A1992HZ17500002
J	HATTERSLEY, AT; TURNER, RC; PERMUTT, MA; PATEL, P; TANIZAWA, Y; CHIU, KC; ORAHILLY, S; WATKINS, PJ; WAINSCOAT, JS				HATTERSLEY, AT; TURNER, RC; PERMUTT, MA; PATEL, P; TANIZAWA, Y; CHIU, KC; ORAHILLY, S; WATKINS, PJ; WAINSCOAT, JS			LINKAGE OF TYPE-2 DIABETES TO THE GLUCOKINASE GENE	LANCET			English	Article							INSULIN GENE; BETA-CELL; ONSET; YOUNG; MELLITUS; FAMILIES; GLUCOSE; TWINS	Maturity-onset diabetes of the young (MODY) is a subtype of type 2 diabetes that presents from the second decade and has an autosomal dominant mode of inheritance. We have investigated the glucokinase gene, a candidate gene for diabetes, in two MODY pedigrees. In a large 5-generation pedigree (BX) with 15 diabetic members, use of a microsatellite polymorphism revealed linkage of diabetes to the glucokinase locus on chromosome 7p. A peak lod score of 4.60 was obtained at a recombination fraction (theta) of zero. This finding suggests that a defective glucokinase gene contributes to the diabetes phenotype in this pedigree. This is not universal in MODY since linkage to the glucokinase locus was excluded in a second pedigree M (lod score= -7.36 at theta = 0). The affected members in pedigree BX were diagnosed either when young (in pregnancy or on screening) or when they presented symptomatically in middle and old age; most of them were treated by diet alone. Defects in the glucokinase gene may play an important part in the pathogenesis of type 2 diabetes.	JOHN RADCLIFFE HOSP,DEPT HAEMATOL,OXFORD OX3 9DU,ENGLAND; WASHINGTON UNIV,SCH MED,DIV METAB,ST LOUIS,MO 63110; UNIV LONDON KINGS COLL HOSP,DIABET UNIT,LONDON SE5 8RX,ENGLAND	University of Oxford; Washington University (WUSTL); King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	HATTERSLEY, AT (corresponding author), RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND.		O'Rahilly, Stephen/ABF-6509-2020; Chiu, Ken/M-6473-2013	O'Rahilly, Stephen/0000-0003-2199-4449; Chiu, Ken/0000-0002-2226-1039; Hattersley, Andrew/0000-0001-5620-473X	NIDDK NIH HHS [DK 16746] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016746, R01DK016746] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREONE T, 1985, DIABETES, V34, P108, DOI 10.2337/diabetes.34.2.108; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BELL JI, 1983, BRIT MED J, V286, P590, DOI 10.1136/bmj.286.6365.590; BOWDEN DW, 1992, DIABETES, V41, P88, DOI 10.2337/diabetes.41.1.88; COOK JTE, 1991, DIABETES S1, V40, pA296; ELBIN SC, 1987, DIABETOLOGIA, V30, P641; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1991, Diabetologia, V34, pA71; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LEVY JC, 1991, DIABETOLOGIA, V34, P488, DOI 10.1007/BF00403285; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; Maniatis T., 1982, MOL CLONING; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; ORAHILLY S, 1988, DIABETOLOGIA, V31, P792; ORAHILLY S, 1988, DIABETOLOGIA, V31, P407, DOI 10.1007/BF00271584; ORAHILLY S, 1989, DIABETES RES CLIN EX, V10, P125; PATEL P, IN PRESS DIABETES; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; TATTERSALL RB, 1974, Q J MED, V43, P339; VINIK AJ, 1988, DIABETOLOGIA, V31, P778, DOI 10.1007/BF00274785; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; 1985, WHO TECH REP SER, V727	30	314	323	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1307	1310		10.1016/0140-6736(92)91958-B	http://dx.doi.org/10.1016/0140-6736(92)91958-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349989				2022-12-28	WOS:A1992HW83700001
J	LESOUEF, PN				LESOUEF, PN			VALIDITY OF METHODS USED TO TEST AIRWAY RESPONSIVENESS IN CHILDREN	LANCET			English	Editorial Material							BRONCHIAL HYPERRESPONSIVENESS; AUSTRALIAN SCHOOLCHILDREN; INHALATION CHALLENGE; RESPIRATORY SYMPTOMS; INHALED HISTAMINE; NORMAL INFANTS; METHACHOLINE; REACTIVITY; STANDARDIZATION; PREVALENCE	Methods to test airway responsiveness to inhaled agonists in children were originally developed for use in adults, and agonist dosage regimens do not adequately correct for the size of the child. Because small children receive a higher dose relative to their body size than do large children, the age-related decline in airway responsiveness reported in many recent studies might reflect failure to adequately size-correct test dosages rather than a genuine physiological event. Until the administered doses of inhaled agonists can be satisfactorily size-corrected, tests of airway responsiveness in children should be regarded as qualitative rather than quantitative.			LESOUEF, PN (corresponding author), PRINCESS MARGARET HOSP,DEPT RESP MED,GPO BOX D184,PERTH,WA 6001,AUSTRALIA.		Le Souef, Peter N/H-5256-2014	Le Souef, Peter/0000-0003-0930-1654				AVITAL A, 1991, AM REV RESPIR DIS, V144, P36, DOI 10.1164/ajrccm/144.1.36; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUA H L, 1991, American Review of Respiratory Disease, V143, pA706; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1126, DOI 10.1136/adc.64.8.1126; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLLIS GG, 1990, LANCET, V336, P341, DOI 10.1016/0140-6736(90)91880-J; DUNNILL M. S., 1962, THORAX, V17, P329, DOI 10.1136/thx.17.4.329; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; GODFREY S, 1979, CLIN PAEDIATRIC PHYS; HOPP RJ, 1986, AM REV RESPIR DIS, V134, P994, DOI 10.1164/arrd.1986.134.5.994; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62, DOI 10.1164/ajrccm/139.1.62; MONTGOMERY GL, 1990, AM REV RESPIR DIS, V142, P1372, DOI 10.1164/ajrccm/142.6_Pt_1.1372; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663, DOI 10.1164/ajrccm/144.3_Pt_1.663; PEAT JK, 1989, CLIN EXP ALLERGY, V19, P299, DOI 10.1111/j.1365-2222.1989.tb02387.x; RUFFIN RE, 1978, AM REV RESPIR DIS, V117, P485; RYAN G, 1981, J ALLERGY CLIN IMMUN, V67, P156, DOI 10.1016/0091-6749(81)90012-9; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; STICK SM, 1991, AM REV RESPIR DIS, V144, P1012, DOI 10.1164/ajrccm/144.5.1012; STICK SM, 1990, AM REV RESPIR DIS, V142, P1143, DOI 10.1164/ajrccm/142.5.1143; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; YOUNG S, 1991, American Review of Respiratory Disease, V143, pA23	27	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 23	1992	339	8804					1282	1284		10.1016/0140-6736(92)91602-5	http://dx.doi.org/10.1016/0140-6736(92)91602-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349677				2022-12-28	WOS:A1992HV19100012
J	TOOLE, MJ				TOOLE, MJ			MICRONUTRIENT DEFICIENCIES IN REFUGEES	LANCET			English	Editorial Material											TOOLE, MJ (corresponding author), CTR DIS CONTROL,ATLANTA,GA 30333, USA.							DESENCLOS JC, 1989, B WORLD HEALTH ORGAN, V67, P309; IRWIN MI, 1976, J NUTR, V106, P824; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; MAGAN AM, 1982, DISASTERS, V7, P93; MOREN A, 1990, LANCET, V335, P1403, DOI 10.1016/0140-6736(90)91283-G; NIEBURG P, 1988, B WORLD HEALTH ORGAN, V66, P698; ROE DA, 1973, PLAGUE CORN, P1; SOMMER A, 1983, LANCET, V2, P585; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3269; YIP R, 1987, OCT ANN M AM PUBL HL; 1989, NUTRITION TIMES DISA; 1967, WHO TECH REP SER, V362, P45; 1989, MMWR, V38, P455; 1989, MMWR, V38, P461; 1991, 1991 INT S RESP NUTR; 1991, MMWR, V40, P209	16	24	24	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1214	1216		10.1016/0140-6736(92)91143-V	http://dx.doi.org/10.1016/0140-6736(92)91143-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349947				2022-12-28	WOS:A1992HU68400013
J	DOGLIONI, C; WOTHERSPOON, AC; MOSCHINI, A; DEBONI, M; ISAACSON, PG				DOGLIONI, C; WOTHERSPOON, AC; MOSCHINI, A; DEBONI, M; ISAACSON, PG			HIGH-INCIDENCE OF PRIMARY GASTRIC LYMPHOMA IN NORTHEASTERN ITALY	LANCET			English	Note								We previously noted an extraordinarily high number of cases of primary gastric lymphoma (PGL) in northeastern Italy. We have now formally compared the. incidence in Feltre, Italy, with that in three similar communities in the UK. Each community has a stable population served by a single endoscopy unit and histopathology laboratory. There were 13 times more cases of PGL in Feltre in 1986-91 than in the UK communities (66 vs 5 per 100000 per 5 years). The incidence of gastric adenocarcinoma was also substantially higher in Feltre than in the UK (270 vs an average of 82 per 100 000 per 5 years), as was the prevalence of gastritis associated with Helicobacter pylori infection (87% of 1343 gastric biopsy samples in 1991	UNIV COLL & MIDDLESEX SCH MED,DEPT HISTOPATHOL,UNIV ST,LONDON WC1E 6JJ,ENGLAND; OSPED CIVILE,FELTRE,ITALY	University of London; University College London				DOGLIONI, Claudio/0000-0002-4969-5216				BROOKS JJ, 1983, CANCER, V51, P701, DOI 10.1002/1097-0142(19830215)51:4<701::AID-CNCR2820510425>3.0.CO;2-D; BUIATTI E, 1989, INT J CANCER, V44, P611, DOI 10.1002/ijc.2910440409; HAYES J, 1989, CANCER, V63, P2073, DOI 10.1002/1097-0142(19890515)63:10<2073::AID-CNCR2820631033>3.0.CO;2-N; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; SHALLCROSS TM, 1989, CAMPYLOBACTER PYLORI, P155; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z	7	246	253	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					834	835		10.1016/0140-6736(92)90280-G	http://dx.doi.org/10.1016/0140-6736(92)90280-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347858				2022-12-28	WOS:A1992HM44100005
J	HUNT, D; VARIGOS, J; DIENSTL, F; LECHLEITNER, P; DEBACKER, G; KORNITZER, M; CAIRNS, J; TURPIE, A; FRITZHANSEN, P; SKAGEN, K; KALA, R; HEIKKILA, J; BOISSEL, JP; LEIZOROVICZ, A; SCHRODER, R; KOTHE, K; KARATZAS, N; HORGAN, J; OCALLAGHAN, D; TOGNONI, G; FRANZOSI, MG; MAGGIONI, A; COHEN, A; KOSTER, R; WHITE, H; MACMAHON, S; KJEKSHUS, J; REIKVAM, A; CEREMUZYNSKI, L; PAOLASSO, E; DIAZ, R; VALENTIN, V; WILHELMSEN, L; LUNDKVIST, L; MOCCETTI, T; MALACRIDA, R; GENONI, M; COLLINS, R; SLEIGHT, P; PETO, R; PARISH, S; DOLL, R; ARMITAGE, P; CEDERHOLMWILLIAMS, S; CONWAY, M; DOVE, P; FLATHER, M; MARSHALL, J; YOUNGMAN, L; JULIAN, D; CHAMBERLAIN, D; WARLOW, C; SANDERCOCK, P; FOX, K; HENNEKENS, C; GOLDHABER, S; TIMMIS, G; YUSUF, S; MEIER, P				HUNT, D; VARIGOS, J; DIENSTL, F; LECHLEITNER, P; DEBACKER, G; KORNITZER, M; CAIRNS, J; TURPIE, A; FRITZHANSEN, P; SKAGEN, K; KALA, R; HEIKKILA, J; BOISSEL, JP; LEIZOROVICZ, A; SCHRODER, R; KOTHE, K; KARATZAS, N; HORGAN, J; OCALLAGHAN, D; TOGNONI, G; FRANZOSI, MG; MAGGIONI, A; COHEN, A; KOSTER, R; WHITE, H; MACMAHON, S; KJEKSHUS, J; REIKVAM, A; CEREMUZYNSKI, L; PAOLASSO, E; DIAZ, R; VALENTIN, V; WILHELMSEN, L; LUNDKVIST, L; MOCCETTI, T; MALACRIDA, R; GENONI, M; COLLINS, R; SLEIGHT, P; PETO, R; PARISH, S; DOLL, R; ARMITAGE, P; CEDERHOLMWILLIAMS, S; CONWAY, M; DOVE, P; FLATHER, M; MARSHALL, J; YOUNGMAN, L; JULIAN, D; CHAMBERLAIN, D; WARLOW, C; SANDERCOCK, P; FOX, K; HENNEKENS, C; GOLDHABER, S; TIMMIS, G; YUSUF, S; MEIER, P			ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							CONTINUOUS INTRAVENOUS HEPARIN; CLINICAL-TRIAL METHODOLOGY; LOW-DOSE ASPIRIN; CORONARY THROMBOLYSIS; SUBCUTANEOUS HEPARIN; RT-PA; VENTRICULAR-FUNCTION; VEIN THROMBOSIS; TIMI TRIAL; PHASE-I	41 299 patients entering 914 hospitals up to 24 h (median 4 h) after the onset of suspected acute myocardial infarction were randomised between streptokinase (SK: 1.5 MU infused over about 1 h), tissue plasminogen activator (tPA, duteplase: 0.60 MU/kg infused over about 4 h), or anisoylated plasminogen-streptokinase activator complex (APSAC, anistreplase: 30 U over about 3 min). All patients were to receive aspirin (162 mg/day enteric-coated), with the first tablet chewed for rapid and full antiplatelet effect. Half of all patients were randomly allocated subcutaneous calcium heparin (12 500 IU starting at 4 h and given twice daily for 7 days or until prior discharge) in addition to aspirin, and the other half were to receive aspirin alone. Aspirin plus heparin versus aspirin alone-The addition of heparin to aspirin was associated with an excess of transfused or other major non-cerebral bleeds (1.0% aspirin plus heparin vs 0.8% aspirin alone; 2p < 0.01) and of definite or probable cerebral haemorrhage (0.56% vs 0.40%; 2p < 0.05), but with no significant differences in total stroke (1.28% vs 1.18%). Reinfarctions were slightly less common among those allocated aspirin plus heparin (3.16% vs 3.47%; 2p = 0.09). There was no significant difference in the pre-specified endpoint of 35-day mortality (2132 [10.3%] aspirin plus heparin vs 2189 [10.6%] aspirin alone). During the scheduled heparin treatment period there were slightly fewer deaths in the aspirin plus heparin group (days 0.7 in hospital: 1534 [7.4%] vs 1633 [7.9%]; 2p = 0.06), with a slight convergence by day 35 (598 further deaths [3.1% of survivors] vs 556 [2.9%]). The pattern was similar to that observed in the GISSI-2 trial, so that in both trials combined there was a significant reduction in mortality during the scheduled treatment period (2071 [6.8% vs 2239 [7.3%]; 2p < 0.01). This indicates avoidance of 5 deaths (SD 2) per 1000 patients allocated this high-dose subcutaneous heparin regimen in addition to aspirin, but some of any early benefit may be lost after heparin ceases, with no significant mortality advantage in days 0.35 (both trials: 3100 [10.0%] vs 3172 (10.2%]) or during follow-up to 6 months. SK versus APSAC-APSAC was associated with significantly more reports of allergy causing persistent symptoms and of non-cerebral bleeds, but not of transfused bleeds or of reinfarctions. There was a slight excess of strokes with APSAC (1.04% SK vs 1.26% APSAC; 2p = 0.08), much of it appearing soon after treatment started (strokes during days 0-1: 0.50% SK vs 0.73% APSAC; 2p < 0.02) and being attributed to cerebral haemorrhage (0.24% SK vs 0.55% APSAC; 2p < 0.0001). No significant difference was observed in reinfarction (3.47% SK vs 3.55% APSAC). There was no significant mortality difference during days 0.35, either among all randomised patients (1455 [10.6%] SK vs 1448 [10.5%] APSAC) or among the pre-specified subset presenting within 0.6 h of pain onset and with ST elevation on the electrocardiogram in whom fibrinolytic treatment may have most to offer (861 [10.0%] SK vs 855 [9.9%] APSAC). No significant difference in 6-month survival was apparent overall or in the subset. SK versus tPA-tPA was associated with significantly fewer reports of allergy causing persistent symptoms and of hypotension requiring drug treatment, and with significantly more reports of non-cerebral bleeds, but not of transfused bleeds. There was a significant excess of strokes with tPA (1.04% SK vs 1.39% tPA; 2p < 0.01 ), much of it appearing soon after treatment started (strokes during days 0-1: 0.50% SK vs 0.92% tPA; 2p <0.0001) and being attributed to cerebral haemorrhage (0.24% SK vs 0.66% tPA; 2p < 0.00001). Fewer reinfarctions were observed with tPA (3.47% SK vs 2.93% tPA; 2p < 0.02).There was no significant mortality difference during days 0-35, either among all randomised patients (1455 [10.6%] SK vs 1418 [10.3%] tPA) or among the 0-6 h ST elevation subset (861 [10.0%] SK vs 822 [9.6%] tPA), and no difference in 6-month survival was apparent. These findings reinforce those from the similar GISSI-2 trial with, in both trials combined, zero difference in 35-day mortality (2413/24 176 [10.0%] SK vs 2411/24 118 [10.0%] tPA) and no significant difference in 6-month survival. There were 5 per 1000 fewer reinfarctions with tPA (783 [3.26%] SK vs 671 [2.80%] tPA; 2p < 0.005), and 4 per 1000 more strokes with tPA (239 [1.00%] SK vs 324 [1.35%] tPA; 2p < 0.001), with half of this excess being of fatal stroke and half of non-fatal stroke.	ROYAL MELBOURNE HOSP, PARKVILLE, VIC 3050, AUSTRALIA; UNIV KLIN INNSBRUCK, INNSBRUCK, AUSTRIA; UNIV ZIEKENHUIS GENT, GHENT, BELGIUM; ERASME UNIV HOSP, BRUSSELS, BELGIUM; HAMILTON GEN HOSP, HAMILTON L8L 2X2, ONTARIO, CANADA; MARIA HOSP, HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, SF-00290 HELSINKI 29, FINLAND; HOP CARDIOL, Lyon, FRANCE; KLINIKUM STEGLITZ, BERLIN, GERMANY; CTR HUMAN DRUG RES, LEIDEN, NETHERLANDS; GREEN LANE HOSP, AUCKLAND 3, NEW ZEALAND; BAERUM HOSP, BAERUM, NORWAY; GROCHOWSKI HOSP, WARSAW, POLAND; CHARITE HOSP, BERLIN, GERMANY; HYGEIA HOSP, ATHENS, GREECE; BEAUMONT HOSP, DUBLIN, IRELAND; MARIO NEGRI HOSP, MILAN, ITALY; DR PESET ALEXANDRE HOSP, VALENCIA, SPAIN; OSTRA HOSP, S-41685 GOTHENBURG, SWEDEN; HUDIKSVALL HOSP, HUDIKSVALL, SWEDEN; CIVICO HOSP, LUGANO, SWITZERLAND; SAN GIOVANNI HOSP, BELLINZONA, SWITZERLAND; UNIV OXFORD, RADCLIFFE INFIRM, OXFORD OX2 6HE, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND; BRITISH HEART FDN, LONDON, ENGLAND; ROYAL SUSSEX CTY HOSP, BRIGHTON BN2 5BE, E SUSSEX, ENGLAND; WESTERN GEN HOSP, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; NATL HEART HOSP, LONDON W1M 8BA, ENGLAND; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; WILLIAM BEAUMONT HOSP, ROYAL OAK, MI 48072 USA; NHLBI, CLIN TRIALS BRANCH, BETHESDA, MD 20892 USA; UNIV CHICAGO, CHICAGO, IL 60637 USA; RADCLIFFE INFIRM, INT STUDY INFARCT SURVIVAL, DEPT CARDIOVASC MED, OXFORD OX2 6HE, ENGLAND	Royal Melbourne Hospital; Medical University of Innsbruck; Ghent University; Ghent University Hospital; Universite Libre de Bruxelles; McMaster University; University of Helsinki; Helsinki University Central Hospital; CHU Lyon; Centre of Postgraduate Medical Education - Poland; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hygeia Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Sahlgrenska University Hospital; Regional Hospital of Bellinzona & Valleys, San Giovanni; Radcliffe Infirmary; University of Oxford; University of Oxford; University of London; University College London; University of Brighton; University of Edinburgh; Imperial College London; Harvard University; Brigham & Women's Hospital; Beaumont Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Chicago; Radcliffe Infirmary	HUNT, D (corresponding author), RADCLIFFE INFIRM, INT STUDY INFARCT SURVIVAL, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.		De Backer, Guy/AAI-4607-2021; Cairns, John/AAI-8744-2021; sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				ANDERSON J L, 1991, European Heart Journal, V12, P97; ANDERSON JL, 1991, CIRCULATION, V83, P126, DOI 10.1161/01.CIR.83.1.126; ANDERSON JL, 1991, AM J CARDIOL, V68, pE11; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1990, Lancet, V336, P65; [Anonymous], 1986, Lancet, V1, P397; BASSAND JP, 1991, CIRCULATION, V84, P1107, DOI 10.1161/01.CIR.84.3.1107; BERGLUND U, 1991, EUR HEART J, V12, P428, DOI 10.1093/oxfordjournals.eurheartj.a059912; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; BRAUNWALD E, 1987, J AM COLL CARDIOL, V10, P970, DOI 10.1016/S0735-1097(87)80296-6; CAIRNS JA, 1989, CHEST, V95, pS73, DOI 10.1378/chest.95.2.73S; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; COLLEN D, 1990, ANN INTERN MED, V112, P529, DOI 10.7326/0003-4819-112-7-529; COLLINS R, 1990, LANCET, V336, P439, DOI 10.1016/0140-6736(90)91985-J; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; DEBONO DP, 1992, BRIT HEART J, V67, P122; DOYLE DJ, 1987, ANN INTERN MED, V107, P441, DOI 10.7326/0003-4819-107-4-441; GRINES C L, 1990, Journal of the American College of Cardiology, V15, p2A; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P533; HOGG KJ, 1990, LANCET, V335, P254, DOI 10.1016/0140-6736(90)90069-H; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; KALBFLEISCH J, 1992, UNPUB BURROUGHS WELL; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; KOSTER RW, 1990, EUR HEART J, V11, P730, DOI 10.1093/oxfordjournals.eurheartj.a059788; LOPEZ-SENDON J, 1988, European Heart Journal, V9, P10; MACMAHON S, 1988, CIRCULATION S2, V78, P98; MAGNANI B, 1989, J AM COLL CARDIOL, V13, P19, DOI 10.1016/0735-1097(89)90543-3; MALCOLM A, 1992, UNPUB BEHALF ESPRIT; MONRAD ES, 1991, J AM COLL CARDIOL, V18, P1573, DOI 10.1016/0735-1097(91)90692-3; MUELLER HS, 1987, J AM COLL CARDIOL, V10, P479, DOI 10.1016/S0735-1097(87)80188-2; NEUHAUS KL, 1988, J AM COLL CARDIOL, V12, P581, DOI 10.1016/S0735-1097(88)80040-8; PACOURET G, 1991, EUR HEART J, V12, P179, DOI 10.1093/oxfordjournals.eurheartj.a059866; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; PATRONO C, 1989, TRENDS PHARMACOL SCI, V10, P453, DOI 10.1016/S0165-6147(89)80010-0; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1978, BIOMEDICINE, V28, P24; PRINS MH, 1991, AM J CARDIOL, V67, pA3; REILLY IAG, 1987, BLOOD, V69, P180; ROBERTS R, 1991, CLIN CHALLENGES ACUT, V1, P1; SCHEIDT S, 1991, CVR R            SEP, P37; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SEABRAGOMES R, 1987, DRUGS, V33, P169, DOI 10.2165/00003495-198700333-00028; SHERRY S, 1991, J AM COLL CARDIOL, V18, P1579, DOI 10.1016/0735-1097(91)90693-4; SIMOONS ML, 1988, LANCET, V1, P199; SOBEL BE, 1991, AM J CARDIOL, V68, P382, DOI 10.1016/0002-9149(91)90836-A; TAVAZZI L, 1989, LANCET, V2, P182; TIEFENBRUNN AJ, 1989, FIBRINOLYSIS, V3, P1, DOI 10.1016/0268-9499(89)90020-9; TOPOL EJ, 1988, AM J CARDIOL, V61, P723, DOI 10.1016/0002-9149(88)91055-7; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VANDEWERF F, 1990, LANCET, V336, P71; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; VOGT P, 1989, European Heart Journal, V10, P124; VONESSEN R, 1991, EUR HEART J SUPPL, V12, P30; WACKERS FJT, 1989, J AM COLL CARDIOL, V13, P998, DOI 10.1016/0735-1097(89)90250-7; WHITE HD, 1989, NEW ENGL J MED, V320, P817, DOI 10.1056/NEJM198903303201301; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124; WILCOX RG, 1988, LANCET, V2, P525; 1992, GUSTO GAZETTE    JAN, P1	61	932	951	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1992	339	8796					753	770						18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347801				2022-12-28	WOS:A1992HL50100001
J	CAMERON, HA; CLOSE, CF; YEO, WW; JACKSON, PR; RAMSAY, LE				CAMERON, HA; CLOSE, CF; YEO, WW; JACKSON, PR; RAMSAY, LE			INVESTIGATION OF SELECTED PATIENTS WITH HYPERTENSION BY THE RAPID-SEQUENCE INTRAVENOUS UROGRAM	LANCET			English	Article							RENAL-ARTERY STENOSIS; RENOVASCULAR HYPERTENSION; ANGIOPLASTY; MANAGEMENT	The rapid-sequence intravenous urogram (IVU) has tended to fall from favour for investigating hypertension because of its perceived imprecision for detecting renovascular disease. However, no study has examined the value of the IVU as a screening test in appropriately selected patients. We have analysed the diagnostic yield of the rapid-sequence IVU in hypertensive patients selected for features suggesting renal or renovascular disease in a retrospective review of case records from a hypertension clinic. The IVU was abnormal in 27% (95% Cl 21-32%) of 241 consecutive patients. The most common abnormalities were chronic pyelonephritis (6%); proven renovascular disease (5%); stone (4%); possible renovascular disease and simple cyst (each 3%); hydronephrosis (2%); and tumour and active tuberculosis (each 1%). The IVU led to intervention aiming to correct hypertension in 5% (95% Cl 2-8%) of patients, and revealed an abnormality needing intervention in its own right in 4% (95% Cl 2-6%). The IVU led to unnecessary invasive investigation in 3% of cases. Individual abnormalities could not be predicted from the clinical or laboratory features. The initial investigation in hypertensive patients with suspected renal or renovascular disease should be a general purpose test able to detect a wide range of abnormalities. The rapid-sequence IVU is the only single test capable of satisfying this requirement. In patients with features suggesting renovascular disease, a normal rapid-sequence IVU excludes renovascular disease with 93% probability, but is an imperfect screening test since it fails to diagnose about 20% of cases. Renal arteriography should be done despite a normal IVU when it is essential to exclude renovascular disease.	UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,GLOSSOP RD,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield				Yeo, Wilfred/0000-0001-9554-5203				ATKINSON A B, 1974, Journal of the Royal College of Physicians of London, V8, P175; BOOKSTEIN JJ, 1972, JAMA-J AM MED ASSOC, V220, P1195; BRAWN LA, 1987, LANCET, V2, P1313; CARMICHAEL DJS, 1986, LANCET, V1, P667; FAIRMAN MJ, 1974, POSTGRAD MED J, V50, P508, DOI 10.1136/pgmj.50.586.508; HAVEY RJ, 1985, JAMA-J AM MED ASSOC, V254, P388, DOI 10.1001/jama.254.3.388; LUSCHER TF, 1985, CARDIOLOGY, V72, P33, DOI 10.1159/000173942; MAXWELL MH, 1964, NEW ENGL J MED, V270, P213, DOI 10.1056/NEJM196401302700501; Pickering T, 1990, HYPERTENSION PATHOPH, P1539; PICKERING TG, 1988, LANCET, V2, P551; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; THORNBURY JR, 1982, AM J ROENTGENOL, V138, P43; THORNBURY JR, 1984, RADIOL CLIN N AM, V22, P333	13	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					658	661		10.1016/0140-6736(92)90805-D	http://dx.doi.org/10.1016/0140-6736(92)90805-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347347				2022-12-28	WOS:A1992HH74300013
J	CAPLAN, LR				CAPLAN, LR			INTRACEREBRAL HEMORRHAGE	LANCET			English	Article							HEMORRHAGE				CAPLAN, LR (corresponding author), TUFTS UNIV,DEPT NEUROL,750 WASHINGTON ST,NEMCH 314,BOSTON,MA 02111, USA.							CAPLAN L, 1988, NEUROLOGY, V38, P624, DOI 10.1212/WNL.38.4.624; FELDMANN E, 1991, STROKE, V22, P684; FISCHER CM, 1971, J NEUROPATHOL EXP NE, V30, P536; GILBERT JJ, 1983, STROKE, V14, P915, DOI 10.1161/01.STR.14.6.915; KASE CS, 1985, NEUROLOGY, V35, P943, DOI 10.1212/WNL.35.7.943; KASE CS, 1986, STROKE, V17, P590, DOI 10.1161/01.STR.17.4.590; LEVINE SR, 1988, STROKE, V19, P779, DOI 10.1161/01.STR.19.6.779; OJERMAN RG, 1983, STROKE, V14, P468; TUHRIM S, 1988, ANN NEUROL, V24, P258, DOI 10.1002/ana.410240213	9	135	140	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					656	658		10.1016/0140-6736(92)90804-C	http://dx.doi.org/10.1016/0140-6736(92)90804-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347346				2022-12-28	WOS:A1992HH74300012
J	VANGIJN, J				VANGIJN, J			SUBARACHNOID HEMORRHAGE	LANCET			English	Article							RUPTURED INTRACRANIAL ANEURYSM; DELAYED CEREBRAL-ISCHEMIA; ACUTE HYDROCEPHALUS; HEMORRHAGE; HEADACHE				VANGIJN, J (corresponding author), UNIV UTRECHT,DEPT NEUROL,POB 85500,3508 GA UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008					HASAN D, 1991, STROKE, V22, P190, DOI 10.1161/01.STR.22.2.190; HASAN D, 1989, STROKE, V20, P747, DOI 10.1161/01.STR.20.6.747; HIJDRA A, 1986, NEUROLOGY, V36, P329, DOI 10.1212/WNL.36.3.329; HIJDRA A, 1982, J NEUROSURG, V57, P765, DOI 10.3171/jns.1982.57.6.0765; HIJDRA A, 1987, J NEUROSURG, V67, P29, DOI 10.3171/jns.1987.67.1.0029; HIJDRA A, 1987, STROKE, V18, P1061, DOI 10.1161/01.STR.18.6.1061; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; KASSELL NF, 1990, J NEUROSURG, V73, P37, DOI 10.3171/jns.1990.73.1.0037; OHMAN J, 1989, J NEUROSURG, V70, P55, DOI 10.3171/jns.1989.70.1.0055; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; RINKEL GJE, 1991, AM J NEURORADIOL, V12, P829; RINKEL GJE, 1991, LANCET, P964; VANGIJN J, 1985, J NEUROSURG, V63, P355, DOI 10.3171/jns.1985.63.3.0355; VANGIJN J, 1982, NEURORADIOLOGY, V23, P153, DOI 10.1007/BF00347559; VANGIJN J, 1985, NEUROLOGY, V35, P493, DOI 10.1212/WNL.35.4.493; VERMEULEN M, 1984, NEW ENGL J MED, V311, P432, DOI 10.1056/NEJM198408163110703; VERMEULEN M, 1989, J NEUROL NEUROSUR PS, V52, P826, DOI 10.1136/jnnp.52.7.826; VERMEULEN M, 1990, J NEUROL NEUROSUR PS, V53, P365, DOI 10.1136/jnnp.53.5.365; VERMEULEN M, 1984, J NEUROSURG, V60, P935, DOI 10.3171/jns.1984.60.5.0935; VERWEIJ RD, 1988, ARCH NEUROL-CHICAGO, V45, P1019, DOI 10.1001/archneur.1988.00520330109018; WIJDICKS EFM, 1985, ANN NEUROL, V18, P211, DOI 10.1002/ana.410180208; WIJDICKS EFM, 1988, LANCET, V2, P68	22	40	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					653	655		10.1016/0140-6736(92)90803-B	http://dx.doi.org/10.1016/0140-6736(92)90803-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347345				2022-12-28	WOS:A1992HH74300011
J	CONVIT, J; SAMPSON, C; ZUNIGA, M; SMITH, PG; PLATA, J; SILVA, J; MOLINA, J; PINARDI, ME; BLOOM, BR; SALGADO, A				CONVIT, J; SAMPSON, C; ZUNIGA, M; SMITH, PG; PLATA, J; SILVA, J; MOLINA, J; PINARDI, ME; BLOOM, BR; SALGADO, A			IMMUNOPROPHYLACTIC TRIAL WITH COMBINED MYCOBACTERIUM-LEPRAE BCG VACCINE AGAINST LEPROSY - PRELIMINARY-RESULTS	LANCET			English	Article								In an attempt to find a vaccine that gives greater and more consistent protection against leprosy than BCG vaccine, we compared BCG with and without killed Mycobacterium leprae in Venezuela. Close contacts of prevalent leprosy cases were selected as the trial population since they are at greatest risk of leprosy. Since 1983, 29 113 contacts have been randomly allocated vaccination with BCG alone or BCG plus 6 x 10(8) irradiated, autoclaved M leprae purified from the tissues of infected armadillos. We excluded contacts with signs of leprosy at screening and a proportion of those whose skin-test responses to M leprae soluble antigen (MLSA) were 10 mm or more (positive reactions). By July, 1991, 59 postvaccination cases of leprosy had been confirmed in 150 026 person-years of follow-up through annual clinical examinations of the trial population (31 BCG, 28 BCG/M leprae). In the subgroup for which we thought an effect of vaccination was most likely (onset more than a year after vaccination, negative MLSA skin-test response before vaccination), leprosy developed in 11 BCG recipients and 9 BCG/M leprae recipients, there were 18% fewer cases (upper 95% confidence limit [CL] 70%) in the BCG/M leprae than in the BCG alone group. For all cases with onset more than a year after vaccination irrespective of MLSA reaction the relative efficacy was 0% (upper 95% CL 54%; 15 cases in each vaccine group). Retrospective analysis of data on the number of BCG scars found on each contact screened suggested that BCG alone confers substantial protection against leprosy (vaccine efficacy 56%, 95% CL 27-74%) and there was a suggestion that several doses of BCG offered additional protection, There is no evidence in the first 5 years of follow-up of this trial that BCG plus M leprae offers substantially better protection against leprosy than does BCG alone, but the confidence interval on the relative efficacy estimate is wide.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; University of London; London School of Hygiene & Tropical Medicine	CONVIT, J (corresponding author), INST BIOMED,APARTADO POSTAL 4043,CARACAS 1010A,VENEZUELA.			Smith, Peter/0000-0003-0080-7560				CONVIT J, 1972, B WORLD HEALTH ORGAN, V46, P821; CONVIT J, 1982, INT J LEPROSY, V50, P415; CONVIT J, 1979, CLIN EXP IMMUNOL, V36, P214; Convit J, 1986, Lepr Rev, V57 Suppl 2, P263; CONVIT J, 1974, CLIN EXP IMMUNOL, V17, P261; DRAPER P, 1979, PURIFICATION LEPRAE; FINE PEM, 1988, BRIT MED BULL, V44, P691, DOI 10.1093/oxfordjournals.bmb.a072277; HART P. D'A., 1967, Tubercle, V48, P201, DOI 10.1016/S0041-3879(67)80024-2; JESUDASAN K, 1984, LEPROSY REV, V55, P353; LARA C. B., 1956, INTERNATL JOUR LEPROSY, V24, P245; NOORDEEN SK, 1991, LEPROSY REV, V62, P72; ULRICH M, 1991, INT J LEPROSY, V59, P405	12	100	104	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					446	450		10.1016/0140-6736(92)91056-E	http://dx.doi.org/10.1016/0140-6736(92)91056-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346818				2022-12-28	WOS:A1992HE93200002
J	ARTHUR, P; KIRKWOOD, B; ROSS, D; MORRIS, S; GYAPONG, J; TOMKINS, A; ADDY, H				ARTHUR, P; KIRKWOOD, B; ROSS, D; MORRIS, S; GYAPONG, J; TOMKINS, A; ADDY, H			IMPACT OF VITAMIN-A SUPPLEMENTATION ON CHILDHOOD MORBIDITY IN NORTHERN GHANA	LANCET			English	Letter									NAVRONGO HLTH RES CTR,NAVRONGO,GHANA; INST CHILD HLTH,CTR INT CHILD HLTH,LONDON WC1N 1EH,ENGLAND; UNIV SCI & TECHNOL,SCH MED SCI,DEPT COMMUNITY MED,KUMASI,GHANA	Navrongo Health Research Center; University of London; University College London; Kwame Nkrumah University Science & Technology	ARTHUR, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,MATERNAL & CHILD EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.			Gyapong, John/0000-0002-8415-1468; Kirkwood, Betty/0000-0001-5274-6072					0	60	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					361	362		10.1016/0140-6736(92)91677-Z	http://dx.doi.org/10.1016/0140-6736(92)91677-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346430				2022-12-28	WOS:A1992HC77100031
J	DOUGLAS, NJ; THOMAS, S; JAN, MA				DOUGLAS, NJ; THOMAS, S; JAN, MA			CLINICAL-VALUE OF POLYSOMNOGRAPHY	LANCET			English	Article							HYPOPNEA SYNDROME; SLEEP	Polysomnography is used increasingly to investigate patients with possible sleep apnoea/hypopnoea syndrome (SAHS), but it has not been assessed critically. We thus examined prospectively the value of electrophysiological and respiratory monitoring in 200 consecutive adults (163 men, 37 women; mean [SD] age 50 [13] years) having polysomnography. At polysomnography, 91 patients had SAHS (> 15 apnoeas + hypopnoeas [A + H] per h asleep) and 11 had periodic limb-movement disorder. Recording sleep electrophysiologically was of no diagnostic value and SAHS could be as accurately defined by A + H per time in bed as by A + H per time asleep. 66% of patients with SAHS could be diagnosed with oximetry alone, but many of the undiagnosed patients had moderately severe SAHS and benefited from treatment. Neurophysiological sleep recording is unnecessary and oximetry alone is of limited value in the overnight in investigation of patients suspected of having SAHS.			DOUGLAS, NJ (corresponding author), CITY HOSP EDINBURGH,DEPT MED,RESP MED UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND.		Douglas, Neil/B-1491-2013					CHESHIRE K, IN PRESS ARCH INTERN; COOPER BG, 1991, THORAX, V46, P586, DOI 10.1136/thx.46.8.586; CROCKER BD, 1990, AM REV RESPIR DIS, V142, P14, DOI 10.1164/ajrccm/142.1.14; DOUGLAS NJ, 1979, LANCET, V1, P1; GOULD GA, 1988, AM REV RESPIR DIS, V137, P895, DOI 10.1164/ajrccm/137.4.895; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HAPONIK EF, 1984, AM J MED, V77, P671, DOI 10.1016/0002-9343(84)90361-9; MARTIN RJ, 1985, SLEEP, V8, P371, DOI 10.1093/sleep/8.4.371; MCAVOY RD, 1988, GUIDELINES RESPIRATO; PARSONS M, 1986, Q J MED, V58, P295; Phillipson E.A., 1989, AM REV RESPIR DIS, V139, P559, DOI 10.1164/ajrccm/139.2.559; Rechtschaffen A, 1968, NIH PUBLICATION, V204; STRADLING J, 1989, J AMBULATORY MONIT, V2, P197; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; VINER S, 1991, ANN INTERN MED, V115, P356, DOI 10.7326/0003-4819-115-5-356; WHYTE KF, 1989, Q J MED, V72, P659; WHYTE KF, IN PRESS SLEEP; 1990, BTS NEWS, V5, P7; 1990, INT CLASSIFICATION S, P65	19	273	279	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					347	350		10.1016/0140-6736(92)91660-Z	http://dx.doi.org/10.1016/0140-6736(92)91660-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346422				2022-12-28	WOS:A1992HC77100017
J	TREACY, MN; NEILSON, LI; TURNER, EE; HE, X; ROSENFELD, MG				TREACY, MN; NEILSON, LI; TURNER, EE; HE, X; ROSENFELD, MG			TWIN OF I-POU - A 2 AMINO-ACID DIFFERENCE IN THE I-POU HOMEODOMAIN DISTINGUISHES AN ACTIVATOR FROM AN INHIBITOR OF TRANSCRIPTION	CELL			English	Article							DNA-BINDING DOMAIN; MAMMALIAN-CELLS; DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; NEGATIVE REGULATOR; CELLULAR PROTEINS; GENE-EXPRESSION; STEROID BINDING; LEUCINE ZIPPER; C-ELEGANS	I-POU, a POU domain nuclear protein that lacks two conserved basic amino acids of the POU homeodomain is coexpressed in the developing Drosophila nervous system with a second POU domain transcription factor, Cf1-a. I-POU does not bind to DNA but forms a POU domain-mediated, high affinity heterodimer with Cf1-a, inhibiting its ability to bind and activate the dopa decarboxylase gene. The I-POU/Cf1-a dimerization interface encompasses only the N-terminal basic region and helices 1 and 2 of the POU homeodomains with precise amino acid and alpha-helical requirements. twin of I-POU, an alternatively spliced transcript of the I-POU gene, encodes a protein containing the two basic amino acid residues absent in I-POU. Twin of I-POU is incapable of dimerizing with Cf1-a, but can act as a positive transcription factor on targets distinct from those regulated by Cf1-a. These findings suggest that the I-POU genomic locus simultaneously generates both a specific activator and inhibitor of gene transcription, capable of modulating two distinct regulatory programs during neural development.	UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT BIOL, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	TREACY, MN (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, EUKARYOT REGULATORY BIOL PROGRAM, LA JOLLA, CA 92093 USA.		Turner, Eric e/K-3556-2015	Turner, Eric e/0000-0001-5499-6788				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; AKAM M, 1987, DEVELOPMENT, V101, P1; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERMINGHAM JR, 1988, EMBO J, V7, P3211, DOI 10.1002/j.1460-2075.1988.tb03188.x; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; BUSTURIA A, 1990, EMBO J, V9, P3551, DOI 10.1002/j.1460-2075.1990.tb07565.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OCONNOR MB, 1988, EMBO J, V7, P435, DOI 10.1002/j.1460-2075.1988.tb02831.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PRATT WB, 1988, J BIOL CHEM, V263, P267; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	83	107	108	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1992	68	3					491	505		10.1016/0092-8674(92)90186-G	http://dx.doi.org/10.1016/0092-8674(92)90186-G			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HD398	1346754				2022-12-28	WOS:A1992HD39800010
J	LANDRY, SJ; JORDAN, R; MCMACKEN, R; GIERASCH, LM				LANDRY, SJ; JORDAN, R; MCMACKEN, R; GIERASCH, LM			DIFFERENT CONFORMATIONS FOR THE SAME POLYPEPTIDE BOUND TO CHAPERONES DNAK AND GROEL	NATURE			English	Article							PROTEINS	THE proteins DnaK (hsp70) and GroEL (cpn60) from Escherichia coli are prototypes of two classes of molecular chaperones conserved throughout evolution 1. The analysis of transferred nuclear Overhauser effects in two-dimensional NMR spectra is ideally suited to determine chaperone-bound conformations of peptides 2. The peptide vsv-C (amino-acid sequence KLIGVLSSLFRPK) stimulates the ATPase of BiP and Hsc70 (ref. 3) and the intrinsic ATPase of DnaK. The affinity of the vsv-C peptide for DnaK is greatly reduced in the presence of ATP. Here we analyse transferred nuclear Overhauser effects and show that the peptide is in an extended conformation while bound to DnaK but is helical when bound to GroEL. NMR also indicates that the mobility of the peptide backbone is reduced more by binding to DnaK than by binding to GroEL, whereas the side chains are less mobile when bound to GroEL.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University	LANDRY, SJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Gierasch, Lila M/D-1494-2009; Landry, Samuel/AAK-5778-2020	Landry, Samuel/0000-0002-4082-0543				BAUMANN R, 1981, J MAGN RESON, V44, P402, DOI 10.1016/0022-2364(81)90179-7; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; Morimoto RI, 1990, STRESS PROTEINS BIOL; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2	13	293	296	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1992	355	6359					455	457		10.1038/355455a0	http://dx.doi.org/10.1038/355455a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB530	1346469				2022-12-28	WOS:A1992HB53000072
J	PETERS, F				PETERS, F			MULTICENTER STUDY OF GESTRINONE IN CYCLICAL BREAST PAIN	LANCET			English	Article							LUTEAL-PHASE; CONTROLLED TRIAL; DISEASE; WOMEN; MASTALGIA; DANAZOL; MASTOPATHY; RECEPTORS; ENDOCRINE; HORMONES	Although the aetiology of cyclical mastalgia is poorly understood, the consistent finding of an increased prolactin stimulation response probably due to oestrogen dominance has led to the use of treatment with prolactin-lowering drugs and anti-oestrogens. The efficacy and safety in cyclical mastalgia of gestrinone, which has androgenic, anti-oestrogenic, and antiprogestagenic properties, were investigated in a multicentre study. In a double-blind randomisation procedure, 72 patients were allocated placebo and 73 treatment with gestrinone (2.5 mg twice a week) for 3 months. The patients recorded the severity of breast pain on a visual analogue scale before and during treatment and scored other breast symptoms as not present (0), mild (1), moderate (2), or severe (3). The gestrinone group had significantly greater reductions than the placebo group in breast pain score at months 1, 2, and 3 of treatment (mean reduction 59.5 [SD 22.6] to 11.7 [17.0] vs 58.2 [17.6] to 36.7 [23.0] at month 3; p < 0.0001). All six breast symptoms had lower scores in the gestrinone than in the placebo group by the end of treatment. In a subset of 30 participants (15 from each group), serum concentrations of oestradiol, progesterone, and tri-iodothyronine were significantly lower than baseline after 3 months of gestrinone, but concentrations of luteinising hormone, follicle-stimulating hormone, prolactin, thyroid-stimulating hormone, and thyroxine did not change. 41% of gestrinone-treated and 14% of placebo-treated patients reported at least one side-effect, most of these were androgen-mediated. 11 placebo-treated patients and 4 on gestrinone discontinued treatment. Thus, gestrinone was very effective in the treatment of cyclical mastalgia and was well tolerated.			PETERS, F (corresponding author), UNIV MAINZ,ST HILDEGARDIS HOSP,DEPT OBSTET & GYNECOL,W-6500 MAINZ,GERMANY.							COUTINHO EM, 1986, AM J OBSTET GYNECOL, V155, P761, DOI 10.1016/S0002-9378(86)80016-3; CUNNINGHAM D, 1987, CANCER TREAT REP, V71, P1091; FENTIMAN IS, 1986, LANCET, V1, P287; GEISTHOVEL F, 1983, FERTIL STERIL, V39, P277; GOLINGER RC, 1978, SURG GYNECOL OBSTET, V146, P273; GOODWIN PJ, 1988, BRIT J SURG, V75, P837, DOI 10.1002/bjs.1800750904; MANSEL RE, 1990, LANCET, V335, P190, DOI 10.1016/0140-6736(90)90278-D; MANSEL RE, 1982, LANCET, V1, P928; Mettler L, 1984, MED MANAGEMENT ENDOM, P233; MOGUILEWSKY M, 1984, MED MANAGEMENT ENDOM, P163; MORA G, 1974, CONTRACEPTION, V10, P145, DOI 10.1016/0010-7824(74)90070-5; PETERS F, 1980, ARCH GYNECOL, V230, P3, DOI 10.1007/BF02108592; PETERS F, 1981, KLIN WOCHENSCHR, V59, P403, DOI 10.1007/BF01698519; PETERS F, 1984, OBSTET GYNECOL, V64, P381; PETERS F, 1987, ACTA ENDOCR-COP    S, V283, P125; PREECE PE, 1976, LANCET, V2, P670; RAYNAUD JP, 1980, J STEROID BIOCHEM, V12, P143, DOI 10.1016/0022-4731(80)90264-2; READ GF, 1985, EUR J CANCER CLIN ON, V21, P9, DOI 10.1016/0277-5379(85)90194-4; ROBYN C, 1984, MED MANAGEMENT ENDOM, P207; SAKIZ E, 1974, CONTRACEPTION, V10, P467, DOI 10.1016/0010-7824(74)90113-9; SITRUKWARE LR, 1977, J CLIN ENDOCR METAB, V44, P771, DOI 10.1210/jcem-44-4-771; SNYDER BW, 1989, FERTIL STERIL, V51, P705; TAMAYA T, 1986, ACTA OBSTET GYN SCAN, V65, P439, DOI 10.3109/00016348609157380; VENTURINI PL, 1989, FERTIL STERIL, V52, P589; WALSH PV, 1984, EUR J CANCER CLIN ON, V20, P1345, DOI 10.1016/0277-5379(84)90052-X; WALSH PV, 1984, EUR J CANCER CLIN ON, V20, P1339, DOI 10.1016/0277-5379(84)90051-8; WATTBOOLSEN A, 1981, HORM METAB RES, V13, P700	27	19	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1992	339	8787					205	208		10.1016/0140-6736(92)90005-N	http://dx.doi.org/10.1016/0140-6736(92)90005-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346172				2022-12-28	WOS:A1992HA58900003
J	TYLLESKAR, T; BANEA, M; BIKANGI, N; COOKE, RD; POULTER, NH; ROSLING, H				TYLLESKAR, T; BANEA, M; BIKANGI, N; COOKE, RD; POULTER, NH; ROSLING, H			CASSAVA CYANOGENS AND KONZO, AN UPPER MOTONEURON DISEASE FOUND IN AFRICA	LANCET			English	Article							EPIDEMIC SPASTIC PARAPARESIS; CYANIDE CONTENT; THIOCYANATE; SULFUR	Konzo is a distinct form of tropical myelopathy characterised by abrupt onset of spastic paraparesis. Epidemics in East Africa have been attributed to dietary cyanide exposure from insufficiently processed cassava but a study done in Zaire disputed such an aetiology. We investigated a konzo-affected population in rural Zaire and measured the cyanogen content of cassava flour, determined urinary thiocyanate as an indicator of cyanide intake, and compared blood cyanide concentrations in cases and controls. The affected population consumed flour made from short-soaked (one day) cassava roots and thus had high dietary cyanide exposure (urinary thiocyanate in 31 children = 757-mu-mol/l) compared with the unaffected population (urinary thiocyanate in 46 children = 50-mu-mol/l) that ate cassava that had been soaked for three days before consumption. 3 konzo patients, but only 2 of 23 controls, had blood cyanide concentrations above 4-mu-mol/l (p < 0.01), although serum thiocyanate concentrations were similar. Our findings indicate a causal role in konzo of sustained high blood cyanide concentrations maintained by a deficient sulphur intake impairing cyanide to thiocyanate conversion. The underlying causes of konzo are poverty and food shortage, but a minor improvement of food processing may, as in beri-beri, be preventive.	CTR NATL PLANIFICAT NUTR HUMAINE, DEPT SANTE PUBL, KINSHASA, DEM REP CONGO; OVERSEAS DEV ADM, INST NAT RESOURCES, CHATHAM, ENGLAND	University of Greenwich	TYLLESKAR, T (corresponding author), UNIV HOSP UPPSALA, DEPT PAEDIAT, INT CHILD HLTH UNIT, S-75185 UPPSALA, SWEDEN.		Tylleskär, Thorkild/S-5529-2017	Tylleskär, Thorkild/0000-0003-4801-4324				[Anonymous], 1984, Lancet, V2, P904; BARRETT MD, 1977, CAN J PHYSIOL PHARM, V55, P134, DOI 10.1139/y77-021; BOURDOUX P, 1982, IDRC MONOGRAPH E, V184, P51; CARTON H, 1986, J NEUROL NEUROSUR PS, V49, P620, DOI 10.1136/jnnp.49.6.620; CASADEI E, 1990, J TROP MED HYG, V93, P257; CLIFF J, 1985, LANCET, V2, P1211; COCK JH, 1982, SCIENCE, V218, P755, DOI 10.1126/science.7134971; COOKE RD, 1978, J FOOD TECHNOL, V13, P299, DOI 10.1016/j.phymed.2006.01.015; COOKE RD, 1978, J SCI FOOD AGR, V29, P345, DOI 10.1002/jsfa.2740290408; ESSERS AJA, IN PRESS ECOL FOOD N; FOMUNYAM RT, 1985, FOOD CHEM, V17, P221, DOI 10.1016/0308-8146(85)90072-X; HALL AH, 1986, ANN EMERG MED, V15, P1067, DOI 10.1016/S0196-0644(86)80131-7; HOWLETT WP, 1990, BRAIN, V113, P223, DOI 10.1093/brain/113.1.223; LUDOLPH AC, 1991, CURR OPIN NEUROL NEU, V4, P458; LUNDQUIST P, 1980, CLIN CHEM, V26, P1178; LUNDQUIST P, 1985, CLIN CHEM, V31, P591; LUNDQVIST P, 1983, CLIN CHEM, V29, P403; MESSING B, 1988, EUR ARCH PSY CLIN N, V237, P139, DOI 10.1007/BF00451281; MLINGI N, 1991, TROP DOCT, V21, P24, DOI 10.1177/004947559102100110; OBRIEN GM, 1991, J SCI FOOD AGR, V56, P277, DOI 10.1002/jsfa.2740560304; Osuntokun B O, 1981, World Rev Nutr Diet, V36, P141; RODGERSJOHNSON PE, 1988, TRENDS NEUROSCI, V11, P526, DOI 10.1016/0166-2236(88)90176-2; ROSLING H, 1988, LANCET, V1, P1222; SABRY ZI, 1965, NATURE, V206, P931, DOI 10.1038/206931b0; SCHULZ V, 1984, CLIN PHARMACOKINET, V9, P239, DOI 10.2165/00003088-198409030-00005; Trolli G., 1938, RESUME OBSERVATIONS, P1; TYLLESKAR T, 1991, B WORLD HEALTH ORGAN, V69, P581; 1984, B WORLD HEALTH ORGAN, V62, P477	28	190	194	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1992	339	8787					208	211		10.1016/0140-6736(92)90006-O	http://dx.doi.org/10.1016/0140-6736(92)90006-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA589	1346173				2022-12-28	WOS:A1992HA58900004
J	DALEY, CL; SMALL, PM; SCHECTER, GF; SCHOOLNIK, GK; MCADAM, RA; JACOBS, WR; HOPEWELL, PC				DALEY, CL; SMALL, PM; SCHECTER, GF; SCHOOLNIK, GK; MCADAM, RA; JACOBS, WR; HOPEWELL, PC			AN OUTBREAK OF TUBERCULOSIS WITH ACCELERATED PROGRESSION AMONG PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS - AN ANALYSIS USING RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY	Background. Tuberculosis typically develops from a reactivation of latent infection. Clinical tuberculosis may also arise from a primary infection, and this is thought to be more likely in persons infected with the human immunodeficiency virus (HIV). However, the relative importance of these two pathogenetic mechanisms in this population is unclear. Methods. Between December 1990 and April 1991, tuberculosis was diagnosed in 12 residents of a housing facility for HIV-infected persons. In the preceding six months, two patients being treated for tuberculosis had been admitted to the facility. We investigated this outbreak using standard procedures plus analysis of the cultured organisms with restriction-fragment-length polymorphisms (RFLPs). Results. Organisms isolated from all 11 of the culture-positive residents had similar RFLP patterns, whereas the isolates from the 2 patients treated for tuberculosis in the previous six months were different strains. This implicated the first of the 12 patients with tuberculosis as the source of this outbreak. Among the 30 residents exposed to possible infection, active tuberculosis developed in 11 (37 percent), and 4 others (13 percent) had newly positive tuberculin skin tests. Of 28 staff members with possible exposure, at least 6 had positive tuberculin-test reactions, but none had tuberculosis. Conclusions. Newly acquired tuberculous infection in HIV-infected patients can spread readily and progress rapidly to active disease. There should be heightened surveillance for tuberculosis in facilities where HIV-infected persons live, and investigation of contacts must be undertaken promptly and be focused more broadly than is usual.	SAN FRANCISCO GEN HOSP,MED CTR,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV GEOG MED,STANFORD,CA 94305; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; DEPT PUBL HLTH CITY & CTY SAN FRANCISCO,SAN FRANCISCO,CA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University; Stanford University; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; San Francisco Department of Public Health			Daley, Charles L./AAC-3231-2021	Jacobs, William/0000-0003-3321-3080	NHLBI NIH HHS [HL 07185] Funding Source: Medline; NIAID NIH HHS [AIZ6170] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Bloch A B, 1989, Semin Respir Infect, V4, P157; DIPERRI G, 1989, LANCET, V2, P1502; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; MCADAM RA, 1990, MOL MICROBIOL, V4, P1607, DOI 10.1111/j.1365-2958.1990.tb02073.x; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; THEIRRY D, 1990, NUCLEIC ACIDS RES, V18, P188; TOMPKINS LS, 1987, J CLIN MICROBIOL, V25, P1875, DOI 10.1128/JCM.25.10.1875-1880.1987; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991	11	874	884	2	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1992	326	4					231	235		10.1056/NEJM199201233260404	http://dx.doi.org/10.1056/NEJM199201233260404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA431	1345800	Bronze			2022-12-28	WOS:A1992HA43100004
J	DEFIGUEIREDO, CEP; ELLORY, JC; HENDRY, BM				DEFIGUEIREDO, CEP; ELLORY, JC; HENDRY, BM			ERYTHROCYTE CHOLINE UPTAKE AFTER RENAL-TRANSPLANTATION	LANCET			English	Article							TRANSPORT; HEMODIALYSIS; FAILURE; CARRIER; UREMIA; ACIDS; PUMP	Erythrocyte membrane choline transport is abnormally high in chronic renal failure. The aim of this study was to find out whether, and how quickly, this abnormality is reversed by renal transplantation. Ten adults with chronic renal failure were studied before and for up to 6 months after renal transplantation. Plasma creatinine concentration and erythrocyte uptake of radiolabelled choline were measured periodically for up to 6 months. The maximum rate of choline transport (V(max)) was abnormally high before transplantation and fell to normal values during the first week after transplantation. This fall matched that in plasma creatinine. A temporary rise in plasma creatinine in one patient, reversed by methylprednisolone treatment, was accompanied by a rise in choline flux, and graft failure in another patient was accompanied by a return to pretransplant rates of choline transport. Thus, the high rates of choline uptake in uraemia are rapidly reduced on recovery of renal function. The speed of the changes suggests the involvement of a plasma factor.	UNIV OXFORD,PHYSIOL LAB,OXFORD,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford			Poli=de-Figueiredo, Carlos Eduardo/A-2027-2013	Poli=de-Figueiredo, Carlos Eduardo/0000-0002-7333-8884				ANCELIN ML, 1991, BIOCHEM J, V273, P701, DOI 10.1042/bj2730701; Cole C H, 1968, Trans Assoc Am Physicians, V81, P213; COTTON JR, 1979, J CLIN INVEST, V63, P501, DOI 10.1172/JCI109328; DEVES R, 1986, J MEMBRANE BIOL, V93, P165, DOI 10.1007/BF01870808; DEVES R, 1979, BIOCHIM BIOPHYS ACTA, V557, P469, DOI 10.1016/0005-2736(79)90344-4; EDMONDSON RPS, 1975, CLIN SCI MOL MED, V49, P213, DOI 10.1042/cs0490213; ESTRADA C, 1990, J NEUROCHEM, V54, P1467, DOI 10.1111/j.1471-4159.1990.tb01193.x; FERVENZA FC, 1991, CLIN SCI, V80, P137, DOI 10.1042/cs0800137; FERVENZA FC, 1990, NEPHROL DIAL TRANSPL, V5, P594, DOI 10.1093/ndt/5.8.594; FERVENZA FC, 1989, NEPHRON, V53, P121, DOI 10.1159/000185723; GRAVES SW, 1983, ANN INTERN MED, V99, P604, DOI 10.7326/0003-4819-99-5-604; KAJI D, 1987, AM J PHYSIOL, V252, pF785, DOI 10.1152/ajprenal.1987.252.5.F785; KELLY RA, 1989, KIDNEY INT, V35, P595, DOI 10.1038/ki.1989.28; KIRK K, 1991, BIOCHEM J, V278, P521, DOI 10.1042/bj2780521; MARTIN K, 1977, MEMBRANE TRANSPORT R, P101; RUIZ P, 1990, NEW ENGL J MED, V322, P717, DOI 10.1056/NEJM199003153221102; WELT LG, 1964, T ASSOC AM PHYSICIAN, V77, P169; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	18	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					146	148		10.1016/0140-6736(92)90211-K	http://dx.doi.org/10.1016/0140-6736(92)90211-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346011				2022-12-28	WOS:A1992GZ96800004
J	VANDERMEER, JTM; VANWIJK, W; THOMPSON, J; VANDENBROUCKE, JP; VALKENBURG, HA; MICHEL, MF				VANDERMEER, JTM; VANWIJK, W; THOMPSON, J; VANDENBROUCKE, JP; VALKENBURG, HA; MICHEL, MF			EFFICACY OF ANTIBIOTIC-PROPHYLAXIS FOR PREVENTION OF NATIVE-VALVE ENDOCARDITIS	LANCET			English	Article							INFECTIVE ENDOCARDITIS; BACTERIAL-ENDOCARDITIS; DENTAL PROCEDURES; CONTROVERSIES; VIEW	Whether antibiotic prophylaxis can prevent bacterial endocarditis is hotly debated. In an attempt to settle this issue, we have assessed the efficacy of prophylaxis for bacterial endocarditis on native valves in a nationwide, case-control study in the Netherlands. Cases were patients with known cardiac disease in whom endocarditis developed within 180 days of a medical or dental procedure for which prophylaxis was indicated. Of a total of 438 patients with endocarditis diagnosed during 2 years, 48 were eligible for the study. Controls were patients with the same cardiac status in whom endocarditis did not develop within 180 days of a similar procedure; of a total of 889 controls from five hospitals, 200 were eligible. Overall, about 1 in 6 patients in both groups had received prophylaxis. The best estimate of protective efficacy was 49% for first-ever endocarditis occurring within 30 days of a procedure. Endocarditis developed within 30 days of a procedure in only 13% of patients with a previously diagnosed heart lesion which predisposed to the disease. The findings suggest that strict adherence to generally accepted recommendations for prophylaxis might do little to decrease the total number of patients with endocarditis in the community.	UNIV HOSP LEIDEN, DEPT CLIN EPIDEMIOL, 2300 RC LEIDEN, NETHERLANDS; ERASMUS UNIV, DEPT CLIN MICROBIOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV, DEPT EPIDEMIOL & BIOSTAT, 3000 DR ROTTERDAM, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Erasmus University Rotterdam; Erasmus University Rotterdam	VANDERMEER, JTM (corresponding author), UNIV HOSP LEIDEN, DEPT INFECT DIS, BLDG 1, C5-P, PO 9600, 2300 RC LEIDEN, NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				[Anonymous], 1990, Lancet, V335, P88; BADDOUR LM, 1988, REV INFECT DIS, V10, P1163; BAYLISS R, 1983, BRIT HEART J, V50, P513, DOI 10.1136/hrt.50.6.513; BROOKS RG, 1988, AM J MED, V18, P74; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DENNING DW, 1984, BRIT MED J, V289, P1499, DOI 10.1136/bmj.289.6457.1499; DINMAN BD, 1980, JAMA-J AM MED ASSOC, V244, P1226, DOI 10.1001/jama.244.11.1226; DURACK DT, 1983, JAMA-J AM MED ASSOC, V250, P2318, DOI 10.1001/jama.250.17.2318; DURACK DT, 1984, PRINCIPLES PRACTICES, P539; FEINSTEIN AR, 1979, J CHRON DIS, V32, P35, DOI 10.1016/0021-9681(79)90009-2; FEKETE T, 1990, DENT CLIN N AM, V34, P79; FINCH R, 1990, SCAND J INFECT DIS, P102; GUTSCHIK E, 1990, SCAND J DENT RES, V98, P144; IMPERIALE TF, 1990, AM J MED, V88, P131, DOI 10.1016/0002-9343(90)90461-L; Jaspers M T, 1984, J Dent Educ, V48, P159; KAPLAN EL, 1986, AM J CARDIOL, V57, P478, DOI 10.1016/0002-9149(86)90777-0; KAYE D, 1986, ANN INTERN MED, V104, P419, DOI 10.7326/0003-4819-104-3-419; LAVIE CJ, 1989, JAMA-J AM MED ASSOC, V262, P3308, DOI 10.1001/jama.262.23.3308; MCGOWAN DA, 1987, J ANTIMICROB CHEMOTH, V20, P105, DOI 10.1093/jac/20.suppl_A.105; MCGOWAN DA, 1978, J ANTIMICROB CHEMOTH, V4, P486, DOI 10.1093/jac/4.6.486; MICHEL MF, 1986, GENEESMIDDELEN B, V20, P53; Murrah V A, 1987, J Dent Educ, V51, P229; OAKLEY CM, 1987, J ANTIMICROB CHEMOTH, V20, P99, DOI 10.1093/jac/20.suppl_A.99; PETERSDORF RG, 1978, AM J MED, V65, P220, DOI 10.1016/0002-9343(78)90811-2; SHANSON DC, 1987, J ANTIMICROB CHEMOTH, V20, P119, DOI 10.1093/jac/20.suppl_A.119; STECKELBERG JM, 1990, AM J MED, V88, P582, DOI 10.1016/0002-9343(90)90521-E; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WALKER M P, 1984, Clinical Preventive Dentistry, V6, P17; 1976, LANCET, V1, P519	29	256	260	2	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	1992	339	8786					135	139		10.1016/0140-6736(92)90207-J	http://dx.doi.org/10.1016/0140-6736(92)90207-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346008				2022-12-28	WOS:A1992GZ96800001
J	OBERHAUSER, AF; MONCK, JR; BALCH, WE; FERNANDEZ, JM				OBERHAUSER, AF; MONCK, JR; BALCH, WE; FERNANDEZ, JM			EXOCYTOTIC FUSION IS ACTIVATED BY RAB3A PEPTIDES	NATURE			English	Article							GTP-BINDING PROTEIN; PERITONEAL MAST-CELLS; CAPACITANCE MEASUREMENTS; MEMBRANE CAPACITANCE; SYNAPTIC VESICLES; GAMMA-S; TRANSPORT; ENDOCYTOSIS; SECRETION; MECHANISM	STUDIES of intracellular traffic in yeast and mammalian systems have implicated members of the Rab family of small GTP-binding proteins as regulators of membrane fusion1-10. We have used the patch clamp technique to measure exocytotic fusion events directly and investigate the role of GTP-binding proteins in regulating exocytosis in mast cells. Intracellular perfusion of mast cells with GTP-gammaS is sufficient to trigger complete exocytotic degranulation in the absence of other intracellular messengers11. Here we show that GTP is a potent inhibitor of GTP-gammaS-induced degranulation, indicating that sustained activation of a GTP-binding protein is sufficient for membrane fusion. We have found that synthetic oligopeptides, corresponding to part of the effector domain of Rab3a12, stimulate complete exocytotic degranulation, similar to that induced by GTP-gammaS. The response is selective for Rab3a sequence and is strictly dependent on Mg2+ and ATP. This suggests that sustained activation of a Rab3 protein causes exocytotic fusion. The peptide response can be accelerated by GDP-betaS, suggesting that Rab3a peptides compete with endogenous Rab3 proteins for a binding site on a target effector protein, which causes fusion on activation.	SCRIPPS RES INST, DEPT MOLEC & CELLULAR BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	OBERHAUSER, AF (corresponding author), MAYO CLIN & MAYO FDN, DEPT PHYSIOL & BIOPHYS, ROCHESTER, MN 55905 USA.			Oberhauser, Andres/0000-0001-7375-7109				ALMERS W, 1987, J PHYSIOL-LONDON, V386, P205, DOI 10.1113/jphysiol.1987.sp016530; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DETOLEDO GA, 1990, J CELL BIOL, V110, P1033, DOI 10.1083/jcb.110.4.1033; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; LINDAU M, 1987, FEBS LETT, V222, P317, DOI 10.1016/0014-5793(87)80393-9; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MONCK JR, 1990, P NATL ACAD SCI USA, V87, P7804, DOI 10.1073/pnas.87.20.7804; MONCK JR, IN PRESS J CELL BIOL; MOUSLI M, 1989, J PHARMACOL EXP THER, V250, P329; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PENNER R, 1987, BIOSCIENCE REP, V7, P313, DOI 10.1007/BF01121453; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	33	166	167	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					270	273		10.1038/360270a0	http://dx.doi.org/10.1038/360270a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1331813				2022-12-28	WOS:A1992JY96000056
J	RUDNICKI, MA; BRAUN, T; HINUMA, S; JAENISCH, R				RUDNICKI, MA; BRAUN, T; HINUMA, S; JAENISCH, R			INACTIVATION OF MYOD IN MICE LEADS TO UP-REGULATION OF THE MYOGENIC HLH GENE MYF-5 AND RESULTS IN APPARENTLY NORMAL MUSCLE DEVELOPMENT	CELL			English	Article							EMBRYONAL CARCINOMA-CELLS; CREATINE-KINASE GENE; MOUSE EMBRYO; ACTIN GENE; EXPRESSION; FAMILY; DIFFERENTIATION; MEMBER; IDENTIFICATION; ENHANCER	The myogenic basic HLH transcription factor family of genes, composed of MyoD, myogenin, Myf-5, and Myf-6, are thought to regulate skeletal muscle differentiation. To understand the role of MyoD in myogenesis, we have introduced a null mutation of MyoD into the germline of mice. Surprisingly, mice lacking MyoD are viable and fertile. Histological examination of skeletal muscle failed to reveal any morphological abnormalities in these mice. Furthermore, Northern analysis revealed normal levels of skeletal muscle-specific mRNAs. Significantly, Myf-5 mRNA levels are elevated in postnatal mutant mice. Normally, Myf-5 expression becomes markedly reduced at day 12 of gestation when MyoD mRNA first appears. This suggests that Myf-5 expression is repressed by MyoD. Our results indicate that MyoD is dispensable for skeletal muscle development in mice, revealing some degree of functional redundancy in the control of the skeletal myogenic developmental program.	MIT, WHITEHEAD INST, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; UNIV HAMBURG, SCH MED, DEPT TOXICOL, W-2000 HAMBURG 13, GERMANY	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Hamburg			Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804	NCI NIH HHS [5R35 CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bancroft JD, 1990, THEORY PRACTICE HIST; BLOCK NE, 1992, MOL CELL BIOL, V12, P2484, DOI 10.1128/MCB.12.6.2484; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Maniatis T., 1982, MOL CLONING; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MILLER JB, 1991, NEUROMUSCULAR DISORD, V61, P7; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; RUDNICKI MA, 1989, DEVELOPMENT, V107, P361; RUDNICKI MA, 1988, MOL CELL BIOL, V8, P406, DOI 10.1128/MCB.8.1.406; RUDNICKI MA, 1991, GENOME ANAL, V2, P13; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	48	813	848	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					383	390		10.1016/0092-8674(92)90508-A	http://dx.doi.org/10.1016/0092-8674(92)90508-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1330322				2022-12-28	WOS:A1992JW43500005
J	LEANING, MS; GALLIVAN, S; NEWLANDS, ES; DENT, J; BRAMPTON, M; SMITH, DB; BAGSHAWE, KD				LEANING, MS; GALLIVAN, S; NEWLANDS, ES; DENT, J; BRAMPTON, M; SMITH, DB; BAGSHAWE, KD			COMPUTER-SYSTEM FOR ASSISTING WITH CLINICAL INTERPRETATION OF TUMOR-MARKER DATA	BRITISH MEDICAL JOURNAL			English	Article							HUMAN CHORIONIC-GONADOTROPIN; GERM-CELL TUMORS; HALF-LIFE; PROGNOSTIC-SIGNIFICANCE; INDUCTION CHEMOTHERAPY; OVARIAN-CARCINOMA; CANCER; CA-125; SURVIVAL	Objective-To design and evaluate a computer advisory system for the treatment of gestational trophoblastic tumour. Design-A comparison of clinicians' treatment decisions with those of the computer system. Two datasets were used: one to calibrate the system and one to independently evaluate it. Setting-Department of medical oncology. Patients-Computerised records of 290 patients with low risk gestational trophoblastic tumour for whom the advisory system could predict the adequacy of treatment. The calibration set comprised patients admitted during 1979-86 (227) and the test set patients during 1986-89 (63). Main outcome measures-The system's accuracy in predicting need to change treatment compared with clinicians' actions. The mean time faster that the system was in predicting the need to change treatment. Results-On the calibration dataset the system was 94% (164/174) accurate in predicting patients whose treatment was adequate, recommending change when none occurred in only 10 (6%) patients. In patients whose treatment was changed the system recommended change earlier than clinicians in 39/53 cases (74%), with a mean time advantage of 14.9 (SE 2.02) days. On the test dataset the system had an accuracy of 91% (31/34) in predicting treatment adequacy and a false positive rate of 9% (3/34). The system recommended change earlier than clinicians in 22/29 cases (76%), with a mean time advantage of 12.5 (2.22) days. Conclusions-The computer advisory system could improve patient management by reducing the time spent receiving ineffective treatment. This has implications for both patient time and clinical costs.	CHARING CROSS HOSP,DEPT MED ONCOL,LONDON W6 8RF,ENGLAND	Imperial College London	LEANING, MS (corresponding author), UNIV LONDON UNIV COLL,DEPT STAT SCI,CLIN OPERAT RES UNIT,LONDON WC1E 6BT,ENGLAND.							ARMITAGE P, 1987, STATISTICAL METHODS; BAGSHAWE KD, 1989, BRIT J OBSTET GYNAEC, V96, P795, DOI 10.1111/j.1471-0528.1989.tb03318.x; BAGSHAWE KD, 1976, CANCER, V38, P1373, DOI 10.1002/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO;2-E; BARTELS C, 1987, P ECCO, P179; HAWKINS RE, 1989, BRIT J OBSTET GYNAEC, V96, P1395, DOI 10.1111/j.1471-0528.1989.tb06301.x; HUNTER VJ, 1990, AM J OBSTET GYNECOL, V163, P1164, DOI 10.1016/0002-9378(90)90680-6; LANGE PH, 1982, J UROLOGY, V128, P708, DOI 10.1016/S0022-5347(17)53149-3; PICOZZI V, 1985, P AM SOC CLIN ONCOL, V910, P102; PICOZZI VJ, 1984, ANN INTERN MED, V100, P183, DOI 10.7326/0003-4819-100-2-183; RUSTIN GJS, 1989, J CLIN ONCOL, V7, P1667, DOI 10.1200/JCO.1989.7.11.1667; TONER GC, 1990, CANCER RES, V50, P5904; VANDERBURG MEL, 1988, GYNECOL ONCOL, V30, P307, DOI 10.1016/0090-8258(88)90244-2; VOGELZANG NJ, 1982, CANCER RES, V42, P4855	13	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					804	807		10.1136/bmj.305.6857.804	http://dx.doi.org/10.1136/bmj.305.6857.804			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1330140	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JT25600021
J	DAMICO, G; GENTILE, MG; MANNA, G; FELLIN, G; CICERI, R; COFANO, F; PETRINI, C; LAVARDA, F; PEROLINI, S; PORRINI, M				DAMICO, G; GENTILE, MG; MANNA, G; FELLIN, G; CICERI, R; COFANO, F; PETRINI, C; LAVARDA, F; PEROLINI, S; PORRINI, M			EFFECT OF VEGETARIAN SOY DIET ON HYPERLIPEMIA IN NEPHROTIC SYNDROME	LANCET			English	Article							RENAL-DISEASE; HORMONAL RESPONSES; PROTEIN INTAKE; CHOLESTEROL; PLASMA; LIPOPROTEINS; PRESSURE; LIPIDS	Nephrotic patients with persistent proteinuria also have various lipid abnormalities that may promote atherosclerosis and more rapid progression of renal disease. We aimed to find out whether dietary manipulation can correct the hyperlipidaemia found in these patients. After a baseline control period of 8 weeks on their usual diets, 20 untreated patients with chronic glomerular diseases, stable long-lasting severe proteinuria (5.9 [SD 3.4] g/24 h) and hyperlipidaemia (mean serum cholesterol 8.69 [3.34] mmol/l) ate a vegetarian soy diet for 8 weeks. The diet was low in fat (28% of total calories) and protein (0.71 [0.36] g/kg ideal body weight daily), cholesterol free, and rich in monounsaturated and polyunsaturated fatty acids (polyunsaturated/saturated ratio 2.5) and in fibre (40 g/day). After the diet period the patients resumed their usual diets for 8 weeks (washout period). During the soy-diet period there were significant falls in serum cholesterol (total, low-density lipoprotein, and high-density lipoprotein) and apolipoproteins A and B, but serum triglyceride concentrations did not change. Urinary protein excretion fell significantly. The concentrations of all lipid fractions and the amount of proteinuria tended to return towards baseline values during the washout period. We do not know whether the favourable effect of this dietary manipulation on proteinuria was due to the qualitative or quantitative modifications of dietary protein intake or was a direct consequence of the manipulation of dietary lipid intake.	SAN CARLO HOSP,CLIN PATHOL LAB,I-20153 MILAN,ITALY; UNIV MILAN,DEPT FOOD SCI & MICROBIOL,I-20122 MILAN,ITALY	San Carlo Borromeo Hospital; University of Milan	DAMICO, G (corresponding author), SAN CARLO HOSP,DIV NEPHROL,VIA PIO II3,I-20153 MILAN,ITALY.		porrini, marisa/AAF-6788-2021	porrini, marisa/0000-0003-2693-3311				APPEL GB, 1985, NEW ENGL J MED, V312, P1544, DOI 10.1056/NEJM198506133122404; BARCELLI UO, 1991, KIDNEY INT, V39, pS57; BRUSSAARD JH, 1982, ATHEROSCLEROSIS, V42, P205, DOI 10.1016/0021-9150(82)90151-4; CONNOR WE, 1990, NEW ENGL J MED, V322, P193, DOI 10.1056/NEJM199001183220309; DAMICO G, 1991, CLIN NEPHROL, V6, P237; DIAMOND JR, 1988, KIDNEY INT, V33, P917, DOI 10.1038/ki.1988.87; FEEHALLY J, 1988, NEPHRON, V50, P247, DOI 10.1159/000185167; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; KASISKE BL, 1990, AM J KIDNEY DIS, V15, P8, DOI 10.1016/S0272-6386(12)80586-5; KAYSEN GA, 1989, J CLIN INVEST, V83, P1623, DOI 10.1172/JCI114060; KAYSEN GA, 1986, KIDNEY INT, V29, P572, DOI 10.1038/ki.1986.36; KAYSEN GA, 1991, AM J PHYSIOL, V260, pF177, DOI 10.1152/ajprenal.1991.260.2.F177; KEANE WF, 1990, NEW ENGL J MED, V323, P603, DOI 10.1056/NEJM199008303230910; KEANE WF, 1991, KIDNEY INT, V39, pS41; KESTIN M, 1990, AM J CLIN NUTR, V51, P1028, DOI 10.1093/ajcn/51.6.1028; KLAHR S, 1983, KIDNEY INT, V24, P579, DOI 10.1038/ki.1983.197; KONTESSIS P, 1990, KIDNEY INT, V38, P136, DOI 10.1038/ki.1990.178; LEVEY AS, 1989, KIDNEY INT, V36, pS73; MALLICK NP, 1981, NEPHRON, V27, P54, DOI 10.1159/000182024; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MEINERTZ H, 1989, AM J CLIN NUTR, V50, P786, DOI 10.1093/ajcn/50.4.786; MOORHEAD JF, 1989, AM J MED, V87, P12; NESTEL P, 1983, ARTERIOSCLEROSIS, V3, P132, DOI 10.1161/01.ATV.3.2.132; REMUZZI A, 1991, AM J KIDNEY DIS, V17, P317, DOI 10.1016/S0272-6386(12)80481-1; ROSENBERG ME, 1987, AM J PHYSIOL, V253, pF1083, DOI 10.1152/ajprenal.1987.253.6.F1083; SACKS FM, 1975, NEW ENGL J MED, V292, P1148, DOI 10.1056/NEJM197505292922203; SCHMITZ PG, 1989, SEMIN NEPHROL, V9, P354; SCHREINER GF, 1991, KIDNEY INT, V39, pS49; SHAEFER EJ, 1981, AM J CLIN NUTR, V34, P1758	29	92	93	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1131	1134		10.1016/0140-6736(92)90731-H	http://dx.doi.org/10.1016/0140-6736(92)90731-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349366				2022-12-28	WOS:A1992HT23600003
J	CHANG, TW				CHANG, TW			ASPIRIN FOR CEREBRAL TRANSIENT ISCHEMIC ATTACKS OR MINOR ISCHEMIC STROKES	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							CONTROLLED TRIAL; PREVENTION				CHANG, TW (corresponding author), TUFTS UNIV,SCH MED,BOSTON,MA 02111, USA.							BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FIELDS WS, 1978, STROKE, V9, P309, DOI 10.1161/01.STR.9.4.309; LEKSTROM A, 1991, MEDICINE, V70, P161; REUTHER R, 1978, ACETYLSALICYLIC ACID, V4, P97; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; UK-TIA Study Group, 1988, BMJ, V296, P316; 1987, STROKE, V18, P325	9	1	1	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1288	1289						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1343814				2022-12-28	WOS:A1992HR44700012
J	LLINAS, R; SUGIMORI, M; SILVER, RB				LLINAS, R; SUGIMORI, M; SILVER, RB			MICRODOMAINS OF HIGH CALCIUM-CONCENTRATION IN A PRESYNAPTIC TERMINAL	SCIENCE			English	Article							SQUID GIANT SYNAPSE; CENTRAL INHIBITORY SYNAPSE; TRANSMITTER RELEASE; CHANNELS; TRANSMISSION; AEQUORINS; INFLUX	Increases in intracellular calcium concentration are required for the release of neurotransmitter from presynaptic terminals in all neurons. However, the mechanism by which calcium exerts its effect is not known. A low-sensitivity calcium-dependent photoprotein (n-aequorin-J) was injected into the presynaptic terminal of the giant squid synapse to selectively detect high calcium concentration microdomains. During transmitter release, light emission occurred at specific points or quantum emission domains that remained in the same place during protracted stimulation. Intracellular calcium concentration microdomains on the order of 200 to 300 micromolar occur against the cytoplasmic surface of the plasmalemma during transmitter secretion, supporting the view that the synaptic vesicular fusion responsible for transmitter release is triggered by the activation of a low-affinity calcium-binding site at the active zone.	MARINE BIOL LAB,WOODS HOLE,MA 02543; CORNELL UNIV,DEPT PHYSIOL,ITHACA,NY 14853; CORNELL UNIV,PHYSIOL SECT,ITHACA,NY 14853	Marine Biological Laboratory - Woods Hole; Cornell University; Cornell University	LLINAS, R (corresponding author), NYU MED CTR,DEPT PHYSIOL & BIOPHYS,550 1ST AVE,NEW YORK,NY 10016, USA.			Sugimori, Mutsuyuki/0000-0002-2908-3167	NINDS NIH HHS [NS13742] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS013742] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; KATZ B, 1969, SHERRINGTON LECTURES, V10; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, BIOL BULL, V181, P316, DOI 10.1086/BBLv181n2p316; LLINAS R, 1972, SCIENCE, V176, P1127, DOI 10.1126/science.176.4039.1127; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; LLINAS R, 1977, SOC NEUROSCIENCE S, V2, P139; PUMPLIN DW, 1978, NEUROSCIENCE, V3, P685, DOI 10.1016/0306-4522(78)90065-9; PUMPLIN DW, 1981, P NATL ACAD SCI-BIOL, V78, P7210, DOI 10.1073/pnas.78.11.7210; SHIMOMURA O, 1989, BIOCHEM J, V261, P913, DOI 10.1042/bj2610913; SHIMOMURA O, 1990, BIOCHEM J, V270, P309, DOI 10.1042/bj2700309; SILVER RB, 1989, DEV BIOL, V131, P11; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; SIMON SM, 1984, BIOPHYS J, V45, pA264; TRILLER A, 1982, J NEUROPHYSIOL, V48, P708, DOI 10.1152/jn.1982.48.3.708; YOUNG GPH, 1984, P NATL ACAD SCI-BIOL, V81, P5155, DOI 10.1073/pnas.81.16.5155; YOUNG JZ, 1973, BRAIN RES, V57, P457, DOI 10.1016/0006-8993(73)90149-2; ZUCKER RS, 1986, P NATL ACAD SCI USA, V83, P3032, DOI 10.1073/pnas.83.9.3032	20	749	759	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					677	679		10.1126/science.1350109	http://dx.doi.org/10.1126/science.1350109			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1350109				2022-12-28	WOS:A1992HR18500037
J	HANKS, GW; JUSTINS, DM				HANKS, GW; JUSTINS, DM			CANCER PAIN - MANAGEMENT	LANCET			English	Article							OPIOID ANALGESICS; PLEXUS BLOCK; BONE PAIN		ST THOMAS HOSP,CTR PAIN MANAGEMENT,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	HANKS, GW (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT PALLIAT MED,LONDON SE1 7EH,ENGLAND.							ARNER S, 1985, ACTA ANAESTH SCAND, V29, P32, DOI 10.1111/j.1399-6576.1985.tb02155.x; ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; BEAVER WT, 1981, ARCH INTERN MED, V141, P293, DOI 10.1001/archinte.141.3.293; BOWSHER D, 1991, BRIT MED BULL, V47, P644, DOI 10.1093/oxfordjournals.bmb.a072498; BRUERA E, 1985, CANCER TREAT REP, V69, P751; DUNLOP RJ, 1991, LANCET, V337, P1347; FERRERBRECHNER T, 1989, CANCER, V63, P2343, DOI 10.1002/1097-0142(19890601)63:11<2343::AID-CNCR2820631145>3.0.CO;2-C; FILSHIE J, 1985, EUR J SURG ONCOL, V11, P389; GALASKO CSB, 1988, CANCER SURV, V7, P102; GOURLAY GK, 1991, PAIN, V47, P135, DOI 10.1016/0304-3959(91)90196-5; HANKS GW, 1984, LANCET, V1, P1477; HANKS GW, 1989, CANCER, V63, P2378, DOI 10.1002/1097-0142(19890601)63:11<2378::AID-CNCR2820631150>3.0.CO;2-8; HANKS GW, 1988, CANCER SURV, V7, P87; HANKS GW, 1991, BRIT MED BULL, V47, P718, DOI 10.1093/oxfordjournals.bmb.a072503; HANKS GW, 1987, PALLIATIVE MED, V1, P1; HOGAN Q, 1991, PAIN, V46, P271, DOI 10.1016/0304-3959(91)90110-J; HOSKIN PJ, 1988, CANCER SURV, V7, P69; MAX MB, 1985, CLIN PHARMACOL THER, V38, P631, DOI 10.1038/clpt.1985.237; MCNAMARA P, 1991, Palliative Medicine, V5, P244, DOI 10.1177/026921639100500310; MILES J, 1989, TXB PAIN, P856; MORGAN M, 1989, BRIT J ANAESTH, V63, P165, DOI 10.1093/bja/63.2.165; PAYNE R, 1987, MED CLIN N AM, V71, P313, DOI 10.1016/S0025-7125(16)30873-2; PLANCARTE R, 1990, ANESTHESIOLOGY, V73, P236, DOI 10.1097/00000542-199008000-00008; Portenoy R.K., 1991, NEW PHARMACOTHERAPY, P393; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; PORTENOY RK, 1986, CANCER TREAT REP, V70, P575; SHARFMAN WH, 1990, PAIN, V41, P267, DOI 10.1016/0304-3959(90)90003-V; Tasker RR, 1990, PAIN SYNDROMES NEURO, P143; TWYCROSS RG, 1988, CANCER SURV, V7, P29; Twycross RG, 1983, SYMPTOM CONTROL FAR; VANHOLTENVERZANTVOORT AT, 1987, LANCET, V2, P983; VENTAFRIDDA V, 1987, CANCER, V59, P851; WALSH TD, 1982, NEW ENGL J MED, V306, P990; 1986, CANCER PAIN RELIEF	34	81	82	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1031	1036						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349061				2022-12-28	WOS:A1992HQ43500014
J	MACKIE, R; HUNTER, JAA; AITCHISON, TC; HOLE, D; MCLAREN, K; RANKIN, R; BLESSING, K; EVANS, AT; HUTCHEON, AW; JONES, DH; SOUTAR, DS; WATSON, ACH; CORNBLEET, MA; SMYTH, JF				MACKIE, R; HUNTER, JAA; AITCHISON, TC; HOLE, D; MCLAREN, K; RANKIN, R; BLESSING, K; EVANS, AT; HUTCHEON, AW; JONES, DH; SOUTAR, DS; WATSON, ACH; CORNBLEET, MA; SMYTH, JF			CUTANEOUS MALIGNANT-MELANOMA, SCOTLAND, 1979-89	LANCET			English	Article								The Scottish Melanoma Group (SMG) was established in 1979 to assess mortality from and incidence, features, pathological data, and management of cutaneous malignant melanoma in Scotland. Incidence during the first five years and five-year survival have already been reported. We now have data about incidence and mortality over eleven years in relation to anatomical site and pathological types. From 1979 to 1989, 1354 male and 2459 female patients with primary cutaneous malignant melanomas were first diagnosed in Scottish residents. The incidence rate per 100 000 population per year has increased from 3.4 in 1979 to 7.1 in 1989 for men, and from 6.6 to 10.4 for women. The overall increase over eleven years is 82% (7.4% per year). The greatest rates of increase are seen in lesions of the superficial spreading histogenetic type, arising on the female leg and the male trunk. Following public education programmes started in 1985, the proportion of all melanomas less than 1.5 mm thick has shown a sustained and significant increase. Mortality data for 1661 patients for whom a minimum of five-year follow-up is available shows five-year survival of 71.6% overall (77.6% for women, 58.7% for men). The survival advantage for women persists when appropriate statistical adjustment is made for thickness, ulceration, and histogenetic type. These data are useful in designing public education programmes aimed at both primary and secondary prevention of melanoma and in auditing changes in trends that might result from such education.	UNIV GLASGOW,DEPT STAT,GLASGOW G12 8QQ,SCOTLAND; UNIV EDINBURGH,DEPT DERMATOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT ONCOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; GREATER GLASGOW HLTH BOARD,CANC SURVEILLANCE UNIT,GLASGOW,SCOTLAND; RAIGMORE HOSP,DEPT PATHOL,INVERNESS,SCOTLAND; RAIGMORE HOSP,DEPT DERMATOL,INVERNESS,SCOTLAND; UNIV ABERDEEN,DEPT PATHOL,ABERDEEN AB9 1FX,SCOTLAND; NINEWELLS HOSP,DEPT PATHOL,DUNDEE,SCOTLAND; ABERDEEN ROYAL INFIRM,DEPT ONCOL,ABERDEEN AB9 2ZB,SCOTLAND; CANNIESBURN HOSP,DEPT PLAST SURG,GLASGOW G61 1QL,SCOTLAND	University of Glasgow; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Aberdeen; University of Dundee; University of Aberdeen	MACKIE, R (corresponding author), UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND.							ACKERMAN AB, 1980, HUM PATHOL, V11, P591, DOI 10.1016/S0046-8177(80)80069-4; CLARK WH, 1969, CANCER RES, V29, P705; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1970, ANAL BINARY DATA; DOHERTY VR, 1986, BRIT MED J, V292, P987, DOI 10.1136/bmj.292.6526.987; DOHERTY VR, 1988, BRIT MED J, V297, P388, DOI 10.1136/bmj.297.6645.388; MACKIE RM, 1985, LANCET, V2, P859; MACKIE RM, IN PRESS BR MED J; MAGNUS K, 1991, INT J CANCER, V47, P12, DOI 10.1002/ijc.2910470104; OSTERLIND A, 1988, APMIS, V96, P953, DOI 10.1111/j.1699-0463.1988.tb00968.x	10	145	146	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					971	975		10.1016/0140-6736(92)91539-K	http://dx.doi.org/10.1016/0140-6736(92)91539-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348807				2022-12-28	WOS:A1992HP03600012
J	GRAHAM, NMH; ZEGER, SL; PARK, LP; VERMUND, SH; DETELS, R; RINALDO, CR; PHAIR, JP				GRAHAM, NMH; ZEGER, SL; PARK, LP; VERMUND, SH; DETELS, R; RINALDO, CR; PHAIR, JP			THE EFFECTS ON SURVIVAL OF EARLY TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; PLACEBO-CONTROLLED TRIAL; MULTICENTER AIDS COHORT; HIV INFECTION; DOUBLE-BLIND; ZIDOVUDINE; EFFICACY; SAFETY; AZT	Background. Zidovudine has been shown to prolong survival in patients with the acquired immunodeficiency syndrome (AIDS) and, in persons with human immunodeficiency virus (HIV) infection but not AIDS, to delay the progression to AIDS. However, it is still uncertain whether treatment before the development of AIDS prolongs survival. Methods. We analyzed data from a cohort of 2162 high-risk men who were already seropositive for HIV type 1 (HIV-1) and 406 men who seroconverted from October 1986 through April 1991. There were 306 deaths. The probabilities of death were compared among men at similar stages of disease who began zidovudine therapy before the diagnosis of AIDS and among those who did not. Relative risks of death were calculated for each of five initial disease states on the basis of CD4+ cell counts and clinical symptoms and signs appearing over follow-up periods of 6, 12, 18, and 24 months. Adjustments were also made for the use of prophylaxis against Pneumocystis carinii pneumonia (PCP). Results. After we controlled for CD4+ cell count and symptoms, the use of zidovudine with or without PCP prophylaxis before the development of AIDS significantly reduced mortality in all follow-up periods. The relative risks of death were 0.43 (95 percent confidence interval, 0.23 to 0.78) at 6 months, 0.54 (95 percent confidence interval, 0.38 to 0.78) at 12 months, 0.59 (95 percent confidence interval, 0.44 to 0.79) at 18 months, and 0.67 (95 percent confidence interval, 0.52 to 0.86) at 24 months. After we adjusted for the effects of PCP prophylaxis, zidovudine alone significantly reduced mortality at 6, 12, and 18 months (relative risks, 0.45, 0.59, and 0.70, respectively), but not at 24 months (relative risk, 0.81). Among zidovudine users, those who also used PCP prophylaxis before the development of AIDS had significantly lower mortality at 18 and 24 months than those who did not (relative risks, 0.62 and 0.60, respectively). Conclusions. The results of this study support the hypothesis that in HIV-1 infection, early treatment with zidovudine and PCP prophylaxis improves survival in addition to slowing the progression to AIDS.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; NIAID,DIV AIDS,BETHESDA,MD 20892; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024; UNIV PITTSBURGH,SCH PUBL HLTH,DEPT INFECT DIS & MICROBIOL,PITTSBURGH,PA 15260; NORTHWESTERN UNIV,HOWARD BROWN MEM CLIN,CHICAGO,IL 60611; NORTHWESTERN UNIV,DEPT MED,CHICAGO,IL 60611	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; Northwestern University	GRAHAM, NMH (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY,BALTIMORE,MD 21205, USA.		Vermund, Sten/AAD-3592-2020	Vermund, Sten/0000-0001-7289-8698; Zeger, Scott/0000-0001-8907-1603	PHS HHS [N01-A1-32535, N01-A1-72676, N01-A1-72634] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHISSON RE, 1991, 7TH INT C AIDS FLOR; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GRAHAM MNH, 1991, LANCET, V338, P265; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; SWANSON CE, 1990, AIDS, V4, P749, DOI 10.1097/00002030-199008000-00006; Vermund Sten H., 1990, Annals of Epidemiology, V1, P141, DOI 10.1016/1047-2797(90)90005-D; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1989, LANCET, V1, P415	18	225	227	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1992	326	16					1037	1042		10.1056/NEJM199204163261601	http://dx.doi.org/10.1056/NEJM199204163261601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN738	1347907				2022-12-28	WOS:A1992HN73800001
J	PELES, E; BACUS, SS; KOSKI, RA; LU, HS; WEN, DZ; OGDEN, SG; BENLEVY, R; YARDEN, Y				PELES, E; BACUS, SS; KOSKI, RA; LU, HS; WEN, DZ; OGDEN, SG; BENLEVY, R; YARDEN, Y			ISOLATION OF THE NEU/HER-2 STIMULATORY LIGAND - A 44KD GLYCOPROTEIN THAT INDUCES DIFFERENTIATION OF MAMMARY-TUMOR CELLS	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CARCINOMA; FACTOR-RECEPTOR; PROTO-ONCOGENE; NEU ONCOGENE; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; C-ERBB-2 ONCOGENE; LIVING CELLS; GENE	The neu/HER-2 proto-oncogene (also called erbB-2) encodes a transmembrane glycoprotein related to the epidermal growth factor receptor. We have purified to homogeneity a 44 kd glycoprotein from the medium of ras-transformed cells that stimulates phosphorylation of the Neu protein and retains activity after elution from the polyacrylamide gel. The protein is active at picomolar concentrations and displays a novel N-terminal sequence. Cross-linking experiments with radiolabeled p44 result in specific labeling of Neu, indicating that p44 is a ligand for Neu or a related receptor. The purified protein induces phenotypic differentiation of cultured human breast cancer cells, including altered morphology and synthesis of milk components. This is accompanied by an increase in nuclear area, inhibition of cell growth (probably by cell cycle arrest at the late S or the G2/M phases), and induction of DNA polyploidy. We propose the name Neu differentiation factor (NDF) for p44.	CELL ANAL SYST INC,ELMHURST,IL 60126; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Amgen	PELES, E (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		YARDEN, YOSEF/K-1467-2012	Peles, Elior/0000-0002-3325-0597	NATIONAL CANCER INSTITUTE [R43CA050843, R44CA050843, R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51712, CA-50843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BACUS SS, 1992, IN PRESS CANCER RES; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; COCHET C, 1988, J BIOL CHEM, V263, P3290; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HUANG SS, 1990, J BIOL CHEM, V265, P3340; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNKAPILLER MW, 1986, MICROCHARACTERIZATIO, P223; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KING CR, 1989, ONCOGENE, V4, P13; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1981, CANCER RES, V41, P2842; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAVERNA D, 1991, GROWTH DIFF, V2, P145; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TSUDA H, 1989, CANCER RES, V49, P3104; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P67; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; YARDEN Y, 1990, MOL IMMUNOL, V27, P1319, DOI 10.1016/0161-5890(90)90037-Z; ZHOU DJ, 1987, CANCER RES, V47, P6123	62	526	566	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					205	216		10.1016/0092-8674(92)90131-U	http://dx.doi.org/10.1016/0092-8674(92)90131-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1348215				2022-12-28	WOS:A1992HM44500019
J	BAROR, O; BLIMKIE, CJR; HAY, JA; MACDOUGALL, JD; WARD, DS; WILSON, WM				BAROR, O; BLIMKIE, CJR; HAY, JA; MACDOUGALL, JD; WARD, DS; WILSON, WM			VOLUNTARY DEHYDRATION AND HEAT INTOLERANCE IN CYSTIC-FIBROSIS	LANCET			English	Article							THIRST	Although exercise may be beneficial in cystic fibrosis (CF), patients' low tolerance to climatic heat stress means that physical exertion can increase morbidity and mortality. We postulated that the high salt content of CF patients' sweat and the consequent absence of body-fluid hyperosmolality during -a long episode of sweating might deprive such patients of a thirst stimulus. Eight children with CF (four boys, four girls, aged 9.5 - 14.1 years) and eight controls, matched for age and sex, attended two randomly ordered sessions of exercise (cycling) in a chamber at 31-33-degrees-C, relative humidity 43-47%. 20 min bouts of exercise (at 45% of predetermined maximum oxygen uptake) were interspersed with 25 min rest periods. At one session, chilled water was given every 15-20 min to replace fluid lost, at the other, drinking was guided by the child's thirst. At the thirst-guided session, CF patients drank much less than the controls did (0.80% vs 1.73% initial body weight) and lost twice as much fluid (1.57% vs 0.78% initial. body weight). The recovery of heart rate after exercise was slower in CF patients, but there were no other signs of heat strain. The groups did not differ in any variable during the forced drinking session. We conclude that children with CF underestimate their fluid needs and undergo excessive dehydration during extended exposure to hot conditions.	MCMASTER UNIV, DEPT PEDIAT, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, SCH PHYS EDUC, HUMAN PHYSIOL LAB, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, CYST FIBROSIS CLIN, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University; McMaster University; McMaster University	BAROR, O (corresponding author), CHEDOKE MCMASTER HOSP, DEPT PEDIAT, CTR CHILDRENS EXERCISE & NUTR, EVEL 4, HAMILTON L8N 3Z5, ONTARIO, CANADA.			Ward, Dianne Stanton/0000-0001-6389-0168				ALLEN TE, 1977, MED SCI SPORT EXER, V9, P159; BAROR O, 1980, J APPL PHYSIOL, V48, P104, DOI 10.1152/jappl.1980.48.1.104; BAROR O, 1983, PEDIATRIC SPORTS MED, P343; CERNY FJ, 1989, PEDIATR EXERC SCI, V1, P116; DANKS DM, 1962, BRIT MED J, P287, DOI 10.1136/bmj.2.5300.287; FITZSIMONS JT, 1976, KIDNEY INT, V10, P3, DOI 10.1038/ki.1976.74; KESSLER WR, 1951, PEDIATRICS, V8, P648; LEITHEAD CS, 1964, HEAT STRESS HEAT DIS, P143; NOSE H, 1985, AM J PHYSIOL, V249, pR166, DOI 10.1152/ajpregu.1985.249.2.R166; NOSE H, 1988, J APPL PHYSIOL, V65, P325, DOI 10.1152/jappl.1988.65.1.325; ORENSTEIN DM, 1983, PEDIATR RES, V17, P267, DOI 10.1203/00006450-198304000-00007; ORENSTEIN DM, 1984, J APPL PHYSIOL, V57, P408, DOI 10.1152/jappl.1984.57.2.408; ORENSTEIN DM, 1985, SCAND J SPORTS SCI, V7, P29; Rolls B.J., 1982, THIRST; ROTHSTEIN A, 1947, PHYSL MAN DESERT, P251; SALTIN B, 1964, J APPL PHYSIOL, V19, P1125, DOI 10.1152/jappl.1964.19.6.1125; STANGHELLE JK, 1988, INT J SPORTS MED, V9, P6; STANGHELLE JK, 1988, INT J SPORTS MED, V9, P45; STRICKER EM, 1988, AM SCI, V76, P261; WILLIAMS AJ, 1976, BRIT MED J, V2, P297, DOI 10.1136/bmj.2.6030.297	20	68	68	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	1992	339	8795					696	699		10.1016/0140-6736(92)90597-V	http://dx.doi.org/10.1016/0140-6736(92)90597-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347582				2022-12-28	WOS:A1992HK32000002
J	EHRENFORTH, S; KREUZ, W; SCHARRER, I; LINDE, R; FUNK, M; GUNGOR, T; KRACKHARDT, B; KORNHUBER, B				EHRENFORTH, S; KREUZ, W; SCHARRER, I; LINDE, R; FUNK, M; GUNGOR, T; KRACKHARDT, B; KORNHUBER, B			INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS	LANCET			English	Article							HEMOPHILIA-A; CLASSIC HEMOPHILIA; LIFE EXPECTANCY; UNITED-KINGDOM; ANTIBODIES; FINLAND	The development of factor VIII:C inhibitors remains one of the most serious complications of repeated transfusion in patients with haemophilia A. The proportion of patients affected has been reported to range from 3.6% to 25%, but these figures have been derived mainly from retrospective data and from total numbers of known haemophiliacs instead of number at true risk. The assessment here is based on a prospective study, started in 1976, on the incidence of inhibitor development in haemophiliacs born after 1970 whose FVIII or FIX activity was 5% or less, and who had received replacement therapy at least once. 46 of 63 children with haemophilia A and 13 of 17 with haemophilia B fulfilled the enrolment criteria. Inhibitors developed only in haemophilia A patients who had previously been treated with FVIII products-inhibitor concentrations were high in 12 and low in 3. Inhibitors developed in 24% (15/63) of all haemophilia A patients, and in 52% (14/27) of those with severe disease. The incidence of inhibitor development for all haemophilia patients was 39.1 per 1000 patient-years of observation. All inhibitors were first detected when patients were aged 0.08-5.2 years. The cumulative risk was 33% at age 6 years. The findings indicate that previous reports have underestimated the risk of acquiring FVIII inhibitors. Prospective, standardised studies, especially in children, are needed for the assessment of the true risk of this complication.	UNIV HOSP FRANKFURT, DEPT ANGIOL, CTR INTERNAL MED, FRANKFURT, GERMANY	Goethe University Frankfurt; Goethe University Frankfurt Hospital	EHRENFORTH, S (corresponding author), UNIV HOSP FRANKFURT, DEPT HAEMATOL & ONCOL, CTR PAEDIAT, THEODOR STERN KAI 7, W-6000 FRANKFURT, GERMANY.		Scharrer, Inge/N-2999-2013	Gungor, Tayfun/0000-0002-3261-1186				ALLAIN JP, 1976, BLOOD, V47, P973; BIGGS R, 1974, BRIT J HAEMATOL, V26, P313, DOI 10.1111/j.1365-2141.1974.tb00476.x; BLOOM AL, 1991, THROMB HAEMOSTASIS, V66, P166; BRINKHOUS KM, 1972, THROMB DIATH HAEMO, V51, P315; Gill FM, 1984, FACTOR 8 INHIBITORS, P19; IKKALA E, 1982, BRIT J HAEMATOL, V52, P7, DOI 10.1111/j.1365-2141.1982.tb03856.x; IKKALA E, 1971, SCAND J HAEMATOL, V8, P16; KASPER CK, 1973, THROMB DIATH HAEMOST, V30, P263, DOI 10.1055/s-0038-1649073; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KESTEVEN PJ, 1984, THROMB HAEMOSTASIS, V52, P50; KREUZ W, 1991, ANN HEMATOL, V62, pA46; LANGDELL RD, 1953, J LAB CLIN MED, V41, P637; LARSSON SA, 1985, BRIT J HAEMATOL, V59, P593, DOI 10.1111/j.1365-2141.1985.tb07353.x; MCMILLAN CW, 1988, BLOOD, V71, P344; RASI V, 1990, BRIT J HAEMATOL, V76, P369, DOI 10.1111/j.1365-2141.1990.tb06370.x; RIZZA CR, 1983, BRIT MED J, V286, P929, DOI 10.1136/bmj.286.6369.929; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; RUGGERI ZM, 1977, WORKSHOP INHIBITORS, P45; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; SCHWARZINGER I, 1987, AM J HEMATOL, V24, P241, DOI 10.1002/ajh.2830240303; SEREMETIS S, 1991, THROMB HAEMOSTASIS, V65, P1160; SHAPIRO S S, 1975, Seminars in Thrombosis and Hemostasis, V1, P336; SHAPIRO SS, 1984, SCAND J HAEMATOL, V33, P181; SHAPIRO SS, 1979, CLIN HAEMATOL, V8, P207; STENBJERG S, 1984, THROMB RES, V34, P533, DOI 10.1016/0049-3848(84)90257-3; STRAUSS HS, 1969, NEW ENGL J MED, V281, P866, DOI 10.1056/NEJM196910162811603	26	517	527	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1992	339	8793					594	598		10.1016/0140-6736(92)90874-3	http://dx.doi.org/10.1016/0140-6736(92)90874-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347102				2022-12-28	WOS:A1992HH07500012
J	VANTRAPPEN, G; DECRAMER, M; HARLET, R				VANTRAPPEN, G; DECRAMER, M; HARLET, R			HIGH-FREQUENCY DIAPHRAGMATIC FLUTTER - SYMPTOMS AND TREATMENT BY CARBAMAZEPINE	LANCET			English	Article								Classic diaphragmatic flutter, a rare disorder associated with dyspnoea, thoracic or abdominal wall pain, and epigastric pulsations, is caused by involuntary contractions of the diaphragm with a frequency of 0.5-8.0 Hz. We have seen three patients with diaphragmatic flutter of higher frequency not associated with respiratory disease. The patients presented with longstanding oesophageal belching, hiccups, and retching, respectively. The diagnosis was established by the presence on electromyography of the diaphragm and scalene and parasternal intercostal muscles of repetitive discharges of 9-15 Hz. Spirographic tracings, especially those of volume or flow vs time, showed similar high-frequency oscillations superimposed on tidal respiratory movements. Treatment with carbamazepine 200-400 mg three times daily led to disappearance or great improvement of flutter and clinical symptoms in all three patients. The phenomenon was not seen in other patients with chronic hiccups or oesophageal belching or in patients without these symptoms who had undergone electromyography or spirography for other reasons. Thus, high-frequency diaphragmatic flutter seems to be a new disease entity. The response to carbamazepine, which suggests that the flutter causes the symptoms, requires further study.	UNIV HOSP LEUVEN, DEPT MED, DIV GASTROENTEROL, LOUVAIN, BELGIUM; UNIV HOSP LEUVEN, DEPT MED, DIV PNEUMOL, LOUVAIN, BELGIUM	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven	VANTRAPPEN, G (corresponding author), UNIV ZIEKENHUIS GASTHUISBERG, DEPT MED, HERESTR 49, B-3000 LOUVAIN, BELGIUM.							DAVIS J N, 1970, Brain Behavior and Evolution, V93, P851, DOI 10.1093/brain/93.4.851; LEEUWENHOEK A, 1973, NEW ENGL J MED, V289, P1390; MONGES H, 1974, DISEASES ESOPHAGUS, P410; PORTER WB, 1963, JAMA-J AM MED ASSOC, V106, P992; RIGATTO M, 1962, AM J MED, V32, P103, DOI 10.1016/0002-9343(62)90186-9; VANTRAPPEN G, 1977, J CLIN INVEST, V59, P1158, DOI 10.1172/JCI108740; VANTRAPPEN G, 1986, DIGEST DIS SCI, V31, pS5	7	20	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 1	1992	339	8788					265	267		10.1016/0140-6736(92)91331-2	http://dx.doi.org/10.1016/0140-6736(92)91331-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346281				2022-12-28	WOS:A1992HB52900003
J	CHEN, LP; ASHE, S; BRADY, WA; HELLSTROM, I; HELLSTROM, KE; LEDBETTER, JA; MCGOWAN, P; LINSLEY, PS				CHEN, LP; ASHE, S; BRADY, WA; HELLSTROM, I; HELLSTROM, KE; LEDBETTER, JA; MCGOWAN, P; LINSLEY, PS			COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4	CELL			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-CELLS; INTERLEUKIN-2 PRODUCTION; GENE-TRANSFER; ANTIGEN; ACTIVATION; RECEPTOR; SIGNAL; TUMORIGENICITY; RECOGNITION	Interaction of the B7 molecule on antigen-presenting cells with its receptors CD28 and CTLA-4 on T cells provides costimulatory signals for T cell activation. We have studied the effects of B7 on antitumor immunity to a murine melanoma that expresses a rejection antigen associated with the E7 gene product of human papillomavirus 16. While this E7+ tumor grows progressively in immunocompetent hosts, cotransfection of its cells with B7 led to tumor regression by a B7-dependent immune response mediated by CD8+ cytolytic T lymphocytes. The immune response induced by E7+B7+ tumor cells also caused regression of E7+B7-tumors at distant sites and was curative for established E7+B7- micrometastases. Our findings suggest that increasing T cell costimulation through the CD28 and CTLA-4 receptors may have therapeutic usefulness for generating immunity against tumors expressing viral antigens.			CHEN, LP (corresponding author), BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA.							AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; AZUMA M, 1992, J IMMUNOL, V149, P1115; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BOON T, 1992, ADV CANCER RES, V58, P177, DOI 10.1016/S0065-230X(08)60295-X; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CHEN L, 1992, J IMMUNOL, V148, P2617; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; DAMLE NK, 1992, J IMMUNOL, V148, P1985; ELLIOTT BE, 1989, ADV CANCER RES, V53, P181; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FELL HP, 1992, J BIOL CHEM, V267, P15552; FIDLER IJ, 1981, CANCER RES, V41, P3266; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; GANSBACHER B, 1990, CANCER RES, V50, P7820; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hellstrom K., 1991, BIOL THERAPY CANCER, P35; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNG G, 1987, P NATL ACAD SCI USA, V84, P4611, DOI 10.1073/pnas.84.13.4611; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LEY V, 1991, EUR J IMMUNOL, V21, P851, DOI 10.1002/eji.1830210350; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NIJHUIS EWP, 1990, CANCER IMMUNOL IMMUN, V32, P245, DOI 10.1007/BF01741708; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; TAN R, 1992, IN PRESS J IMMUNOL; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; YANG L, 1992, CURR OPIN IMMUNOL, V4, P265, DOI 10.1016/0952-7915(92)90075-P	52	1038	1157	5	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1093	1102		10.1016/S0092-8674(05)80059-5	http://dx.doi.org/10.1016/S0092-8674(05)80059-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335364				2022-12-28	WOS:A1992KE60400005
J	JACOBS, HS; LOEFFLER, FE				JACOBS, HS; LOEFFLER, FE			REGULAR REVIEW - POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ESTROGEN REPLACEMENT; BREAST-CANCER; HIP FRACTURE; WOMEN; PREVENTION; MENOPAUSE; RISK; OSTEOPOROSIS; ESTRADIOL		ST MARYS HOSP, LONDON W2 1PG, ENGLAND	Imperial College London	JACOBS, HS (corresponding author), UCL, MIDDLESEX HOSP, SCH MED, LONDON W1N 8AA, ENGLAND.		Jacobs, Howard/A-9845-2009					[Anonymous], 1991, Osteoporos Int, V1, P114; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BARABAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63; BARRETTCONNOR E, 1992, BRIT MED BULL, V48, P345, DOI 10.1093/oxfordjournals.bmb.a072550; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BATES SK, 1991, J SOC OBSTETRICS GYN, V12, P9; BEWLEY S, 1992, LANCET, V339, P290, DOI 10.1016/0140-6736(92)91344-8; BOURNE T, 1990, LANCET, V335, P1470, DOI 10.1016/0140-6736(90)91505-5; Bush T L, 1991, Aging (Milano), V3, P3; CHRISTIANSEN C, 1991, BAILIERES CLIN OBSTE, V4, P785; COMPSTON JE, 1992, BRIT MED BULL, V48, P309, DOI 10.1093/oxfordjournals.bmb.a072549; COOPER C, 1992, TRENDS ENDOCRIN MET, V3, P224, DOI 10.1016/1043-2760(92)90032-V; CREASMAN WT, 1991, OBSTET GYNECOL, V77, P308, DOI 10.1097/00006250-199102000-00031; DAVIES MC, 1990, BRIT MED J, V301, P790, DOI 10.1136/bmj.301.6755.790; DEMPSTER DW, 1986, J BONE MINER RES, V1, P15; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUURSMA SA, 1992, GYNECOL ENDOCRINOL, V6, P205, DOI 10.3109/09513599209015556; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; FARISH E, 1991, BRIT MED J, V303, P694, DOI 10.1136/bmj.303.6804.694; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GANGAR KF, 1991, LANCET, V338, P839; GARNETT T, 1990, BRIT J OBSTET GYNAEC, V97, P917, DOI 10.1111/j.1471-0528.1990.tb02447.x; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; HELLER RF, 1978, BRIT MED J, V1, P472, DOI 10.1136/bmj.1.6111.472; JENSEN J, 1991, BAILLIERE CLIN OB GY, V5, P867, DOI 10.1016/S0950-3552(05)80294-9; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LEATHER AT, 1991, OBSTET GYNECOL, V78, P1008; LINDSAY R, 1980, BRIT MED J, V280, P1207, DOI 10.1136/bmj.280.6225.1207; LINDSAY R, 1991, BAILLIERE CLIN OB GY, V5, P837, DOI 10.1016/S0950-3552(05)80291-3; MANN RD, 1992, HORMONE REPLACEMENT; MANNING DL, 1992, RECENT ADV ENDOCRINO, V4, P133; MARSH MS, 1992, BRIT MED BULL, V48, P426, DOI 10.1093/oxfordjournals.bmb.a072554; MCFARLAND KF, 1989, AM HEART J, V117, P1209, DOI 10.1016/0002-8703(89)90398-0; MEADE TW, 1992, BRIT MED BULL, V48, P276, DOI 10.1093/oxfordjournals.bmb.a072548; MELTON LJ, 1991, BAILLIERE CLIN OB GY, V5, P785, DOI 10.1016/S0950-3552(05)80287-1; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; NICHOLSON RI, 1992, RECENT ADV ENDOCRINO, V4, P151; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; REES A, 1990, BRIT MED BULL, V46, P873, DOI 10.1093/oxfordjournals.bmb.a072444; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; SILLEROARENAS M, 1992, OBSTET GYNECOL, V79, P286; SLYPER AH, 1992, LANCET, V340, P289, DOI 10.1016/0140-6736(92)92368-P; SOMA M, 1991, LANCET, V337, P612, DOI 10.1016/0140-6736(91)91674-J; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STEVENSON JC, 1990, LANCET, V336, P265, DOI 10.1016/0140-6736(90)91801-G; STOLL BA, 1989, EUR J CANCER CLIN ON, V25, P1909, DOI 10.1016/0277-5379(89)90372-6; STUDD J, 1992, J ROY SOC MED, V85, P376; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; THAM KT, 1992, BR MED B, V48, P249; TIKKANEN MJ, 1978, LANCET, V2, P490; TUNSTALLPEDOE H, 1992, BRIT MED J, V305, P1096, DOI 10.1136/bmj.305.6861.1096-b; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; 1991, LANCET, V337, P397; 1992, CURRENT PROBLEMS JUN	61	56	56	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1403	1408		10.1136/bmj.305.6866.1403	http://dx.doi.org/10.1136/bmj.305.6866.1403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1343093	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992KB85600024
J	RAPOPORT, TA				RAPOPORT, TA			TRANSPORT OF PROTEINS ACROSS THE ENDOPLASMIC-RETICULUM MEMBRANE	SCIENCE			English	Article							SIGNAL-RECOGNITION PARTICLE; RIBOSOME-BINDING-ACTIVITY; METHIONINE-RICH DOMAIN; ESCHERICHIA-COLI; NASCENT PREPROLACTIN; MICROSOMAL-MEMBRANES; SECRETORY PROTEINS; SEQUENCE RECEPTOR; ROUGH MICROSOMES; CROSS-LINKING	The biosynthesis of many eukaryotic proteins requires their transport across the endoplasmic reticulum (ER) membrane. The process can be divided into two phases: (i) a targeting cycle, during which, by virtue of their signal sequences, nascent polypeptides are directed to translocation sites in the ER and (ii) the actual transfer of proteins across the membrane. The first phase has been well characterized, whereas the latter until recently was completely unresolved. Key components of the translocation apparatus have now been identified and it seems likely that they form a protein-conducting channel in the ER membrane. The transport process is similar to the process of protein export in bacteria.			RAPOPORT, TA (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,O-1115 BERLIN,GERMANY.							AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BOEHNI PC, 1988, J CELL BIOL, V106, P1035; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; Brodsky Joseph, COMMUNICATION; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, IN PRESS CELL; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HARTMANN E, IN PRESS MEMBRANE BI; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HIGH S, COMMUNICATION; JOHNSON A, COMMUNICATION; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUIRINK J, IN PRESS NATURE; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MEYER DI, 1982, NATURE, V297, P503; MIGLIACCIO G, 1992, J CELL BIOL, V117, P12; MUSCH A, 1992, IN PRESS CELL, V69, P343; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NUNNARI JM, 1991, NATURE, V352, P638, DOI 10.1038/352638a0; PHILLIPS GJ, IN PRESS NATURE; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; RAPOPORT TA, 1991, NATURE, V349, P107, DOI 10.1038/349107a0; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROBINSON A, 1987, BIOCHEM J, V242, P767, DOI 10.1042/bj2420767; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, IN PRESS CELL, V69, P353; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, COMMUNICATION; WATANABE M, 1990, P NATL ACAD SCI USA, V87, P1960, DOI 10.1073/pnas.87.5.1960; Wiech H, 1990, Semin Cell Biol, V1, P55; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; YADEAU JT, 1989, J BIOL CHEM, V264, P2928; ZIMMERMAN DL, 1991, CELL REGUL, V2, P851, DOI 10.1091/mbc.2.10.851; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	80	305	311	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					931	936		10.1126/science.1332192	http://dx.doi.org/10.1126/science.1332192			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1332192				2022-12-28	WOS:A1992JW79600021
J	NAKANISHI, S				NAKANISHI, S			MOLECULAR DIVERSITY OF GLUTAMATE RECEPTORS AND IMPLICATIONS FOR BRAIN-FUNCTION	SCIENCE			English	Article							AMINO-ACID RECEPTORS; RETINAL BIPOLAR CELLS; LONG-TERM DEPRESSION; RAT SPINAL-CORD; NMDA-RECEPTOR; ACETYLCHOLINE-RECEPTOR; HIPPOCAMPAL-NEURONS; OPERATED CHANNELS; KAINATE RECEPTOR; XENOPUS OOCYTES	The glutamate receptors mediate excitatory neurotransmission in the brain and are important in memory acquisition, learning, and some neurodegenerative disorders. This receptor family is classified in three groups: the N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-kainate, and metabotropic receptors. Recent molecular studies have shown that many receptor subtypes exist in all three groups of the receptors and exhibit heterogeneity in function and expression patterns. This article reviews the molecular and functional diversity of the glutamate receptors and discusses their implications for integrative brain function.			NAKANISHI, S (corresponding author), KYOTO UNIV, FAC MED, INST IMMUNOL, YOSHIDA, SAKYO KU, KYOTO 606, JAPAN.							ABE T, 1992, J BIOL CHEM, V267, P13361; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BARNARD EA, 1982, PROC R SOC SER B-BIO, V215, P241, DOI 10.1098/rspb.1982.0040; BASKYS A, 1992, TRENDS NEUROSCI, V15, P92, DOI 10.1016/0166-2236(92)90018-4; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BESSHO Y, IN PRESS J NEUROCHEM; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DINGLEDINE R, 1991, TRENDS PHARMACOL SCI, V12, P360, DOI 10.1016/0165-6147(91)90602-O; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; GILBERTSON TA, 1991, SCIENCE, V251, P1613, DOI 10.1126/science.1849316; GONZALES RA, 1992, J NEUROCHEM, V58, P579, DOI 10.1111/j.1471-4159.1992.tb09758.x; HAYASHI Y, IN PRESS BR J PHARM; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HONORE T, 1989, EUR J PHARM-MOLEC PH, V172, P239, DOI 10.1016/0922-4106(89)90054-0; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; IKIN AF, 1990, BIOCHEMISTRY-US, V29, P2290, DOI 10.1021/bi00461a012; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; ISHIDA M, 1990, BRAIN RES, V537, P311, DOI 10.1016/0006-8993(90)90375-L; ISHII T, UNPUB; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KARP S, UNPUB; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KUMAR KN, 1991, NATURE, V354, P70, DOI 10.1038/354070a0; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LY AM, 1991, BIOCHEMISTRY-US, V30, P4307, DOI 10.1021/bi00231a029; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MILLER RJ, 1991, TRENDS NEUROSCI, V14, P477, DOI 10.1016/0166-2236(91)90054-X; MILLER RJ, 1991, TRENDS PHARMACOL SCI, V12, P365, DOI 10.1016/0165-6147(91)90604-Q; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONAGHAN DT, 1988, P NATL ACAD SCI USA, V85, P9836, DOI 10.1073/pnas.85.24.9836; MONAGHAN DT, 1991, NEUROSCI LETT, V122, P21, DOI 10.1016/0304-3940(91)90183-T; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MORI H, 1992, NATURE, V358, P673, DOI 10.1038/358673a0; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLER T, 1992, SCIENCE, V256, P1563, DOI 10.1126/science.1317969; NAKAJIMA Y, UNPUB; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NUMA S, 1989, HARVEY LECT, V83, P121; SAKIMURA K, 1992, NEURON, V8, P267, DOI 10.1016/0896-6273(92)90293-M; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SAKURADA K, IN PRESS J BIOL CHEM; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SHINOZAKI H, 1989, BRIT J PHARMACOL, V98, P1213, DOI 10.1111/j.1476-5381.1989.tb12667.x; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SONDERS MS, 1990, J BIOL CHEM, V265, P6776; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANABE Y, UNPUB; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; YAMAMOTO C, 1976, NATURE, V262, P786, DOI 10.1038/262786a0; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I	73	2321	2401	0	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					597	603		10.1126/science.1329206	http://dx.doi.org/10.1126/science.1329206			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1329206				2022-12-28	WOS:A1992JU74500046
J	ZARKOWER, D; HODGKIN, J				ZARKOWER, D; HODGKIN, J			MOLECULAR ANALYSIS OF THE C-ELEGANS SEX-DETERMINING GENE TRA-1 - A GENE ENCODING 2 ZINC FINGER PROTEINS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; X-CHROMOSOME DOSAGE; BINDING DOMAINS; MESSENGER-RNAS; FEM GENES; GLI GENE; DROSOPHILA; FAMILY; COMPENSATION; TRANSCRIPTS	The tra-1 gene is the terminal control gene for somatic sex determination in the nematode Caenorhabditis elegans. Here we identify two tra-1 mRNAs: one is a 1.5 kb transcript that peaks in abundance in the second larval stage, and the other is a 5 kb transcript that is present at relatively constant abundance throughout development. Both RNAs occur at similar levels in both sexes, suggesting that regulation of tra-1 is posttranscriptional. Neither RNA is germline restricted. The two RNAs are colinear at their 5' ends: the shorter RNA encodes a protein with two zinc finger motifs, and the longer RNA encodes a protein with five zinc fingers. The identification of eight nonsense mutations confirms that these are authentic tra-1 RNAs and demonstrates that the longer one is essential for tra-1 activity. The transcription pattern reveals that alternative mRNA processing governs the number of zinc fingers in the resulting tra-1 protein. The tra-1 fingers are strikingly similar to those of three other proteins, the products of the human GLI and GLI3 and Drosophila cubitus interruptus Dominant (ci(D)) genes.			ZARKOWER, D (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							AHRINGER J, 1992, IN PRESS EMBO J; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BLUMENTHAL T, 1984, J MOL BIOL, V174, P1, DOI 10.1016/0022-2836(84)90361-9; BORDEREAUX D, 1990, ONCOGENE, V5, P925; BURTIS KC, 1991, EMBO J, V10, P2577, DOI 10.1002/j.1460-2075.1991.tb07798.x; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; FAIRALL L, 1992, IN PRESS J MOL BIOL; FILES JG, 1983, J MOL BIOL, V164, P355, DOI 10.1016/0022-2836(83)90056-6; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HODGKIN J, 1986, GENETICS, V114, P15; HODGKIN J, 1987, ANNU REV GENET, V21, P133, DOI 10.1146/annurev.ge.21.120187.001025; HODGKIN J, 1983, NATURE, V304, P267, DOI 10.1038/304267a0; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HODGKIN JA, 1977, GENETICS, V86, P275; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; HUNTER CP, 1990, CELL, V63, P1193, DOI 10.1016/0092-8674(90)90415-B; HUNTER CP, 1992, NATURE, V355, P551, DOI 10.1038/355551a0; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; MADL JE, 1979, GENETICS, V93, P393; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NELSON GA, 1978, DEV BIOL, V66, P386, DOI 10.1016/0012-1606(78)90247-6; Nigon V., 1951, B BIOL FR BELG, V85, P187; NIWA M, 1991, GENE EXPRESSION, V1, P5; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NUSBAUM C, 1989, GENETICS, V122, P579; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; ROSENQUIST TA, 1988, GENE DEV, V2, P606, DOI 10.1101/gad.2.5.606; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7306; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEDL T, 1989, GENETICS, V123, P755; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHEN MM, 1988, CELL, V54, P1019, DOI 10.1016/0092-8674(88)90117-1; SHEN WF, 1991, NUCLEIC ACIDS RES, V19, P539, DOI 10.1093/nar/19.3.539; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TRENT C, 1991, MECH DEVELOP, V34, P43, DOI 10.1016/0925-4773(91)90090-S; TRENT C, 1988, GENETICS, V120, P145; VIERA J, 1987, METHOD ENZYMOL, V153, P3; Villeneuve A.M., 1990, Advances in Genetics, V27, P117; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7; VORTKAMP A, 1991, NATURE, V352, P359; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WRIGHT CVE, 1987, EMBO J, V6, P4083, DOI 10.1002/j.1460-2075.1987.tb02754.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	78	214	230	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					237	249		10.1016/0092-8674(92)90099-X	http://dx.doi.org/10.1016/0092-8674(92)90099-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1339311				2022-12-28	WOS:A1992JE75700008
J	JONES, DRE; HOPKINSON, ND; POWELL, RJ				JONES, DRE; HOPKINSON, ND; POWELL, RJ			AUTOANTIBODIES IN PET DOGS OWNED BY PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS	LANCET			English	Article							ANTIBODIES; HOUSEHOLD	Systemic lupus erythematosus (SLE) occurs in human beings and in dogs. There is evidence to suggest that the disease is caused by a transmissible factor that may cross the species barrier. We investigated this possibility by looking for autoantibodies and serum protein abnormalities in serum samples from 15 pet dogs owned by patients with SLE and comparing results with those obtained with serum from 10 healthy dogs kept in a controlled environment and 9 dogs with autoimmune diseases. We used standard immunological assays modified for use with canine samples. Compared with the normal dogs, increased amounts of antibody to double-stranded DNA were found in serum from the SLE patients' dogs (median optical density [405 nm] = 0.117 vs 0.299; p = 0.0001), this latter amount being similar to that found in serum from the autoimmune group (0.201; p = 0.6). Abnormal serum protein electrophoresis patterns were found in samples from the autoimmune and SLE patients' dogs but not the normal dogs. These findings support the idea that exposure to common environmental factors or transmissible agents may have a role in causing SLE.			JONES, DRE (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT IMMUNOL,NOTTINGHAM NG7 2UH,ENGLAND.							BEAUCHER WN, 1977, NEW ENGL J MED, V296, P982, DOI 10.1056/NEJM197704282961707; Bennett D., 1987, Veterinary Annual, V27, P350; CLAIR D, 1980, ARTHRITIS RHEUM, V23, P251, DOI 10.1002/art.1780230219; COSTA O, 1984, VET IMMUNOL IMMUNOP, V7, P369, DOI 10.1016/0165-2427(84)90094-1; DEAPEN D M, 1986, Arthritis and Rheumatism, V29, pS26; FESSEL WJ, 1988, RHEUM DIS CLIN N AM, V14, P15; FRYE F L, 1976, Theriogenology, V6, P127; JONES DRE, 1987, VET IMMUNOL IMMUNOP, V16, P11, DOI 10.1016/0165-2427(87)90170-X; KALLICK CA, 1972, NATURE-NEW BIOL, V236, P145, DOI 10.1038/newbio236145a0; KRISTENSEN S, 1979, VET REC, V105, P422, DOI 10.1136/vr.105.18.422; LEWIS RM, 1974, NATURE, V252, P78, DOI 10.1038/252078a0; LEWIS RM, 1972, AM J PATHOL, V69, P537; LEWIS RM, 1971, J EXP MED, V134, P417, DOI 10.1084/jem.134.2.417; LEWIS RM, 1973, J CLIN INVEST, V52, P1893, DOI 10.1172/JCI107373; MAYR A, 1989, ZBL HYG UMWELTMED, V187, P508; MONIER JC, 1980, ARTHRITIS RHEUM, V23, P294, DOI 10.1002/art.1780230305; REINERTSEN JL, 1980, ARTHRITIS RHEUM-US, V23, P564, DOI 10.1002/art.1780230507; Shanley K J, 1985, Clin Dermatol, V3, P131, DOI 10.1016/0738-081X(85)90086-0; SHARP J T, 1971, Hospital Practice, V6, P142; SILMAN AJ, 1990, BRIT J RHEUMATOL, V29, P494; THOBURN R, 1972, P NATL ACAD SCI USA, V69, P3327, DOI 10.1073/pnas.69.11.3327; WALLACE DJ, 1987, DUBOIS LUPUS ERYTHEM; WALLINGTON TB, 1990, CLIN IMMUNOLOGY PRAC, P212; ZAMBINSKI M, 1989, 53RD P ANN GEN M CIN, pS25	24	20	20	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1378	1380		10.1016/0140-6736(92)91197-G	http://dx.doi.org/10.1016/0140-6736(92)91197-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350806				2022-12-28	WOS:A1992HX63600004
J	SMITH, CAD; GOUGH, AC; LEIGH, PN; SUMMERS, BA; HARDING, AE; MARANGANORE, DM; STURMAN, SG; SCHAPIRA, AHV; WILLIAMS, AC; SPURR, NK; WOLF, CR				SMITH, CAD; GOUGH, AC; LEIGH, PN; SUMMERS, BA; HARDING, AE; MARANGANORE, DM; STURMAN, SG; SCHAPIRA, AHV; WILLIAMS, AC; SPURR, NK; WOLF, CR			DEBRISOQUINE HYDROXYLASE GENE POLYMORPHISM AND SUSCEPTIBILITY TO PARKINSONS-DISEASE	LANCET			English	Article							COMPLEX-I DEFICIENCY; POOR METABOLIZERS; CYP2D LOCUS; 4-HYDROXYLATION; PHENOTYPES; NEUROTOXIN; OXIDATION; DEFECT	The pathogenesis of Parkinson's disease may be influenced by genetic and environmental factors. Cytochrome P450 mono-oxygenases help to protect against toxic environmental compounds and individual variations in cytochrome P450 expression might, therefore, influence susceptibility to environmentally linked diseases. The frequency of mutant CYP2D6 alleles was studied in 229 patients with Parkinson's disease and 720 controls. Individuals with a metabolic defect in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype had a 2.54-fold (95% CI 1.51-4.28) increased risk of Parkinson's disease. Determination of CYP2D6 phenotype and genotype may help to identify those at greatest risk of Parkinson's disease and may also help to identify the environmental or metabolic agents involved in the pathogenesis of this disease.	IMPERIAL CANC RES FUND, MOLEC PHARMACOL GRP, GEORGE SQ, EDINBURGH EH8 9XD, SCOTLAND; IMPERIAL CANC RES FUND, HUMAN GENET RESOURCES, CLARE HALL LABS, S MIMMS, ENGLAND; UNIV LONDON, INST PSYCHIAT, DEPT NEUROL, LONDON, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, LONDON WC2R 2LS, ENGLAND; UNIV LONDON, INST NEUROL, DEPT CLIN NEUROL, LONDON, ENGLAND; UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, DEPT NEUROL, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT NEUROSCI, LONDON, ENGLAND	University of London; King's College London; University of London; King's College London; University of London; University College London; University of Birmingham; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Schapira, Anthony H V/A-1245-2010; Leigh, Peter/AAD-5638-2019	Schapira, Anthony H V/0000-0002-3018-3966; 				BARBEAU A, 1985, LANCET, V2, P1213; BENITEZ J, 1990, J NEUROL NEUROSUR PS, V53, P289, DOI 10.1136/jnnp.53.4.289; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; CHIBA Z, 1987, BIOCHEM BIOPH RES CO, V120, P574; COMELLA C L, 1987, Neurology, V37, P261; EICHELBAUM M, 1990, PHARMACOL THERAPEUT, V46, P377, DOI 10.1016/0163-7258(90)90025-W; FONNEPFISTER R, 1987, BIOCHEM BIOPH RES CO, V148, P1144, DOI 10.1016/S0006-291X(87)80252-8; GAEDIGK A, 1991, AM J HUM GENET, V48, P943; GIBB WRG, 1989, NEUROPATH APPL NEURO, V15, P27, DOI 10.1111/j.1365-2990.1989.tb01147.x; GOLBE LI, 1990, NEUROLOGY, V40, P7; GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0; GUDJONSSON O, 1990, BRIT J CLIN PHARMACO, V30, P301, DOI 10.1111/j.1365-2125.1990.tb03780.x; HANIOKA N, 1990, AM J HUM GENET, V47, P994; HEIM M, 1990, LANCET, V336, P529, DOI 10.1016/0140-6736(90)92086-W; ISLAM SA, 1991, CARCINOGENESIS, V12, P2211, DOI 10.1093/carcin/12.12.2211; JOHNSON WG, 1991, NEUROLOGY, V41, P82, DOI 10.1212/WNL.41.5_Suppl_2.82; KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209; KALLIO J, 1991, ACTA NEUROL SCAND, V83, P194, DOI 10.1111/j.1600-0404.1991.tb04676.x; Langdon J.S., 1985, RECENT ADV AQUACULTU, P79, DOI [10.4324/9780429303937-3, DOI 10.4324/9780429303937-3]; MARAGANORE DM, 1991, MOVEMENT DISORD, V6, P205, DOI 10.1002/mds.870060303; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; NIZNIK HB, 1990, ARCH BIOCHEM BIOPHYS, V276, P424, DOI 10.1016/0003-9861(90)90741-G; POIRIER J, 1987, LANCET, V2, P386; PRICEEVANS DA, 1980, J MED GENET, V17, P102; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SPURR NK, 1991, METHOD ENZYMOL, V206, P149; STEIGER MJ, IN PRESS ACTA NEUROL; STEVENTON G B, 1989, Medical Science Research, V17, P163; WOLF CR, 1990, CANCER SURV, V9, P437; WOLF CR, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93163-J; WOLF CR, IN PRESS CARCINOGENE; YOUNGSTER SK, 1990, BIOCHEM BIOPH RES CO, V169, P758, DOI 10.1016/0006-291X(90)90396-5	34	455	460	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 6	1992	339	8806					1375	1377		10.1016/0140-6736(92)91196-F	http://dx.doi.org/10.1016/0140-6736(92)91196-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350805				2022-12-28	WOS:A1992HX63600003
J	YEAGER, CL; ASHMUN, RA; WILLIAMS, RK; CARDELLICHIO, CB; SHAPIRO, LH; LOOK, AT; HOLMES, KV				YEAGER, CL; ASHMUN, RA; WILLIAMS, RK; CARDELLICHIO, CB; SHAPIRO, LH; LOOK, AT; HOLMES, KV			HUMAN AMINOPEPTIDASE-N IS A RECEPTOR FOR HUMAN CORONAVIRUS-229E	NATURE			English	Article							AMINO-ACID SEQUENCE; ENDOPEPTIDASE 24.11 ENKEPHALINASE; MEMBRANE ANTIGEN GP150; NEUTRAL ENDOPEPTIDASE; MOLECULAR-CLONING; LEUKEMIA ANTIGEN; GENE; KIDNEY; IDENTIFICATION; EXPRESSION	HUMAN coronaviruses (HCV) in two serogroups represented by HCV-229E and HCV-OC43 are an important cause of upper respiratory tract infections 1. Here we report that human aminopeptidase N, a cell-surface metalloprotease on intestinal, lung and kidney epithelial cells 2-5, is a receptor for human coronavirus strain HCV-229E, but not for HCV-OC43. A monoclonal antibody, RBS, blocked HCV-229E virus infection of human lung fibroblasts, immunoprecipitated aminopeptidase N and inhibited its enzymatic activity. HCV-229E-resistant murine fibroblasts became susceptible after transfection with complementary DNA encoding human aminopeptidase N. By contrast, infection of human cells with HCV-OC43 was not inhibited by antibody RBS and expression of aminopeptidase N did not enhance HCV-OC43 replication in mouse cells. A mutant aminopeptidase lacking the catalytic site of the enzyme did not bind HCV-229E or RBS and did not render murine cells susceptible to HCV-229E infection, suggesting that the virus-binding site may lie at or near the active site of the human aminopeptidase molecule.	UNIFORMED SERV UNIV HLTH SCI, DEPT PATHOL, 4301 JONES BRIDGE RD, BETHESDA, MD 20814 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	Uniformed Services University of the Health Sciences - USA; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center								ASHMUN RA, 1990, BLOOD, V75, P462; ASHMUN RA, IN PRESS BLOOD; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LOOK AT, 1985, J CLIN INVEST, V75, P569, DOI 10.1172/JCI111733; LOOK AT, 1986, J CLIN INVEST, V78, P914, DOI 10.1172/JCI112680; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; LOOK AT, 1989, LEUCOCYTE TYPING, V4, P784; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MATSAS R, 1985, BIOCHEM J, V231, P445, DOI 10.1042/bj2310445; MCINTOSH K, 1990, VIROLOGY, P857; NOREN O, 1989, FEBS LETT, V259, P107, DOI 10.1016/0014-5793(89)81506-6; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; RICH DH, 1984, J MED CHEM, V27, P417, DOI 10.1021/jm00370a001; SAKAGUCHI AY, 1982, SOMAT CELL GENET, V8, P83, DOI 10.1007/BF01538652; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; TURNER AJ, 1987, MAMMALIAN ECTOENZYME, P211; UMEZAWA H, 1985, J ANTIBIOT, V38, P1629, DOI 10.7164/antibiotics.38.1629; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WATT VM, 1989, J BIOL CHEM, V264, P5480; WILKES SH, 1985, J BIOL CHEM, V260, P3154; WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990; WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533; WU Q, 1991, P NATL ACAD SCI USA, V88, P676, DOI 10.1073/pnas.88.2.676; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; [No title captured]	30	645	710	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					420	422		10.1038/357420a0	http://dx.doi.org/10.1038/357420a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1350662	Green Published, Bronze			2022-12-28	WOS:A1992HX17200069
J	LUNGU, O; SUN, XW; FELIX, J; RICHART, RM; SILVERSTEIN, S; WRIGHT, TC				LUNGU, O; SUN, XW; FELIX, J; RICHART, RM; SILVERSTEIN, S; WRIGHT, TC			RELATIONSHIP OF HUMAN PAPILLOMAVIRUS TYPE TO GRADE OF CERVICAL INTRAEPITHELIAL NEOPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENITAL-TRACT; LESIONS	Objective. - To determine the relationship of human papillomavirus (HPV) type to grade of cervical intraepithelial neoplasia (CIN) in a large series of cases. Design. - A survey of HPV types in CIN lesions detected using a new, highly accurate method for typing HPV that is based on restriction fragment length polymorphism analysis of amplimers produced during polymerase chain amplification of the conserved L1 region of HPV using consensus primers. Setting. - Private gynecologists' offices and inner-city colposcopy clinics. Patients. - A convenience sample of 276 HPV DNA-positive cervical biopsy specimens or samples from patients undergoing colposcopy for abnormal Papanicolaou smears. Intervention. - None. Main Outcome Measure(s). - Human papillomavirus type(s). Results. - Cervical intraepithelial neoplasia 1 lesions were relatively heterogeneous with regard to associated HPV types. Nineteen percent of CIN 1 lesions were associated with HPV types 6 or 11; 29% contained HPV types 16, 18, or 33; and 19% were associated with "novel types" of HPV. It was also found that 22% of CIN 1 lesions were associated with more than one HPV type. In contrast to CIN 1, both CIN 2 and CIN 3 were relatively homogeneous with regard to associated HPV types. Eighty-eight percent of CIN 2 and 3 lesions contained HPV types 16,18, or 33. Unlike CIN 1 lesions, which often contained multiple types of HPV, only 7% of CIN 2 and 3 lesions were associated with multiple HPV types. Conclusions. - Cervical intraepithelial neoplasia should be classified into two separate categories-low-grade and high-grade CIN. Since only 29% of low-grade lesions are associated with HPV types 16,18, or 33, HPV type could potentially play a role in determining the most appropriate clinical management of patients with low-grade CIN. However, prospective follow-up studies of lesional behavior based on HPV type are required before clinical recommendations can be made.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, DIV OBSTET GYNECOL PATHOL, ROOM 16-402 P&S, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT OBSTET & GYNECOL, NEW YORK, NY 10032 USA; COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; CORNELL MED SCH, DEPT PATHOL, NEW YORK, NY USA	Columbia University; Columbia University; Columbia University; Columbia University; NewYork-Presbyterian Hospital; Cornell University					NCI NIH HHS [CA27367] Funding Source: Medline; PHS HHS [CCU206822] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARRON BA, 1968, J NATL CANCER I, V41, P1343; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BURMER GC, 1990, AM J CLIN PATHOL, V94, P554, DOI 10.1093/ajcp/94.5.554; CAMPION MJ, 1986, LANCET, V2, P237; CRUM CP, 1985, J VIROL, V54, P675, DOI 10.1128/JVI.54.3.675-681.1985; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P191; FRANQUEMONT DW, 1989, AM J CLIN PATHOL, V92, P577, DOI 10.1093/ajcp/92.5.577; GRAVITT P, 1991, MOL CELL PROBE, V5, P65, DOI 10.1016/0890-8508(91)90039-M; KOUTSKY LA, 1988, EPIDEMIOL REV, V10, P122, DOI 10.1093/oxfordjournals.epirev.a036020; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; LUNGU O, IN PRESS MOL CELL PR; Manos M. M., 1990, PCR PROTOCOLS GUIDE, P356; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; NUOVO GJ, 1990, GYNECOL ONCOL, V36, P256, DOI 10.1016/0090-8258(90)90184-M; REID R, 1987, AM J OBSTET GYNECOL, V156, P212, DOI 10.1016/0002-9378(87)90241-9; REID R, 1991, J FAM PRACTICE, V32, P183; RICHART RM, 1990, OBSTET GYNECOL, V75, P223; RICHART RM, 1990, OBSTET GYNECOL, V75, P131; ROMAN A, 1989, CLIN MICROBIOL REV, V2, P166, DOI 10.1128/CMR.2.2.166-190.1989; SINGER A, 1991, BRIT MED J, V302, P251, DOI 10.1136/bmj.302.6771.251; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; SYRJANEN KJ, 1991, PAPILLOMAVIRUS REP, V1, P1; WILLETT GD, 1989, INT J GYNECOL PATHOL, V8, P18, DOI 10.1097/00004347-198903000-00003; WRIGHT TC, 1990, GYNECOL ONCOL, V37, P151, DOI 10.1016/0090-8258(90)90327-H	25	108	114	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2493	2496		10.1001/jama.267.18.2493	http://dx.doi.org/10.1001/jama.267.18.2493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349360				2022-12-28	WOS:A1992HT06800029
J	BRAHAMS, D				BRAHAMS, D			COSMETIC SURGERY FOR PORTWINE STAIN	LANCET			English	Editorial Material																		1992, MED LR, V3, P81	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1045	1046		10.1016/0140-6736(92)90555-H	http://dx.doi.org/10.1016/0140-6736(92)90555-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349063				2022-12-28	WOS:A1992HQ43500017
J	SCHOMBURG, AG; KIRCHNER, HH; ATZPODIEN, J				SCHOMBURG, AG; KIRCHNER, HH; ATZPODIEN, J			CYTOKINES AND INFECTION IN CANCER-PATIENTS	LANCET			English	Letter							RECOMBINANT INTERLEUKIN-2; IMMUNOTHERAPY; THERAPY				SCHOMBURG, AG (corresponding author), MED HSCH HANNOVER,UNIV MED CTR,DEPT HEMATOL & ONCOL,W-3000 HANNOVER 61,GERMANY.							ATZPODIEN J, 1990, LANCET, V335, P1509, DOI 10.1016/0140-6736(90)93039-R; CLARK JW, 1990, CANCER RES, V50, P7343; CREEKMORE SP, 1989, J CLIN ONCOL, V7, P276, DOI 10.1200/JCO.1989.7.2.276; DUTCHER JP, 1991, J CLIN ONCOL, V9, P641, DOI 10.1200/JCO.1991.9.4.641; JABLONS D, 1990, J IMMUNOL, V144, P3630; JONES, 1992, LANCET, V339, P181; KLEMPNER MS, 1990, NEW ENGL J MED, V322, P959, DOI 10.1056/NEJM199004053221404; PLORDE JJ, 1991, HARRISONS PRINCIPLES; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; SAXON RR, 1991, AM J ROENTGENOL, V156, P281, DOI 10.2214/ajr.156.2.1898799	10	1	1	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1061	1061		10.1016/0140-6736(92)90588-T	http://dx.doi.org/10.1016/0140-6736(92)90588-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349091				2022-12-28	WOS:A1992HQ43500053
J	VANLIESHOUT, JJ; TENHARKEL, ADJ; WIELING, W				VANLIESHOUT, JJ; TENHARKEL, ADJ; WIELING, W			PHYSICAL MANEUVERS FOR COMBATING ORTHOSTATIC DIZZINESS IN AUTONOMIC FAILURE	LANCET			English	Note							PRESSURE	Some patients with orthostatic hypotension combat orthostatic dizziness by leg-crossing and squatting. Changes in blood pressure with these manoeuvres were studied in 7 patients with hypoadrenergic orthostatic hypotension and in 6 healthy subjects. Without leg-crossing, 5 of the patients reported dizziness within 10 min of standing up. Crossing of the legs allowed all to stand for 1 0 min or more, and there was an associated increase in mean blood pressure of 13 (SD 6) mm Hg compared with 1 (4) in healthy controls, the corresponding figures for squatting were 44 (18) and 8 (6) mm Hg. Patients with orthostatic intolerance should be told about these blood-pressure-raising manoeuvres.			VANLIESHOUT, JJ (corresponding author), UNIV AMSTERDAM,ACAD MED CTR F4 264,DEPT MED,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Van Lieshout, Johannes/P-5499-2019; Ten Harkel, Arend/ABE-1169-2021; van Lieshout, Johannes J/B-6674-2011	Van Lieshout, Johannes/0000-0002-3646-2122; van Lieshout, Johannes J/0000-0002-3646-2122				BIAGGIONI I, 1990, NEUROLOGY, V40, P370, DOI 10.1212/WNL.40.2.370; GUYTON AC, 1962, CIRC RES, V11, P431, DOI 10.1161/01.RES.11.3.431; Hainsworth R, 1988, AUTONOMIC FAILURE TX, P142; IMHOLZ BPM, 1990, CARDIOVASC RES, V24, P214, DOI 10.1093/cvr/24.3.214; Jeffers WA, 1941, AM J MED SCI, V202, P1, DOI 10.1097/00000441-194107000-00001; SHARPEYSCHAFER EP, 1956, BRIT MED J, V1, P1072, DOI 10.1136/bmj.1.4975.1072; SMITH ML, 1987, MED SCI SPORT EXER, V19, P436; VANLIESHOUT JJ, 1989, CLIN SCI, V76, P523, DOI 10.1042/cs0760523	8	109	119	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					897	898		10.1016/0140-6736(92)90932-S	http://dx.doi.org/10.1016/0140-6736(92)90932-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348300				2022-12-28	WOS:A1992HN48300006
J	FOWKES, FGR; CONNOR, JM; SMITH, FB; WOOD, J; DONNAN, PT; LOWE, GDO				FOWKES, FGR; CONNOR, JM; SMITH, FB; WOOD, J; DONNAN, PT; LOWE, GDO			FIBRINOGEN GENOTYPE AND RISK OF PERIPHERAL ATHEROSCLEROSIS	LANCET			English	Article							ISCHEMIC HEART-DISEASE; PLASMA-FIBRINOGEN; CARDIOVASCULAR-DISEASE; HEMOSTATIC VARIABLES; DETERMINANTS; SMOKING; MEN	There is conflicting evidence about the influence of fibrinogen genotype on plasma fibrinogen concentrations, and the relation between genotype and atherosclerotic disease has not been studied. In a population-based case-control study we aimed to find out whether certain fibrinogen genotypes are associated with an increased risk of peripheral atherosclerosis. 121 subjects with peripheral arterial disease and 126 healthy controls matched for age and sex were selected from a random population sample aged 55-74 years in the Edinburgh Artery Study. Mean fibrinogen concentrations were higher in cases than in controls (3.12 [95% confidence interval 2.99-3.26] vs 2.75 [2.64-2.85], p < 0.001). A greater proportion of cases than controls were homozygous or heterozygous for an allele at the beta-fibrinogen locus (4.2 kb allele, Bcl I digestion); the allele frequency was 0.197 in cases and 0.097 in controls (p < 0.005). Extended haplotypes for 4.2 kb heterozygotes were also associated with an increased risk of peripheral arterial disease. However, haplotype had only a small effect on the association of plasma fibrinogen concentration with disease, and the relation of haplotype with disease was independent of age, sex, social class, smoking status, plasma fibrinogen, alcohol consumption, body mass index, and diabetes mellitus. We conclude that variation at the beta-fibrinogen locus is associated with an increased risk of peripheral atherosclerosis. The influence is not mediated simply by way of increased fibrinogen concentrations but could be due to a structurally variant fibrinogen or linkage disequilibrium with a neighbouring gene.	UNIV GLASGOW,WESTERN INFIRM,DUNCAN GUTHRIE INST,DEPT MED GENET,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,MOLEC MED LAB,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,GLASGOW,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow	FOWKES, FGR (corresponding author), UNIV EDINBURGH,DEPT PUBL HLTH SCI,WOLFSON UNIT PREVENT PERIPHERAL VASC,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.			Donnan, Peter/0000-0001-7828-0610				[Anonymous], 1980, CLASSIFICATION OCCUP; BAKER JD, 1978, ARCH SURG-CHICAGO, V113, P1171; BERG K, 1989, CLIN GENET, V36, P229; BERNSTEIN EF, 1982, SURG CLIN N AM, V62, P473; CONNOR JM, IN PRESS J MED GENET; DIXON WJ, 1988, BMDP STATISTICAL SOF; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FOWKES FGR, 1992, AM J EPIDEMIOL, V135, P331; FULLER JH, 1979, BMJ-BRIT MED J, V2, P964, DOI 10.1136/bmj.2.6196.964; HAMSTEN A, 1987, LANCET, V2, P988; HUMPHRIES SE, 1987, LANCET, V1, P1452, DOI 10.1016/S0140-6736(87)92205-7; KANNEL W B, 1990, Journal of the American College of Cardiology, V15, p156A; KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; LOWE GDO, 1991, BR J HAEMATOL S1, V77, P27; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1977, BRIT MED BULL, V33, P283, DOI 10.1093/oxfordjournals.bmb.a071448; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Prineas R., 1982, MINNESOTA CODE MANUA; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; Sambrook J, 1989, MOL CLONING LABORATO; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Smith WCS, 1991, EPIDEMIOLOGY PERIPHE, P117; STONE MC, 1984, ATHEROSCLEROSIS CARD, P3; THOMAS AE, 1991, THROMB HAEMOSTASIS, V65, P487; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; YARNELL JWG, 1983, J EPIDEMIOL COMMUN H, V37, P137, DOI 10.1136/jech.37.2.137; [No title captured]	31	127	129	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					693	696		10.1016/0140-6736(92)90596-U	http://dx.doi.org/10.1016/0140-6736(92)90596-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347581				2022-12-28	WOS:A1992HK32000001
J	GOSSMANN, J				GOSSMANN, J			SALT TRIAL	LANCET			English	Letter											GOSSMANN, J (corresponding author), JOHANN WOLFGANG GOETHE UNIV KLINIKUM,DEPT NEPHROL,W-6000 FRANKFURT 71,GERMANY.							1991, NEW ENGL J MED, V325, P1261; 1991, LANCET, V338, P1345	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					377	377		10.1016/0140-6736(92)91703-B	http://dx.doi.org/10.1016/0140-6736(92)91703-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346461				2022-12-28	WOS:A1992HC77100063
J	CHISAKA, O; MUSCI, TS; CAPECCHI, MR				CHISAKA, O; MUSCI, TS; CAPECCHI, MR			DEVELOPMENTAL DEFECTS OF THE EAR, CRANIAL NERVES AND HINDBRAIN RESULTING FROM TARGETED DISRUPTION OF THE MOUSE HOMEOBOX GENE HOX-1.6	NATURE			English	Article							STEM-CELLS; EXPRESSION; EMBRYO; MURINE; GENOME; CHICK	Gene targeting in mouse embryo-derived stem cells has been used to generate mice with a disruption in the homeobox gene Hox-1.6 Mice heterozygous at the Hox-1.6 locus appear normal, whereas Hox-1.6-/Hox-1.6- mice die at or shortly after birth. These homozygotes exhibit profound defects in the formation of the external, middle and inner ears as well as in specific hindbrain nuclei, and in cranial nerves and ganglia. The affected tissues lie within a narrow region along the anteroposterior axis of the mouse but are of diverse embryonic origin. The set of defects associated with the disruption of Hox-1.6 is distinct from and nonoverlapping with that of the closely linked Hox-1.5 gene. But both mutations cause loss, rather than homeotic transformation, of tissues and structures.			CHISAKA, O (corresponding author), UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1987, DEVELOPMENT, V101, P1; ALTMAN J, 1982, ADV ANAT EMBRYOL CEL, V74, P1; BARON A, 1987, EMBO J, V6, P2977, DOI 10.1002/j.1460-2075.1987.tb02603.x; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DEOL MS, 1980, MORPHOGENESIS MALFOR, P243; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HUNT P, 1991, DEVELOPMENT, V112, P43; INGHAM PN, 1989, NATURE, V335, P25; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; Le Douarin N., 1999, DEV CELL BIOL SERIES, V2nd, DOI [10.1017/CBO9780511897948, DOI 10.1017/CBO9780511897948, 10.1017/cbo9780511897948]; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, IN PRESS DEVELOPMENT; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Van de Water T R, 1980, Birth Defects Orig Artic Ser, V16, P147; VANDEWATER TR, 1980, MORPHOGENESIS MALFOR, P5	30	480	499	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1992	355	6360					516	520		10.1038/355516a0	http://dx.doi.org/10.1038/355516a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC526	1346922				2022-12-28	WOS:A1992HC52600047
J	ALEDORT, LM; HILGARTNER, MW; PIKE, MC; GJERSET, GF; KOERPER, MA; LIAN, EYC; LUSHER, JM; MOSLEY, JW				ALEDORT, LM; HILGARTNER, MW; PIKE, MC; GJERSET, GF; KOERPER, MA; LIAN, EYC; LUSHER, JM; MOSLEY, JW			VARIABILITY IN SERIAL CD4 COUNTS AND RELATION TO PROGRESSION OF HIV-I INFECTION TO AIDS IN HEMOPHILIC PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EDINBURGH HEMOPHILIAC COHORT; CONTROLLED TRIAL; QUALITY-CONTROL; ZIDOVUDINE; FOLLOW; TYPE-1; RISK; AZT	Objective - To examine the CD4 count and its near term changes relative to progression to AIDS within 30 months and to subsequent CD4 counts. Design - Longitudinal clinical and laboratory study. Setting - Haemophilia treatment centres in six large American cities. Patients - 555 people with congenital clotting disorders who were infected with HIV, initially without AIDS, and seen at follow up for 6-30 months in 1986-9. Main outcome measures - Absolute CD4 counts and incidence of AIDS. Results - Outset CD4 count and age were independently related to progression to AIDS (p < 0.0001 and p < 0.005 respectively). Patients with CD4 counts of 0.30-0.49 X 10(9) cells/l had an age adjusted risk of AIDS within 30 months of only 9% that of patients with counts < 0.20 X 10(9)/l. Children under 10 years old had only 16% of the CD4 adjusted risk of AIDS of people aged greater-than-or-equal-to 45 years. Analysis of 149 patients' CD4 counts at the beginning and end of two successive six month intervals showed an average decrease of 11% in each six months regardless of the outset count (greater-than-or-equal-to 0.20 X 10(9)/l). For individual patients the decrease in the second six month period was unaffected by the decrease in the first six month period. Conclusions - Antiviral treatment of asymptomatic people, particularly children, with CD4 counts greater-than-or-equal-to 0.3 X 10(9)/l is questionable if predicated on near term progression to AIDS. Because of individual CD4 count variability and the low rate of progression to AIDS near term declines in individual CD4 counts are a poor index for identifying people who will rapidly progress to AIDS.	MT SINAI MED CTR,MED,NEW YORK,NY 10029; CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021; UNIV SO CALIF,DEPT PREVENT MED,LOS ANGELES,CA 90089; PUGET SOUND BLOOD CTR,MED,SEATTLE,WA 98104; UNIV CALIF SAN FRANCISCO,MED,SAN FRANCISCO,CA 94143; WAYNE STATE UNIV,PAEDIAT,DETROIT,MI 48202; UNIV MIAMI,MED,MIAMI,FL 33152	Icahn School of Medicine at Mount Sinai; Cornell University; NewYork-Presbyterian Hospital; University of Southern California; Puget Sound Blood Center; University of California System; University of California San Francisco; Wayne State University; University of Miami					DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047003, N01HB097074] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-9-7074, N01-HB-4-7003] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN BL, 1990, NEW ENGL J MED, V323, P755; COX DR, 1972, J R STAT SOC B, V34, P187; CUTHBERT RJG, 1990, BMJ-BRIT MED J, V301, P956, DOI 10.1136/bmj.301.6758.956; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; DETRUCHIS P, 1991, LANCET, V337, P1109, DOI 10.1016/0140-6736(91)91766-N; EDWARDS VM, 1989, AM J CLIN PATHOL, V91, P75, DOI 10.1093/ajcp/91.1.75; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; Goedert James J., 1990, Annals of Epidemiology, V1, P129, DOI 10.1016/1047-2797(90)90004-C; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HAMILTON JD, 1990, NEW ENGL J MED, V323, P754, DOI 10.1056/NEJM199009133231112; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN JE, 1988, JAMA-J AM MED ASSOC, V260, P2694, DOI 10.1001/jama.260.18.2694; KLEINBAUM DG, 1988, APPLIED REGRESSION A; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MEDLEY GF, 1988, PROC R SOC SER B-BIO, V233, P367, DOI 10.1098/rspb.1988.0026; MOSS AR, 1990, J ACQ IMMUN DEF SYND, V3, pS69; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PARKER JW, 1990, CLIN IMMUNOL IMMUNOP, V55, P187, DOI 10.1016/0090-1229(90)90097-A; PHILLIPS AN, 1991, LANCET, V337, P389; PIZZO PA, 1990, J INFECT DIS, V161, P316, DOI 10.1093/infdis/161.2.316; RAGNI MV, 1990, J ACQ IMMUN DEF SYND, V3, P708; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SIMMONDS P, 1988, BRIT MED J, V296, P593, DOI 10.1136/bmj.296.6622.593; THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4; Vermund Sten H., 1990, Annals of Epidemiology, V1, P141, DOI 10.1016/1047-2797(90)90005-D; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1987, MMWR, V36, P3	31	35	35	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1992	304	6821					212	216		10.1136/bmj.304.6821.212	http://dx.doi.org/10.1136/bmj.304.6821.212			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA980	1346752	Green Published, Bronze			2022-12-28	WOS:A1992HA98000022
J	RUSSELL, JA; POON, MC; JONES, AR; WOODMAN, RC; RUETHER, BA				RUSSELL, JA; POON, MC; JONES, AR; WOODMAN, RC; RUETHER, BA			ALLOGENEIC BONE-MARROW TRANSPLANTATION WITHOUT PROTECTIVE ISOLATION IN ADULTS WITH MALIGNANT DISEASE	LANCET			English	Article							INTRAVENOUS IMMUNOGLOBULIN; HOST-DISEASE; DOUBLE-BLIND; LEUKEMIA; INFECTION; PROPHYLAXIS; PREVENTION; TRIAL; GRAFT	Bone-marrow transplant (BMT) patients are severely immunocompromised immediately after the procedure and they are commonly nursed in strict protective isolation to reduce the risk of both infection and graft-versus-host disease (GvHD). We have studied a consecutive series of patients to see whether protective isolation is of benefit as prophylaxis against infectious complications of BMT. 50 consecutive patients who had malignant disease and received their first BMT from siblings or unrelated donors were nursed in standard single rooms with visitors instructed to wash their hands. A subset of 20 patients living locally spent a median of 25 days in hospital after BMT, they also spent some time at home on a median of 8 days before engraftment and 3 patients went home on more than 90% of their hospital days. 16 patients (32%) had positive bacterial cultures and/or focal infection. Gram-positive bacteraemia was found in 12 subjects (24%) but there were no gram-negative or deep fungal infections. Grade II or III acute GvHD developed in 17 patients (34%). There were no deaths from infection or acute GvHD. Transplant-related mortality was 6% in the first 100 days and 18% overall with a median follow-up of 22 months. Our mortality data compare favourably with those from institutions with strict isolation procedures. We conclude that BMT may be safely completed in some institutions without either protective isolation or the need to confine patients continuously in hospital.	FOOTHILLS PROV GEN HOSP, DEPT MED, CALGARY, ALBERTA, CANADA	University of Calgary	RUSSELL, JA (corresponding author), TOM BAKER CANC CLIN, DEPT MED, 1331-29TH ST NW, CALGARY T2N 4N2, ALBERTA, CANADA.							COPELAN EA, 1991, BLOOD, V78, P838, DOI 10.1182/blood.V78.3.838.838; GRAHAMPOLE J, 1988, BONE MARROW TRANSPL, V3, P559; HANN IM, 1983, BMJ-BRIT MED J, V287, P384, DOI 10.1136/bmj.287.6389.384; HEIDT PJ, 1988, CANCER DETECT PREV, V12, P609; KELSEY SM, 1990, J CLIN PATHOL, V43, P783, DOI 10.1136/jcp.43.9.783-a; NAVARI RM, 1984, AM J MED, V76, P564, DOI 10.1016/0002-9343(84)90274-2; OGDEN AK, 1990, MED PEDIATR ONCOL, V18, P1, DOI 10.1002/mpo.2950180102; PETERSEN F, 1988, INFECTION, V16, P199, DOI 10.1007/BF01650752; POWLES R, 1990, LANCET, V336, P1417, DOI 10.1016/0140-6736(90)93111-2; RUSSELL J A, 1991, Bone Marrow Transplantation, V7, P72; SCHMEISER T, 1988, SCAND J INFECT DIS, V20, P625, DOI 10.3109/00365548809035663; SHERERTZ RJ, 1987, AM J MED, V83, P709, DOI 10.1016/0002-9343(87)90902-8; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; VOSSEN JM, 1990, EUR J CLIN MICROBIOL, V9, P14, DOI 10.1007/BF01969527	15	45	45	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 4	1992	339	8784					38	40		10.1016/0140-6736(92)90153-T	http://dx.doi.org/10.1016/0140-6736(92)90153-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345961				2022-12-28	WOS:A1992GY04300014
J	SCHWARTZ, RH				SCHWARTZ, RH			COSTIMULATION OF LYMPHOCYTES-T - THE ROLE OF CD28, CTLA-4, AND B7/BB1 IN INTERLEUKIN-2 PRODUCTION AND IMMUNOTHERAPY	CELL			English	Review							ACTIVATION ANTIGEN-B7; EXPRESSION				SCHWARTZ, RH (corresponding author), NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892, USA.							CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHEN L, 1992, SCIENCE, V243, P355; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARPER K, 1991, J IMMUNOL, V147, P1037; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JENKINS MK, 1992, IMMUNOL TODAY, V13, P69, DOI 10.1016/0167-5699(92)90137-V; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LINSLEY PS, 1992, IN PRESS J EXP MED; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; TURKA LA, 1992, IN PRESS P NATL ACAD	22	1275	1389	1	85	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1065	1068		10.1016/S0092-8674(05)80055-8	http://dx.doi.org/10.1016/S0092-8674(05)80055-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335362				2022-12-28	WOS:A1992KE60400001
J	EISENLOHR, LC; BACIK, I; BENNINK, JR; BERNSTEIN, K; YEWDELL, JW				EISENLOHR, LC; BACIK, I; BENNINK, JR; BERNSTEIN, K; YEWDELL, JW			EXPRESSION OF A MEMBRANE PROTEASE ENHANCES PRESENTATION OF ENDOGENOUS ANTIGENS TO MHC CLASS I-RESTRICTED LYMPHOCYTES-T	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANGIOTENSIN-CONVERTING ENZYME; CELL-SURFACE EXPRESSION; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTRACELLULAR-TRANSPORT; INFLUENZA NUCLEOPROTEIN; VACCINIA VIRUS; RECOGNITION; MOLECULES	We find that expression of the membrane dipeptidyl carboxypeptidase angiotensin-converting enzyme (ACE) enhances presentation of certain endogenously synthesized peptides to major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes. ACE appears to function only in an intracellular secretory compartment of antigen-presenting cells. ACE-enhanced antigen presentation requires the expression of the putative antigenic peptide transporters, TAP1 and TAP2. These findings demonstrate that a protease can influence the processing of endogenously synthesized antigens and strongly suggest that longer peptides can be transported from the cytosol to a secretory compartment where trimming of antigenic peptides to the lengths preferred by MHC class I molecules can occur if the appropriate protease is present.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20906; EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emory University			yewdell, jyewdell@nih.gov jonathan/A-1702-2012					ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BENNINK JR, 1986, J VIROL, V57, P786, DOI 10.1128/JVI.57.3.786-791.1986; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; EISENLOHR LC, 1992, J EXP MED, V175, P481, DOI 10.1084/jem.175.2.481; EISENLOHR LC, 1992, J IMMUNOL METHODS, V154, P131, DOI 10.1016/0022-1759(92)90220-N; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KOSLOWSKI S, 1992, J EXP MED, V175, P1417; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; NEELS HM, 1983, CLIN CHEM, V29, P1399; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SHERMAN LA, 1992, J EXP MED, V175, P1221, DOI 10.1084/jem.175.5.1221; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SWEETSER MT, 1988, J IMMUNOL, V141, P3324; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANPEL A, 1989, IMMUNOGENETICS, V29, P75; WEI L, 1991, J BIOL CHEM, V266, P5540; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033; YEWDELL JW, 1988, CELL, V52, P843, DOI 10.1016/0092-8674(88)90426-6; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	47	161	165	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					963	972		10.1016/0092-8674(92)90392-P	http://dx.doi.org/10.1016/0092-8674(92)90392-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1333889				2022-12-28	WOS:A1992KB99000009
J	WANG, MX; CHURCH, GM				WANG, MX; CHURCH, GM			A WHOLE GENOME APPROACH TO INVIVO DNA-PROTEIN INTERACTIONS IN ESCHERICHIA-COLI	NATURE			English	Article							MANNITOL MTL OPERON; ESCHERICHIA-COLI; RESTRICTION ENZYMES; BINDING-SITES; METHYLATION; SEQUENCE; GENE; METHYLTRANSFERASE; ENDONUCLEASE; RECOGNITION	THE increasingly rapid pace at which genomic DNA sequences are being determined has created a need for more efficient techniques to determine which parts of these sequences are bound in vivo by the proteins controlling processes such as gene expression, DNA replication and chromosomal mechanics. Here we describe a whole-genome approach to identify and characterize such DNA sequences. The method uses endogenous or artificially introduced methylases to methylate all genomic targets except those protected in vivo by protein or non-protein factors interfering with methylase action. These protected targets remain unmethylated in purified genomic DNA and are identified using methylation-sensitive restriction endonucleases. When the method was applied to the Escherichia coli genome, 0.1% of the endogenous adenine methyltransferase (Dam methylase) targets were found to be unmethylated. Five foreign methylases were examined by transfection. Database-matched DNA sequences flanking the in vivo-protected Dam sites all fell in the non-coding regions of seven E. coli operons (mtl, cdd, flh, gut, car, psp and fep). In the first four operons these DNA sequences closely matched the consensus sequence that binds to the cyclic AMP-receptor protein. The in vivo protection at the Dam site upstream of the car operon was correlated with a downregulation of car expression, as expected of a feedback repressor-binding model.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Jefferson University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	WANG, MX (corresponding author), THOMAS JEFFERSON UNIV,WILLS EYE HOSP,DIV RES,ONCOL RES LAB,PHILADELPHIA,PA 19107, USA.			church, george/0000-0001-6232-9969				BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BIRD AP, 1978, J MOL BIOL, V118, P27, DOI 10.1016/0022-2836(78)90242-5; BLYN LB, 1990, EMBO J, V9, P4045, DOI 10.1002/j.1460-2075.1990.tb07626.x; BRAATEN BA, 1992, P NATL ACAD SCI USA, V89, P4250, DOI 10.1073/pnas.89.10.4250; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CAMPBELL JL, 1988, GENE, V74, P189, DOI 10.1016/0378-1119(88)90283-1; CARTWRIGHT IL, 1991, BIOTECHNIQUES, V11, P188; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; DAVIS T, 1988, MOL MICROBIOL, V2, P405, DOI 10.1111/j.1365-2958.1988.tb00045.x; EBRIGHT R, 1982, MOL STRUCTURE BIOL A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FEHER Z, 1989, CURR GENET, V16, P461, DOI 10.1007/BF00340726; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GUNASEKERA A, 1990, NUCLEIC ACIDS RES, V18, P6853, DOI 10.1093/nar/18.23.6853; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JIANG W, 1990, MOL MICROBIOL, V4, P2003, DOI 10.1111/j.1365-2958.1990.tb02050.x; KWOH TJ, 1988, NUCLEIC ACIDS RES, V16, P11489, DOI 10.1093/nar/16.24.11489; LENGELER J, 1978, MOL GEN GENET, V164, P163, DOI 10.1007/BF00267381; LYONS SM, 1984, J BACTERIOL, V159, P421, DOI 10.1128/JB.159.1.421-423.1984; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; RAZIN A, 1980, NUCLEIC ACIDS RES, V8, P1783, DOI 10.1093/nar/8.8.1783; RINGQUIST S, 1992, P NATL ACAD SCI USA, V89, P4539, DOI 10.1073/pnas.89.10.4539; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SALUZ HP, 1991, TRENDS GENET, V7, P207, DOI 10.1016/0168-9525(91)90366-X; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SILVERMAN M, 1974, J BACTERIOL, V120, P1196, DOI 10.1128/JB.120.3.1196-1203.1974; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; STORMO GD, 1989, P NATL ACAD SCI USA, V86, P1183, DOI 10.1073/pnas.86.4.1183; VALENTINHANSEN P, 1989, MOL MICROBIOL, V3, P1385, DOI 10.1111/j.1365-2958.1989.tb00120.x; VOVIS GF, 1977, J MOL BIOL, V115, P525, DOI 10.1016/0022-2836(77)90169-3; WILSON GG, 1988, GENE, V74, P281, DOI 10.1016/0378-1119(88)90304-6; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; YMADA M, 1987, J BIOL CHEM, V265, P5455	36	56	58	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					606	610		10.1038/360606a0	http://dx.doi.org/10.1038/360606a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1334233				2022-12-28	WOS:A1992KB95900092
J	VUKMANOVIC, S; GRANDEA, AG; FAAS, SJ; KNOWLES, BB; BEVAN, MJ				VUKMANOVIC, S; GRANDEA, AG; FAAS, SJ; KNOWLES, BB; BEVAN, MJ			POSITIVE SELECTION OF LYMPHOCYTES-T INDUCED BY INTRATHYMIC INJECTION OF A THYMIC EPITHELIAL-CELL LINE	NATURE			English	Article							PEPTIDE BINDING; VIRAL PEPTIDES; ANTIGEN; MHC; SELF; RECOGNITION; REPERTOIRE; THYMOCYTES; MOLECULES; MUTATIONS	T LYMPHOCYTES recognize antigens as peptide fragments associated with molecules encoded by the major histocompatibility complex (MHC) and expressed on the surface of antigen-presenting cells'. In the thymus, T cells bearing alphabeta receptors that react with the MHC molecules expressed by radioresistant stromal elements are positively selected for maturation2-5. In (A x B --> A) bone marrow chimaeras, T cells restricted to the MHC-A haplotype are positively selected, whereas MHC-B-reactive thymocytes are not. We investigated whether the introduction of particular thymic stromal elements bearing MHC-B molecules could alter the fate of B-reactive T cells in these (A x B --> A) chimaeras. Thymic epithelial cell (TEC) lines expressing H-2b were introduced by intrathymic injection into (H-2b/s --> H2s) bone marrow chimaeras and we measured their ability to generate H-2b-restricted cytotoxic T-lymphocytes (CTLs). We report here that one TEC line, 427.1, was able positively to select CTLs specific for influenza and vesicular stomatitis virus antigens in association with class I H-2b molecules. In addition, line 427.1 can process cytoplasmic proteins for presentation to H-2K(b)- and H-2D(b)-restricted CTLs. Thus, a TEC line capable of normal class I MHC antigen processing and presentation in vitro can induce positive selection after intrathymic injection.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; WISTAR INST,PHILADELPHIA,PA 19104; UNIV PENN,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; The Wistar Institute; University of Pennsylvania	VUKMANOVIC, S (corresponding author), UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195, USA.			Vukmanovic, Stanislav/0000-0003-3547-8349; Knowles, Barbara B./0000-0002-2597-5619	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI019335-19, R01 AI019335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019335] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; DENNERT G, 1980, CELL IMMUNOL, V53, P350, DOI 10.1016/0008-8749(80)90335-4; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FINK PJ, 1988, IMMUNOL TODAY, V9, P377, DOI 10.1016/0167-5699(88)91238-8; GOLDSCHNEIDER I, 1986, J EXP MED, V163, P1, DOI 10.1084/jem.163.1.1; GRANDEA AG, 1992, P NATL ACAD SCI USA, V89, P2794, DOI 10.1073/pnas.89.7.2794; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; MARRACK P, 1988, IMMUNOL TODAY, V9, P308, DOI 10.1016/0167-5699(88)91324-2; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MIZUOCHI T, 1992, J EXP MED, V175, P1601, DOI 10.1084/jem.175.6.1601; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; NIKOLICZUGIC J, 1990, EUR J IMMUNOL, V20, P2431, DOI 10.1002/eji.1830201111; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NUCHTERN JG, 1989, NATURE, V339, P23; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPRENT J, 1978, J EXP MED, V146, P1838; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YEWDELL JW, IN PRESS ADV IMMUN; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	32	104	106	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					729	732		10.1038/359729a0	http://dx.doi.org/10.1038/359729a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1331804	Green Accepted			2022-12-28	WOS:A1992JU65000056
J	LIU, J; LISSENS, W; DEVROEY, P; VANSTEIRTEGHEM, A; LIEBAERS, I				LIU, J; LISSENS, W; DEVROEY, P; VANSTEIRTEGHEM, A; LIEBAERS, I			EFFICIENCY AND ACCURACY OF POLYMERASE-CHAIN-REACTION ASSAY FOR CYSTIC-FIBROSIS ALLELE DELTA-F508 IN SINGLE CELL	LANCET			English	Article							HUMAN PREIMPLANTATION EMBRYOS; ENZYMATIC AMPLIFICATION; DNA AMPLIFICATION; IDENTIFICATION; DIAGNOSIS; INVITRO; BIOPSY; GENE; PCR	Diagnosis of genetic disorders in the embryo before implantation, though possible by removal of one or two blastomeres at the eight-cell stage, is still experimental because the procedures of gene analysis of DNA from a single cell are not yet reliable enough for clinical application. We have evaluated the efficiency and accuracy of polymerase-chain-reaction (PCR) amplification of a single-copy gene, wild-type or cystic fibrosis DELTA-F508 allele, on single sperm cells from a donor known to be a heterozygous carrier of the DELTA-F508 mutation. DNA from single spermatozoa was decontaminated by restriction-enzyme treatment, then the region around the DELTA-F508 site was amplified by nested PCR. The distribution of the wild-type and mutant alleles (59 [55%] and 48 [45%, respectively]) in the 107 single spermatozoa did not differ from that expected (50% each). 1 sample did not provide an amplified signal. To check that the two alleles would be amplified with equal efficiency when they were both present within a cell, we did PCR for 51 two-sperm samples. Again the distribution did not deviate from that expected (17 [33%] both wild-type; 21 [41 %] one wild-type, one DELTA-F508; 13 [26%] both DELTA-F508 vs 25%; 50%; 25% expected). None of the 74 blanks in these experiments was contaminated. We conclude that our DELTA-F508 single-cell assay is efficient and accurate and can be used for analysis of blastomere DNA to diagnose cystic fibrosis before embryo implantation.	VRIJE UNIV BRUSSELS HOSP,DEPT MED GENET,LAARBEEKLAAN 101,B-1090 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,CTR REPROD MED,B-1050 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,DEPT MED GENET,B-1050 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel			Lissens, Willy/B-2892-2013	Lissens, Willy/0000-0003-3875-9955				GYLLENSTEN U, 1990, PCR PROTOCOLS GUIDE, P300; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HARDY K, 1990, HUM REPROD, V5, P708, DOI 10.1093/oxfordjournals.humrep.a137173; JINNO Y, 1990, NUCLEIC ACIDS RES, V18, P6739, DOI 10.1093/nar/18.22.6739; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; NAVIDI W, 1991, HUM REPROD, V6, P836, DOI 10.1093/oxfordjournals.humrep.a137438; QUINN P, 1985, ANN NY ACAD SCI, V442, P195, DOI 10.1111/j.1749-6632.1985.tb37520.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR G, 1990, NATURE, V343, P27, DOI 10.1038/343027a0; STROM CM, 1990, LANCET, V336, P306, DOI 10.1016/0140-6736(90)91835-X; VARAWALLA NY, 1991, PRENATAL DIAG, V11, P775, DOI 10.1002/pd.1970111006	15	44	44	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1190	1192		10.1016/0140-6736(92)91133-S	http://dx.doi.org/10.1016/0140-6736(92)91133-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349937				2022-12-28	WOS:A1992HU68400003
J	REGNSTROM, J; NILSSON, J; TORNVALL, P; LANDOU, C; HAMSTEN, A				REGNSTROM, J; NILSSON, J; TORNVALL, P; LANDOU, C; HAMSTEN, A			SUSCEPTIBILITY TO LOW-DENSITY-LIPOPROTEIN OXIDATION AND CORONARY ATHEROSCLEROSIS IN MAN	LANCET			English	Article							HERITABLE HYPERLIPIDEMIC RABBIT; GRADIENT ULTRACENTRIFUGATION; DEGRADATION; PROGRESSION; PLASMA; INVIVO	Animal studies indicate a possible role for lipid oxidation in the development of atherosclerosis. We set out to investigate whether there was a relation between the ability of low-density lipoprotein (LDL) to resist oxidation in vitro and the severity of coronary atherosclerosis in man. 35 unselected young (mean [SD] age 39.9 [4.2] years) male survivors of myocardial infarction underwent angiography, and LDL was isolate from their plasma by density gradient ultracentrifugation. In-vitro LDL susceptibility to oxidation was assessed by determination of the lag phase for the formation of conjugated dienes in the presence of copper ions. An inverse relation was found between lag phase and quantitative estimates of global coronary atherosclerosis (r = - 0.45; p < 0.02). Multivariate analysis indicated that the lag phase for oxidative modification of LDL and LDL cholesterol concentration correlated independently with seversity of coronary atherosclerosis. The lag phase for oxidation of LDL was also related to the triglyceride content of the LDL fraction (r = - 0.55; p < 0.002). The finding that susceptibility of LDL oxidation is associated with severity of coronary atherosclerosis may indicate that lipid oxidation promotes premature coronary atherosclerosis and that individuals with an LDL enriched in triglycerides are at particular risk.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT MED,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT THORAC RADIOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	REGNSTROM, J (corresponding author), KAROLINSKA INST,KAROLINSKA HOSP,KING GUSTAF VTH RES INST,BOX 60004,S-10401 STOCKHOLM 60,SWEDEN.							AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; Carlson K, 1973, J Clin Pathol Suppl (Assoc Clin Pathol), V5, P32; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CHAPMAN MJ, 1988, J LIPID RES, V29, P442; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; HAMSTEN A, 1986, CIRCULATION, V73, P1097, DOI 10.1161/01.CIR.73.6.1097; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STRINGER MD, 1989, BRIT MED J, V298, P281, DOI 10.1136/bmj.298.6669.281; TORNVALL P, 1991, ATHEROSCLEROSIS, V90, P67, DOI 10.1016/0021-9150(91)90245-X	19	507	519	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1183	1186		10.1016/0140-6736(92)91129-V	http://dx.doi.org/10.1016/0140-6736(92)91129-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349935				2022-12-28	WOS:A1992HU68400001
J	GREEN, A; GALE, EAM; PATTERSON, CC				GREEN, A; GALE, EAM; PATTERSON, CC			INCIDENCE OF CHILDHOOD-ONSET INSULIN-DEPENDENT DIABETES-MELLITUS - THE EURODIAB ACE STUDY	LANCET			English	Article							RISING INCIDENCE; CHILDREN; EUROPE; IDDM; AGE	EURODIAB ACE is a collaborative European study that was set up to assess incidence of childhood insulin-dependent diabetes mellitus (IDDM) in Europe, test the proposal of a south-north gradient, and to gather information to determine the causes and pathogenesis of the disease. Here, the basic epidemiological results are reported. Newly diagnosed cases of IDDM in children aged up to 15 years were identified prospectively in twenty-four geographically well-defined study regions in Europe and Israel (a total of 16.8 million children) during 1989 and 1990. 3060 cases were identified with estimated ascertainment rates exceeding 90% in all study regions. Age-standardised and sex-standardised incidence rates varied widely, ranging from 4.6 (northern Greece) to 42.9 (two regions in Finland) cases per 100 000 per year. Rates in southern Europe were generally higher than previously assumed, and there was an unexpectedly high incidence in Sardinia, which had the second highest rate (30.2 cases per 100 000 per year) recorded in Europe. Eastern European regions had generally low rates. The collaborative network now established provides a framework for further studies to examine the complex interaction between genetic and environmental factors in the cause and pathogenesis of IDDM.	ODENSE UNIV,GENET EPIDEMIOL RES UNIT,DK-5230 ODENSE,DENMARK; ST BARTHOLOMEWS HOSP,DEPT DIABET & METAB,LONDON EC1A 7BE,ENGLAND; QUEENS UNIV BELFAST,DEPT EPIDEMIOL & PUBL HLTH,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	University of Southern Denmark; University of London; Queen Mary University London; Queens University Belfast				Gorus, Frans/0000-0002-9007-6177				AKERBLOM HK, 1985, DIABETES CARE, V8, P10, DOI 10.2337/diacare.8.1.S10; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BISHOP YMM, 1974, DISCRETE MULTIVARIAT, P229; CARCASSI C, 1990, DIABETES S1, V39; Christy M, 1979, Diabetes Care, V2, P127, DOI 10.2337/diacare.2.2.127; DEBEAUFORT CE, 1988, DIABETOLOGIA, V31, P758, DOI 10.1007/BF00274779; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; GREEN A, 1986, DIABETES 1985, P443; GREEN A, IN PRESS DIABETES EU; HOLFORD TR, 1980, BIOMETRICS, V36, P299, DOI 10.2307/2529982; HOURS M, 1984, REV EPIDEMIOL SANTE, V32, P107; JONER G, 1989, DIABETOLOGIA, V32, P79, DOI 10.1007/BF00505178; KALITS I, 1990, DIABETOLOGIA, V33, P346, DOI 10.1007/BF00404638; LAPORTE RE, 1985, DIABETES CARE, V8, P101, DOI 10.2337/diacare.8.1.S101; LARON Z, 1985, DIABETES CARE, V8, P24, DOI 10.2337/diacare.8.1.S24; LESTRADET H, 1977, DIABETES METAB, V3, P29; LEVYMARCHAL C, 1990, DIABETOLOGIA, V33, P465, DOI 10.1007/BF00405107; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; NYSTROM L, 1990, INT J EPIDEMIOL, V19, P141, DOI 10.1093/ije/19.1.141; REWERS M, 1987, DIABETES, V36, P106, DOI 10.2337/diabetes.36.1.106; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SCHOBER E, 1988, ACTA PAEDIATR SCAND, V77, P299, DOI 10.1111/j.1651-2227.1988.tb10646.x; SHUBNIKOV E, 1991, DIABETES S1, V40; SOLTESZ G, 1990, DIABETIC MED, V7, P111, DOI 10.1111/j.1464-5491.1990.tb01343.x; THORSSON AV, 1991, MAY INT S EP ET IDDM; TUOMILEHTOWOLF E, 1989, LANCET, V2, P299; VAANDRAGER GJ, 1984, DIABETOLOGIA, V27, P203	29	403	408	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					905	909		10.1016/0140-6736(92)90938-Y	http://dx.doi.org/10.1016/0140-6736(92)90938-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348306				2022-12-28	WOS:A1992HN48300012
J	HANSEN, HH				HANSEN, HH			MANAGEMENT OF SMALL-CELL CANCER OF THE LUNG	LANCET			English	Article							RANDOMIZED TRIAL; CHEMOTHERAPY; ETOPOSIDE				HANSEN, HH (corresponding author), RIGSHOSP,FINSEN INST,DEPT ONCOL,DK-2100 COPENHAGEN,DENMARK.							AISNER SC, 1990, J CLIN ONCOL, V8, P402, DOI 10.1200/JCO.1990.8.3.402; ALBAIN KS, 1991, CHEST, V99, P1425, DOI 10.1378/chest.99.6.1425; ANDERSEN M, 1990, CANCER TREAT REV, V17, P427, DOI 10.1016/0305-7372(90)90083-R; ARRIAGADA R, 1989, LUNG CANCER, V5, P237; BERGMAN B, 1991, ACTA ONCOL, V30, P947, DOI 10.3109/02841869109088248; BLEEHEN NM, 1989, BRIT J CANCER, V59, P584; CHAHINIAN AP, 1989, J CLIN ONCOL, V7, P993, DOI 10.1200/JCO.1989.7.8.993; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; DEARING MP, 1990, J CLIN ONCOL, V8, P1042, DOI 10.1200/JCO.1990.8.6.1042; GOLDIE JH, 1982, CANCER TREAT REP, V66, P439; GREEN JA, 1991, P AN M AM SOC CLIN, V10, P243; GREEN MR, 1989, LUNG CANCER, V5, P178; HANSEN HH, 1991, EUR J CANCER, V27, P342, DOI 10.1016/0277-5379(91)90543-M; HANSEN HH, 1989, LUNG CANCER, V5, P119; HIRSCH FR, 1987, J CLIN ONCOL, V5, P585, DOI 10.1200/JCO.1987.5.4.585; HIRSCH FR, 1988, CANCER, V62, P973, DOI 10.1002/1097-0142(19880901)62:5<973::AID-CNCR2820620521>3.0.CO;2-O; KRISTJANSEN PEG, 1990, J NATL CANCER I, V82, P263, DOI 10.1093/jnci/82.4.263; LEONARD RCF, 1990, CANCER RES, V50, P6545; MATTSON K, IN PRESS EUR J CANCE; MOUNTAIN CF, 1987, LUNG CANCER, V3, P4; MULSHINE J, 1990, P AN M AM SOC CLIN, V9, P230; MURRAY N, 1991, P AN M AM SOC CLIN, V10, P243; ROSTI G, 1991, P AN M AM SOC CLIN, V10, P268; SHEPHERD FA, 1991, J THORAC CARDIOV SUR, V101, P385; SLEVIN ML, 1989, J CLIN ONCOL, V7, P1333, DOI 10.1200/JCO.1989.7.9.1333; SOUHAMI RL, 1990, BRIT J CANCER, V61, P584, DOI 10.1038/bjc.1990.131; SPIRO SG, 1989, BRIT J CANCER, V59, P578, DOI 10.1038/bjc.1989.117	27	88	93	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					846	849		10.1016/0140-6736(92)90287-D	http://dx.doi.org/10.1016/0140-6736(92)90287-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347865				2022-12-28	WOS:A1992HM44100012
J	DAMBLYCHAUDIERE, C; JAMET, E; BURRI, M; BOPP, D; BASLER, K; HAFEN, E; DUMONT, N; SPIELMANN, P; GHYSEN, A; NOLL, M				DAMBLYCHAUDIERE, C; JAMET, E; BURRI, M; BOPP, D; BASLER, K; HAFEN, E; DUMONT, N; SPIELMANN, P; GHYSEN, A; NOLL, M			THE PAIRED BOX GENE POX-NEURO - A DETERMINANT OF POLY-INNERVATED SENSE-ORGANS IN DROSOPHILA	CELL			English	Article							DEVELOPING EXCRETORY SYSTEM; PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE COMPLEX; SPATIAL EXPRESSION; DNA; LOCUS; MELANOGASTER; EMBRYOS; SEGMENTATION; ELEMENTS	This study describes the structure and function of pox neuro (poxn), a gene previously isolated by virtue of a conserved domain, the paired box, which it shares with the segmentation genes paired and gooseberry. Its expression pattern has been analyzed, particularly during development of the PNS. We propose that poxn is a "neuroblast identity" gene acting in both the PNS and the CNS on the basis of the following evidence. Its expression is restricted to four neuronal precursors in each hemisegment: two neuronal stem cells (neuroblasts) in the CNS, and two sensory mother cells (SMCs) in the PNS. The SMCs that express poxn produce the poly-innervated external sense organs of the larva. In poxn- embryos, poly-innervated sense organs are transformed into mono-innervated. Conversely, ectopic expression of poxn in embryos transformed with a heat-inducible poxn gene can switch mono-innervated to poly-innervated sense organs. Expression of poxn in the wing disc is restricted to the SMCs of the poly-innervated sense organs, suggesting that poxn also determines the lineage of poly-innervated adult sense organs.	UNIV ZURICH,INST MOLEK BIOL 2,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich; University of Zurich	DAMBLYCHAUDIERE, C (corresponding author), UNIV LIBRE BRUXELLES,GENET LAB,B-1640 RHODE ST GENESE,BELGIUM.		Jamet, Elisabeth/Z-2476-2019; Bopp, Daniel/L-3517-2018	Bopp, Daniel/0000-0002-0740-9672; Basler, Konrad/0000-0003-3534-1529; Spielmann, Patrick/0000-0001-7056-0351				BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; Bate C.M., 1978, HDB SENSORY PHYSL, V9, P1, DOI [10.1007/978-3-642-66880-7_1, DOI 10.1007/978-3-642-66880-7_1]; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1986, ROUX ARCH DEV BIOL, V195, P222, DOI 10.1007/BF02438954; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DAVIS MB, 1988, GENETICS, V120, P755; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1991, IN PRESS DETERMINANT; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; FREI E, 1985, EMBO J, V4, P979, DOI 10.1002/j.1460-2075.1985.tb03727.x; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; Hertweck H, 1931, Z WISS ZOOL ABT A, V139, P559; HUANG F, 1991, DEVELOPMENT, V111, P1087; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; Kankel D.R., 1980, Genetics and Biology of Drosophila, V2d, P295; Keilin D, 1911, CR HEBD ACAD SCI, V153, P977; Keilin D., 1915, B SCI FR BELG, V49, P15; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LAKES R, 1990, CELL TISSUE RES, V259, P93, DOI 10.1007/BF00571434; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Maniatis T., 1982, MOL CLONING; NORNES HO, 1990, DEVELOPMENT, V109, P797; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TIX S, 1989, DEVELOPMENT, V107, P855; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; WEISCHAUS E, 1986, DROSOPHILA PRACTICAL, P199	60	118	120	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					159	172		10.1016/0092-8674(92)90127-X	http://dx.doi.org/10.1016/0092-8674(92)90127-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1348214	Green Accepted			2022-12-28	WOS:A1992HM44500015
J	TENENBEIN, M; KOWALSKI, S; SIENKO, A; BOWDEN, DH; ADAMSON, IYR				TENENBEIN, M; KOWALSKI, S; SIENKO, A; BOWDEN, DH; ADAMSON, IYR			PULMONARY TOXIC EFFECTS OF CONTINUOUS DESFERRIOXAMINE ADMINISTRATION IN ACUTE IRON POISONING	LANCET			English	Article							RESPIRATORY-DISTRESS SYNDROME; INTRAVENOUS DEFEROXAMINE	The drug of choice for the treatment of iron poisoning is desferrioxamine, though the best route of administration, dose, and duration of treatment are unclear. We report fatal lung injury in four patients who were treated with continuous intravenous infusions. The patients, aged 19-26 years, had received desferrioxamine infusions of 15 mg/kg per h for 65-92 h. Respiratory distress developed after 32-72 h. The patients met clinical, physiological, and necropsy criteria for the diagnosis of adult respiratory distress syndrome (ARDS); none had any of the known risk factors for the development of this disorder. We reviewed the records of forty-three iron-poisoned patients treated with desferrioxamine infusions. No patient treated for less than 24 h had pulmonary complications, however, of the fourteen treated for longer than 24 h, four were the patients with ARDS and four others had pulmonary oedema of other causes. We suggest that the pulmonary complications are caused by continuous infusion of desferrioxamine and that the ARDS in these patients was a consequence of free-radical generation. We recommend that desferrioxamine infusion should not be administered for longer than 24 h.	MANITOBA POISON CONTROL,WINNIPEG,MANITOBA,CANADA; UNIV MANITOBA,DEPT PEDIAT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT PHARMACOL,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT MED,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT ANESTHESIA,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT PATHOL,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba								ADAMSON IYR, 1970, ARCH PATHOL, V90, P463; BARNES R, 1972, BIOCHEM J, V128, P1042; BORG D C, 1986, Journal of Free Radicals in Biology and Medicine, V2, P237, DOI 10.1016/S0748-5514(86)80004-6; COHEN AR, 1989, J PEDIATR-US, V115, P151, DOI 10.1016/S0022-3476(89)80353-1; DONFRANCESCO A, 1990, CANCER RES, V50, P4929; FREEDMAN MH, 1990, AM J DIS CHILD, V144, P565, DOI 10.1001/archpedi.1990.02150290059028; HENRETIG FM, 1983, ANN EMERG MED, V12, P306, DOI 10.1016/S0196-0644(83)80515-0; Lovejoy F H Jr, 1982, J Toxicol Clin Toxicol, V19, P871; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; PECK MG, 1982, J TOXICOL-CLIN TOXIC, V19, P865; ROBOTHAM JL, 1980, AM J DIS CHILD, V134, P875, DOI 10.1001/archpedi.1980.02130210059016; ROYALL JA, 1988, J PEDIATR-US, V112, P169, DOI 10.1016/S0022-3476(88)80053-2; TENENBEIN M, 1987, J PEDIATR-US, V111, P142, DOI 10.1016/S0022-3476(87)80365-7; TENENBEIN M, 1988, MED TOXICOL ADV DRUG, V3, P77, DOI 10.1007/BF03259934; WEITMAN SD, 1991, J NATL CANCER I, V83, P1834, DOI 10.1093/jnci/83.24.1834-a; 1990, MED LETT DRUG THER, V32, P88	16	82	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					699	701		10.1016/0140-6736(92)90598-W	http://dx.doi.org/10.1016/0140-6736(92)90598-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347583				2022-12-28	WOS:A1992HK32000003
J	NOKES, C; BUNDY, DAP				NOKES, C; BUNDY, DAP			TRICHURIS-TRICHIURA INFECTION AND MENTAL-DEVELOPMENT IN CHILDREN	LANCET			English	Letter											NOKES, C (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,WELLCOME RES CTR PARASIT INFECT,DEPT BIOL,LONDON SW7 2BB,ENGLAND.							CALLENDER, 1992, LANCET, V339, P181; NOKES C, IN PRESS P R SOC L B; NOKES C, IN PRESS PARASITOLOG	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					500	500		10.1016/0140-6736(92)91115-O	http://dx.doi.org/10.1016/0140-6736(92)91115-O			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346859				2022-12-28	WOS:A1992HE93200049
J	MOUKARZEL, AA; SONG, MK; BUCHMAN, AL; VARGAS, J; GUSS, W; MCDIARMID, S; REYEN, L; AMENT, ME				MOUKARZEL, AA; SONG, MK; BUCHMAN, AL; VARGAS, J; GUSS, W; MCDIARMID, S; REYEN, L; AMENT, ME			EXCESSIVE CHROMIUM INTAKE IN CHILDREN RECEIVING TOTAL PARENTERAL-NUTRITION	LANCET			English	Article							MILD PERIPHERAL NEUROPATHY; GLUCOSE-TOLERANCE; DEFICIENCY; SUPPLEMENTATION; SUFFICIENCY; VITAMINS; INFANTS; INSULIN; BLOOD; SERUM	Various expert bodies have recommended that the daily parental intake of chromium in children receiving total parenteral nutrition (TPN) should be 0.20-mu-g/kg. To test whether this-recommendation is appropriate, we assessed chromium intake, serum chromium concentrations, and renal function in 15 children receiving TPN. The median duration of TPN use was 9.5 (range 1.3-14) years. The children's glomerular filtration rate (GFR), measured by plasma clearance of indium-111-DTPA was lower than that of non-TPN controls (70 [SD 17) vs 110 [10] ml/min per 1.73 m2). The daily chromium intake averaged 0.15 (0.09) mu-g/kg daily but the serum chromium concentration was 20 (4 to 42) times higher than that of the controls (2.1 [1.2] vs 0.10 [0.03] mu-g/l; p < 0.0001). GFR was significantly inversely correlated with serum chromium concentration (r = -0.60, p < 0.02), daily chromium intake (r = -0.69, p <0.01), cumulative parenteral chromium intake (r = -0.72, p < 0.01), and TPN duration (r = -0.52, p < 0.05). We discontinued chromium supplementation of TPN solutions and reassessed the children a year later. Contaminating chromium concentrations were 1.0-1.8-mu-g/l in TPN solutions and 0.9-mu-g/l in fat emulsions. Drinking water contained 4.3-5.7-mu-g/l. Thus, the chromium intake without supplementation was only 0.05 (0.01) mu-g/kg daily. The mean serum chromium concentration fell to 0.50 (0.30) mu-g/l but was still significantly higher than that in the controls (p < 0.01). The GFR did not change significantly (65 [14] ml/min per 1.73 m2). No patient has shown signs of chromium deficiency. Although our patients were receiving less than the recommended chromium intake during supplementation, their high serum concentrations suggested excessive intake. The recommended parenteral chromium intake for children should be lowered.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV PEDIAT GASTROENTEROL & NUTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ANDERSON RA, 1989, SCI TOTAL ENVIRON, V86, P75, DOI 10.1016/0048-9697(89)90196-4; BROWN RO, 1986, DIGEST DIS SCI, V31, P661, DOI 10.1007/BF01318699; BYRNE WJ, 1979, SURG GYNECOL OBSTET, V149, P593; CASEY CE, 1984, BRIT J NUTR, V52, P73, DOI 10.1079/BJN19840072; CHASSON AL, 1961, AM J CLIN PATHOL, V35, P83, DOI 10.1093/ajcp/35.1_ts.83; ESPINAL J, 1987, NATURE, V328, P574, DOI 10.1038/328574a0; EVANS GW, 1973, BIOCHEM BIOPH RES CO, V50, P718, DOI 10.1016/0006-291X(73)91303-X; FREUND H, 1979, JAMA-J AM MED ASSOC, V241, P496, DOI 10.1001/jama.241.5.496; GHISOLFI J, 1984, JOURNEES PARISIENNES, P97; GREENE HL, 1988, AM J CLIN NUTR, V48, P1324; GURSON CT, 1971, AM J CLIN NUTR, V24, P1313; HAMBRIDGE KM, 1989, TXB GASTROENTEROLOGY, P398; HOPKINS LL, 1968, AM J CLIN NUTR, V21, P203, DOI 10.1093/ajcn/21.3.203; ITO Y, 1990, JPEN-PARENTER ENTER, V14, P610, DOI 10.1177/0148607190014006610; JEEJEEBHOY KN, 1977, AM J CLIN NUTR, V30, P531; KIEN CL, 1986, JPEN-PARENTER ENTER, V10, P662, DOI 10.1177/0148607186010006662; KUMPULAINEN J, 1980, AM J CLIN NUTR, V33, P2299, DOI 10.1093/ajcn/33.11.2299; MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018; MERTZ W, 1969, PHYSIOL REV, V49, P163, DOI 10.1152/physrev.1969.49.2.163; MOORE MC, 1986, PEDIATRICS, V77, P530; RIALES R, 1981, AM J CLIN NUTR, V34, P2670, DOI 10.1093/ajcn/34.12.2670; SCHERMAIER AJ, 1985, CLIN CHIM ACTA, V152, P123, DOI 10.1016/0009-8981(85)90183-4; SCHROEDER HA, 1966, J NUTR, V88, P439, DOI 10.1093/jn/88.4.439; SCHWARZ K, 1959, ARCH BIOCHEM BIOPHYS, V85, P292, DOI 10.1016/0003-9861(59)90479-5; 1989, FOOD NUTRITION BOARD, P242; 1988, CHROMIUM ENV HLTH CR, P61; 1979, DIABETES, V28, P1039; 1979, JAMA-J AM MED ASSOC, V241, P2051	28	70	70	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1992	339	8790					385	388		10.1016/0140-6736(92)90078-H	http://dx.doi.org/10.1016/0140-6736(92)90078-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346659				2022-12-28	WOS:A1992HD65900003
J	MARMOT, MG; POULTER, NR				MARMOT, MG; POULTER, NR			PRIMARY PREVENTION OF STROKE	LANCET			English	Article							FACTOR INTERVENTION TRIAL; CORONARY HEART-DISEASE; RISK FACTOR; MORTALITY; CONSUMPTION; JAPAN		ST MARYS HOSP,SCH MED,DEPT CLIN PHARMACOL,LONDON,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND	Imperial College London; University of London; London School of Hygiene & Tropical Medicine	MARMOT, MG (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT EPIDEMIOL & PUBL HLTH,66-72 GOWER ST,LONDON WC1E 6EA,ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ACHESON RM, 1983, LANCET, V1, P1191; AMERY A, 1985, LANCET, V1, P1349; Carstairs V., 1991, DEPRIVATION HLTH SCO; CRUICKSHANK JK, 1991, LANCET, P842; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JOOSSENS JV, 1980, EPIDEMIOLOGY ARTERIA, P489; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; MACMAHON SW, 1986, J HYPERTENS, V4, pS14; MARMOT MG, 1984, LANCET, V1, P1455, DOI 10.1016/S0140-6736(84)91943-3; Marmot MG, 1982, NUTRITION HLTH, P243; POULTER NR, IN PRESS ADV CONTRAC; RUTAN GH, 1988, CIRCULATION, V77, P504, DOI 10.1161/01.CIR.77.3.504; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STAMLER J, 1989, HYPERTENSION, V14, P570, DOI 10.1161/01.HYP.14.5.570; STRACHAN DP, 1991, BMJ-BRIT MED J, V302, P84, DOI 10.1136/bmj.302.6768.84; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; UEDA K, 1988, STROKE, V19, P49; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; 1981, RCGP19 ROYAL COLL GE	23	76	77	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1992	339	8789					344	347		10.1016/0140-6736(92)91659-V	http://dx.doi.org/10.1016/0140-6736(92)91659-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC771	1346421				2022-12-28	WOS:A1992HC77100016
J	VANDERGRAAF, Y; DEWAARD, F; VANHERWERDEN, LA; DEFAUW, J				VANDERGRAAF, Y; DEWAARD, F; VANHERWERDEN, LA; DEFAUW, J			RISK OF STRUT FRACTURE OF BJORK-SHILEY VALVES	LANCET			English	Article							MECHANICAL FAILURE; INFORMATION; PROSTHESIS	The incidence of and factors that predispose to outlet strut fracture of Bjork-Shiley heart valves are still not known. To obtain such information a retrospective cohort study was conducted on all 2303 patients in the Netherlands with a 60-degrees convexo-concave (60-degrees-CC) or a 70-degrees convexo-concave (70-degrees-CC) Bjork-Shiley heart valve. Patients have been followed-up for a mean of 6.6 years (range 1-4271 days). 42 cases of mechanical failure due to outlet strut fracture have been recorded-6 of the 7 patients with fracture of the aortic valve died, as did 18 of the 35 patients with fracture of the mitral valve. Multivariate analysis identified wide opening angle (70-degrees), large valve size (greater-than-or-equal-to 29 mm diameter), and young age (< 50 years) as risk factors for outlet strut fracture. For large 70-degrees-CC mitral valves the cumulative risk of outlet strut fracture after 8 years was 17.4% (95% Cl 9.1-31.6). Unlike previous findings, this excessive risk applied to late as well as to early batches of valves. In patients with a large 60-degrees-CC mitral valve the cumulative risk after 8 years was 4.2% (95% Cl 2.7-6.5). The incidence rate of outlet strut fracture in 60-degrees-CC and 70-degrees-CC valves (aortic and mitral) was constant over time. Overall survival since implantation was better for patients with 60-degrees-CC prostheses than for those with 70-degrees-CC prostheses; the adjusted hazard ratio for mortality for patients receiving a 70-degrees-CC prosthesis was 1.5 (95% Cl 1.1-2.0). Together with the low (24%) necropsy rate, this ratio suggests that the reported incidence of strut fracture for the 70-degrees-CC valves is an underestimate. The data indicate that prophylactic replacement of 60-degrees-CC and 70-degrees-CC valves is advisable for selected groups of patients. Since the case-fatality rate is 50% for emergency replacement of faulty valves, patients suspected of Bjork-Shiley heart-valve failure should be referred without delay to a cardiothoracic centre.	ST ANTONIUS HOSP,DEPT CARDIOPULM SURG,NIEUWEGEIN,NETHERLANDS; ERASMUS UNIV,HOSP DIJKZIGT,DEPT CARDIOPULM SURG,ROTTERDAM,NETHERLANDS	St. Antonius Hospital Utrecht; Erasmus University Rotterdam; Erasmus MC				van Herwerden, Lex A./0000-0003-1087-1275				COX DR, 1972, J R STAT SOC B, V34, P187; HIRATZKA LF, 1988, J AM COLL CARDIOL, V11, P1130, DOI 10.1016/S0735-1097(98)90075-4; HUSEBYE DG, 1983, J THORAC CARDIOV SUR, V86, P543; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LINDBLOM D, 1986, J THORAC CARDIOV SUR, V92, P894; LINDBLOM D, 1989, J THORAC CARDIOV SUR, V97, P95; MARSHALL WG, 1984, ANN THORAC SURG, V37, P398, DOI 10.1016/S0003-4975(10)60764-3; OSTERMEYER J, 1987, THORAC CARDIOV SURG, V35, P71, DOI 10.1055/s-2007-1020200; SACKS SH, 1986, THORAX, V41, P142, DOI 10.1136/thx.41.2.142; SHILEY, 1988, COMMUNICATION   0218; TAYLOR K, 1988, BRIT MED J, V297, P996, DOI 10.1136/bmj.297.6655.996; VANSWIETEN HA, 1990, SURG HEART VALVE DIS, P616; WIDEMAN FE, 1981, J THORAC CARDIOV SUR, V82, P692; WOODYARD CH, 1991, LOS ANGELES TIM 0428; 1990, LANCET, V336, P152; 1990, BJORKSHILEY HEART VA; 1990, STATISTICS EPIDEMIOL	17	78	79	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					257	261		10.1016/0140-6736(92)91328-6	http://dx.doi.org/10.1016/0140-6736(92)91328-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346279				2022-12-28	WOS:A1992HB52900001
J	RATCLIFFE, WA; HUTCHESSON, ACJ; BUNDRED, NJ; RATCLIFFE, JG				RATCLIFFE, WA; HUTCHESSON, ACJ; BUNDRED, NJ; RATCLIFFE, JG			ROLE OF ASSAYS FOR PARATHYROID-HORMONE-RELATED PROTEIN IN INVESTIGATION OF HYPERCALCEMIA	LANCET			English	Article							2-SITE IMMUNORADIOMETRIC ASSAY; PRIMARY HYPERPARATHYROIDISM; MALIGNANCY; PEPTIDE; CANCER; SERUM	Parathyroid-hormone-related protein (PTHrP) has been implicated as a humoral mediator of hypercalcaemia in malignant disease. We have investigated the contributions of PTHrP and parathyroid hormone (PTH) to the hypercalcaemia seen in routine clinical practice by means of highly sensitive immunoradiometric assays. PTHrP concentrations in plasma and PTH concentrations in serum were measured in 121 consecutive patients with hypercalcaemia (corrected serum calcium above 2.65 mmol/l) identified from routine biochemical profiles in a district general hospital. Hypercalcaemia was due to primary hyperparathyroidism in 63 (52%) patients and to malignant disease in 40 (49%). Plasma PTHrP was detectable in 35 (88%) of 40 patients with solid tumours and 3 of 9 patients with haematological malignant disease; it was undetectable in 92% of patients with primary hyperparathyroidism. 7 patients with malignant disease had PTH concentrations above 4.0 pmol/l, consistent with coexisting primary hyperparathyroidism. Measurement of both PTH and PTHrP in all patients led to a change in the diagnosis in 7% of patients. This study provides direct evidence for a humoral role of tumour-derived PTHrP in hypercalcaemia, and shows how PTHrP assays can be used appropriately, in conjunction with PTH assays, to investigate hypercalcaemia in routine clinical practice.	SELLY OAK HOSP,DEPT CLIN CHEM,BIRMINGHAM,ENGLAND; SELLY OAK HOSP,DEPT SURG,BIRMINGHAM,ENGLAND		RATCLIFFE, WA (corresponding author), QUEEN ELIZABETH MED CTR,WOLFSON RES LABS,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							BUDAYR AA, 1989, ANN INTERN MED, V111, P807, DOI 10.7326/0003-4819-111-10-807; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; DOCHERTY HM, 1991, J ENDOCRINOL, V129, P431, DOI 10.1677/joe.0.1290431; DREZNER MK, 1978, LANCET, V1, P1004; FARR HW, 1973, AM J SURG, V126, P539, DOI 10.1016/S0002-9610(73)80046-7; FISKEN RA, 1981, LANCET, V1, P202; GUTIERREZ GE, 1990, BAILLIERE CLIN ENDOC, V4, P119, DOI 10.1016/S0950-351X(05)80319-2; HENDERSON JE, 1990, J BONE MINER RES, V5, P105, DOI 10.1002/jbmr.5650050203; IKEDA K, 1989, J CLIN ENDOCR METAB, V69, P1240, DOI 10.1210/jcem-69-6-1240; ISALES C, 1987, AM J MED, V82, P1143, DOI 10.1016/0002-9343(87)90216-6; MARTIN TJ, 1989, CLIN ENDOCRINOL, V31, P631, DOI 10.1111/j.1365-2265.1989.tb01288.x; MUNDY GR, 1988, J CLIN INVEST, V82, P1, DOI 10.1172/JCI113555; MUNDY GR, 1989, CALCIUM HOMEOSTASIS, P51; NUSSBAUM S, 1991, CLIN CHEM, V37, P142; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; PALMER M, 1988, AM J EPIDEMIOL, V127, P1031, DOI 10.1093/oxfordjournals.aje.a114879; PERCIVAL RC, 1987, EUR J SURG ONCOL, V13, P41; RATCLIFFE WA, 1991, CLIN CHEM, V37, P678; RATCLIFFE WA, 1989, CLIN CHEM, V35, P1957; SHEK CC, 1990, Q J MED, V77, P1277, DOI 10.1093/qjmed/77.3.1277; SHIGENO C, 1988, J BIOL CHEM, V263, P18369; STONE MJ, 1982, JAMA-J AM MED ASSOC, V247, P823, DOI 10.1001/jama.247.6.823; WYNICK D, 1990, BRIT MED J, V300, P1314, DOI 10.1136/bmj.300.6735.1314; YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406; YOSHIMOTO K, 1989, J CLIN ENDOCR METAB, V68, P976, DOI 10.1210/jcem-68-5-976	25	114	117	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					164	167		10.1016/0140-6736(92)90220-W	http://dx.doi.org/10.1016/0140-6736(92)90220-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346019				2022-12-28	WOS:A1992GZ96800013
J	PIGNON, JP; ARRIAGADA, R; IHDE, DC; JOHNSON, DH; PERRY, MC; SOUHAMI, RL; BRODIN, O; JOSS, RA; KIES, MS; LEBEAU, B; ONOSHI, T; OSTERLIND, K; TATTERSALL, MHN; WAGNER, H				PIGNON, JP; ARRIAGADA, R; IHDE, DC; JOHNSON, DH; PERRY, MC; SOUHAMI, RL; BRODIN, O; JOSS, RA; KIES, MS; LEBEAU, B; ONOSHI, T; OSTERLIND, K; TATTERSALL, MHN; WAGNER, H			A METAANALYSIS OF THORACIC RADIOTHERAPY FOR SMALL-CELL LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRIALS	Background. In spite of 16 randomized trials conducted during the past 15 years, the effect of thoracic radiotherapy on the survival of patients with limited small-cell lung cancer remains controversial. The majority of these trials did not have enough statistical power to detect a difference in survival of 5 to 10 percent at five years. This meta-analysis was designed to evaluate the hypothesis that thoracic radiotherapy contributes to a moderate increase in overall survival in limited small-cell lung cancer. Methods. We collected individual data on all patients enrolled before December 1988 in randomized trials comparing chemotherapy alone with chemotherapy combined with thoracic radiotherapy. Trials that included only patients with extensive disease were excluded. Results. The meta-analysis included 13 trials and 2140 patients with limited disease. A total of 433 patients with extensive disease were excluded. Overall, 1862 of 2103 patients who could be evaluated died; the median follow-up period for the surviving patients was 43 months. The relative risk of death in the combined-therapy group as compared with the chemotherapy group was 0.86 (95 percent confidence interval, 0.78 to 0.94; P = 0.001), corresponding to a 14 percent reduction in the mortality rate. The benefit in terms of overall survival at three years (+/-SD) was 5.4+/-1.4 percent. Indirect comparison of early with late radiotherapy and of sequential with non-sequential radiotherapy did not reveal any optimal time for treatment. There was a trend toward a larger reduction in mortality among younger patients: the relative risk of death in the combined-therapy as compared with the chemotherapy group ranged from 0.72 for patients less than 55 years old (95 percent confidence interval, 0.56 to 0.93) to 1.07 (0.70 to 1.64) for patients over 70. Conclusions. Thoracic radiotherapy moderately improves survival in patients with limited small-cell lung cancer who are treated with combination chemotherapy. Identification of the optimal combination of chemotherapy and radiotherapy will require further trials.	NCI,BETHESDA,MD 20892; VANDERBILT UNIV,MED CTR,SCH MED,NASHVILLE,TN 37232; UNIV COLL & MIDDLESEX SCH MED,LONDON,ENGLAND; UNIV UPPSALA,S-75105 UPPSALA,SWEDEN; KANTONSSPITAL,CH-6004 LUZERN,SWITZERLAND; NORTHWESTERN UNIV,FAC MED,CHICAGO,IL 60611; HOP ST ANTOINE,F-75571 PARIS 12,FRANCE; OKAYAMA UNIV,OKAYAMA 700,JAPAN; RIGS HOSP,COPENHAGEN,DENMARK; ROYAL PRINCE ALFRED HOSP,CAMPERDOWN,NSW 2050,AUSTRALIA; UNION UNIV,ALBANY,NY 12208	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; University of London; University College London; Uppsala University; Kantonsspital Aarau AG (KSA); Lucerne Cantonal Hospital; Northwestern University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Okayama University; University of Sydney; Union College	PIGNON, JP (corresponding author), INST GUSTAVE ROUSSY,DEPT BIOSTAT,F-94805 VILLEJUIF,FRANCE.		Johnson, David H./A-7437-2009	PIGNON, Jean-Pierre/0000-0003-2047-1582				ARRIAGADA R, 1990, INT J RADIAT ONCOL, V19, P1279, DOI 10.1016/0360-3016(90)90244-E; ARRIAGADA R, 1989, LUNG CANCER, V5, P237; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; MORSTYN G, 1984, INT J RADIAT ONCOL, V10, P515, DOI 10.1016/0360-3016(84)90032-4; NICOLUCCI A, 1989, JAMA-J AM MED ASSOC, V262, P2101, DOI 10.1001/jama.262.15.2101; Payne DG, 1989, LUNG CANCER, V5, P135; Warde P, 1991, INT J RAD ONCOL B S1, V19, P146	8	1000	1044	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1992	327	23					1618	1624		10.1056/NEJM199212033272302	http://dx.doi.org/10.1056/NEJM199212033272302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA260	1331787	Bronze			2022-12-28	WOS:A1992KA26000002
J	CHEN, LC; ROHDE, JE; JOLLY, R				CHEN, LC; ROHDE, JE; JOLLY, R			A LOOMING CRISIS - HEALTH IN THE CENTRAL-ASIAN REPUBLICS	LANCET			English	Article									UNICEF,NEW DELHI,INDIA; UNICEF,NEW YORK,NY	UNICEF	CHEN, LC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.							BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; FESBACH M, 1982, ISSUES SOVIET HLTH P; POPOV AA, 1991, STUD FAMILY PLANN, V22, P368, DOI 10.2307/1966450; Sen A, 1981, POVERTY FAMINES; 1989, PROTECTING PROMOTING	5	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1465	1467		10.1016/0140-6736(92)92044-G	http://dx.doi.org/10.1016/0140-6736(92)92044-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351137				2022-12-28	WOS:A1992HY31700015
J	COLAGIURI, S; MILLER, JJ; PETOCZ, P				COLAGIURI, S; MILLER, JJ; PETOCZ, P			DOUBLE-BLIND CROSSOVER COMPARISON OF HUMAN AND PORCINE INSULINS IN PATIENTS REPORTING LACK OF HYPOGLYCEMIA AWARENESS	LANCET			English	Article							HYPOGLYCEMIA; UNAWARENESS	There has been much debate about reports that some insulin-treated diabetic patients lose awareness of hypoglycaemic symptoms on changing from porcine to human insulin. In a double-blind, crossover study, we sought differences between porcine and human insulin in the frequency and characteristics of hypoglycaemic episodes among patients who reported a reduction of awareness of hypoglycaemia after changing treatment. We studied 50 patients referred by their physicians because of complaints of lack of awareness of hypoglycaemia on human insulin. They had had diabetes for a mean of 20 (SD 12) years and 70% had good or acceptable glycaemic control. Each patient was treated in a double-blind manner for four 1-month periods, two with human and two with porcine insulin, in random order. Only 2 patients correctly identified the sequence of insulin treatments used; 8 or 9 would have been expected to do so by chance alone. The mean percentage of hypoglycaemic episodes associated with reduced or absent awareness was 64% (SD 30%) for human insulin and 69% (31%) for porcine insulin. We could find no statistically significant differences between the insulin species with respect to glycaemic control or the frequency, timing, severity, or awareness of hypoglycaemia. Reduced hypoglycaemia awareness is common with both human and porcine insulins.	NOVO NORDISK PHARMACEUT,N ROCKS,AUSTRALIA; UNIV TECHNOL SYDNEY,SCH MATH SCI,SYDNEY,NSW,AUSTRALIA	Novo Nordisk; University of Technology Sydney	COLAGIURI, S (corresponding author), PRINCE WALES HOSP,DEPT ENDOCRINOL DIABET & METAB,HIGH ST,RANDWICK,NSW 2031,AUSTRALIA.			Colagiuri, Stephen/0000-0002-2398-4781				ANDERSON J H, 1990, Diabetologia, V33, pA122; [Anonymous], 1991, LANCET, V338, P853; BERGER M, 1987, DIABETOLOGIA, V30, P829; BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; BERGER WG, 1987, DIABETES CARE, V10, P260, DOI 10.2337/diacare.10.2.260; BREIDAHL HD, 1991, MED J AUSTRALIA, V154, P493, DOI 10.5694/j.1326-5377.1991.tb121203.x; CLARKE WL, 1991, DIABETES, V40, P680, DOI 10.2337/diabetes.40.6.680; EGGER M, 1991, DIABETES CARE, V14, P1001, DOI 10.2337/diacare.14.11.1001; EGGER M, 1991, BMJ-BRIT MED J, V303, P617, DOI 10.1136/bmj.303.6803.617; EGGER M, 1991, BMJ-BRIT MED J, V303, P622, DOI 10.1136/bmj.303.6803.622; EGGER M, 1991, LANCET, V338, P950, DOI 10.1016/0140-6736(91)91820-K; GALE EAM, 1989, LANCET, V2, P1264; GORDEN P, 1990, NEW ENGL J MED, V322, P1007; HAUPT E, 1991, HYPOGLYCAEMIA HUMAN, P119; HEINE RJ, 1990, LANCET, V335, P62, DOI 10.1016/0140-6736(90)90203-H; HEPBURN DA, 1989, DIABETIC MED, V6, P586, DOI 10.1111/j.1464-5491.1989.tb01233.x; HEPBURN DA, 1991, DIABETES CARE, V14, P949, DOI 10.2337/diacare.14.11.949; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; JICK H, 1990, PHARMACOTHERAPY, V10, P395; JICK SS, 1990, PHARMACOTHERAPY, V10, P398; MOSES RG, 1991, MED J AUSTRALIA, V154, P364, DOI 10.5694/j.1326-5377.1991.tb112898.x; ORCHARD TJ, 1991, DIABETIC MED, V8, P469, DOI 10.1111/j.1464-5491.1991.tb01634.x; PATRICK AW, 1991, LANCET, V338, P528, DOI 10.1016/0140-6736(91)91098-F; PRAMMING S, 1990, J INTERN MED, V228, P641, DOI 10.1111/j.1365-2796.1990.tb00292.x; RIFKIN H, 1988, PHYSICIANS GUIDE NON; STOCKS AE, 1991, MED J AUSTRALIA, V154, P295, DOI 10.5694/j.1326-5377.1991.tb121117.x; TEUSCHER A, 1987, LANCET, V2, P382	27	39	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1432	1435		10.1016/0140-6736(92)92028-E	http://dx.doi.org/10.1016/0140-6736(92)92028-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351127				2022-12-28	WOS:A1992HY31700002
J	LARON, Z; ANIN, S; KLIPPERAURBACH, Y; KLINGER, B				LARON, Z; ANIN, S; KLIPPERAURBACH, Y; KLINGER, B			EFFECTS OF INSULIN-LIKE GROWTH-FACTOR ON LINEAR GROWTH, HEAD CIRCUMFERENCE, AND BODY-FAT IN PATIENTS WITH LARON-TYPE DWARFISM	LANCET			English	Article							HORMONE-RECEPTOR GENE; FACTOR-I; BINDING-PROTEIN; IGF-I; DEFICIENCY; THERAPY	Patients with Laron-type dwarfism are clinically indistinguishable from those with isolated growth hormone (GH) deficiency, yet have high circulating GH concentrations associated with an inability to generate endogenous insulin-like growth factor I (IGF-I). Biosynthetic IGF-I was administered subcutaneously once daily for 3 to 10 months to 5 children with Laron-type dwarfism aged 3.3 to 14.5 years. There was a rapid stimulation of linear growth in body limbs, with a striking increase in head circumference, increased body weight, and a reduction in subcutaneous fat. Administration of IGF-I to patients with Laron-type dwarfism seems to have a beneficial effect on growth similar to that observed with long-term administration of GH in children with GH deficiency.			LARON, Z (corresponding author), TEL AVIV UNIV,SACKLER FAC MED,CHILDRENS MED CTR,INST PAEDIAT & ADOLESCENT ENDOCRINOL,IL-49100 PETAH TIQWA,ISRAEL.							ACETO T, 1972, J CLIN ENDOCR METAB, V35, P483, DOI 10.1210/jcem-35-4-483; AMSELEM S, 1989, NEW ENGL J MED, V321, P989, DOI 10.1056/NEJM198910123211501; BAUMANN G, 1987, J CLIN ENDOCR METAB, V65, P814, DOI 10.1210/jcem-65-4-814; ESHET R, 1984, ISRAEL J MED SCI, V20, P8; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; JORGENSEN JOL, 1989, LANCET, V1, P1221; JOSEFSBERG Z, 1987, HORM RES, V27, P126, DOI 10.1159/000180800; LARON Z, 1990, ACTA ENDOCRINOL-COP, V123, P378, DOI 10.1530/acta.0.1230378; LARON Z, 1991, CLIN ENDOCRINOL, V35, P145, DOI 10.1111/j.1365-2265.1991.tb03513.x; LARON Z, 1988, LANCET, V2, P1170; LARON Z, 1966, ISRAEL J MED SCI, V2, P152; LARON Z, 1968, HELV PAEDIATR ACTA, V23, P37; LARON Z, 1979, CLIN ENDOCRINOL, V10, P393, DOI 10.1111/j.1365-2265.1979.tb02094.x; LARON Z, 1971, J CLIN ENDOCR METAB, V33, P332, DOI 10.1210/jcem-33-2-332; LARON Z, 1989, ACTA ENDOCRINOL-COP, V121, P603, DOI 10.1530/acta.0.1210603; LARON Z, 1974, HORM METAB RES S, V5, P162; LARON Z, 1972, GROWTH GROWTH HORMON, P458; Laron Z, 1984, ADV INTERNAL MED PED, P117; MEACHAM LR, 1990, 72ND P ANN M AM END, P373; NELLHAUS G, 1968, PEDIATRICS, V41, P106; NIWA M, 1986, ANN NY ACAD SCI, V469, P31, DOI 10.1111/j.1749-6632.1986.tb26482.x; TAKANO K, 1990, ENDOCRINOL JAPON, V37, P309; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613	24	172	173	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 23	1992	339	8804					1258	1261		10.1016/0140-6736(92)91594-X	http://dx.doi.org/10.1016/0140-6736(92)91594-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349669				2022-12-28	WOS:A1992HV19100004
J	COFRANCESCO, E; BOSCHETTI, C; LEONARDI, P; CORTELLARO, M				COFRANCESCO, E; BOSCHETTI, C; LEONARDI, P; CORTELLARO, M			DERMATAN SULFATE IN ACUTE-LEUKEMIA	LANCET			English	Letter							ACUTE PROMYELOCYTIC LEUKEMIA; SULFATE				COFRANCESCO, E (corresponding author), UNIV MILAN,INST INTERNAL MED,DEPT INFECT DIS & IMMUNOPATHOL,I-20122 MILAN,ITALY.							AGNELLI G, 1992, THROMB HAEMOSTASIS, V67, P203; BAUER KA, 1984, BLOOD, V64, P791; COFRANCESCO E, 1990, THROMB RES, V57, P405, DOI 10.1016/0049-3848(90)90256-C; CUNNINGHAM I, 1989, BLOOD, V73, P1116; FERNANDEZ F, 1986, BRIT J HAEMATOL, V64, P309, DOI 10.1111/j.1365-2141.1986.tb04124.x; LANE, 1992, LANCET, V339, P334; RODEGHIERO F, 1990, BLOOD, V75, P2112	7	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1177	1178		10.1016/0140-6736(92)90782-X	http://dx.doi.org/10.1016/0140-6736(92)90782-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349404				2022-12-28	WOS:A1992HT23600045
J	SU, LK; KINZLER, KW; VOGELSTEIN, B; PREISINGER, AC; MOSER, AR; LUONGO, C; GOULD, KA; DOVE, WF				SU, LK; KINZLER, KW; VOGELSTEIN, B; PREISINGER, AC; MOSER, AR; LUONGO, C; GOULD, KA; DOVE, WF			MULTIPLE INTESTINAL NEOPLASIA CAUSED BY A MUTATION IN THE MURINE HOMOLOG OF THE APC GENE	SCIENCE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL-CARCINOMA; CHROMOSOME-5; LOCALIZATION; COLI; CANCER	Germ-line mutations of the APC gene are responsible for familial adenomatous polyposis (FAP), an autosomal dominantly inherited disease in humans. Patients with FAP develop multiple benign colorectal tumors. Recently, a mouse lineage that exhibits an autosomal dominantly inherited predisposition to multiple intestinal neoplasia (Min) was described. Linkage analysis showed that the murine homolog of the APC gene (mApc) was tightly linked to the Min locus. Sequence comparison of mApc between normal and Min-affected mice identified a nonsense mutation, which cosegregated with the Min phenotype. This mutation is analogous to those found in FAP kindreds and in sporadic colorectal cancers.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; JOHNS HOPKINS UNIV,SCH MED,MOLEC GENET LAB,BALTIMORE,MD 21231	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University			Tuluc, Petronel/C-2527-2011		NCI NIH HHS [CA-23076, CA-07175, CA-06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175, P01CA023076, P30CA006973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BULOW S, 1990, FAMILIAL ADENOMATOUS, P109; DELATTRE O, 1989, LANCET, V2, P353; GARDNER EJ, 1953, AM J HUM GENET, V5, P139; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; JAGELMAN DG, 1987, CANCER GENET CYTOGEN, V27, P319, DOI 10.1016/0165-4608(87)90014-8; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KHAN PM, 1988, HUM GENET, V79, P183, DOI 10.1007/BF00280563; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; ROWLATT C, 1969, JNCI-J NATL CANCER I, V43, P1353; SASAKI M, 1989, CANCER RES, V49, P4402; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; Su L., UNPUB; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	26	1323	1361	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					668	670		10.1126/science.1350108	http://dx.doi.org/10.1126/science.1350108			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1350108				2022-12-28	WOS:A1992HR18500033
J	TADMOR, B; PUTTERMAN, C; NAPARSTEK, Y				TADMOR, B; PUTTERMAN, C; NAPARSTEK, Y			EMBRYONAL GERM-LAYER ANTIGENS - TARGET FOR AUTOIMMUNITY	LANCET			English	Note							CELL-ADHESION MOLECULES; DISEASE	Histopathological analysis of some systemic autoimmune diseases and syndromes led us to the conclusion that the common feature of the organs involved might be their embryonal origin. We suggest that organs derived from the same germ layer express common germ-layer-specific antigens. Such antigens could serve as target antigens for the autoimmune response.	HADASSAH UNIV HOSP,CLIN IMMUNOL & ALLERGY UNIT,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ALDOBENSON MA, 1989, ARTHRITIS ALLIED CON, P972; BOTTAZZO GF, 1983, LANCET, V2, P1115; BRYANT GL, 1986, SEMIN ARTHRITIS RHEU, V15, P297, DOI 10.1016/0049-0172(86)90025-9; CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870; CHRISTENSEN E, 1980, GASTROENTEROLOGY, V78, P236; DANGELO WA, 1969, AM J MED, V46, P428, DOI 10.1016/0002-9343(69)90044-8; GECZY AF, 1986, J EXP MED, V164, P932, DOI 10.1084/jem.164.3.932; HAYNES BF, 1980, MEDICINE, V59, P426, DOI 10.1097/00005792-198011000-00003; LANGMAN J, 1988, MED EMBRYOLOGY; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MENDELSOHN J, 1988, HARRISONS PRINCIPLES, P430; NEDELEC J, 1990, J NEUROIMMUNOL, V29, P49, DOI 10.1016/0165-5728(90)90146-E; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; OKADA Y, 1990, LANCET, V335, P1302, DOI 10.1016/0140-6736(90)91187-F; PRYSTOWSKY SD, 1978, ARCH DERMATOL, V114, P705, DOI 10.1001/archderm.114.5.705; ROITT IM, 1988, ESSENTIAL IMMUNOLOGY, P238; ROTHFIELD N, 1982, ARTHRITIS RHEUM, V25, P624, DOI 10.1002/art.1780250604; ROUGON G, 1986, J BIOL CHEM, V261, P3396; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	19	19	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					975	978		10.1016/0140-6736(92)91540-O	http://dx.doi.org/10.1016/0140-6736(92)91540-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348808				2022-12-28	WOS:A1992HP03600013
J	DALGLEISH, AG; WILSON, S; GOMPELS, M; LUDLAM, C; GAZZARD, B; COATES, AM; HABESHAW, J				DALGLEISH, AG; WILSON, S; GOMPELS, M; LUDLAM, C; GAZZARD, B; COATES, AM; HABESHAW, J			T-CELL RECEPTOR VARIABLE GENE-PRODUCTS AND EARLY HIV-1 INFECTION	LANCET			English	Article							IMMUNE-DEFICIENCY SYNDROME; AIDS; PATHOGENESIS; ENVELOPE; SYSTEM; CD4	To assess the hypothesis that the human immunodeficiency virus (HIV) might mimic major histocompatibility complex (MHC) allodeterminants and interact with T-cell receptors (TCRs) of alloreactive T-cells, we have done a preliminary analysis of the range of alpha-beta-TCR gene products in 16 HIV-1 -seropositive individuals with normal CD4 counts and in 16 healthy HIV-1-negative controls. Using a panel of monoclonal antibodies with a two-colour direct immunofluorescence method, we found a significant increase in the expression of the V-beta-5.3 subfamily in the HIV-positive patient group compared with controls (p < 0.01). Selected increase in expression of V-beta sequences has been described in various autoimmune conditions and our findings raise the possibility that the immunopathological damage from HIV infection may be due to the induction of autoreactivity. If HIV does mimic MHC II, the normal immune response to the virus could represent an autoimmune process similar to graft-versus-host disease.	ROYAL INFIRM,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ST MARYS HOSP,LONDON,ENGLAND; HIVER LTD,LONDON NW1,ENGLAND	Royal Infirmary of Edinburgh; Imperial College London	DALGLEISH, AG (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CELLULAR & MOLEC SCI,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.		Dalgleish, Angus/AAZ-4450-2020	Dalgleish, Angus/0000-0003-3511-3059; Coates, Anthony/0000-0001-8052-3175				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; BRANDLE D, 1991, EUR J IMMUNOL, V21, P2195, DOI 10.1002/eji.1830210930; CLOUSE KA, 1991, J IMMUNOL, V147, P2892; DALGLEISH AG, 1991, BRIT MED BULL, V47, P21, DOI 10.1093/oxfordjournals.bmb.a072457; DALGLEISH AG, 1990, AIDS NEW VIRUSES; DANES TF, 1991, NEW ENGL J MED, V325, P238; DIGIORGI L, 1990, CLIN EXP IMMUNOL, V79, P130; HABESHAW JA, 1989, J ACQ IMMUN DEF SYND, V2, P457; HABESHAW JA, 1990, IMMUNOL TODAY, V11, P418, DOI 10.1016/0167-5699(90)90162-3; HENEY D, 1991, BRIT J HAEMATOL, V78, P23, DOI 10.1111/j.1365-2141.1991.tb04377.x; HOUNSELL L, IN PRESS MOL ASPECTS; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; KAY RA, 1991, CLIN EXP IMMUNOL, V85, P262; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; KNOBLOCH C, 1991, J IMMUNOL, V146, P4157; KNULST AC, 1991, EUR J IMMUNOL, V21, P103, DOI 10.1002/eji.1830210116; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUTZ CT, 1981, EUR J IMMUNOL, V11, P726, DOI 10.1002/eji.1830110911; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MALLAL S, 1990, LANCET, V335, P1591, DOI 10.1016/0140-6736(90)91418-A; MANCA F, 1990, LANCET, V335, P811, DOI 10.1016/0140-6736(90)90935-X; MANCA F, 1991, J IMMUNOL, V146, P1964; ORBEA HA, 1991, IMMUNOL TODAY, V12, P356; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; SCHATTNER A, 1990, REV INFECT DIS, V12, P204; SCHECHTER MT, 1990, AIDS, V4, P185, DOI 10.1097/00002030-199003000-00002; SHEARER G, 1983, IMMUNOL TODAY, V4, P181, DOI 10.1016/0167-5699(83)90075-0; SHEPPARD HW, 1991, J ACQ IMMUN DEF SYND, V4, P704; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SIMMONDS P, 1991, LANCET, V338, P1159, DOI 10.1016/0140-6736(91)92029-2; STOTT J, 1991, NATURE, V353, P393; VIA CS, 1990, IMMUNOL TODAY, V11, P250, DOI 10.1016/0167-5699(90)90099-U; WATANABE M, 1991, J VIROL, V65, P3344, DOI 10.1128/JVI.65.6.3344-3348.1991; WUCHERPFENNIG KW, 1991, IMMUNOL TODAY, V12, P277, DOI 10.1016/0167-5699(91)90126-E; YANAGI Y, 1990, J VIROL, V64, P5919, DOI 10.1128/JVI.64.12.5919-5926.1990	38	104	105	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					824	828		10.1016/0140-6736(92)90277-A	http://dx.doi.org/10.1016/0140-6736(92)90277-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347855				2022-12-28	WOS:A1992HM44100002
J	GEDROYC, WMW; NEGUS, R; ALKUTOUBI, A; PALMER, A; TAUBE, D; HULME, B				GEDROYC, WMW; NEGUS, R; ALKUTOUBI, A; PALMER, A; TAUBE, D; HULME, B			MAGNETIC-RESONANCE ANGIOGRAPHY OF RENAL-TRANSPLANTS	LANCET			English	Article							ARTERY-STENOSIS; MR ANGIOGRAPHY	Stenosis of the artery of transplanted kidneys is an important cause of graft dysfunction. Diagnosis and follow-up of this condition normally requires intraarterial digital-subtraction angiography (IADSA), which is invasive and may cause complications. A possible alternative to IADSA is magnetic resonance angiography (MRA), and we have assessed this technique in 50 renal transplant patients who were referred for investigation of possible renal arterial stenosis. In every patient, MRA was compared prospectively with conventional IADSA. Compared with IADSA, MRA had a sensitivity of 83% and a specificity of 97%, and when all images were graded retrospectively for severity of stenosis, the two techniques showed a significant correlation (r = 0.74, p < 0.001). MRA can provide an accurate image of the renal transplant artery in a non-invasive manner with a high sensitivity and specificity.	ST MARYS HOSP,RENAL UNIT,LONDON W2 1NY,ENGLAND	Imperial College London	GEDROYC, WMW (corresponding author), ST MARYS HOSP,DEPT RADIOL,LONDON W2 1NY,ENGLAND.							DEANE C, 1990, TRANSPLANT P, V22, P1395; EDELMAN RR, 1990, CLIN MAGNETIC RESONA, P109; GREENSTEIN SM, 1987, TRANSPLANTATION, V43, P29, DOI 10.1097/00007890-198701000-00007; KIM D, 1990, RADIOLOGY, V174, P727, DOI 10.1148/radiology.174.3.2305057; PERNICONE JR, 1990, AM J NEURORADIOL, V11, P457; TILNEY NL, 1984, ANN SURG, V199, P454, DOI 10.1097/00000658-198404000-00013	6	52	52	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					789	791		10.1016/0140-6736(92)91905-N	http://dx.doi.org/10.1016/0140-6736(92)91905-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347813				2022-12-28	WOS:A1992HL50100013
J	KOLL, H; GUIARD, B; RASSOW, J; OSTERMANN, J; HORWICH, AL; NEUPERT, W; HARTL, FU				KOLL, H; GUIARD, B; RASSOW, J; OSTERMANN, J; HORWICH, AL; NEUPERT, W; HARTL, FU			ANTIFOLDING ACTIVITY OF HSP60 COUPLES PROTEIN IMPORT INTO THE MITOCHONDRIAL MATRIX WITH EXPORT TO THE INTERMEMBRANE SPACE	CELL			English	Article							TRANSLOCATION CONTACT SITES; CYTOCHROME C1 PRESEQUENCE; ESCHERICHIA-COLI; PROCESSING PEPTIDASE; YEAST MITOCHONDRIA; RIBULOSEBISPHOSPHATE-CARBOXYLASE; PRECURSOR PROTEINS; SENSITIVE METHOD; BINDING-PROTEIN; INNER MEMBRANE	Cytochrome b2 reaches the intermembrane space of mitochondria by transport into the matrix followed by export across the inner membrane. While in the matrix, the protein interacts with hsp60, which arrests its folding prior to export. The bacterial-type export sequence in pre-cytochrome b2 functions by inhibiting the ATP-dependent release of the protein from hsp60. Release for export apparently requires, in addition to ATP, the interaction of the signal sequence with a component of the export machinery in the inner membrane. Export can occur before import is complete provided that a critical length of the polypeptide chain has been translocated into the matrix. Thus, hsp60 combines two activities: catalysis of folding of proteins destined for the matrix, and maintaining proteins in an unfolded state to facilitate their channeling between the machineries for import and export across the inner membrane. Antifolding signals such as the hydrophobic export sequence in cytochrome b2 may act as switches between these two activities.	UNIV PIERRE & MARIE CURIE, CTR GENET MOLEC, CNRS, F-91190 GIF SUR YVETTE, FRANCE; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; MEM SLOAN KETTERING CANC CTR, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA; YALE UNIV, SCH MED, DEPT HUMAN GENET, NEW HAVEN, CT 06510 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Howard Hughes Medical Institute; Yale University; Memorial Sloan Kettering Cancer Center; Yale University	KOLL, H (corresponding author), INST PHYSIOL CHEM, GOETHESTR 33, W-8000 MUNICH 2, GERMANY.		Hartl, F. Ulrich/Y-8206-2019					APPLEBY CA, 1959, BIOCHEM J, V71, P492, DOI 10.1042/bj0710492; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOHNI P, 1980, ORG EXPRESSION MITOC, P423; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HALLERMAYER G, 1977, EUR J BIOCHEM, V81, P523, DOI 10.1111/j.1432-1033.1977.tb11978.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MACIEWICZ RA, 1988, ANAL BIOCHEM, V175, P85, DOI 10.1016/0003-2697(88)90364-8; MAHLKE K, 1990, EUR J BIOCHEM, V192, P551, DOI 10.1111/j.1432-1033.1990.tb19260.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PAULING L, 1951, P NATL ACAD SCI USA, V37, P729, DOI 10.1073/pnas.37.11.729; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; STUART RA, 1990, J BIOL CHEM, V265, P20210; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; Towbin H., 1979, P NATL ACAD SCI USA, V79, P267; VANLOON APGM, 1987, EMBO J, V6, P2433, DOI 10.1002/j.1460-2075.1987.tb02522.x; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; ZIMMERMANN R, 1980, EUR J BIOCHEM, V109, P217, DOI 10.1111/j.1432-1033.1980.tb04787.x	61	183	186	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1163	1175		10.1016/0092-8674(92)90086-R	http://dx.doi.org/10.1016/0092-8674(92)90086-R			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1347713	Green Published			2022-12-28	WOS:A1992HK67400018
J	ILLINGWORTH, DR; VAKAR, F; MAHLEY, RW; WEISGRABER, KH				ILLINGWORTH, DR; VAKAR, F; MAHLEY, RW; WEISGRABER, KH			HYPOCHOLESTEROLEMIC EFFECTS OF LOVASTATIN IN FAMILIAL DEFECTIVE APOLIPOPROTEIN-B-100	LANCET			English	Article							HYPERCHOLESTEROLEMIA	Familial defective apolipoprotein B-100 (FDB) is an autosomal dominant disorder associated with hypercholesterolaemia in which an aminoacid substitution in apoprotein B-100 leads to low-density lipoprotein (LDL) particles which have defective binding to the LDL receptor. All known patients are heterozygous, and their plasma contains normal and poorly binding LDL particles. 12 hypercholesterolaemic patients from 10 unrelated families with FDB were treated with lovastatin. In 6 patients treated with 20 mg lovastatin daily, LDL cholesterol decreased by 2l.5% from 6.23 to 4.89 mmol/l (95% confidence interval 0.74, 1.96 mmol/l), whereas it fell by 32.1 %, from 6.99 to 4.81 mmol/l (95% Cl 1.55, 2.70 mmol/l), in 9 patients who received 40 mg daily. These results indicate that the hypercholesterolaemia of FDB may respond to treatment with statins.	UNIV CALIF SAN FRANCISCO,GLADSTONE FDN LABS CARDIOVASC DIS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; The J David Gladstone Institutes	ILLINGWORTH, DR (corresponding author), OREGON HLTH SCI UNIV,DEPT MED L465,DIV ENDOCRINOL DIABET & CLIN NUTR,PORTLAND,OR 97201, USA.							BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; CORSINI A, 1991, LANCET, V337, P305, DOI 10.1016/0140-6736(91)90920-K; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; HANSEN PS, 1991, J LIPID RES, V32, P1229; HAVEL RJ, 1987, ANN INTERN MED, V107, P609, DOI 10.7326/0003-4819-107-5-609; Hunninghake D, 1986, JAMA-J AM MED ASSOC, V256, P2829; ILLINGWORTH DR, 1991, CURR OPIN LIPIDOL, V2, P24; INNERARITY TL, 1990, J LIPID RES, V31, P1337; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; MYANT NB, 1991, ARTERIOSCLER THROMB, V11, P691, DOI 10.1161/01.ATV.11.3.691; SCHUSTER H, 1990, ARTERIOSCLEROSIS, V10, P577, DOI 10.1161/01.ATV.10.4.577	11	26	26	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					598	600		10.1016/0140-6736(92)90875-4	http://dx.doi.org/10.1016/0140-6736(92)90875-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347103				2022-12-28	WOS:A1992HH07500013
J	ISOBE, M; YAGITA, H; OKUMURA, K; IHARA, A				ISOBE, M; YAGITA, H; OKUMURA, K; IHARA, A			SPECIFIC ACCEPTANCE OF CARDIAC ALLOGRAFT AFTER TREATMENT WITH ANTIBODIES TO ICAM-1 AND LFA-1	SCIENCE			English	Article							ADHESION MOLECULE-1 ICAM-1; CELL-ASSOCIATED ANTIGEN; MEDIATED CYTO-TOXICITY; MONOCLONAL-ANTIBODY; IMMUNE-SYSTEM; ACTIVATION; LIGAND; INHIBITION; RECEPTORS; MALA-2	An indefinite survival of cardiac allografts between fully incompatible mice strains was observed when monoclonal antibodies (MAbs) to intercellular adhesion molecule-1 (ICAM-1) and leukocyte function-associated antigen-1 (LFA-1) were simultaneously administered after the transplantation for 6 days. Mice with long-term surviving cardiac allografts accepted skin grafts from the donor-strain but rejected skin grafts from a third-party strain. Because MAbs to ICAM-1 or LFA-1 alone were insufficient for prolonged tolerance, the two MAbs probably acted synergistically to induce specific unresponsiveness. Thus, ICAM-1-LFA-1 adhesion participates in the induction of allograft rejection and MAbs may be useful as therapeutic agents.	MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,PATHOL RES LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,TOKYO 113,JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Juntendo University								ALTMANN DM, 1989, NATURE, V338, P512, DOI 10.1038/338512a0; BENJAMIN RJ, 1988, EUR J IMMUNOL, V18, P1079, DOI 10.1002/eji.1830180717; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DANG LH, 1991, J IMMUNOL, V146, P3273; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFRANCO AL, 1991, NATURE, V351, P603, DOI 10.1038/351603a0; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GEPPERT TD, 1990, IMMUNOL REV, V117, P5, DOI 10.1111/j.1600-065X.1990.tb00566.x; ISOBE M, 1992, CIRCULATION, V85, P738, DOI 10.1161/01.CIR.85.2.738; ISOBE M, 1991, CIRCULATION, V84, P1246, DOI 10.1161/01.CIR.84.3.1246; MAKGOBA MW, 1988, EUR J IMMUNOL, V18, P637, DOI 10.1002/eji.1830180423; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NISHIMURA T, 1987, CELL IMMUNOL, V107, P32, DOI 10.1016/0008-8749(87)90263-2; NISHIMURA T, 1985, CELL IMMUNOL, V94, P122, DOI 10.1016/0008-8749(85)90090-5; PRIETO J, 1989, EUR J IMMUNOL, V19, P1551, DOI 10.1002/eji.1830190906; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAKEI F, 1985, J IMMUNOL, V134, P1403; VANDIJKEN PJ, 1990, TRANSPLANTATION, V49, P882, DOI 10.1097/00007890-199005000-00009; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579	26	782	829	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1125	1127		10.1126/science.1347662	http://dx.doi.org/10.1126/science.1347662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1347662				2022-12-28	WOS:A1992HF63200040
J	JEPSON, BA				JEPSON, BA			RELIEVING THE PAIN OF PRESSURE SORES	LANCET			English	Letter											JEPSON, BA (corresponding author), CALVARY HOSP KOGARAH,POB 261,KOGARAH,NSW 2217,AUSTRALIA.							EPSTEIN JB, 1989, INT J RADIAT ONCOL, V16, P1571, DOI 10.1016/0360-3016(89)90964-4; TWYCROSS R, 1990, THERAPEUTICS TERMINA, P155	2	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					503	504		10.1016/0140-6736(92)91124-Q	http://dx.doi.org/10.1016/0140-6736(92)91124-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346867				2022-12-28	WOS:A1992HE93200058
J	TIVERON, MC; BARBONI, E; RIVERO, FBP; GORMLEY, AM; SEELEY, PJ; GROSVELD, F; MORRIS, R				TIVERON, MC; BARBONI, E; RIVERO, FBP; GORMLEY, AM; SEELEY, PJ; GROSVELD, F; MORRIS, R			SELECTIVE-INHIBITION OF NEURITE OUTGROWTH ON MATURE ASTROCYTES BY THY-1 GLYCOPROTEIN	NATURE			English	Article							RAT; CULTURES; NEURONS; TISSUE; GROWTH; NERVE; CELLS; REGENERATION; EXPRESSION; ORIGIN	THY-1, the smallest member of the immunoglobulin superfamily 1, is a major cell-surface component expressed by several tissues 2. The protein 1, carbohydrate 3 and gene 4 Structures of this molecule are known, yet its function is not. It is highly expressed in nervous tissue 5, where it appears on virtually all neurons after the cessation of axonal growth 6. Here we show that expression of Thy-1 by a neural cell line inhibits neurite outgrowth on mature astrocytes, but not on other cellular substrata which include Schwann cells and embryonic glia. This inhibition of neurite extension on astrocytes can be reversed by low concentrations (nanomolar) of soluble Thy-1. If a similar interaction between neuronal Thy-1 and astrocytes occurs in vivo, it could stabilize neuronal connections and suppress axonal regrowth after injury in the astrocyte-rich areas of adult central nervous system.	UNIV ROME LA SAPIENZA,FAC MED & CHIRURG,DEPT HUMAN BIOPATHOL,I-00185 ROME,ITALY; NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND	Sapienza University Rome; MRC National Institute for Medical Research	TIVERON, MC (corresponding author), NATL INST MED RES,NEUROBIOL LAB,NORMAN & SADIE LEE RES CTR,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		TIVERON, Marie-Catherine/AAR-1142-2020; Morris, Roger/C-4615-2008					BAEHR M, 1990, GLIA, V3, P293, DOI 10.1002/glia.440030409; BARBONI E, 1991, IMMUNOLOGY, V72, P457; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CAJAL SRY, 1927, DEGENERATION REGENER, V2; CARLSTEDT T, 1989, BRAIN RES BULL, V22, P93, DOI 10.1016/0361-9230(89)90133-0; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; EMMETT CJ, 1988, BRAIN RES, V447, P223, DOI 10.1016/0006-8993(88)91123-7; FAWCETT JW, 1989, DEV BIOL, V135, P449, DOI 10.1016/0012-1606(89)90193-0; Graziadei PPC, 1978, NEURONAL PLASTICITY, P131; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HATANAKA H, 1981, BRAIN RES, V215, P305, DOI 10.1016/0006-8993(81)90509-6; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; KOLLIAS G, 1987, CELL, V51, P21, DOI 10.1016/0092-8674(87)90006-7; KUCHEL PW, 1978, BIOCHEM J, V169, P411, DOI 10.1042/bj1690411; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; MORRIS R, 1985, DEV NEUROSCI-BASEL, V7, P133, DOI 10.1159/000112283; MORRIS RJ, 1980, BRAIN RES, V182, P119, DOI 10.1016/0006-8993(80)90835-5; NOBLE M, 1984, J NEUROSCI, V4, P1892; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; RAFF MC, 1979, BRAIN RES, V174, P283, DOI 10.1016/0006-8993(79)90851-5; REIF AE, 1964, J EXP MED, V120, P413, DOI 10.1084/jem.120.3.413; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; SIEGAL JD, 1990, EXP NEUROL, V109, P111; SMITH GM, 1990, DEV BIOL, V138, P377, DOI 10.1016/0012-1606(90)90204-V; SPRINGER TA, 1991, NATURE, V353, P704, DOI 10.1038/353704a0; Stensaas LJ, 1987, PROG BRAIN RES <D>, V71, P457; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; WILLIAMS AF, 1989, CELL SURFACE ANTIGEN, P49; XUE GP, 1991, DEVELOPMENT, V112, P161	30	127	128	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					745	748		10.1038/355745a0	http://dx.doi.org/10.1038/355745a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1346926				2022-12-28	WOS:A1992HE60400071
J	CRANAGE, MP; BASKERVILLE, A; ASHWORTH, LAE; DENNIS, M; COOK, N; SHARPE, S; FARRAR, G; ROSE, J; KITCHIN, PA; GREENAWAY, PJ				CRANAGE, MP; BASKERVILLE, A; ASHWORTH, LAE; DENNIS, M; COOK, N; SHARPE, S; FARRAR, G; ROSE, J; KITCHIN, PA; GREENAWAY, PJ			INTRARECTAL CHALLENGE OF MACAQUES VACCINATED WITH FORMALIN-INACTIVATED SIMIAN IMMUNODEFICIENCY VIRUS	LANCET			English	Note							SIV	Macaques can be protected from intravenous infection with simian immunodeficiency virus (SIV) by vaccination with chemically inactivated virus. However, protection against infection via a mucosal surface has not been demonstrated. We vaccinated four rhesus macaques with formalin-inactivated SIV given intramuscularly. These monkeys, which had remained virus free for 10 months after intravenous challenge with SIV, were given a further dose of vaccine and together with four unvaccinated controls were challenged intrarectally with SIV. Subsequently, virus was isolated from all control animals on five successive occasions, but the vaccinated animals remained free of virus. Proviral DNA could not be detected in peripheral blood mononuclear cells from the vaccinated animals. Preliminary data indicate that vaccinated animals make a local antibody response.	NATL INST BIOL STAND & CONTROLS,PCR REFERENCE LAB,POTTERS BAR,HERTS,ENGLAND	National Institute for Biological Standards & Control	CRANAGE, MP (corresponding author), PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,DIV PATHOL,PORTON DOWN SP4 0JG,WILTS,ENGLAND.							CRANAGE MP, 1989, NATURE, V342, P349, DOI 10.1038/342349a0; CRANAGE MP, 1990, ANIMAL MODELS AIDS, P115; DESROSIERS RC, 1989, AIDS RES HUM RETROV, V5, P465, DOI 10.1089/aid.1989.5.465; GARDNER MB, 1990, AIDS S1, V4, P5137; KITCHIN PA, 1990, J VIROL METHODS, V28, P85, DOI 10.1016/0166-0934(90)90090-3; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0	7	83	84	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					273	274		10.1016/0140-6736(92)91335-6	http://dx.doi.org/10.1016/0140-6736(92)91335-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346285				2022-12-28	WOS:A1992HB52900007
J	ROBSON, MC; PHILLIPS, LG; THOMASON, A; ROBSON, LE; PIERCE, GF				ROBSON, MC; PHILLIPS, LG; THOMASON, A; ROBSON, LE; PIERCE, GF			PLATELET-DERIVED GROWTH FACTOR-BB FOR THE TREATMENT OF CHRONIC PRESSURE ULCERS	LANCET			English	Note								A randomised, phase I/II, double-blind, placebo-controlled study was designed to assess the effect of topically applied recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic pressure ulcers. Twenty patients were randomly allocated daily treatment for 28 days with 1, 10, or 100-mu-g/ml rPDGF-BB (0.01, 0.1, or 1.0-mu-g per cm2 ulcer area) or placebo. Patients treated with 100-mu-g/ml rPDGF-BB showed a greater healing response than the placebo group, but the lower doses had little effect. After 28 days, ulcers treated with 100-mu-g/ml rPDGF-BB were smaller than those treated with placebo (mean [SE] volume 6.4 [4.0] vs 21.8 [5.6]% of day 0 volume). There were no toxic effects. These preliminary findings suggest that rPDGF-BB is a potent wound-healing agent in soft tissue.	AMGEN INC,THOUSAND OAKS,CA	Amgen	ROBSON, MC (corresponding author), UNIV TEXAS,MED BRANCH,DIV PLAST SURG,301 UNIV BLVD,GALVESTON,TX 77550, USA.							DEUEL TF, 1982, J CLIN INVEST, V69, P1046, DOI 10.1172/JCI110509; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; LYNCH SE, 1989, J CLIN INVEST, V84, P640, DOI 10.1172/JCI114210; MUSTOE TA, 1989, AM J SURG, V158, P345, DOI 10.1016/0002-9610(89)90131-1; PIERCE GF, 1988, J EXP MED, V167, P974, DOI 10.1084/jem.167.3.974; PIERCE GF, 1991, J CELL BIOCHEM, V45, P319, DOI 10.1002/jcb.240450403; PIERCE GF, 1991, AM J PATHOL, V138, P629; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; RESCH CS, 1988, J AM GERIATR SOC, V36, P444, DOI 10.1111/j.1532-5415.1988.tb02385.x; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584	10	287	303	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					23	25		10.1016/0140-6736(92)90143-Q	http://dx.doi.org/10.1016/0140-6736(92)90143-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345953				2022-12-28	WOS:A1992GY04300005
J	MENG, TC; FISCHL, MA; BOOTA, AM; SPECTOR, SA; BENNETT, D; BASSIAKOS, Y; LAI, S; WRIGHT, B; RICHMAN, DD				MENG, TC; FISCHL, MA; BOOTA, AM; SPECTOR, SA; BENNETT, D; BASSIAKOS, Y; LAI, S; WRIGHT, B; RICHMAN, DD			COMBINATION THERAPY WITH ZIDOVUDINE AND DIDEOXYCYTIDINE IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A PHASE-I-II STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV; ZIDOVUDINE; DIDEOXYCYTIDINE; ANTIVIRAL AGENTS	PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; P24 ANTIGEN LEVELS; DOUBLE-BLIND; AZIDOTHYMIDINE AZT; HTLV-III/LAV; 3'-AZIDO-3'-DEOXYTHYMIDINE; INVITRO; HIV; 2',3'-DIDEOXYNUCLEOSIDES	Objective: To evaluate the safety and immunologic and antiviral effects of combination therapy with zidovudine and dideoxycytidine (ddC) in patients with advanced human immunodeficiency virus type 1 (HIV infection. Design: A phase I/II open-label, dose-ranging study. Setting: Two AIDS Clinical Trials Group units. Patients: Patients (56) with advanced HIV disease. Interventions: Patients were randomly assigned to one of three paired regimens of zidovudine and ddC. We evaluated six dosing regimens, each involving oral administration of the study drugs at 8-hour intervals. Measurements: Pharmacokinetics, toxicity, CD4 counts, p24 antigenemia and clinical end points. Main Results: The median follow-up period was 40.6 weeks (range, 0.3 to 70 weeks). Neither drug affected the pharmacokinetic profile of the other. Episodes of serious hematologic toxicity were infrequent, occurring in only 17.9% of patients, and did not differ among the regimens (P = 0.1 5). Severe sensory peripheral neuropathy occurred in two patients (one patient each in regimens 1 and 4). One patient receiving regimen 4 died. The mean maximal increase in CD4 counts exceeded 109 cells/mm3, and 69% of patients receiving combinations containing 300 or 600 mg of zidovudine daily had an increase in CD4 counts of 50 cells/mm3 or greater. Regimens containing 600 mg of zidovudine daily (regimens 2 and 5) were also more likely to result in persistent increases in CD4 counts above pretreatment values than were the two lowest dose regimens (P = 0.003). The decline in CD4 counts was more rapid, and the suppression of the p24 antigenemia was less rapid and less sustained in patients receiving the lowest zidovudine dose alone (regimen 6). The addition of ddC to regimen 6 (regimen 3) resulted in a slower decline in the CD4 counts (P = 0.06). Conclusions: Combination therapy with zidovudine and ddC at the doses tested was well tolerated and did not result in toxicity. A daily oral dose of 150 mg of zidovudine appeared to produce a suboptimal effect on p24 antigenemia and CD4 counts. Combination therapy with ddC and higher doses of zidovudine produced greater and more persistent effects in patients with advanced HIV infection compared with other study regimens and with the results of previous trials of zidovudine monotherapy.	VET AFFAIRS MED CTR, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)			Bassiakos, Yiannis C./AAA-3678-2020	Bassiakos, Yiannis C./0000-0002-7094-4125	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027675, U01AI027670] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27675, AI-27670] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA M, 1987, ANTIMICROB AGENTS CH, V31, P1613, DOI 10.1128/AAC.31.10.1613; CHAISSON RE, 1988, ARCH INTERN MED, V148, P2151, DOI 10.1001/archinte.148.10.2151; DEVITA VT, 1973, NEW ENGL J MED, V288, P998, DOI 10.1056/NEJM197305102881905; ERON JJ, 1991, 7TH INT C AIDS FLOR; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HICKS CR, 1982, FUNDAMENTAL CONCEPTS, P36; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KLASTERSKY J, 1986, AM J MED, V80, P2; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SPECTOR SA, 1989, J INFECT DIS, V159, P822, DOI 10.1093/infdis/159.5.822; TORNEVIK Y, 1990, MOL PHARMACOL, V38, P237; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1988, LANCET, V1, P76	25	217	219	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					13	20		10.7326/0003-4819-116-1-13	http://dx.doi.org/10.7326/0003-4819-116-1-13			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1345755				2022-12-28	WOS:A1992GX15700003
J	SMITH, CL				SMITH, CL			SERVICE INCREMENT FOR TEACHING AND RESEARCH (SIFTR) - THE SOUTHAMPTON EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article											SMITH, CL (corresponding author), SOUTHAMPTON GEN HOSP,FAC MED,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							SHELDON TA, 1990, DISTRICT COMMUNITY H	1	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1992	305	6845					97	98		10.1136/bmj.305.6845.97	http://dx.doi.org/10.1136/bmj.305.6845.97			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1342782	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JD85000028
J	FROST, P; LEVIN, B				FROST, P; LEVIN, B			CLINICAL IMPLICATIONS OF METASTATIC PROCESS	LANCET			English	Article							CLONAL ORIGIN; HUMAN-TUMORS; CANCER; CHROMOSOME-1; CELLS		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77025; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED ONCOL,GI ONCOL & DIGEST DIS SECT,HOUSTON,TX 77025	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center								ATKIN NB, 1986, CANCER GENET CYTOGEN, V21, P279, DOI 10.1016/0165-4608(86)90206-2; BELL C, 1991, CANCER GENET CYTOGEN, V54, P153, DOI 10.1016/0165-4608(91)90203-7; BELL C, 1990, INT J CANCER, V645, P968; DUFFY MJ, 1987, EUR J CANCER CLIN ON, V23, P583, DOI 10.1016/0277-5379(87)90326-9; DVORAK HF, 1987, HUM PATHOL, V18, P275, DOI 10.1016/S0046-8177(87)80010-2; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FIALKOW PJ, 1979, ANNU REV MED, V30, P135, DOI 10.1146/annurev.me.30.020179.001031; FOULDS L, 1954, CANCER RES, V14, P327; FOULDS L, 1975, NEOPLASTIC DEV, P675; FROST P, 1989, Cancer Bulletin (Houston), V41, P139; FROST P, 1990, CANCER METAST REV, V9, P93, DOI 10.1007/BF00047591; Garrido F, 1991, Semin Cancer Biol, V2, P3; GIAVAZZI R, 1991, CANCER RES, V266, P14869; GORELIK E, 1988, BIOCHEM CELL BIOL, V66, P617, DOI 10.1139/o88-071; GRANT SGN, 1991, CANCER RES, V51, P4917; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANNA N, 1983, CIBA S FUND CANC RES, V36, P309; KELLY SA, 1991, CANCER RES, V51, P4020; KENDAL WS, 1986, PATHOL IMMUNOPATH R, V5, P455, DOI 10.1159/000157032; Linehan W.M., 1989, CANCER PRINCIPLES PR, P979; Liotta L A, 1988, Prog Clin Biol Res, V256, P3; Liotta LA, 1989, CANCER PRINCIPLES PR, P98; McCarthy J B, 1991, Semin Cancer Biol, V2, P155; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; ROWLEY JD, 1978, VIRCHOWS ARCH B, V29, P129; SIRDANSKY D, 1992, NEW ENGL J MED, V326, P737; STAROSELSKY AN, IN PRESS INT J CANCE; TARIN D, 1984, CANCER RES, V44, P3584; TARIN D, 1984, INVAS METAST, V4, P1; VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WAGHORNE C, 1988, CANCER RES, V48, P6109; WEISS L, 1988, INT J CANCER, V41, P450, DOI 10.1002/ijc.2910410323	35	55	56	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1458	1461		10.1016/0140-6736(92)92040-M	http://dx.doi.org/10.1016/0140-6736(92)92040-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351135				2022-12-28	WOS:A1992HY31700013
J	BRAHAMS, D				BRAHAMS, D			GP MATERNITY UNITS	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1407	1407		10.1016/0140-6736(92)91217-V	http://dx.doi.org/10.1016/0140-6736(92)91217-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350816				2022-12-28	WOS:A1992HX63600017
J	KRIVINE, A; FIRTION, G; CAO, L; FRANCOUAL, C; HENRION, R; LEBON, P				KRIVINE, A; FIRTION, G; CAO, L; FRANCOUAL, C; HENRION, R; LEBON, P			HIV REPLICATION DURING THE 1ST WEEKS OF LIFE	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INFANTS BORN; TRANSMISSION; CHILDREN; TYPE-1; DNA; AMPLIFICATION; RETROVIRUS; INFECTION	Diagnosis of HIV infection among children born to HIV-positive mothers can be made in the first 12 months, but few studies have examined HIV status during the first weeks of life. In a prospective longitudinal study of 50 infants born to HIV-1 seropositive women, blood samples were obtained at birth and at 4-9 weeks and 5-9 months of age, and were tested for HIV-1 by the polymerase chain reaction (PCR), viral culture, and p24 antigen measurements. 16 were diagnosed as HIV-infected by the age of 4-9 weeks according to both PCR and culture; by contrast, infection could be detected in only 5 children at birth. No changes in HIV status were observed between 4-9 weeks and 5-9 months in the 44 children who could be retested. Perinatal HIV-1 infection can therefore be diagnosed in the first 2 months of life, either by PCR or viral culture. Our inability to detect HIV-1 infection at birth in almost 70% of babies subsequently found infected suggests an active replication of HIV during the first weeks of life. Our results might favour the hypothesis that transmission of HIV-1 takes place either at the end of pregnancy or at delivery.	UNIV PARIS 05,HOP ST VINCENT DE PAUL,DEPT GYNAECOL & OBSTET,F-75014 PARIS,FRANCE; CLIN UNIV PORT ROYAL,DEPT GYNAECOL & OBSTET,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	KRIVINE, A (corresponding author), UNIV PARIS 05,HOP ST VINCENT DE PAUL,DEPT VIROL,82 AVE DENFERT ROCHEREAU,F-75014 PARIS,FRANCE.							BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; EDWARDS JR, 1989, J PEDIATR-US, V115, P200, DOI 10.1016/S0022-3476(89)80065-4; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HOLODNIY M, 1991, J INFECT DIS, V163, P862, DOI 10.1093/infdis/163.4.862; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; JOVAISAS E, 1985, LANCET, V2, P1129; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; LAURE F, 1988, LANCET, V2, P538; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; OTTMANN M, 1991, J VIROL METHODS, V31, P273, DOI 10.1016/0166-0934(91)90165-V; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RUBINSTEIN A, 1983, JAMA-J AM MED ASSOC, V249, P2345; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPRECHER S, 1986, LANCET, V2, P288; WEINBRECK P, 1988, LANCET, V1, P482; ZIEGLER JB, 1985, LANCET, V1, P896; 1991, LANCET, V337, P253	23	170	173	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1187	1189		10.1016/0140-6736(92)91131-Q	http://dx.doi.org/10.1016/0140-6736(92)91131-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349936				2022-12-28	WOS:A1992HU68400002
J	SEED, P				SEED, P			CORONARY ATHEROMA REGRESSION TRIALS	LANCET			English	Letter											SEED, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,MED STAT UNIT,LONDON WC1E 7HT,ENGLAND.		Seed, Paul T/C-4435-2008	Seed, Paul T/0000-0001-7904-7933					0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1241	1241						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349982				2022-12-28	WOS:A1992HU68400057
J	FLANIGAN, T; WHALEN, C; TURNER, J; SOAVE, R; TOERNER, J; HAVLIR, D; KOTLER, D				FLANIGAN, T; WHALEN, C; TURNER, J; SOAVE, R; TOERNER, J; HAVLIR, D; KOTLER, D			CRYPTOSPORIDIUM INFECTION AND CD4 COUNTS	ANNALS OF INTERNAL MEDICINE			English	Note						CRYPTOSPORIDIOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGENS, CD4; CD4-CD8 RATIO; HUMAN IMMUNODEFICIENCY VIRUS		Cryptosporidium infection in immunocompetent persons is associated with self-limited diarrhea. In contrast, in persons with the acquired immunodeficiency syndrome (AIDS), cryptosporidiosis causes persistent enteritis that is refractory to treatment. In our clinical practices, we observed men infected with the human immunodeficiency virus (HIV) who had self-limited diarrhea due to Cryptosporidium infection. To better define the characteristics associated with self-limited disease, we did a retrospective chart review of HIV-seropositive patients with Cryptosporidium infection. We compared 13 HIV-positive persons with self-limited cryptosporidiosis with 34 persons with AIDS who had persistent Cryptosporidium infection. The mean CD4 count was significantly greater in patients with self-limited infection (312 cells/mm3, range, 14 to 651 cells/mm3) than in patient with persistent infection (57 cells/mm3, range 4 to 150 cells/mm3, P < 0.001). A similar relationship was found for the mean CD8 count, the mean ratio of CD4 to CD8 count, and the mean hematocrit. All patients with CD4 counts of 180 cells/mm3 or greater (n = 8) cleared the infection spontaneously over a period of 7 days to 1 month. This observation is important both in predicting the natural history of Cryptosporidium infection and in designing therapeutic trials.	UNIV HOSP CLEVELAND, CLEVELAND, OH 44106 USA; GRAD HOSP PHILADELPHIA, PHILADELPHIA, PA 19146 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, NEW YORK, NY 10021 USA; WHITMAN WALKER CLIN, WASHINGTON, DC 20009 USA; UNIV CALIF SAN DIEGO, CTR TREATMENT, SAN DIEGO, CA 92103 USA; ST LUKES ROOSEVELT HOSP, NEW YORK, NY 10025 USA	University Hospitals of Cleveland; University of Pennsylvania; Pennsylvania Medicine; Cornell University; NewYork-Presbyterian Hospital; University of California System; University of California San Diego; Mount Sinai St. Luke's; Mount Sinai West	FLANIGAN, T (corresponding author), MIRIAM HOSP, DEPT GEOG MED, 164 SUMMIT AVE, PROVIDENCE, RI 02906 USA.				NIAID NIH HHS [AI-25879, AI-01038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025879] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CONNOLLY GM, 1988, GUT, V29, P593, DOI 10.1136/gut.29.5.593; FAYER R, 1986, MICROBIOL REV, V50, P458, DOI 10.1128/MMBR.50.4.458-483.1986; GREENBERG RE, 1989, GASTROENTEROLOGY, V97, P1327, DOI 10.1016/0016-5085(89)91708-3; HOJLYNG N, 1990, 6 INT C AIDS SAN FRA; JACOBSON MA, 1991, J INFECT DIS, V164, P994, DOI 10.1093/infdis/164.5.994; SOAVE R, 1988, J INFECT DIS, V157, P225, DOI 10.1093/infdis/157.2.225; 1987, MMWR, V36, pS3; 1986, SUGI SUPPLEMENTAL LI, P270	8	198	205	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					840	842		10.7326/0003-4819-116-10-840	http://dx.doi.org/10.7326/0003-4819-116-10-840			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1348918				2022-12-28	WOS:A1992HT80200009
J	MUIR, K; TODD, WTA; WATSON, WH; FITZSIMONS, E				MUIR, K; TODD, WTA; WATSON, WH; FITZSIMONS, E			VIRAL-ASSOCIATED HEMOPHAGOCYTOSIS WITH PARVOVIRUS-B19-RELATED PANCYTOPENIA	LANCET			English	Note							HEMOPHAGOCYTIC SYNDROME; HUMAN PARVOVIRUS; HISTIOCYTOSIS; CRISIS; MARROW; VIRUS; B19	Viral-associated haemophagocyte syndrome in response to infection with human parvovirus B19 was seen in 2 patients with hereditary spherocytosis. Depressed reticulocyte response during acute parvovirus infection is a known cause of hypoproliferative crises in patients with reduced erythrocyte lifespan; the observation of parvovirus-associated haemophagocytosis could account for the pancytopenia that may accompany human parvovirus B19 infection.	MONKLANDS DIST GEN HOSP, DEPT HAEMATOL, AIRDRIE ML6 OJS, SCOTLAND				Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X				ANDERSON MJ, 1985, J INFECT DIS, V152, P257, DOI 10.1093/infdis/152.2.257; BORUCHOFF SE, 1990, ARCH INTERN MED, V150, P897, DOI 10.1001/archinte.150.4.897; LEFRERE JJ, 1986, AM J HEMATOL, V23, P271, DOI 10.1002/ajh.2830230311; MORTIMER PD, 1985, NATURE, V302, P426; PATTISON JR, 1981, LANCET, V1, P664; POTTER CG, 1987, J CLIN INVEST, V79, P1486, DOI 10.1172/JCI112978; REINER AP, 1988, MEDICINE, V67, P369, DOI 10.1097/00005792-198811000-00002; RISDALL RJ, 1979, CANCER, V44, P993, DOI 10.1002/1097-0142(197909)44:3<993::AID-CNCR2820440329>3.0.CO;2-5; YOUNG NS, 1989, ANN NY ACAD SCI, V554, P75, DOI 10.1111/j.1749-6632.1989.tb22411.x	9	64	65	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	1992	339	8802					1139	1140		10.1016/0140-6736(92)90735-L	http://dx.doi.org/10.1016/0140-6736(92)90735-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349370				2022-12-28	WOS:A1992HT23600007
J	BARR, LC; BAUM, M				BARR, LC; BAUM, M			TIME TO ABANDON TNM STAGING OF BREAST-CANCER	LANCET			English	Editorial Material							PROGNOSTIC INDEX		ROYAL MARSDEN HOSP,BREAST UNIT,FULHAM RD,LONDON SW3 6JJ,ENGLAND	Royal Marsden NHS Foundation Trust				Barr, Lester/0000-0003-4030-8192				BRYAN RM, 1986, BRIT J SURG, V73, P267, DOI 10.1002/bjs.1800730408; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; HAAGENSON CD, 1986, MASTECTOMY SUPPLEMEN, P949; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Hermanek P, 1987, TNM CLASSIFICATION M; HUTTER RVP, 1987, ARCH SURG-CHICAGO, V122, P1235; ROSNER D, 1991, CANCER, V68, P1482, DOI 10.1002/1097-0142(19911001)68:7<1482::AID-CNCR2820680704>3.0.CO;2-J; SCANLON EF, 1990, CANCER, V65, P2110, DOI 10.1002/1097-0142(19900501)65:9+<2110::AID-CNCR2820651405>3.0.CO;2-Z; SCHOTTENFELD D, 1976, CANCER, V38, P1001, DOI 10.1002/1097-0142(197608)38:2<1001::AID-CNCR2820380252>3.0.CO;2-5; SLAMON DJ, 1991, J NATL CANCER I, V83, P229, DOI 10.1093/jnci/83.4.229; 1991, JAMA-J AM MED ASSOC, V265, P391; 1992, LANCET, V339, P71	13	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					915	917		10.1016/0140-6736(92)90941-U	http://dx.doi.org/10.1016/0140-6736(92)90941-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348309				2022-12-28	WOS:A1992HN48300015
J	MOORE, DP; WESTON, AR; HUGHES, JMB; OAKLEY, CM; CLELAND, JGF				MOORE, DP; WESTON, AR; HUGHES, JMB; OAKLEY, CM; CLELAND, JGF			EFFECTS OF INCREASED INSPIRED OXYGEN CONCENTRATIONS ON EXERCISE PERFORMANCE IN CHRONIC HEART-FAILURE	LANCET			English	Article							SKELETAL-MUSCLE; BLOOD-FLOW; ABNORMALITIES; BREATHLESSNESS; VENTILATION; CAPACITY	Exercise capacity in patients with stable heart failure may be influenced by prolonged drug treatment or exercise training, but acute interventions are generally thought to have little effect. Cardiorespiratory responses to exercise were studied in 12 consecutive patients with chronic congestive heart failure who underwent serial submaximal and maximal exercise tests at inspired oxygen concentrations of 21% (room air), 30%, and 50%. Mean (SD) exercise duration during progressive testing to maximum exercise capacity was prolonged from 548 (276) s on room air to 632 (285) s on 50% oxygen (p = 0.01 2). During steady-state exercise at 45 W, oxygen enrichment to 50% was associated with significantly increased arterial oxygen saturation (94.6 [1.9] % to 97.5 [1.3] %), and significantly reduced minute ventilation (36.1 [8.6] l/min to 28.1 [5.9] l/min), cardiac output (7.5 [2.3] l/min to 6.5 [1.9] l/min), and subjective scores for fatigue and breathlessness (13.9 [3.1] to 11.5 [3.5]) compared with room air, intermediate changes were observed with 30% inspired oxygen. Increased inspired oxygen concentrations can improve exercise performance acutely and modify the ventilatory response to exercise in patients with heart failure. Hyperoxia reduces ventilatory response and circulatory demand while maintaining oxygen delivery at a given workload. The potential benefits of increased inspired oxygen concentrations in the treatment of chronic heart failure merit further assessment.	ROYAL POSTGRAD MED SCH,DIV CLIN CARDIOL,DUCANE RD,LONDON W12 0NN,ENGLAND; ROYAL POSTGRAD MED SCH,DIV RESP MED,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London			Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016				ADAMS L, 1985, CLIN SCI, V69, P663, DOI 10.1042/cs0690663; BANNISTER RG, 1954, J PHYSIOL-LONDON, V125, P118, DOI 10.1113/jphysiol.1954.sp005145; CHRONOS N, 1988, CLIN SCI, V74, P531, DOI 10.1042/cs0740531; COATS AJS, 1990, LANCET, V335, P63, DOI 10.1016/0140-6736(90)90536-E; HIGGINBOTHAM MB, 1986, CIRCULATION S2, V74, P178; HUGHES RL, 1968, J APPL PHYSIOL, V24, P336, DOI 10.1152/jappl.1968.24.3.336; JONES HA, 1991, CARDIOVASC RES, V25, P523, DOI 10.1093/cvr/25.6.523; KING AJ, 1973, CLIN SCI, V44, P151, DOI 10.1042/cs0440151; KRAMER BL, 1983, CIRCULATION, V67, P807, DOI 10.1161/01.CIR.67.4.807; LEIER CV, 1983, CIRCULATION, V67, P817, DOI 10.1161/01.CIR.67.4.817; LEJEMTEL TH, 1986, CIRCULATION, V74, P245, DOI 10.1161/01.CIR.74.2.245; LIPKIN DP, 1988, INT J CARDIOL, V18, P187, DOI 10.1016/0167-5273(88)90164-7; LIPKIN DP, 1986, CIRCULATION, V74, P140; MANCINI DM, 1989, CIRCULATION, V80, P1338, DOI 10.1161/01.CIR.80.5.1338; MASKIN CS, 1983, AM J CARDIOL, V51, P177, DOI 10.1016/S0002-9149(83)80032-0; MASSIE BM, 1988, CIRCULATION, V78, P320, DOI 10.1161/01.CIR.78.2.320; MOORE DP, 1989, BRIT HEART J, V61, P435; RUBIN SA, 1984, AM REV RESPIR DIS, V129, pS63, DOI 10.1164/arrd.1984.129.2P2.S63; SINOWAY LI, 1988, AM J CARDIOL, V62, pE45, DOI 10.1016/S0002-9149(88)80010-9; SULLIVAN MJ, 1988, CIRCULATION, V77, P552, DOI 10.1161/01.CIR.77.3.552; WEBER KT, 1982, CIRCULATION, V65, P1213, DOI 10.1161/01.CIR.65.6.1213; 1973, NOMENCLATURE CRITERI	22	72	72	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					850	853		10.1016/0140-6736(92)90288-E	http://dx.doi.org/10.1016/0140-6736(92)90288-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347866				2022-12-28	WOS:A1992HM44100013
J	NEWCOMBE, DS				NEWCOMBE, DS			IMMUNE SURVEILLANCE, ORGANOPHOSPHORUS EXPOSURE, AND LYMPHOMAGENESIS	LANCET			English	Article							MONOCYTE ESTERASE-ACTIVITY; NATURAL-KILLER CELLS; EPSTEIN-BARR; INTOXICATION; ABERRATIONS; INHIBITION; PESTICIDES; MORTALITY; INDUSTRY; WORKERS	Prevalence of lymphoproliferative disorders is increased in populations with various chemical exposures, including organophosphorus compounds. Lymphomas are also more common in individuals with a substantially decreased monocyte esterase activity. Organophosphorus compounds inhibit esterases associated with monocytes, natural killer (NK) cells, lymphokine-activated killer (LAK) cells, and cytotoxic T lymphocytes, and these inhibitory effects impair immune surveillance and cytotoxic functions mediated by such cells. Lymphoma development is also associated with Epstein-Barr virus (EBV) and human herpesvirus-6 (HHV-6) infections, which are regulated by cytotoxic immune responses mediated by monocytes, T cells, and NK cells. My hypothesis is that lymphomagenesis is a multistep process, and the absence or inhibition of monocyte esterase and perhaps other immune cell esterases alters esterase-dependent detoxification of a factor critical for the early steps of oncogenesis. Also, such an enzyme deficit might impair the processes that regulate the dissemination and limit the total burden of pathogens such as the lymphoma-associated herpesviruses. An added risk to any viral-mediated lymphoproliferation might be an organophosphorus-induced oncogenic genetic change.			NEWCOMBE, DS (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.							ALAVANJA MCR, 1990, J NATL CANCER I, V82, P840, DOI 10.1093/jnci/82.10.840; ALAVANJA MCR, 1987, J NATL CANCER I, V78, P247; AMBINDER RF, 1990, MOL CELL PROBE, V4, P397, DOI 10.1016/0890-8508(90)90030-4; AMBINDER RF, 1990, HEMATOL ONCOL CLIN N, V4, P821, DOI 10.1016/S0889-8588(18)30469-6; BIEMER JJ, 1990, ANN CLIN LAB SCI, V20, P175; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BLAIR A, 1985, SCAND J WORK ENV HEA, V11, P397, DOI 10.5271/sjweh.2208; DULOUT FN, 1985, MUTAT RES, V143, P237, DOI 10.1016/0165-7992(85)90087-9; EMMETT EA, 1985, J OCCUP ENVIRON MED, V27, P905; GAIL MH, 1991, JNCI-J NATL CANCER I, V83, P695, DOI 10.1093/jnci/83.10.695; HALL NEL, 1991, AM J IND MED, V19, P145, DOI 10.1002/ajim.4700190203; KIRALY J, 1979, ARCH ENVIRON CON TOX, V8, P309, DOI 10.1007/BF01056247; LAVECCHIA C, 1989, BRIT J CANCER, V60, P385, DOI 10.1038/bjc.1989.290; LEE MJ, 1977, BLOOD, V50, P947; MANDEL JS, 1989, AM J IND MED, V15, P207, DOI 10.1002/ajim.4700150209; MARKEY GM, 1990, J CLIN PATHOL, V43, P282, DOI 10.1136/jcp.43.4.282; MCCORMICK JA, 1991, BRIT J HAEMATOL, V77, P287, DOI 10.1111/j.1365-2141.1991.tb08572.x; MULE JJ, 1985, J IMMUNOL, V135, P646; Newcombe D.S., 1992, CLIN IMMUNOTOXICOLOG, P349; OEHMICHEN M, 1984, FORENSIC SCI INT, V25, P181, DOI 10.1016/0379-0738(84)90192-0; OERTEL J, 1985, BRIT J HAEMATOL, V61, P717, DOI 10.1111/j.1365-2141.1985.tb02886.x; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; REYNOLDS T, 1991, J NATL CANCER I, V83, P232, DOI 10.1093/jnci/83.4.232; ROGERS KE, 1988, J IMMUNOL, V140, P564; ROGERS KE, 1986, IMMUNOPHARMACOLOGY, V12, P193; RUZICSKA P, 1973, MUTAT RES, V21, P187; SOBTI RC, 1982, MUTAT RES, V102, P89, DOI 10.1016/0165-1218(82)90149-5; STEINER PE, 1960, CANCER-AM CANCER SOC, V13, P1084, DOI 10.1002/1097-0142(196011/12)13:6&lt;1085::AID-CNCR2820130603&gt;3.0.CO;2-Y; SUBAR M, 1988, BLOOD, V72, P667; TALCOTT RE, 1979, TOXICOL APPL PHARM, V49, P107, DOI 10.1016/0041-008X(79)90282-5; TORELLI G, 1991, BLOOD, V77, P2251, DOI 10.1182/blood.V77.10.2251.2251; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VANBAO T, 1974, HUMANGENETIK, V24, P33; WU TC, 1991, AM J PATHOL, V138, P1461; YODER J, 1973, MUTAT RES, V21, P335	35	32	33	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 29	1992	339	8792					539	541		10.1016/0140-6736(92)90349-8	http://dx.doi.org/10.1016/0140-6736(92)90349-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346889	hybrid			2022-12-28	WOS:A1992HF63100014
J	SPIRO, HM				SPIRO, HM			DIAGNOSTIC LAPAROSCOPIC CHOLECYSTECTOMY	LANCET			English	Editorial Material											SPIRO, HM (corresponding author), YALE UNIV,SCH MED,333 CEDAR ST,BOX 3333,NEW HAVEN,CT 06510, USA.							GRACIE WA, 1982, NEW ENGL J MED, V307, P798, DOI 10.1056/NEJM198209233071305; HOLOHAN TV, 1991, LANCET, V338, P801, DOI 10.1016/0140-6736(91)90678-I; RIGAS B, 1990, J CLIN GASTROENTEROL, V12, P409, DOI 10.1097/00004836-199008000-00011; SPIRO HM, 1976, NEW ENGL J MED, V294, P829, DOI 10.1056/NEJM197604082941509; WILSON P, 1991, LANCET, V338, P795, DOI 10.1016/0140-6736(91)90674-E; 1991, LANCET, V338, P789	6	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					167	168		10.1016/0140-6736(92)90221-N	http://dx.doi.org/10.1016/0140-6736(92)90221-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346020				2022-12-28	WOS:A1992GZ96800014
J	WITHERS, HR				WITHERS, HR			BIOLOGICAL BASIS OF RADIATION-THERAPY FOR CANCER	LANCET			English	Article							DOSE FRACTIONATION; RADIOTHERAPY; REPOPULATION; CARCINOMA; HEAD; NECK				WITHERS, HR (corresponding author), UNIV CALIF LOS ANGELES,MED CTR,DEPT RADIAT ONCOL,LOS ANGELES,CA 90024, USA.							BEGG AC, 1990, INT J RADIAT ONCOL, V19, P1449, DOI 10.1016/0360-3016(90)90357-P; BROWN JM, 1987, INNOVATIONS RAD ONCO, P247; Chapman JD, 1988, PREDICTION TUMOR TRE; Hall E.J., 2019, RADIOBIOLOGY RADIOLO, Veighth; HORIOT JC, 1990, EUR J CANCER, V26, P779, DOI 10.1016/0277-5379(90)90150-R; KALLMAN RF, 1972, RADIOLOGY, V105, P135, DOI 10.1148/105.1.135; KNEE R, 1985, RADIOTHER ONCOL, V4, P1, DOI 10.1016/S0167-8140(85)80055-4; MACIEJEWSKI B, 1989, INT J RADIAT ONCOL, V16, P831, DOI 10.1016/0360-3016(89)90503-8; Million R R, 1988, Front Radiat Ther Oncol, V22, P79; PETERS LJ, 1988, AM J CLIN ONCOL-CANC, V11, P275, DOI 10.1097/00000421-198806000-00005; SAUNDERS MI, 1989, INT J RADIAT ONCOL, V17, P1287, DOI 10.1016/0360-3016(89)90538-5; Steel G, 1983, BIOL BASIS RADIOTHER; THAMES HD, 1982, INT J RADIAT ONCOL, V8, P219, DOI 10.1016/0360-3016(82)90517-X; TROTT KR, 1985, RADIOTHER ONCOL, V3, P1, DOI 10.1016/S0167-8140(85)80002-5; Wang C C, 1988, Front Radiat Ther Oncol, V22, P93; WITHERS HR, 1975, RADIOLOGY, V114, P199, DOI 10.1148/114.1.199; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; WITHERS HR, 1987, INNOVATIONS RAD ONCO; WITHERS HR, 1980, TXB RADIOTHERAPY, P103	19	52	52	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					156	159						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346018				2022-12-28	WOS:A1992GZ96800011
J	TUDORWILLIAMS, G; STCLAIR, MH; MCKINNEY, RE; MAHA, M; WALTER, E; SANTACROCE, S; MINTZ, M; ODONNELL, K; RUDOLL, T; VAVRO, CL; CONNOR, EM; WILFERT, CM				TUDORWILLIAMS, G; STCLAIR, MH; MCKINNEY, RE; MAHA, M; WALTER, E; SANTACROCE, S; MINTZ, M; ODONNELL, K; RUDOLL, T; VAVRO, CL; CONNOR, EM; WILFERT, CM			HIV-1 SENSITIVITY TO ZIDOVUDINE AND CLINICAL OUTCOME IN CHILDREN	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; THERAPY; RESISTANT; TYPE-1; AZT	In adults with the acquired immunodeficiency syndrome, long-term monotherapy with zidovudine selects for human immunodeficiency virus type 1 (HIV-1) strains with substantially reduced in-vitro susceptibility to the drug. We have assessed the relation between in-vitro resistance to zidovudine and clinical outcome in children, in whom disease progression is more rapid than in adults. We studied 23 children with symptoms of HIV-1 disease during extended monotherapy with zidovudine. An in-vitro assay was used to determine the concentration of zidovudine required to inhibit by 50% the replication of viral isolates (IC50) obtained after 9 to 39 months of treatment. Viral stocks of high enough titre to yield reproducible results were obtained from 19 of the children. During the following 6 months of therapy, 9 children were stable, 7 deteriorated, and 3 died. There was a highly significant relation between decreased zidovudine susceptibility and poor clinical outcome (p < 0.001) but no relation between IC50 and age at start of therapy or length of time on treatment. Age-adjusted CD4 lymphocyte counts were lower at the start of treatment (p = 0.02) and at the time of sampling (p = 0.01) in children whose viral isolates had an increased zidovudine IC50. Initial serum p24 antigen levels were not predictive of subsequent emergence of resistant virus, but at the time of sampling for viral sensitivity higher p24 antigen levels were associated with raised IC50 (p = 0.004). The findings suggest that most children who become unresponsive to monotherapy with zidovudine, as judged by clinical criteria, will have changes in in-vitro sensitivity to the drug. In these children, an alternative antiretroviral therapy should be considered.	CHILDRENS HOSP NEW JERSEY,NEWARK,NJ; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709	Duke University; Duke University; Burroughs Wellcome Fund								BACH MC, 1990, NEW ENGL J MED, V323, P275; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; ISRAELE V, 1991, 7 INT C AIDS FLOR, V1, P80; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCKINNEY RE, 1990, J PEDIATR-US, V116, P640, DOI 10.1016/S0022-3476(05)81619-1; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; PHILLIPS AN, 1991, LANCET, V337, P389; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; ROOKE R, 1989, AIDS, V3, P411, DOI 10.1097/00002030-198907000-00001; SCHWARTZ O, 1988, AIDS RES HUM RETROV, V4, P441, DOI 10.1089/aid.1988.4.441; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1991, MMWR, V40, P1; 1987, MMWR, V36, P225	17	137	139	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					15	19		10.1016/0140-6736(92)90140-X	http://dx.doi.org/10.1016/0140-6736(92)90140-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345951				2022-12-28	WOS:A1992GY04300002
J	EVANS, CJ; KEITH, DE; MORRISON, H; MAGENDZO, K; EDWARDS, RH				EVANS, CJ; KEITH, DE; MORRISON, H; MAGENDZO, K; EDWARDS, RH			CLONING OF A DELTA OPIOID RECEPTOR BY FUNCTIONAL EXPRESSION	SCIENCE			English	Article							MOLECULAR CHARACTERIZATION; PEPTIDES; BINDING; BRAIN; PROTEIN	Opiate drugs have potent analgesic and addictive properties. These drugs interact with receptors that also mediate the response to endogenous opioid peptide ligands. However, the receptors for opioids have eluded definitive molecular characterization. By transient expression in COS cells and screening with an iodinated analog of the opioid peptide enkephalin, a complementary DNA clone encoding a functional delta opioid receptor has been identified. The sequence shows homology to G protein-coupled receptors, in particular the receptors for somatostatin, angiotensin, and interleukin-8.	UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	EVANS, CJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT,LOS ANGELES,CA 90024, USA.				NIDA NIH HHS [DA05010, P50 DA005010] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Bertolucci M., 1992, Society for Neuroscience Abstracts, V18, P1368; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADBURY AF, 1976, NATURE, V260, P165, DOI 10.1038/260165a0; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; LAW PY, 1983, MOL PHARMACOL, V23, P26; LAW PY, 1982, MOL PHARMACOL, V21, P438; LOH HH, 1988, SYNAPSE, V2, P457, DOI 10.1002/syn.890020414; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MAIDMENT NT, 1989, NEUROSCIENCE, V33, P549, DOI 10.1016/0306-4522(89)90407-7; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MATTIA A, 1992, J PHARMACOL EXP THER, V260, P518; MILLER RJ, 1978, LIFE SCI, V22, P379, DOI 10.1016/0024-3205(78)90284-9; MILLIGAN CE, 1992, MOL BIOL CELL, V3, P242; MULDER H, 1991, EUR J PHARMACOL, V205, P211; PASTERNAK GW, 1988, OPIATE RECEPTORS, P75; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TERENIUS L, 1973, ACTA PHARMACOL TOX, V32, P317; TERENIUS L, 1976, EUR J PHARMACOL, V38, P211, DOI 10.1016/0014-2999(76)90221-1; WEBER E, 1983, TRENDS NEUROSCI, V6, P333, DOI 10.1016/0166-2236(83)90150-9; XIE GX, 1992, P NATL ACAD SCI USA, V89, P4124, DOI 10.1073/pnas.89.9.4124	31	1158	1203	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1952	1955		10.1126/science.1335167	http://dx.doi.org/10.1126/science.1335167			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1335167				2022-12-28	WOS:A1992KD08800037
J	SMITH, RG; HAMILTON, S; HOFMANN, F; SCHNEIDER, T; NASTAINCZYK, W; BIRNBAUMER, L; STEFANI, E; APPEL, SH				SMITH, RG; HAMILTON, S; HOFMANN, F; SCHNEIDER, T; NASTAINCZYK, W; BIRNBAUMER, L; STEFANI, E; APPEL, SH			SERUM ANTIBODIES TO L-TYPE CALCIUM CHANNELS IN PATIENTS WITH AMYOTROPHIC-LATERAL-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOTOR-NEURON DISEASE; EATON MYASTHENIC SYNDROME; GRAY-MATTER DISEASE; SKELETAL-MUSCLE; SPINAL-CORD; PROTEINS; SUBUNIT; AUTOANTIBODIES; IGG; AUTOIMMUNITY	Background and Methods. Sporadic amyotrophic lateral sclerosis is a chronic, progressive degenerative disease of the motor neurons of the spinal cord and motor cortex. The cause is unknown. Recent electrophysiologic studies in animals indicate that immunoglobulins from patients with this disease alter presynaptic voltage-dependent calcium currents and calcium-dependent release of neurotransmitters. To determine whether similar interactions might be identified biochemically, we used an enzyme-linked immunosorbent assay (ELISA) to detect the reaction of serum IgG with purified complexes of L-type voltage-gated calcium channels from rabbit skeletal muscle. The results from patients with amyotrophic lateral sclerosis were compared with those obtained from patients with other types of motor neuron disease, patients with autoimmune. and non-autoimmune neurologic diseases, and normal subjects. Results. Serum samples from 36 of 48 patients with sporadic amyotrophic lateral sclerosis (75 percent) contained IgG that reacted with L-type calcium-channel protein, and serum reactivity on ELISA correlated with the rate of disease progression (Spearman rank-correlation coefficient, 0.62). Reactive serum was present in only 1 of 25 normal subjects and 1 of 35 control patients with no motor neuron disease. Antibodies to L-type voltage-gated calcium channels were identified in 6 of 9 patients with Lambert-Eaton syndrome, and in 3 of 15 patients with Guillain-Barre syndrome. Conclusions. Antibodies to L-type voltage-gated calcium channels are present in the serum of patients with amyotrophic lateral sclerosis, and antibody titers correlate with the rate of disease progression. Together with previous data, these results suggest a role for autoimmune mechanisms in the pathogenesis of sporadic amyotrophic lateral sclerosis.	BAYLOR COLL MED,DEPT NEUROL,6501 FANNIN,NB 302,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV SAARLAND,W-6650 HOMBURG,GERMANY	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Saarland University				Hamilton, Susan/0000-0003-0241-9369				AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; APPEL SH, 1986, ARCH NEUROL-CHICAGO, V43, P234, DOI 10.1001/archneur.1986.00520030026007; APPEL SH, 1991, P NATL ACAD SCI USA, V88, P647, DOI 10.1073/pnas.88.2.647; APPEL SH, 1988, ARCH NEUROL-CHICAGO, V45, P381, DOI 10.1001/archneur.1988.00520280027011; APPEL SH, 1991, CURRENT NEUROLOGY, V10, P287; APPEL V, 1987, ANN NEUROL, V22, P328, DOI 10.1002/ana.410220308; CRAWFORD GD, 1992, J NEUROSCI, V12, P3392; DELBONO O, 1991, AM J PHYSIOL, V260, pC1347, DOI 10.1152/ajpcell.1991.260.6.C1347; DELBONO O, 1991, J PHYSIOL-LONDON, V444, P723, DOI 10.1113/jphysiol.1991.sp018903; ENDO T, 1984, J IMMUNOL, V132, P1793; ENGEL AG, 1989, ANN NY ACAD SCI, V560, P278, DOI 10.1111/j.1749-6632.1989.tb24105.x; ENGELHARDT JI, 1989, ANN NEUROL, V26, P368, DOI 10.1002/ana.410260310; ENGELHARDT JI, 1990, ARCH NEUROL-CHICAGO, V47, P1210, DOI 10.1001/archneur.1990.00530110068019; ENGELHARDT JI, 1990, J NEUROIMMUNOL, V27, P21, DOI 10.1016/0165-5728(90)90132-7; HAMILTON SL, 1989, BIOCHEMISTRY-US, V28, P7820, DOI 10.1021/bi00445a044; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HAUSER SL, 1986, NEUROLOGY, V36, P1614, DOI 10.1212/WNL.36.12.1614; HORWICH MS, 1974, ARCH NEUROL-CHICAGO, V30, P332, DOI 10.1001/archneur.1974.00490340060015; HOU KC, 1986, BIOTECHNIQUES, V4, P358; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HULSIZER S C, 1991, Society for Neuroscience Abstracts, V17, P1159; INGVARMAEDER M, 1986, ACTA NEUROL SCAND, V74, P218, DOI 10.1111/j.1600-0404.1986.tb07858.x; KELEMEN J, 1983, ARCH NEUROL-CHICAGO, V40, P752, DOI 10.1001/archneur.1983.04050110070012; KIM YI, 1988, SCIENCE, V239, P405, DOI 10.1126/science.2447652; LANG B, 1987, J PHYSIOL-LONDON, V390, P257, DOI 10.1113/jphysiol.1987.sp016698; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MAGNELLI V, IN PRESS J PHYSL LON; MEININGER V, 1990, Neurology, V40, P183; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; MULDER DW, 1969, CONT NEUROLOGY S, V2, P12; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NASTAINCZYK W, 1990, GEN PHYSIOL BIOPHYS, V9, P321; NORMAN RI, 1989, ANN NY ACAD SCI, V560, P258, DOI 10.1111/j.1749-6632.1989.tb24103.x; OLDSTONE MBA, 1976, LANCET, V2, P169; ORDONEZ G, 1989, NEUROLOGY, V39, P683, DOI 10.1212/WNL.39.5.683; PALO J, 1978, LANCET, V1, P1270; PESTRONK A, 1989, ANN NEUROL, V25, P98, DOI 10.1002/ana.410250118; POWERS AC, 1985, ANNU REV MED, V36, P533; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROWLAND LP, 1984, TRENDS NEUROSCI, V7, P110, DOI 10.1016/S0166-2236(84)80236-2; SAKAMOTA J, 1991, PHYSIOLOGIST, V34, P109; SAWADA T, 1992, Biophysical Journal, V61, pA401; SCHNEIDER T, IN PRESS METHODS MOL, V13; SCOTT D, 1985, J BIOL CHEM, V260, P736; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; SMITH R G, 1991, Society for Neuroscience Abstracts, V17, P1451; STEFANSSON K, 1985, SCIENCE, V228, P1117, DOI 10.1126/science.4039466; TAJTI J, 1991, J NEUROIMMUNOL, V34, P143, DOI 10.1016/0165-5728(91)90123-O; TOUZEAU G, 1986, NEUROLOGY, V36, P573, DOI 10.1212/WNL.36.4.573; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WILLIAMS DB, 1991, MAYO CLIN PROC, V66, P54, DOI 10.1016/S0025-6196(12)61175-6; YOUNGER DS, 1990, NEUROLOGY, V40, P595, DOI 10.1212/WNL.40.4.595; [No title captured]	57	173	179	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1721	1728		10.1056/NEJM199212103272405	http://dx.doi.org/10.1056/NEJM199212103272405			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1331790				2022-12-28	WOS:A1992KA89700005
J	SCHUTZE, S; POTTHOFF, K; MACHLEIDT, T; BERKOVIC, D; WIEGMANN, K; KRONKE, M				SCHUTZE, S; POTTHOFF, K; MACHLEIDT, T; BERKOVIC, D; WIEGMANN, K; KRONKE, M			TNF ACTIVATES NF-KAPPA-B BY PHOSPHATIDYLCHOLINE-SPECIFIC PHOSPHOLIPASE-C-INDUCED ACIDIC SPHINGOMYELIN BREAKDOWN	CELL			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; ENHANCER-BINDING-PROTEIN; GH3 PITUITARY-CELLS; IMMUNODEFICIENCY VIRUS TYPE-1; NIEMANN-PICK DISEASE; HUMAN LYMPHOCYTES-T; FACTOR-ALPHA; TRANSCRIPTION FACTOR; MOLECULAR-CLONING	In this paper, we describe a phospholipid transmission pathway mediating tumor necrosis factor (TNF) activation of the nuclear transcription factor kappaB (NF-kappaB). Central to this TNF signaling route is the second messenger-like molecule ceramide, which is generated by sphingomyelin (SM) breakdown catalyzed by a sphingomyelinase (SMase). SMase activation is secondary to the generation of 1,2-diacylglycerol (DAG) produced by a TNF-responsive PC-specific phospholipase C (PC-PLC). The functional coupling of these two C type phospholipases is revealed by D609, a selective inhibitor of PC-PLC. SMase itself, or SMase-inducing regimens such as exogenous PLC or synthetic DAGs, induces NF-kappaB activation at pH 5.0, suggesting the operation of an acidic SMase. A model is proposed in which a TNF-responsive PC-PLC via DAG couples to an acidic SMase, resulting in the generation of ceramide, which eventually triggers rapid induction of nuclear NF-kappaB activity.	UNIV GOTTINGEN, ZENTRUM INNERE MED, HAMATOL ONKOL ABT, W-3400 GOTTINGEN, GERMANY	University of Gottingen	SCHUTZE, S (corresponding author), TECH UNIV MUNICH, INST MED MIKROBIOL & HYG, W-8000 MUNICH 80, GERMANY.		Schütze, Stefan/C-8596-2011					ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; ATKINSON YH, 1990, IMMUNOLOGY, V70, P82; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EIBL H, 1969, ANAL BIOCHEM, V30, P51, DOI 10.1016/0003-2697(69)90372-8; FAURE R, 1992, J BIOL CHEM, V267, P11215; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GODFREY RW, 1987, BIOCHEM BIOPH RES CO, V142, P235, DOI 10.1016/0006-291X(87)90476-1; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; KORATCHER S, 1978, ENZYMES LIPID METABO, P221; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LE JM, 1987, LAB INVEST, V56, P234; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; RAO BG, 1976, J LIPID RES, V17, P506; RAO GR, 1981, BIOCHEM J, V198, P9, DOI 10.1042/bj1980009; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSTENBECK I, 1990, J CHROMATOGR-BIOMED, V525, P85, DOI 10.1016/S0378-4347(00)83381-2; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TOMITA M, 1990, J BIOCHEM-TOKYO, V108, P811, DOI 10.1093/oxfordjournals.jbchem.a123285; VANBELZEN N, 1990, J CELL PHYSIOL, V145, P365, DOI 10.1002/jcp.1041450223; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZOU L, 1989, BIOTECHNOL APPL BIOC, V11, P217	72	1046	1061	2	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					765	776		10.1016/0092-8674(92)90553-O	http://dx.doi.org/10.1016/0092-8674(92)90553-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330325				2022-12-28	WOS:A1992JZ63300007
J	BEAM, KG; ADAMS, BA; NIIDOME, T; NUMA, S; TANABE, T				BEAM, KG; ADAMS, BA; NIIDOME, T; NUMA, S; TANABE, T			FUNCTION OF A TRUNCATED DIHYDROPYRIDINE RECEPTOR AS BOTH VOLTAGE SENSOR AND CALCIUM-CHANNEL	NATURE			English	Article							DYSGENIC SKELETAL-MUSCLE; 2 SIZE FORMS; CHARGE MOVEMENT; ALPHA-1; PHOSPHORYLATION; SUBUNITS; CELLS; CDNAS; ACID; RAT	THE skeletal muscle dihydropyridine (DHP) receptor serves dual functions, as a voltage sensor for excitation-contraction coupling and as an L-type calcium channel1-3. Biochemical analysis indicates the presence of two forms of the DHP receptor polypeptide in skeletal muscle, a full-length translation product present as a minor species and a much more abundant form that has a truncated carboxy-terminus4-6. On the basis of these and other observations7, it has been proposed8 that, in skeletal muscle, only the full-length DHP receptor can function as a calcium channel and that the truncated form can only function as a voltage sensor for excitation-contraction coupling. To resolve this issue, we have now constructed a complementary DNA (pC6DELTA1) encoding a protein corresponding to the truncated DHP receptor in skeletal muscle. Expression of pC6DELTA1 in dysgenic myotubes fully restores both excitation-contraction coupling and calcium current, consistent with the idea that a single class of DHP receptors performs both functions.	KYOTO UNIV,FAC MED,DEPT MED CHEM,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MOLEC GENET,KYOTO 606,JAPAN	Kyoto University; Kyoto University	BEAM, KG (corresponding author), COLORADO STATE UNIV,COLL VET MED & BIOMED SCI,DEPT PHYSIOL,FT COLLINS,CO 80523, USA.		Tuluc, Petronel/C-2527-2011					ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; LAI Y, 1990, J BIOL CHEM, V265, P20839; LAMB GD, 1987, J PHYSIOL-LONDON, V393, P595, DOI 10.1113/jphysiol.1987.sp016843; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764	18	95	95	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					169	171		10.1038/360169a0	http://dx.doi.org/10.1038/360169a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1331811				2022-12-28	WOS:A1992JX75200063
J	WANG, JX; BEST, PM				WANG, JX; BEST, PM			INACTIVATION OF THE SARCOPLASMIC-RETICULUM CALCIUM-CHANNEL BY PROTEIN-KINASE	NATURE			English	Article							PURIFIED RYANODINE RECEPTOR; RABBIT SKELETAL-MUSCLE; RELEASE CHANNEL; CA-2+ CHANNELS; FIBERS; PHOSPHORYLATION; SARCOBALLS; EXPRESSION; SYSTEM	THE ryanodine receptor protein of skeletal muscle sarcoplasmic reticulum (SR) membranes is a calcium ion channel which allows movement of calcium from the SR lumen into the cytoplasm during muscle activation1-5. Gating of this channel is modulated by a number of physiologically important substances including calcium. Interestingly, calcium has both activating and inactivating effects which are concentration- and tissue-specific. In skeletal muscle, calcium-dependent inactivation of calcium release occurs at concentrations reached physiologically, suggesting that calcium may modulate the release process by a negative feedback mechanism6-9. To determine the cellular mechanism responsible for calcium-dependent inactivation, we have investigated the ability of protein phosphorylation to affect single channel gating behaviour using the patch clamp technique. Here we demonstrate that the ryanodine receptor protein/calcium release channel of skeletal muscle SR is inactivated under conditions permissive for protein phosphorylation. This inactivation is reversed by the application of phosphatase and prevented by a peptide inhibitor specific for calcium/calmodulin-dependent protein kinase II. The results provide evidence for an endogenous protein kinase which is closely associated with the ryanodine receptor protein and regulates channel gating.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,524 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801; UNIV ILLINOIS,SCH MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign				Wang, Jixin/0000-0001-9285-1002				BAYLOR SM, 1983, J PHYSIOL-LONDON, V344, P625, DOI 10.1113/jphysiol.1983.sp014959; CAMPBELL KP, 1982, J BIOL CHEM, V257, P1238; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; HALS GD, 1989, J GEN PHYSIOL, V93, P385, DOI 10.1085/jgp.93.3.385; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; KIM DH, 1986, J BIOL CHEM, V261, P1674; KWOK WM, 1991, PFLUG ARCH EUR J PHY, V419, P166, DOI 10.1007/BF00373003; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LUTTGAU HC, 1968, J PHYSIOL-LONDON, V194, P51; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MORII H, 1987, J BIOCHEM-TOKYO, V102, P263, DOI 10.1093/oxfordjournals.jbchem.a122050; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P727, DOI 10.1113/jphysiol.1988.sp017358; SIMON BJ, 1991, J GEN PHYSIOL, V97, P437, DOI 10.1085/jgp.97.3.437; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; STEIN P, 1988, BIOPHYS J, V54, P357, DOI 10.1016/S0006-3495(88)82967-9; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WITCHER DR, 1991, J BIOL CHEM, V266, P11144	23	119	120	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					739	741		10.1038/359739a0	http://dx.doi.org/10.1038/359739a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1331805				2022-12-28	WOS:A1992JU65000059
J	HENDRICKSE, MT; THULUVATH, PJ; TRIGER, DR				HENDRICKSE, MT; THULUVATH, PJ; TRIGER, DR			NATURAL-HISTORY OF AUTONOMIC NEUROPATHY IN CHRONIC LIVER-DISEASE	LANCET			English	Article							CIRRHOSIS; PROGNOSIS; PRESSURE	To determine the natural history of autonomic neuropathy in chronic liver disease we used standard cardiovascular autonomic tests to evaluate prospectively 60 patients (33 male, 27 female) with initially well-preserved hepatic function. On initial testing, 27 patients (45%, median [range] age 56 [32-67] years) had vagal neuropathy. Autonomic dysfunction was equally common in patients with alcohol-related and non-alcoholic-related liver disease. The cumulative 4-year mortality rate in patients with vagal neuropathy was 30% compared with 6% in those with normal autonomic function. Multiple logistic regression analysis showed that presence of vagal neuropathy and severity of hepatic damage were independent predictors of mortality. Serial testing showed that whereas disease progression occurred in some patients, in others mild abnormalities in autonomic function were reversible. Vagal dysfunction is common in well-compensated chronic liver disease and its presence identifies a subgroup of patients with a substantially worse outlook.	ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield								DALY LE, 1991, INTERPRETATION USES, P258; EWING DJ, 1986, CLIN ENDOCRINOL META, V15, P855, DOI 10.1016/S0300-595X(86)80078-0; EWING DJ, 1980, Q J MED, V49, P95; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; HENDRICKSE MT, 1990, GUT, V31, pA1164; JOHNSON RH, 1988, J NEUROL NEUROSUR PS, V51, P476, DOI 10.1136/jnnp.51.4.476; LLACH J, 1988, GASTROENTEROLOGY, V94, P482, DOI 10.1016/0016-5085(88)90441-6; LUNZER M, 1973, GUT, V14, P354, DOI 10.1136/gut.14.5.354; LUNZER MR, 1975, LANCET, V2, P382; MACGILCHRIST AJ, 1990, AM J GASTROENTEROL, V85, P288; O'Brien IA, 1991, Q J MED, V79, P495; PAGE MM, 1978, LANCET, V1, P14; PUGH RWH, 1983, BRIT J SURG, V60, P646; SATCHELL PM, 1988, AUTONOMIC FAILURE, P159; SCHUMER M, 1988, AM J MED, V85, P144, DOI 10.1016/0002-9343(88)90407-X; TAGEJENSEN U, 1988, J HEPATOL, V6, P350, DOI 10.1016/S0168-8278(88)80053-9; TAN ETH, 1984, J NEUROL NEUROSUR PS, V47, P1335, DOI 10.1136/jnnp.47.12.1335; THULUVATH PJ, 1989, Q J MED, V72, P737; 1985, WHO TECH REP SER, V727, P10; 1989, LANCET, V2, P721	20	153	158	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1462	1464		10.1016/0140-6736(92)92042-E	http://dx.doi.org/10.1016/0140-6736(92)92042-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351136				2022-12-28	WOS:A1992HY31700014
J	DUJARDIN, B; DESCHAMPHELEIRE, I; SENE, H; NDIAYE, F				DUJARDIN, B; DESCHAMPHELEIRE, I; SENE, H; NDIAYE, F			VALUE OF THE ALERT AND ACTION LINES ON THE PARTOGRAM	LANCET			English	Article								A partogram based on a World Health Organisation model has been used for many years in the peripheral maternity clinics of Pikine, Senegal, to monitor labour. We have assessed the value of the partogram and efficacy of the alert and action lines. 1022 pregnant women were monitored by partogram during 4 months. The alert line was crossed in 100 (9.8%) of these cases and the frequency of neonatal resuscitation was higher for this group (relative risk 4.0, 95% confidence interval 2.3-7.1; p < 0.0001), as was the number of "fresh" stillbirths (5.3, 1.8-15.6; p < 0.01) (recent death may have occurred during labour). Among the women who crossed the alert but not the action line, neonatal resuscitation was also four times more likely than for the normal labour group (4.0, 2.1-7.6; p < 0.001), and the fresh stillbirth rate was higher but not significantly so. For women who crossed both lines, the fresh stillbirth rate was ten times higher than for women in the normal labour group (9.9, 2.8-34.7; p < 0001). Crossing the alert line had a sensitivity of 27%, a specificity of 93%, and a positive predictive value of 17% for neonatal resuscitation. If the action line was chosen as the decision level, the positive predictive value remained the same but the sensitivity was only 8%. Health workers intervened (eg, artificial rupture of the membranes, administration of oxytocics) in half the dystocic cases. Of the women who did not receive any such treatment 44% crossed the action line compared with only 26% of those who did receive treatment (p = 0.06) The results show the usefulness and efficacy of the partogram and underscore the value of medical intervention as soon as the alert line is crossed.	BELGIUM MED COOPERAT PRIMARY HLTH CARE,PIKINE,SENEGAMBIA; YEMBEUL HLTH CTR,PIKINE,SENEGAMBIA; DEGGO HLTH CTR,DAKAR,SENEGAMBIA		DUJARDIN, B (corresponding author), INST TROP MED PRINCE LEOPOLD,PUBL HLTH RES & TRAINING UNIT,NATINALESTR 155,B-2000 ANTWERP,BELGIUM.							BIRD GC, 1978, TROP DOCT, V8, P78, DOI 10.1177/004947557800800213; DROUIN P, 1979, OBSTET GYNECOL, V53, P741; MAHLER H, 1987, LANCET, V1, P668; PHILPOTT RH, 1972, J OBSTET GYN BR COMM, V79, P592; STUDD J, 1973, BRIT MED J, V4, P451, DOI 10.1136/bmj.4.5890.451; 1988, WHOMCH883; 1988, WHOMCH891; 1986, CHRONIQUE OMS, V40, P193; 1988, WHOMCH884; 1988, WHOMCH892	10	36	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1336	1338		10.1016/0140-6736(92)91969-F	http://dx.doi.org/10.1016/0140-6736(92)91969-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1350000				2022-12-28	WOS:A1992HW83700012
J	ROLANDI, E; FRANCESCHINI, R; CATALDI, A; BARRECA, T				ROLANDI, E; FRANCESCHINI, R; CATALDI, A; BARRECA, T			ENDOCRINE EFFECTS OF SUMATRIPTAN	LANCET			English	Letter											ROLANDI, E (corresponding author), UNIV GENOA,DEPT INTERNAL MED,I-16132 GENOA,ITALY.							CADY RK, 1991, JAMA-J AM MED ASSOC, V265, P2831, DOI 10.1001/jama.265.21.2831; DAUGHADAY WH, 1989, ENDOCRINOLOGY, P318; EDWARDS E, 1991, NEUROPHARMACOLOGY, V30, P101, DOI 10.1016/0028-3908(91)90050-L	3	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1365	1365		10.1016/0140-6736(92)92022-8	http://dx.doi.org/10.1016/0140-6736(92)92022-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1350038				2022-12-28	WOS:A1992HW83700061
J	GERMOND, M; DESSOLE, S; SENN, A; LOUMAYE, E; HOWLES, C; BELTRAMI, V				GERMOND, M; DESSOLE, S; SENN, A; LOUMAYE, E; HOWLES, C; BELTRAMI, V			SUCCESSFUL INVITRO FERTILIZATION AND EMBRYO TRANSFER AFTER TREATMENT WITH RECOMBINANT HUMAN FSH	LANCET			English	Letter									ARES SERONO,DEPT MED,CH-1202 GENEVA,SWITZERLAND		GERMOND, M (corresponding author), CHU VAUDOIS,DEPT OBSTET & GYNECOL,FERTIL UNIT,CH-1011 LAUSANNE,SWITZERLAND.			DESSOLE, Salvatore/0000-0001-8287-9079				CHAPPEL S, 1992, 3RD P WORLD C GYN EN, P179; GEMZELL CA, 1960, CIBA F COLLOQ ENDOCR, V13, P191; GERMOND M, 1990, SCHWEIZ MED WSCHR, V120, P260; Rabau E, 1962, C R SOC FR GYNECOL, V5, P30; SHAW RW, 1985, LANCET, V2, P506	5	49	53	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1170	1170		10.1016/0140-6736(92)90770-4	http://dx.doi.org/10.1016/0140-6736(92)90770-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349391				2022-12-28	WOS:A1992HT23600031
J	HARLEY, HG; RUNDLE, SA; REARDON, W; MYRING, J; CROW, S; BROOK, JD; HARPER, PS; SHAW, DJ				HARLEY, HG; RUNDLE, SA; REARDON, W; MYRING, J; CROW, S; BROOK, JD; HARPER, PS; SHAW, DJ			UNSTABLE DNA-SEQUENCE IN MYOTONIC-DYSTROPHY	LANCET			English	Article								A variable DNA sequence has been detected in patients with myotonic dystrophy. We set out to determine whether identification of this specific molecular defect would improve clinical management of patients and families with myotonic dystrophy. 127 affected patients who were studied had an expanded DNA fragment not seen in 73 normal controls. The increase in length of the fragment correlated broadly with disease severity, and we noted expansion of the sequence in successive generations of the same family. Progressive expansion of the affected gene provides a molecular explanation for an apparently earlier onset in successive generations (anticipation) in myotonic dystrophy and supports the role of an unstable repeat sequence as the basis of the defect. The specificity of this finding will assist in accurate diagnosis of myotonic dystrophy and genetic counselling of affected families.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	HARLEY, HG (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 6EJ,WALES.			Brook, John David/0000-0002-5946-6740	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; Fleiseher B., 1918, ALBRECHT GRAEFES ARC, V96, P91, DOI DOI 10.1007/BF02018704; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1972, LANCET, V2, P53; HARPER PS, IN PRESS AM J HUM GE; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; SHAW DJ, 1989, BRIT MED BULL, V45, P745, DOI 10.1093/oxfordjournals.bmb.a072355; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P	13	178	185	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1125	1128		10.1016/0140-6736(92)90729-M	http://dx.doi.org/10.1016/0140-6736(92)90729-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349364				2022-12-28	WOS:A1992HT23600001
J	ARMSTRONG, M; DALY, AK; CHOLERTON, S; BATEMAN, DN; IDLE, JR				ARMSTRONG, M; DALY, AK; CHOLERTON, S; BATEMAN, DN; IDLE, JR			MUTANT DEBRISOQUINE HYDROXYLATION GENES IN PARKINSONS-DISEASE	LANCET			English	Note							4-HYDROXYLATION; METABOLISM; ETIOLOGY	The frequency of fifteen genotypes of CYP2D6 (debrisoquine 4-hydroxylase) in 53 patients with Parkinson's disease was determined by the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses and compared with the findings in 72 healthy controls. The commonest mutant allele, CYP2D6B, was twice as frequent among patients as in controls, with an approximate relative risk ratio of 2.70 (95% confidence interval 1.14-6.41; p = 0.0063) for subjects homozygous or heterozygous for this allele.	MED SCH NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,PHARMACOGENET RES UNIT,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND; MED SCH NEWCASTLE UPON TYNE,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK; Newcastle University - UK			Daly, Ann/H-3144-2011	Daly, Ann/0000-0002-7321-0629; Bateman, David Nicholas/0000-0002-8971-862X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBEAU A, 1985, LANCET, V2, P1213; BENITEZ J, 1990, J NEUROL NEUROSUR PS, V53, P289, DOI 10.1136/jnnp.53.4.289; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; DALY AK, 1991, PHARMACOGENETICS, V1, P33, DOI 10.1097/00008571-199110000-00006; FONNEPFISTER R, 1987, BIOCHEM BIOPH RES CO, V148, P1144, DOI 10.1016/S0006-291X(87)80252-8; OHTA S, 1990, LIFE SCI, V46, P599, DOI 10.1016/0024-3205(90)90128-E; POIRIER J, 1987, LANCET, V2, P386; TANNER CM, 1987, CAN J NEUROL SCI, V14, P419, DOI 10.1017/S0317167100037835; TYNDALE R, 1991, PHARMACOGENETICS, V1, P26, DOI 10.1097/00008571-199110000-00005; TYNDALE RF, 1991, MOL PHARMACOL, V40, P63	10	244	246	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1017	1018		10.1016/0140-6736(92)90537-D	http://dx.doi.org/10.1016/0140-6736(92)90537-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349052				2022-12-28	WOS:A1992HQ43500005
J	PITT, GS; MILONA, N; BORLEIS, J; LIN, KC; REED, RR; DEVREOTES, PN				PITT, GS; MILONA, N; BORLEIS, J; LIN, KC; REED, RR; DEVREOTES, PN			STRUCTURALLY DISTINCT AND STAGE-SPECIFIC ADENYLYL CYCLASE GENES PLAY DIFFERENT ROLES IN DICTYOSTELIUM DEVELOPMENT	CELL			English	Article							GUANYLATE-CYCLASE; GUANINE-NUCLEOTIDES; SURFACE RECEPTOR; G-PROTEINS; DISCOIDEUM; BINDING; DNA; EXPRESSION; ACTIVATION; MUTANTS	We have isolated two adenylyl cyclase genes, designated ACA and ACG, from Dictyostelium. The proposed structure for ACA resembles that proposed for mammalian adenylyl cyclases: two large hydrophilic domains and two sets of six transmembrane spans. ACG has a novel structure, reminiscent of the membrane-bound guanylyl cyclases. An aca mutant, created by gene disruption, has little detectable adenylyl cyclase activity and falls to aggregate, demonstrating that cAMP is required for cell-cell communication. cAMP is not required for motility, chemotaxis, growth, and cell division, which are unaffected. Constitutive expression in aca- cells of either ACA or ACG, which is normally expressed only during germination, restores aggregation and the ability to complete the developmental program. ACA expression restores receptor and guanine nucleotide-regulated adenylyl cyclase activity, while activity in cells expressing ACG is insensitive to these regulators. Although they lack ACA, which has a transporter-like structure, the cells expressing ACG secrete cAMP constitutively.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	PITT, GS (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA.		Pitt, Geoffrey/L-4927-2019; Reed, Russell/HGU-0528-2022	Pitt, Geoffrey/0000-0003-2246-0289	NIGMS NIH HHS [T32GM07309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEVREOTES P, 1987, DICTYOSTELIUM DISCOI, P299; DEVREOTES PN, 1982, DEV DICTYOSTELIUM DI, P117; DOWD BF, 1989, ANNU REV NEUROSCI, V12, P67; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KALPAXIS D, 1991, GENETICS, V11, P396; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KESSIN RH, 1979, P NATL ACAD SCI USA, V76, P5450, DOI 10.1073/pnas.76.11.5450; KIMMEL AR, 1982, DEV DICTYOSTELIUM DI, P234; KLEIN C, 1976, FEBS LETT, V68, P125, DOI 10.1016/0014-5793(76)80419-X; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PODGORSKI G, 1984, MOL CELL BIOL, V4, P2784, DOI 10.1128/MCB.4.12.2784; PUGSLEY A, 1989, PROTEIN TARGETTING; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; PUPILLO M, 1988, COLD SPRING HARB SYM, V53, P657, DOI 10.1101/SQB.1988.053.01.075; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; ROOS W, 1975, FEBS LETT, V53, P139, DOI 10.1016/0014-5793(75)80005-6; ROOS W, 1976, FEBS LETT, V68, P170, DOI 10.1016/0014-5793(76)80429-2; ROSS DT, 1991, EMBO J, V10, P2047, DOI 10.1002/j.1460-2075.1991.tb07735.x; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAP P, 1986, DIFFERENTIATION, V33, P1, DOI 10.1111/j.1432-0436.1986.tb00404.x; Schultz G., 1984, METHOD ENZYMAT AN, P379; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VERGHESE MW, 1985, J BIOL CHEM, V260, P6769; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989; 1990, SPRING CATALOG, P19	56	288	292	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					305	315		10.1016/0092-8674(92)90411-5	http://dx.doi.org/10.1016/0092-8674(92)90411-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1348970	hybrid			2022-12-28	WOS:A1992HQ18300010
J	KARL, SA; AVISE, JC				KARL, SA; AVISE, JC			BALANCING SELECTION AT ALLOZYME LOCI IN OYSTERS - IMPLICATIONS FROM NUCLEAR RFLPS	SCIENCE			English	Article							GROWTH-RATE; CRASSOSTREA-VIRGINICA; AMERICAN OYSTER; MYTILUS-EDULIS; MITOCHONDRIAL-DNA; GENETIC-VARIATION; HETEROZYGOSITY; POPULATION; DOMINANCE	Population genetic analyses that depend on the assumption of neutrality for allozyme markers are used widely. Restriction fragment length polymorphisms in nuclear DNA of the American oyster evidence a pronounced population subdivision concordant with mitochondrial DNA. This finding contrasts with a geographic uniformity in allozyme frequencies previously thought to reflect high gene flow mediated by the pelagic gametes and larvae. The discordance likely is due to selection on protein electrophoretic characters that balances allozyme frequencies in the face of severe constraints to gene flow. These results raise a cautionary note for studies that rely on assumptions of neutrality for allozyme markers.	UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602	University System of Georgia; University of Georgia								AVISE JC, IN PRESS OIKOS; BUROKER NE, 1983, MAR BIOL, V75, P99, DOI 10.1007/BF00392635; BUROKER NE, 1979, J FISH RES BOARD CAN, V36, P1313, DOI 10.1139/f79-189; DIEHL WJ, 1985, MAR BIOL, V88, P265, DOI 10.1007/BF00392588; GARTON DW, 1984, GENETICS, V108, P445; HILBISH TJ, 1985, EVOLUTION, V39, P1302, DOI 10.1111/j.1558-5646.1985.tb05696.x; HILBISH TJ, 1985, SCIENCE, V229, P52, DOI 10.1126/science.4012310; KARL SA, IN PRESS GENETICS; Koehn R.K., 1983, P115; KOEHN RK, 1987, AM SCI, V75, P134; KOEHN RK, 1984, MAR BIOL, V82, P1, DOI 10.1007/BF00392757; LEWONTIN RC, 1973, GENETICS, V74, P175; MITTON JB, 1985, J EXP MAR BIOL ECOL, V90, P73, DOI 10.1016/0022-0981(85)90075-9; MITTON JB, 1984, ANNU REV ECOL SYST, V15, P479; NEI M, 1978, GENETICS, V89, P583; REEB CA, 1990, GENETICS, V124, P397; SINGH SM, 1978, EVOLUTION, V32, P342, DOI 10.1111/j.1558-5646.1978.tb00650.x; WILSON AC, 1985, BIOL J LINN SOC, V26, P375, DOI 10.1111/j.1095-8312.1985.tb02048.x; ZOUROS E, 1980, EVOLUTION, V34, P856, DOI [10.2307/2407992, 10.1111/j.1558-5646.1980.tb04024.x]; [No title captured]	20	416	429	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					100	102		10.1126/science.1348870	http://dx.doi.org/10.1126/science.1348870			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1348870				2022-12-28	WOS:A1992HL82200036
J	BOOY, R; AITKEN, SJM; TAYLOR, S; TUDORWILLIAMS, G; MACFARLANE, JA; MOXON, ER; ASHWORTH, LAE; MAYONWHITE, RT; GRIFFITHS, H; CHAPEL, HM				BOOY, R; AITKEN, SJM; TAYLOR, S; TUDORWILLIAMS, G; MACFARLANE, JA; MOXON, ER; ASHWORTH, LAE; MAYONWHITE, RT; GRIFFITHS, H; CHAPEL, HM			IMMUNOGENICITY OF COMBINED DIPHTHERIA, TETANUS, AND PERTUSSIS-VACCINE GIVEN AT 2, 3, AND 4 MONTHS VERSUS 3, 5, AND 9 MONTHS OF AGE	LANCET			English	Article							IMMUNIZATION; POLIOMYELITIS	In the UK an accelerated schedule for immunisation against diphtheria, tetanus, and pertussis (injections at 2, 3, and 4 months of age) was introduced in 1990 to replace the more widely spaced schedule of 3, 5, and 9 months. There is concern, however, that the new schedule may be less immunogenic and therefore less protective than the old schedule. We have measured serum concentrations of antibodies against diphtheria, pertussis, and tetanus in infants immunised according to the two regimens. Both schedules resulted in protective concentrations of antibody against tetanus and diphtheria and in satisfactory antibody responses to three pertussis antigens (filamentous haemagglutinin, pertussis toxin, fimbriae). However, immunisation by the old schedule led to significantly higher antibody concentrations against both diphtheria and tetanus than did immunisation by the new schedule (p < 0.01). In infants immunised with the new schedule, postimmunisation antibody concentrations against tetanus toxoid and against two pertussis antigens (pertussis toxin and fimbriae) were significantly lower in infants in whom pre-immunisation (maternally derived) antibody concentrations were high (p < 0.02). The findings suggest that with an accelerated immunisation schedule maternal antibodies can have an inhibitory effect on the responses to immunisation against tetanus and, pertussis.	JOHN RADCLIFFE HOSP,DEPT IMMUNOL,OXFORD OX3 9DU,ENGLAND; PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,PORTON DOWN,ENGLAND; RADCLIFFE INFIRM,DEPT COMMUNITY HLTH,OXFORD OX2 6HE,ENGLAND; DEPT PUBL HLTH,OXFORD,ENGLAND	University of Oxford; Radcliffe Infirmary	BOOY, R (corresponding author), JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.							BARAFF LJ, 1984, PEDIATRICS, V73, P37; BARR M, 1955, BRIT MED J, V2, P635, DOI 10.1136/bmj.2.4940.635; BARR M, 1949, LANCET, V2, P324; BARRETT CD, 1962, PEDIATRICS, V30, P720; BROWN GC, 1964, PUBLIC HEALTH REP, V79, P585, DOI 10.2307/4592199; CHEN ST, 1983, B WORLD HEALTH ORGAN, V61, P159; DIXON AM, 1988, BMJ-BRIT MED J, V297, P598, DOI 10.1136/bmj.297.6648.598; ESKOLA J, 1988, PEDIATR INFECT DIS J, V7, P480, DOI 10.1097/00006454-198807000-00006; HALSEY N, 1985, B WORLD HEALTH ORGAN, V63, P1151; HARDEGREE MC, 1983, PEDIATR RES, V17, P272; JONES AE, 1989, VACCINE, V7, P300, DOI 10.1016/0264-410X(89)90189-8; PARKE JC, 1991, J PEDIATR-US, V118, P184, DOI 10.1016/S0022-3476(05)80480-9; RAMSAY MEB, 1991, BRIT MED J, V302, P1489, DOI 10.1136/bmj.302.6791.1489; RUTTER DA, 1988, VACCINE, V6, P30; SANGPETCHSONG V, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P117; SMITH JWG, 1969, BRIT MED BULL, V25, P177, DOI 10.1093/oxfordjournals.bmb.a070689; VAHLQUIST B, 1949, Lancet, V1, P16; WATEMBERG N, 1991, PEDIATR INFECT DIS J, V10, P758, DOI 10.1097/00006454-199110000-00008; WINDEBANK KP, 1987, J IMMUNOL METHODS, V104, P143, DOI 10.1016/0022-1759(87)90498-4	19	89	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					507	510		10.1016/0140-6736(92)90336-2	http://dx.doi.org/10.1016/0140-6736(92)90336-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346876				2022-12-28	WOS:A1992HF63100001
J	MANJARREZHERNANDEZ, HA; BALDWIN, TJ; AITKEN, A; KNUTTON, S; WILLIAMS, PH				MANJARREZHERNANDEZ, HA; BALDWIN, TJ; AITKEN, A; KNUTTON, S; WILLIAMS, PH			INTESTINAL EPITHELIAL-CELL PROTEIN-PHOSPHORYLATION IN ENTEROPATHOGENIC ESCHERICHIA-COLI DIARRHEA	LANCET			English	Note							KINASE-C; ADHESION; MYOSIN	The ability of enteropathogenic Escherichia coli (EPEC) to cause diarrhoea in man is associated with the formation of characteristic histopathological lesions in small-intestine enterocytes, with gross cytoskeletal damage and loss of brush-border microvilli. Investigation of enterocyte protein phosphorylation in response to EPEC infection showed that the major phosphorylated protein, identified by immunoprecipitation, is myosin light-chain an important cytoskeletal protein known to affect actin organisation in non-muscle cells. High enterocyte concentrations of actin and myosin were observed at sites of bacterial infection. Our findings indicate that enterocyte cytoskeletal changes in response to EPEC may be directly triggered by bacterial adherence through signal transduction pathways that stimulate protein kinase activity.	UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND; NATL INST MED RES,PROT STRUCTURE LAB,LONDON NW7 1AA,ENGLAND; UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Leicester; MRC National Institute for Medical Research; University of Birmingham					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDWIN TJ, 1990, INFECT IMMUN, V58, P761, DOI 10.1128/IAI.58.3.761-765.1990; BENNETT JP, 1988, J CELL BIOL, V107, P2623, DOI 10.1083/jcb.107.6.2623; BLADWIN TJ, 1991, INFECT IMMUN, V59, P1599; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; FONDACARO JD, 1985, AM J PHYSIOL, V249, pG422, DOI 10.1152/ajpgi.1985.249.3.G422; KELLER TCS, 1982, J CELL BIOL, V95, P943, DOI 10.1083/jcb.95.3.943; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; KNUTTON S, 1987, INFECT IMMUN, V55, P69, DOI 10.1128/IAI.55.1.69-77.1987; ROBINSBROWNE RM, 1987, REV INFECT DIS, V9, P28; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543	10	62	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					521	523		10.1016/0140-6736(92)90340-9	http://dx.doi.org/10.1016/0140-6736(92)90340-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346880				2022-12-28	WOS:A1992HF63100005
J	ODONNELL, LJD; WILSON, P; GUEST, P; CATNACH, SM; MCLEAN, A; WICKHAM, JEA; FAIRCLOUGH, PD				ODONNELL, LJD; WILSON, P; GUEST, P; CATNACH, SM; MCLEAN, A; WICKHAM, JEA; FAIRCLOUGH, PD			INDOMETHACIN AND POSTPRANDIAL GALLBLADDER EMPTYING	LANCET			English	Note							GUINEA-PIG; GALLSTONE FORMATION; CHOLESTEROL	Patients with gallstone disease commonly have impaired gallbladder emptying. To see whether non-steroidal anti-inflammatory drugs (NSAIDs) prevent gallstone formation by improving gallbladder emptying, we assessed the effect of indomethacin on postprandial emptying in healthy subjects and in patients with gallstone disease. Subjects received indomethacin 25 mg three times a day for a week and matching placebo for another week. Compared with placebo, indomethacin improved postprandial gallbladder emptying in all 7 patients with gallstone disease. This finding was not recorded in healthy subjects with normal gallbladders. The prevention of gallstone formation associated with ingestion of NSAIDs may be due mainly to a prokinetic effect on the gallbladder since there is no evidence to suggest that these drugs affect cholesterol crystal nucleation at ordinary therapeutic doses in man or animals.	ST BARTHOLOMEWS HOSP,DEPT RADIOL,LONDON EC1A 7BE,ENGLAND; ST PETERS HOSP,INST UROL,LONDON WC2A 2EX,ENGLAND	University of London; Queen Mary University London; University of London; University College London	ODONNELL, LJD (corresponding author), ST BARTHOLOMEWS HOSP,DEPT GASTROENTEROL,LONDON EC1A 7BE,ENGLAND.							BROTSCHI EA, 1984, DIGEST DIS SCI, V29, P1050, DOI 10.1007/BF01311258; DODDS WJ, 1985, AM J ROENTGENOL, V145, P1009, DOI 10.2214/ajr.145.5.1009; HOOD K, 1988, LANCET, V2, P1233; LAMORTE WW, 1985, SURGERY, V98, P445; LEE SP, 1981, SCIENCE, V211, P1429, DOI 10.1126/science.7466399; ODONNELL LDJ, 1988, GUT, V29, P655, DOI 10.1136/gut.29.5.655; OLEARY DP, 1991, GASTROENTEROLOGY, V101, P812, DOI 10.1016/0016-5085(91)90544-U; POSTON GJ, 1990, GASTROENTEROLOGY, V98, P993, DOI 10.1016/0016-5085(90)90024-U; RHODES M, 1991, Gastroenterology, V100, pA337; YUSKO P, 1983, PROSTAGLANDINS, V25, P397, DOI 10.1016/0090-6980(83)90043-6	10	40	42	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1992	339	8788					269	271		10.1016/0140-6736(92)91333-4	http://dx.doi.org/10.1016/0140-6736(92)91333-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB529	1346283				2022-12-28	WOS:A1992HB52900005
J	VANFURTH, R; VANTWOUT, JW; WERTHEIMER, PA; ZWARTENDIJK, J				VANFURTH, R; VANTWOUT, JW; WERTHEIMER, PA; ZWARTENDIJK, J			CIPROFLOXACIN FOR TREATMENT OF MALACOPLAKIA	LANCET			English	Note							MACROPHAGES	The tumour-like lesions of the rare disease malakoplakia, which consist of macrophages containing undigested coliform bacteria, are often misdiagnosed as a carcinoma. Although an infectious aetiology is likely, no antimicrobial therapy has been successful in the long-term. Since ciprofloxacin penetrates well into macrophages, this drug was given to two patients with advanced malakoplakia (500 mg twice daily). After long-term treatment all granulomatous lesions disappeared. Thus, malakoplakia can be cured by antibiotic treatment.	UNIV HOSP LEIDEN,DEPT UROL,2300 RC LEIDEN,NETHERLANDS; REFAJA HOSP,DEPT UROL,DORDRECHT,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	VANFURTH, R (corresponding author), UNIV HOSP LEIDEN,DEPT INFECT DIS,POB 9600,2300 RC LEIDEN,NETHERLANDS.							ABDOU NI, 1977, NEW ENGL J MED, V297, P1413, DOI 10.1056/NEJM197712292972601; Damjanov I, 1981, Pathol Annu, V16, P103; EASMON CSF, 1985, J CLIN PATHOL, V38, P442, DOI 10.1136/jcp.38.4.442; LEIJH PCJ, 1980, SCAND J IMMUNOL, V13, P159; LOU TY, 1974, HUM PATHOL, V5, P191, DOI 10.1016/S0046-8177(74)80066-3; OLIVER JM, 1976, AM J PATHOL, V85, P395; RENZ H, 1988, J IMMUNOL, V141, P2388; VANDENBROEK PJ, 1989, REV INFECT DIS, V11, P213	8	54	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1992	339	8786					148	148		10.1016/0140-6736(92)90212-L	http://dx.doi.org/10.1016/0140-6736(92)90212-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ968	1346012				2022-12-28	WOS:A1992GZ96800005
J	LEHMANN, JM; JONG, L; FANJUL, A; CAMERON, JF; LU, XP; HAEFNER, P; DAWSON, MI; PFAHL, M				LEHMANN, JM; JONG, L; FANJUL, A; CAMERON, JF; LU, XP; HAEFNER, P; DAWSON, MI; PFAHL, M			RETINOIDS SELECTIVE FOR RETINOID-X RECEPTOR RESPONSE PATHWAYS	SCIENCE			English	Article							THERAPEUTIC ANTICANCER AGENTS; ACID; GENE; ISOTRETINOIN; PREVENTION; DETERMINES; BINDING; ELEMENT	Retinoids have a broad spectrum of biological activities and are useful therapeutic agents. Their physiological activities are mediated by two types of receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). RARs, as well as several related receptors, require heterodimerization with RXRs for effective DNA binding and function. However, in the presence of 9-cis-retinoic acid, a ligand for both RARs and RXRs, RXRs can also form homodimers. A series of retinoids is reported that selectively activates RXR homodimers but does not affect RAR-RXR heterodimers and thus demonstrates that both retinoid response pathways can be independently activated.	SRI INT,DIV LIFE SCI,MENLO PK,CA 94025; LA JOLLA CANC RES FDN,CTR CANC,LA JOLLA,CA 92037	SRI International; Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [P01 CA51993, CA50676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051993, R01CA050676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLLAG W, 1983, LANCET, V1, P860; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DAWSON MI, UNPUB; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; FANJUL A, UNPUB; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1734; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P493; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1991, NEW BIOL, V3, P169; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	31	350	363	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1944	1946		10.1126/science.1335166	http://dx.doi.org/10.1126/science.1335166			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1335166				2022-12-28	WOS:A1992KD08800034
J	PHILLIPS, GJ; SILHAVY, TJ				PHILLIPS, GJ; SILHAVY, TJ			THE ESCHERICHIA-COLI FFH-GENE IS NECESSARY FOR VIABILITY AND EFFICIENT PROTEIN EXPORT	NATURE			English	Article							SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI; 4.5S RNA; SACCHAROMYCES-CEREVISIAE; RIBONUCLEOPROTEIN; SEQUENCE; SUBUNIT	HOMOLOGUES of the gene encoding the 54K (M(r) 54,000) subunit of the mammalian signal recognition particle have been identified in different organisms1-5. The Escherichia coli homologue, termed ffh (for fifty-four homologue), specifies a protein (Ffh) that shares many properties with its eukaryotic counterpart, including association with mammalian 7S RNA6 and the ability to bind signal sequences specifically7,8. Ffh also associates with E. coli 4.5S RNA, showing that it can form a ribonucleoprotein complex in prokaryotes6,9,10. These results are intriguing because extensive genetic and biochemical characterization of E. coli failed to identify a signal recognition particle-like mechanism for protein export11 Here we address this issue directly by construction of a strain in which ffh expression is arabinose-dependent. Results of depletion experiments indicate that Ffh is important in protein translocation.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University	PHILLIPS, GJ (corresponding author), COLL WILLIAM & MARY,DEPT BIOL,WILLIAMSBURG,VA 23185, USA.			Silhavy, Thomas/0000-0001-7672-5153				BASSFORD P, 1991, CELL, V65, P367, DOI 10.1016/0092-8674(91)90453-6; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HN, UNPUB; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BROWN S, 1991, NEW BIOL, V3, P430; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; DAVIS RW, 1986, ADV BACTERIAL GENETI; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; KOHL J, 1990, NUCLEIC ACIDS RES, V18, P1069, DOI 10.1093/nar/18.4.1069; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Silhavy T. J., 1984, EXPT GENE FUSIONS; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	23	237	240	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					744	746		10.1038/359744a0	http://dx.doi.org/10.1038/359744a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1331806				2022-12-28	WOS:A1992JU65000061
J	DULIC, V; LEES, E; REED, SI				DULIC, V; LEES, E; REED, SI			ASSOCIATION OF HUMAN CYCLIN-E WITH A PERIODIC G(1)-S PHASE PROTEIN-KINASE	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; CDC28 MUTATION; YEAST; GENE; COMPLEMENTATION; HOMOLOG; POLYMERASE; MITOSIS; FAMILY	G1 cyclins control the G1 to S phase transition in the budding yeast, Saccharomyces cerevisiae. Cyclin E was discovered in the course of a screen for human complementary DNAs that rescue a deficiency of G1 cyclin function in budding yeast. The amounts of both the cyclin E protein and an associated protein kinase activity fluctuated periodically through the human cell cycle; both were maximal in late G1 and early S phases. Cyclin E-associated kinase activity was correlated with the appearance of complexes containing cyclin E and the cyclin-dependent kinase Cdk2. Thus, the cyclin E-Cdk2 complex may constitute a human G1-S phase-specific regulatory protein kinase.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA	Scripps Research Institute; Harvard University; Massachusetts General Hospital				Dulic, Vjekoslav/0000-0003-1201-3901	NCI NIH HHS [CA55339] Funding Source: Medline; NIGMS NIH HHS [GM38328, GM46006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038328, P01GM046006, R01GM038328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, UNPUB; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLIOTT SG, 1978, P NATL ACAD SCI USA, V75, P4384, DOI 10.1073/pnas.75.9.4384; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS P, IN PRESS CELL; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEES E, IN PRESS GENES DEVD; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	27	879	906	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1992	257	5078					1958	1961		10.1126/science.1329201	http://dx.doi.org/10.1126/science.1329201			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1329201				2022-12-28	WOS:A1992JP59400035
J	CADOZ, M; STRADY, A; MEIGNIER, B; TAYLOR, J; TARTAGLIA, J; PAOLETTI, E; PLOTKIN, S				CADOZ, M; STRADY, A; MEIGNIER, B; TAYLOR, J; TARTAGLIA, J; PAOLETTI, E; PLOTKIN, S			IMMUNIZATION WITH CANARYPOX VIRUS EXPRESSING RABIES GLYCOPROTEIN	LANCET			English	Article							VACCINIA VIRUS; FOWLPOX VIRUS; PROTECTIVE IMMUNITY; RECOMBINANT; VECTOR; GENE; DNA	Poxviruses have many useful features as vectors for genes that carry immunising antigens from other viruses, such as ease of production and induction of cellular and humoral immunity, but there is concern about the safety of vaccinia virus. We turned to an avian poxvirus (canarypox); this virus undergoes abortive replication in mammalian cells that enables presentation of early gene products to the immune system. Canarypox virus was used as a vector for the rabies glycoprotein G gene. The safety and efficacy of the recombinant (ALVAC-RG; vCP65) were tested in several animal species, then it was subjected to a phase 1 clinical trial. Twenty-five volunteers were randomly assigned to subcutaneous injections of the recombinant (three groups [A, B, and C] received two doses each of 10(3.5), 10(4.5), and 10(5.5) tissue-culture infectious doses50, respectively) or of human diploid cell culture vaccine (HDC; 6.52 international potency units per dose). 28 days after the second dose, all nine ALVAC-RG group-C subjects and two of three group-B subjects had rabies neutralising antibody concentrations of at least 0.5 IU/ml, the level associated with protection in animals. Although the geometric mean titre of these antibodies at that time was lower in group C than in the ten HDC recipients (4.4 [range 0.9-12.5] vs 11.5 [4.7-25.3] IU/ml), a single booster dose at 6 months induced a recall response in volunteers primed with either vaccine. Side-effects associated with ALVAC-RG were mild and of short duration and occurred at similar frequency to those of HDC vaccine. This study has shown the potential of non-replicating poxviruses as vectors for vaccination in human beings. Trials of canarypox-virus recombinants at higher doses and by other routes of administration are needed.	CTR HOSP REG & UNIV REIMS,REIMS,FRANCE; VIROGENETICS,TROY,NY	CHU de Reims	CADOZ, M (corresponding author), PASTEUR MERIEUX SERUMS & VACCINS,3 AVE PASTEUR,F-92430 MARNES COQUETTE,FRANCE.				Wellcome Trust [089701] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAXBY D, 1992, VACCINE, V10, P8, DOI 10.1016/0264-410X(92)90411-C; BROCHIER B, 1991, NATURE, V354, P520, DOI 10.1038/354520a0; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; ETLINGER HM, 1991, VACCINE, V9, P470, DOI 10.1016/0264-410X(91)90030-A; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOEBEL SJ, 1990, VIROLOGY, V179, P5517; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KLIETMANN W, 1981, CELL CULTURE RABIES, P330; Kuwert E., 1981, CELL CULTURE RABIES, P160; MACKERT M, 1982, P NATL ACAD SCI USA, V7, P7415; PANICALI D, 1982, P NATL ACAD SCI-BIOL, V79, P4927, DOI 10.1073/pnas.79.16.4927; PICCINI A, 1987, METHOD ENZYMOL, V153, P545; SMITH JS, 1973, WHO MONOGR SERIES, P23; TAYLOR J, 1988, VACCINE, V6, P497, DOI 10.1016/0264-410X(88)90100-4; TAYLOR J, 1988, VACCINE, V6, P466, DOI 10.1016/0264-410X(88)90091-6; TAYLOR J, 1991, VACCINE, V9, P190, DOI 10.1016/0264-410X(91)90152-V; TAYLOR J, 1992, VIROLOGY, V187, P321, DOI 10.1016/0042-6822(92)90321-F; TAYLOR J, 1988, VACCINE, V6, P504, DOI 10.1016/0264-410X(88)90101-6; WIKTOR TJ, 1984, P NATL ACAD SCI-BIOL, V81, P7194, DOI 10.1073/pnas.81.22.7194; WILD F, 1990, VACCINE, V8, P441, DOI 10.1016/0264-410X(90)90243-F; 1990, VACCINE, V8, P425	21	151	167	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1429	1432		10.1016/0140-6736(92)92027-D	http://dx.doi.org/10.1016/0140-6736(92)92027-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351126				2022-12-28	WOS:A1992HY31700001
J	WONG, BI; MCLEAN, RF; NAYLOR, CD; SNOW, WG; HARRINGTON, EM; GAWEL, MJ; WOODS, RB; FREMES, SE				WONG, BI; MCLEAN, RF; NAYLOR, CD; SNOW, WG; HARRINGTON, EM; GAWEL, MJ; WOODS, RB; FREMES, SE			CENTRAL-NERVOUS-SYSTEM DYSFUNCTION AFTER WARM OR HYPOTHERMIC CARDIOPULMONARY BYPASS	LANCET			English	Note								The increasing popularity of warm heart surgery led us to assess the effect of temperature during cardiopulmonary bypass (CPB) on neuropsychological function after coronary surgery. 34 patients enrolled in a randomised trial of normothermic versus hypothermic CPB were subjected to a battery of psychomotor and memory tests before and after their operations. The mean nasopharyngeal temperature for warm CPB was 34.7 (SD 0.5)-degrees-C and that for hypothermic CPB was 27.8 (2.0)-degrees-C. In all seven neuropsychological tests the postoperative scores were better in the warm CPB than in the hypothermic group, although only one difference achieved significance (trial-making test A; p < 0.023). Thus, neurological function after normothermic CPB seems to be no worse than that after hypothermic procedures.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT ANAESTHESIA,C818,2075 BAYVIEW AVE,N YORK M4N 3M5,ONTARIO,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT CLIN EPIDEMIOL,N YORK M4N 3M5,ONTARIO,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT PATHOL,N YORK M4N 3M5,ONTARIO,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT MED,DIV NEUROL,N YORK M4N 3M5,ONTARIO,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT SURG,DIV CARDIOVASC SUR,N YORK M4N 3M5,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center			Fremes, Stephen E/P-7928-2015	Fremes, Stephen E/0000-0003-1723-3049				BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Halstead WC, 1985, HALSTEADREITAN NEURO; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LICHTENSTEIN SV, 1991, J THORAC CARDIOV SUR, V101, P269; SHAW PJ, 1987, STROKE, V18, P700, DOI 10.1161/01.STR.18.4.700; TOWNES BD, 1989, J THORAC CARDIOV SUR, V98, P774; Wechsler D., 1945, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL, P257	10	56	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1383	1384		10.1016/0140-6736(92)91200-R	http://dx.doi.org/10.1016/0140-6736(92)91200-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350809				2022-12-28	WOS:A1992HX63600007
J	ALDERMAN, MH				ALDERMAN, MH			WHICH ANTIHYPERTENSIVE DRUGS 1ST - AND WHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HYPERTENSION				ALDERMAN, MH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT EPIDEMIOL & SOCIAL MED, BRONX, NY 10461 USA.							[Anonymous], 1970, JAMA, V213, P1143; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DOLLERY CT, 1987, J HYPERTENS, V5, pS75; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; GOLDSTEIN G, 1990, HYPERTENSION, V15, P361, DOI 10.1161/01.HYP.15.4.361; HUNT D, 1992, LANCET, V339, P753; KAPLAN NM, 1991, AM J HYPERTENS, V4, P970, DOI 10.1093/ajh/4.12.970; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANGANO DT, 1991, CIRCULATION, V84, P1879, DOI 10.1161/01.CIR.84.4.1879; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PEART S, 1985, British Medical Journal, V291, P97; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; SHEKELLE RB, 1984, ATHER REV, V12, P113; STASON WB, 1989, HYPERTENSION S, V13, P45; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1971, CIRCULATION, V44, pA263; 1991, JAMA-J AM MED ASSOC, V266, P3255; 1990, NATIONAL DISEASE THE, V1; 1991, BIRTHS MARRIAGE DIVO, V39	22	37	37	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2786	2787		10.1001/jama.267.20.2786	http://dx.doi.org/10.1001/jama.267.20.2786			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1349655				2022-12-28	WOS:A1992HV26500028
J	PETO, R; LOPEZ, AD; BOREHAM, J; THUN, M; HEATH, C				PETO, R; LOPEZ, AD; BOREHAM, J; THUN, M; HEATH, C			MORTALITY FROM TOBACCO IN DEVELOPED-COUNTRIES - INDIRECT ESTIMATION FROM NATIONAL VITAL-STATISTICS	LANCET			English	Article							CANCER	Prolonged cigarette smoking causes even more deaths from other diseases than from lung cancer. In developed countries, the absolute age-sex-specific lung cancer rates can be used to indicate the approximate proportions due to tobacco of deaths not only from lung cancer itself but also, indirectly, from vascular disease and from various other categories of disease. Even in the absence of direct information on smoking histories, therefore, national mortality from tobacco can be estimated approximately just from the disease mortality statistics that are available from all major developed countries for about 1985 (and for 1975 and so, by extrapolation, for 1995). The relation between the absolute excess of lung cancer and the proportional excess of other diseases can only be approximate, and so as not to overestimate the effects of tobacco it has been taken to be only half that suggested by a recent large prospective study of smoking and death among one million Americans. Application of such methods indicates that in developed countries alone, annual deaths from smoking number about 0.9 million in 1965, 1.3 million in 1975, 1.7 million in 1985, and 2.1 million in 1995 (and hence about 21 million in the decade 1990-99: 5-6 million European Community, 5-6 million USA, 5 million former USSR, 3 million Eastern and other Europe, and 2 million elsewhere, [ie, Australia, Canada, Japan, and New Zealand]). More than half these deaths will be at 35-69 years of age: during the 1990s tobacco will in developed countries cause about 30% of all deaths at 35-69 (making it the largest single cause of premature death) plus about 14% of all at older ages. Those killed at older ages are on average already almost 80 years old, however, and might have died soon anyway, but those killed by tobacco at 35-69 lose an average of about 23 years of life. At present just under 20% of all deaths in developed countries are attributed to tobacco, but this percentage is still rising, suggesting that on current smoking patterns just over 20% of those now living in developed countries will eventually be killed by tobacco (ie, about a quarter of a billion, out of a current total population of just under one and a quarter billion).	WHO, TOBACCO HLTH UNIT, CH-1211 GENEVA 27, SWITZERLAND; AMER CANC SOC, EPIDEMIOL UNIT, ATLANTA, GA USA	World Health Organization; American Cancer Society	PETO, R (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC STUDIES UNIT, OXFORD OX2 6HE, ENGLAND.		Lopez, Alan D/F-1487-2010; Lopez, Alan/AAA-2734-2022	Lopez, Alan D/0000-0001-5818-6512; 				DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DOLL R, 1971, J R STAT SOC SER A-G, V134, P133, DOI 10.2307/2343871; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Garfinkel L, 1985, Natl Cancer Inst Monogr, V67, P49; GARFINKEL L, 1988, CANCER RES, V48, P6951; HIRAYAMA T, 1990, CONTRIB EPIDEMIOL BI, V6; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; MARTIN MJ, 1986, LANCET, V2, P933; Peto R, 1986, IARC Sci Publ, P23; ZARIDZE D, 1986, IARC SCI PUBLICATION, V74; 1991, TOBACCO ALERT, V1, P4; 1991, SMOKING EPIDEMIC; 1986, IARC MONOGRAPHS EVOL, V38; 1987, WORLD HLTH STATISTIC; 1971, J ROY STAT SOC A GEN, V134, P133; 1980, HLTH CONSEQUENCES SM, P86; 1989, USDHHS PHS CDC898411; 1982, USDHHS PHS CDC825017	18	965	995	0	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	1992	339	8804					1268	1278		10.1016/0140-6736(92)91600-D	http://dx.doi.org/10.1016/0140-6736(92)91600-D			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349675				2022-12-28	WOS:A1992HV19100010
J	JAFFE, DB; JOHNSTON, D; LASSERROSS, N; LISMAN, JE; MIYAKAWA, H; ROSS, WN				JAFFE, DB; JOHNSTON, D; LASSERROSS, N; LISMAN, JE; MIYAKAWA, H; ROSS, WN			THE SPREAD OF NA+ SPIKES DETERMINES THE PATTERN OF DENDRITIC CA2+ ENTRY INTO HIPPOCAMPAL-NEURONS	NATURE			English	Article							LONG-TERM POTENTIATION; PYRAMIDAL CELLS; RAT HIPPOCAMPUS; CALCIUM; EXCITABILITY; ORGANIZATION; INDICATORS; ACTIVATION; INDUCTION; SYNAPSES	THE dendrites of many types of neurons contain voltage-dependent Na+ and Ca2+ conductances that generate action potentials (see ref. 1 for review). The function of these spikes is not well understood, but the Ca2+ entry stimulated by spikes probably affects Ca2+-dependent processes in dendrites. These include synaptic plasticity 2,3, cytotoxicity 4 and exocytosis 5. Several lines of evidence suggest that dendritic spikes occur within subregions of the dendrites 6-8. To study the mechanism that govern the spread of spikes in the dendrites of hippocampal pyramidal cells, we imaged Ca2+ entry with Fura-2 (ref. 9) and Na+ entry with a newly developed Na+-sensitive dye 10). Our results indicate that Ca2+ entry into dendrites is triggered by Na+ spikes that actively invade the dendrites. The restricted spatial distribution of Ca2+ entry seems to depend on the spread of Na+ spikes in the dendrites, rather than on a limited distribution of Ca2+ channels. In addition, we have observed an activity-dependent process that modulates the invasion of spikes into the dendrites and progressively restricts Ca2+ entry to more proximal dendritic regions.	NEW YORK MED COLL,DEPT PHYSIOL,VALHALLA,NY 10595; BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; YAMAGATA UNIV,SCH MED,DEPT PHYSIOL,YAMAGATA 99023,JAPAN; MARINE BIOL LAB,WOODS HOLE,MA 02543	New York Medical College; Baylor College of Medicine; Brandeis University; Yamagata University; Marine Biological Laboratory - Woods Hole					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016295] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS016295] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSEN P, 1987, J PHYSIOL-LONDON, V383, P509; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; JOHNSTON D, 1983, J NEUROPHYSIOL, V50, P464, DOI 10.1152/jn.1983.50.2.464; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LASSERROSS N, 1992, P ROY SOC B-BIOL SCI, V247, P35, DOI 10.1098/rspb.1992.0006; LASSERROSS N, 1991, J NEUROSCI METH, V36, P253, DOI 10.1016/0165-0270(91)90051-Z; LEV-RAM V, 1990, Society for Neuroscience Abstracts, V16, P894; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LLINAS RR, 1987, P NATL ACAD SCI USA, V84, P3047, DOI 10.1073/pnas.84.9.3047; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MASUKAWA LM, 1984, J NEUROSCI, V4, P217; MINTA A, 1989, J BIOL CHEM, V264, P19449; MIYAKAWA H, 1986, BRAIN RES, V5399, P303; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; ROSS W N, 1991, Society for Neuroscience Abstracts, V17, P581; ROSS WN, 1990, PROC R SOC SER B-BIO, V240, P173, DOI 10.1098/rspb.1990.0032; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; TURNER RW, 1989, J NEUROPHYSIOL, V62, P1375, DOI 10.1152/jn.1989.62.6.1375; TURNER RW, 1991, J NEUROSCI, V11, P2270; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WONG RKS, 1979, SCIENCE, V204, P1228, DOI 10.1126/science.451569	28	377	379	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					244	246		10.1038/357244a0	http://dx.doi.org/10.1038/357244a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1350327				2022-12-28	WOS:A1992HV19500055
J	GILL, D				GILL, D			EUROPEAN BOARDS AND COLLEGES - EUROPAEDS OR UROPHOBIA	LANCET			English	Editorial Material											GILL, D (corresponding author), ROYAL COLL SURG IRELAND,DEPT PAEDIAT,123 ST STEPHENS GREEN,DUBLIN 2,IRELAND.							BREARLEY S, 1992, BRIT MED J, V304, P41, DOI 10.1136/bmj.304.6818.41; 1990, PAEDIATRIC TRAINING	2	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1216	1217		10.1016/0140-6736(92)91144-W	http://dx.doi.org/10.1016/0140-6736(92)91144-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349948				2022-12-28	WOS:A1992HU68400014
J	WEN, DZ; PELES, E; CUPPLES, R; SUGGS, SV; BACUS, SS; LUO, Y; TRAIL, G; HU, S; SILBIGER, SM; BENLEVY, R; KOSKI, RA; LU, HS; YARDEN, Y				WEN, DZ; PELES, E; CUPPLES, R; SUGGS, SV; BACUS, SS; LUO, Y; TRAIL, G; HU, S; SILBIGER, SM; BENLEVY, R; KOSKI, RA; LU, HS; YARDEN, Y			NEU DIFFERENTIATION FACTOR - A TRANSMEMBRANE GLYCOPROTEIN CONTAINING AN EGF DOMAIN AND AN IMMUNOGLOBULIN HOMOLOGY UNIT	CELL			English	Review							EPIDERMAL GROWTH-FACTOR; HUMAN INTERLEUKIN-2 RECEPTOR; HUMAN-BREAST-CARCINOMA; HUMAN MAMMARY-TUMORS; FACTOR-ALPHA; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; PROTO-ONCOGENE; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION	We recently reported that a 44 kd glycoprotein secreted by transformed fibroblasts stimulates tyrosine Phosphorylation of the product of the neu proto-oncogene and induces differentiation of mammary tumor cells to milk-producing, growth-arrested cells. A partial amino acid sequence of the protein, termed Neu differentiation factor (NDF), enabled cloning of the corresponding complementary DNA. The deduced structure of the precursor of NDF indicated that it is a transmembrane protein whose extracellular portion contains an EGF-like domain that probably functions as a receptor recognition site. In addition, the ectodomain contains one immunoglobulin homology unit. Despite the lack of a recognizable hydrophobic signal peptide at the N-terminus, a recombinant NDF, like the natural molecule, is released into the medium of transfected COS-7 cells in a biologically active form. Northern blot analysis indicated the existence of several NDF transcripts, the major ones being 1.8, 2.6, and 6.7 kb in size. Transformation by the ras oncogene dramatically elevated the expression of NDF in fibroblasts.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; CELL ANAL SYST INC, ELMHURST, IL 60126 USA	Weizmann Institute of Science	WEN, DZ (corresponding author), AMGEN INC, THOUSAND OAKS, CA 91320 USA.		YARDEN, YOSEF/K-1467-2012; Mieszkowska, Magdalena/O-6753-2017	Peles, Elior/0000-0002-3325-0597	NCI NIH HHS [CA-51712, CA-50843] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA050843, R43CA050843, R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BACUS SS, 1992, IN PRESS CANCER RES; BACUS SS, 1992, INPRESS CELL GROWTH; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BERGER MS, 1988, CANCER RES, V48, P1238; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHANG W, 1987, MOL CELL BIOL, V7, P535, DOI 10.1128/MCB.7.1.535; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DEFEOJONES D, 1989, MOL CELL BIOL, V9, P4083, DOI 10.1128/MCB.9.9.4083; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GULLICK WJ, 1990, INT J CANCER, P55; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HARRIS AL, 1989, CANCER CEL, V7, P353; HEATH WF, 1986, P NATL ACAD SCI USA, V83, P6367, DOI 10.1073/pnas.83.17.6367; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNKAPILLER MW, 1986, MICROCHARACTERIZATIO, P223; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAMPS MP, 1988, ONCOGENE, V2, P305; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAZAR E, 1989, MOL CELL BIOL, V9, P860, DOI 10.1128/MCB.9.2.860; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; Maniatis T., 1982, MOL CLONING; MARCHESI VT, 1976, ANNU REV BIOCHEM, V45, P667, DOI 10.1146/annurev.bi.45.070176.003315; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MARUYAMA T, 1986, NUCLEIC ACIDS RES, V14, pR151, DOI 10.1093/nar/14.suppl.r151; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MEEK RL, 1982, J BIOL CHEM, V257, P2245; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; TSUDA H, 1989, CANCER RES, V49, P3104; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UPTON C, 1987, J VIROL, V61, P1271, DOI 10.1128/JVI.61.4.1271-1275.1987; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yarden Y, 1991, CURR OPIN STRUC BIOL, V1, P582, DOI 10.1016/S0959-440X(05)80081-8; ZHOU DJ, 1987, CANCER RES, V47, P6123	105	590	640	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					559	572		10.1016/0092-8674(92)90456-M	http://dx.doi.org/10.1016/0092-8674(92)90456-M			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1349853				2022-12-28	WOS:A1992HT07800017
J	GUTIERREZ, AA; LEMOINE, NR; SIKORA, K				GUTIERREZ, AA; LEMOINE, NR; SIKORA, K			GENE-THERAPY FOR CANCER	LANCET			English	Review							BONE-MARROW; CELLS; EXPRESSION; PHENOTYPE; MELANOMA; IMPACT	The molecular basis of cancer is now understood to involve activation of dominant oncogenes and inactivation of tumour suppressor genes, and these genetic events may represent novel targets for cancer therapy. This review focuses on the potential use and ethical implications of gene transfer to after the behaviour of somatic cells in cancer patients. Antisense nucleic acids and ribozymes represent informational drugs that may be used to modulate the expression of selected genes and suppress malignant behaviour in cancer cells. Genetic immunomodulation by introducing genes for cytokines into cancer cells or lymphocytes can stimulate a cytotoxic immune response against the tumour. Gene transfer techniques can be applied to target prodrug activation specifically to tumour cells and also to protect normal tissues against toxic chemotherapy. Gene replacement therapy could even be used to restore the function of defective tumour suppressor genes.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN ONCOL,IMPERIAL CANC RES FUND,ONCOL GRP,LONDON W12 0NN,ENGLAND	Cancer Research UK; Imperial College London								AEBERSOLD P, 1991, JNCI-J NATL CANCER I, V83, P932, DOI 10.1093/jnci/83.13.932; ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; ASCADI G, 1991, NATURE, V352, P815; BENVENISTY N, 1986, P NATL ACAD SCI USA, V83, P275; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORG A, 1991, ONCOGENE, V6, P137; BRODEUR G, 1984, SCIENCE, V24, P1121; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; CHOCHUNG YS, 1991, LIFE SCI, V48, P1123, DOI 10.1016/0024-3205(91)90449-L; COREY CA, 1990, BLOOD, V75, P337; CULVER KW, 1991, TRANSPLANT P, V23, P170; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; FRIEDMANN T, 1972, SCIENCE, V175, P949, DOI 10.1126/science.175.4025.949; GALSKI H, 1989, MOL CELL BIOL, V9, P4357, DOI 10.1128/MCB.9.10.4357; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P8950, DOI 10.1073/pnas.87.22.8950; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; JAMES RFL, 1991, IMMUNOLOGY, V72, P213; JOHNSON AW, IN PRESS J BIOL CHEM; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KEITH WN, 1990, BRIT J CANCER, V62, P388, DOI 10.1038/bjc.1990.304; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOHN DB, 1987, BLOOD CELLS, V13, P285; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MASTRANGELO MJ, 1988, SEMIN ONCOL, V15, P589; MCMANAWAY ME, 1990, LANCET, V335, P808, DOI 10.1016/0140-6736(90)90934-W; MELANI C, 1991, CANCER RES, V51, P2897; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MOTULSKY AG, 1983, SCIENCE, V219, P135, DOI 10.1126/science.6336852; MURRAY TH, 1991, FASEB J, V5, P55, DOI 10.1096/fasebj.5.1.1825074; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; SADANO H, 1990, FEBS LETT, V271, P23, DOI 10.1016/0014-5793(90)80363-N; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; TEMIN HM, 1990, J MED VIROL, V31, P13, DOI 10.1002/jmv.1890310105; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WEATHERALL DJ, 1991, NATURE, V349, P255; WEISSMAN BE, 1987, SCIENCE, V175, P181; WHITESELL L, 1991, MOL CELL BIOL, V11, P1360, DOI 10.1128/MCB.11.3.1360; WU CH, 1989, J BIOL CHEM, V264, P16985; 1988, LANCET, V1, P1271	48	145	171	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					715	721		10.1016/0140-6736(92)90606-4	http://dx.doi.org/10.1016/0140-6736(92)90606-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347590				2022-12-28	WOS:A1992HK32000011
J	MULLER, D; KOLLER, BH; WHITTON, JL; LAPAN, KE; BRIGMAN, KK; FRELINGER, JA				MULLER, D; KOLLER, BH; WHITTON, JL; LAPAN, KE; BRIGMAN, KK; FRELINGER, JA			LCMV-SPECIFIC, CLASS-II RESTRICTED CYTOTOXIC T-CELLS IN BETA-2-MICROGLOBULIN DEFICIENT MICE	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MONOCLONAL-ANTIBODIES; EXPRESSION; ANTIGENS; INFECTION; DISEASE; CLONES; LYSIS	Intracranial infection of normal mice with lymphocytic choriomeningitis virus (LCMV) causes meningitis and death mediated by CD8+ major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes (CTLs). Beta-2-microglobulin-deficient mice (beta-2M-/-) do not express functional MHC class I proteins and do not produce significant numbers of CD8+ T cells. When beta-2M-/- mice were infected with LCMV, many died from LCMV disease and produced a specific response to LCMV mediated by CD4+ CTLs that were class II-restricted. In these mice, CD4+ CTLs may compensate for the lack of CD8+ CTLs.	UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT MED, DIV RHEUMATOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; Scripps Res Inst, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, LINEBERGER CANC RES CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill			Frelinger, Jeffrey A/F-2448-2014	Frelinger, Jeffrey A/0000-0002-2503-6267	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029324, R01AI020288, R37AI020288] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20288, AI-29324] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNOLD LG, COMMUNICATION; BINNENDIJK RS, 1989, J IMMUNOL, V142, P2847; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BROWNING M, 1990, J VIROL, V64, P3810, DOI 10.1128/JVI.64.8.3810-3816.1990; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; BYRNE JA, 1984, J IMMUNOL, V133, P433; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; COLE GA, 1972, NATURE, V238, P335, DOI 10.1038/238335a0; DURAN LW, 1989, J IMMUNOL, V142, P288; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; HOTCHIN J, 1962, COLD SPRING HARB SYM, V27, P479, DOI 10.1101/SQB.1962.027.001.046; KAPLAN DR, 1984, CELL IMMUNOL, V88, P193, DOI 10.1016/0008-8749(84)90064-9; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LAPAN KE, 1991, MOL IMMUNOL, V28, P499, DOI 10.1016/0161-5890(91)90164-F; LAPAN KE, IN PRESS HYBRIDOMA; LISOWSKAGROSPIERRE B, 1985, J CLIN INVEST, V76, P381, DOI 10.1172/JCI111974; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; McKenzie I F, 1979, Adv Immunol, V27, P179, DOI 10.1016/S0065-2776(08)60263-1; MOSKOPHIDIS D, 1987, J VIROL, V61, P1867, DOI 10.1128/JVI.61.6.1867-1874.1987; MULLER D, UNPUB; MURRAY R, 1990, CELL IMMUNOL, V128, P220, DOI 10.1016/0008-8749(90)90020-R; OEHEN S, 1991, SCIENCE, V251, P195, DOI 10.1126/science.1824801; OZATO K, 1981, J IMMUNOL, V126, P317; QUINN D, UNPUB; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; TING JPY, 1981, P NATL ACAD SCI-BIOL, V78, P3170, DOI 10.1073/pnas.78.5.3170; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; YASUKAWA M, 1984, J IMMUNOL, V133, P422; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL RM, 1985, NATURE, V316, P814, DOI 10.1038/316814a0	32	183	184	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 20	1992	255	5051					1576	1578		10.1126/science.1347959	http://dx.doi.org/10.1126/science.1347959			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1347959				2022-12-28	WOS:A1992HJ80900042
J	SANDERCOCK, P; WILLEMS, H				SANDERCOCK, P; WILLEMS, H			MEDICAL-TREATMENT OF ACUTE ISCHEMIC STROKE	LANCET			English	Article							ISCHEMIC STROKE; RANDOMIZED TRIALS; NEED				SANDERCOCK, P (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				ANDERSON DC, 1991, STROKE, V22, P1137, DOI 10.1161/01.STR.22.9.1137; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1990, Lancet, V336, P1205; ASPLUND K, 1991, CEREBROVASC DIS, V1, P129, DOI 10.1159/000108908; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; CANDELISE L, 1988, LANCET, V1, P318; CIUFFETTI G, 1990, ANGIOLOGY, V41, P505, DOI 10.1177/000331979004100701; GELMERS HJ, 1988, NEW ENGL J MED, V318, P203, DOI 10.1056/NEJM198801283180402; GELMERS HJ, 1990, STROKE, V21, P81; MATTHEWS WB, 1976, BRAIN, V99, P193, DOI 10.1093/brain/99.2.193; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; 1991, LANCET, V337, P1129	14	64	65	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 29	1992	339	8792					537	539		10.1016/0140-6736(92)90348-7	http://dx.doi.org/10.1016/0140-6736(92)90348-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346888				2022-12-28	WOS:A1992HF63100013
J	BAMFORD, J				BAMFORD, J			CLINICAL EXAMINATION IN DIAGNOSIS AND SUBCLASSIFICATION OF STROKE	LANCET			English	Article							LACUNAR INFARCTION; NATURAL-HISTORY; DATA-BANK; DESIGN; PROJECT				BAMFORD, J (corresponding author), ST JAMES UNIV HOSP, DEPT NEUROL, BECKETT ST, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND.		Bamford, John/ABE-6218-2021					ALLEN CMC, 1983, Q J MED, V52, P515; Aring CD, 1935, ARCH INTERN MED, V56, P435, DOI 10.1001/archinte.1935.00170010023002; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; GENT M, 1988, STROKE, V19, P1203, DOI 10.1161/01.STR.19.10.1203; HARRISON MJG, 1980, POSTGRAD MED J, V56, P629, DOI 10.1136/pgmj.56.659.629; HOROWITZ SH, 1991, STROKE, V22, P1245, DOI 10.1161/01.STR.22.10.1245; KAPPELLE LJ, 1988, STROKE, V19, P1093, DOI 10.1161/01.STR.19.9.1093; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MOHR JP, 1986, STROKE PATHOPHYSIOLO, P281; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; PRICE TR, 1986, STROKE PATHOPHYSIOLO, P1060; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SACCO SE, 1991, STROKE, V22, P1236, DOI 10.1161/01.STR.22.10.1236; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; STERMAN AB, 1987, STROKE, V18, P524, DOI 10.1161/01.STR.18.2.524; TURNEY TM, 1984, STROKE, V15, P790, DOI 10.1161/01.STR.15.5.790; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707; 1989, STROKE BETTER MANAGE	23	56	57	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1992	339	8790					400	402		10.1016/0140-6736(92)90085-H	http://dx.doi.org/10.1016/0140-6736(92)90085-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD659	1346666				2022-12-28	WOS:A1992HD65900010
J	ABE, O; ABE, R; ASAISHI, K; ENOMOTO, K; HATTORI, T; INO, Y; KIKUCHI, K; KOYAMA, H; SAWA, K; UCHINO, J; YOSHIDA, M; HAYBITTLE, JL; VANDEVELDE, T; VERMORKEN, JB; HARVEY, VJ; HOLDAWAY, TM; KAY, RG; MASON, BH; FORBES, JF; BASTERT, G; SAUERBREI, W; SCHEURLEN, H; SCHUMACHER, M; FOCAN, C; LOBELLE, JP; PEEK, U; OATES, GD; POWELL, J; DURAND, M; MAURIAC, L; GELMAN, RS; HENDERSON, IC; SHAPIRO, CL; HANCOCK, AK; JACKSON, S; RAGAZ, J; HENDERSON, IC; KORZUN, A; WOOD, WC; YOSHIMOTO, M; BAUM, M; HOUGHTON, J; HORGAN, K; HUGHES, L; STEWART, HJ; GORDON, NH; DAVIS, HL; DELOZIER, T; MACELESECH, J; RAMBERT, P; ANDRYSEK, O; BARKMANOVA, J; OWEN, JR; HOWELL, A; RIBEIRO, GC; SWINDELL, R; DEOLIVEIRA, CF; CARSTENSEN, B; PALSHOF, T; JOHANSEN, H; KORZENIOWSKI, S; SKOLYSZEWSKI, J; ANDERSEN, KW; DOMBERNOWSKY, P; MOURIDSEN, HT; ROSE, C; CORCORAN, N; TRAMPISCH, HJ; ABELOFF, MD; CARBONE, PC; GLICK, J; GRAY, R; TORMEY, DC; BUYSE, M; MIGNOLET, F; PARIDAENS, R; VANDRIEL, OJR; SYLVESTER, RJ; VANDEVELDE, CJH; VANDONGEN, JA; WELVAART, K; SCANLON, EF; SCHURMAN, S; CATALANO, R; CREECH, RH; DESCHRYVER, A; MCGREGOR, K; YOSEF, HMA; MCARDLE, CS; SMITH, DC; LARA, PC; DENT, DM; GUDGEON, CA; HACKING, A; BOCCARDO, F; IZUO, M; BENTLEY, A; DORAN, Z; FENTIMAN, IS; HAYWARD, JL; RUBENS, RD; KAUFMANN, M; JONAT, W; SCHEURLEN, H; VONFOURNIER, D; KAUFMANN, M; KLEFSTROM, P; CUZICK, J; MARGREITER, R; ASSELAIN, B; POUILLARD, P; BAHI, J; MILLA, A; SANCHIZ, F; CASTIGLIONE, M; CAVALLI, F; COLLINS, J; GELBER, RD; GOLDHIRSCH, A; ISLEY, MR; LINDTNER, J; PRICE, KN; RUDENSTAM, CM; SENN, HJ; BLISS, JM; CHILVERS, CED; COOMBES, RC; MARTY, M; BOROVIK, R; BRUFMAN, G; ROBINSON, E; PANNUTI, F; TAKASHIMA, S; YASUTOMI, T; HOLM, LE; SONOO, H; YAMASHITA, J; BONTE, J; BUZDAR, AU; SMITH, T; MARTIN, P; ROMAIN, S; AHMANN, D; SCHAID, DJ; HAKES, T; NORTON, L; WITTES, R; FOROGLOU, P; LISSAIOS, B; BONADONNA, G; DELVECCHIO, M; VALAGUSSA, P; VERONESI, U; DUBOIS, JB; BRUFMAN, G; HAYAT, H; BIANCO, AR; LIPPMAN, ME; PIERCE, LJ; SIMON, R; STEINBERG, SM; NOMURA, Y; DELAHUERTA, R; SAINZ, MG; BROWN, A; FISHER, B; REDMOND, C; WOLMARK, N; BAUM, M; JACKSON, IM; PALMER, MK; INGLE, JN; SCHAID, DJ; BENGTSSON, NO; LARSSON, LG; LYTHGOE, JP; SWINDELL, R; KISSIN, M; BLAMEY, RW; MITCHELL, AK; ROBERTSON, JFR; CASTIGLIONE, M; FLUCKIGER, H; SENN, HJ; NAKAMURA, Y; MATHE, G; MISSET, JL; DESHPANDE, N; DIMARTINO, L; CLARKE, EA; MCLAUGHLIN, JR; CLARK, RM; LEVINE, M; MORIMOTO, K; GUNDERSEN, S; HAUERJENSEN, M; HOST, H; CROSSLEY, E; DURRANT, K; HARRIS, A; CLARKE, M; COLLINS, R; GODWIN, J; GRAY, R; GREAVES, E; HARWOOD, C; MEAD, G; PETO, R; WHEATLEY, K; HILL, C; LACOUR, J; LAPLANCHE, A; LE, M; SARRAZIN, D; SEMIGLAZOV, V; BROCKSCHMIDT, J; COOPER, MR; MEAKIN, JW; PANZARELLA, T; PRITCHARD, KI; TREURNIETDONKER, AD; VANPUTTEN, WLJ; EASTON, D; POWLES, TJ; GAZET, JC; DOUGLAS, P; HACKING, A; HOST, H; LINDTNER, A; NOTTER, G; BRYANT, AJS; EWING, GH; KRUSHEN, JL; NISSENMEYER, R; FORREST, APM; MCDONALD, C; STEWART, HJ; MOLLER, TR; RYDEN, S; CARSTENSEN, J; HATSCHEK, T; SODERBERG, M; CARPENTER, JT; CRAWLEY, J; GREEN, S; OSBORNE, CK; RUTQVIST, LE; WALLGREN, A; BRENNER, H; HERCBERGS, A; DEBOER, G; PATERSON, AHG; PRITCHARD, KI; NAJA, A; REID, M; SPITTLE, M; SENANAYAKE, F; MEIER, P; TENGRUP, I; TENNVALLNITTBY, L; CAFFIER, H; BEZWODA, WR; HOLMBERG, L; SEVELDA, P; ZIELINSKY, CC; JAKESZ, R; BUCHANAN, RB; CROSS, M; DUNN, JA; GILLESPIE; KELLY, K; MORRISON, JM; LITTON, A; CHLEBOWSKI, RT				ABE, O; ABE, R; ASAISHI, K; ENOMOTO, K; HATTORI, T; INO, Y; KIKUCHI, K; KOYAMA, H; SAWA, K; UCHINO, J; YOSHIDA, M; HAYBITTLE, JL; VANDEVELDE, T; VERMORKEN, JB; HARVEY, VJ; HOLDAWAY, TM; KAY, RG; MASON, BH; FORBES, JF; BASTERT, G; SAUERBREI, W; SCHEURLEN, H; SCHUMACHER, M; FOCAN, C; LOBELLE, JP; PEEK, U; OATES, GD; POWELL, J; DURAND, M; MAURIAC, L; GELMAN, RS; HENDERSON, IC; SHAPIRO, CL; HANCOCK, AK; JACKSON, S; RAGAZ, J; HENDERSON, IC; KORZUN, A; WOOD, WC; YOSHIMOTO, M; BAUM, M; HOUGHTON, J; HORGAN, K; HUGHES, L; STEWART, HJ; GORDON, NH; DAVIS, HL; DELOZIER, T; MACELESECH, J; RAMBERT, P; ANDRYSEK, O; BARKMANOVA, J; OWEN, JR; HOWELL, A; RIBEIRO, GC; SWINDELL, R; DEOLIVEIRA, CF; CARSTENSEN, B; PALSHOF, T; JOHANSEN, H; KORZENIOWSKI, S; SKOLYSZEWSKI, J; ANDERSEN, KW; DOMBERNOWSKY, P; MOURIDSEN, HT; ROSE, C; CORCORAN, N; TRAMPISCH, HJ; ABELOFF, MD; CARBONE, PC; GLICK, J; GRAY, R; TORMEY, DC; BUYSE, M; MIGNOLET, F; PARIDAENS, R; VANDRIEL, OJR; SYLVESTER, RJ; VANDEVELDE, CJH; VANDONGEN, JA; WELVAART, K; SCANLON, EF; SCHURMAN, S; CATALANO, R; CREECH, RH; DESCHRYVER, A; MCGREGOR, K; YOSEF, HMA; MCARDLE, CS; SMITH, DC; LARA, PC; DENT, DM; GUDGEON, CA; HACKING, A; BOCCARDO, F; IZUO, M; BENTLEY, A; DORAN, Z; FENTIMAN, IS; HAYWARD, JL; RUBENS, RD; KAUFMANN, M; JONAT, W; SCHEURLEN, H; VONFOURNIER, D; KAUFMANN, M; KLEFSTROM, P; CUZICK, J; MARGREITER, R; ASSELAIN, B; POUILLARD, P; BAHI, J; MILLA, A; SANCHIZ, F; CASTIGLIONE, M; CAVALLI, F; COLLINS, J; GELBER, RD; GOLDHIRSCH, A; ISLEY, MR; LINDTNER, J; PRICE, KN; RUDENSTAM, CM; SENN, HJ; BLISS, JM; CHILVERS, CED; COOMBES, RC; MARTY, M; BOROVIK, R; BRUFMAN, G; ROBINSON, E; PANNUTI, F; TAKASHIMA, S; YASUTOMI, T; HOLM, LE; SONOO, H; YAMASHITA, J; BONTE, J; BUZDAR, AU; SMITH, T; MARTIN, P; ROMAIN, S; AHMANN, D; SCHAID, DJ; HAKES, T; NORTON, L; WITTES, R; FOROGLOU, P; LISSAIOS, B; BONADONNA, G; DELVECCHIO, M; VALAGUSSA, P; VERONESI, U; DUBOIS, JB; BRUFMAN, G; HAYAT, H; BIANCO, AR; LIPPMAN, ME; PIERCE, LJ; SIMON, R; STEINBERG, SM; NOMURA, Y; DELAHUERTA, R; SAINZ, MG; BROWN, A; FISHER, B; REDMOND, C; WOLMARK, N; BAUM, M; JACKSON, IM; PALMER, MK; INGLE, JN; SCHAID, DJ; BENGTSSON, NO; LARSSON, LG; LYTHGOE, JP; SWINDELL, R; KISSIN, M; BLAMEY, RW; MITCHELL, AK; ROBERTSON, JFR; CASTIGLIONE, M; FLUCKIGER, H; SENN, HJ; NAKAMURA, Y; MATHE, G; MISSET, JL; DESHPANDE, N; DIMARTINO, L; CLARKE, EA; MCLAUGHLIN, JR; CLARK, RM; LEVINE, M; MORIMOTO, K; GUNDERSEN, S; HAUERJENSEN, M; HOST, H; CROSSLEY, E; DURRANT, K; HARRIS, A; CLARKE, M; COLLINS, R; GODWIN, J; GRAY, R; GREAVES, E; HARWOOD, C; MEAD, G; PETO, R; WHEATLEY, K; HILL, C; LACOUR, J; LAPLANCHE, A; LE, M; SARRAZIN, D; SEMIGLAZOV, V; BROCKSCHMIDT, J; COOPER, MR; MEAKIN, JW; PANZARELLA, T; PRITCHARD, KI; TREURNIETDONKER, AD; VANPUTTEN, WLJ; EASTON, D; POWLES, TJ; GAZET, JC; DOUGLAS, P; HACKING, A; HOST, H; LINDTNER, A; NOTTER, G; BRYANT, AJS; EWING, GH; KRUSHEN, JL; NISSENMEYER, R; FORREST, APM; MCDONALD, C; STEWART, HJ; MOLLER, TR; RYDEN, S; CARSTENSEN, J; HATSCHEK, T; SODERBERG, M; CARPENTER, JT; CRAWLEY, J; GREEN, S; OSBORNE, CK; RUTQVIST, LE; WALLGREN, A; BRENNER, H; HERCBERGS, A; DEBOER, G; PATERSON, AHG; PRITCHARD, KI; NAJA, A; REID, M; SPITTLE, M; SENANAYAKE, F; MEIER, P; TENGRUP, I; TENNVALLNITTBY, L; CAFFIER, H; BEZWODA, WR; HOLMBERG, L; SEVELDA, P; ZIELINSKY, CC; JAKESZ, R; BUCHANAN, RB; CROSS, M; DUNN, JA; GILLESPIE; KELLY, K; MORRISON, JM; LITTON, A; CHLEBOWSKI, RT			SYSTEMIC TREATMENT OF EARLY BREAST-CANCER BY HORMONAL, CYTOTOXIC, OR IMMUNE THERAPY-133 RANDOMIZED TRIALS INVOLVING 31000 RECURRENCES AND 24000 DEATHS AMONG 75000 WOMEN .2.	LANCET			English	Review							REQUIRING PROLONGED OBSERVATION; SURGICAL ADJUVANT BREAST; TAMOXIFEN THERAPY; CHEMOTHERAPY; IRRADIATION; PATIENT; DESIGN		INTEGRAAL KANKERCTR, AMSTERDAM, NETHERLANDS; AUCKLAND BREAST CANC STUDY GRP, AUCKLAND, NETHERLANDS; AKAD WISSENSCH DDR, O-1086 BERLIN, GERMANY; BIRMINGHAM GEN HOSP, BIRMINGHAM, ENGLAND; FDN BERGONIE, F-33076 BORDEAUX, FRANCE; HARVARD UNIV, SCH MED,DANA FARBER CANC INST, BOSTON, MA 02115 USA; BRADFORD ROYAL INFIRM, BRADFORD, ENGLAND; BRITISH COLUMBIA CANC FDN, VANCOUVER V5Z 3J3, BC, CANADA; CANC INST HOSP, TOKYO, JAPAN; CANC RES CAMPAIGN, LONDON, ENGLAND; CARDIFF SURG TRIALISTS, CARDIFF, WALES; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; CTR REG FRANCOIS BACLESSE, CAEN, FRANCE; CTR RENE HUGUENIN, ST CLOUD, FRANCE; CHARLES UNIV, CS-11636 PRAGUE 1, CZECHOSLOVAKIA; CHELTENHAM GEN HOSP, CHELTENHAM, ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST, MANCHESTER M20 9BX, LANCS, ENGLAND; COIMBRA INST ONCOL, COIMBRA, PORTUGAL; DANISH CANC REGISTRY, COPENHAGEN, DENMARK; COPENHAGEN RADIUM CTR, COPENHAGEN, DENMARK; CRACOW INST ONCOL, KRAKOW, POLAND; ST LUKES HOSP, DUBLIN, IRELAND; UNIV DUSSELDORF, W-4000 DUSSELDORF 1, GERMANY; EUROPEAN ORG RES TREATMENT CANC, BRUSSELS, BELGIUM; EASTERN COOPERAT ONCOL GRP, BOSTON, MA USA; DANISH BREAST CANC COOPERAT GRP, COPENHAGEN, DENMARK; CANC & LEUKEMIA GRP B, BROOKLINE, MA USA; EVANSTON HOSP CORP, EVANSTON, IL 60201 USA; FOX CHASE CANC INST, PHILADELPHIA, PA 19111 USA; STATE UNIV GHENT HOSP, B-9000 GHENT, BELGIUM; GLASCOW BEATSON ONCOL CTR, GLASGOW, SCOTLAND; VICTORIA INFIRM, GLASGOW G42 9TY, SCOTLAND; GRANADA UNIV HOSP, GRANADA, SPAIN; GROOTE SCHUUR HOSP, CAPE TOWN 7925, SOUTH AFRICA; GUNMA UNIV, MAEBASHI, GUNMA 371, JAPAN; GUYS HOSP, LONDON SE1 9RT, ENGLAND; UNIV HEIDELBERG, W-6900 HEIDELBERG, GERMANY; UNIV HEIDELBERG 2, HEIDELBERG, GERMANY; UNIV HEIDELBERG 1, HEIDELBERG, GERMANY; DEACONESS MED CTR, HELSINKI, FINLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; UNIV INNSBRUCK, A-6020 INNSBRUCK, AUSTRIA; INST CURIE, F-75231 PARIS 05, FRANCE; INST SALAH AZAIZ, TUNIS, TUNISIA; INST POLICLIN, BARCELONA, SPAIN; INT LUDWIG BREAST CANC STUDY GRP, LONDON, ENGLAND; CHARING CROSS HOSP, INT COLLABORAT CANC GRP, LONDON W6 8RP, ENGLAND; TECHNION ISRAEL INST TECHNOL, RAMBAM MED CTR, HAIFA, ISRAEL; KAROLINSKA HOSP, S-10401 STOCKHOLM 60, SWEDEN; Kawasaki Med Sch, KURASHIKI, OKAYAMA 70101, JAPAN; KUMAMOTO UNIV GRP, KUMAMOTO, JAPAN; ACAD HOSP ST RAFAEL, B-3000 LOUVAIN, BELGIUM; MD ANDERSON CANC CTR, HOUSTON, TX USA; LAB CANEROL BIOL APM, MARSEILLE, FRANCE; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; METAXAS MEM CANC HOSP, ATHENS, GREECE; IST NAZL STUDIO & CURA TUMORI, I-20133 MILAN, ITALY; CTR PAUL LAMARQUE, F-34033 MONTPELLIER, FRANCE; NAPLES UNIV, I-80138 NAPLES, ITALY; NCI, BETHESDA, MD 20892 USA; NATL KYUSHU CANC CTR HOSP, KYUSHU, JAPAN; NATL MED CTR, MEXICO CITY, DF, MEXICO; NATL SURG ADJUVANT PROJECT BREAST & BOWEL CANC, PITTSBURGH, PA USA; N CENT CANC TREATMENT GRP, ROCHESTER, MN USA; NORTHWICK PK HOSP & CLIN RES CTR, HARROW HA1 3UJ, MIDDX, ENGLAND; NOTTINGHAM CITY HOSP, NOTTINGHAM NG5 1PB, ENGLAND; OITA PREFECTURAL HOSP, OITA, JAPAN; ONCOL HOSP A BUSINICO, SARDINIA, FRANCE; ONTARIO CANC TREATMENT & RES FDN, TORONTO, ONTARIO, CANADA; ONTARIO CLIN ONCOL GRP, TORONTO, ONTARIO, CANADA; OSAKA CITY MED SCH, OSAKA, JAPAN; OSLO RADIUM HOSP, OSLO, NORWAY; CHURCHILL HOSP, OXFORD OX3 7LJ, ENGLAND; IMPERIAL CANC RES FUND, MRC,CLIN TRIAL SERV UNIT, OXFORD, ENGLAND; INST GUSTAVE ROUSSY, F-94805 VILLEJUIF, FRANCE; NN PETROV ONCOL RES INST, LENINGRAD 188646, USSR; PIEDMONT ONCOL ASSOC, ATLANTA, GA USA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA; ROTTERDAM RADIOTHERAPEUT INST, ROTTERDAM, NETHERLANDS; ROYAL MARSDEN HOSP, INST CANC RES, LONDON, ENGLAND; ST GEORGE HOSP, LONDON, ENGLAND; SASKATCHEWAN CANC FDN, SASKATOON, SASKATCHEWAN, CANADA; SW ONCOL GRP, KANSAS CITY, KS 66103 USA; STOCKHOLM BREAST CANC STUDY GRP, STOCKHOLM, SWEDEN; TEL AVIV UNIV, IL-69978 TEL AVIV, ISRAEL; TORONTO EDMONTON BREAST CANC STUDY GRP, TORONTO, ONTARIO, CANADA; TOULOUSE CTR CLAUDIUS REGAUD, TOULOUSE, FRANCE; UNIV CHICAGO, CHICAGO, IL 60637 USA; UNIV LUND, S-22101 LUND, SWEDEN; UNIV WURZBURG, W-8700 WURZBURG, GERMANY; UNIV WITWATERSRAND, JOHANNESBURG 2001, SOUTH AFRICA; UPPSALA OREBRO CANC STUDY GRP, UPPSALA, SWEDEN; VIENNA UNIV HOSP, DEPT GYNAECOL 1, VIENNA, AUSTRIA; VIENNA UNIV HOSP, DEPT SURG 1, VIENNA, AUSTRIA; WESSEX RADIOTHERAPY CTR, WESSEX, ENGLAND; ADDENBROOKES HOSP, CAMBRIDGE CB2 2QQ, ENGLAND	University of Birmingham; UNICANCER; Institut Bergonie; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Bradford Royal Infirmary; Japanese Foundation for Cancer Research; Case Western Reserve University; UNICANCER; Centre Francois Baclesse; Rene Huguenin Hospital; Charles University Prague; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; Christie NHS Foundation Trust; Christie Hospital; Maria Sklodowska-Curie National Research Institute of Oncology; Trinity College Dublin; Heinrich Heine University Dusseldorf; European Organisation for Research & Treatment of Cancer; Danish Breast Cancer Cooperative Group (DBCG); NorthShore University Health System; Fox Chase Cancer Center; Ghent University; Ghent University Hospital; Beatson Oncology Centre; University of Cape Town; Gunma University; Guy's & St Thomas' NHS Foundation Trust; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Cancer Research UK; University of Innsbruck; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Tunis-El-Manar; Institut Salah Azaiez; Imperial College London; Rambam Health Care Campus; Technion Israel Institute of Technology; Karolinska Institutet; Karolinska University Hospital; Kawasaki Medical School; Kumamoto University; KU Leuven; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Memorial Sloan Kettering Cancer Center; Fondazione IRCCS Istituto Nazionale Tumori Milan; Universite de Montpellier; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyushu Cancer Center; Imperial College London; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Oxford; University of Oxford; UNICANCER; Gustave Roussy; N.N. Petrov Research Institute of Oncology; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; St Georges University London; University of Saskatchewan; Southwest Oncology Group; Tel Aviv University; UNICANCER; Institut Claudius Regaud; University of Chicago; Lund University; University of Wurzburg; University of Witwatersrand; University Hospital Vienna; University Hospital Vienna; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	ABE, O (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, ICRF MRC CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.		Jonat, Walter/E-3024-2010; Brenner, Hermann/ABE-6383-2020; Brenner, Hermann/B-4627-2017; Fentiman, Ian S/I-7644-2019; Boccardo, Francesco Mario/AAF-2654-2019; Schurman, Shepherd/ABF-8125-2021; Fentiman, Ian/AAB-9886-2020; Pritchard, Kathleen I/I-2184-2014; Barkmanova, Jaroslava/A-1411-2017; McLaughlin, John R/E-4577-2013	Brenner, Hermann/0000-0002-6129-1572; Brenner, Hermann/0000-0002-6129-1572; Boccardo, Francesco Mario/0000-0002-5392-4077; Pritchard, Kathleen I/0000-0003-0758-9666; Barkmanova, Jaroslava/0000-0003-1406-7292; Bliss, Judith/0000-0001-7957-7424; Schurman, Shepherd/0000-0002-9133-7906; Coombes, Raoul Charles/0000-0002-4811-1100				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; [Anonymous], 1984, Lancet, V2, P1205; [Anonymous], 1985, JAMA, V254, P3461; BIANCO AR, 1991, BRIT J CANCER, V63, P799, DOI 10.1038/bjc.1991.177; BONADONNA G, 1985, BREAST CANCER RES TR, V5, P95, DOI 10.1007/BF01805984; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; CARBONE PP, 1990, CANCER, V66, P1378, DOI 10.1002/1097-0142(19900915)66:14+<1378::AID-CNCR2820661413>3.0.CO;2-J; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; FISHER B, 1986, J CLIN ONCOL, V4, P459, DOI 10.1200/JCO.1986.4.4.459; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FORNANDER T, 1989, LANCET, V1, P117; GOLDHIRSCH A, 1985, J CLIN ONCOL, V3, P1059; HALL WH, 1991, JAMA-J AM MED ASSOC, V265, P391; HORTOBAGYI GN, 1978, IMMUNOTHERAPY CANCER, P155; JORDAN VC, 1990, J NATL CANCER I, V82, P1662, DOI 10.1093/jnci/82.21.1662; LEGHA SS, 1988, ANN INTERN MED, V109, P219, DOI 10.7326/0003-4819-109-3-219; LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MEAKIN JW, 1979, CAN MED ASSOC J, V120, P1221; NEVINNY HB, 1969, AM J SURG, V117, P531, DOI 10.1016/0002-9610(69)90012-9; NISSENMEYER R, 1991, ANN ONCOL, V2, P343, DOI 10.1093/oxfordjournals.annonc.a057952; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POWLES TJ, 1991, MED MANAGEMENT BREAS; RAVDIN RG, 1970, SURG GYNECOL OBSTETR, V131, P1055; RICHARDS MA, 1990, J CLIN ONCOL, V8, P2032, DOI 10.1200/JCO.1990.8.12.2032; SMITH PG, 1976, BRIT J RADIOL, V49, P224, DOI 10.1259/0007-1285-49-579-224; STEWART HJ, 1987, LANCET, V2, P171; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; ZAMBETTI M, 1989, P AN M AM SOC CLIN, V8, P21; 1991, WORLD HLTH STATISTIC; 1988, BRIT J CANC, V57, P608; 1986, CARCINOGENICITY ALKY; 1986, BRIT MED J, V293, P946; 1990, SERIES MBI, V18	39	1226	1229	3	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 11	1992	339	8785					71	85						15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345869				2022-12-28	WOS:A1992GZ15600001
J	BROWNE, S; HYLAND, ME				BROWNE, S; HYLAND, ME			MOOD AND PEAK FLOW IN ASTHMA	LANCET			English	Letter											BROWNE, S (corresponding author), POLYTECH SW,DEPT PSYCHOL,PLYMOUTH PL4 8AA,ENGLAND.							HYLAND ME, 1990, BRIT J MED PSYCHOL, V63, P379, DOI 10.1111/j.2044-8341.1990.tb01633.x; STEPTOE A, 1985, BRIT J MED PSYCHOL, V58, P87, DOI 10.1111/j.2044-8341.1985.tb02619.x; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063	3	2	2	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					118	119		10.1016/0140-6736(92)91022-Z	http://dx.doi.org/10.1016/0140-6736(92)91022-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ156	1345834				2022-12-28	WOS:A1992GZ15600021
J	MUR, JM; MANDEREAU, L; DEPLAN, F; PARIS, A; RICHARD, A; HEMON, D				MUR, JM; MANDEREAU, L; DEPLAN, F; PARIS, A; RICHARD, A; HEMON, D			SPONTANEOUS-ABORTION AND EXPOSURE TO VINYL-CHLORIDE	LANCET			English	Letter									INSERM,U170,F-94800 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	MUR, JM (corresponding author), INST NATL RECH SCI,BP 27,F-54501 VANDOEUVRE NANCY,FRANCE.		Hémon, Denis/P-8695-2017					EDMONDS LD, 1978, TERATOLOGY, V17, P137, DOI 10.1002/tera.1420170205; EDMONDS LD, 1975, LANCET, V1, P1098; INFANTE PF, 1976, LANCET, V1, P734; LINDBOHM ML, 1985, AM J IND MED, V8, P579, DOI 10.1002/ajim.4700080609; THERIAULT G, 1983, TERATOLOGY, V27, P359, DOI 10.1002/tera.1420270310; WILCOX AJ, 1984, AM J EPIDEMIOL, V120, P727, DOI 10.1093/oxfordjournals.aje.a113940	6	2	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					127	128		10.1016/0140-6736(92)91041-6	http://dx.doi.org/10.1016/0140-6736(92)91041-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345856				2022-12-28	WOS:A1992GZ15600047
J	SALVESEN, KA; BAKKETEIG, LS; EIKNES, SH; UNDHEIM, JO; OKLAND, O				SALVESEN, KA; BAKKETEIG, LS; EIKNES, SH; UNDHEIM, JO; OKLAND, O			ROUTINE ULTRASONOGRAPHY INUTERO AND SCHOOL PERFORMANCE AT AGE 8-9 YEARS	LANCET			English	Article							DIAGNOSTIC ULTRASOUND; EXPOSURE; TIME	Most fetuses in developed countries are exposed in utero to diagnostic ultrasound examination. Many pregnant women express concern about whether the procedure harms the fetus. Since most routine ultrasound examinations are done at weeks 16-22, when the fetal brain is developing rapidly, effects on neuronal migration are possible. We have sought an association between routine ultrasonography in utero and reading and writing skills among children in primary school. At the age of 8 or 9 years, children of women who had taken part in two randomised, controlled trials of routine ultrasonography during pregnancy were followed-up. The women had attended the clinics of 60 general practitioners in central Norway during 1979-81. The analysis of outcome was by intention to treat 92% of the "screened" group had been exposed to ultrasound screening at weeks 16-22, and 95% of controls had not been so exposed, but there was some overlap. 2428 singletons were eligible for follow-up, and the school performance of 2011 children (83%) was assessed by their teachers on a scale of 1-7; the teachers were unaware of ultrasound exposure status. A subgroup of 603 children underwent specific tests for dyslexia. There were no statistically significant differences between children screened with ultrasound and controls in the teacher-reported school performance - (scores for reading, spelling, arithmetic, or overall performance). Results from the dyslexia test sample showed no differences between screened children and controls in reading, spelling, and intelligence scores, or in discrepancy scores between intelligence and reading or spelling. The test results classified 21 of the 309 screened children (7% [95% confidence interval 3-10%]) and 26 of the 294 controls (9% [4-12%]) as dyslexic. The fisk of having poor skills in reading and writing was no greater for children whose mothers had been offered routine ultrasonography than for those whose mothers had not been offered the procedure.	TRONDHEIM REG & UNIV HOSP,NATL CTR FETAL DIAG & THERAPY,TRONDHEIM,NORWAY; ALESUND CENT HOSP,DEPT PEDIAT,ALESUND,NORWAY; UNIV TRONDHEIM,DEPT PSYCHOL,TRONDHEIM,NORWAY; NATL INST PUBL HLTH,OSLO 1,NORWAY; NATL INST PUBL HLTH,DEPT EPIDEMIOL,OSLO 1,NORWAY	Norwegian University of Science & Technology (NTNU)	SALVESEN, KA (corresponding author), UNIV TRONDHEIM,CTR MED TECH,DEPT COMMUNITY MED & GEN PRACTICE,N-7005 TRONDHEIM,NORWAY.							ANDREWS M, 1987, BRIT J OBSTET GYNAEC, V94, P843, DOI 10.1111/j.1471-0528.1987.tb03751.x; BAKKETEIG LS, 1984, LANCET, V1, P1179; BJORGEN IA, 1987, EUROPEAN J PSYCHOL E, V38, P283; EIKNES SH, 1984, LANCET, V1, P1347; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P427; HUGDAHL K, 1990, NEUROPSYCHOLOGIA, V28, P673, DOI 10.1016/0028-3932(90)90122-5; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LIEBESKIND D, 1982, BRIT J CANCER, V45, P176; MOLE R, 1986, BIRTH-ISS PERINAT C, V13, P29, DOI 10.1111/j.1523-536X.1986.tb00999.x; MORTIMER AJ, 1988, ULTRASOUND MED BIOL, V14, P499, DOI 10.1016/0301-5629(88)90111-1; Neilson J., 1989, EFFECTIVE CARE PREGN; POCOCK SJ, 1988, CLIN TRIALS PRACTICA; Salvesen K A, 1990, Tidsskr Nor Laegeforen, V110, P1506; STARK CR, 1984, OBSTET GYNECOL, V63, P194; UNDHEIM JO, 1984, 5 U TRONDH RAPP; WELLS PNT, 1985, BIOL EFFECTS ULTRASO; 1988, J ULTRAS MED, V7, P1; 1984, PHS NIH84667 US DEP	18	63	65	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1992	339	8785					85	89		10.1016/0140-6736(92)90998-I	http://dx.doi.org/10.1016/0140-6736(92)90998-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ156	1345870				2022-12-28	WOS:A1992GZ15600002
J	KINGSLEY, DM; BLAND, AE; GRUBBER, JM; MARKER, PC; RUSSELL, LB; COPELAND, NG; JENKINS, NA				KINGSLEY, DM; BLAND, AE; GRUBBER, JM; MARKER, PC; RUSSELL, LB; COPELAND, NG; JENKINS, NA			THE MOUSE SHORT-EAR SKELETAL MORPHOGENESIS LOCUS IS ASSOCIATED WITH DEFECTS IN A BONE MORPHOGENETIC MEMBER OF THE TGF-BETA SUPERFAMILY	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MESODERM-INDUCING FACTOR; GENETIC-LINKAGE MAP; MESSENGER-RNA; EMBRYONIC-DEVELOPMENT; OSTEOGENIC PROTEIN; PATTERN-FORMATION; RETINOIC ACID; GERM LAYERS; ACTIVIN-A	The mouse short ear gene is required for normal growth and patterning of skeletal structures, and for repair of bone fractures in adults. We have carried out an extensive chromosome walk in the chromosome region that surrounds this locus. Here we show that the short ear region contains the gene for a TGFbeta-related protein called bone morphogenetic protein 5 (Bmp-5). This gene is deleted or rearranged in several independent mutations at the short ear locus. Mice homozygous for large deletions of the Bmp-5 coding region are viable and fertile. Mutations at the short ear locus provide an important new tool for defining the normal functions of BMPs in mammals. The specific skeletal defects seen in short-eared animals, which occur against a background of otherwise normal skeletal structures, suggest that particular aspects of skeletal morphology may be determined by individual members of a family of signaling factors that can induce the formation of cartilage and bone in vivo.	OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	United States Department of Energy (DOE); Oak Ridge National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KINGSLEY, DM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,BECKMAN CTR B300,STANFORD,CA 94305, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANO RM, 1990, DEVELOPMENT, V110, P435; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BATCHELOR AL, 1966, MUTAT RES, V3, P218, DOI 10.1016/0027-5107(66)90063-7; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURKE DT, 1991, MAMM GENOME, V1, P65, DOI 10.1007/BF00350849; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DICKINSON ME, 1990, GENOMICS, V6, P673; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; GELBART WM, 1989, DEVELOPMENT, V107, P65; Green EL, 1942, J MORPHOL, V70, P1, DOI 10.1002/jmor.1050700102; GREEN EL, 1946, AM NAT, V80, P619, DOI 10.1086/281482; GREEN JD, 1951, AM J ANAT, V88, P1; GREEN MARGARET C., 1957, JOUR HEREDITY, V48, P205; GREEN MARGARET C., 1952, OHIO JOUR SCI, V52, P31; GREEN MC, 1958, J EXP ZOOL, V137, P75, DOI 10.1002/jez.1401370105; GREEN MC, 1968, J EXP ZOOL, V167, P129, DOI 10.1002/jez.1401670202; Green MC., 1989, GENETIC VARIANTS STR, P12; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JONES CM, 1991, DEVELOPMENT, V111, P531; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KINGSLEY DM, 1990, EMBO J, V9, P395, DOI 10.1002/j.1460-2075.1990.tb08123.x; KINGSLEY DM, 1989, GENETICS, V123, P165; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; Lynch CJ, 1921, AM NAT, V55, P421, DOI 10.1086/279826; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NESBITT MN, 1973, MOUSE NEWS LETT, V49, P23; OTTIGER HP, 1990, J NEUROSCI, V10, P3135; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PETRAGLIA F, 1989, P NATL ACAD SCI USA, V86, P5114, DOI 10.1073/pnas.86.13.5114; RAY RP, 1991, DEVELOPMENT, V113, P35; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; REUTER R, 1990, DEVELOPMENT, V110, P1031; RINCHIK EM, 1986, GENETICS, V112, P321; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; RUSSELL LB, 1989, P NATL ACAD SCI USA, V86, P3704, DOI 10.1073/pnas.86.10.3704; RUSSELL LB, 1971, MUTAT RES, V11, P107, DOI 10.1016/0027-5107(71)90036-4; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; RUSSELL WL, 1951, COLD SPRING HARB SYM, V16, P327, DOI 10.1101/SQB.1951.016.01.024; Sambrook J, 1989, MOL CLONING LABORATO; SEARLE AG, 1989, GENETIC VARIANTS STR, P582; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	66	421	438	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					399	410		10.1016/0092-8674(92)90510-J	http://dx.doi.org/10.1016/0092-8674(92)90510-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1339316				2022-12-28	WOS:A1992JW43500007
J	MERSON, S; TYRER, P; ONYETT, S; LACK, S; BIRKETT, P; LYNCH, S; JOHNSON, T				MERSON, S; TYRER, P; ONYETT, S; LACK, S; BIRKETT, P; LYNCH, S; JOHNSON, T			EARLY INTERVENTION IN PSYCHIATRIC EMERGENCIES - A CONTROLLED CLINICAL-TRIAL	LANCET			English	Article							SCALE	In the UK, psychiatric care of patients with acute and chronic disorders has increasingly moved from hospital to the community. We have evaluated in a controlled trial patients with severe mental illness, who were assigned to early intervention by community services or to standard hospital treatment. 100 patients aged 16 to 65 years presenting as psychiatric emergencies to an inner London teaching hospital were randomly allocated to a multidisciplinary community-based team (n = 48) or conventional hospital-based psychiatric services (n = 52) and assessed over a 3-month period. Ratings of psychopathology and social functioning were made before treatment and after 2, 4, and 12 weeks by independent assessors. 85 patients completed all assessments, and all patients had evaluable data beyond 2 weeks. 3 patients died during the study, 2 from natural causes and 1 from an accident. Patients referred to the community service showed greater improvement in symptoms and were more satisfied with services than those in the hospital-based service. Patients treated in the hospital-based service spent eight times as many days as psychiatric inpatients as those treated in the community-based service. Patients both prefer and seem to benefit from community-based psychiatric care, and our early-intervention community service might be a good model for such care.	ST CHARLES HOSP,ST MARYS HOSP,SCH MED,ACAD UNIT PSYCHIAT,LONDON W10 6DZ,ENGLAND; UNIV KENT,INST SOCIAL & APPL PSYCHOL,CANTERBURY CT2 7NZ,KENT,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND	Imperial College London; University of Kent; MRC Biostatistics Unit			Birkett, Paul/B-4662-2009					[Anonymous], 1988, INT CLASSIFICATION D; ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BURNS T, 1990, PUBLIC HEALTH IMPACT OF MENTAL DISORDER, P197; CREED F, 1991, BRIT MED J, V300, P1033; HOULT J, 1986, BRIT J PSYCHIAT, V149, P137, DOI 10.1192/bjp.149.2.137; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; KNAPP M, 1990, BRIT J PSYCHIAT, V157, P661, DOI 10.1192/bjp.157.5.661; LIM MH, 1983, BRIT J PSYCHIAT, V143, P460, DOI 10.1192/bjp.143.5.460; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; MUIJEN M, 1992, BRIT MED J, V304, P749, DOI 10.1136/bmj.304.6829.749; ONYETT A, 1990, PSYCHIATR B, V14, P267; REMINGTON M, 1979, SOC PSYCHIATR, V14, P151, DOI 10.1007/BF00582182; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; TYRER P, 1990, Irish Journal of Psychological Medicine, V7, P132; TYRER P, 1984, J NEUROL NEUROSUR PS, V47, P970, DOI 10.1136/jnnp.47.9.970; Tyrer P, 1990, MEASURING HUMAN PROB, P119; TYRER PJ, 1979, LANCET, V1, P1014; WELLER MPI, 1985, LANCET, V1, P569; 1983, 2 DEP ENV INF NOT	19	98	98	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1311	1314		10.1016/0140-6736(92)91959-C	http://dx.doi.org/10.1016/0140-6736(92)91959-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW837	1349990				2022-12-28	WOS:A1992HW83700002
J	POOLE, J				POOLE, J			TIME FOR THE VATICAN TO BEND	LANCET			English	Editorial Material																		DUNSTAN GR, 1988, STATUS EMBRYO PERSPE; GREELEY A, 1991, AMERICA         0921; SCHEPERHUGHES N, 1991, LANCET, V337, P1144, DOI 10.1016/0140-6736(91)92800-H	3	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1340	1341						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1350002				2022-12-28	WOS:A1992HW83700014
J	POWIS, SJ; DEVERSON, EV; COADWELL, WJ; CIRUELA, A; HUSKISSON, NS; SMITH, H; BUTCHER, GW; HOWARD, JC				POWIS, SJ; DEVERSON, EV; COADWELL, WJ; CIRUELA, A; HUSKISSON, NS; SMITH, H; BUTCHER, GW; HOWARD, JC			EFFECT OF POLYMORPHISM OF AN MHC-LINKED TRANSPORTER ON THE PEPTIDES ASSEMBLED IN A CLASS-I MOLECULE	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; INFLUENZA NUCLEOPROTEIN; VIRAL PEPTIDES; T-CELLS; ANTIGEN; REGION; GENE; RECOGNITION; SPECIFICITY; RESISTANCE	Short antigenic peptides bound in the groove of class I major histocompatibility complex molecules enable T cells to detect intracellular pathogens. It has been assumed that structural features of the class I molecule alone select which peptides are bound. It is now demonstrated that a complex polymorphism in one of the major histocompatibility complex-encoded putative peptide-transporter genes is associated with an altered spectrum of bound peptides.	AFRC,INST ANIM PHYSIOL & GENET RES,MICROCHEM FACIL,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	POWIS, SJ (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND.			Powis, Simon/0000-0003-4218-2984; Howard, Jonathan/0000-0003-2756-5143				ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BJORKMAN PJ, 1987, NATURE, V329, P507; BUTCHER GW, 1987, J IMMUNOGENET, V14, P163; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Howard J C, 1978, Curr Top Microbiol Immunol, V81, P54; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LIVINGSTONE AM, 1983, TRANSPLANT P, V15, P1557; LIVINGSTONE AM, 1991, IMMUNOGENETICS, V34, P157, DOI 10.1007/BF00205818; LIVINGSTONE AM, 1989, J EXP MED, V170, P777, DOI 10.1084/jem.170.3.777; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MURPHY DB, 1987, H2 ANTIGENS GENES MO, P359; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; PAZMANY L, 1992, J EXP MED, V175, P361, DOI 10.1084/jem.175.2.361; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; POWIS SJ, 1990, TRANSPLANT P, V22, P2517; POWIS SJ, 1991, J EXP MED, V173, P913, DOI 10.1084/jem.173.4.913; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; RADA C, 1990, P NATL ACAD SCI USA, V87, P2167, DOI 10.1073/pnas.87.6.2167; ROBERTSON M, 1991, NATURE, V353, P300, DOI 10.1038/353300a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SILVA A, 1983, IMMUNOL REV, V76, P105, DOI 10.1111/j.1600-065X.1983.tb01099.x; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1984, CELL, V39, P13, DOI 10.1016/0092-8674(84)90187-9; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VANBLEEK GM, 1990, NATURE, V348, P213	45	363	368	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					211	215		10.1038/357211a0	http://dx.doi.org/10.1038/357211a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1350326				2022-12-28	WOS:A1992HV19500045
J	ELLIOTT, J; WHITE, H				ELLIOTT, J; WHITE, H			CORONARY ATHEROMA REGRESSION TRIALS	LANCET			English	Letter							DISEASE; MEN				ELLIOTT, J (corresponding author), GREEN LANE HOSP,DEPT CARDIOL,AUCKLAND 3,NEW ZEALAND.							BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KNUIMAN JT, 1982, AM J EPIDEMIOL, V116, P631, DOI 10.1093/oxfordjournals.aje.a113446; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1241	1241						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349981				2022-12-28	WOS:A1992HU68400056
J	SCHNEIDER, JS; POPE, A; SIMPSON, K; TAGGART, J; SMITH, MG; DISTEFANO, L				SCHNEIDER, JS; POPE, A; SIMPSON, K; TAGGART, J; SMITH, MG; DISTEFANO, L			RECOVERY FROM EXPERIMENTAL PARKINSONISM IN PRIMATES WITH GM1 GANGLIOSIDE TREATMENT	SCIENCE			English	Article							DOPAMINERGIC-NEURONS; NERVOUS-SYSTEM; MPTP; MONKEYS; BRAIN; STRIATUM; DEFICITS; DISEASE; RATS	A parkinsonian syndrome can be produced in nonhuman primates by administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Parkinsonian-like symptoms induced acutely by MPTP were ameliorated after treatment with G(M1) ganglioside, a substance shown to have neurotrophic effects on the damaged dopamine system in rodents. Treatment with G(M)1 ganglioside also increased striatal dopamine and metabolite levels and enhanced the dopaminergic innervation of the striatum as demonstrated by tyrosine hydroxylase immunohistochemistry. These results suggest that G(M1) ganglioside may hold promise as a therapeutic agent for the treatment of Parkinson's disease.	HAHNEMANN UNIV, SCH MED, INST NEUROSCI, PHILADELPHIA, PA 19102 USA	Drexel University	SCHNEIDER, JS (corresponding author), HAHNEMANN UNIV, SCH MED, CTR NEUROL RES, DEPT NEUROL, PHILADELPHIA, PA 19102 USA.							AGNATI LF, 1983, ACTA PHYSIOL SCAND, V119, P347, DOI 10.1111/j.1748-1716.1983.tb07350.x; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P637, DOI 10.1111/j.1749-6632.1990.tb48913.x; ELSWORTH JD, 1987, BRAIN RES, V415, P293, DOI 10.1016/0006-8993(87)90211-3; FALARDEAU P, 1988, NEUROSCI LETT, V86, P225, DOI 10.1016/0304-3940(88)90575-7; GHIDONI R, 1989, NEUROCHEM INT, V15, P455, DOI 10.1016/0197-0186(89)90164-2; HADJICONSTANTINOU M, 1989, BRAIN RES, V484, P297, DOI 10.1016/0006-8993(89)90373-9; HADJICONSTANTINOU M, 1986, NEUROPHARMACOLOGY, V25, P1075; Hornykiewicz O, 1986, ADV NEUROL, V45, P19; KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402; KOFMAN OS, 1991, J CAN SCI NEUROL, V18, P83; KOVELOWSKI CJ, 1990, SOC NEUR ABSTR, V16, P1341; KURLAN R, 1991, MOVEMENT DISORD, V6, P111, DOI 10.1002/mds.870060205; Kurland L. T, 1958, PATHOGENESIS TREATME, P5; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; MELAMED E, 1988, PARKINSONS DISEASE M, P87; Nagai Y, 1988, NEW TRENDS GANGLIOSI, P329; RAHMANN H, 1983, NEUROCHEM INT, V5, P539, DOI 10.1016/0197-0186(83)90044-X; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; SABEL BA, 1984, SCIENCE, V225, P340, DOI 10.1126/science.6740316; SCHNEIDER JS, 1990, BRAIN RES, V519, P122, DOI 10.1016/0006-8993(90)90069-N; SCHNEIDER JS, 1992, J NEUROSCI RES, V31, P112, DOI 10.1002/jnr.490310116; SCHNEIDER JS, 1988, BRAIN, V111, P1265, DOI 10.1093/brain/111.6.1265; SCHNEIDER JS, 1990, BRAIN RES, V534, P25, DOI 10.1016/0006-8993(90)90108-N; SCHNEIDER JS, IN PRESS VULNERABLE; SCHOENBERG BS, 1986, ADV NEUROL, V45, P277; SKAPER SD, 1989, MOL NEUROBIOL, V3, P173, DOI 10.1007/BF02935630; STULL N, 1991, Society for Neuroscience Abstracts, V17, P702; TAYLOR JR, 1990, PROG BRAIN RES, V82, P543; TAYLOR JR, 1990, BRAIN, V113, P617, DOI 10.1093/brain/113.3.617; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; TETRUD JW, 1989, NEW ENGL J MED, V321, P1364; TILSON HA, 1988, J NEUROSCI RES, V19, P88, DOI 10.1002/jnr.490190112; TOFFANO G, 1984, BRAIN RES, V296, P233, DOI 10.1016/0006-8993(84)90061-1; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; YU RK, 1988, NEW TRENDS GANGLIOSI, P461; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1	36	186	188	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					843	846		10.1126/science.1350379	http://dx.doi.org/10.1126/science.1350379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1350379				2022-12-28	WOS:A1992HT23500047
J	VANDENPLAS, Y				VANDENPLAS, Y			ATOPY AT 3 YEARS IN HIGH-RISK INFANTS FED WHEY HYDROLYSATE OR CONVENTIONAL FORMULA	LANCET			English	Letter											VANDENPLAS, Y (corresponding author), FREE UNIV BRUSSELS,ACAD CHILDRENS HOSP,B-1090 BRUSSELS,BELGIUM.							ATHERTON DJ, 1988, CLIN ALLERGY, V18, P3215; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; VANDENPLAS Y, IN PRESS ANN ALLERGY; 1990, SUBCOMMITTEE NUTRITI	5	17	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1118	1118		10.1016/0140-6736(92)90716-G	http://dx.doi.org/10.1016/0140-6736(92)90716-G			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349137				2022-12-28	WOS:A1992HR44600046
J	WRIGHT, TL; MAMISH, D; COMBS, C; KIM, M; DONEGAN, E; FERRELL, L; LAKE, J; ROBERTS, J; ASCHER, NL				WRIGHT, TL; MAMISH, D; COMBS, C; KIM, M; DONEGAN, E; FERRELL, L; LAKE, J; ROBERTS, J; ASCHER, NL			HEPATITIS-B VIRUS AND APPARENT FULMINANT NON-A, NON-B HEPATITIS	LANCET			English	Article							SURFACE-ANTIGEN; POLYPEPTIDE; SECRETION; SERUM; LIVER; DNA	While there is evidence that hepatitis C virus (HCV) does not cause fulminant non-A, non-B hepatitis, the causal agent remains unknown. To evaluate the role of hepatitis B virus (HBV) in this disease, we used a two-step polymerase chain reaction (PCR) to amplify the surface and core regions of HBV DNA in serum and liver samples taken prospectively from twenty-six patients (mean age 36 years, range 1 to 64) with acute hepatic failure undergoing liver transplantation. HBV DNA was absent from the serum of all patients before transplantation. Seventeen patients were diagnosed as having non-A, non-B hepatitis because they lacked serological evidence of hepatitis A virus or HBV infection. Liver samples were taken from twelve of these patients, and six samples were positive for HBV DNA. By contrast HBV DNA was not detected in liver from three patients with acute liver failure caused by hepatitis A or toxins. HCV RNA was not found in pretransplant samples by PCR. Four of the six patients with detectable HBV DNA in liver and presumptive non-A, non-B hepatitis had detectable HBV DNA in serum after transplantation. One additional patient who did not donate pretransplant liver had HBV DNA in a post-transplant serum sample. Thus, HBV DNA was present before or after transplantation in seven of seventeen patients with apparent non-A, non-B hepatitis. Three of five patients with detectable post-transplant serum HBV DNA were serologically positive for HBV surface antigen. These findings indicate that HBV may be a common cause of fulminant hepatic failure in patients lacking serological evidence of HBV infection.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	WRIGHT, TL (corresponding author), VET AFFAIRS MED CTR,4150 CLEMENT ST,SAN FRANCISCO,CA, USA.			Lake, John/0000-0002-4332-0528	NIAID NIH HHS [R29AI32242-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032242] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BISMUTH H, 1987, ANN INTERN MED, V107, P337, DOI 10.7326/0003-4819-107-2-337; BRECHOT C, 1984, BRIT MED J, V288, P270, DOI 10.1136/bmj.288.6413.270; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; CRISTIANO K, 1991, HEPATOLOGY, V14, P51, DOI 10.1002/hep.1840140109; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; FAVOROV MO, 1992, IN PRESS J MED VIROL; FERAY C, 1991, HEPATOLOGY, V14, pA130; LAVINE JE, 1991, GASTROENTEROLOGY, V100, P263, DOI 10.1016/0016-5085(91)90611-N; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; LIANG TJ, 1990, HEPATOLOGY, V12, P204, DOI 10.1002/hep.1840120205; LIANG TJ, 1991, HEPATOLOGY, V14, pA129; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MAS A, 1990, HEPATOLOGY, V11, P1062, DOI 10.1002/hep.1840110624; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; PERSING DH, 1986, SCIENCE, V234, P1388, DOI 10.1126/science.3787251; SALLIE R, 1991, HEPATOLOGY, V14, pA68; TODO S, 1991, HEPATOLOGY, V13, P619, DOI 10.1002/hep.1840130402; WRIGHT TL, 1991, ANN INTERN MED, V115, P111, DOI 10.7326/0003-4819-115-2-111; YANAGI M, 1991, NEW ENGL J MED, V324, P1895, DOI 10.1056/NEJM199106273242615; ZELDIS JB, 1989, J CLIN INVEST, V84, P1503, DOI 10.1172/JCI114326	22	134	135	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					952	955		10.1016/0140-6736(92)91530-L	http://dx.doi.org/10.1016/0140-6736(92)91530-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348798				2022-12-28	WOS:A1992HP03600003
J	BRIGHT, RA; EVERITT, DE				BRIGHT, RA; EVERITT, DE			BETA-BLOCKERS AND DEPRESSION - EVIDENCE AGAINST AN ASSOCIATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIOCHEMICAL MANIFESTATIONS; PROPRANOLOL; THERAPY; HYPERTENSION; NEUROBIOLOGY; STRESS; DRUGS	Objective. - To evaluate the relationship between beta-blockers and depression. Design. - Case-control study. Setting. - New Jersey Medicaid recipients during July 1980 to December 1983. Participants. - New depression case patients (N = 4302) were identified from Medicaid claims for depression markers (antidepressant drugs, in-hospital depression diagnosis, or electroconvulsive therapy). Control patients were randomly selected and matched on the basis of Medicaid enrollment on the case patients' date for first depression marker (index date), birth year, sex, race, and nursing home residency status. Main Exposure Measure. - Beta-blocker use as evidenced by prescription claims in the year before the index date. Results. - Case patients overall were more likely to have taken beta-blockers (simple, matched odds ratio [OR] of 1.45; 95% confidence interval [Cl], 1.29 to 1.62). Controlling for confounders (benzodiazepine use, frequent outpatient visits, and frequent use of medications other than beta-blockers) resulted in a null effect (OR = 0.98; 95% Cl, 0.87 to 1.12). The ORs were consistently lower for case patients with a depression diagnosis or electroconvulsive therapy than for cases with only antidepressant use as a marker. These results did not vary by age, sex, race, nursing home status, or use of other selected specific medications. Conclusions. - Ongoing beta-blocker use was not causally related to markers of depression. The difference between this study and those it contradicts is that this one identified certain confounding variables that accounted for the apparent relationship.	BETH ISRAEL HOSP,DEPT MED,PROGRAM ANAL CLIN STRATEGIES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Bright, Roselie A/D-2240-2016		FDA HHS [FD-0015-D] Funding Source: Medline	FDA HHS		AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; BLOOM JR, 1981, AM J PUBLIC HEALTH, V71, P1228, DOI 10.2105/AJPH.71.11.1228; BRADBURN NM, 1987, SCIENCE, V236, P157, DOI 10.1126/science.3563494; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V40, P91; BULPITT CJ, 1989, J CARDIOVASC PHARM, V14, pS21; CARNEY RM, 1987, AM J MED, V83, P223, DOI 10.1016/0002-9343(87)90689-9; CRAIG TJ, 1982, NEW YORK STATE J MED, V82, P1439; CREMONABARBARO A, 1983, LANCET, V1, P185; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DIMSDALE JE, 1989, ARCH INTERN MED, V149, P514, DOI 10.1001/archinte.149.3.514; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; FLEMINGER R, 1978, BMJ-BRIT MED J, V1, P1182, DOI 10.1136/bmj.1.6121.1182; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GURLAND BJ, 1980, PSYCHOPATHOLOGY AGED, P37; JANKOVIC J, 1980, ANN INTERN MED, V93, P460, DOI 10.7326/0003-4819-93-3-460; KATON W, 1984, J CLIN PSYCHIAT, V45, P4; KRAMERGINSBERG E, 1989, J AM GERIATR SOC, V37, P507, DOI 10.1111/j.1532-5415.1989.tb05680.x; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993; LESSLER JT, 1984, 1 RES TRIANGL I TECH; ORSULAK PJ, 1989, J FAM PRACTICE, V28, P209; PAYKEL ES, 1982, J CLIN PSYCHOPHARM, V2, P14, DOI 10.1097/00004714-198202000-00004; PETRIE WM, 1982, AM J PSYCHIAT, V139, P92; ROBINS JM, 1986, BIOMETRICS, V42, P293, DOI 10.2307/2531050; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P250; SCHWARTZ AH, 1980, AM J PUBLIC HEALTH, V70, P406, DOI 10.2105/AJPH.70.4.406; STEPHEN SA, 1966, AM J CARDIOL, V18, P463, DOI 10.1016/0002-9149(66)90071-3; THIESSEN BQ, 1990, ARCH INTERN MED, V150, P2286, DOI 10.1001/archinte.150.11.2286; WEISSMAN MM, 1987, AM J PUBLIC HEALTH, V77, P445, DOI 10.2105/AJPH.77.4.445; WHITE WB, 1982, NEW ENGL J MED, V307, P558; 1987, PHYSICIAN CURRENT PR; 1989, INT CLASSIFICATION D	33	69	69	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1783	1787						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK672	1347572				2022-12-28	WOS:A1992HK67200027
J	MARGOLICK, JB; MUNOZ, A; VLAHOV, D; SOLOMON, L; ASTEMBORSKI, J; COHN, S; NELSON, KE				MARGOLICK, JB; MUNOZ, A; VLAHOV, D; SOLOMON, L; ASTEMBORSKI, J; COHN, S; NELSON, KE			CHANGES IN LYMPHOCYTE-T SUBSETS IN INTRAVENOUS-DRUG-USERS WITH HIV-1 INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; PERIPHERAL-BLOOD; HOMOSEXUAL MEN; AIDS; COHORT; TYPE-1; CD4; SEROCONVERSION; MARKERS	Objective. - To evaluate changes in T-cell subsets in prevalent human immunodeficiency virus type 1 (HIV-1) seronegative and seropositive intravenous drug users (IVDUs) and in HIV-1 seropositive IVDUs with known time of seroconversion. Design. - Cohort study with a median 18-month follow-up. Setting. - Community-based clinic established to study the natural history of HIV infection in IVDUs. Subjects. - Eight hundred fifty-nine self-referred IVDUs aged 18 through 49 years who injected drugs within the last 10 years and who did not have an AIDS (acquired immunodeficiency syndrome)-defining illness; 152 were seronegative for HIV-1, 621 were seropositive, and 86 seroconverted during the study. Outcome Measures. - Proportions and absolute numbers of lymphocytes and CD3, CD4, and CD8 T cells as determined at 6-month intervals by flow cytometry and complete blood cell counts with automated differential. Results. - Median numbers of.CD4 lymphocytes at enrollment were 1061/mu-L (1.06 x 10(9)/L) for seronegative IVDUs, 508/mu-L for seropositive IVDUs, and 733/mu-L for those who seroconverted (enrolled a median of 4.5 months after seroconversion); the corresponding figures for CD8 lymphocytes were 628, 894, and 889/mu-L, respectively. Median rates of decline in absolute numbers and percentages of CD4 lymphocytes per 6 months were 7.6/mu-L (0.0%) for seropositive IVDUs and 55.1/mu-L (1.9%) for IVDUs who seroconverted (median follow-up after seroconversion was 12 months). Multivariate regression analysis that incorporated the within-individual correlation of the CD4 lymphocyte counts showed no significant change in these cells over time and no change due to use of drugs. Conclusion. - Our data suggest that progression of HIV-1 infection in IVDUs, as reflected in decline of CD4 cell counts, is no more rapid than that reported for other risk groups.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	MARGOLICK, JB (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, 615 N WOLFE ST, ROOM 7032, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R56DA004334, R01DA004334] Funding Source: NIH RePORTER; NIAID NIH HHS [AI72634] Funding Source: Medline; NIDA NIH HHS [DA05664, DA04334] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALCABES P, 1991, 7TH INT C AIDS FLOR; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FERNANDEZCRUZ E, 1990, AIDS, V4, P987, DOI 10.1097/00002030-199010000-00007; GALLI M, 1989, CLIN IMMUNOL IMMUNOP, V50, pS166, DOI 10.1016/0090-1229(89)90124-4; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; JARLAIS DCD, 1987, AIDS, V1, P105; KLIMAS NG, 1991, AM J MED, V90, P163, DOI 10.1016/0002-9343(91)80155-F; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; MUNOZ A, 1986, BIOMETRICS, V42, P653, DOI 10.2307/2531215; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; ROSENBLATT JD, 1990, BLOOD, V76, P409; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHOENBAUM EE, 1989, 5TH INT C AIDS MONTR, P157; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; STONEBURNER R, 1991, SCIENCE, V242, P916; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; Tukey J. W., 1977, EXPLORATORY DATA ANA; ULSTRUP JC, 1986, LANCET, V1, P1151; VLAHOV D, 1991, J DRUG ISSUES, V21, P759, DOI 10.1177/002204269102100406; VLAHOV D, 1991, NIDA RES MONOGRAPH S, V103; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; ZOLLAPAZNER S, 1987, P NATL ACAD SCI USA, V84, P5404, DOI 10.1073/pnas.84.15.5404; 1987, MMWR, V36, pS3	29	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1631	1636		10.1001/jama.267.12.1631	http://dx.doi.org/10.1001/jama.267.12.1631			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1347321				2022-12-28	WOS:A1992HJ59700030
J	ARCHER, TK; LEFEBVRE, P; WOLFORD, RG; HAGER, GL				ARCHER, TK; LEFEBVRE, P; WOLFORD, RG; HAGER, GL			TRANSCRIPTION FACTOR LOADING ON THE MMTV PROMOTER - A BIMODAL MECHANISM FOR PROMOTER ACTIVATION	SCIENCE			English	Article							NUCLEAR FACTOR-I; MAMMALIAN-CELLS; BINDING-SITE; DNA-BINDING; PROTEINS; EXTRACTS; ELEMENT; INVIVO; CRUDE; SP1	The mouse mammary tumor virus (MMTV) promoter attains a phased array of six nucleosomes when introduced into rodent cells. This architecture excludes nuclear factor 1/CCAAT transcription factor (NF1/CTF) from the promoter before glucocorticoid treatment and hormone-dependent access of nucleolytic agents to promoter DNA. In contrast, when the promoter was transiently introduced into cells, NF1/CTF was bound constitutively and nucleolytic attack was hormone-independent. Thus, induction at this promoter was a bimodal process involving receptor-dependent remodeling of chromatin that allows NF1/CTF loading and direct receptor-mediated recruitment of additional transcription factors.	NCI,MOLEC VIROL LAB,HORMONE ACT & ONCOGENESIS SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Lefebvre, Philippe/F-2685-2010; Archer, Trevor K/E-5191-2019	Lefebvre, Philippe/0000-0002-9366-5129; Archer, Trevor K/0000-0001-7651-3644				ARCHER TK, 1985, J BIOL CHEM, V260, P1676; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1989, STEROID THYROID HORM, P221; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CORDINGLEY MG, 1988, NUCLEIC ACIDS RES, V16, P609, DOI 10.1093/nar/16.2.609; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KUHNEL B, 1986, J MOL BIOL, V190, P367, DOI 10.1016/0022-2836(86)90008-2; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WOLFFE A P, 1990, New Biologist, V2, P211; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0	26	370	373	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 20	1992	255	5051					1573	1576		10.1126/science.1347958	http://dx.doi.org/10.1126/science.1347958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1347958				2022-12-28	WOS:A1992HJ80900041
J	INOUE, J; KERR, LD; KAKIZUKA, A; VERMA, IM				INOUE, J; KERR, LD; KAKIZUKA, A; VERMA, IM			I-KAPPA-B-GAMMA, A 70 KD PROTEIN IDENTICAL TO THE C-TERMINAL HALF OF P110 NF-KAPPA-B - A NEW MEMBER OF THE I-KAPPA-B FAMILY	CELL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ENHANCER-BINDING-PROTEIN; REL ONCOGENE PRODUCT; CELL-CYCLE CONTROL; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; DORSAL PROTEIN; 65-KD SUBUNIT; DNA; DROSOPHILA	A cDNA corresponding to the 2.6 kb NF-kappa-B mRNA species present in a variety of lymphoid cell lines has been molecularly cloned. The deduced 607 amino acid sequence is identical to the sequence of the C-terminal region of 110 kd NF-kappa-B protein. A 70 kd protein can be identified in lymphoid cells using antibodies raised against the C-terminal region of pi 10 NF-kappa-B. Comparison of the two-dimensional tryptic peptide maps of the 70 kd protein expressed in cells and the in vitro translated product encoded by the cDNA display extensive homology. The 70 kd protein expressed in bacteria prevents sequence-specific DNA binding of p50-p65 NF-kappa-B heterodimer, p50 homodimer, and c-rel. p70 also interferes with transactivation by c-rel and prevents its nuclear translocation. The 70 kd protein, predominantly found in lymphoid cells, is a new member of the I-kappa-B family of proteins and is referred to as I-kappa-B-gamma.			INOUE, J (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92186, USA.				FOGARTY INTERNATIONAL CENTER [F05TW004430] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026444] Funding Source: NIH RePORTER; FIC NIH HHS [F5TWO4430] Funding Source: Medline; NCI NIH HHS [T2CA09370C] Funding Source: Medline; NIGMS NIH HHS [5R01GM26444] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE JI, 1992, IN PRESS P NATL ACAD; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; LUO K, 1990, ONCOGENE, V5, P921; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	47	269	272	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1109	1120		10.1016/0092-8674(92)90082-N	http://dx.doi.org/10.1016/0092-8674(92)90082-N			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1339305				2022-12-28	WOS:A1992HK67400014
J	LEWIS, EB				LEWIS, EB			CLUSTERS OF MASTER CONTROL GENES REGULATE THE DEVELOPMENT OF HIGHER ORGANISMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOMEOBOX-CONTAINING GENES; BITHORAX COMPLEX; DROSOPHILA-MELANOGASTER; MOLECULAR-GENETICS; HOMOEOTIC MUTATION; MUTANT EMBRYOS; HOMEOTIC GENES; BETA-GLOBIN; EXPRESSION; ULTRABITHORAX				LEWIS, EB (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD006331, R01HD006331] Funding Source: NIH RePORTER; NICHD NIH HHS [HD06331] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEEMAN RW, 1987, NATURE, V327, P247, DOI 10.1038/327247a0; BEEMAN RW, 1989, DEV BIOL, V133, P196, DOI 10.1016/0012-1606(89)90311-4; BENDER M, 1987, DEV BIOL, V119, P418, DOI 10.1016/0012-1606(87)90046-7; BENDER W, 1985, COLD SPRING HARB SYM, V50, P173, DOI 10.1101/SQB.1985.050.01.023; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BLATT C, 1988, BIOCHEM BIOPH RES CO, V156, P1265, DOI 10.1016/S0006-291X(88)80769-1; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; BOULET AM, 1991, DEVELOPMENT, V111, P393; Bridges CB, 1936, SCIENCE, V83, P210, DOI 10.1126/science.83.2148.210; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; CELNIKER SE, 1987, GENE DEV, V1, P111, DOI 10.1101/gad.1.2.111; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DELORENZI M, 1990, DEVELOPMENT, V108, P323; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; GARBER RL, 1983, EMBO J, V2, P2027, DOI 10.1002/j.1460-2075.1983.tb01696.x; Garcia-Bellido A., 1978, CLONAL BASIS DEV, P3; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GREEN MM, 1949, P NATL ACAD SCI USA, V35, P586, DOI 10.1073/pnas.35.10.586; Hayes W., 1968, GENETICS BACTERIA TH; HOGNESS DS, 1985, COLD SPRING HARB SYM, V50, P181, DOI 10.1101/SQB.1985.050.01.024; HUMPHREYS T, 1987, ZOOL SCI, V4, P1129; INGHAM P, 1980, MOL GEN GENET, V179, P607, DOI 10.1007/BF00271751; INGHAM PW, 1981, ROUX ARCH DEV BIOL, V190, P365, DOI 10.1007/BF00863275; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1986, NATURE, V324, P592, DOI 10.1038/324592a0; INGHAM PW, 1986, EMBO J, V5, P1659, DOI 10.1002/j.1460-2075.1986.tb04409.x; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; ITIKAWA NOBUKAZU, 1952, BULL SERICUL EXPT STA [JAPAN], V14, P23; JACOB F, 1961, COLD SPRING HARB SYM, V26, P193, DOI 10.1101/SQB.1961.026.01.024; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; Kaufman T C, 1990, Adv Genet, V27, P309; KAUFMAN TC, 1980, GENETICS, V94, P115; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; KRUMLAUF R, 1987, DEVELOPMENT, V99, P603; LAWRENCE PA, 1985, PHILOS T R SOC B, V312, P83, DOI 10.1098/rstb.1985.0179; LEWIS E. B., 1942, GENETICS, V27, P153; Lewis E. B., 1939, P MINN ACAD SCI, V7, P23; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1955, AM NAT, V89, P73, DOI 10.1086/281867; LEWIS EB, 1951, COLD SPRING HARB SYM, V16, P159, DOI 10.1101/SQB.1951.016.01.014; LEWIS EB, 1945, GENETICS, V30, P137; LEWIS EB, 1985, COLD SPRING HARB SYM, V50, P155, DOI 10.1101/SQB.1985.050.01.021; LEWIS EB, 1968, 12TH P INT C GEN, P96; LEWIS EB, 1964, ROLE CHROMOSOMES DEV, P231; LINDSLEY DL, 1968, PUBL CARNEGIE I, V627, P1; LIPSHITZ HD, 1987, GENE DEV, V1, P307, DOI 10.1101/gad.1.3.307; MACIAS A, 1990, DEVELOPMENT, V110, P1197; MAEDA N, 1986, ANNU REV GENET, V20, P81; MARTINEZARIAS A, 1988, DEVELOPMENT, V102, P325; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MULLER HJ, 1936, CR DOKLADY ACAD SCI, V1, P87; NICKOL JM, 1988, P NATL ACAD SCI USA, V85, P2548, DOI 10.1073/pnas.85.8.2548; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Oliver CP, 1940, P NATL ACAD SCI USA, V26, P452, DOI 10.1073/pnas.26.7.452; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; Rapoport J. A., 1936, Bull Biol Med exp URSS Moscow, V2, P242; SANCHEZHERRERO E, 1989, DEVELOPMENT, V107, P321; SCHUGHART K, 1989, P NATL ACAD SCI USA, V86, P7067, DOI 10.1073/pnas.86.18.7067; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; Sturtevant AH, 1925, GENETICS, V10, P117; Sturtevant AH, 1940, GENETICS, V25, P337; Tazima Y, 1964, GENETICS SILKWORM; TSUJITA MITSUO, 1955, JAPANESE JOUR GENETICS, V30, P227, DOI 10.1266/jjg.30.227; WALLDORF U, 1989, P NATL ACAD SCI USA, V86, P9971, DOI 10.1073/pnas.86.24.9971; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x	91	79	91	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1524	1531		10.1001/jama.267.11.1524	http://dx.doi.org/10.1001/jama.267.11.1524			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1347087				2022-12-28	WOS:A1992HH48800036
J	BRAHAMS, D				BRAHAMS, D			ABORTION IN IRELAND	LANCET			English	Editorial Material																		1992, LANCET, V339, P485	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					608	609		10.1016/0140-6736(92)90885-7	http://dx.doi.org/10.1016/0140-6736(92)90885-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH075	1347105				2022-12-28	WOS:A1992HH07500017
J	MCGINNIS, W; KRUMLAUF, R				MCGINNIS, W; KRUMLAUF, R			HOMEOBOX GENES AND AXIAL PATTERNING	CELL			English	Review							ANTERIOR POSTERIOR AXIS; BITHORAX COMPLEX GENES; DROSOPHILA HEAD DEVELOPMENT; HOMEODOMAIN-DNA COMPLEX; HOMEOTIC SELECTOR GENE; CENTRAL NERVOUS-SYSTEM; ECTOPIC EXPRESSION; SEX-COMBS; ULTRABITHORAX PROTEINS; VISCERAL MESODERM		NATL INST MED RES, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research	MCGINNIS, W (corresponding author), YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06511 USA.		Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927				AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AKAM ME, 1985, EMBO J, V4, P1689, DOI 10.1002/j.1460-2075.1985.tb03838.x; ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BEEMAN RW, 1987, NATURE, V327, P247, DOI 10.1038/327247a0; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIENZ M, 1988, CELL, V53, P567, DOI 10.1016/0092-8674(88)90573-9; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BREEN TR, 1986, DEV BIOL, V118, P442, DOI 10.1016/0012-1606(86)90015-1; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CARROLL SB, 1988, GENE DEV, V2, P350, DOI 10.1101/gad.2.3.350; CARROLL SB, 1986, CELL, V47, P113, DOI 10.1016/0092-8674(86)90372-7; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; CHADWICK R, 1990, DEV BIOL, V141, P130, DOI 10.1016/0012-1606(90)90108-U; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; COHEN S, 1991, TRENDS GENET, V7, P267; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; DRESSLER GR, 1989, DIFFERENTIATION, V41, P193, DOI 10.1111/j.1432-0436.1989.tb00747.x; DUBOULE D, 1990, GENOMICS, V7, P458, DOI 10.1016/0888-7543(90)90185-W; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; Duncan I., 1982, DEV ORDER ITS ORIGIN, P533; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; DURA JM, 1988, DEVELOPMENT, V103, P733; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; FINKELSTEIN R, 1991, DEVELOPMENT, V112, P899; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; GARCIABELLIDO A, 1977, AM ZOOL, V17, P613; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GHYSEN A, 1985, CELL, V40, P943, DOI 10.1016/0092-8674(85)90354-X; GIBSON G, 1988, DEVELOPMENT, V102, P657; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRAHAM A, 1991, DEVELOPMENT, V112, P255; GRAHAM A, 1988, GENE DEV, V2, P1424, DOI 10.1101/gad.2.11.1424; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; HAFEN E, 1984, NATURE, V307, P287, DOI 10.1038/307287a0; HARDING K, 1988, EMBO J, V7, P205, DOI 10.1002/j.1460-2075.1988.tb02801.x; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HAYES PH, 1984, P NATL ACAD SCI-BIOL, V81, P545, DOI 10.1073/pnas.81.2.545; HOLDER N, 1991, IN PRESS DEVELOPMENT; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HOOPER JE, 1986, EMBO J, V5, P2321, DOI 10.1002/j.1460-2075.1986.tb04500.x; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; INGHAM PW, 1986, NATURE, V324, P592, DOI 10.1038/324592a0; INGHAM PW, 1983, NATURE, V306, P591, DOI 10.1038/306591a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JACK T, 1988, GENE DEV, V2, P635, DOI 10.1101/gad.2.6.635; JACK T, 1990, EMBO J, V9, P1187, DOI 10.1002/j.1460-2075.1990.tb08226.x; JONES CM, 1991, DEVELOPMENT, V111, P531; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; Kaufman T C, 1990, Adv Genet, V27, P309; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRUMLAUF R, 1987, DEVELOPMENT, V99, P603; KUROIWA A, 1985, EMBO J, V4, P3757, DOI 10.1002/j.1460-2075.1985.tb04145.x; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1964, CHROMOSOMES DEV; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, IN PRESS DEVELOPMENT, V113; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MAHAFFEY JW, 1987, GENETICS, V117, P51; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MARTINEZARIAS A, 1987, DEVELOPMENT, V100, P673; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MERRILL VKL, 1989, DEV BIOL, V135, P376, DOI 10.1016/0012-1606(89)90187-5; MERRILL VKL, 1987, DEV BIOL, V122, P379, DOI 10.1016/0012-1606(87)90303-4; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MLODZIK M, 1990, DEVELOPMENT, V109, P271; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MORRISSKAY G, 1991, IN PRESS EMBO J; MULLER J, 1989, EMBO J, V8, P4143, DOI 10.1002/j.1460-2075.1989.tb08599.x; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; OLIVER G, 1988, CELL, V55, P1017, DOI 10.1016/0092-8674(88)90246-2; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; PULTZ MA, 1988, GENE DEV, V2, P901, DOI 10.1101/gad.2.7.901; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; RANDAZZO FM, 1991, DEVELOPMENT, V111, P1; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; REGULSKI M, 1985, CELL, V43, P71, DOI 10.1016/0092-8674(85)90013-3; REUTER R, 1990, DEVELOPMENT, V109, P289; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROBINSON G, 1991, IN PRESS NEW BIOL, V3; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SCHUGHART K, 1988, BRIT J CANCER, V58, P9; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHEARN A, 1989, GENETICS, V121, P517; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; Snodgrass RE, 1935, PRINCIPLES INSECT MO; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1984, NATURE, V308, P454, DOI 10.1038/308454a0; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STRUHL G, 1985, CELL, V43, P507, DOI 10.1016/0092-8674(85)90180-1; STUART JJ, 1991, NATURE, V350, P72, DOI 10.1038/350072a0; SUNKEL CE, 1987, ROUX ARCH DEV BIOL, V196, P124, DOI 10.1007/BF00402034; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8; WHITE RAH, 1985, NATURE, V318, P563, DOI 10.1038/318563a0; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Whittington Harry B, 1985, BURGESS SHALE; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x	186	2347	2403	7	161	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1992	68	2					283	302		10.1016/0092-8674(92)90471-N	http://dx.doi.org/10.1016/0092-8674(92)90471-N			20	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HB353	1346368				2022-12-28	WOS:A1992HB35300009
J	SHARLAND, M; PATTON, MA; TALBOT, S; CHITOLIE, A; BEVAN, DH				SHARLAND, M; PATTON, MA; TALBOT, S; CHITOLIE, A; BEVAN, DH			COAGULATION-FACTOR DEFICIENCIES AND ABNORMAL BLEEDING IN NOONANS SYNDROME	LANCET			English	Article							CONGENITAL HEART-DISEASE; FACTOR-VIII; FACTOR-XI	Noonan's syndrome is characterised by a dysmorphic facies, congenital heart disease, and short stature, and is inherited as an autosomal dominant trait. Because abnormal bleeding has also been reported, we investigated a group of patients for coagulation-factor deficits. Of the 72 individuals studied (37 male, 35 female, mean age 11.4 years), 47 (65%) had a history of abnormal bruising or bleeding. 29 patients (40%) had a prolonged activated partial thromboplastin time. Specific abnormalities in the intrinsic pathway of coagulation (partial factor XI:C, XII:C, and VIII:C deficiencies) were found in 36 patients (50%). Multiple abnormalities among these 36 patients included combined factor XI:C and XII:C deficiencies (4 patients) and factor XI:C and VIII:C deficiencies .(4), and 1 patient had combined factor VIII:C, XI:C, and XII:C deficiency. There was poor correlation between a history of abnormal bleeding and coagulation-factor deficit. In five families, similar coagulation-factor deficiencies were present in first-degree relatives with the syndrome. The pattern of inherited bleeding abnormalities seen in Noonan's syndrome suggests autosomal regulation of the intrinsic coagulation pathway.	ST GEORGE HOSP,SCH MED,SW THAMES REG GENET SERV,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT HAEMATOL,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London				sharland, mike/0000-0001-8626-8291				ALLANSON JE, 1987, J MED GENET, V24, P9, DOI 10.1136/jmg.24.1.9; BOLTONMAGGS PHB, 1988, BRIT J HAEMATOL, V69, P521, DOI 10.1111/j.1365-2141.1988.tb02409.x; CALVERT GD, 1973, LANCET, V1, P320; CHAR F, 1972, Birth Defects Original Article Series, V8, P110; COLLINS E, 1973, J PEDIATR-US, V83, P941, DOI 10.1016/S0022-3476(73)80527-X; COLONOTERO G, 1987, MAYO CLIN PROC, V62, P379, DOI 10.1016/S0025-6196(12)65442-1; CREMERS CWR, 1974, MAANDSCHR KINDERGENE, V42, P322; DEHAAN M, 1988, AM J MED GENET, V29, P277, DOI 10.1002/ajmg.1320290205; ESKERT H, 1970, J PEDIATR, V76, P221; EVANS DGR, 1991, CLIN GENET, V39, P228; FESTEN C, 1980, CHIR PEDIATR, V21, P393; GIDDINGS JC, 1977, BRIT J HAEMATOL, V37, P257, DOI 10.1111/j.1365-2141.1977.tb06842.x; GRAHAM JB, 1980, LANCET, V1, P340; HATHAWAY WE, 1971, AM J DIS CHILD, V121, P127, DOI 10.1001/archpedi.1971.02100130081009; HENRIKSSON P, 1979, BRIT HEART J, V41, P23; HUBERT JR, 1970, LANCET, V2, P770; KITCHENS CS, 1983, J PEDIATR-US, V102, P224, DOI 10.1016/S0022-3476(83)80525-3; KLINGER HP, 1989, CYTOGENET CELL GENET, V51; KOMP DM, 1975, PEDIATR RES, V9, P184, DOI 10.1203/00006450-197504000-00009; NOONAN JA, 1968, AM J DIS CHILD, V116, P373, DOI 10.1001/archpedi.1968.02100020377005; NOONAN JA, 1963, J PEDIATR-US, V63, P468; WITT DR, 1988, AM J MED GENET, V31, P305, DOI 10.1002/ajmg.1320310208	22	80	84	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1992	339	8784					19	21		10.1016/0140-6736(92)90141-O	http://dx.doi.org/10.1016/0140-6736(92)90141-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY043	1345952				2022-12-28	WOS:A1992GY04300003
J	PARISI, AF; FOLLAND, ED; HARTIGAN, P				PARISI, AF; FOLLAND, ED; HARTIGAN, P			A COMPARISON OF ANGIOPLASTY WITH MEDICAL THERAPY IN THE TREATMENT OF SINGLE-VESSEL CORONARY-ARTERY DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; BLOOD-INSTITUTE; NATIONAL-HEART; CLINICAL-TRIAL; PTCA REGISTRY; FOLLOW-UP; LUNG; RESTENOSIS; EFFICACY; SURVIVAL	Background. Despite the widespread use of percutaneous transluminal coronary angioplasty (PTCA), only a few prospective trials have assessed its efficacy. We compared the effects of PTCA with those of medical therapy on angina and exercise tolerance in patients with stable single-vessel coronary artery disease. Methods. Patients with 70 to 99 percent stenosis of one epicardial coronary artery and with exercise-induced myocardial ischemia were randomly assigned either to undergo PTCA or to receive medical therapy and were evaluated monthly. The patients assigned to PTCA were urged to have repeat angioplasty if their symptoms suggested restenosis. After six months, all the patients had repeat exercise testing and coronary angiography. Results. A total of 107 patients were randomly assigned to medical therapy and 105 to PTCA. PTCA was clinically successful in 80 of the 100 patients who actually had the procedure, with an initial reduction in mean percent stenosis from 76 to 36 percent. Two patients in the PTCA group required emergency coronary-artery bypass surgery. By six months after the procedure, 16 patients had had repeat PTCA. Myocardial infarction occurred in five patients assigned to PTCA and in three patients assigned to medical therapy. At six months 64 percent of the patients in the PTCA group (61 of 96) were free of angina, as compared with 46 percent of the medically treated patients (47 of 102; P < 0.01). The patients in the PTCA group were able to increase their total duration of exercise more than the medical patients (2.1 vs. 0.5 minutes, P < 0.0001) and were able to exercise longer without angina on treadmill testing (P < 0.01). Conclusions. For patients with single-vessel coronary artery disease, PTCA offers earlier and more complete relief of angina than medical therapy and is associated with better performance on the exercise test. However, PTCA initially costs more than medical treatment and is associated with a higher frequency of complications.	VET AFFAIRS MED CTR,RES SERV,BOSTON,MA	US Department of Veterans Affairs; Veterans Health Administration (VHA)								BRUCE RA, 1971, ANN CLIN RES, V3, P323; COX DR, 1972, J R STAT SOC B, V34, P187; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; Dupuy H.J., 1984, ASSESSMENT QUALITY L, P170; GLAZIER JJ, 1989, BRIT HEART J, V61, P485; GRUENTZIG AR, 1987, NEW ENGL J MED, V316, P1127, DOI 10.1056/NEJM198704303161805; GRUNTZIG AR, 1979, NEW ENGL J MED, V301, P61, DOI 10.1056/NEJM197907123010201; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; KALTENBACH M, 1985, EUR HEART J, V6, P276, DOI 10.1093/oxfordjournals.eurheartj.a061852; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KENT KM, 1984, AM J CARDIOL, V53, pC27, DOI 10.1016/0002-9149(84)90741-0; MOCK MB, 1989, CIRCULATION, V80, P700, DOI 10.1161/01.CIR.80.3.700; MOCK MB, 1985, NEW ENGL J MED, V312, P916, DOI 10.1056/NEJM198504043121410; MYLER RK, 1990, CIRCULATION, V82, P88; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; PEPINE CJ, 1990, MOD CONC CARDIOV DIS, V59, P55; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RYAN TJ, 1990, J AM COLL CARDIOL, V16, P66, DOI 10.1016/0735-1097(90)90457-Z; SCHOLL JM, 1982, CIRCULATION, V66, P380, DOI 10.1161/01.CIR.66.2.380; STACK RS, 1988, J AM COLL CARDIOL, V11, P1141, DOI 10.1016/0735-1097(88)90274-4; STRAUSS WE, 1982, AM J CARDIOL, V49, P560, DOI 10.1016/S0002-9149(82)80012-X; TALLEY JD, 1988, CIRCULATION, V77, P820, DOI 10.1161/01.CIR.77.4.820; TARONE RE, 1977, BIOMETRIKA, V64, P156, DOI 10.1093/biomet/64.1.156; THOMAS ES, 1988, J AM COLL CARDIOL, V11, P217, DOI 10.1016/0735-1097(88)90083-6; WILLIAMS DO, 1984, AM J CARDIOL, V53, pC32, DOI 10.1016/0002-9149(84)90742-2; 1977, AM J CARDIOL, V40, P212; 1984, NEW ENGL J MED, V310, P750; 1983, CIRCULATION, V68, P951; 1988, J AM COLL CARDIOL, V12, P529; 1990, LANCET, V335, P1315	32	554	573	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1992	326	1					10	16		10.1056/NEJM199201023260102	http://dx.doi.org/10.1056/NEJM199201023260102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX315	1345754				2022-12-28	WOS:A1992GX31500002
J	AOUN, H				AOUN, H			FROM THE EYE OF THE STORM, WITH THE EYES OF A PHYSICIAN	ANNALS OF INTERNAL MEDICINE			English	Note						ACQUIRED IMMUNODEFICIENCY SYNDROME; PHYSICIAN-PATIENT RELATIONS; EDUCATION, MEDICAL; SOCIAL SUPPORT; ETHICS, MEDICAL		A physician acquires a terrible disease and, as a patient, is confronted with aspects of medical care that contribute to the suffering rather than the healing. As a result of these experiences, his views on what constitutes a good physician become simpler. A good physician cares for his patients and works toward preserving their dignity and independence. The issue is raised of whether current medical education can be effective in producing that caring physician, for it is particularly in caring for patients with catastrophic or incurable illnesses that the role of the physician is more, not less, important.										AOUN H, 1989, NEW ENGL J MED, V321, P693, DOI 10.1056/NEJM198909073211020; AOUN H, 1991, NEW ENGL J MED, V324, P265, DOI 10.1056/NEJM199101243240412; Harrison TR, 1950, PRINCIPLES INTERNAL; NATELSON BH, 1990, TOMORROWS DOCTORS PA; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; RABIN D, 1982, NEW ENGL J MED, V307, P506, DOI 10.1056/NEJM198208193070827; RABIN R, 1985, 6 PARTS LOVE ONE FAM; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405	8	23	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1992	116	4					335	338		10.7326/0003-4819-116-4-335	http://dx.doi.org/10.7326/0003-4819-116-4-335			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD546	11651175				2022-12-28	WOS:A1992HD54600012
